<SEC-DOCUMENT>0001121702-23-000012.txt : 20230314
<SEC-HEADER>0001121702-23-000012.hdr.sgml : 20230314
<ACCEPTANCE-DATETIME>20230314161348
ACCESSION NUMBER:		0001121702-23-000012
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230314
DATE AS OF CHANGE:		20230314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			YIELD10 BIOSCIENCE, INC.
		CENTRAL INDEX KEY:			0001121702
		STANDARD INDUSTRIAL CLASSIFICATION:	AGRICULTURE PRODUCTION - CROPS [0100]
		IRS NUMBER:				043158289
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33133
		FILM NUMBER:		23731049

	BUSINESS ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY
		STREET 2:		SUITE 201
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		617-583-1700

	MAIL ADDRESS:	
		STREET 1:		19 PRESIDENTIAL WAY
		STREET 2:		SUITE 201
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLIX, INC.
		DATE OF NAME CHANGE:	20060717

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	METABOLIX INC
		DATE OF NAME CHANGE:	20000810
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>yten-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e,d:c02604fb0219453aa54b246df7a39126--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns="http://www.w3.org/1999/xhtml" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:yten="http://www.yield10bio.com/20221231" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>yten-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN18zLTEtMS0xLTU1Njc2_08a138b2-9824-4757-bf24-d832f5dd4a0f">0001121702</ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN180LTEtMS0xLTU1Njc2_e7f8fc56-7243-43ba-a1e4-645ef5bcf331">2022</ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN181LTEtMS0xLTU1Njc2_21a0963b-c36e-4e4c-bb9e-fcfb192fc593">FY</ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN182LTEtMS0xLTU1Njc2_c73f42fa-e3c8-4de7-8927-847ef40ef110">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5NzI_92e01ef7-0471-4c44-a8d1-ce238526654a">P1Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="yten-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac86a3d09d164b4a93df64e6e398cda3_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i0ec0531db504460d878e8a5b16adba16_I20230313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i966a0b1f35af427492d1da0e13191558_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6e4e205f139470c9d01730aa2cae2bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i0fa4f596e68b435cb25ae4cba2423590_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee3c65cebf3e4b5cae9b882ffa69ba4b_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97019bfe3e334d528406e95e102e2364_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3d3121e408a4cc2bbbbfbad11389e16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40955b8933394980b43a112a70cb81dd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if50f9d23f34d4f029330039500bd46fc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i684d6f37920d42318715b4946e6c8249_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia191e1112ea14abb840d58c60e120043_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58fce4089bcb426e8039bc6cbfa6106c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7526ac612c264449a3e3ac301d55542f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica80c64d92b04d749e752fded64ecc53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6a79d372a4443d8d41d7ee23cabec4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3efc24abbd6441ca82da51c9deb09b3_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad8a0121d2bc47a58199c38a729c4349_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b28bd8c03f94f9981d0b15e39eff5f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief1ac89ff5a2424396d026131c1fdf13_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i337d07789e89467e9cfd5f2c41ac49b3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>yten:segment</xbrli:measure></xbrli:unit><xbrli:context id="i53f6338f531042b4a04410a3879ac996_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie14d20621fd74f3f903765f72c4cb378_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb9c616adc7405cb3808b71146eb760_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4648116206044ea1ab0d5587be0e4138_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da9d58e3fa24edebed51009dfec4598_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibadc13ffe064427483b95cf9d059239f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbc4ce7ce80f437bb07e269549f899be_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic119f79d77f64ab3b8eeebb87c15caa6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic77d372fcd3a4dc0b1f445bc7272f30c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if123f89aae974cfab1c6bc2456615632_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0987e598fd44b77bbed7faceb8e8bfd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id73e87c2e2c4452cb9bcdb46ea70f888_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i745a819a98b64320aa580b32fb4def9c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib708dd5f8a6f488982b1a6a8631cabc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04f100c5f4eb4b2fbb1336ee32b69ec2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb545bab60de47478b6320dbdab7d781_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b04174d783444b5a91b08f126c073ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc0a6c75312c46e680b72b0b6f4f19e9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aa5b795834d44dd8e3b1fcc2a74afad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ccbc1ced9aa46338a3306667ca0aff1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94927ee7145149928eb35b6455abe6cd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ecc835c25a3427287cfa2313952f908_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0097ebc1457c424689098cd526fc4a70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie72dd2c270874bbd9c0f5786c80f1ce8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4551191c4634001a933c43c11c34a07_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c52dafa175b4fc68b9d93299520cd17_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144df6c356284a69bdf5ec6b09bde5a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84682813ef2546fba512f9a3d6c563ad_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaf30edacde94c84a05341ca5dd0512f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec9b06e45af54e8f9a8de5e18ac09e35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ca1e9b355104bd08b48abb4bb45290e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e3db911982426a8a17792e40222a8f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fec75a43493400b8c38e54079d13b02_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1479bec68b2c4d46978bb015eb204350_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0041b2aac5540ffb18d839925fa734d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7d8c98f7a2c42188fb89171b9b7189a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2c0fa82f93e4dbbbedf6619da265b98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0d96fc98eceb4bd6bec5c50fb28726ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd98a258635e48699f1a798857c5c38b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5eb1729532b6499587ce5b81b2cb2556_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7908f4e474c344729dd788b217be9fa9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd0d338183674907923554d81edf4952_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f310cf5c534afebc48ec2031f27370_I20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-12</xbrli:startDate><xbrli:endDate>2020-11-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78f5c017d62d4136be49a824fedd9fa5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-03</xbrli:startDate><xbrli:endDate>2021-02-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icff22d25d26146d48d6decdae2cb0324_I20210203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia723adea7be546caa73fa33c727a5588_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesBWarrantExpiringMay2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie858d5dd08b14a2188004834d4b1e502_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesBWarrantExpiringMay2027Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fc2e0c481974966a604c4a0215f7915_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:WarrantExpiringJanuary2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c1edd8e75c4550a03bf3e5051b199f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:WarrantExpiringSeptember2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c88b89cfb1647cd9d8bbb0a82bfcbc0_D20220519-20220519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesAWarrantsIssuedNovember2019Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-19</xbrli:startDate><xbrli:endDate>2022-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6251c05d326e4a9386219cd404a47d8a_D20220519-20220519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesAWarrantsIssuedDecember2017Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-19</xbrli:startDate><xbrli:endDate>2022-05-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07391aec75484ead8a61a6df73afeff4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i027dffbf78374212835464d3640c101d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0ad4c8865ec4c419c5b12e819189c76_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i260c3b3f20bf4f4681bc4a91f421bbe5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2832ee80f63d460b8492d8bcc0b5909c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0a7f5e745594f2dbf695fb7330eae73_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic32cbf34fc774d82a6a93117e76c1b14_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic327f368a9714dc0a2557c36d8a5e3da_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77415003bed3430f96c1e0adf0960a62_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2014Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd09c1537caf432ab0e3feb9155a01fd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i30d73005a58b4b22bf596e5a6abcca81_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if44b5193639a4f39b9593f64ec0b5853_D20210101-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9337506ea45848f1ab5679c11ff6aeea_D20210524-20210524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-24</xbrli:startDate><xbrli:endDate>2021-05-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b5c8104784a476492d5c745748a9745_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">yten:EmployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e337683c876475fbd6132b78b10119d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">yten:EmployeeAndDirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7683e5fee18c49a889b650734cfda999_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cc722f803314436a9c7c6caad2c8578_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadffb97e562c40ab9d5c4ca96b69c01a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81e4afc9063e482c8ea9bcff80c5bc79_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i115962649b404c9dad81db13df9ab327_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea7a2db667b9494c88b89ceeae9fafd9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie879a42901184b87a0029ddae2ba967e_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i119b882f71fe4a1082a3446bb15acbec_D20160101-20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i91e719d6dc084b8eb65833dd9f3d826e_I20191130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1669a5dd6ba54e94a94243d28e96c30c_D20161001-20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-10-01</xbrli:startDate><xbrli:endDate>2016-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9567ed174d68444dbf277b216ec8dcbb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id253aebbd61b4ee5a2318fd621623370_I20161031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">yten:CJCheilJedangCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedea1c8eb9444c6bea044622e488712_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:A410DowneyRoadAnd110GymnasiumPlaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e3f12dc3c148188c3b9a72081bb52a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71199acae9bc42239b72a1e18ce921fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9695ea37c9b341f2b0c620593bc7e168_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51098c3d74424991ace97eec86e2af91_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9843252c42d74447b91e88027db863ce_I20210226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51fd40cc2e254ece8789b8a8cd184ae8_D20170915-20170915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-09-15</xbrli:startDate><xbrli:endDate>2017-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65d3bb815986434388d03c0031f92093_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i700069e2fa634d1189b702db4b2c4eaa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6dc4ad390504593af4a7847e1ed85a6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f30c8f754de4a0f87018176ab9201bb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib809cccb2c294bd5843cf6785af9651f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id239db0d46964587ab76bc81df6f1ee4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8ed864be1c04cbca5272439e51ebf52_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3432e814c7b446a9bbe66a61846e2cde_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bd17402842448b7b9f9be98aca430e4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bc505e998514513905d81d0f376c451_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d4d7b016184bf3ab8c1d7180e6719f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3182629b0bab4d00be6bc9a3a8bd468a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09214b6a6ff746c2aa27601f31735dc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629b7830786c41b6bda1598354d3a5b4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8415c21be2b24e3d8bf42091cf9a338e_I20021231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2002-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i201dadb72c254a7c8f4f4491ef87c2ed_I20230124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-01-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-24</xbrli:startDate><xbrli:endDate>2023-03-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb4322ccfe3e4eb29b27ffe467b4d129_I20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e7eed8de0164fab84eedcfec07eed0a_I20230314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001121702</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-14</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ic02604fb0219453aa54b246df7a39126_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40Use these links to rapidly review the document</span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">TABLE OF CONTENTS</a></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_79">Index to Consolidated Financial Statements</a></span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE1_c154591d-c113-434a-b35d-fe02f5b2e851">10-K</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:483.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZWRhNGU4ZTEwNTEwNDAxMGJiZGFlYjBjNWRlYWVlYmMvdGFibGVyYW5nZTplZGE0ZThlMTA1MTA0MDEwYmJkYWViMGM1ZGVhZWViY18wLTAtMS0xLTU1Njc2_3b63c279-5103-4794-92f5-95611f86f0be">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yMjc_91570595-e4b7-451a-8615-3a9ec744f132"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yMjc_a1a14724-8109-4aa7-a53b-e83323ac1060">December&#160;31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:504.00pt"><tr><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:483.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6NzcxNDNiYTUzY2RkNGI4ZWJjYjk0ZjhiNGU3MGQxOGEvdGFibGVyYW5nZTo3NzE0M2JhNTNjZGQ0YjhlYmNiOTRmOGI0ZTcwZDE4YV8wLTAtMS0xLTU1Njc2_089e2b4d-bb3f-4a83-bce5-240ae49efc3f">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF&#160;1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number&#160;<ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEx_147f0d75-cb17-45b6-9496-a1e0186aacc7">001-33133</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIw_f104e373-3bc3-44ab-b3f0-16bba2a9c479">YIELD10 BIOSCIENCE,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:354.00pt"><tr><td style="width:1.0pt"></td><td style="width:171.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:175.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8wLTAtMS0xLTU1Njc2L3RleHRyZWdpb246NGQ4OTA5OGExNzZkNDE2MmJhYTRjZTNmMzQ5ODgwZmNfNA_d9ed6812-dd34-44f8-a7c8-ef96a06ebe59">Delaware</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8wLTItMS0xLTU1Njc2L3RleHRyZWdpb246NjhhYzUxMTAwYWE4NDZkNThhOTU5OTIxMjI5MDA0ODJfNQ_41548169-5ec5-41d9-8e92-755241c83b16">04-3158289</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfNQ_59c35c4f-1ece-4b06-9de8-321a440678f3">19 Presidential Way</ix:nonNumeric>, <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfOQ_c397f76a-6064-4497-8e56-527dc611bc34">Woburn</ix:nonNumeric>, <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfMTM_fff5b77c-d7f5-45bc-a65a-dae39624334b">MA</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTItMS0xLTU1Njc2L3RleHRyZWdpb246MjAzMzIwMzhmOWVhNDQyNDk5OTUzMjQ4ZTAwMDUwNDlfNQ_109e402a-e8f7-426e-8150-7d0b48651ab3">01801</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant's telephone number, including area code): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIx_3f07ede2-3320-4df0-b6a2-ed26eb9e3cfe">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE3_04113618-072e-4e54-9989-8a2a1e682474">583-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________________________________</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:495.75pt"><tr><td style="width:1.0pt"></td><td style="width:147.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:144.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTAtMS0xLTU1Njc2_013b75f2-bd73-42cd-aa3c-2c742041fb60">Common Stock</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTEtMS0xLTU1Njc2_c91c2380-80cd-4b76-b845-1e5cbe0cb441">YTEN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTItMS0xLTU1Njc2L3RleHRyZWdpb246NzdiZDBiZjhjYmVlNDA5NWFkMmYxZmI0MmE0ZjVjNzJfOA_8c41c040-d7e4-414b-b641-0d01c52212af">Nasdaq</ix:nonNumeric> Capital Market</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEy_c74d051f-0e6c-4995-bd14-def5d871c4c0">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act. Yes&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEz_41e64033-7718-48c7-ac32-370e88c7d1fd">No</ix:nonNumeric>&#160;&#9746;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE2_c328d597-0f22-4f36-9844-b40b3add2c69">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIy_1ba82fa6-df23-4b63-810b-0a1d11858bfe">Yes</ix:nonNumeric>&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#9744;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act:</span></div><div style="margin-bottom:3pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:354.00pt"><tr><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:16.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:157.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:12.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8xLTAtMS0xLTU1Njc2_a42ac868-6603-497e-8fa1-2c15858db13a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8xLTMtMS0xLTU1Njc2_dc3dc77b-87b6-45f3-8af6-bc8a03edad75">&#9746;</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8yLTMtMS0xLTU1Njc2_19a7b9e7-7034-4ebe-9a22-ac404fdf9d2f">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE5_4ed29849-30e6-4d2c-8ba1-ef0b1a9d6234">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). Yes&#160;&#9744;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE0_8ba5202a-37f1-4135-880d-12bfe47552e6">&#253;</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold on the Nasdaq Capital Market on June&#160;30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="iac86a3d09d164b4a93df64e6e398cda3_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yODI5_c419ae38-6870-4341-881d-1f942352b818">8,867,945</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares outstanding of the registrant's common stock as of March&#160;13, 2023 was <ix:nonFraction unitRef="shares" contextRef="i0ec0531db504460d878e8a5b16adba16_I20230313" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yOTEz_e3b88f0f-be69-47f8-a9ac-2c17303e3cf2">5,074,085</ix:nonFraction>.</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEw_79dd8781-4ae3-4ac4-9a4b-97e315c89585" escape="true"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to General Instruction G to Form 10-K, the information required by Part III, Items 10, 11, 12, 13 and 14 is incorporated herein by reference from the Company's proxy statement for the Annual Meeting of Stockholders to be held on May 25, 2023, which is expected to be filed not later than 120 days after the fiscal year end covered by this Form 10-K.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Year Ended December&#160;31, 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.167%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.895%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_13">PART I.</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_16">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_16">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_19">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_19">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_22">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_22">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_25">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_25">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_28">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_28">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_31">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_31">46</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_1382">Information about Our Directors and Officers</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_1382">46</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_34">PART II.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_37">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_37">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_37">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_40">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_40">Reserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_40">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_43">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_43">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_43">48</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_46">Item 7A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_46">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_46">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_49">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_49">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_49">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_52">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_52">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_52">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_55">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_55">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_55">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_58">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_58">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_58">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_61">Item 9C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_61">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_58">56</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_34">PART III.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_64">56</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_67">PART IV.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_70">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_70">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_70">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_73">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_73">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_73">60</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_76">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_76">60</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K contains "forward-looking statements" within the meaning of 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act").  These statements relate to our future plans, objectives, expectations and intentions and may be identified by words such as "may," "will," "should," "expects," "plans," "anticipate," "intends," "target," "projects," "contemplates," "believe," "estimates," "predicts," "potential," and "continue," or similar words.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that our expectations are based on reasonable assumptions within the limits of our knowledge of our business and operations, the forward-looking statements contained in this document are neither promises nor guarantees.  Our business is subject to significant risks and uncertainties and there can be no assurance that our actual results will not differ materially from our expectations.  These forward-looking statements include, but are not limited to, statements concerning our business plans and strategies; expected future financial results and cash requirements; plans for obtaining additional funding; plans and expectations that depend on our ability to continue as a going concern; and plans for development and commercialization of our crop yield traits, technologies and intellectual property.  Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated including, without limitation, risks related to our limited cash resources, uncertainty about our ability to secure additional funding, risks related to the execution of our business plans and strategies, risks associated with the protection and enforcement of our intellectual property rights, as well as other risks and uncertainties set forth below under the caption "Risk Factors" in Part&#160;I, Item&#160;1A, of this report.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements and risk factors presented in this document are made only as of the date hereof and we do not intend to update any of these risk factors or to publicly announce the results of any revisions to any of our forward-looking statements other than as required under the federal securities laws.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Annual Report on Form&#160;10-K to "Yield10 Bioscience," "Yield10," "we," "our," "us," "our company" or "the company" refer to Yield10 Bioscience,&#160;Inc., a Delaware corporation and its subsidiaries.</span></div><div id="ic02604fb0219453aa54b246df7a39126_13"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="ic02604fb0219453aa54b246df7a39126_16"></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(With the exception of stock prices and earnings per share disclosures, all dollar amounts throughout this report are shown in thousands unless otherwise indicated.)</span></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;BUSINESS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company focused on the large-scale production of low carbon sustainable products from processing Camelina seed using the oilseed Camelina sativa ("Camelina") as a platform crop. These seed products include:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina oil for use as a low carbon biofuel feedstock</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Omega-3 oils for nutrition </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PHA Bioplastics for biodegradable zero waste packaging solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The co-product from producing these seed products is Camelina meal which has a protein content of over 40% and is currently approved for use in a range of animal feed rations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from our development pipeline which are being designed to offer improved on-farm performance that we anticipate will lead to increased acreage adoption and seed product revenue.  Yield10 is headquartered in Woburn, Massachusetts and has a Canadian subsidiary, Yield10 Oilseeds Inc., located in Saskatoon, Saskatchewan, Canada.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina, an annual oilseed plant in the mustard family, was selected as our platform crop based on its unique attributes, including its excellent agronomic traits such as low water and fertilizer input, drought resistance and short life cycle, making it suitable as a rotation crop within the U.S. Northwest and regions of Canada, as well as a relay or cover crop </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with corn and soybean in the U.S. Midwest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate there is the potential for over 30 million acres of Camelina production in North America.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina, is in the same plant family as canola and naturally produces a relatively abundant harvest of oil-containing protein-rich seeds.  Camelina is highly amenable to advanced genetic engineering and genome-editing technologies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Over the last twelve years, we have been developing improved Camelina seed varieties through identification and deployment of our gene trait discoveries followed by performance evaluation in field tests.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our new seed product traits include the PHA bioplastic trait developed by us and the omega-3 (EPA, DHA+EPA) oil traits on which we secured exclusive rights to a commercial license option in 2020.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital light business model is based on contracting with growers to produce Camelina grain using our proprietary Camelina seed.  Yield10 will have the exclusive right to purchase the harvested grain from these growers for downstream processing to separate and sell the seed products into the different markets.  Our commercial launch plan is to leverage the growing global demand for biofuels to decarbonize the transportation sector, and in particular, the renewable diesel ("RD") and sustainable aviation fuel ("SAF") markets.  We recognized early on that we could play an important role in the biofuel value chain through the use of our advanced Camelina platform to address a key industry bottleneck; the significant shortfall in the supply of low carbon intensity feedstock oil.  The establishment of downstream value chain partnerships represents a critical step towards enabling Yield10 to scale this business.  We expect to build the operating foundation of our products business by securing offtake agreements with downstream oilseed processing/biofuel partners.  Sources of revenue from our first Camelina seed product will be based on the financial terms negotiated with these biofuel offtake partners.  Here our goal is to link the base oil price for other commodity seed oils, such as soybean, and share in the economic value of the lower carbon intensity score of the Camelina oil.  Initial revenue growth from this business will scale up based on increasing the number of acres of our Camelina planted during each growing season.  Feedback from our grower outreach has identified weed control and soil residues from the herbicides used on prior crop as key limitations to the adoption of existing Camelina varieties.  To achieve our revenue targets, improved Camelina varieties with new genetic traits are being accelerated through our development pipeline in order to offer farmers weed control and a seamless integration into their current crop rotations.  We expect to be able to substantiate increasing revenue for our growers by introducing proprietary performance traits from the Yield10 pipeline, including higher seed oil content and seed yield traits that can increase the per acre harvest value of the Camelina grain.  Improved grower income is expected to lead to increasing numbers of growers under contract, increased acres planted and higher product revenue and income for the Company. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advancements in Camelina varieties, seed operations capabilities, grower network and supply chain developed for biofuels and underwritten by biofuel partnerships will position Yield10 for the subsequent launch of its second Camelina seed product omega-3 oils and in the future, PHA bioplastics.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a first stage in our initial Camelina commercialization, during the third quarter of 2022, we engaged growers in contracts for the production of Camelina grain and Camelina seed having a total acreage of approximately 1,000 acres.  These growers are located in the U.S. and Canada with each grower planting between 30 and 160 acres of our WDH2 (winter, cold tolerant) and WDH3 (winter, early maturing) seed varieties, with harvest expected to occur in the summer of 2023.  We intend to use the seed harvest for toll crushing and further seed production that will provide us with seed inventory for future grower contracts during 2023 and beyond.  Also, during 2022, we contracted with other growers to plant our E3902 (spring, high oil yield), WDH2 (winter, increased cold tolerance) and WDH3 (winter, early flowering) Camelina plant varieties to produce commercial planting seed. This activity is an essential part of our business model to produce commercial seed inventory for future grower contracts.  We expect future grower contracts to cover Camelina grain production for large-scale grain processing to supply low-carbon intensity feedstock oil for the biofuel market and high-protein meal for the animal feed market.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently pursuing the development of elite Camelina germplasm exhibiting herbicide tolerance, disease resistance and other traits that we believe in the near future, will form improved elite Camelina varieties for the biofuel market and will later be combined with the new seed product traits in development to expand our markets.  We ultimately expect to have three types of elite Camelina seed varieties in contracted production to address our product markets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the market opportunity for biofuel feedstocks from our elite Camelina varieties, as well as our other proprietary seed products in development, including performance traits for use in other crops, is significant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are targeting uses for our Camelina seed products in commercial applications such as: low-carbon feedstock oils for renewable diesel and sustainable aviation fuel, PHA bioplastics, and omega-3 oils for aquaculture and nutrition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, we signed a nonbinding memorandum of understanding ("MOU") with Mitsubishi Corporation to evaluate the establishment of a partnership to supply, offtake and market Camelina as a low-carbon feedstock oil for biofuel, and in February 2023, we signed another nonbinding MOU with American Airlines to collaborate in the development of the value chain for Camelina </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as a low-carbon feedstock oil for sustainable aviation fuel.  We believe performance traits from our gene discovery and development platform (the "Trait Factory") and value-added product strategy will provide strong differentiation for Yield10's elite Camelina seed varieties, making them preferred by growers to address large product market opportunities as illustrated below. These traits will also be made available to leading seed companies for use in other crops to create licensing revenue.</span></div><div><img src="yten-20221231_g1.jpg" alt="yten-20221231_g1.jpg" style="height:180px;margin-bottom:5pt;vertical-align:text-bottom;width:666px"/></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:12pt">Internal Company estimates of 2030 product revenue potential.</span></div><div style="margin-bottom:9pt;margin-top:9pt;padding-left:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Camelina platform and each of our seed product targets are well-aligned with global trends in reducing carbon emissions and improving sustainability, including the need for:</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Producing low-carbon intensity biofuel feedstock oil for renewable diesel and aviation biofuel.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing the production of cover crops to reduce the climate change impact from agriculture.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Producing PHA bioplastics to enable single use food service items and packaging with zero waste.</span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Increasing global food security by:</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">producing land-based omega-3 (EPA, DHA+EPA) fatty acid oils for use in aquaculture and nutraceuticals;</span></div><div style="margin-bottom:6pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">increasing high quality protein production from Camelina seed; and</span></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">developing performance traits to increase yield and/or seed oil per acre for major food crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a pipeline of more than 10 novel yield and/or seed oil content performance traits currently in research and development.  Today, we also have research agreements in place for a number of our yield trait gene candidates, including agreements with GDM Seeds (&#8220;GDM&#8221;) and JR Simplot Company (&#8220;Simplot&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies are currently progressing the development of our traits in soybean and potato.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to support these licensees as they work to generate proof points using our traits in their crops of interest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to find partners for our traits in canola, corn and other crops as we generate additional data and new trait leads using our Trait Factory.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building an intellectual property portfolio around our crop technologies and traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we own or hold exclusive rights to 19 patent families, including 15 issued patents and 41 pending patent applications, related to advanced technologies for increasing crop performance and composition traits in oils and PHA bioplastics, in the United States and throughout the world.  As part of our agreement with Rothamsted Research Limited ("Rothamsted"), we have an exclusive option to license two patent families, including six issued patents and four pending applications, including both the original patent filing for the production of EPA, DHA+EPA oil in Camelina and for an improvement patent filed after the agreement was signed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Yield10 and Rothamsted agreed to extend the exclusive option and license agreement until December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Unmet Need: Global Food Supply, Reducing Carbon Emissions and Producing Sustainable Products</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to a number of studies, including a report entitled &#8220;The Future of Food: Complexities and Compromises,&#8221; published December 6, 2020, by Morgan Stanley, the world's agri-food system needs to transform in order to produce 50% more food, eliminate malnutrition and cut 13 gigatons of greenhouse gas emissions by the year 2050. Agriculture will also need to become a source of low-carbon feedstocks for fuels, chemicals and plastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This will result in a significant increase </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in demand for feed grains, seed oils, protein, and farmed seafood with an increasing emphasis on sustainable growth metrics and climate change, as highlighted in the Morgan Stanley report.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Incentives to Reduce Carbon Emissions:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Converting biomass feedstocks to biofuels is an environmentally friendly process.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When renewable biodiesel is used instead of traditional petroleum diesel, it helps reduce carbon emissions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina oil has a particular advantage because of its low carbon footprint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory environment for carbon emissions is rapidly changing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, there are existing regulatory incentives from regional greenhouse gas reduction mandates established for fuel producers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This includes California's Low Carbon Fuel Standards market, which measures the specific carbon index, or CI, of every type of fuel, assigns a credit/deficit for every gallon of fuel produced based on its CI, and requires all fuel producers selling into California to purchase enough credits to keep their portfolio CI score below an established baseline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biofuel manufacturers are highly motivated to utilize compatible feedstocks with a low-carbon footprint in order to meet the regulatory standards to lower carbon emissions.  As a benchmark, petroleum diesel has a reported CI of 100, soybean oil has a CI of 56, and in the case of Camelina oil, Sustainable Oils, a subsidiary of Global Clean Energy Holdings, Inc., recently reported a CI of 23.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Renewable Diesel and Sustainable Aviation Fuel:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As part of the energy transition, a substantial increase in renewable diesel capacity in the United States and Canada is currently underway, with proposed and funded renewable diesel facilities having a total capacity of over 6 billion gallons of biofuels per year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewable diesel expansion has surged due to its low carbon footprint, federal and local subsidies, and its ability to be used as a drop-in replacement for petroleum diesel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewable diesel feedstock is supplied primarily from used cooking oil, animal fats (e.g., tallow), and vegetable oil, with the former two feedstock sources in short supply due to limited production capacity. Yield10 therefore expects the increase in demand for renewable diesel feedstock over the next few years will be filled by vegetable oils, which have a current global production and consumption demand of 50 billion gallons per year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a third of vegetable oils produced globally today are palm oils, which do not qualify for many biofuels subsidies because of their high carbon footprint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous studies and regulatory approvals have shown Camelina oil&#8217;s usefulness as a low-carbon feedstock oil for renewable diesel and sustainable aviation fuel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Residual Camelina protein meal remaining after oil extraction using cold crushing has been approved by regulatory authorities for use in animal feed applications in the U.S. and Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina&#8217;s low-carbon footprint, and ability to be grown as a cover crop on otherwise fallow land, makes it an attractive choice to fill the renewable diesel feedstock supply gap.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the assumption of 60-100 gallons of Camelina oil per acre, 1 billion gallons of feedstock oil would require 10 to 15 million acres of Camelina production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we later launch our elite PHA Camelina product, we estimate Camelina acreage could more than double.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For comparison purposes, canola is currently grown on approximately 20 million acres per year in Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have described the case for renewable diesel, feedstock demand for biodiesel and renewable aviation biofuel may also increase demand for Camelina oil.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cover Crops:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To meet growing demand for oils and protein, and to mitigate the negative environmental impacts of current farming practices, particularly in the corn belt, the development of cash cover crops or relay crops is another means to increase land productivity and address growing demand.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cover or relay crops are planted between harvest and sowing of major commodities, such as soybean, in effect increasing the number of harvests per growing season.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 believes that Camelina, with its short growing season, has considerable potential to be used as a cover crop to reduce soil erosion, improve soil quality, and control diseases and pests and nutrient run-off from land that is used for row crop production.  Camelina can also be used in crop rotation with other crops such as wheat, cereals, corn and soybean.  Third party estimates indicate that Camelina has up to 30 million acres of potential as a cover crop in the United States midwest, and we believe that the product value-add from Yield10&#8217;s proprietary products will be a key differentiator for farmers making planting decisions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to evaluate the CI of Camelina oil from cover cropping where we anticipate there may be further CI improvements from the positive environmental impact of cover cropping in general, although this remains to be demonstrated.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PHA Bioplastic, Alternatives to Plastic:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Global plastic production today is estimated at 380 million tonnes per year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The largest market for this plastic is for packaging materials and food service items, which accounts for nearly half of all plastic waste generated globally, most of which is never recycled or incinerated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, there is growing pressure from consumers, major brand owners and the financial sector to develop alternative materials and alternative end-of life solutions for plastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This has resulted in additional capital investment to produce compostable materials like polylactic acid ("PLA") and fermentation based PHA bioplastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHA bioplastics are natural microbial high molecular weight polymeric storage </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">polymers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The value chain from microbial production to plastic product manufacturing, performance in use and end of life based on natural biodegradation has already been validated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHAs can be recovered from the microbes which produce them, processed into standard plastic pellets and used in existing plastics processing equipment to make a range of food service items and packaging product forms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of PHAs based on fermentation technologies continues to receive considerable investment, even though this approach has very high capital investment and operating costs that will limit supply and market penetration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that in longer term, the direct production of PHA bioplastics in Camelina seed would represent a disruptive manufacturing technology for PHA bioplastics due to its significantly lower production costs and very large-scale potential.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This opportunity could provide significant additional economic returns for farmers and would justify large acreage adoption of elite PHA Camelina as a cover crop and would support broad adoption of PHA Camelina materials for large markets including water treatment and sustainable biodegradable plastics replacement applications.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PHA Bioplastic, Water Treatment: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In water treatment, the PHA biomaterial acts as a growth substrate and energy source for the denitrifying of bacteria, which convert nitrate, a primary cause of water pollution and algal growth, to nitrogen gas, which returns to the air.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This application is technically straight-forward, requiring only the production and shipment of PHA biomaterials in pellet form.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The model for this business is to supply the continuous replenishment of the PHA pellets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that this application is less demanding on the purity and quality of the PHA produced and represents a favorable technical path to initial commercialization for PHA Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This application may also serve as a market for PHA produced in the future for bioplastic applications, which do not meet the product specifications or ultimately as a way to generate value by &#8220;upcycling&#8221; post-consumer PHA bioplastic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 is in the early stages of developing the business model for this opportunity.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Omega-3 (EPA, DHA+EPA) Oils:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The aquaculture sector will play a major role in meeting the growing global demand for fish, an important high value protein source in human diets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sustainable land-based sources of key feed ingredients will need to be developed and adopted to support this demand.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This includes high value specialty ingredients, including in particular new sources of omega-3 oils to replace oil from stagnating supplies of ocean-harvested fish used in feed production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fish oil supplied from ocean-harvested fish is particularly important for farmed salmon.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Atlantic salmon aquaculture sector is expected to grow at 4% CAGR through 2026, reaching an annual harvest of over 3 million tonnes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of the salmon farming sector along with additional demand from new nutraceutical markets for direct human consumption are expected to exceed the world's sustainable supply.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, 4.7 million metric tonnes of fish feed was used globally for salmon aquafarming.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although it can vary by geographic location, during 1990 fish oil represented 24% of the contents making up fish feed.  This equates to 2,487 million pounds of oil (fish and other sources of  omega-3 rich oil) consumed annually in salmon feed production.  Some industry experts predict the demand for omega-3 will increase by more than 7% per year over the next 5 years.  The demand from salmon farming alone is expected to grow by approximately 4% per year going forward, according to the 2022 Salmon Farming Industry Handbook.  Fish oil is also the key raw material source for producing purified omega-3 fatty acids for the growing use of these omega-3 acids in the nutrition, nutraceutical and pharmaceutical markets.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">High Protein Meal: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a growing global demand for additional protein sources for animal feed and food applications. Camelina seed can be processed using existing oilseed processing facilities to extract the oil, and the residual meal that remains is a high-quality protein.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a dry basis, the meal contains approximately 30-35% protein with a good amino acid profile for animal feed applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina meal has been approved for use in some animal feed applications, and we expect that with additional accelerated breeding using genome editing, the meal quality can be further enhanced to further improve its feed value and expand this application.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Trait Development and Licensing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Using our GRAIN system, we have identified and are evaluating novel yield trait genes to improve the field performance of Camelina that will be used in our products business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These traits will be made available to leading seed companies for use in other crops to create licensing revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Strategy</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In defining our business strategy, it is important to understand that Yield10 is not a seed company in the traditional sense of developing new seed varieties solely for sale to growers.  Our goals are to 1) commercialize a series of seed products </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on developing proprietary varieties of Camelina seed for contract production, the output of which will enable the supply chain for our seed products, and 2) license our yield and seed oil content gene traits to major seed companies for other crops including corn, soybean and canola.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our Camelina products will address key sustainability drivers, we believe they should reward farmers and increase profitability across the value chain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe that any sustainability benefits will provide a marketing advantage for our future customers along with a potential upside from any available government credits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to continue to seek non-dilutive financing opportunities from government grants and funded partnerships.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our Trait Factory may enable multiple commercial opportunities going forward, we will maintain our capital efficient approach, focusing internal resources on developing elite varieties of Camelina germplasm for biofuel feedstock, omega-3 oils and PHA bioplastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have relied primarily on Rothamsted to continue to develop and improve the omega-3 oil trait for Camelina, during 2023 we expect to become more directly involved in establishing the path to commercialization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our focus on establishing and growing our Camelina seed products business, we plan to rely on granting research licenses to interested seed companies for the development of our traits in the major food crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Using this approach, we are developing the following three potential revenue streams:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina grain production to be sold into the biofuel oil markets; including the low carbon renewable diesel feedstock and the sustainable aviation fuel markets; </span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Omega-3 Camelina grain production for high EPA omega-3 oil for nutrition and pharmaceutical markets; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">R&amp;D revenue from government grants and/or partners.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Target Crop:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Oilseed Camelina</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina was grown extensively in Europe, Russia and Central Asia since medieval times for oil and protein but was replaced by cultivation of rapeseed during the 1940s. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina has the potential to replicate the development of modern canola from rapeseed on an accelerated timeline based on modern biotechnologies, both components of our Trait Factory.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Starting in the 1960s, the breeding of canola from rapeseed to the first generation was not completed until 1982, and was based on improving the oil for human consumption (low euricic acid in oil) and improving the protein meal (low glucosinolates) for use in animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This was followed by incorporating herbicide tolerance and hybrid technologies in the 1990s.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, canola is grown on 20 million acres in Canada and is estimated to generate around $25 billion for the Canadian economy, according to the Canola Council of Canada.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina has not been subject to intensive plant breeding efforts or crop production improvements, so the full potential of this crop has not yet been achieved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initial interest in using Camelina oil in biofuels resulted in additional investment in the development of the crop in North America.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This work demonstrated that Camelina has several beneficial attributes;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t is amenable to production practices used for canola, grows on marginal lands, has enhanced drought and cold tolerance, demonstrates early maturation and requires fewer inputs than other oilseed crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina is also naturally resistant to diseases that impact canola and its fast growing cycle makes this crop suitable for spring and winter planting in the Northwest U.S. and into Canada as an alternative rotation crop where the relatively overall short growing season would make double cropping very challenging. Further south, the longer overall growing season in the upper mid-west together with Camelina&#8217;s short growing season makes it an attractive winter oilseed for relay or cover cropping in corn and soybean rotations. Although the double cropping scenario is where we see the greatest long-term potential for Camelina, our current varieties and capabilities are better positioned for the initial commercial launch geography in the Northwest U.S. and western Canada.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our vision is to complete development of Camelina lines containing herbicide tolerance ("HT") and downy mildew resistance ("DMR") traits, and to combine these new lines with our proprietary performance traits to increase Camelina seed oil content and yield for the existing oil and protein meal markets. We recognized early on the need to develop Camelina lines optimized for seamless integration into both crop and chemical rotations in our target geographies. For the Northwest U.S. and Canada, the herbicide tolerance traits selected for accelerated development were chosen to address critical farmer issues in our launch geography. The first requirement is for broadleaf and grassy weed control. An ideal herbicide trait package for growers would have the following key elements:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Control of grassy weeds (GW-HT)</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Control of broadleaf weeds (BW-HT)</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Tolerance to soil residues of Group 2 herbicides of which there are two different types: sulfonylureas (SU-HT) and imidazolonones (IMI-HT) when combined SU/IMI-HT.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina is already naturally tolerant to the grass herbicide Clethodin, so there is no need to develop traits in Camelina to provide tolerance to the chemical.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The BW-HT trait offers farmers an important tool for fighting broadleaf weeds that, if left uncontrolled, can reduce crop yields significantly and increase weed pressure on that land for subsequent crop plantings.  Building on encouraging field trial results generated in the spring of 2022, we conducted contra-season field tests of our lead BW-HT trait in Camelina which also demonstrated herbicide tolerance.  To speed up development we also selected potential commercial Camelina BW-HT lines displaying strong tolerance to the herbicide with no impact on seed yield for seed scale-up activities to produce seed for larger field tests planned for the spring of 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to have elite HT Camelina varieties entering commercial production in the next few years followed shortly thereafter by triple stacked commercial BW-HT/SU/IMI-HT Camelina varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SU-HT and IMI-HT are being developed to enable Camelina to be tolerant to Class 2 herbicides commonly used in that region for certain cereals and other crops.  These weed control chemistries persist for longer in the soil which results in plant back restrictions for the next crop in the rotation and in some cases, this can be up to two years.  Camelina is very sensitive to these herbicide residues which can prevent seed emergence and severely impair seed yields.  Based on discussions with farmers we know the stacked HT/SU/IMI-HT trait package will be an important enabler for large acre adoption in this region.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For these reasons we are advancing the development of Camelina lines with stacked HT/SU/IMI-HT traits.  These traits and the availability of Clethodin for grassy weed control will provide Yield10 with an ideal herbicide package for the chosen commercial launch region.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Greenhouse studies have already identified lead candidate lines with the stacked herbicide requirements and we are in the planning process to enable initial field trials in 2023. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Downy mildew is a common name for a widespread plant disease (pathogen) that if left uncontrolled, can generate significant losses in crop yields.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near-term there are fungicide treatments that can control downy mildew disease.  However, this approach adds grower cost so we are also developing genetic solutions using breeding,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genetic modification and genome-editing to incorporate DMR traits into the plants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of our elite Camelina lines with HT and DMR traits is an important criteria needed for broad-based commercial acceptance of our Camelina plant varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, we believe optimizing the production of the PHA bioplastics in Camelina will enable large acreage production, initially in spring varieties, and over time, in winter varieties for use as a cash cover crop.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some estimates from the United States Department of Agriculture ("USDA") indicate a potential of up to 30 million acres of Camelina in the upper corn belt of the U.S., which would potentially make PHA Camelina the third largest crop in the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with this development of PHA Camelina, we plan to develop the high value omega-3 regulated trait based on our November 2020 agreement with Rothamsted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This omega-3 Camelina is at a high technology readiness level, and we are now progressing in early commercialization activities for this program.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To summarize, Camelina is an attractive choice of crop for the following reasons:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina, as an underdeveloped crop, has high technology upside potential to improve agronomics (including herbicide tolerance), seed yield, and seed value.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">There is a growing demand for crops that diversify the crop landscape, have a lower environmental footprint and have the potential to produce high value secondary products, opening new opportunities for farmers.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina is readily segregated from the major row crops and readily engineered using genetic engineering tools, making it an ideal platform for producing novel seed products.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Yield10 has demonstrated that Camelina can be readily engineered to incorporate well-proven herbicide trait technologies with the potential to take advantage of the more favorable regulatory systems in place in the U.S. under the SECURE rule and under development in Canada.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina has been engineered to produce high levels of omega-3 (EPA and DHA+EPA) fatty acids as a drop-in replacement oil for fish oil in aquafeed markets as well as for use in nutraceutical and pharmaceutical applications.</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina has potential to become a high value crop with very large non-traditional markets in water treatment and plastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We first demonstrated proof-of-concept for PHA bioplastics in Camelina in our 2020 field tests, and the result was confirmed in our 2021 and 2022 field tests.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This ability to produce PHA in Camelina is providing us with the potential to link a new high value Camelina crop with very large non-traditional markets in water treatment and plastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal analysis indicates this could drive very large acreage adoption.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The higher per acre value enabled by Yield10's agronomic and product traits could make Yield10 the preferred production contractor for growers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Production of Camelina seed in double cropping situations results in a favorable CI for the oil, making it an attractive feedstock for renewable diesel in geographies such as California where there are low carbon fuel standards in place and the economic value of carbon savings can be substantial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Low-carbon fuel standards are being established in other regions of the U.S., Canada and the E.U., which is increasing demand for renewable diesel feedstocks.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Camelina Seed Products Business </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term vision is to develop and commercialize three types of elite Camelina varieties (Elite Camelina, Elite PHA Camelina, and Elite Omega-3 Camelina) as large acreage cover crops that will increase farm revenue and support the production of low carbon sustainable seed products with the additional positive environmental impact of reducing nutrient pollution from fertilizer use and increasing soil carbon content.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">develop proprietary elite Camelina varieties offering superior returns to farmers and increased seed product revenue and margins to Yield10,</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">contract production of Camelina grain with farmers for processing into seed products, and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">enter into offtake agreements for the Camelina grain products in each market segment.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To achieve this, Yield10 has been developing proprietary Camelina seed lines which are being progressed to elite Camelina variety status and ultimately to product commercialization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gene traits currently in our development pipeline fall into three categories:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">input traits including traits for HT and DMR,</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">performance traits from our GRAIN platform including traits to increase seed oil content and seed yield, and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">new seed product traits including PHA bioplastics and omega-3 (EPA, DHA+EPA) oil.</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to launch the new Camelina varieties incorporating these traits in the sequence illustrated below with the E3902/WD-HT Camelina being closest to commercial launch following the completion of two successful seasons of field trials.  The trait demonstrated excellent tolerance to the herbicide which we plan to use for commercial production with no impairment of seed yield.  The lead lines are now in seed scale up phase while our application for non-regulated status using the RSR process is pending with USDA-APHIS.  In addition, we are progressing discussions with the herbicide producers to have Camelina added to their labels, an essential step towards enabling growers to use the herbicide with Yield10's new varieties. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spring E3902/WD-HT varieties will be closely followed by winter WD-HT lines and then by lines containing stacked WD/IMI/SU-HT to enable broadleaf weed control and tolerance to soil residues of previously used herbicides.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><img src="yten-20221231_g2.jpg" alt="yten-20221231_g2.jpg" style="height:263px;margin-bottom:5pt;vertical-align:text-bottom;width:659px"/></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our best Camelina lines currently progressing to elite variety status will be suitable for our initial commercial launch and the first tens of thousands of acres of contract production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These first Camelina seed varieties will be replaced over the next 2-4 years when the next generation varieties incorporating input traits, including herbicide tolerance and disease resistant genes, are available. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that successful implementation of the input traits will be important in order to achieve broad-based farmer adoption of our elite Camelina and to achieve expansion of production in the hundreds of thousands to millions of acres scale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Input traits currently progressing separately in our pipeline will eventually be combined, or &#8220;stacked,&#8221; into our highest performing elite Camelina varieties in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to have elite Camelina varieties enter commercial production in the next few years with stacked tolerance to three herbicides, stacked HT/SSU/IMI-HT traits and DMR.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This development process with sequential release of improved elite Camelina varieties is illustrated above using our E3902 spring line.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A similar process is being carried out in parallel for our lead winter Camelina lines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have begun progressing early commercialization of the business based on the current best Camelina lines and the first seed product launch will be to supply feedstock oil for the renewable fuel market with the residual protein meal going into animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently working on seed scale up of our non-regulated spring and winter varieties of Camelina to establish our products operating business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial team has outreach to growers underway to build a grower network and to execute production contracts albeit at small scale.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These activities are complemented by extensive business development outreach to seed processing facilities and prospective oil and protein meal offtake partners.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our plan is to execute the sequential launch of our products from our Camelina oilseed platform as follows:</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products Produced by Processing Camelina Grain from Yield10 Varieties</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biofuel feedstock oil:  Elite Camelina - stacked input traits and performance traits on current best varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In launching our Camelina products business, we plan to provide our seed to growers under contracts with Yield10, to use existing third-party oilseed processing assets through toll arrangements and to enter into offtake agreements with end users for the oil and protein meal to address current markets, including low-carbon feedstock oil for the biofuels and protein meal for animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technology team will continue to develop improved varieties of elite Camelina germplasm with herbicide tolerance, disease resistance, seed yield and oil content traits currently progressing through our trait pipeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elite Camelina varieties will serve current markets and represent a foundation for the future commercialization of our PHA bioplastic and omega-3 traits, which we will develop separately and introduce into the elite varieties by plant breeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to position Yield10 to execute on this plan, we harvested our first 50 acres of Camelina seed grown under contract in Montana in 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2021 and 2022, we conducted seed scale up activities with both spring and winter Camelina lines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During August 2022, we harvested 17 acres of winter Camelina seed grown under contract in Saskatoon that we have processed and provided to growers in the U.S. and Canada under contracts for the 2022/2023 winter season.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nutritional Products</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omega-3 (EPA, DHA+EPA):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elite Omega-3 Camelina - omega-3 trait.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omega-3 fatty acids are found in foods such as fish and plant oils (flaxseed, soybean, canola and Camelina oils).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three main omega-3 fatty acids are alpha-linolenic acid ("ALA"), eicosapentaenoic acid ("EPA"), and docosahexaenoic acid ("DHA").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALA is found primarily in plant oils and DHA and EPA are found in fish and other seafood.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Omega-3 fatty acids provide many health benefits, including preventing and managing heart disease.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Heart Association recommends that everyone eat fish at least twice a week, such as salmon that is high in omega-3 acids and/or adding fish oils supplements to their diets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of ocean wild caught fish containing omega-3 oil used in nutritional oils and aquafarming is declining due to overfishing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to launch a proprietary Camelina omega-3 seed product into the food and nutrition market based on the omega- 3 trait developed over the last 10 years by the Rothamsted Institute in the UK.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 signed an Exclusive Collaboration and Option Agreement for this technology with Rothamsted in November 2020.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Yield10 and Rothamsted agreed to extend this exclusive collaboration and option agreement until December 31, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rothamsted has progressed the omega-3 trait beyond the proof of concept stage with their completion of multiple field trials, oil production, and product validation in aquaculture feed and human nutrition studies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under its agreement with us, Rothamsted is responsible for making improvements and further optimization of this exciting trait at their facilities in the UK.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the current omega-3 trait is already at a sufficient technology readiness level to begin commercialization activities for the aquaculture and nutrition markets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 will continue its focus on developing elite Camelina varieties with herbicide tolerance, disease resistance, higher yield and oil content, with the intent to breed the Rothamsted omega-3 product trait into this germplasm in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near term, Yield10 is working on the business strategy for this technology to enable production of elite omega-3 Camelina in Canada as early as the 2025 spring planting season.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PHA bioplastic:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Elite PHA Camelina - PHA bioplastic trait.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second proprietary product we are developing as a sustainable replacement to petroleum-based products is the result of new technology for the large scale, low-cost production of natural biodegradable PHA bioplastic.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By genetically reprogramming our Elite Camelina to produce PHA bioplastic in the seed, the harvested seed can be processed to simultaneously produce three coproducts: feedstock oil, PHA bioplastic and protein meal for animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The typical costs for producing edible oils are a useful benchmark for the potential long-term cost structure for crop-based PHA bioplastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this scenario, crop-based PHAs could have a cost advantage over petroleum-based plastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We successfully field tested prototype PHA bioplastic trait Camelina lines during the 2020 and 2021 growing seasons.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the 2022 growing season, we planted our best prototype PHA Camelina line at acre-scale for seed process development and plastic prototyping, however, we recognize that this version of our PHA trait is at an early technology readiness level.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In parallel, we are developing the next generation versions of the PHA trait targeting 10% to 20% of total seed weight as PHA bioplastic and expect to achieve initial proof of concept for two PHA copolymer targets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that by producing PHA bioplastic in Camelina seed as a third seed product along with processing the seed to produce oil and protein meal, we can achieve a cost structure with the benefits of integrated economics that optimize revenue as each market fluctuates with customer demand.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Protein meal for animal feed:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina meal is a high-quality and high-protein meal that has been approved by the U.S. Food and Drug Administration ("FDA"), as well as by the Canadian Food Inspection Agency ("CFIA") for feed use in poultry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It has also been approved by the FDA for feed use in beef cattle and by the CFIA for feed use in salmon and trout.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cold-pressed Camelina meal, which is the residual coproduct remaining after removing most of the oil, has been extensively studied for use in animal feed and proven to be well-tolerated by livestock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The meal also provides substantial health benefits when used as an animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Camelina meal, as a coproduct of our Elite Camelina, Elite PHA Camelina and Elite Omega-3 Camelina plant varieties, may represent a significant additional source of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">R&amp;D Revenue from Government Grants and/or Partners</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 has historically sought and participated in government grants in collaboration with leading academic institutions to develop early crop innovations and to secure rights to intellectual property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently a participant in a grant from the Department of Energy with Michigan State University, which is currently our primary source of grant revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, $0.1 million remained to be earned under this sub-award.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our intention to continue this practice where grant opportunities are consistent with progressing our commercial goals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential sources of non-</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product revenue include funded partnerships or collaborations with companies interested in the use of our GRAIN platform to identify gene targets for traits in crops of commercial interest and potential partners or customers in the Camelina products value chain.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Camelina Grain Product Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In fall 2022, we signed growers' contracts with multiple growers for production at small scale ranging from 30 to 160 acres.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The harvest of this</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">grain production is expected to begin in the summer of 2023, at which time we anticipate that we will begin to recognize grain revenue in amounts scaled to the number of acres under contract.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future grain revenues will be based, among other things, on our ability to scale-up commercial seed production, engage with growers and seed retailers, and enter into offtake agreements with customers in the renewable diesel market.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our History</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a significant track record and expertise in the metabolic engineering (synthetic biology) of plants.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our predecessor company Metabolix, co-founded by our CEO, was a pioneer in synthetic biology for the development of advanced PHA bioplastics production and applications technology using engineered microbes and fermentation, and as a result developed deep experience across the PHA bioplastics value chain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Metabolix supported a crop science research program to produce PHA bioplastic in crops as a potential low-cost production system and it was this crop science activity that became the foundation of Yield10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, these efforts focused on producing the simplest member of the PHA family, known as PHB, which is a microbial carbon storage biopolymer, in high concentration within the seeds of oilseed crops or within the leaves of biomass crops such as switchgrass.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHA bioplastics are useful as biodegradable alternatives for petroleum-based plastics in many single use packaging and food service products.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Approach</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our GRAIN platform provides us with a unique approach for discovering novel yield trait genes and producing higher value sustainable products in Camelina.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have integrated advanced metabolic flux modeling capabilities with transcriptome network analysis to form the foundation of our Gene Ranking Artificial Intelligence Network ("GRAIN") big data mining gene discovery platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRAIN is the gene discovery tool in our trait gene development platform, which encompasses three components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRAIN target gene identification; modification of the target gene activity in Camelina using CRISPR genome-editing or traditional genetic engineering; and Camelina field testing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We refer to the integrated system as the Trait Factory, however, the GRAIN discovery tool is unique to Yield10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the case of crops, the levers to increase seed yield are the metabolic infrastructure through which carbon flows from photosynthesis to seed production and the gene regulators or transcription factors, which control various pathways of plant metabolism.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last 20 years, the agricultural sector has generated vast numbers of data points.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During this same period, however, there have been very few new crop traits produced.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRAIN is a next generation crop big data mining system based on over 30 years of advanced synthetic biology expertise and is protected by the Company as a trade secret.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The system efficiently mines big data sets and prioritizes actionable gene targets to improve crop productivity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have employed this approach to discover a range of potential yield trait genes and used the data from the traits generated in Camelina to create interest in our traits for major food crops through research license agreements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an example, our new oil content gene trait target C3020 was previously an uncharacterized gene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GRAIN was able to select this gene target out of tens of thousands of Camelina genes and we consider the experimental results achieved with C3020 Camelina as a good proof point for the value of this platform.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We believe Camelina has high potential to become a large acreage commercial crop for producing low-carbon biofuel feedstock oils, PHA bioplastics and nutritional oils including omega-3 (EPA, DHA+EPA) oils in North and South America.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of an evolution to sustainable energy, a substantial increase in renewable diesel capacity in the United States and Canada is currently underway, with proposed and funded renewable diesel facilities having a total capacity of over 6 billion gallons of biofuels per year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewable diesel expansion has surged due to its low-carbon footprint, federal and local subsidies to reduce carbon emissions, and its ability to be used as a drop-in replacement for petroleum diesel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Renewable </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diesel feedstock is supplied mainly from used cooking oil, animal fats (e.g., tallow), and vegetable oil, with the former two feedstock sources in short supply due to limited production capacity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 therefore expects to meet the demand of the increase in renewable diesel feedstock over the next few years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, a third of vegetable oils globally produced today are palm oils, which do not qualify for many biofuels subsidies because of their high carbon footprint.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous studies and regulatory approvals have shown Camelina oil&#8217;s usefulness as a low-carbon feedstock oil for renewable diesel and sustainable aviation fuel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Residual Camelina protein meal remaining after oil extraction is approved by regulatory authorities for use in animal feed applications in the U.S. and Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina&#8217;s low-carbon footprint and its ability to be grown as a cover crop on otherwise fallow land make it an attractive choice to fill the renewable diesel feedstock supply gap.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the assumption of 60 to 100 gallons of Camelina oil per acre, 1 billion gallons of feedstock oil would require 10 to 15 million acres of Camelina production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For comparison purposes, canola production is currently around 20 million acres per year in Canada.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina also has the potential to be a platform crop for the production of proprietary crop products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is proven to be amenable to genetic engineering through Yield10&#8217;s GRAIN platform, resulting in a number of oil and yield traits with demonstrated field trial success.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 has also demonstrated proof-of-concept PHA bioplastic production in Camelina, both in the greenhouse in 2019, and in successful field trials in 2020 and 2021 producing 6% PHA bioplastic in the seed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Yield10 also signed an Exclusive Collaboration and Option Agreement with Rothamsted for an advanced trait technology for the production of omega-3 (EPA, DHA+EPA) oils in Camelina.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our Camelina development capabilities, together with our yield and oil content trait improvements, enable a strong competitive advantage in building an attractive Camelina products business focused on low-carbon biofuels feedstock oils.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the long term, the potential for production of PHA biomaterials in Camelina could provide economic returns for farmers to justify very large acreage adoption.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHA biomaterials also have the potential to reduce the CI of feedstock oils from carbon savings derived through the replacement of petroleum plastics and the low-cost production of these products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHA biomaterials with the right cost structure have applications in very large markets not currently served by agriculture, including water treatment and biodegradable bioplastic applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe crop-based production will enable broad-based global adoption of these materials.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have assembled a pipeline of crop performance traits for development that are applicable to both Camelina and major commercial crops and have established research agreements with major seed companies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unique approach to crop yield or seed oil content trait discovery utilizing our GRAIN platform, which integrates advanced metabolic engineering concepts to address critical bottlenecks in carbon metabolism, has enabled us to discover a series of yield genes with potential use for producing step-change improvements in crop yield.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our research and early development efforts we have identified and begun characterizing our C3000 and C4000 series of traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To initially characterize the potential of yield or seed oil content trait genes, we test our trait candidates using our Camelina platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our objective is to identify novel yield traits that act at a fundamental level in crop metabolism to provide the potential for broad deployment of our traits across multiple crop types.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following our work with these trait genes in Camelina, we seek to enter into license agreements or form collaborations with major agricultural companies so they can incorporate our novel yield traits into their seed products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We believe our business model will allow us to develop our Camelina products business and capture value for important new yield traits for major crops.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to advance our own trait developments in Camelina for our seed products business as well as to form business alliances to progress our traits through development, launch and commercialization in major food crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key to our strategy is to retain control of timelines and to maximize, where possible, the opportunity for future value creation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on identifying and signing additional research and development collaborations to accelerate commercial development of our promising yield traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on this strategy, Yield10 intends to focus internal resources on trait gene discovery and developing improved versions of our elite Camelina varieties for our seed products business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have signed non-exclusive research licenses for our novel yield traits with agriculture industry leaders.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10's</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approach to capturing value from the utilization of its proprietary traits in major food and feed crops is to enter into research licenses with large seed companies to maximize the numbers of acres in which the traits are adopted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our capital efficient approach for trait development in major food and feed crops is to utilize field results obtained from our work with traits in Camelina to create interest from large seed companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We then execute non-exclusive research licenses for traits of interest, enabling these companies to progress our traits within their crop(s) of interest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These research agreements have a limited term and require data sharing with Yield10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the work performed under these research agreements is successful, the seed companies have the right to negotiate a commercial agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a network of commercial science advisors and collaborators to provide us with insight and opportunities to advance our industry alliances, crop research and development, and key intellectual property.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 has pursued academic collaborations that have led to the discovery of novel yield trait genes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018 and 2019, Yield10 announced signing global license agreements with the University of Missouri for advanced technology to boost oil content in oilseed crops, including C3007, C3010, and C3012, which are based on the discovery of a key regulatory mechanism controlling oil production in oilseed crops and which can be used to increase oil content.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the Rothamsted collaboration agreement, Prof. Johnathan Napier, a world-leading scientist in the development of sustainable plant omega-3 (EPA, DHA+EPA) oil traits, also joined our advisory team.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We plan to seek U.S. and Canadian government grants and/or partners to support our research and development goals.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 has historically sought and participated in government research grants in collaboration with leading academic institutions to develop early crop innovations and to secure rights to intellectual property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been awarded grants over the last several years supporting research on strategies to improve the efficiency of photosynthesis, increase seed oil content, identify novel yield traits, and to test these novel traits in Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This work is valuable because traits developed in Camelina also have the potential to be developed and deployed in other oilseed crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2017, we were selected as a sub-awardee on a DOE grant led by Michigan State University to conduct research aimed at boosting oilseed yield in Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020 and 2021, we received three small Canadian government research grants awarded through the Industrial Research Assistance Program administered by National Research Council Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to continue to pursue government grants to defray research costs associated with our research and development activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other potential sources of non-product revenue include 1) potential partners or customers in the Camelina products value chain, and 2) funded partnerships or collaborations with companies interested in the use of our GRAIN platform to identify gene targets for traits in crops of commercial interest.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are operating with a lean organizational footprint, which is evaluating our novel yield traits in greenhouse and field tests while maintaining efficient use of cash resources.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 30 full-time employees, with the majority directly involved with our research and development activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our organizational capabilities align with our research priorities and are complemented by our use of third-party infrastructure and certain service providers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With this approach we can leverage third-party infrastructure and capability without having to spend the time and capital needed to recreate them in-house.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This allows us to focus our limited resources on deploying our core strengths against our key development goals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to grow our research and development operations and commercial seed operations over time commensurate with building value in our business and advancing our traits through commercialization while at the same time tightly managing overhead costs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building capabilities in seed scale-up and certified seed production to build an inventory of Camelina seed </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">supply to growers under contract for producing grain suitable for offtake into the biofuels market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we advance field testing of our Camelina varieties, we will choose Camelina lines as lead and back-up candidates for commercialization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, field tests can be conducted for a Camelina line with 20 to 100 grams of seed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a line is selected for possible commercial sales, inventory of the seed must then be ramped up.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rule of thumb we use is that a one-acre planting of Camelina will produce sufficient seed to enable planting of 150 to 200 acres.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021/2022 we conducted seed scale-up activities for WDH3, our winter short cycle Camelina line as well as for WDH2, our winter cold tolerant line. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2022, we engaged growers in contracts for the production of our WDH2 and WDH3 </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina grain and Camelina seed having a total acreage of approximately 1,000 acres.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These growers are located in the U.S. and Canada and planted between 30 and 160 acres each, with harvest expected to occur in the summer of 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to use the seed harvest for toll crushing and further seed production that will provide us with seed inventory for future grower contracts during 2023 and beyond.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For certain spring and winter varieties in development for commercialization, including WDH2, WDH3, E3902 and certain candidate herbicide tolerant lines, we are conducting contract seed scale-up and production in contra-season at sites in South America and plan to continue seed scale-up activities in spring 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">           </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Traits in Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 has established a strong pipeline of performance and product traits in development. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2020, we added programs for the deployment of input traits including herbicide tolerance and disease resistance traits for Camelina into our pipeline and prioritized this development to enable larger scale production of elite Camelina varieties for biofuel feedstock production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also prioritized development of performance traits for increasing seed oil content ahead of seed yield traits.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INPUT TRAITS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Herbicide Tolerance and Downy Mildew Resistance</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are progressing the development of genetic traits for tolerance to Class 10 and Class 2 herbicides in Camelina. We plan to use the Class-10 herbicide glufosinate tolerance gene for management of broadleaf weeds for commercial production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing glufosinate tolerant Camelina because it will fit in well with crop rotations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The genetic trait we are using has a long history of safe use in other crops including canola.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe this approach could potentially enable faster regulatory approvals for the trait in Camelina under the SECURE Rule in the United States.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have multiple candidate glufosinate tolerant Camelina lines in our pipeline.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In spring 2022, we conducted our first field testing of candidate herbicide tolerant Camelina lines in order to identify lead and back up lines for commercial development and regulatory approval. We have selected lines for further testing and seed scale-up at two sites located in the southern U.S. over winter 2022/2023, and have plans to conduct further testing and seed scale up in spring 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class 2 herbicides (imidazolonones ("IMI") and sulfonyl ureas ("SU")) are used extensively in the geographic regions we are targeting for Camelina production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soil residues from their use in the previous growing season can impair Camelina growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For this reason, we are progressing Class 2 tolerance traits in our Camelina pipeline based on modified versions of the ALS gene ("acetolactate synthase") to produce tolerance to both types of Class 2 herbicides.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approach is intended to leverage</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trait genetics and the well-established roadmap from the successful development of IMI and SU resistance in other commercial crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are progressing traits for tolerance to the fungal pathogen downy mildew, which can negatively impact Camelina seed yields.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we acquired the rights to a Camelina line with DMR and plan to evaluate it in 2023 on land having significant levels of this fungal pathogen.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have two backup Camelina lines demonstrating partial resistance and a funded breeding program ongoing for producing additional DMR lines.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these input traits are being developed independently, however once validated, our plan is to stack these traits into our current, best elite Camelina varieties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In late 2020, we initiated an intensive effort to develop herbicide tolerance traits in Camelina.  In our spring 2022 field testing program, we indicated that we would be evaluating over 30 candidate Camelina lines that have been engineered for tolerance to over-the-top spray of a commercial broadleaf weed herbicide. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we reported that we observed good herbicide tolerance to an established broadleaf herbicide at 1 time or 2 times the spray rate that is typically applied commercially to herbicide tolerant canola.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The over-the-top spraying consisted of 2 spray applications of the broadleaf herbicide at different times of the Camelina growth cycle.  In February 2023, we reported that we retested our lead commercial candidate HT spring Camelina lines in field trials in the Southern U.S. and the previous successful results were replicated.  We further reported these HT spring Camelina lines were also tolerant to the application of a grassy weed control product.   </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In our spring 2022 field test program, we</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">also tested a Camelina line for tolerance to IMIs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In August 2022, we reported that our candidate IMI tolerant line has normal growth in the presence of IMI soil residues applied to the soil at 1-time or 2-times the commercially used rates, whereas the control line shows impaired growth.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, our researchers developed multiple E3902 spring Camelina lines with "stacked" herbicide tolerance traits.  In February 2023, we reported results from greenhouse studies indicating that we have achieved proof-of-concept for creating E3902 Camelina lines with tolerance to both over-the-top herbicide application and soil residual herbicide.   </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We plan to conduct our first field tests of stacked herbicide tolerant E3902 spring Camelina lines in spring 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our researchers have also developed candidate broadleaf herbicide tolerant winter Camelina in WDH2 and WDH3 germplasm.  In recently completed greenhouse studies, these candidate winter Camelina lines demonstrated tolerance to spray application of commercial levels of a commonly used broadleaf herbicide.  These events are on-track for field testing in winter 2023/2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are also developing &#8220;stacked&#8221; herbicide tolerance traits in our winter Camelina lines with the goal of conducting our first field tests in winter 2023/2024.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">   </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to collect data on tolerance to the herbicides, seed yield and oil content data on these Camelina lines in the months ahead.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE TRAITS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Seed Oil Enhancing Traits: C3007, C3008, C3009, C3010, C3012 and C3020</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 is progressing a series of novel traits targeted at increasing the oil content in Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building significant capabilities and intellectual property around key oil biosynthesis pathways in plants based on technologies for increasing oil content in seeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Improving the oil content and yield of Camelina seed would increase the value per acre for this crop for the production of generic oils for biofuel markets in the near term and omega-3 (EPA, DHA+EPA) oils in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results we obtain with Camelina, we may be able to license these traits to seed companies for use in other oilseed crops, including canola and soybean. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began the technical work in Camelina during 2016 with our C3008a, C3008b and C3009 traits, which regulate the production and degradation of oils in oilseed crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017 and 2018, we received confirmation from the U.S. Department of Agriculture - Animal and Plant Health Inspection Service's ("USDA-APHIS") Biotechnology Regulatory Services ("BRS") that two types of our genome-edited Camelina plant lines developed using CRISPR/Cas-9 genome editing technology for increased oil content were not considered to be regulated articles under 7 CFR part 340, clearing the way for field testing in the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Edits to three different gene types were made to truncate the resulting encoded proteins.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These edits were designed to enhance the production of oil and decrease its turnover in mature seeds.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The best line containing these modifications is designated as our triple-edited, or C3008a, C3008b and C3009 trait containing spring Camelina line E3902.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our first field trial with these edited Camelina lines in the U.S. during the 2019 growing season and these trials were repeated in 2020 and 2021 with the E3902 line consistently showing an approximately 4.7 percent increase in seed oil content as a percentage of overall seed weight.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No significant change in oil composition was observed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the Ministry of Agriculture, Livestock and Fisheries in Argentina indicated that Camelina line E3902 would not be subject to regulation in that country.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are performing activities related to seed scale-up  with Camelina line E3902 including pure seed production in anticipation of potential commercial use.  In 2022, the Ministry of Agriculture on Agricultural Protection in Chile indicated that Camelina line E3902 would not be subject to regulation in Chile.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, we signed an exclusive global license agreement with the University of Missouri for advanced oilseed technology, including the C3007 and C3010 gene traits, which are promising targets focused on the central role of Acetyl-CoA Carboxylase ("ACCase") a key metabolic control point for oil production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have produced several CRISPR genome edited versions of C3007 in both Camelina and canola.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina contains three copies of three different BADC genes, BADC-1, BADC-2 and BADC-3 while canola contains two versions of each gene.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through a series of submissions to USDA-APHIS, we have developed several lines of Camelina and canola that USDA-APHIS BRS does not consider to be regulated under 7 CFR part 340.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in late 2021 the Ministry of Agriculture, Livestock and Fisheries in Argentina indicated that two C3007 Camelina lines would not be subject to regulation in that country.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 researchers achieved proof of concept showing that four novel gene targets identified using the GRAIN platform impact seed development and/or oil content.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In greenhouse testing in 2020, one of the three targets, C3020, produced a 10% increase in seed oil content when engineered with increased activity in Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data obtained from increasing activity of the other three targets, C3019, C3021, and C3022 indicates these represent good targets for CRISPR </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">genome-editing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pure field grown seed of C3020 was produced in 2021 for subsequent larger scale evaluation in field tests.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from the 2021 field production showed up to a 9 percent increase in oil content. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novel Yield Trait Genes C3003 and C3004</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal development work with performance traits C3003 and C3004 has been paused to focus resources on the development of our input traits and oil content traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">C3003 is an algal gene, in-licensed from the University of Massachusetts.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe, based on GRAIN modeling and early positive results, that C3003 reduces the well-understood yield losses that occur through photorespiration, a side reaction of photosynthesis in C3 crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simplot is working with C3003 in their potato programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our C3004 gene trait was identified based on molecular genetic analysis of C3003 Camelina.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In studies conducted between 2018 and 2021, stable C3004 Camelina lines with increased expression of C3004 resulted in a significant increase in plant growth and vigor, increased branching and seed yield, and in some cases increased individual seed weight.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have research license agreements in place with seed companies to evaluate the Camelina C3004 gene in soybean and potato.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">C4000 Series Traits</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simplot is testing the C4001 trait in potato.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect evaluation of C4000 series traits in these target crops will continue to advance during 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Traits in this series and the proof points we expect to generate may provide us with an opportunity to selectively partner with others for the development of these traits in major commercial food, feed, and forage crops.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT TRAITS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PHA Bioplastic Trait</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PHA bioplastics are produced today using sugar or vegetable oil feedstocks by fermentation of microorganisms. Fermentation-based production of PHAs is constrained by the high capital cost of manufacturing facilities and the high processing costs resulting from feedstock conversion losses due to the inefficiency of converting sugar or oils to PHA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, it requires over 3 pounds of sugar to produce 1 pound of PHA or 1.5 - 2 pounds of vegetable oil to produce 1 pound of PHA, making the feedstock cost alone very high.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These types of processes also require other manufacturing inputs and are energy intensive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe crop-based production will enable an advantaged cost structure thereby eliminating a barrier to entry for large-scale adoption of PHA materials for use as renewable, biodegradable plastic replacement in many single use food serviceware and packing applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another application of PHAs includes wastewater treatment.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeds are natural, stable storage sites for large amounts of oil and proteins deposited by plants to nourish seedlings following seed germination in the field.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stability of seeds at ambient temperatures allows them to be readily harvested, transported and stored prior to processing, and makes them the ideal vehicle for crop seed production of PHA bioplastics.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key concept is to introduce the PHA bioplastic as a new component of the seed composition and by processing the PHA bioplastic producing seed, to produce oil, polymer, and protein rich seed meal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe this can be done in a capital efficient manner using incremental capital added to an existing oilseed facility.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The combination of all three products improves the overall value proposition and we believe that in time this will result in PHA bioplastics costs ultimately in line with canola and soybean oils.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 plans to develop and commercialize Camelina seed-based PHA bioplastics by selling a resin grade PHA bioplastic raw material to the bioplastics industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is actively pursuing business development opportunities to identify and secure partnerships for plastics replacement markets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 filed a U.S. patent application in 2019 for new technology potentially enabling low-cost production of PHA biomaterials in the seeds of Camelina</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Yield10 patent application describes a discovery around maintaining the viability and vigor of Camelina seed programmed to produce high levels of the PHA biomaterial PHB.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By introducing the three genes encoding the pathway for producing PHA from the plant metabolite acetyl-CoA, we have demonstrated the production of up to 10 percent PHB in seeds of Camelina with good seedling viability in growth chambers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have two PHA biomaterial traits, C3014 and C3015, in our development pipeline and we carried out successful field tests in 2020 and 2021.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are now progressing to scale up the best prototype line, based on the C3015 trait, which showed PHA levels of up to 6% </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seed weight, to begin early product prototyping and market development studies for feed and water treatment applications.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we completed a 3-acre scale-up of this line.  In parallel, we have a research and development program underway to optimize and develop commercial quality PHA trait lines based on insights from the field tests and our GRAIN platform with a goal to achieve 10 - 20% PHA in seed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Omega-3 (EPA, DHA+EPA) oil trait</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The omega-3 (EPA, DHA+EPA) oil trait, for which Yield10 has secured an option to commercial rights, is being developed by the research team at Rothamsted as part of their program to develop a sustainable drop-in replacement for fish oil used in the production of aquaculture feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 is providing financial support to the ongoing Rothamsted program and has secured an exclusive option to commercialize the technology and improvements made during the term of the agreement.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Yield10 and Rothamsted agreed to a no-cost extension of the exclusive option and license agreement until December 31, 2023.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most important omega-3 fatty acids for human health are ALA, DHA and EPA and the primary source of these is fish in the diet.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These omega-3 fatty acids are produced by algae, where they are thought to protect their cell membranes in cold water.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The algal omega-3 oils progress up the food chain and accumulate in fish and eventually into the human diet.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Northern Hemisphere fish oil contains approximately 10% DHA and 10% EPA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina oil already contains the omega-3 fatty acid ALA and the Rothamsted Institute has developed engineered Camelina lines, which produce approximately 20% of DHA+EPA fatty acids, similar to the composition of Northern Hemisphere fish oil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of these Camelina lines have been successfully field tested by Rothamsted and us during the last four years at different locations within the UK, Canada and the U.S. with oil samples produced for salmon and human feeding studies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rothamsted is continuing its research program to further improve the oil composition of Camelina oil with the goal of developing a land-based production system for a Camelina oil composition as a drop in replacement for Southern Hemisphere fish oils, which has an DHA+EPA fatty acid content in the oil of approximately 30%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there may be intellectual property challenges related to the production of omega-3 oils in crops in North America until certain existing patents in Canada expire during 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently progressing business development activities to determine the feasibility of progressing the omega-3 Camelina in North America in the near term.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, in the interim, Yield10 will focus its research and development efforts on developing advanced Camelina germplasm with the intention to introduce the omega-3 trait in the future.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the first successful commercialization of a biotechnology-derived agricultural crop in the 1990s, many new crop varieties have been developed and made available to farmers in the U.S. and worldwide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. farmers have rapidly adopted many of these new biotechnology-derived varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the USDA, in 2020 over 90 percent of U.S. corn, upland cotton and soybeans planted in the U.S. were varieties produced through traditional forms of genetic engineering.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant percentage of the production of other crops planted and harvested in the U.S., such as alfalfa, papaya and sugar beet are also biotechnology-derived.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology-derived or genetically engineered ("GE") crops are subject to a significant amount of regulation in the U.S. and worldwide.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Field tests and field trials of such crops need to ensure that traits in development do not escape or mix with native plants, and crops that may be used in human and animal food chain must meet certain safety standards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulations, regulatory systems and the political environment that influence them vary significantly among jurisdictions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of this discussion, the term &#8220;GE&#8221; includes both biotechnology-derived or genetically engineered plants that are modified by the insertion of recombinant DNA (&#8220;Traditional Genome Modification&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biotechnology-derived or genetically engineered plants can also be modified through the application of more modern techniques of genome editing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have seed traits that fall within each of these two generalized categories of GE plants, as summarized above under the subheading &#8220;Traits in Development.&#8221;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States Regulation</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. government agencies primarily responsible for overseeing the products of modern agricultural biotechnology are the USDA, the FDA and the EPA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on its characteristics, a product may be subject to the jurisdiction of one or more of these agencies under the federal government&#8217;s 1986 Coordinated Framework for the Regulation of Biotechnology, as updated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory officials from the three agencies regularly communicate and exchange information to ensure that any safety or regulatory issues that may arise are appropriately resolved within the scope of authority afforded to each agency under their respective statutes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other environmental laws or regulations also apply, depending on the specific product and its potential applications or intended uses.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy for major grain crops is to develop yield and performance traits for licensing to the major seed companies.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our seed traits and any future products that are successfully developed containing our seed traits are subject to USDA, FDA and EPA regulatory requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Those requirements will vary depending on the particular seed trait and the type and intended use of any product that will be commercialized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future products that we plan to produce and sell, for example deployment of herbicide tolerant traits, are likely to have EPA regulatory requirements, and the regulations relating to manufacturing and consumer protection will also need to be addressed.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within USDA, APHIS administers the regulations in 7 CFR part 340, &#8216;&#8216;Introduction of organisms and products altered or produced through genetic engineering which are plant pests or which there is reason to believe are plant pests.&#8217;&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulations govern the introduction (importation, interstate movement, or release into the environment) of certain GE organisms. Along with the EPA and the FDA, APHIS is responsible for the oversight and review of GE organisms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 18, 2020, the USDA updated the biotechnology regulations in the Plant Protection Act (7 C.F.R. Part 340) and set up a new paradigm called the Sustainable, Ecological, Consistent, Uniform, Responsible, Efficient (&#8220;SECURE&#8221;) rule. This Act establishes updated regulations for importation, interstate movement, and environmental release of GE organisms and products.  It provides exemptions for plants if the genetic modification is solely a deletion of any size, or the genetic modification is a single base pair substitution or if the genetic modification is solely introducing nucleic acid sequences from within the plant&#8217;s natural gene pool.  Exemptions also apply if the modification is from editing nucleic acid sequences in a plant to correspond to a sequence known to occur in that plant&#8217;s natural gene pool or if the plant is an offspring of a GE plant and does not retain the genetic modification in the GE plant parent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, &#167; 340.1(c) states that modified plants would not be subject to the regulations if they have plant-trait mechanism of action (&#8220;MOA&#8221;) combinations that are the same as those of modified plants for which APHIS has conducted a regulatory status review and found not to be subject to the regulations under part 340.  The focus rests on the organism itself rather than the methods and technologies used to generate it, which is important given improvements in delivery and genome editing modalities over the past 33 years.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seed traits developed using Traditional Genome Modification, such as our C3003 yield trait that leverages the biological functions of an algal gene, are regulated under 7 CFR part 340.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulated articles are subject to extensive USDA-APHIS oversight, including but not limited to permitting requirements for import, handling, interstate movement and release into the environment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, we have obtained determinations from USDA-APHIS that some of our genome edited lines are exempted from the 7 CFR part 340 framework administered by the agency.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases (i) through (iv) below, USDA-APHIS's Biotechnology Regulatory Services approved our petitions and confirmed that each of these novel plant lines would not be treated as a regulated article through the previous APHIS &#8220;Am I Regulated?&#8221; process.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)   The single trait C3008 Camelina plant line, developed using CRISPR genome editing technology for increased oil content.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)   The triple-edited Camelina line E3902 that combines three gene traits, C3008a, C3008b and C3009, to increase  oil production.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)  The Camelina CRISPR edited line edited for the C3007 trait for increased oil production in Camelina.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)  The canola CRISPR edited line edited for the C3007 trait for improved oil production in canola.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To our knowledge, our triple-edited Camelina line E3902 which was determined to not be regulated under 7 CFR part 340 in September 2018, is the first CRISPR-edited triple-trait plant determined by the agency to be not to be regulated under 7 CFR part 340.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since 2018, our CRISPR-edited lines that are exempt from regulation by APHIS (under 7 CFR part 340) have been studied in field tests conducted in the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue to make appropriate use of SECURE Rule procedures to clarify the regulatory status of our new GE seed traits as they are developed.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In  2020, the regulatory exemptions and confirmation process under the SECURE rule took effect, representing the first comprehensive revision of APHIS&#8217; biotechnology regulations since 1987.  The revisions enable APHIS to regulate organisms developed using genetic engineering for plant pest risk with greater precision and reduces the regulatory burden for developers of organisms that are unlikely to pose plant pest risks.  Once a specific plant developed through genetic engineering is found not to require regulation, new varieties of the plant containing the same genetic modification would similarly not be regulated.   Since the new process was enacted, certain of our CRISPR edited Camelina C3007 lines have been confirmed by APHIS as being exempt from regulation by USDA-APHIS under 7 CFR part 340.  In addition, in 2022 we filed a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">request under the SECURE Rule for Regulatory Status Review (RSR) with USDA-APHIS Biotechnology Regulatory Services (BRS) for herbicide tolerant Camelina.  As of March 2023, a response from the agency is pending.    </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EPA is responsible under the Federal Insecticide, Fungicide and Rodenticide Act for regulating pesticides with public health uses, as well as ensuring that these products do not pose unintended or unreasonable risks to humans, animals and the environment.</span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For </span><span style="background-color:#ffffff;color:#5f6368;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herbicide</span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="background-color:#ffffff;color:#5f6368;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tolerant crops</span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the EPA regulates the herbicide while the USDA-APHIS regulates the crops.</span><span style="color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The </span><span style="background-color:#ffffff;color:#5f6368;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EPA</span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> establishes tolerances for the allowable amount of </span><span style="background-color:#ffffff;color:#5f6368;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">herbicide</span><span style="background-color:#ffffff;color:#4d5156;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> residues that may remain on the crop.</span><span style="color:#202124;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#202124;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tolerances, as defined by the EPA, are &#8220;the maximum amount of a pesticide allowed to remain in or on a food&#8221; as part of the process of regulating pesticides.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate from approval for genetic modifications from USDA-APHIS regulations under 7 CFR part 340, a GE plant also will be regulated by the FDA if it is intended to be used as human food or animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the safety of food for humans and animals, and foods derived from GE plants must meet the same food safety requirements as foods derived from traditionally bred plants (also called &#8220;conventional foods&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1992, the FDA has had in place a voluntary consultation process for developers of bioengineered food (&#8220;Biotechnology Consultations&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Final agency decisions and other information from these Biotechnology Consultations are made publicly available by the FDA.&#8239; Biotechnology Consultations are data-intensive and examine the new food product&#8217;s safety and nutritional profile, among other issues. &#8239;Generally, the FDA has found that such food products do not pose unique health risks to humans or animals, but if a novel allergen or other distinction from the conventional food is present in the new plant variety, the agency may require specific label statements on the product to ensure that consumers are made aware of material differences between GE and conventional versions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA primarily derives its regulatory power from the Federal Food, Drug, and Cosmetic Act, which has been amended over time by several subsequent laws.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other oversight and inspection responsibilities, the FDA regulates ingredients, packaging, and labeling of foods, including nutrition and health claims and the nutrition facts panel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foods are typically not subject to premarket review and approval requirements, with limited exceptions.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of a broader effort to modernize its regulatory approach to all biotechnology-derived products, the FDA is currently re-evaluating its regulatory approach in light of the increasing prevalence of certain genome edited plants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FDA asked for public input to help inform its thinking about human and animal foods derived from new plant varieties produced using genome editing techniques.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, the FDA&#8217;s request for comments asked for data and information in response to questions about the safety of foods from genome edited plants, such as whether certain categories of genome edited plants present food safety risks different from other plants produced through traditional plant breeding.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, FDA leadership issued a document entitled the &#8220;Plant and Animal Biotechnology Innovation Action Plan&#8221; (the &#8220;Action Plan&#8221;) that identified three key priorities for the agency in this area: 1) advancing human and animal health by promoting product innovation and applying modern, efficient and risk-based regulatory pathways; 2) strengthening public outreach and communication regarding the FDA&#8217;s approach to innovative plant and animal biotechnology; and 3) increasing engagement with domestic and international partners on biotechnology issues.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Action Plan also stated that the FDA has reviewed the comments and other information it received in response to the January 2017 request for comments, and that it intends to develop guidance for the industry explaining how the FDA&#8217;s existing regulatory policy for foods derived from new plant varieties applies to foods produced using genome editing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also stated in the Action Plan that it intends to begin updating the existing procedures for voluntary Biotechnology Consultations to reflect the agency&#8217;s 25 years of experience with foods derived from biotechnology plants and to incorporate any additional issues related to genome editing of food crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such procedural updates are expected to be developed and implemented over the next two years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Regulation</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Canada, GE crops, and the food products into which they are incorporated, are regulated by multiple government agencies under a federal framework for the regulation of biotechnology products that is similar to the U.S. system.&#8239; First, the CFIA is the lead agency for ensuring that a new agricultural biotechnology crop will not pose new risks to Canadian plants, animals, and other agricultural commodities.&#8239; The Plant Biosafety Office ("PBO") is responsible for conducting environmental assessments of biotechnology-derived plants, referred to as "plants with novel traits" ("PNT"). &#8239;Authority for the PBO includes both approving confined field trials with the PNT through permits and authorizing their &#8220;unconfined release&#8221; as a first step towards commercialization.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PNTs are defined in the Canadian Seeds Regulations (i) as plants into which a trait or traits have been intentionally introduced, and (ii) where the trait is new in Canada and has the potential to impact the environment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CFIA also has in place a remutation policy, whereby plants containing the same mutation as a previously authorized plant of the same species are included in the authorization of the original PNT and are therefore subject to the same conditions. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Food and Drugs Act and related regulations, Health Canada is responsible for reviewing a pre-market safety assessment that must be submitted by the manufacturer or importer of a &#8220;novel food,&#8221; a term of art that includes any PNT or other biotechnology-derived foods.&#8239; The safety assessment should provide assurances that the novel food is safe when prepared or consumed according to its intended use before it enters the Canadian market and food system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A multi-disciplinary team of experts from Health Canada evaluates the data and information about the novel food and make a determination regarding whether it is safe and nutritious before it can be sold in Canada, as well as whether any restrictions are warranted under applicable law or the product&#8217;s safety profile.&#8239;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health Canada&#8217;s final decision documents regarding the safety of these novel foods are made available to the public by the government.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the U.S., approval of a PNT or a novel food product does not take into account the method with which such product was produced.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rather, Health Canada employs a product-based (as opposed to a process-based) approach to its regulatory oversight of such emerging foods and food ingredients.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the lead agency for public health and safety, Health Canada also works in conjunction with the CFIA on food labeling oversight when it identifies a potential health or safety issues with a food that could be mitigated through labeling or other disclosures.&#8239; For example, if the biotechnology-derived food contains a new allergen that is otherwise not present in the conventional version of the food, then specific label statements are required to alert consumers to that important health information. &#8239;However, the CFIA has primary oversight over non-health issues related to food labeling, packaging, and advertising.&#8239; Accordingly, the CFIA is the lead agency for ensuring that food labeling and advertising meet the legal requirements of the Food and Drugs Act, and that labeling representations do not create a potential risk of fraud or consumer confusion and are compliant with Canada&#8217;s voluntary disclosure standard for GE food ingredients.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Environment Canada is also available to serve as a regulatory &#8220;safety net&#8221; if a novel product does not naturally fall within the jurisdiction of the CFIA, Health Canada, or the Pest Management Regulatory Agency that oversees pesticide products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our work involving the development, greenhouse testing, and field testing of novel yield trait genes in crop plants requires certain government and municipal permits, and we must ensure compliance with all applicable regulations, including regulations relating to GE crops.&#8239; With laboratories and greenhouses in both the U.S. and Canada, we are also subject to regulations governing the shipment of seeds and other plant material (including GE seeds and GE plant material) between our facilities in the U.S. and Canada, including USDA-APHIS and CFIA permits for the import and phytosanitary certificates for the export of plant materials that could pose a risk to domestic agriculture.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Having deployed our own research and development operations in Saskatoon, Canada in 2010, we have been conducting field studies of various yield traits in that country since 2016 under PNT permits issued by Canadian regulators. In recent years, we have conducted field studies in Canada of multiple traits including our PHA bioplastic trait, under PNT permits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulation in Other Jurisdictions</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions and governmental authorities, including in South America and Asia, are increasingly taking an interest in regulating agricultural products of biotechnology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approaches vary by jurisdiction, including the existing public health framework and phytosanitary laws in the country, and other less tangible factors such as cultural and religious norms that may have an impact on individual country risk assessments and decision-making.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict future changes in the global regulatory landscape regarding GE plants subjected to Traditional Genome Modification or GE </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plants subjected to genome editing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, although U.S. and Canadian regulatory authorities have taken similar approaches to overseeing both traditional biotechnology-derived plants and genome edited plants under their national plant health and biosafety laws, regulation of all GE plants in the EU is significantly more stringent than in North America.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and Canadian regulators have also determined that genome edited GE plants pose fewer risks that those subjected to Traditional Genome Modification.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A July 2018, Court of Justice of the European Union legal ruling indicates that the existing European regulations for GE plants modified by the insertion of recombinant DNA should be strictly applied to genome edited plants as well.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is thus a sharp distinction between how European and North American regulatory agencies oversee novel seed traits, including those that are generated using the more modern techniques of genome editing. Although we are not currently targeting European markets for the development or commercialization of our products, the EU approach to regulating GE plants without regard to the scientific distinctions between Traditional Genome Modification and directed genome editing could be adopted by emerging oversight regimes for GE products in other jurisdictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, an increasing number of countries that dominate GE crop production such as Argentina, Brazil and China are adopting a more favorable regulatory approach towards genome edited plants that do not contain foreign DNA by equating the crops to conventionally bred varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This approach first implemented by Argentina, followed by many other countries, demonstrates the evolving landscape for GE crops informed by over 25 years of regulation and GE crop production.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, Japan published final guidelines for genome edited plants and food that state that these can be sold to the public, without the need for pre-market authorization provided they meet the criteria of being similar to products of traditional breeding.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021, Yield10 received a favorable determination from the Argentine Biosafety Commission that our genome edited Camelina lines, E3902 and the two C3007 lines, developed for increased oil content, were similar to conventional bred Camelina varieties and are not regulated under the biotechnology resolution No. 763/11 of the Ministry of Agriculture, Livestock and Fisheries in Argentina.  In practice, the Argentinian authorities have confirmed that because the genome edited Camelina lines do not contain any foreign inserted DNA, these varieties can be marketed in Argentina like conventional Camelina varieties without the need for any pre-market authorizations. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fourth quarter 2022, the Agricultural Protection Division &#8211; Forestry and Seeds in Chile  indicated that our genome edited E3902 Camelina line is not under the scope of the Chilean Biotechnology Crops Resolution  No. 1523 of 2001, and its amendments regarding GMOs confirming that this  line is considered not regulated (non-GM) in Chile and can be cultivated like conventional crops.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the Chinese Ministry of Agriculture and Rural Affairs published new guidelines for the review and approval of genome edited crops and products paving the way for faster commercialization in that country.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-License Agreements </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Collaboration Agreement with Rothamsted Research </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">            </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, Yield10 signed an exclusive collaboration agreement with Rothamsted to support Rothamsted&#8217;s Flagship Program to develop omega-3 oils in Camelina.  The technology developed by Rothamsted could enable the sustainable, plant-based production of omega-3 (EPA, DHA+EPA) nutritional oils that closely mimic the composition of Southern Hemisphere fish oil, an important ingredient in the production of aquaculture feed.  Omega-3 oils are also essential for human nutrition and have demonstrated benefits in heart health.  Rothamsted is a world-leading nonprofit research center based in Harpenden, UK, that focuses on strategic agricultural science to the benefit of farmers and society worldwide.  Over the last decade, the team led by Professor Johnathan Napier, Ph.D., Science Director, has demonstrated the production of EPA, DHA+EPA oils in Camelina seed.  In addition, Prof. Napier&#8217;s team has carried out multi-year field trials and multiple feeding studies with research partners using the EPA, DHA+EPA Camelina oil in different fish species.  Their partners have included at least one major aquafeed company.  Under the agreement, Yield10 has provided financial support for Prof. Napier&#8217;s ongoing research including further EPA, DHA+EPA trait improvement, field testing and nutritional studies.  As part of the agreement, Yield10 received an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology.  In November 2022, Yield10 and Rothamsted agreed to extend the collaboration agreement, including the license option, without additional funding support, through December 31, 2023.  Under this collaboration, Yield10 will monitor the ongoing progress by Rothamsted while developing the business plan for the initial commercial launch, which is expected to serve the salmon feed market in Chile.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with the University of Missouri</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a license agreement with the University of Missouri (&#8220;UM&#8221;) dated as of May 17, 2018, we have an exclusive, worldwide license to two novel gene technologies to boost oil content in crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first technology, named C3007, is a gene for a negative controller that inhibits the enzyme activity of ACCase.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The second technology, named C3010, is a gene which, if over-expressed, results in increased activity of ACCase.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that we have designated C3012, that may complement the activity of C3007 to boost oil content in crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the UM license agreement, we are required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In that regard, we are obligated to fulfill certain research, development, and regulatory milestones relating to C3007, C3010 and C3012, including completion of multi-site field demonstrations of a crop species in which C3007, C3010 and C3012 have been introduced, and filing for regulatory approval of a crop species in which C3007, C3010 and C3012 have been introduced within a specified period.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless we are able to reach agreement with UM as to the potential adjustment of the applicable milestone.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties related to the licensed products.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may terminate the license agreement at any time upon 90 days&#8217; prior written notice to UM. Either party may terminate the license agreement upon written notice for a breach that is not cured within 30 days after receiving written notice of the breach.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, UM may terminate the license agreement with respect to certain patent rights immediately upon written notice in the event we contest the validity or enforceability of such patent rights.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competitive Landscape for our Business</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina Oilseed and Alternative Cover Crops</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">PHA Biomaterials</span></div><div style="margin-bottom:6pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Omega-3 Oil</span></div><div style="margin-bottom:12pt;padding-left:45pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Trait Licensing: Agricultural Industry Landscape</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Camelina Oilseed and Alternative Cover Crops</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Camelina, because it is not currently a major food crop, has been of recent interest in North America for large-scale production of  feedstock oil for biofuels, both renewable diesel and sustainable aviation fuel. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that there is a  growing interest among oilseed crushers and energy companies in sourcing non-food, low CI feedstock oil for supplying the biofuel market.  Camelina is attractive, not only as a spring rotation crop, but also as a winter cover crop, enabling a second oil harvest annually for each acre planted.  The general interest in cover crops has been steadily increasing over the last several years.  The companies focusing on Camelina include Sustainable Oils, S&amp;W Seed, and Smart Earth.  There have also been recent investments in oilseed cover crop alternatives to Camelina including the development of carinata by NuSeed and the efforts by CoverCress Inc. over the last several years to develop pennycress as a cover crop for the mid-west corn and soybean belt. </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PHA Bioplastics: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party PHA producers are pursuing fermentation-based production systems to produce PHA bioplastics for the biodegradables market.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These producers include Cheil Jedang, or CJ, of South Korea (which acquired the fermentation and polymer processing technology from Yield10 in 2016 when we were still named Metabolix Inc.), Kaneka of Japan, and Danimer Scientific.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Danimer has a bioplastics compounding business that produces PHAs from fermentation of seed oils and has developed revenuegenerating relationships with a number of brand owners and consumer products companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of smaller pre-commercial PHA bioplastic companies, all of which, to our knowledge, are based on fermentation platforms in North America and in China.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although these companies use genetically engineered microbes and feedstocks from GMO crops for their fermentation processes, some brand owners may prefer to accept the higher cost structure for the fermentation-derived PHA bioplastic as compared to PHA Camelina because they are not made from a GMO crop.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Omega-3 Oil:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growing demand for alternative sustainable sources of fish oil for human nutrition, pharmaceutical, and aquafeed applications has made this an attractive area for investment by several companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternative sources include microbial fermentation processes commercialized by Veramaris (the joint venture between Evonic and DSM, with a production facility in Blair, Nebraska) and by Archer Daniels Midland Co. (with a production facility in Clinton, Iowa).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the crop-based production side, two different genetically engineered varieties of the oilseed canola have been developed and approved by USDA-APHIS to address this growing demand.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASF Plant Sciences has developed a canola variety that produces low amounts of the omega-3 fatty acid EPA and the Australian company Nuseed has developed a canola variety that produces the omega-3 fatty acid DHA in the oil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BASF currently has patents on genes for the production of omega-3 oils in canola dating back to applications made on or before 2005.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NuSeed exclusively licensed patents on the production of omega-3 oils in canola from Australia&#8217;s Commonwealth Scientific and Industrial Research Organization (CSIRO).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the Rothamsted technology which enables production of omega-3 EPA, DHA+EPA oil has higher potential as a drop-in replacement for fish oil in aquafeed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trait Licensing: Agricultural Industry Landscape</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Following advances in biotechnology in the 1970s through the early 1990s, the first GM crops were commercially introduced in the U.S. in the mid-1990s.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Today, the U.S. leads the world in the adoption of GM crops in terms of crop value and acreage planted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GM crops (also referred to as GMO or Agbiotech) have had both supporters and detractors over the years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer sentiment about the safety of GM crops have limited the introduction and adoption of GM crops in Europe.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, recent studies by the National Academy of Science continue to support the 20-year history of safe use of GM crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International Service for the Acquisition of Agri-Biotech Applications (ISAAA), an industry research group, reported that 470 million acres worldwide were planted with GM crops during 2019, the most recent year for which data is available.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The planting of GM crops is centered in the Americas with North America and South America each representing approximately 44 percent of the total worldwide acres.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">China and India follow with approximately 8 percent and the balance of the total worldwide GM crop acreage during 2019.  The remaining GM acreage was planted in the EU and the rest of world.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary GM crops in the U.S. are corn, soybean, cotton and sugar beet.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Canada, the oilseed crop canola is the primary GM crop.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cotton is the primary GM crop grown in India and China.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast to the Americas, the EU has been resistant to the adoption of GM crops and has relied heavily on plant breeding programs for capturing crop yield improvements over the last 20 years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, Spain was the largest producer of GM crops in Europe, based on cultivation of GM corn representing approximately 20 percent of the country&#8217;s crop that year.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain GM crops have been approved for cultivation in some European countries, while other countries have imposed outright bans on cultivation of GM crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the market sector research and analytics firm, Markets and Markets, the total global seed market was estimated at $63 billion in 2021 and is projected to grow to more than $86 billion by 2026.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">According to the ISAAA, in 2019 the global adoption of biotech crops was recorded for 72 countries with 29 planting and an additional 43 importing for food, feed, and processing.  That year, a total of 190.4 million hectares of biotech crops were grown in 29 countries.   The top five biotech crop growing countries worldwide are the United States, Brazil, Argentina, Canada, and India. The traits being commercialized today by the agricultural industry mainly address crop protection, which involves preventing crop damage by weeds, insects and other pests that lower expected crop yield.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As technology has advanced, &#8220;trait stacking,&#8221; or the practice of adding multiple traits to an elite plant line, has become commonplace as a strategy to protect yield.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the industry has developed, the practice of inter-licensing traits between research and development driven seed companies has led to a proliferation of branded seed products on the market today.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GM seed business in North America is dominated by large multinational companies and their subsidiaries including BASF Corporation, Bayer Crop Science, Corteva Agriscience, Syngenta, and AgReliant Genetics, LLC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies have significant resources, extensive experience and track records of successfully developing, testing and commercializing high performing seed lines as well as new traits for GM crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They offer farmers conventional and biotechnology seeds as well as crop protection chemicals, biologicals, fertilizers and other products and technologies aimed at supporting the on-farm efficiency of managing crops in the field as well as managing the overall cost of crop production through to successful harvest.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Privately owned, U.S. retail seed companies play a key role in the industry by developing, marketing and selling high performing seed to U.S. farmers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These companies include Beck&#8217;s Hybrids and Stine Seed, which have capabilities in both biotechnology and plant breeding.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They source traits from the multinational companies and input these traits into elite plant germplasm to produce seeds optimized for a variety of soil, climate and field conditions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both companies offer a broad arrange of GM corn and soybean products to their customers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent advances in biotechnology, including gene editing, have led to the formation of companies focusing on yield trait discovery, biologicals for pest control, agbiome strategies and precision agriculture.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are startups, privately held and publicly traded companies involved in this space.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such companies include AgBiome LLC, Arcadia Biosciences, Inc., Benson Hill Biosystems, Inc., BioCeres S.A., Calyxt, Inc., Cibus Ltd., Evogene Ltd., Inari Agriculture, Inc., Indigo Agriculture, Inc., Kaiima Bio-Agritech Ltd.,  and Pairwise Plants LLC, many of which have greater resources and experience than we have.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued success depends in large part on our proprietary technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we owned or held exclusive rights to 19 patent families, including 15 issued patents and 41 pending patent applications, related to advanced technologies for increasing yield in crops, in the United States and throughout the world.  As part of our agreement with Rothamsted, we have an exclusive option to license two patent families, RR213 and RR305, including six issued patents and four pending applications, including both the original patent filing for the production of EPA, DHA+EPA oil in Camelina and for an improvement patent filed after the agreement was signed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of patent applications includes plant science technologies we have in-licensed globally and exclusively from the University of Massachusetts related to the yield trait gene C3003 and other advanced technologies based on advanced metabolic engineering methods to improve carbon capture and selectively control carbon partitioning in plants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our portfolio of patent applications also includes advanced technologies for oilseed crops that we in-licensed globally and exclusively from the University of Missouri in 2018 and 2019 related to the yield trait genes C3007, C3010 and C3012.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to seek, develop and evaluate new technologies and related intellectual property that might enhance our business strategy, industry position or deployment options.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we had 30 full-time employees.  Of those employees, 24 were in research and development.  Among our staff, 15 hold Ph.D.&#8217;s and 11 hold masters&#8217; or bachelors&#8217; degrees in their respective disciplines. Our technical staff has expertise in the following areas: plant genetics, plant biology, microbial genetics, bioinformatics, metabolic engineering and systems biology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our headquarters is located in Massachusetts, and our wholly-owned subsidiary, Yield10 Oilseeds Inc. ("YOI"), maintains a research and development facility, including greenhouse facilities, in Saskatoon, Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our employees are subject to a collective bargaining agreement and we consider our relationship with our employees to be good.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Talent Acquisition and Retention</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that our employees largely contribute to our success.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To this end, we support business growth by seeking to attract and retain best-in-class talent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use internal and external resources to recruit highly skilled candidates for open positions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are able to attract and retain superior talent as measured by our minimal turnover rate and high employee service tenure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Total Rewards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total rewards philosophy has been to create investment in our workforce by offering a competitive compensation and benefits package for the two geographies in which we have offices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide employees with compensation packages that include base salary, annual incentive bonuses, and long-term equity incentive awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer comprehensive employee benefits, such as life, disability, and health insurance as well as flexible spending accounts, paid time off, and a 401(k) plan.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is our expressed intent to be an employer of choice in our industry by providing a market-competitive compensation and benefits package.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health, Safety, and Wellness</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The health, safety, and wellness of our employees is a priority in which we have always invested and will continue to do so.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide our employees with access to a variety of innovative, flexible, and convenient health and wellness programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Program benefits are intended to provide protection and security, so employees can have peace of mind concerning events that may require time away from work or that may impact their financial well-being. </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These investments and the prioritization of employee health, safety, and wellness took on particular significance in 2020 through 2022 in light of COVID-19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To protect and support our team members, we implemented health and safety measures that included maximizing personal workspaces, altering work schedules, and providing personal protective equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To aid in containing the spread of COVID-19, we also implemented remote-work options and limited employee travel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor this rapidly evolving situation and will continue to seek programs to educate and assist employees whenever possible.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity, Equity, and Inclusion</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe a diverse workforce is critical to our success.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to value differences in races, ethnicities, religions, nationalities, genders, ages, and sexual orientations, as well as education, skill sets and experience.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on inclusive hiring practices, fair and equitable treatment, organizational flexibility, and training and resources.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate History and Investor Information</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1992, our Company was incorporated in Massachusetts under the name Metabolix, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 1998, we reincorporated in Delaware and in January 2017, we changed our name to Yield10 Bioscience, Inc. to reflect our change in mission around innovations in agricultural biotechnology focused on developing disruptive technologies for step-change improvements in crop yield.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial and other information about our Company is available on our website at www.yield10bio.com.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available on our website, free of charge, copies of our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after filing such material electronically or otherwise furnishing it to the Securities and Exchange Commission (the "SEC").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the SEC maintains an internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our filings with the SEC may be accessed through the SEC's website at http://www.sec.gov.</span></div><div id="ic02604fb0219453aa54b246df7a39126_19"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks.  We encourage you to carefully review the full risk factors contained in this Annual Report on Form 10-K.  Some of the principal risk factors are summarized below:</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">We have a history of net losses and our future profitability is uncertain.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">We will need to secure additional funding to finance our operations and may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to us.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.05pt">Our seed products and crop science technologies are at an early stage of development. We may never commercialize a technology or product that will generate meaningful, or any, revenues.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">There can be no assurance that we will be able to comply with the continued listing standards of The Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Currently, our primary source of our revenue is government grants; continued availability of grant funding is uncertain and contingent on compliance with the requirements of the grant.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our financial condition and results of operations could be adversely affected by public health epidemics, including the continued evolution of the coronavirus outbreak.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our business operations could be adversely affected by the impact of the war in Ukraine.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">The crop science product development cycle is lengthy and uncertain, and our progress will depend on our ability to attract third-party investment in research under license agreements and on our ability to establish collaborative partnerships to develop and commercialize our innovations.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Any potential collaborative partnerships that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our innovations.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our crop science program may not be successful in developing commercial products or if our future collaborators are successful in developing commercial products that incorporate our traits, such products may not achieve commercial success.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the markets in which we may compete in the future achieve growth, our business could fail to achieve the same growth rates as others in the industry.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">If ongoing or future field trials conducted by us or our future collaborators are unsuccessful, we may be unable to complete the regulatory process for, or commercialize, our products in development on a timely basis.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Adverse weather conditions, natural disasters, crop disease, pests and other natural conditions can impose significant costs and losses on our business.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Competition in the market for traits and seeds is intense and requires continuous technological development, and, if we are unable to compete effectively, our financial results will suffer.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our business is subject to various government regulations in the United States and Canada; the regulatory requirements for our future products in development are evolving and are subject to change, and if there are adverse changes to the current regulatory framework, our or our future collaborators&#8217; ability to market our traits could be delayed, prevented or limited.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">If we or our future collaborators are unable to comply with and timely complete the regulatory process in the United States and Canada for our future products in development, our or our future collaborators&#8217; ability to market our traits could be delayed, prevented or limited.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">The regulatory environment for genetically engineered crops in jurisdictions outside the United States and Canada varies greatly, and some jurisdictions have more restrictive regulations that could delay, prevent or limit our or our future collaborators&#8217; ability to market our traits.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Consumer resistance to genetically engineered crops may negatively affect the ability to commercialize future crops containing our traits, as well as our public image, and may reduce any future sales of seeds containing our yield traits.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Government policies and regulations, particularly those affecting the agricultural sector and related industries, could adversely affect our operations and our ability to generate future revenues and to achieve profitability.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">The products of third parties, or the environment itself, may be negatively affected by the unintended appearance of our trait genes, novel seed compositions and novel seed products.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Loss of or damage to our elite novel trait events and plant lines would significantly slow our product development efforts.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our insurance coverage may be inadequate to cover all the liabilities we may incur.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">We rely on third parties to conduct, monitor, support, and oversee field trials and, in some cases, to maintain regulatory files for those products in development, and any performance issues by third parties, or our inability to engage third parties on acceptable terms, may impact our ability to complete the regulatory process for or commercialize such products.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">If we lose key personnel or are unable to attract and retain necessary talent, we may be unable to develop or commercialize our products under development.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Patent protection for our technologies is both important and uncertain.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Portions of our crop science technology are owned by or subject to retained rights of third parties.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">We may not be successful in obtaining necessary rights to additional technologies for the development of our products through acquisitions and in-licenses.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Our license agreements include milestone and royalty payments that we are required to make to third parties.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">The intellectual property landscape around genome editing technology, such as CRISPR, is highly dynamic and uncertain, and any resolution of this uncertainty could have a material adverse effect on our business.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Raising additional funds may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Trading volume in our stock can fluctuate and an active trading market for our common stock may not be available on a consistent basis to provide stockholders with adequate liquidity.  Our stock price may be volatile, and our stockholders could lose a significant part of their investment.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Provisions in our certificate of incorporation and by-laws and Delaware law might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="margin-bottom:9pt;padding-left:58.5pt;padding-right:49.5pt;text-indent:-20.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:16.75pt">Concentration of ownership among our officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We caution you that the following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in filings with the SEC, press </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">releases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">, communications with investors and oral </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.  Any or all of our forward-looking statements contained in this Annual Report on Form 10-K and in any other public statements we make may </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">turn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> out to be wrong.  They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties.  Many factors mentioned in the discussion below will be important in determining future results.  Consequently, no forward-looking statement can be guaranteed. Actual future results may differ materially from those anticipated in forward-looking statements.  We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.  You are advised, however, to consult any further disclosure we make in our reports filed with the SEC.</span></div><div style="margin-bottom:12pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Financial Position</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses and our future profitability is uncertain.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recorded losses every year since our inception, with the exception of 2012.  As of December&#160;31, 2022, our accumulated deficit was $399,697.  Since 1992, we have been engaged primarily in research and development and early-stage commercial activities.  Because our crop science technology is at an early stage of development, we cannot be certain that our business will generate sufficient revenue to become profitable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to have significant losses and negative cash flow for at least the next several years, as we incur additional costs and expenses for the continued development of our technology, including the ongoing expenses of research, development, commercialization and administration.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of money we spend will impact our need for capital resources as well as our ability to become profitable and this will depend, in part, on the number of new technologies that we attempt to develop.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not achieve any or all of these goals and, thus, we cannot provide assurances that we will ever be profitable or achieve significant, or any, product revenues.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to secure additional funding to finance our operations and may not be able to do so when necessary, and/or the terms of any financings may not be advantageous to us.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had unrestricted cash, cash equivalents and short-term investments of $4,347.  We estimate that our cash resources will be sufficient to fund operations and meet our obligations into the second quarter of 2023.  We follow the guidance of ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements-Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued.  Based on our current cash forecast, we expect that our present capital resources will not be sufficient to fund our planned operations for that period of time, which raises substantial doubt as to the Company's ability to continue as a going concern.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to continue operations after our current cash resources are exhausted will depend upon our ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurances can be given.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not know whether additional financing will be available on terms favorable or acceptable to us when needed, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If additional funds are not available when required, we will be forced to curtail our research efforts, explore strategic alternatives and/or wind down our operations and pursue options for liquidating our remaining assets, including intellectual property and equipment.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to face significant challenges and uncertainties and, as a result, our available capital resources may be consumed more rapidly than currently expected due to any or all of the following:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">lower than expected revenues from grants and licenses related to our technologies;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes we may make to the business that affect ongoing operating expenses;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">further changes we may make to our business strategy;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in our research and development spending plans; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other items affecting our forecasted level of expenditures and use of cash resources.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will require additional capital resources to support the implementation of our business strategy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that our financing efforts will be successful.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we issue equity or debt securities to raise additional funds in the future, we may incur fees associated with such issuances, our existing stockholders may experience dilution from the issuance of new equity securities, we may incur ongoing interest expense and be required to grant a security interest in our assets in connection with any debt issuance, and the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, utilization of our net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, due to ownership changes resulting from equity financing transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies or grant licenses on terms that are not favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our seed products and crop science technologies are at an early stage of development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may never commercialize a technology or product that will generate meaningful, or any, revenues.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The crop science products and technologies we are currently developing are at an early stage of development, and the process of developing them is lengthy and uncertain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to introduce and commercialize a seed product that meets customers&#8217; expectations, our growth prospects may be materially and adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our current management has limited experience in developing technologies for the crop science industry and has never commercialized a product or technology in this industry.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may never reach a point at which our efforts result in products that allow us to achieve revenue from their license or sale.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will be able to comply with the continued listing standards of The Nasdaq Capital Market.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot assure you that we will be able to comply with the standards that we are required to meet in order to maintain a listing of our common stock on The Nasdaq Capital Market ("Nasdaq").</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq listing rules require us to maintain certain closing bid price, stockholders&#8217; equity and other financial metric criteria in order for our common stock to continue trading on Nasdaq.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, Nasdaq Listing Rule 5550(a)(4) requires companies to maintain a minimum of 500,000 publicly held shares.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.  To meet the criteria for continued listing under the equity standard, Nasdaq Listing Rule 5550(b)(1) requires companies to demonstrate stockholders' equity of at least $2.5 million.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Currently, our primary source of our revenue is government research grants; continued availability </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> grant funding is uncertain and contingent on our compliance with the requirements of the grant.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, a portion of our revenue has been generated from payments to us from government entities in the form of government grants, whereby we are reimbursed for certain expenses incurred in connection with our research and development activities, subject to our compliance with the specific requirements of the applicable grant, including rigorous documentation requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we do not comply with these requirements, the expenses that we incur may not be reimbursed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our existing grant or new grants that we may obtain in the future may be terminated or modified.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a participant in a grant from the Department of Energy with Michigan State University, as amended, which has been our primary source of grant revenue over the past five years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The final year of the grant ends on September 14, 2023, and we may be unable to obtain a new grant to replace the loss of this source of grant revenue.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain grants or incentives from government entities in the future is subject to the availability of funds under applicable government programs and approval of our applications to participate in such programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The application process for these grants and other incentives is highly competitive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in obtaining any additional grants, loans or other incentives.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent political focus on reducing spending at the U.S. federal and state levels may continue to reduce the scope and amount of funds dedicated to crop science products, if such funds will continue to be available at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we are unsuccessful in being awarded any additional government grants in the future, we would lose a potential source of revenue.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our government grants may subject us to government audits, which could expose us to penalties if we have failed to comply with the terms of the grants.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to audits by government agencies as part of routine audits of our activities funded by our government grants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of an audit, these agencies may review our performance, cost structures and compliance with applicable laws, regulations and standards and the terms and conditions of the grant.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our costs are found to be allocated improperly, the costs may not be reimbursed, and any costs already reimbursed for such contract may have to be refunded.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, an audit could result in a material adjustment to our results of operations and financial condition.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if an audit uncovers improper or illegal activities, we may be subject to civil and criminal penalties and administrative sanctions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our financial condition, research and development efforts, and results of operations could be further adversely affected by the continued evolution of the coronavirus outbreak.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any outbreak of contagious diseases, such as COVID-19, or other adverse public health developments, could have a material and adverse effect on our business operations.  The continued evolution of COVID-19 and its variants, as well as periodic spikes in infection rates and local outbreaks, in spite of safety measures or vaccinations, could cause disruptions to our operations or those of third parties with whom we engage.  The COVID-19 pandemic has led to global supply chain challenges, which could adversely impact our ability to conduct business in the manner and timelines presently planned.  As new variants of the virus appear, especially variants that are more easily spread, cause more serious outcomes, or are resistant to existing vaccines, new health orders and safety protocols could further impact our operations.  We will continue to monitor developments of the pandemic and continuously assess its potential further impact on our operations to prevent any </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions to the conduct of our business.  In the event of a prolonged continuation of the pandemic, it is not clear what the potential impact may be on our business, financial position and financial performance.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions and uncertainties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or instance, for the twelve months ended December 31 2022, the U.S. Bureau of Labor Statistics reported that the Consumer Price Index for All Urban Consumers increased 6.5 percent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence of inflation in the economy has resulted in, and may continue to result in, higher interest rates and capital costs, supply shortages, increased cost of labor, weakening exchange rates and other similar effects.  Recently inflation has increased throughout the U.S. economy.  Inflation can adversely affect us by increasing the costs of our research and developments, administration and other costs of doing business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation could also adversely affect the ability of growers to enter into and fulfill their obligations under Camelina grain production agreements with the Company.  An economic downturn, including as a result of COVID-19, could result in a variety of risks to our business, including weakened demand for our products and our inability to raise additional capital when needed on acceptable terms, if at all.  A weak or declining economy could also strain our manufacturers and suppliers, possibly resulting in supply disruption. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing war between Russia and Ukraine may adversely affect our business, financial condition or results of operations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The short and long-term implications of the ongoing war between Russia and Ukraine are difficult to predict at this time.  To date, we have not experienced any material interruptions in our infrastructure, supplies, technology systems, or networks needed to support our operations.  However, Ukraine, and the Black Sea region in general, are a major exporter of wheat and corn to the world, and the disruption of supply could cause volatility in prices and margins of these commodities and related products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ukraine is also the largest supplier of sun seed and sun oil in the world, which cannot be completely replaced from other geographic regions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conflict in Ukraine has created disruptions in global supply chains and is expected to create dislocations of key agricultural commodities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While Yield10 has no direct business operations or assets within either Ukraine or Russia, the Company's plans and operating results could be adversely affected by a number of factors, including the crop growing decisions made by farmers in the U.S., Canada, and South America as a consequence of supply shortages and rising commodity prices.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These rising prices may negatively impact our ability to contract suitable acreage for future crop trials or could delay our plans to commercialize Yield10's first Camelina plant varieties.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of cybersecurity incidents has increased in connection with the ongoing war.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the war has been accompanied by cyberattacks against the Ukrainian government and other countries in the region.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proliferation of malware from the war into systems unrelated to the war, or cyberattacks against U.S. companies in retaliation for U.S. sanctions against Russia or U.S. support of Ukraine, could also adversely affect our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with industry standards, we insure ourselves against many types of risks, including cybersecurity risks.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While this insurance may mitigate certain of the risks associated with the ongoing Ukraine-Russia war, our level of insurance may not cover all losses we could incur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential effects of these conditions could have a material adverse effect on our business, results of operations and financial condition.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor this fluid situation and develop contingencies as necessary to address any disruptions to our business operations as they develop.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Yield10 Bioscience Crop Science Program</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The crop science product development cycle is lengthy and uncertain, and our progress will depend significantly on our ability to attract third-party investment in research under license agreements and on our ability to establish collaborative partnerships to develop and commercialize our innovations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The technology and processes used in our crop science program and the application of our technology to develop Camelina as a platform crop for large scale production of low-carbon sustainable seed products to address applications in petroleum replacement, food and nutrition markets, are at an early stage of development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development in the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seed, agricultural biotechnology, and larger agriculture industries is expensive and prolonged and entails considerable uncertainty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completion of development work with respect to our products will require a significant investment of both time and money, if it can be completed at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that collaborations with established agricultural industry companies may be required to successfully develop and commercialize our innovations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in establishing or maintaining suitable additional relationships with established agricultural industry companies for research licenses in the future, and there can be no assurance that any such relationships will result in future collaboration agreements to develop and commercialize our innovations, with terms that are satisfactory to us or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, industry collaborators have significant resources and development capabilities and may develop products and technologies that compete with or negatively impact the development and commercialization of our technologies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any potential collaborative partnerships that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our innovations.</span></div><div style="margin-bottom:9pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that collaborations with established agricultural industry companies may be required for us to successfully develop and commercialize our innovations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agriculture industry is highly concentrated and dominated by a small number of large companies, which could impact efforts to form the collaborations that we will need in order to complete the development of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we pursue such arrangements, we will face significant competition in seeking appropriate partners.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, such arrangements are complex and time-consuming to negotiate, document, implement and maintain.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in establishing or implementing such arrangements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The terms of any partnerships, joint ventures or other collaborative arrangements that we may establish may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of any future collaborative partnerships is uncertain and will depend heavily on the efforts and activities of our potential partners.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such arrangements are subject to numerous risks, including the risks that:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners may have significant discretion in determining the efforts and resources that they will apply to the arrangement;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners may not pursue the development and commercialization of our product candidates based on trial results, changes in their strategic focus, competing priorities, availability of funding, or other external factors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners may delay or abandon field trials, fail to conduct field trials that produce sufficient conclusory data, provide insufficient funding for field trials, or repeat or conduct new field trials;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">partners who have marketing, manufacturing and distribution rights with respect to a product may not commit sufficient resources to, or otherwise may not perform satisfactorily in carrying out, these activities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">to the extent that such arrangements provide for exclusive rights, we may be precluded from collaborating with others;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners may not properly maintain or defend our intellectual property rights, or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">disputes may arise between us and a partner that causes the delay or termination of the research, development or commercialization of our current or future products, or that results in costly litigation or arbitration that diverts management attention and resources;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">such arrangements may be terminated, and, if terminated, may result in a need for additional capital for our independent pursuit of matters previously covered by such arrangement;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our partners may own or co-own intellectual property that results from our arrangement; and</span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a partner&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our crop science program may not be successful in developing commercial products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our potential future collaborators may spend many years and dedicate significant financial and other resources developing traits or other seed products that will never be commercialized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeds containing the traits that we develop may never become commercialized for any of the following reasons:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our traits may not be successfully validated in the target crops;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our traits may not achieve our targeted yield improvements;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not be able to secure sufficient funding to progress our traits through development and commercial validation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our traits may not have the desired effects sought by future collaborators for the relevant crops;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">development and validation of traits, particularly during field trials, may be adversely affected by environmental or other circumstances beyond our control;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we or our future collaborators may be unable to obtain the requisite regulatory approvals for the seeds containing our traits, to the extent regulatory approvals are required;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">competitors may launch competing or more effective seed traits or seeds;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a market may not exist for seeds containing our traits or such seeds may not be commercially successful;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">future collaborators may be unable to fully develop and commercialize products containing our seed traits or may decide, for whatever reason, not to commercialize such products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may be unable to patent our traits in the necessary jurisdictions; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our efforts to develop niche crop products based on our Camelina platform, including specialty oils and PHB biomaterials, are in the early stages and may not be successful.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these things were to occur, it could have a material adverse effect on our business and our results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development in the crop science industry is expensive and prolonged and entails considerable uncertainty.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the stringent product performance and safety criteria applied in development of crop science products, products currently under development may not survive the development process or may ultimately not receive requisite regulatory approvals that may be needed to market such products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when such approvals are obtained, there can be no assurance that a new product will be commercially successful.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, research undertaken by competitors may lead to the launch of competing or improved products, which may affect sales of any products that we are able to develop.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we or our future collaborators are successful in developing commercial products that incorporate our traits, such products may not achieve commercial success.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy depends upon our or our future collaborators&#8217; ability to incorporate our traits into a wide range of crops in significant markets and geographies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we or our future collaborators are able to develop commercial products that incorporate our traits, any such products may not achieve commercial success for one or more of the following reasons, among others:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">products may fail to be effective in particular crops, geographies, or circumstances, limiting their commercialization potential;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">our competitors, or competitors of our collaborators, may launch competing or more effective traits or products;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">significant fluctuations in market prices for agricultural inputs and crops could have an adverse effect on the value of our traits;</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">farmers are generally cautious in their adoption of new products and technologies, with conservative initial purchases and proof of product required prior to widespread deployment, and accordingly, it may take several growing seasons for farmers to adopt our or our collaborators&#8217; products on a large scale;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not be able to produce high-quality seeds in sufficient amounts to meet demand; and</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">we may not be able to secure the financial or other resources needed to achieve commercial success.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition and results of operations could be materially and adversely affected if any of the above were to occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">the markets in which we may compete in the future achieve growth, our business could fail to achieve the same growth rates as others in the industry.</span></div><div style="margin-bottom:12pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market opportunity estimates and market growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates and forecasts relating to the size and expected growth of the global seed industry and the biotechnology seeds market, and the market size for any products that we may develop in our Camelina products business, such as PHA biomaterials, and the estimated ranges of incremental value increase that a novel, newly developed crop trait may produce, may prove to be inaccurate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the markets in which we may compete in the future achieve these opportunity estimates and market growth forecasts, our business could fail to grow at similar rates, if at all.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If ongoing or future field trials conducted by us or our future collaborators are unsuccessful, we may be unable to complete the regulatory process for, or commercialize, our products in development on a timely basis.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful completion of multi-year, multi-site field trials is critical to the success of product development and marketing efforts for products containing our traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our ongoing or future field trials, or those of our future collaborators, are unsuccessful or produce inconsistent results or unanticipated adverse effects on crops, or if we or our collaborators are unable to collect reliable data, regulatory review of products in development containing our traits could be delayed or commercialization of products in development containing our traits may not be possible.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, more than one growing season may be required to collect sufficient data to develop or market a product containing our traits, and it may be necessary to collect data from different geographies to prove performance for customer adoption.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even in cases where field trials are successful, we cannot be certain that additional field trials conducted on a greater number of acres, or in different crops or geographies, will be successful.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, we or our research licensees conduct these field trials, or we pay third parties, such as farmers, consultants, contractors, and universities, to conduct field trials on our behalf.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Poor trial execution or data collection, failure to follow required agronomic practices, regulatory requirements, or mishandling of products in development by our collaborators or these third parties could impair the success of these field trials.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse weather conditions, natural disasters, crop disease, pests and other natural conditions can impose significant costs and losses on our business.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors that may adversely affect the success of our field trials, seed inventory and seed production are beyond our control, including weather and climatic variations, such as drought or floods, severe heat or frost, hail, tornadoes and hurricanes, uncommon or unanticipated pests and diseases, or acts of protest or vandalism.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, if there were a prolonged or permanent disruption to the electricity, climate control, or water supply operating systems in our greenhouses or laboratories, the crops in which we or our collaborators are testing our traits and the samples we or our collaborators store in freezers, both of which are essential to our research and development activities including field tests, could be severely damaged or destroyed, adversely affecting these activities and thereby our business and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unfavorable weather conditions including drought or excessive rain, or fluctuations in temperature, which we have experienced from time to time in our field trials, can also reduce both acreages planted and incidence, or timing of, certain crop diseases or pest infestations, each of which may halt or delay our field trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any field test failure we may experience may not be covered by insurance and, therefore, could result in increased cost for the field trials and development of our traits, which may negatively impact our business, results of operations, and ability to secure financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such factors outside of our control can create substantial volatility relating to our business and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, seed crops are vulnerable to crop disease and to pests, which may vary in severity and effect, depending on the stage of production at the time of infection or infestation, the type of treatment applied and climatic conditions. Unfavorable growing conditions can reduce both crop size and quality and may reduce our available inventory.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Competition in the market for traits and seeds is intense and requires continuous technological development, and, if we are unable to compete effectively, our financial results will suffer.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in the markets in which we operate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The markets for traits and agricultural biotechnology products are intensely competitive and rapidly changing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In most segments of the seed and agricultural biotechnology market, the number of products available to consumers is steadily increasing as new products are introduced. At the same time, the expiration of patents covering existing products reduce the barriers to entry for competitors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to compete successfully against our current and future competitors, which may result in price reductions, reduced margins and the inability to achieve market acceptance for any products that we or our future collaborators commercialize containing our traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, most of our competitors have substantially greater financial, marketing, sales, distribution, research and development, and technical resources than we have, and some of our potential future collaborators have more experience in research and development, regulatory matters, manufacturing, and marketing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate increased competition in the future as new companies enter the market and new technologies become available.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our technologies may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors, which will prevent or limit our ability to generate revenues from the commercialization of our traits being developed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to various government regulations in the United States and Canada, the regulatory requirements for our future products in development are evolving and are subject to change, and if there are adverse changes to the current regulatory framework, our or our future collaborators&#8217; ability to market our traits could be delayed, prevented or limited.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and Canada, where our seed traits and biotechnology-derived plant lines are developed and field tested, changes in regulatory requirements applicable to our seed traits or future products in development containing our traits could result in a substantial increase in the time and costs associated with developing and commercializing future products containing our traits, and could materially affect our ability to meet our desired development timelines or to develop and commercialize a future product containing our traits at all.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, our seed traits and any future products that are successfully developed containing our seed traits are or will be subject to USDA and FDA regulatory requirements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USDA and FDA requirements will vary depending on the particular seed trait and the intended use of any product that will be commercialized.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy is focused on crop yield traits and we have no current plans for the development of pesticide or herbicide traits, which would be subject to regulation by the EPA.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within USDA, the APHIS is responsible for protecting agricultural plants under the Plant Protection Act.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USDA-APHIS regulates organisms and products that are known or are suspected to be plant pests or to pose a plant pest risk, including those that have been altered or produced through various genetic engineering techniques.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USDA-APHIS has proposed regulations that could impact our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in recent years, we and others have submitted various petitions to USDA-APHIS to determine whether particular biotechnology-derived plants developed through the use of different genome editing techniques may be considered to be not regulated under the framework administered by the agency.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USDA also announced in March 2018 that it would not require an assessment on products that used modern forms of mutagenesis if it was clear these outcomes could occur in nature.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USDA stated at that time that it did not &#8220;have any plans to regulate plants that could otherwise have been developed through traditional breeding techniques as long as they are developed without the use of a plant pest as the donor or vector and they are not themselves plant pests.&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This USDA policy statement applies to genetic deletions of any size, which would include genome editing through CRISPR-Cas9 and other emerging technologies, although it remains to be seen how this policy announcement will be implemented by USDA-APHIS and what practical effect that may have on seed trait developers like us and our competitors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no guarantee that the USDA-APHIS governing regulations and policies will not change again in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether advocacy groups will challenge existing regulations and USDA determinations, whether </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the USDA will alter its interpretations of existing regulations, modify existing regulations or promulgate new regulations, or whether additional laws will come into effect.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these or other developments resulted in adverse changes to the current regulatory framework, our seed traits or future products in development containing our traits could be subjected to more burdensome regulatory standards, thereby substantially increasing the time and costs associated with developing and commercializing any future products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we cannot assure you that USDA-APHIS will analyze any of our future yield traits or products in development containing our traits in a manner consistent with its analysis of our genome edited yield traits to date.  Complying with the USDA&#8217;s plant pest regulations for traits that are classified as &#8220;regulated articles,&#8221; including the permitting requirements for field testing and environmental release, is a costly, time-consuming process and could substantially delay or prevent the commercialization of any future products containing traits that we expected to be deemed non-regulated by USDA-APHIS under 7 CFR part 340.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to USDA-APHIS regulation of plant breeding and planting, a biotechnology-derived plant also will be regulated by the FDA if it is intended to be used as human food or animal feed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA regulates the safety of food for humans and animals, and foods derived from novel plant varieties must meet the same food safety requirements as foods derived from traditionally bred plants (also called conventional foods).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 1992, the FDA has had in place a voluntary consultation process for developers of bioengineered food (&#8220;Biotechnology Consultations&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not participated in any Biotechnology Consultations or engaged in any informal discussions with the FDA about our novel yield traits, whether those traits have been developed using genome editing or traditional genome modification using the insertion of recombinant DNA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay in the regulatory consultation process, or a determination by the FDA that future product candidates containing our traits raise different safety issues than the relevant conventional crop and therefore must be approved by the agency as a new food additive through an intensive premarket safety review process, could increase the costs associated with or delay or prevent the commercialization of the future product candidate. Such delays may lead to reduced acceptance by farmers, food manufacturers or the public and an increase in competitor products that may directly compete with ours.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, if the FDA enacts new regulations or policies with respect to genome edited plants in particular, such policies could result in additional compliance costs or delay or prevent the commercialization of any potential commercial products containing our seed traits, which could adversely affect our ability to generate revenues and to achieve profitability.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Canada, genetically engineered crops and the food products into which they are incorporated are regulated by multiple government agencies under a federal framework for the regulation of biotechnology products that is similar to the U.S. system.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any commercialization of our yield crops in Canada is expected to be done by a third-party collaborator or other partner and complying with Health Canada&#8217;s pre-market notification requirement and safety assessment for novel foods would be the obligation of that third-party collaborator.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Complying with the Canadian regulations is a costly, time-consuming process and could substantially delay or prevent the commercialization of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we cannot assure that CFIA and Health Canada regulations or the agencies&#8217; implementation of those regulations will not change, or that the legislative framework in Canada for biotechnology-derived crops, whether for genome edited plants or plants modified using the insertion of recombinant DNA, will not be amended or otherwise changed in a manner that could result in additional compliance costs or delay, or prevent the commercialization of any potential commercial products containing our seed traits, which could adversely affect our ability to generate revenues and to achieve profitability.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with applicable regulatory requirements may, among other things, result in fines, suspensions of regulatory approvals, product recalls, product seizures, operating restrictions and criminal prosecution.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our future collaborators are unable to comply with and timely complete the regulatory process in the United States and Canada for our future products in development, our or our future collaborators&#8217; ability to market our traits could be delayed, prevented or limited.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We apply for and maintain the regulatory permits in the United States and Canada necessary for our operations, particularly those covering our field trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that we or our future collaborators will apply for and maintain regulatory approvals, if any, necessary for the commercialization of any future products containing our seed traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we and our collaborators make timely and appropriate applications for regulatory permits for our field trials, government delays in issuing such permits can significantly affect the development timelines for our traits, particularly if the planting period for a crop growing season expires before the necessary permits are obtained.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory process is expensive and time-consuming, and the time required to complete the process is difficult to predict and depends upon numerous factors, including the substantial discretion of the regulatory authorities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not completed all phases of the regulatory process for any of our traits in development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our traits could require a significantly longer time to complete the regulatory process than expected, or may never gain approval, even if we and our collaborators expend substantial time and resources seeking such approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required for regulatory approval, or any delay or denial of such approval, could negatively impact our ability to generate revenues and to achieve profitability and finance our ongoing operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changes in regulatory review policies during the development period of any of our traits, changes in, or the enactment of, additional regulations or statutes, or changes in regulatory review practices for a submitted product application may cause a delay in obtaining approval or result in the rejection of an application for regulatory approval.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval, if obtained, may be made subject to limitations on the intended uses for which we or our collaborators may market a future product containing our traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These limitations could adversely affect our potential revenues.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory environment for genetically engineered crops in jurisdictions outside the United States and Canada varies greatly, and some jurisdictions have more restrictive regulations that could delay, prevent or limit our or our future collaborators&#8217; ability to market our traits.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other jurisdictions and governmental authorities, including in South America and Asia, are increasingly taking an interest in regulating agricultural products of biotechnology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approaches vary by jurisdiction as a result of the existing public health frameworks and phytosanitary laws, as well as other less tangible factors such as cultural and religious norms that may have an impact on individual country risk assessments and decision-making.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each jurisdiction may have its own regulatory framework, which may include restrictions and regulations on planting and growing genetically engineered plants, import of grain and other plant products, and in the consumption and labeling of feed and foods derived from such novel plants, and which may apply to future products containing our traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict future changes in the global regulatory landscape regarding genetically engineered plants or commercial products incorporating such novel plant varieties. The regulatory environment for such plants is greatly uncertain outside of the U.S. and Canada, and some jurisdictions have more restrictive regulations that could delay, prevent or limit our or our future collaborators&#8217; ability to market our traits.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, regulation of all genetically engineered plants in the European Union ("EU") is far more stringent than in the U.S. and Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. and Canadian regulators have determined that genome edited plants pose fewer risks than traditional biotechnology-derived plants subjected to modification through the insertion of recombinant DNA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast, a recent EU legal ruling indicated that the existing EU regulations for genetically engineered plants modified by the insertion of recombinant DNA, which were already more stringent than corresponding U.S. and Canadian regulations, should be strictly applied to genome edited plants as well.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, there is a sharp distinction between how EU and U.S. and Canadian regulatory agencies oversee novel seed traits, and in particular those that are generated using the more modern techniques of genome editing.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are not currently targeting EU markets for the development or commercialization of future products containing our traits, emerging oversight regimes for genetically engineered products in other jurisdictions may follow the EU approach and impose similarly strict requirements for the release of such products into the environment and their incorporation into human food or other consumer products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such jurisdictions may also elect to regulate genetically engineered plants without distinguishing between traditional biotechnology-derived plants modified with recombinant DNA and genome edited plants.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that countries for which we may have or may develop future marketing plans would not take a stricter legal and regulatory approach to controlling genetically engineered plants similar to that of the EU, which could increase regulatory costs and delay, prevent or limit our or our future collaborators&#8217; ability to market our traits in such jurisdictions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer resistance to genetically engineered crops may negatively affect the ability to commercialize future crops containing our traits, as well as our public image, and may reduce any future sales of seeds containing our yield traits.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Food and feed made from genetically engineered seeds and plants are not accepted by some consumers, and in certain countries production of certain genetically engineered crops is effectively prohibited, including throughout the EU, due to concerns over such products&#8217; effects on food safety and the environment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Advocacy groups have engaged in publicity campaigns and filed lawsuits in various countries against companies and regulatory authorities, seeking to halt regulatory approval activities or influence public opinion against genetically engineered and/or genome edited products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actions by </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consumer groups and others also may disrupt research and development or production of genetically engineered plants, seeds or food products that incorporate such novel plant varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The high public profile of the biotechnology industry in food and feed production, and a lack of consumer acceptance of the types of products to which we have devoted substantial development resources, could have a negative impact on the commercial success of any of products incorporating our traits that may successfully complete the development process, as to which no assurance can be given, and could materially and adversely affect our ability to obtain future collaborations and to finance our crop science program.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we could incur substantial liability and/or legal expenses if there are claims that genetically engineered crops damage the environment or contaminate other farm crops.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This could distract our management and cause us to spend resources defending against such claims.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government policies and regulations, particularly those affecting the agricultural sector and related industries, could adversely affect our operations and our ability to generate future revenues and to achieve profitability.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agricultural production and trade flows are subject to government policies and regulations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental policies and approvals of technologies affecting the agricultural industry, such as taxes, tariffs, duties, subsidies, incentives and import and export restrictions on agricultural commodities and commodity products can influence the planting of certain crops, the location and size of crop production, and the volume and types of imports and exports.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future government policies in the United States, Canada or in other countries could discourage farmers from using any of our products that may successfully complete the development process, as to which no assurance can be given.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, these policies could discourage food processors from purchasing harvested crops containing our traits or could encourage the use of our competitors&#8217; products, which would put us at a commercial disadvantage and could negatively impact our ability to generate any revenues and to achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The products of third parties, or the environment itself, may be negatively affected by the unintended appearance of our trait genes, novel seed compositions and novel seed products.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The potential for unintended but unavoidable trace amounts, sometimes called &#8220;adventitious presence,&#8221; of trait genes, novel seed compositions and novel seed products in conventional seed, or in the grain or products produced from conventional or organic crops, could affect acceptance by the general public or by the agricultural industry of these traits.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trace amounts of yield trait genes may unintentionally be found outside our containment area in the products of third parties, which may result in negative publicity and claims of liability brought by such third parties against us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in the event of an unintended dissemination of our genetically engineered materials to the environment, we could be subject to claims by multiple parties, including environmental advocacy groups, as well as governmental actions such as mandated crop destruction, product recalls or additional stewardship practices and environmental cleanup or monitoring.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of these events could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss of or damage to our elite novel trait events and plant lines would significantly slow our product development efforts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collection of elite novel trait events and plant lines in which we are developing traits for incorporation into elite germplasm and potential seed products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our elite novel trait events and plant lines are a key strategic asset since they form the basis for the introgression of our traits into plant breeding programs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we suffer loss or damage to our elite novel trait events and plant lines, our research and development activities could be negatively impacted.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our insurance coverage may be inadequate to cover all the liabilities we may incur.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face the risk of exposure to liability claims if any products that are successfully developed containing our seed traits, as to which no assurance can be given, are defective and if any product that we develop or any product that uses our technologies or incorporates any of our traits causes injury.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we carry insurance at levels customary for companies in our industry, such coverage may become unavailable or be inadequate to cover all liabilities we may incur.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be able to continue to maintain such insurance, or obtain comparable insurance at a reasonable cost, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain sufficient insurance coverage at an acceptable cost or otherwise, or if the amount of any claim against us exceeds the coverage under our policies, we may face significant expenses.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct, monitor, support, and oversee field trials and, in some cases, to maintain regulatory files for those products in development, and any performance issues by third parties, or our inability to engage third parties on acceptable terms, may impact our ability to complete the regulatory process for or commercialize such products.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties to conduct, monitor, support, and oversee field trials.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we have less control over the timing and cost of these trials than if we conducted these trials with our own personnel.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or enter into agreements with these third parties on acceptable terms, or if any such engagement is terminated prematurely, we may be unable to conduct and complete our trials in the manner we anticipate.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is no guarantee that these third parties will devote adequate time and resources to our studies or perform as required by our contract or in accordance with regulatory requirements, including maintenance of field trial information regarding our products in development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these third parties fail to meet expected deadlines, fail to transfer to us any regulatory information in a timely manner, fail to adhere to protocols, or fail to act in accordance with regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way that compromises the quality or accuracy of their activities or the data they obtain, then field trials of our traits in development may be extended or delayed with additional costs incurred, or our data may be rejected by the applicable regulatory agencies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ultimately, we are responsible for ensuring that each of our field trials is conducted in accordance with the applicable protocol and with legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be subject to penalties, fines and liabilities if our third-party contractors fail to perform as required.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our relationship with any of these third parties is terminated, we may be unable to enter into arrangements with alternative parties on commercially reasonable terms, or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Switching or adding service providers can involve substantial cost and require extensive management time and focus.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays may occur, which can materially impact our ability to meet our desired development timelines.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to seek alternative service arrangements, the resulting delays and potential inability to find a suitable replacement could materially and adversely impact our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there has been an increasing trend towards consolidation in the agricultural biotechnology industry. Consolidation among our competitors and third parties upon whom we rely could lead to changes in the competitive landscape, capabilities, and strategic priorities among potential service providers, which could have an adverse effect on our business and operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose key personnel or are unable to attract and retain necessary talent, we may be unable to develop or commercialize our products under development.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on our key technical and scientific personnel, who possess unique knowledge and skills related to our research and technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we were to lose the services of these individuals, we may be unable to readily find suitable replacements with comparable knowledge and the experience necessary to advance the research and development of our products.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the unique talents and experience of many of our scientific and technical staff, competition for our personnel is intense.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loss of key personnel or our inability to hire and retain personnel who have the required expertise and skills could have a material adverse effect on our research and development efforts, our business, and our ability to secure additional required financing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations would suffer in the event of system failures.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize information technology systems and networks to process, transmit and store electronic information in connection with our business activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance that we will be successful in preventing cyber-attacks or successful in mitigating their efforts.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from such cyber-attacks, including computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such an event could cause interruption of our operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the loss of data from completed field tests for our yield traits could result in delays in our regulatory approval efforts and significantly increase our costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that any disruption or security breach were to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could suffer reputational harm or face litigation, or adverse regulatory action and the development of our product candidates could be delayed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Intellectual Property</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent protection for our technologies is both important and uncertain.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on our obtaining and maintaining patent protection for our technologies in the United States and other jurisdictions, as well as successfully enforcing and defending this intellectual property against third-party challenges.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to obtain or defend patent protection for our technologies, then we will not be able to exclude competitors from developing or marketing such technologies, and this could negatively impact our ability to generate sufficient revenues or profits from product sales and/or licensing to justify the cost of development of our technologies and to achieve or maintain profitability.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently issued patents include five patents on our C3003 gene in-licensed from the University of Massachusetts, three patents on C4001 and other novel yield traits, and one patent relating to our historical business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently issued patents have expiration dates ranging from 2033 through 2038.  New pending patent applications owned by or licensed to us relating to crop yield improvements have earliest effective filing dates ranging from 2013 through 2023 and include a new patent application on a breakthrough technology for producing PHA biomaterials in crops.  This patent application would have an expiration date in 2040 if granted, however, we may not be able to obtain sufficiently broad claims to cover the new invention.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our patent position involves complex legal and factual questions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents may not be issued for any pending or future pending patent applications owned by or licensed to us, and claims allowed under any issued patent or future issued patent owned or licensed by us may not be valid or sufficiently broad to protect our technologies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be unable to protect certain of our intellectual property in the United States or in foreign countries.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign jurisdictions may not afford the same protections as U.S. law, and we cannot ensure that foreign patent applications will have the same scope as the U.S. patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There will be many countries in which we will choose not to file or maintain patents because of the costs involved.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may also design around our patents or develop competing technologies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, any issued patents owned by or licensed to us now or in the future may be challenged, invalidated, or circumvented.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could incur substantial costs to bring suits or other proceedings in which we may assert or defend our patent rights or challenge the patent rights of third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An unfavorable outcome of any such litigation could have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may claim that we infringe their intellectual property, and we could suffer significant litigation or licensing expense as a result.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various U.S. and foreign issued patents and pending patent applications owned by third parties exist in areas relevant to our products and processes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could incur substantial costs to challenge third-party patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties assert claims against us or our customers alleging infringement of their patents or other intellectual property rights, we could incur substantial costs and diversion of management resources in defending these claims, and the defense of these claims could have a material adverse effect on our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are unsuccessful in defending against these claims, these third parties may be awarded substantial damages, as well as injunctive or other equitable relief against us, which could effectively block our ability to make, use, sell, distribute, or market our technologies and services based on our technologies in the United States or abroad.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alternatively, we may seek licenses to such third-party intellectual property. However, we may be unable to obtain these licenses on acceptable terms, if at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain the necessary licenses or other rights could prevent the sale, manufacture, or distribution of some of our products based on our technologies and, therefore, could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Portions of our crop science technology are owned by or subject to retained rights of third parties.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed and optioned from academic institutions certain patent rights that may be necessary or important to the development and commercialization of our crop science technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These licenses and options may not provide exclusive rights to use such intellectual property in all fields of use in which we may wish to develop or commercialize our </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">technology.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to timely exercise our option rights and/or we are unable to negotiate license agreements for optioned patent rights on acceptable terms, the academic institutions may offer such patent rights to third parties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with our obligations under these license agreements, or if we are subject to a bankruptcy or insolvency proceeding, the licensor may have the right to terminate the license.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some circumstances, we may not have the right to control the preparation, filing and prosecution of licensed patent applications or the maintenance of the licensed patents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, we cannot be certain that these patents and applications will be prosecuted, maintained and enforced in a manner consistent with the best interests of our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the research resulting in certain of our licensed and optioned patent rights was funded by the U.S. government.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, the government may have certain rights to such patent rights and technology.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining necessary rights to additional technologies for the development of our products through acquisitions and in-licenses.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to acquire or in-license additional technologies from third parties that we decide we need in order to develop our business.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of more established companies may also pursue strategies to license or acquire crop science technologies that we may consider attractive.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These established companies may have a competitive advantage over us due to their size, cash resources and greater development and commercialization capabilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure on our part to reach an agreement for any applicable intellectual property could result in a third party acquiring the related rights and thereby harm our business.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also may be unable to license or acquire relevant crop science technologies on terms that would allow us to make an appropriate return on our investment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that competition for acquiring and in-licensing crop science technologies that are attractive to us may increase in the future, which may mean fewer suitable opportunities for us as well as higher acquisition or licensing costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully obtain rights to suitable crop science technologies on reasonable terms, or at all, our business and financial condition could suffer.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our license agreements include royalty payments that we are required to make to third parties.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements that require us to remit royalty payments and other payments related to our licensed intellectual property.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our in-license agreements, we may pay upfront fees and milestone payments and be subject to future royalties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot precisely predict the amount, if any, or timing of royalties we may owe in the future. Furthermore, we may enter into additional license agreements in the future, which may also include royalty, milestone and other payments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The intellectual property landscape around genome editing technology, such as CRISPR, is highly dynamic and uncertain, and any resolution of this uncertainty could have a material adverse effect on our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The field of genome editing, especially in the area of CRISPR technology, is still in its infancy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the intense research and development that is taking place in this field by several companies, including us and our competitors, the intellectual property landscape is in flux, and it may remain uncertain for the coming years.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been, and may continue to be, significant intellectual property related litigation and proceedings relating to this area in the future.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If it is later determined that any patent rights using the CRISPR technology that we obtained under license are invalid or owned by other parties, this could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely in part on trade secrets to protect our technology, and our failure to obtain or maintain trade secret protection could harm our business.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect some of our technology and proprietary information, especially where we believe patent protection is not appropriate or obtainable as is the case for our GRAIN trait gene discovery platform.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, trade secrets are difficult to protect.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigating a claim that a third-party had illegally obtained and was using our trade secrets would be expensive and time consuming, and the outcome would be unpredictable.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, if our competitors </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independently develop similar knowledge, methods and know-how, it will be difficult for us to enforce our rights and our business could be harmed.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Owning our Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional funds may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Execution of our business plan requires additional financing.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through equity offerings or offerings of equity-linked securities, including warrants or convertible debt securities, we expect that our existing stockholders will experience significant dilution, and the terms of such securities may include liquidation or other preferences that adversely affect the rights of current stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt financing, if available, may subject us to restrictive covenants that could limit our flexibility in conducting future business activities, including covenants limiting or restricting our ability to incur additional debt, dispose of assets, or make capital expenditures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also incur ongoing interest expense and be required to grant a security interest in our assets in connection with any debt issuance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through strategic partnerships or licensing agreements with third parties, we may have to relinquish valuable rights to our technologies or grant licenses on terms that are not favorable to us.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading volume in our stock can fluctuate and an active trading market for our common stock may not be available on a consistent basis to provide stockholders with adequate liquidity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile, and our stockholders could lose a significant part of their investment.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The public trading price for our common stock will be affected by a number of factors, including:</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any change in the status of our Nasdaq listing;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">the need for near-term financing to continue operations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">reported progress in our efforts to develop crop related technologies, relative to investor expectations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in earnings estimates, investors&#8217; perceptions, recommendations by securities analysts or our failure to achieve analysts&#8217; earnings estimates;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">general market conditions and other factors unrelated to our operating performance or the operating performance of our competitors;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">future issuances and/or sales of our securities;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements or the absence of announcements by us, or our competitors, regarding acquisitions, new products, regulatory developments, significant contracts, commercial relationships or capital commitments;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">commencement of, or involvement in, litigation;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">any major change in our board of directors or management;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">changes in governmental regulations or in the status of our regulatory approvals;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">announcements related to patents issued to us or our competitors and to litigation involving our intellectual property;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a lack of, or limited, or negative industry or security analyst coverage;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">uncertainty regarding our ability to secure additional cash resources with which to operate our business;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">a decision by our significant stockholders to increase or decrease their holdings in our common stock;</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">short-selling or similar activities by third parties; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">other factors described elsewhere in these risk factors.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, our stockholders may not be able to resell their shares at, or above, their purchase price.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock prices of many technology companies have experienced wide fluctuations that have often been unrelated to the operating performance of those companies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any negative change in the public&#8217;s perception of the prospects of industrial or agricultural biotechnology companies could depress our stock price regardless of our results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors may have a material adverse effect on the market price and liquidity of our common stock and affect our ability to obtain required financing.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our certificate of incorporation and by-laws and Delaware law might discourage, delay or prevent a change of control of our company or changes in our management and, therefore, depress the trading price of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions of our certificate of incorporation and by-laws and Delaware law may discourage, delay or prevent a merger, acquisition or other change in control that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Section 203 of the Delaware General Corporation Law ("DGCL") prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, which generally refers to a person which together with its affiliates owns, or within the last three years has owned, 15 percent or more of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They could also deter potential acquirers of our company, thereby reducing the likelihood that our stockholders could receive a premium for their common stock in an acquisition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of ownership among our officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the number of shares outstanding as of March 7, 2023, our officers, directors and stockholders who hold at least 5 percent of our stock beneficially own a combined total of approximately 30.8 percent of our outstanding common stock, including shares of common stock subject to stock options and warrants that are currently exercisable or are exercisable within 60 days after March 7, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these officers, directors, and principal stockholders or a group of our principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and control matters requiring stockholder approval, including the election of directors and approval of mergers, business combinations or other significant transactions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interests of one or more of these stockholders may not always coincide with our interests or the interests of other stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, officers, directors, and principal stockholders, acting together, could cause us to enter into transactions or agreements that we would not otherwise consider.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, this concentration of ownership may have the effect of delaying or preventing a change in control of our company otherwise favored by our other stockholders.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 7, 2023, Jack W. Schuler (and his related entities) beneficially owned approximately 23.7 percent of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that this or any other significant stockholders oppose any proposal put forth for stockholder approval by our board of directors, they control a sufficient percentage of our outstanding shares to cause such proposal to either fail or be very difficult to achieve without their support.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This, in turn, could have a negative effect on the market price of our common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It could also prevent our stockholders from realizing a premium over the market price for their shares of common stock.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The concentration of ownership also may contribute to the low trading volume and volatility of our common stock.</span></div><div id="ic02604fb0219453aa54b246df7a39126_22"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.&#160;&#160;&#160;&#160;UNRESOLVED STAFF COMMENTS</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic02604fb0219453aa54b246df7a39126_25"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;PROPERTIES</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own any real property.  We are party to a lease agreement pursuant to which we lease 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts.  This lease began on June 1, 2016 and will end on November 30, 2026, and does not include any options for the early termination or the extension of the lease.  We have provided the landlord with a security deposit of $229.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") for CJ's sublease of 9,874 square feet of our Woburn facility.  The subleased space was determined to be in excess of our needs as a result of our strategic shift and the related restructuring of our operations during 2016.  The sublease is coterminous with our master lease.  CJ pays rent and operating expenses equal to its pro-rata share of the amounts payable to the landlord by us, as adjusted from time-to-time in accordance with the terms of the master lease.  CJ has provided us with a security deposit of $103 in the form of an irrevocable letter of credit.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 9,600 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place.  These leases do not contain renewal or early termination options.  YOI's leases for these facilities generally have terms of one year, and are extended annually through amendment.  Most of these leases will expire on various dates through September 30, 2023.</span></div><div id="ic02604fb0219453aa54b246df7a39126_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. We are not currently aware of any such proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.</span></div><div id="ic02604fb0219453aa54b246df7a39126_31"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic02604fb0219453aa54b246df7a39126_1382"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION ABOUT OUR DIRECTORS AND EXECUTIVE OFFICERS </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Directors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert L. Van Nostrand</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chairman of the Board of Directors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oliver P. Peoples, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sherri M. Brown, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independent Consultant</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard W. Hamilton, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer and Director at Prosper DNA, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Willie Loh, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Independent Consultant</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthony J. Sinskey, Sc.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professor of Microbiology, Massachusetts Institute of Technology</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oliver P. Peoples, Ph.D.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">President and Chief Executive Officer</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lynne H. Brum</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Planning and Corporate Communications</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charles B. Haaser</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vice President, Finance, Chief Accounting Officer and Treasurer</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kristi D. Snell, Ph.D.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vice President, Research and Chief Science Officer</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="ic02604fb0219453aa54b246df7a39126_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is traded on the Nasdaq Capital Market under the symbol "YTEN."</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;8, 2023, there were 5,069,380 shares of our common stock outstanding held by 27 stockholders of record.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unregistered Sales of Securities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2023, we issued 17,578 shares of common stock to participants in our Yield10 Bioscience,&#160;Inc. 401(k) Plan as a matching contribution.  The issuance of these securities was exempt from registration pursuant to Section&#160;3(a)(2) of the Securities Act.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended December&#160;31, 2022, there were no repurchases made by us or on our behalf, or by any "affiliated purchasers," of shares of our common stock.</span></div><div id="ic02604fb0219453aa54b246df7a39126_40"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.  [RESERVED]</span></div><div id="ic02604fb0219453aa54b246df7a39126_43"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in this Annual Report on Form&#160;10-K.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All dollar amounts are stated in thousands.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company focused on the large-scale production of low carbon sustainable products from processing Camelina seed using the oilseed Camelina sativa ("Camelina") as a platform crop. These seed products include:</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Camelina oil for use as a low carbon biofuel feedstock</span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Omega-3 oils for nutrition </span></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PHA Bioplastics for biodegradable zero waste packaging solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The co-product from producing these seed products is Camelina meal which has a protein content of over 40% and is currently approved for use in a range of animal feed rations.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from our development pipeline which offer improved on-farm performance that we anticipate will lead to increased acreage adoption and seed and grain product revenue.  We also plan to create additional value for our shareholders by licensing yield and seed oil traits from our pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola.  Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Grants</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, Yield10 Oilseeds, Inc. (&#8220;YOI&#8221;), the Company&#8217;s wholly-owned Canadian research subsidiary, received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC").  The objective of the grant was to provide financial research assistance to innovative, early-stage </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">small and medium-sized enterprises.  Under the terms of the agreement, NRC agreed to contribute up to a maximum of $39 for payroll costs incurred by YOI during the period from December 20, 2020 to March 13, 2021.  During the first quarter of 2021, YOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, we entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Systems Approach to Increasing Carbon Flux to Seed Oil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"  Our participation under this five-year grant has been awarded incrementally on an annual basis with the first year commencing on September 15, 2017.  Funding for this sub-award for the full grant amount of $2,957 was appropriated by the U.S. Congress through the contractual year ending in September 2022.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, we recognized $450 and $575, respectively, from this sub-award.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, proceeds of $60 remain to be recognized under our MSU sub-award as shown in the table below.  During June 2022, the parties amended the sub-award to extend its termination date to September 15, 2023, to allow Yield10 time to utilize the remaining grant funds.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.167%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.185%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program&#160;Title</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Funding<br/>Agency</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Government Funds</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total revenue</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">recognized through</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining amount to be recognized</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31, 2022</span></div></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contract/Grant<br/>Expiration</span></td></tr><tr style="height:24pt"><td colspan="33" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subcontract from Michigan State University project funded by DOE entitled "A Systems Approach to Increasing Carbon Flux to Seed Oil"</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Department of Energy</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,957&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,897&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 15, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Funding from National Research Council Canada through its Industrial Research Assistance Program (NRC-IRAP) entitled "Innovation Assistance Program"</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">National Research Council Canada</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 13, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimates and Judgments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").  The preparation of these consolidated financial statements often requires us to make judgments and accounting estimates that can materially affect the amounts reported in the consolidated financial statements and accompanying notes.  These judgments and estimates can have a significant effect on the financial statements because they result primarily from estimates about the effects of matters that are inherently uncertain.  We make these estimates and judgments based on guidance provided by current GAAP, historical experience and various other assumptions that we believe to be reasonable under the circumstances.  Our actual results may differ from these estimates.    </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the specific accounting policies and significant judgments described below are the most critical to aid in fully understanding and evaluating our consolidated financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting standards for stock-based compensation require that all stock-based awards be recognized as an expense in the consolidated financial statements and that such expense be measured based on the fair value of the award.  We use the Black-Scholes option-pricing model to value our service-based option grants and to determine the related compensation expense to be recognized over each award's vesting period.  Calculating the fair value of stock-based payment awards using modeling techniques requires the use of assumptions.  These assumptions represent our best estimates, but the estimates involve inherent uncertainties and the application of judgment.  We adjust our modeling assumptions when valuing new stock awards based on actual experience.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Due to the Company's history of annual income tax losses, it has never incurred significant income tax expense.  We have, however, historically recorded and disclosed in our financial statements significant </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">deferred income tax assets for net operating loss carry forwards and research tax credits that may be available to offset future taxable income.  We routinely assess the realizability of the Company's deferred tax assets and have historically concluded that it is unlikely that deferred tax assets derived from our U.S. operations will be realized under current accounting standards and therefore we have consistently maintained a full valuation allowance against these tax assets.  Our U.S. deferred tax assets are also subject to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">substantial annual limitation under Section 382 of the Internal Revenue Code of 1986 due to stock ownership changes that have occurred, primarily as a result of our securities offerings.  The calculation of Section 382 limitations is highly judgmental and the calculations are complex.  Based on an analysis completed during 2021, we have concluded that all of our historical U.S. deferred tax assets generated through November 31, 2019 are no longer available to us for future use to offset taxable income.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2022, YOI performed research and development services for Yield10 under a research services agreement subject to intercompany transfer pricing regulations established in the U.S. and Canada.  These regulations required that YOI earn an arms-length profit from the research services, calculated in accordance with U.S. and Canadian tax regulations.  YOI has historically filed for research tax credit carryforwards in the past that have been used to offset its taxable income generated as a result of the intercompany profit.  These accumulated Canadian research credits were recorded as a deferred tax asset within our consolidated balance sheet at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021, </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">based on our judgment that YOI would continue to earn taxable income in the future and the deferred tax asset would be realized.  However, in our current estimation, the negative evidence related to the Company's decline in its cash and short-term investment balances through the end of 2022 now outweighs the positive evidence of YOI's historic earnings.  We believe that it is now more likely than not that the remaining deferred tax assets will not be utilized and, as such, we have recorded a full valuation allowance against the remaining deferred tax asset in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Offerings</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We offer our securities for sale to public and private investors from time to time.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The structure of these offerings can be relatively straight-forward or they can be highly complex, requiring significant judgment in their accounting treatment and financial reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our historical offerings completed to date have included different classes of securities, including common stock, convertible preferred stock and warrants with various exercise prices and terms.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Depending on the facts and circumstances of each offering, including; the offering and market price of our common stock, the amount of cash proceeds received, the fair value determination of each type of security issued, the availability of authorized and unissued common shares to support conversion of preferred shares or the exercise of the warrants, the specific terms of securities purchase agreements and other factors that may come into consideration, the shares of an offering may be recorded as permanent or temporary equity within our balance sheets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of warrants issued in an offering, under certain situations, may be recorded as a liability and be subject to mark-to-market adjustments on each balance sheet date based on changes in their fair value determined using the Black-Scholes valuation model. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We carefully analyze our securities offerings to ensure that we record them in accordance with current accounting guidance.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a lessee, we follow the lease accounting guidance codified in ASC 842.  Under this guidance, a lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease.  Any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  The application of this guidance requires judgment.  Under ASC 842, a lease liability is recorded on the commencement date of a lease and is calculated as the present value of the remaining lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the lessee's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  If a lease subject to ASC 842 is amended, the right-of-use asset and lease liability are adjusted, if appropriate.  These mathematical calculations to comply with ASC 842 can be complex.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comparison of the Years Ended December&#160;31, 2022 and 2021 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:54.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Grant revenue was $450 and $614 for the years ended December&#160;31, 2022 and 2021, respectively.  All of the grant revenue recorded during the year ended December&#160;31, 2022 was derived from the Company's DOE sub-award with MSU.  </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, grant revenue of $575 and $39 was recognized from the DOE sub-award and the short-term NRC grant that was awarded to YOI in February 2021, respectively.</span></div><div style="margin-bottom:9pt;padding-right:13.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that grant revenue will decrease during the year ended December 31, 2023 in comparison to the year ended December&#160;31, 2022, as a result of lower remaining grant appropriations of $60 that we expect to earn during the first quarter of 2023 from our MSU sub-award that ends in September 2023.  We currently cannot assess whether additional U.S. or Canadian government research grants will be awarded to us during 2023.  Our forecast related to grant revenue is subject to change, however, should we receive new grants or if our ability to earn revenue from our existing grant is negatively impacted by the COVID-19 pandemic.</span></div><div style="margin-bottom:12pt;padding-right:13.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contracted with growers in Canada and the U.S. for small-scale Camelina winter grain production in the fall of 2022, for approximately 1,000 total acres, to supply oil to the renewable diesel fuel market.  Harvest of this first winter commercial grain production is expected to occur in the summer of 2023, at which time we anticipate that we may begin to recognize grain revenue in amounts scaled to the grain yield and the number of acres under contract.  Future grain revenue derived from our upcoming spring 2023 grower agreements and future growing seasons will be based, among other things, on our ability to scale up commercial seed production, engage with growers and enter into offtake agreements with customers in the renewable diesel market.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.702%"><tr><td style="width:1.0%"></td><td style="width:54.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,201&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,549&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,306&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense increased by $1,549, or 25%, from $6,201 during the year ended December&#160;31, 2021 to $7,750 during the year ended December&#160;31, 2022.  The 2022 increase is primarily due to higher employee compensation and benefits expense, expanded crop trial costs, higher third-party research services, costs associated with pre-commercial Camelina seed production and increased facility-related expenses.  Employee compensation and benefits increased by $497 from $3,547 during the year ended December&#160;31, 2021 to $4,044 during the year ended December&#160;31, 2022.  The increase is primarily the result of a $600 increase in payroll charges generated from annual employee compensation increases and our hiring of additional staff.  Stock-based employee compensation expense also increased by $82 during the year ended December&#160;31, 2022 due to employee stock options awarded during the past year.  Lower recruiting related expenses of $74 offset a portion of these increased employee related expenses.  Crop trial expense increased by $366 during the year ended December&#160;31, 2022 in comparison to the year ended December&#160;31, 2021 and primarily stems from our evaluation of Camelina plant varieties, including those demonstrating herbicide tolerance.  Third-party research services increased by $154 during the year ended December&#160;31, 2022 in comparison to the previous year and is primarily the result of DNA sequencing and other analytical work undertaken for regulatory purposes.  During the year ended December&#160;31, 2022, we also incurred $226 in charges for pre-commercial Camelina seed production, including seed multiplication, cleaning, packaging and storage costs.  We did not have similar expenses during the year ended December&#160;31, 2021.  Facility-related expenses increased by $138 during the year ended December&#160;31, 2022, primarily as a result of our leasing additional laboratory and greenhouse space in support of our Camelina research activities in Saskatoon, Saskatchewan, Canada.</span></div><div style="margin-bottom:12pt;padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current planning and forecasting, we anticipate that our research and development expenses during the year ended December 31, 2023 will increase above levels incurred during the year ended December&#160;31, 2022, as we continue our efforts to develop and commercialize Camelina plant varieties for the following markets: feedstock oil for renewable diesel, PHA bioplastics, omega-3 oil for nutraceuticals, and aquaculture fish feed and as a protein meal to be used in animal feed markets.  The increased expenses will include employee compensation and benefits from recent and future personnel hiring, further expansion of our crop trial programs, seed scale up and pre-commercial Camelina production activities.  Our forecast related to research and development expense is subject to change and may be impacted by our ability to raise additional working capital to support our planned operations, the potential impact of the COVID-19 pandemic or the advent of third-party collaborations or other business opportunities that could alter our plans.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $6,151 and $6,105 for the fiscal years ended December&#160;31, 2022 and December&#160;31, 2021, respectively.  The increase of $46, or 1%, was primarily due to increased employee compensation and benefits expense that increased by $66, from $2,762 during the year ended December&#160;31, 2021 to $2,828 during the year ended December&#160;31, 2022.  The net increase was primarily the result of a $146 increase in stock-based compensation expense partially offset by reductions in employee payroll and bonus expenses of $32 and lower recruiting-related expenses of $56.</span></div><div style="padding-right:4.5pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on current planning and forecasting, we anticipate that our general and administrative expenses during the year ended December 31, 2023 will increase to levels above expenses incurred during the year ended December&#160;31, 2022, as we scale up activities in support of our commercial growth, including increasing employee headcount, legal expenses, license payments and travel-related expenses in support of business development.  Our forecast related to general and administrative expense is subject to change and may be impacted by our ability to raise additional working capital to support our plans, the potential impact of the COVID-19 pandemic or the advent of new third-party collaborations or other business opportunities that could alter our plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income (Expense), net</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended<br/>December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(700)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Gain on Investment in Related Party</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 1999, Yield10 entered into a technology sublicense agreement with Tepha, Inc. ("Tepha"), a privately held related party engaged in the development of medical products.  Yield10 received 648,149 shares of Series A Convertible Preferred Stock of Tepha ("Tepha Shares") during 2002 as consideration for outstanding license payments due to Yield10 totaling $700.  During 2005, the Company determined the value of the Tepha Shares was impaired resulting in their write off through a charge to other income (expense).  In May 2021, the board of directors of Tepha approved and authorized the merger of Tepha with Becton Dickinson Global Holdings, Inc. ("Becton Dickinson").  On July 26, 2021, Yield10 received cash consideration of $700 in exchange for the surrender of its Tepha Shares upon the closing of the sale of Tepha to Becton Dickinson.  As a result, the Company recorded the $700 as a gain on investment in related party within other income (expense) during the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Income (expense), net</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Other income (expense) for the years ended December&#160;31, 2022 and December&#160;31, 2021 was derived primarily from investment income earned from the Company's cash equivalents and investments offset by interest expense and investment management fees incurred during the year.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant expenses related to our research, development and commercialization efforts, which in recent years have been focused on Camelina.  With the exception of 2012, we have recorded annual losses since the Company's initial founding, including our fiscal year ended December&#160;31, 2022.  As of December&#160;31, 2022, we had an accumulated deficit of $399,697.  Our total unrestricted cash, cash equivalents and short-term investments as of December&#160;31, 2022, totaled $4,347 as compared to $15,990 at December&#160;31, 2021.  As of December&#160;31, 2022, we had no outstanding debt.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and short-term investments at December&#160;31, 2022 were held for working capital purposes.  As of December&#160;31, 2022, we had restricted cash of $264, which consisted of $229 held in connection with the lease agreement for our Woburn, Massachusetts facility and $35 held in connection with our corporate credit card program.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments are made in accordance with our corporate investment policy, as approved by our Board of Directors. The primary objective of this policy is to preserve principal, and consequently, investments are limited to high quality </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">corporate debt, U.S. Treasury bills and notes, money market funds, bank debt obligations, municipal debt obligations and asset-backed securities.  The policy establishes maturity and concentration limits, and liquidity requirements.  As of December&#160;31, 2022, we were in compliance with this policy.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Material Cash Requirements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to obtaining additional working capital funding, we currently anticipate net cash usage of $13,000 to $14,000 to fund our operations during 2023, including our expanded research and development, administrative and Camelina commercial launch activities.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We require cash to fund our working capital needs, to purchase capital assets, to pay our lease obligations and other operating costs.  The primary sources of our liquidity have historically included equity financings, government research grants and income earned on cash equivalents and short-term investments.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We routinely enter into contractual commitments with third parties to support our operating activities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The more significant of these commitments includes real estate operating leases for our office, laboratory and greenhouse facilities located in the U.S. and Canada.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we typically enter into annual premium funding arrangements through our insurance broker that allows us to spread the payment of our directors' and officers' liability and other business insurance premiums over the terms of the policies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our material commitments also include arrangements with third party growers located in North and South America for the execution of crop trials and seed scale-up activities to further our trait development goals and to progress the commercial development of our Camelina plant varieties.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The aggregate cost of these contracted crop activities is substantial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the fall of 2022, we also began entering into Camelina grain production contracts for the winter 2022/2023 season that contain minimum guaranteed payments per acre as an incentive for growers to work with us.  From time-to-time, we also enter into exclusive research licensing and collaboration arrangements with third parties for the development of intellectual property related to trait development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These long-term agreements typically include initial licensing payments and future contingent milestone payments associated with regulatory filings and approvals as well as potential royalty payments based on future product sales.  Generally, these licensing arrangements contain early termination provisions within the terms of the respective agreements.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has no off-balance sheet arrangements as defined in Item 303(b) of Regulation S-K of the Securities Exchange Act of 1934.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Going Concern</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We follow the guidance of ASC Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements-Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about our ability to continue as a going concern for one year after the date our financial statements are issued.  Based on our current cash forecast, we expect that our present capital resources will not be sufficient to fund our planned operations for at least that period of time, which raises substantial doubt as to the Company's ability to continue as a going concern.  This forecast of cash resources is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.  Our ability to continue operations after our current cash resources are exhausted will depend upon our ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, and additional government research grants or collaborative arrangements with third parties, as to which no assurances can be given.  We do not know whether additional financing will be available on terms favorable or acceptable to us when needed, if at all.  If additional funds are not available when required, we will be forced to curtail our research efforts, explore strategic alternatives and/or wind down our operations and pursue options for liquidating our remaining assets, including intellectual property and equipment.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we issue equity or debt securities to raise additional funds, (i)&#160;the Company may incur fees associated with such issuance, (ii)&#160;our existing stockholders will experience dilution from the issuance of new equity securities, (iii)&#160;the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv)&#160;the new equity or debt securities may have rights, preferences and privileges senior to those of our existing stockholders.  In addition, utilization of our net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section&#160;382 of the Internal Revenue Code of 1986 due to ownership changes resulting from future equity financing transactions.  If we raise additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to our potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market ("ATM") Program</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;24, 2023, we entered into an Equity Distribution Agreement (the "Sales Agreement") with Maxim Group LLC ("Maxim"), under which we may offer and sell shares of our common stock, $0.01 par value per share, having an aggregate offering price of up to $4,200 from time to time through Maxim, acting exclusively as the Company's sales agent (the "Offering").  On January&#160;24, 2023, we filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering under our existing Registration Statement on Form S-3 (File No 333-254830), which was declared effective on April 2, 2021.  We intend to use the net proceeds of the Offering primarily for working capital and general corporate purposes.  Maxim will be entitled to compensation at a fixed commission rate of 2.75% of the gross sales price per share sold.  In addition, we agreed to reimburse Maxim for its costs and out-of-pocket expenses incurred in connection with its services, including the fees and out-of-pocket expenses of its legal counsel.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not obligated to make any sales under the Sales Agreement and no assurance can be given that we will sell any shares,, or the dates on which any such sales will take place.  The Sales Agreement will continue until the earliest of (i) twelve (12) months following the date of the Sales Agreement, (ii) the sale of shares thereunder having an aggregate offering price of $4,200, and (iii) the termination by us upon ten (10) days written notice or by Maxim immediately upon written notification to the Company.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January&#160;24, 2023 through  March&#160;14, 2023, we issued 94,665 shares of common stock in connection with the ATM at per share prices between $3.03 and $4.08, resulting in net proceeds to the Company of approximately $290 after subtracting sales commissions.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Year 2022 Cash Usage</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $11,404 during the year ended December&#160;31, 2022, compared to net cash used by operating activities during 2021 of $9,253.  Net cash used by operations during the year ended December&#160;31, 2022 primarily reflects the net loss of $13,566, cash payments made to reduce the Company's lease liabilities of $520 and our payment of 2021 bonus compensation of $378 during early 2022.  Non-cash charges offsetting a portion of the net loss include depreciation and amortization expense of $263, stock-based compensation expense of $1,903, our 401(k) stock matching contribution expense of $133 and non-cash lease expense of $393 resulting from amortization of our right-of-use asset.  The net cash usage for operating activities during the year ended December&#160;31, 2021 of $9,253 was primarily the result of the Company's net loss of $11,031, cash payments to reduce the Company's lease liabilities of $463 and our payment of 2020 bonus compensation of $460.  Non-cash charges offsetting a portion of the net loss included depreciation and amortization expense of $220, stock-based compensation expense of $1,675, our 401(k) stock matching contribution expense of $112 and non-cash lease expense of $358.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash of $8,522 was provided by investing activities during the year ended December&#160;31, 2022, compared to net cash used for investing activities during 2021 of $4,578.  During the year ended December&#160;31, 2022, the Company purchased $2,445 in short-term investments, primarily U.S. Treasury notes and federal agency bonds.  Also during 2022, $11,121 of our short-term investments matured and converted to cash.  During the year ended December&#160;31, 2021, we purchased $10,639 in similar short-term investments and investments totaling $6,250 matured and converted to cash.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash of $37 was used by financing activities during the year ended December&#160;31, 2022, compared to net cash provided by financing activities of $15,746 during the year ended December&#160;31, 2021.  During the year ended December&#160;31, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a price of $12.25 per share, receiving proceeds of $12,740 before issuance costs of $747.  Also during 2021, a total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing $3,856 in cash proceeds.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 1999, the Company entered into a technology sublicense agreement with Tepha, which was a related party engaged in the development of medical products.  Yield10 received 648,149 shares of Series A Convertible Preferred Stock </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Tepha during 2002 as consideration for outstanding license payments due to Yield10 totaling $700.  In July 2021, Tepha merged with Becton Dickinson and we received cash consideration of $700 in exchange for our Tepha Shares.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Changes</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of recent accounting standards please read Note&#160;2, Summary of Significant Accounting Policies, to our consolidated financial statements included in this report.</span></div><div id="ic02604fb0219453aa54b246df7a39126_46"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic02604fb0219453aa54b246df7a39126_49"></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements and related financial statement schedules required to be filed are indexed on page&#160;F-1 and are incorporated herein.</span></div><div id="ic02604fb0219453aa54b246df7a39126_52"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.&#160;&#160;&#160;&#160;CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic02604fb0219453aa54b246df7a39126_55"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the end of the period covered by this Annual Report on Form&#160;10-K, under the supervision of our Chief Executive Officer and our Chief Accounting Officer, we evaluated the effectiveness of our disclosure controls and procedures, as such term is defined in Rule&#160;13a-15(e) and Rule&#160;15d-15(e) under the Exchange Act.  Based on this evaluation, our Chief Executive Officer and our Chief Accounting Officer concluded that as of December&#160;31, 2022 our disclosure controls and procedures were effective to provide reasonable assurance that the information we are required to disclose in reports that we file or submit under the Exchange Act (1)&#160;is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (2)&#160;is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Accounting Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures include components of our internal control over financial reporting.  Management's assessment of the effectiveness of our internal control over financial reporting is expressed at the level of reasonable assurance because a control system, no matter how well designed and operated, can provide only reasonable, but not absolute, assurance that the control system's objectives will be met.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management's Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules&#160;13a-15(f) and 15d-15(f) of the Exchange Act.  Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.  Our internal control over financial reporting includes those policies and procedures that (i)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii)&#160;provide reasonable assurance that transactions are recorded to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are made only in accordance with authorizations of our management and directors; and (iii)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2022.  In making this assessment, management used the criteria set forth in the 2017&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on its assessment of internal control over financial reporting, management has concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule&#160;13a-15(d) of the Exchange Act that occurred during our last fiscal quarter in the period covered by this Annual Report on Form&#160;10-K that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="ic02604fb0219453aa54b246df7a39126_58"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ic02604fb0219453aa54b246df7a39126_61"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.&#160;&#160;&#160;&#160;DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic02604fb0219453aa54b246df7a39126_64"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.     DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Directors and Executive Officers,&#8221; &#8220;Corporate Governance and Board Matters&#8221; and &#8220;Code of Business Conduct and Ethics&#8221; in our proxy statement for the 2023 annual meeting of stockholders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.      EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Executive Compensation,&#8221; &#8220;Director Compensation,&#8221; &#8220;Corporate Governance and Board Matters&#8221; and &#8220;Compensation Risk Assessment&#8221; in our proxy statement for the 2023 annual meeting of stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.     SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Security Ownership of Certain Beneficial Owners and Management,&#8221; &#8220;Securities Authorized for Issuance under Equity Compensation Plans&#8221; and "Proposal 2: Approval of an Amendment to the Company's 2018 Stock Option and Incentive Plan" in our proxy statement for the 2023 annual meeting of stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.     CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the captions &#8220;Certain Relationships and Related Person Transactions,&#8221; &#8220;Corporate Governance and Board Matters&#8221; and &#8220;The Board of Directors and its Committees&#8221; in our proxy statement for the 2023 annual meeting of stockholders.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.     PRINCIPAL ACCOUNTANT FEES AND SERVICE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The response to this item is incorporated by reference from the discussion responsive thereto under the caption &#8220;Independent Registered Public Accountants&#8221; in our proxy statement for the 2023 annual meeting of stockholders.</span></div><div><span><br/></span></div><div id="ic02604fb0219453aa54b246df7a39126_67"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="ic02604fb0219453aa54b246df7a39126_70"></div><div style="-sec-extract:summary;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160;&#160;&#160;&#160;EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">The following documents are filed as part of this Report:</span></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Financial Statements</span></div><div style="margin-bottom:9pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements on page&#160;F-1.</span></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Supplemental Schedules</span></div><div style="margin-bottom:9pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules have been omitted because the required information is not present in amounts sufficient to require submission of the schedule, or because the required information is included in the consolidated financial statements or notes thereto.</span></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.34pt">Exhibits</span></div><div style="margin-bottom:9pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item&#160;15(b) below.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">The following exhibits are filed as part of, or incorporated by reference into, this Annual Report on Form&#160;10-K:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filed Herewith</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Incorporated by Reference herein from Form or Schedule</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Filing Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SEC File/ Reg. Number</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170216000081/exhibit21apa.htm">Asset Purchase Agreement between Metabolix, Inc. and CJ Research Center LLC, dated September 16, 2016.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 2.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9/21/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170218000031/ex-31x20180630.htm">Amended and Restated Certificate of Incorporation, as amended, of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170220000009/exhibit31011520.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/15/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170219000090/yten-closing8xkexhibit31se.htm">Certificate of Designation of Preferences, Rights and Limitations with respect to the Series A Preferred Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170219000090/yten-closing8xkexhibit32se.htm">Certificate of Designation of Preferences, Rights and Limitations with respect to the Series B Preferred Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 3.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170221000059/ex-31x20210930.htm">Amended and Restated By-laws of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/10/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh41.htm">Description of Securities of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170220000081/ex-4x20200930.htm">Specimen Stock Certificate for shares of the Registrant's Common Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 4.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/12/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465917043593/a17-16039_3ex4d1.htm">Form of Investor Warrant to Purchase Common Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 4.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/5/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465917073677/a17-28240_4ex4d3.htm">Form of Series A Common Warrant to purchase shares of Common Stock.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-1/A (Exhibit 4.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/15/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-221283</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170219000090/yten-closing8xkexhibit41no.htm">Form of Common Stock Purchase Warrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 4.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000104746906012980/a2173393zex-10_3.txt">2006 Stock Option and Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-1/A (Exhibit 10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-135760</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000104746906012980/a2173393zex-10_31.txt">2006 Stock Option and Incentive Plan, Form of Incentive Stock Option Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-1/A (Exhibit 10.3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-135760</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000104746906012980/a2173393zex-10_32.txt">2006 Stock Option and Incentive Plan, Form of Non-Qualified Stock Option Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-1/A (Exhibit 10.3.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-135760</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000104746906012980/a2173393zex-10_33.txt">2006 Stock Option and Incentive Plan, Form of Director Non-Qualified Stock Option Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S-1/A (Exhibit 10.3.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-135760</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170215000032/ex-101x2014stock_optionxan.htm">2014 Stock Option and Incentive Plan, Revised and Restated.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/13/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170215000010/a20141231_exhibit1031.htm">2014 Stock Option and Incentive Plan, Form of Incentive Stock Option Award.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.3.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170215000010/a20141231_exhibit1032.htm">2014 Stock Option and Incentive Plan, Form of Non-Qualified Stock Option Award.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.3.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170215000010/a20141231_exhibit1033.htm">2014 Stock Option and Incentive Plan, Form of Restricted Stock Unit Award.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.3.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170221000045/exhibit101.htm">Amended and Restated 2018 Stock Option and Incentive Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/11/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170219000007/yten-20181231_exhibit1025.htm">Amended and Restated 2018 Stock Option and Incentive Plan, Form of Stock Option Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.2.5)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/28/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170220000019/yten-20191231x10kexh10262.htm">2018 Stock Option and Incentive Plan, Form of Restricted Stock Unit Agreement.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.2.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit103.htm">Employment Agreement between the Company and Oliver P. Peoples dated March 28, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit104.htm">Employment Agreement between the Company and Charles B. Haaser dated March 28, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.4)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit106.htm">Employment Agreement between the Company and Lynne H. Brum dated March 28, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.6)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit108.htm">Employment Agreement between the Company and Kristi Snell dated March 28, 2017.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.8)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit109.htm">Form of Employee Noncompetition, Confidentiality and Inventions Agreement between the Company and its Employee.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.9)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000104746906012980/a2173393zex-10_14.txt">Form of Indemnification Agreement between the Registrant and its Directors and Officers.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form S/1/A (Exhibit 10.14)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/20/2006</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-135760</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465915045951/a15-12923_4ex10d1.htm">Standstill Agreement dated June 19, 2015 between the Company and Jack W. Schuler, Renate Schuler and the Schuler Family Foundation.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/17/2015</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465916091448/a16-2611_2ex10d1.htm">Lease Agreement between the Company and ARE MA Region No. 20, LLC dated January 20, 2016 for the premises located at 19 Presidential Way, Woburn, MA.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/26/2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170217000024/yten-20161231_exhibit1020.htm">Sublease between CJ Research Center LLC and the Company, dated as of September 16, 2016.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 10.20)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/30/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465917043593/a17-16039_3ex10d1.htm">Form of Securities Purchase Agreement dated July 3, 2017 between the Company and the Purchasers named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/5/2017</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14@</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170218000031/ex-102x20180630.htm">Exclusive License Agreement, dated May 17, 2018, between the Company and the University of Missouri.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-Q (Exhibit 10.2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/9/2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465919015034/a19-6414_3ex10d1.htm">Form of Securities Purchase Agreement dated March 14, 2019 between the Company and the Investors named therein.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/15/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170219000090/yten-closing8xkexhibit101s.htm">Securities Purchase Agreement, dated as of November 14, 2019, by and between Yield10 Bioscience, Inc. and the Investors listed on Schedule I thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11/20/2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465920098372/tm2029125d3_ex10-1.htm">Securities Purchase Agreement, dated as of August 22, 2020, by and between Yield10 Bioscience, Inc. and the Investors listed on Schedule I thereto.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/25/2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh1018.htm">Collaboration and Option Agreement, dated November 12, 2020, by and between Yield10 Bioscience, Inc. and Rothamsted Research Institute, as amended.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.977%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000110465923005942/tm234196d1_ex1-1.htm">Equity Distribution Agreement, dated January 23, 2023, by and between the Company and Maxim Group LLC. </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 8-K (Exhibit 1.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/24/23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1121702/000112170221000010/yten-20201231_exhibit211.htm">Subsidiaries of the Registrant.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form 10-K (Exhibit 21.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/16/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33133</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh231.htm">Consent of RSM US&#160;LLP, an independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh311.htm">Certification Pursuant to Rule&#160;13a-14(a) or Rule&#160;15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh312.htm">Certification Pursuant to Rule&#160;13a-14(a) or Rule&#160;15d-14(a) of the Securities Exchange Act of 1934.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="yten-20221231x10kexh321.htm">Certification Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial information from the Yield10 Bioscience,&#160;Inc. Annual Report on Form&#160;10-K for the year ended December&#160;31, 2022 formatted in XBRL; (i)&#160;Consolidated Balance Sheets, December&#160;31, 2022 and December&#160;31, 2021; (ii)&#160;Consolidated Statements of Operations, Years Ended December&#160;31, 2022 and 2021; (iii)&#160;Consolidated Statements of Comprehensive Income (Loss), Years Ended December&#160;31, 2022 and 2021; (iv)&#160;Consolidated Statements of Cash Flows, Years Ended December&#160;31, 2022 and 2021; (v)&#160;Consolidated Statements of Stockholders' Equity for the Years Ended December&#160;31, 2022 and 2021; and (vi)&#160;Notes to Consolidated Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.740%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">@</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain confidential portions of this Exhibit were omitted by means of marking such portions with brackets ("[***]") because the identified confidential portions (i) are not material and (ii) is the type of information that the Company treats as private or confidential.</span></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.    FORM 10-K SUMMARY</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ic02604fb0219453aa54b246df7a39126_76"></div><div style="margin-bottom:9pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.884%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YIELD10 BIOSCIENCE, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ OLIVER P. PEOPLES</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oliver P. Peoples, Ph.D.<br/>President and Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.959%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.098%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ OLIVER P. PEOPLES</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oliver P. Peoples, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CHARLES B. HAASER</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance, and Chief Accounting Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles B. Haaser</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SHERRI M. BROWN</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sherri M. Brown</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ RICHARD W. HAMILTON</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard W. Hamilton, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ WILLIE LOH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Willie Loh, Ph.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ANTHONY J. SINSKEY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthony J. Sinskey, Sc.D.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ ROBERT L. VAN NOSTRAND</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 14, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert L. Van Nostrand</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_79"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:94.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.662%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_82">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl83OS9mcmFnOjMxNzc1OGVkMzY1ZjRkMTNiOWI1ODdkY2QwYWZkOWVmL3RhYmxlOmRjNGM2MWUxNjkyZTQzNjRiODIxNjNjYmM5MjM3ZjkxL3RhYmxlcmFuZ2U6ZGM0YzYxZTE2OTJlNDM2NGI4MjE2M2NiYzkyMzdmOTFfMi0wLTEtMS01NTY3Ni90ZXh0cmVnaW9uOjEyZWE3ZTFiMTk4YTRmMzU4YzU4YWY3NjYxNmI3NGE1Xzcx_2ca7b590-764e-492f-987c-190c52ab8759">49</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_82">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_85">Consolidated Balance Sheets as of December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_85">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_88">Consolidated Statements of Operations for the Years Ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_88">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_91">Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_91">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_94">Consolidated Statements of Cash Flows for the Years Ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_94">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_97">Consolidated Statements of Stockholders' Equity for the Years Ended December 31, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_97">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_100">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F- <a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_100">8</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 1</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_82"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Yield10 Bioscience, Inc.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Yield10 Bioscience, Inc. and its subsidiaries (the Company) as of December&#160;31, 2022 and 2021, the related consolidated statements of operations, comprehensive loss, stockholders' equity and cash flows for each of the years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements).  In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emphasis of Matter-Going Concern</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and does not have sufficient liquidity to meet forecasted costs.  This raises substantial doubt about the Company's ability to continue as a going concern.  Management's plans in regard to these matters also are described in Note 1.  The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Opinion</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management.  Our responsibility is to express an opinion on the Company's financial statements based on our audits.  We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB.  Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.  The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting.  As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting.  Accordingly, we express no such opinion.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks.  Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.  Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.  We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.  We determined that there are no critical audit matters.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84Mi9mcmFnOjIwZGMzMzllYjlhZTQzNDlhMTk4YzQ1MjA3NjA0NThjL3RleHRyZWdpb246MjBkYzMzOWViOWFlNDM0OWExOThjNDUyMDc2MDQ1OGNfMzc0NQ_329a16b6-869f-454d-9001-c033793c11d8">RSM US&#160;LLP</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2017.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84Mi9mcmFnOjIwZGMzMzllYjlhZTQzNDlhMTk4YzQ1MjA3NjA0NThjL3RleHRyZWdpb246MjBkYzMzOWViOWFlNDM0OWExOThjNDUyMDc2MDQ1OGNfMzc0Ng_0ebbad02-2e39-46f5-aad3-9de110fab5ac">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;14, 2023</span></div><div><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 2</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_85"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.775%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMy0xLTEtMS01NTY3Ng_b6a196e4-d9a5-44a6-8891-c16b840a0347">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMy0zLTEtMS01NTY3Ng_3e146b86-4582-4cd4-b5f2-40bc37b34bdb">5,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNC0xLTEtMS01NTY3Ng_55bc1030-10b2-4ced-bc9c-3b7d62212d60">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNC0zLTEtMS01NTY3Ng_288a7aeb-2e66-42fd-a6f6-48a2f82d6c8a">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNS0xLTEtMS01NTY3Ng_a461c1ac-f92e-40bd-8f26-ae9ce9a38f74">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNS0zLTEtMS01NTY3Ng_db44706a-b854-4ee4-bdbe-61eed31215b8">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:UnbilledContractsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNi0xLTEtMS01NTY3Ng_4920991e-023b-4ce9-a61e-a8facf7b672b">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:UnbilledContractsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNi0zLTEtMS01NTY3Ng_ea1899ec-95c3-4800-be36-a8cec2ad5bb3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNy0xLTEtMS01NTY3Ng_7a0df96c-e802-4e19-b424-0f67f38446a2">641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNy0zLTEtMS01NTY3Ng_70c02a36-ab7a-4265-be72-d20dde673c17">436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOC0xLTEtMS01NTY3Ng_97f01a4c-cfa5-493b-b1d8-52a04234912b">5,018</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOC0zLTEtMS01NTY3Ng_360431ef-80b2-4b4d-9b48-f1e43bd22f3e">16,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOS0xLTEtMS01NTY3Ng_2914b9d9-4a37-4ff5-bd84-858fde2c05e5">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOS0zLTEtMS01NTY3Ng_d9f6ec3e-46aa-4568-844e-45239b5bf92d">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTAtMS0xLTEtNTU2NzY_95b91f3e-c3ed-45c4-a72a-acc8edea7d45">775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTAtMy0xLTEtNTU2NzY_a9273a4c-5715-40ea-a152-b8de358aed68">890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTEtMS0xLTEtNTU2NzY_6dc9f08f-17af-4d1d-873a-fd28b9f0301a">1,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTEtMy0xLTEtNTU2NzY_78b9a9e5-b793-4bda-9df2-70ed7119e0f0">2,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTItMS0xLTEtNTU2NzY_94e41408-ea26-432a-9bcb-a2dcdc53f553">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTItMy0xLTEtNTU2NzY_a250cc82-ead4-4619-b711-5635def155ef">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTMtMS0xLTEtNTU2NzY_a961c0ef-9659-490f-9c8d-106d985cf747">8,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTMtMy0xLTEtNTU2NzY_3de859c5-bd36-4a94-858e-cdbaa692fc58">20,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders' Equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTctMS0xLTEtNTU2NzY_cca0adb7-ff1d-42b7-8b95-86821edede74">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTctMy0xLTEtNTU2NzY_17ba0128-6ede-4359-844e-4257a9b5d51f">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTgtMS0xLTEtNTU2NzY_95406552-80b9-48cf-94fe-25fed78890e1">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTgtMy0xLTEtNTU2NzY_bd7f81af-2e0f-4c08-8f62-f8739570374e">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTktMS0xLTEtNTU2NzY_576d9aea-a9a2-4f67-bf86-e2b16bb9d5f6">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTktMy0xLTEtNTU2NzY_079ce5da-078b-496f-8587-64c5c693f56b">514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjAtMS0xLTEtNTU2NzY_b214a910-66be-40f2-9bbd-543e5e021d63">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjAtMy0xLTEtNTU2NzY_b1d2ceb3-02ba-44f5-a531-11f544c8ff1c">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjEtMS0xLTEtNTU2NzY_5f1c8c62-3f19-497b-9410-f4608d802f0b">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjEtMy0xLTEtNTU2NzY_8e789675-4aae-4b15-9d92-0275bc087ed4">2,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjMtMS0xLTEtNTU2NzY_868f6e8c-6453-4929-b047-ef9374604e7a">3,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjMtMy0xLTEtNTU2NzY_89909940-bb6e-4a84-8d96-d3af27df3d92">4,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note&#160;7)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjQtMS0xLTEtNTU2NzY_88d39459-ced3-49da-a740-165cafe6ea2e"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjQtMy0xLTEtNTU2NzY_0f60ac53-1fe2-4c92-9fb8-15732f3f5549"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY18yMQ_2eba5c78-3654-402d-bd74-18cfed34b2d3"><ix:nonFraction unitRef="usdPerShare" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY18yMQ_3a9aa73e-d0f7-46b7-ae63-1df8e20550fe">0.01</ix:nonFraction></ix:nonFraction> par value per share); <ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY180Ng_0c950f6f-1e31-4d9a-be7e-59b93c9041ab"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY180Ng_6ba6deb5-f59b-45e9-86a3-e31feb427654">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_0c0463b4-5697-4ffb-a15b-9b47122de593"><ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_321e50f0-c66d-434d-a4f9-fc8eeb9f39e5"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_45f102dc-eed6-4dbd-8c07-ac8449707611"><ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_b8585bc4-4cbb-4417-9c6b-160658918258">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMS0xLTEtNTU2NzY_f255064a-a0e3-4da9-9ded-8da57133f5c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMy0xLTEtNTU2NzY_298a48ec-9390-46c1-9746-c972bcad1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock ($<ix:nonFraction unitRef="usdPerShare" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV8xOA_7a004c6e-d316-4825-8aae-ea0749c2ed19"><ix:nonFraction unitRef="usdPerShare" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV8xOA_a3a10b3d-dfe8-4056-966b-9c2e0218c476">0.01</ix:nonFraction></ix:nonFraction> par value per share); <ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV80Mw_7938f41a-fc48-454f-a180-66a4922832f7"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV80Mw_c0537bd3-6674-4c76-88ef-d3e1142100fa">60,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31, 2022 and 2021, and <ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84Mg_600b67f5-e4a0-410f-82f7-5a2cabb7c707"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84Mg_95bcd474-75a1-4902-b70f-803d70a217d9">4,944,202</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84OQ_827fdba9-96b5-4889-91a3-96cc985d84ff"><ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84OQ_94e83e86-3fdd-4d6d-a353-5551469854cd">4,881,851</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMS0xLTEtNTU2NzY_d4e11a4f-1e1d-4264-bdc4-8c0a45942d9c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMy0xLTEtNTU2NzY_c836179b-bd33-4bed-8d91-2313a9e35d2c">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjgtMS0xLTEtNTU2NzY_829c852e-8551-4885-9bb7-d54201e0643b">404,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjgtMy0xLTEtNTU2NzY_ff605d24-a041-4fb6-a849-9f7bc63188db">402,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjktMS0xLTEtNTU2NzY_54a11c5f-8ae8-4586-8897-ff96733347b3">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjktMy0xLTEtNTU2NzY_66f96cd7-91e7-41a6-b496-5e22efa8a523">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzAtMS0xLTEtNTU2NzY_3d7f713e-f513-4437-83f0-df46cbe6f4d6">399,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzAtMy0xLTEtNTU2NzY_e7b8baf5-887f-4b83-b9da-f9744687d68b">386,131</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzEtMS0xLTEtNTU2NzY_7203da47-a245-4a4c-b71c-97a39a5ff9e4">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzEtMy0xLTEtNTU2NzY_575ad9c0-6031-42c2-8e3f-07396494a073">16,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzItMS0xLTEtNTU2NzY_fef15646-b175-4549-98d6-05b8ff685e67">8,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzItMy0xLTEtNTU2NzY_f65406b8-7f2c-47c4-810a-3c7e9073836e">20,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 3</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share and per share amounts)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fa4f596e68b435cb25ae4cba2423590_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMy0yLTEtMS01NTY3Ng_6c1f4b5a-f078-4d02-849b-7e89ce40d251">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee3c65cebf3e4b5cae9b882ffa69ba4b_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMy00LTEtMS01NTY3Ng_8ed038ac-9f63-4f38-9460-8f86cf6027ac">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfNi0yLTEtMS01NTY3Ng_9960cd7c-2db5-4878-81f5-df68a4880438">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfNi00LTEtMS01NTY3Ng_fc3f8586-590f-4e97-95df-dd56f258690c">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="yten:CostOfRevenueResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOC0yLTEtMS01NTY3Ng_8829cd46-2241-491a-b024-f7fc5dc6ed8f">7,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="yten:CostOfRevenueResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOC00LTEtMS01NTY3Ng_5a0812bc-9b0d-458a-a343-2f908dd77dda">6,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOS0yLTEtMS01NTY3Ng_c05acef6-4394-4510-a439-67f8a6d7319c">6,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOS00LTEtMS01NTY3Ng_d32ba628-a53c-456d-a902-d212f0db1e5a">6,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTAtMi0xLTEtNTU2NzY_c35d9d89-bd76-4bc4-b02c-9214a437a893">13,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTAtNC0xLTEtNTU2NzY_e8954ac3-ecb1-42c1-ad9c-fd386f00c722">12,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTEtMi0xLTEtNTU2NzY_8c068dc8-5dc1-46bc-8afe-045332468c16">13,451</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTEtNC0xLTEtNTU2NzY_7d8f279b-c31d-4d09-886f-8cdd383f928a">11,692</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on investment in related party</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="yten:GainOnRelatedPartyInvestment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTMtMi0xLTEtNTU2NzY_25a03573-6921-4a6f-a832-1d92b7b4ef7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="yten:GainOnRelatedPartyInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTMtNC0xLTEtNTU2NzY_ca9af1e2-1068-4047-b8e5-b30d72e84733">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTYtMi0xLTEtNTU2NzY_02c4b723-70e8-4e23-adde-d0e470304e20">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTYtNC0xLTEtNTU2NzY_6fdcb7bb-52b2-440c-9c61-d96885e36711">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTctMi0xLTEtNTU2NzY_05de82fe-09a1-445c-a602-1e102ab90114">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTctNC0xLTEtNTU2NzY_a0086f11-9c44-4966-b5db-41120b64ab6a">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTgtMi0xLTEtNTU2NzY_a0f412b1-ca2c-4be3-99b5-4660c4b04e3b">13,410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTgtNC0xLTEtNTU2NzY_b6336791-bf64-44b4-bf97-21e866c9fd5d">10,995</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTktMi0xLTEtNTU2NzY_a830c9de-ac39-4f38-b695-33062c80cfdb">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTktNC0xLTEtNTU2NzY_90fcca39-4edf-495e-9e5c-dac1de3aa90f">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjAtMi0xLTEtNTU2NzY_d1a68092-da3b-4e9f-b777-924b387d0109">13,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjAtNC0xLTEtNTU2NzY_4d440f3d-7baf-445c-9f49-fa46d7c1583a">11,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctMi0xLTEtNTU2NzY_0e78ef97-f6c0-477d-b917-8c896668f0e0"><ix:nonFraction unitRef="usdPerShare" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctMi0xLTEtNTU2NzY_c2241853-297b-479b-9243-8f1a7deecc91">2.76</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctNC0xLTEtNTU2NzY_12f50f85-9e63-41fb-bc80-1790ab0a5cb8"><ix:nonFraction unitRef="usdPerShare" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctNC0xLTEtNTU2NzY_9551abde-324a-4f13-990b-98bd1fa78e34">2.33</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of shares used in per share calculations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtMi0xLTEtNTU2NzY_0d46f57c-464c-46a7-a153-77787066d235"><ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtMi0xLTEtNTU2NzY_ae28ac7c-7613-4107-b753-4fad76e82523">4,914,565</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtNC0xLTEtNTU2NzY_22485454-c100-4a10-b9b3-0292dfa89895"><ix:nonFraction unitRef="shares" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtNC0xLTEtNTU2NzY_5f81c4ef-f852-4036-941e-9e6b553779ac">4,731,833</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 4</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:71.776%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.569%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi0yLTEtMS01NTY3Ng_9956a4a2-6857-4d1c-bf86-b6263c2b7fb5"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi0yLTEtMS01NTY3Ng_e637779e-261c-45ec-990b-f8c1a5041a51">13,566</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi00LTEtMS01NTY3Ng_57361f55-473b-4fcd-b476-b4b8ca441330">11,031</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized gain (loss) on investments, net of income tax</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNC0yLTEtMS01NTY3Ng_2e7d03e0-6436-4e07-a959-2e50a421b583">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNC00LTEtMS01NTY3Ng_21437fa6-3863-4b4e-b352-2d0d32476445">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in foreign currency translation adjustment, net of income tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNS0yLTEtMS01NTY3Ng_43db437c-1b73-4f34-86f9-2402709a7b8f">61</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNS00LTEtMS01NTY3Ng_4347cd7a-53ff-492b-af14-c66adef93c22">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNi0yLTEtMS01NTY3Ng_253fa4f4-7399-4b00-be0c-2f394c623420">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNi00LTEtMS01NTY3Ng_4aac93ec-c13f-4242-9efd-76aa7b25e729">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNy0yLTEtMS01NTY3Ng_d1d0ebd6-02a2-4f40-97cc-e23995e2cba4">13,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNy00LTEtMS01NTY3Ng_a6808baf-7257-4a61-93a9-7fbc0c69899d">11,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 5</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_94"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.062%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMy0yLTEtMS01NTY3Ng_b4231ee5-84a4-498c-bdf4-f2486d4e4a19">13,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMy00LTEtMS01NTY3Ng_239bc190-86d9-41d5-a630-f4880901f549">11,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNS0yLTEtMS01NTY3Ng_a63b9951-1653-45d3-b762-04b0b6217fe8">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNS00LTEtMS01NTY3Ng_0e1486c8-9494-475e-a56f-febf85ee512d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expense for 401(k) company common stock match</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="yten:ChargeForCompanyCommonStockMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfOS0yLTEtMS01NTY3Ng_e53bda09-abd2-4ba7-a83f-a1d48f1f02da">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="yten:ChargeForCompanyCommonStockMatch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfOS00LTEtMS01NTY3Ng_049104b5-885b-4954-ad2c-2a6b7024adaa">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTAtMi0xLTEtNTU2NzY_6313a2a5-89f6-40eb-a0da-fc01ed884dc0">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTAtNC0xLTEtNTU2NzY_521a4d2c-2c29-4b78-b069-5e496da5839b">1,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncash lease expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="yten:NoncashLeaseExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTEtMi0xLTEtNTU2NzY_5ad0323d-56b7-48ba-a060-ad065449e608">393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="yten:NoncashLeaseExpenseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTEtNC0xLTEtNTU2NzY_127235bd-dcac-4d6e-89a1-0af5f5420664">358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTItMi0xLTEtNTU2NzY_0ece706f-d110-41c8-99ec-2855d99df491">165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTItNC0xLTEtNTU2NzY_8e3f5ed8-290c-4cc2-82dd-4bebfc34bacf">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTYtMi0xLTEtNTU2NzY_35907a85-4e95-4967-b31b-91bf23d295c9">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTYtNC0xLTEtNTU2NzY_07c3b6df-6940-4e8c-956b-61d59cd4f201">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unbilled receivables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTgtMi0xLTEtNTU2NzY_1c3148e6-2f81-4767-a99c-ce05c7e2c590">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTgtNC0xLTEtNTU2NzY_b7a5df4d-84ad-42e8-8c2a-f99ca6fdc2c3">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjAtMi0xLTEtNTU2NzY_8c3d39d5-bc82-4fd0-bdb7-3815eec59a04">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjAtNC0xLTEtNTU2NzY_183e7b48-c07f-4545-ac90-d9d8a4dd6baa">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjEtMi0xLTEtNTU2NzY_78a2122d-d921-48a5-bbeb-1aa75de4674d">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjEtNC0xLTEtNTU2NzY_ecdbde38-babb-4c47-a6c3-de2d0d92f7ef">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjItMi0xLTEtNTU2NzY_062a6645-7bfd-4889-b9a1-61d8a47793a4">209</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjItNC0xLTEtNTU2NzY_87412476-45c0-41fd-9854-3d3eadc24aac">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="yten:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjQtMi0xLTEtNTU2NzY_6c249f30-d529-40b2-8539-7bb62d00ccbb">520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="yten:IncreaseDecreaseInLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjQtNC0xLTEtNTU2NzY_66ed7f12-439a-4aa1-aa4c-1517c60663e3">463</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtMi0xLTEtNTU2NzY_92fc0c65-06ea-43b3-bb28-77ddcf6b311f"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtMi0xLTEtNTU2NzY_b623e68b-c320-4540-9129-f5380dca5802">11,404</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtNC0xLTEtNTU2NzY_34a2e204-f9aa-47dd-962a-74d9f9e022cc"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtNC0xLTEtNTU2NzY_502caa0b-2159-40bd-9a52-899635fc94a6">9,253</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzEtMi0xLTEtNTU2NzY_f65c04b6-0f9d-4171-bc05-17d84097324b">154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzEtNC0xLTEtNTU2NzY_6690b3e3-8fc4-4c4f-96f8-7b9b8be71d05">189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzQtMi0xLTEtNTU2NzY_bb29a477-6100-4629-a9ba-506277ade50b">2,445</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzQtNC0xLTEtNTU2NzY_afc22f29-d746-4d89-9932-1272b3c2ad77">10,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale and maturity of short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzUtMi0xLTEtNTU2NzY_5add4138-cc09-4f54-a3b6-edd992c0a82c">11,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzUtNC0xLTEtNTU2NzY_e8df0d5a-12ac-4574-bb27-caa56776c827">6,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzYtMi0xLTEtNTU2NzY_d09b3e25-3a5d-4ef7-b0f3-6c60e1cf112e">8,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzYtNC0xLTEtNTU2NzY_d8ef418f-6558-416b-97a0-80deaecc59b6">4,578</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from warrants exercised</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDItMi0xLTEtNTU2NzY_92d4eec8-d663-4401-95c7-8ff0f758efdb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDItNC0xLTEtNTU2NzY_eaf09f1d-194b-4f33-8e0e-503eb6485424">3,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from securities offerings, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDQtMi0xLTEtNTU2NzY_f3f5f7de-5fbb-403f-9294-a4347c6753bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDQtNC0xLTEtNTU2NzY_ea16a785-56e6-4257-993a-b495fc631958">11,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid on employees' behalf related to vesting of stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDUtMi0xLTEtNTU2NzY_6ae08b62-3d0b-4be1-8a7b-e8b1dd54ce24">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDUtNC0xLTEtNTU2NzY_abfde8be-d4df-419d-9e6c-ad3b4cab23ae">103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtMi0xLTEtNTU2NzY_9dffc0b6-07f3-44cf-9a20-0f5b680c9138"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtMi0xLTEtNTU2NzY_f9d53116-13b3-41d3-892d-be06486fa642">37</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtNC0xLTEtNTU2NzY_1aad6679-44aa-46db-9b59-12456386658a"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtNC0xLTEtNTU2NzY_2e5234f4-73fe-4e26-b4df-a982aefe997b">15,746</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDgtMi0xLTEtNTU2NzY_ea0c8993-cfd6-4020-b986-ab51ca681c91">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDgtNC0xLTEtNTU2NzY_cfd7c50c-4e85-43e5-81f2-eb33c626da93">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDktMi0xLTEtNTU2NzY_01fb210a-af88-407a-b616-0e279cf17b45">2,973</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDktNC0xLTEtNTU2NzY_39c586d4-f863-4e1d-8a2c-b66f2a1ee386">1,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTAtMi0xLTEtNTU2NzY_8d893a89-76b4-49ef-8dc4-7fd5d554e5b1">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTAtNC0xLTEtNTU2NzY_6ff29d1d-51e7-4c92-8443-a2439f37b0ec">3,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTEtMi0xLTEtNTU2NzY_1243fe94-2b86-4bb6-ad22-7a6166019a78">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTEtNC0xLTEtNTU2NzY_52afff5f-b9e8-4980-a44a-bfcfa6508120">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental Cash Flow Disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTQtMi0xLTEtNTU2NzY_9ea84668-0af0-4064-b57d-2fa5ff6fcdca">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTQtNC0xLTEtNTU2NzY_94fe6a05-6fae-4deb-a0fa-c77ed48d39a6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 6</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_97"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.895%"><tr><td style="width:1.0%"></td><td style="width:49.393%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.156%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.290%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.254%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.571%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.348%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.020%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Stockholders' Equity</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i97019bfe3e334d528406e95e102e2364_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy04LTEtMS01NTY3Ng_d904f740-625c-41c3-8dd1-612c4b11de6e">3,334,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97019bfe3e334d528406e95e102e2364_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xMC0xLTEtNTU2NzY_6001e2f2-a1ad-425d-ac44-05569c89a892">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3d3121e408a4cc2bbbbfbad11389e16_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xMi0xLTEtNTU2NzY_3c8f8e5b-6d85-43aa-823c-88f0b585c7ad">384,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40955b8933394980b43a112a70cb81dd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xNC0xLTEtNTU2NzY_2aaee7fd-ca64-4ac9-b22b-3049e6ce965c">159</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if50f9d23f34d4f029330039500bd46fc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xNi0xLTEtNTU2NzY_1fdd8497-51cf-4d16-a65f-649c9e92064c">375,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xOC0xLTEtNTU2NzY_48ed6299-89f1-426e-8ba2-d18843c251b0">9,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNC0xMi0xLTEtNTU2NzY_3da1deb8-9785-490d-b23b-3c53a8671a05">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNC0xOC0xLTEtNTU2NzY_62883e3d-04c5-4726-a94b-41927f93db1f">1,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for 401(k) match</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS04LTEtMS01NTY3Ng_bfb3202b-a5ec-4d40-b64d-39b4db14274f">13,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS0xMi0xLTEtNTU2NzY_220faa05-ad08-4849-a1c1-035ee774102a">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS0xOC0xLTEtNTU2NzY_93e96e7e-3ece-4a85-834d-938ac999d43d">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi04LTEtMS01NTY3Ng_e9fbcf84-200f-48e2-8eb1-db779ee230df">12,219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi0xMi0xLTEtNTU2NzY_bb533cb0-31f9-4943-9398-cb9d64865293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi0xOC0xLTEtNTU2NzY_7e271572-ddce-4526-968a-4e7693ca6f03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid on employees' behalf related to vesting of stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNy0xMi0xLTEtNTU2NzY_ba1bdecf-9a0b-4a9e-bd92-857098a1121e">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNy0xOC0xLTEtNTU2NzY_a97c65a1-064c-46af-99f5-63e042d02091">102</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for warrant exercises</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC04LTEtMS01NTY3Ng_84248a21-bce9-4c5c-91d6-3acefa7e9f88">481,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xMC0xLTEtNTU2NzY_f41b3e0b-e3d5-4ac0-bb7e-2729450530ca">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xMi0xLTEtNTU2NzY_8ed1b2e2-666c-460e-a0aa-1933324db245">3,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xOC0xLTEtNTU2NzY_52a08387-e556-4e56-9992-9e77a32d9afc">3,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock in connection with stock offering, net of offering costs of $<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0wLTEtMS01NTY3Ni90ZXh0cmVnaW9uOjBjM2JhOGQzNGM3YjQ0MDY5OWE0OTA4ZTFhZjY0YzM1XzMyOTg1MzQ4ODM0MjU_1c6b4b1d-46fa-4172-a21d-08a959c518aa">747</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS04LTEtMS01NTY3Ng_3e638ca3-9bac-42de-83f5-c02525913349">1,040,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xMC0xLTEtNTU2NzY_9773b83b-1333-45fc-a325-26c09c745d68">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xMi0xLTEtNTU2NzY_5950007e-7b65-4e43-9053-2755c43f4af9">11,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xOC0xLTEtNTU2NzY_01cac995-64a4-45cb-b32c-22821fa16d03">11,993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign currency translation </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i684d6f37920d42318715b4946e6c8249_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTMtMTQtMS0xLTU1Njc2_09387b84-e34f-4e9d-98fb-09d4f04e848a">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTMtMTgtMS0xLTU1Njc2_6ebec9e4-f477-40f4-b37b-318a45659396">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia191e1112ea14abb840d58c60e120043_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTQtMTYtMS0xLTU1Njc2_1817a237-95ef-4605-8487-571d8dc9fa06">11,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTQtMTgtMS0xLTU1Njc2_4d9e9cb7-ae35-439c-a36b-0786554f48a5">11,031</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i58fce4089bcb426e8039bc6cbfa6106c_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtOC0xLTEtNTU2NzY_2da733ed-d809-4c95-9ac3-994856cf7aa7">4,881,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58fce4089bcb426e8039bc6cbfa6106c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTAtMS0xLTU1Njc2_715f725f-6f6e-4ab9-aad2-d69ad17770a3">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7526ac612c264449a3e3ac301d55542f_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTItMS0xLTU1Njc2_de34d31c-48b3-431e-96cd-ff7b5a24cb64">402,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica80c64d92b04d749e752fded64ecc53_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTQtMS0xLTU1Njc2_4b286ed6-a0ed-4497-9e0c-1aa20f7ee22c">175</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e6a79d372a4443d8d41d7ee23cabec4_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTYtMS0xLTU1Njc2_16be69c7-4630-4d3d-9457-e0567f66f6c9">386,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTgtMS0xLTU1Njc2_f2b9a08c-f303-474d-8326-e5f6710c962c">16,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTctMTItMS0xLTU1Njc2_ec1bd42c-dd2f-4230-b391-3ed460c60797">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTctMTgtMS0xLTU1Njc2_6f4b5198-73aa-4928-905f-e314f6552752">1,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock for 401(k) match</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtOC0xLTEtNTU2NzY_7edf31c9-85db-4bef-b62a-55ddf270dbbe">36,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtMTItMS0xLTU1Njc2_1a0d82bd-9994-4e72-99c5-04016cb308a0">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtMTgtMS0xLTU1Njc2_b13fd1a3-52f8-4961-8323-e973b95795b9">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktOC0xLTEtNTU2NzY_848d5df3-8a5f-4606-bb8d-f89132754983">25,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktMTItMS0xLTU1Njc2_63144e3d-6e7f-4b96-bd3a-c3ab2015e0e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktMTgtMS0xLTU1Njc2_33f48ef3-8784-4898-b8d7-792a47c637be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes paid on employees' behalf related to vesting of stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjAtMTItMS0xLTU1Njc2_d7c3f340-01d4-4fed-b1d3-7ec142db27b5">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjAtMTgtMS0xLTU1Njc2_3290c9ec-c7dd-4fa2-87cd-c2a376494303">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign currency translation and unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3efc24abbd6441ca82da51c9deb09b3_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjMtMTQtMS0xLTU1Njc2_cd796857-e1d4-4e4c-9c98-6624c1840aa9">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjMtMTgtMS0xLTU1Njc2_8b1b33ec-b055-4e5a-b945-0a93e57ecd37">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad8a0121d2bc47a58199c38a729c4349_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjQtMTYtMS0xLTU1Njc2_b173975c-894e-42f8-8593-7893ae5740f6">13,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjQtMTgtMS0xLTU1Njc2_39fffe93-a0c3-453d-bb3b-bfdc64494d59">13,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtOC0xLTEtNTU2NzY_dc9a4c84-3607-46d8-808c-adcdfd491e8b">4,944,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTAtMS0xLTU1Njc2_17fd6086-8c2a-46fb-8076-9458736da59e">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b28bd8c03f94f9981d0b15e39eff5f3_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTItMS0xLTU1Njc2_d45dadb2-af58-4a33-852f-068da84176a9">404,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief1ac89ff5a2424396d026131c1fdf13_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTQtMS0xLTU1Njc2_8876dedd-811b-4854-9d87-cec02ed72247">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i337d07789e89467e9cfd5f2c41ac49b3_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTYtMS0xLTU1Njc2_c32b3a4c-050f-48bf-ae3b-bbb958bdf5e4">399,697</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTgtMS0xLTU1Njc2_4825336e-fa51-49ce-ae9d-7d7ad063f607">4,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 7</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_100"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="ic02604fb0219453aa54b246df7a39126_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDMvZnJhZzplYmIwM2IzZWE1NGE0YTQxOWY1N2FlOWQzZjdlMjEzMS90ZXh0cmVnaW9uOmViYjAzYjNlYTU0YTRhNDE5ZjU3YWU5ZDNmN2UyMTMxXzU3ODg_32045abf-9cbc-4fd3-b1e3-f8c1c9c6df3f" continuedAt="ie7e2058ef2f8403bb78c42cf27457a45" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="ie7e2058ef2f8403bb78c42cf27457a45" continuedAt="ia874fc6e9feb44208fa3be21617c00cc"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address 1) petroleum replacement markets: Camelina oil for use as a biofuel feedstock and PHA bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and 2) food and nutrition markets: omega-3 (EPA, DHA+EPA) oils produced in Camelina seed for aquaculture and nutraceuticals; and for protein meal for animal feed markets.  The commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from the Company's development pipeline which offer improved on-farm performance that will lead to increased acreage and seed product revenue.  Yield10 also plans to create additional value for its shareholders by licensing yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola.  Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.  Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December&#160;31, 2022.  The Company ended 2022 with unrestricted cash, cash equivalents and short-term investments of $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDMvZnJhZzplYmIwM2IzZWE1NGE0YTQxOWY1N2FlOWQzZjdlMjEzMS90ZXh0cmVnaW9uOmViYjAzYjNlYTU0YTRhNDE5ZjU3YWU5ZDNmN2UyMTMxXzE4NzI_3796a455-c75b-4eea-ba87-ab022ffa4969">4,347</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements-Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its consolidated financial statements are issued.  The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given.  Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all.  If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment.  Based on its current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern.  This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders.  In addition, utilization of the Company&#8217;s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions.  If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ("COVID-19") and the risks to the international community as the virus spreads globally beyond its point of origin.  In March 2020, the WHO classified COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.  The full impact of the COVID-19 pandemic continues to evolve as of the </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia874fc6e9feb44208fa3be21617c00cc">date of this report.  As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain.  While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce in future periods.</ix:continuation></span></div><div id="ic02604fb0219453aa54b246df7a39126_106"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQ2_e2cba786-6f00-4a1a-81c1-a7b2607516d9" continuedAt="icd76e79a7a464c9c857624b10fa8640c" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="icd76e79a7a464c9c857624b10fa8640c" continuedAt="i6e76ae38d15c44cda11a714dc1a35720"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzg5_0be8b88a-ffff-4fd9-b079-4590180d1ec1" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB").  The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported.  References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODEx_c2275c8a-2700-4f95-a1ad-8b13d5988016" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions were eliminated, including transactions with its subsidiaries, Yield10 Oilseeds Inc. and Yield10 Bioscience Securities Corp.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODY1_661969bb-5305-42e2-8b33-3fbd1d3c02e3" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk5_ac1dfdae-b9b3-4a97-8353-1c7bc06898b0" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODkz_7a3871b7-60da-43dc-8764-eee20afe16c0" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzEtMS0xLTEtNTU2NzY_b6a196e4-d9a5-44a6-8891-c16b840a0347">2,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzEtMy0xLTEtNTU2NzY_3e146b86-4582-4cd4-b5f2-40bc37b34bdb">5,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzItMS0xLTEtNTU2NzY_2914b9d9-4a37-4ff5-bd84-858fde2c05e5">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzItMy0xLTEtNTU2NzY_d9f6ec3e-46aa-4568-844e-45239b5bf92d">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzMtMS0xLTEtNTU2NzY_22952e24-e3fb-4c96-917b-fcfa6cfa8e10">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzMtMy0xLTEtNTU2NzY_6824b80d-aad4-4003-ae83-be380f0af6b7">5,593</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODYw_49ede043-7ee4-403d-8d24-5d78cacc46b3" escape="true">Amounts included in restricted cash represent those required to be set aside by contractual agreement.  Restricted cash of $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzIzODk_2914b9d9-4a37-4ff5-bd84-858fde2c05e5">264</ix:nonFraction> at December&#160;31, 2022 and December&#160;31, 2021, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i6e76ae38d15c44cda11a714dc1a35720" continuedAt="i5337e4c6fb224e4884b22ae644131fb8"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc3_12b3cab8-5c13-4ff3-ae87-562a53ed04e4" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy.  The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term. The Company held <ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzI5NTg_11976bc5-7028-41d4-9cd5-d9ac0b0ce499"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzI5NTg_6f3f1f24-5063-4988-8987-08e8425b0f3f">no</ix:nonFraction></ix:nonFraction> long-term investments at December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred.  Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis.  Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense).  The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.  Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations.  The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODgy_6da6dc1b-c11e-45b5-b36e-a5b7ff7f67a8" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date.  Revenues and expenses are translated at average exchange rates prevailing during the period.  Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet.  When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODkx_cefa1d9f-9ee1-4021-91cc-5a9aaa50ce24" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net  loss.  The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTMy_308090d6-2b54-420a-8d01-b4ca97b0805e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable.  The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes.  Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company's unbilled receivables of $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="yten:AccountsReceivableTradeAndUnbilledReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzU5ODM_003e396b-8896-4c7b-8e5f-a79e0903d461">30</ix:nonFraction> were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor.  The Company believes these receivables have a low risk of default.  At December&#160;31, 2021, all of the Company's accounts and unbilled receivables of $<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="yten:AccountsReceivableTradeAndUnbilledReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzU0OTc1NTgzMjc0Ng_69e94215-987a-400c-a4e6-66fdb7ae0f37">198</ix:nonFraction> were due from MSU for support of the DOE grant.</span></div></ix:nonNumeric></ix:continuation><div style="text-indent:22.5pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i5337e4c6fb224e4884b22ae644131fb8" continuedAt="i20099572b5f848168e3da1323b395115"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk2_6229f83d-904f-47af-8b3c-0e01d32b6155" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's financial instruments as of December&#160;31, 2022 and December&#160;31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.  See Note 4 for further discussion on fair value measurements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODA1_ca8be478-115d-4c51-b683-585a93318672" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements.  The Company is an agricultural bioscience company operating in <ix:nonFraction unitRef="segment" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzcxNTE_bdb7227f-966c-4d66-b558-d019b8800354">one</ix:nonFraction> segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops.&#160; The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTMz_6e1817a4-16f1-4757-aab9-1777766f58e4" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization.  Repairs and maintenance are charged to operating expense as incurred.  <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODUz_94cbaa8d-a1ba-4d71-bbab-ad4d3f1c4e49" continuedAt="ie50450c090834900a65d39e5f2f564f8" escape="true">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="ie50450c090834900a65d39e5f2f564f8" continuedAt="ia80162a84660481e8a7dadaf60feafb5"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:62.834%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.645%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i53f6338f531042b4a04410a3879ac996_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzEtMi0xLTEtNTU2NzY_822a562e-461c-4e6f-a8d1-1137593898c9">3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie14d20621fd74f3f903765f72c4cb378_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzItMi0xLTEtNTU2NzY_525ce710-feaa-4d67-87b7-f549134081b1">5</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iceb9c616adc7405cb3808b71146eb760_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzMtMi0xLTEtNTU2NzY_717cfc55-59dd-4f2a-9ddf-1ad9ffbe2fa1">3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzgy_f6bfbf3d-38ca-4042-a898-65188644aeae" continuedAt="i81744cb71cdb4e338e0787af88b9b161" escape="true">Lease Accounting</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-indent:36pt"><ix:continuation id="i81744cb71cdb4e338e0787af88b9b161" continuedAt="i5da7c08b4fe746b9bef1ad802178661f"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a lessee, the Company follows the lease accounting guidance codified in ASC 842.  A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i5da7c08b4fe746b9bef1ad802178661f">.</ix:continuation> </span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODY2_eb2100d4-c134-445f-8801-86c532da5e33" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODU4_43186382-e807-4968-87b3-eafe2f84b992" continuedAt="i58e3ca182f8e46439eb6b750c8fb4012" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor.  These grants are considered an ongoing major and central operation of the Company's business.  Revenue is earned as research expenses related to the grants are incurred.  Revenue earned on </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i20099572b5f848168e3da1323b395115" continuedAt="i0b086ae69c3b43dc9e732b737a766cd3"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i58e3ca182f8e46439eb6b750c8fb4012">government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December&#160;31, 2022 and December&#160;31, 2021.  Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.</ix:continuation></span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk1_0f918c46-72dd-4b3b-90bd-fa48ae14395c" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs associated with internal research and development are expensed as incurred.  Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation.  Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory.  Costs incurred in connection with government research grants are recorded as research and development expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQz_007c37fc-33e5-4aee-9322-3360ea0d77f7" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative and business development of the Company.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="yten:IntellectualPropertyCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODEz_ef4fb4ca-fb01-458b-8d8c-73db4f9be19d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODQ4_dd104fa6-3b1a-49a1-aa9b-aef749c8013e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.  See Note&#160;10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODcy_94008409-7aeb-454a-89ec-f668143a92be" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding.  Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period.  Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced.  Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same.  Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc0_f21b5fcf-b684-4a59-aeb6-658a479640b7" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4648116206044ea1ab0d5587be0e4138_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzItMi0xLTEtNTU2NzY_33423ce0-0529-45f2-a060-ac01eaf8983a">979,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4da9d58e3fa24edebed51009dfec4598_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzItNC0xLTEtNTU2NzY_aa38b39f-406b-4e2b-af05-2af4be995945">722,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibadc13ffe064427483b95cf9d059239f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzMtMi0xLTEtNTU2NzY_f595317d-cf1d-4a94-8b34-930424f0e5c5">27,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icbc4ce7ce80f437bb07e269549f899be_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzMtNC0xLTEtNTU2NzY_8c0eaa8b-b562-4bae-bca4-3966b2c0cc0d">9,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic119f79d77f64ab3b8eeebb87c15caa6_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzYtMi0xLTEtNTU2NzY_8df6b5e3-6c5a-4b67-8a1b-15c0793aecd8">1,129,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic77d372fcd3a4dc0b1f445bc7272f30c_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzYtNC0xLTEtNTU2NzY_d851d011-581b-417c-8361-99fdb253748b">2,361,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzctMi0xLTEtNTU2NzY_e8d169b4-9471-4b71-b76b-0112724e508f">2,136,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzctNC0xLTEtNTU2NzY_f0089ede-2188-4746-b66e-cc40e15ee410">3,093,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i0b086ae69c3b43dc9e732b737a766cd3"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc1_31eb53aa-aa3c-4520-9292-8569df2b5ae3" escape="true"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions.  The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.  The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any.  The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;13 for further discussion of income taxes.  The Company had <ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE1NDUx_46e09ba9-f476-4618-909a-31860ee829a3"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE1NDUx_b6e00abe-8405-4aff-b2e7-e6e0adc6beb5">no</ix:nonFraction></ix:nonFraction> amounts recorded for unrecognized tax expense or benefits as of December&#160;31, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQ3_b1ef0b83-3874-413d-9810-2ab688d6a286" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Changes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU became effective for annual periods beginning after December 15, 2021.  The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.</span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement.  This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.  This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance is effective for fiscal years beginning after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC&#8217;s definition</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and interim periods within those fiscal years.  The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_112"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzIxNw_31b12422-cc6c-4226-9545-f6f40f378ede" continuedAt="idfccd0e5b98247b8b09700af710ad539" escape="true">INVESTMENTS</ix:nonNumeric></span></div><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idfccd0e5b98247b8b09700af710ad539" continuedAt="i822ae31c0a454ee5aba832e45a4a1344"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzIxOA_2314570c-110e-40e2-9573-148a9b068a75" continuedAt="i09d866fd867942bb915a5d5913f7e031" escape="true">The Company's investments consist of the following:</ix:nonNumeric></ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i822ae31c0a454ee5aba832e45a4a1344"><ix:continuation id="i09d866fd867942bb915a5d5913f7e031"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtMS0xLTEtNTU2NzY_b1f9c98b-b419-4a7e-9ada-9f5d86b7f4df">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtMy0xLTEtNTU2NzY_d7553134-63ce-4e84-b68b-246a73b7c7c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtNS0xLTEtNTU2NzY_448c9fa6-e455-45d3-b46a-194796f684ed">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtNy0xLTEtNTU2NzY_227e275b-41a8-403d-aac7-c6da35788f0a">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtMS0xLTEtNTU2NzY_cb3434de-ee5f-4d5d-82cc-9a409ec801b8">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtMy0xLTEtNTU2NzY_131a41b9-ccd7-4a7b-9b23-cdfdfb74d44b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtNS0xLTEtNTU2NzY_ad5601e4-2083-4cfb-a551-135ec4b1501c">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtNy0xLTEtNTU2NzY_0d92af04-16e1-4d74-a7d8-ec690fdc994a">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123f89aae974cfab1c6bc2456615632_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtMS0xLTEtNTU2NzY_cc4397e3-e7e0-4ab4-b875-6769f3a8aab0">10,669</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123f89aae974cfab1c6bc2456615632_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtMy0xLTEtNTU2NzY_d47436bd-d83f-4d1c-a547-9d3c3f661823">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if123f89aae974cfab1c6bc2456615632_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtNS0xLTEtNTU2NzY_50ed3121-40fa-4f32-a4c9-e5357bc0c383">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if123f89aae974cfab1c6bc2456615632_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtNy0xLTEtNTU2NzY_be0016e9-9b66-4e78-aa3f-3921bf20c307">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtMS0xLTEtNTU2NzY_34e6b72c-d609-463e-921f-1bdb94404c55">10,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtMy0xLTEtNTU2NzY_14bbd98b-3326-4ad0-9256-b124266a35d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtNS0xLTEtNTU2NzY_533f8237-0fff-41d7-adc8-976bec8ae457">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtNy0xLTEtNTU2NzY_dc5908d9-1a22-4746-8aa9-e4748583fdc4">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All short-term investments are classified as available for sale as of December&#160;31, 2022 and December&#160;31, 2021.  The Company held <ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzE3OA_8c6526fe-324f-4a43-8bcd-65d01b414cff"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:LongTermInvestments" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzE3OA_de2a2364-1c0d-4ef5-834d-8cddb446dc4c">no</ix:nonFraction></ix:nonFraction> long-term investments at December&#160;31, 2022 and December&#160;31, 2021.</span></div><div id="ic02604fb0219453aa54b246df7a39126_115"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90ZXh0cmVnaW9uOjlkNDM2YzVlYmY4ODQ0N2ZhYzk2MjExZGExMTVhM2YzXzM3MDI_6a8f145b-640c-45ce-b082-b1b17d29087a" continuedAt="i20683b42731742bca03d29b6a7fc3953" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i20683b42731742bca03d29b6a7fc3953" continuedAt="i42afbe4caa8a4f8a8568cf6a6ec2a9b1"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets recorded at fair value which have been classified as Level&#160;1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements.  Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date.  Fair values determined by Level&#160;1 inputs utilize observable data such as quoted prices in active markets for identical instruments.  Fair values determined by Level&#160;2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly.  Fair values determined by Level&#160;3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions.  The fair value hierarchy level is determined by the lowest level of significant input.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets classified as Level&#160;2 at December&#160;31, 2022 and December&#160;31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services.  Because the Company&#8217;s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities.  The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources.  After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90ZXh0cmVnaW9uOjlkNDM2YzVlYmY4ODQ0N2ZhYzk2MjExZGExMTVhM2YzXzM3MDQ_3c83d2e8-fe7b-4656-8625-4595e9456ece" continuedAt="i5772a9a020094455a5292e9728f9cfe9" escape="true">The tables below present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2022 and December&#160;31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i42afbe4caa8a4f8a8568cf6a6ec2a9b1"><ix:continuation id="i5772a9a020094455a5292e9728f9cfe9"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for &#160;identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0987e598fd44b77bbed7faceb8e8bfd_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtMS0xLTEtNTU2NzY_3251021a-1584-4d50-85a4-1830c6472e5e">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73e87c2e2c4452cb9bcdb46ea70f888_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtMy0xLTEtNTU2NzY_8379566f-ea7c-48c2-8179-e6fdce61d9e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i745a819a98b64320aa580b32fb4def9c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtNS0xLTEtNTU2NzY_1badc4ec-5bf8-42a3-beff-95416e0d9b89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib708dd5f8a6f488982b1a6a8631cabc2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtNy0xLTEtNTU2NzY_37b6e853-6a56-43c0-bb29-2f707b8fe8f9">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04f100c5f4eb4b2fbb1336ee32b69ec2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtMS0xLTEtNTU2NzY_384ea03c-65c2-4b47-b64a-2da5bfe1e5cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb545bab60de47478b6320dbdab7d781_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtMy0xLTEtNTU2NzY_2355050b-df09-49bf-94fe-7d4ee8b5a0ec">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b04174d783444b5a91b08f126c073ed_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtNS0xLTEtNTU2NzY_39b78a10-649f-42ad-9143-ce71b28f7ba6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc0a6c75312c46e680b72b0b6f4f19e9_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtNy0xLTEtNTU2NzY_2fb729f4-e138-435b-a3bb-349b98e15346">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aa5b795834d44dd8e3b1fcc2a74afad_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktMS0xLTEtNTU2NzY_19f21075-b816-42d4-972d-f0cc56c7cbae">1,633</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ccbc1ced9aa46338a3306667ca0aff1_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktMy0xLTEtNTU2NzY_753f350b-e796-4246-b947-812e49499ce7">1,991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94927ee7145149928eb35b6455abe6cd_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktNS0xLTEtNTU2NzY_aa4cbe1f-3035-4181-871f-45ac1c9966b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ecc835c25a3427287cfa2313952f908_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktNy0xLTEtNTU2NzY_2c833d9e-ab4a-46db-b413-91f6cc88dff7">3,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:37.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for&#160; identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0097ebc1457c424689098cd526fc4a70_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtMS0xLTEtNTU2NzY_6ea96c73-2073-4651-9951-c788e352b14a">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72dd2c270874bbd9c0f5786c80f1ce8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtMy0xLTEtNTU2NzY_e91a485b-fba6-4f48-9896-9821f10953a2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4551191c4634001a933c43c11c34a07_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtNS0xLTEtNTU2NzY_4f196551-d75c-4e8f-b78f-5817c8754845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c52dafa175b4fc68b9d93299520cd17_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtNy0xLTEtNTU2NzY_b189dc66-742c-4ca3-8c3e-211c88cb4e35">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i144df6c356284a69bdf5ec6b09bde5a7_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctMS0xLTEtNTU2NzY_a6fe35c8-bc75-4c52-b8c0-d736e41d26b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84682813ef2546fba512f9a3d6c563ad_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctMy0xLTEtNTU2NzY_63ff506c-ead4-424a-bebd-995b24d4ac76">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaf30edacde94c84a05341ca5dd0512f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctNS0xLTEtNTU2NzY_39a5cf24-0cd4-4842-b7e9-edcf8fd310c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec9b06e45af54e8f9a8de5e18ac09e35_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctNy0xLTEtNTU2NzY_2d9bed48-a261-4807-b95e-e8198b96d4e0">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ca1e9b355104bd08b48abb4bb45290e_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtMS0xLTEtNTU2NzY_40b1ff15-19aa-4eb1-92cf-8933785dfd20">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e3db911982426a8a17792e40222a8f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtMy0xLTEtNTU2NzY_ab8c303f-e084-4308-9840-453164ab8a2a">10,661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fec75a43493400b8c38e54079d13b02_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtNS0xLTEtNTU2NzY_63a831fe-49b4-4a78-82be-2c72430f246f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1479bec68b2c4d46978bb015eb204350_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtNy0xLTEtNTU2NzY_106b5968-c8b3-48e2-ab03-84fecbb6e766">15,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities between category levels for the years ended December&#160;31, 2022 and December&#160;31, 2021.</span></div></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_121"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE4Nw_3a4b9559-84bf-4933-bb1d-2f3fa03066cc" continuedAt="ic015293dc50f44ccba89e76c985ca1d2" escape="true">Property and Equipment, Net</ix:nonNumeric></span></div><ix:continuation id="ia80162a84660481e8a7dadaf60feafb5"><ix:continuation id="ic015293dc50f44ccba89e76c985ca1d2" continuedAt="ief033737d6424e65a586d992e7f16083"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0041b2aac5540ffb18d839925fa734d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzItMi0xLTEtNTU2NzY_5b094ccd-4adf-4842-91e3-730ba825cc35">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7d8c98f7a2c42188fb89171b9b7189a_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzItNC0xLTEtNTU2NzY_a1c753c6-35f3-4fce-ad8b-0464504a0401">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2c0fa82f93e4dbbbedf6619da265b98_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzMtMi0xLTEtNTU2NzY_f25b8cd5-91fc-4949-a346-3636ebf8a4ef">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d96fc98eceb4bd6bec5c50fb28726ec_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzMtNC0xLTEtNTU2NzY_d76fbc0c-c5cd-42f8-9e26-a12ed343a6cd">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd98a258635e48699f1a798857c5c38b_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzQtMi0xLTEtNTU2NzY_cd5d7285-935a-4760-9dfe-c4f062c3c822">1,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb1729532b6499587ce5b81b2cb2556_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzQtNC0xLTEtNTU2NzY_d1aa7679-d483-4744-a0a6-29dc8108780f">1,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7908f4e474c344729dd788b217be9fa9_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzUtMi0xLTEtNTU2NzY_a143680c-af00-4e63-bf02-1dea9ddfb96e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd0d338183674907923554d81edf4952_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzUtNC0xLTEtNTU2NzY_3a5b1935-e077-4600-8164-b75f5da00889">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzYtMi0xLTEtNTU2NzY_318b4268-7348-44bf-9a06-f7754343b824">2,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzYtNC0xLTEtNTU2NzY_ae1c4f1a-247e-4412-a36a-dcca3e7acaf0">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzctMi0xLTEtNTU2NzY_8d48350c-8223-4827-ad47-6c1e58551ad2">1,242</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzctNC0xLTEtNTU2NzY_fd4d2834-eddd-40ab-b4af-ddcab299853a">1,168</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzgtMi0xLTEtNTU2NzY_7b3d0702-6cf9-4bb3-8f17-4dc2f0dcd658">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzgtNC0xLTEtNTU2NzY_f0340d2e-cdfc-45d7-b862-99c76d13de9d">890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ief033737d6424e65a586d992e7f16083">Depreciation and amortization expense for the years ended December&#160;31, 2022 and December&#160;31, 2021, was $<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE2MA_a63b9951-1653-45d3-b762-04b0b6217fe8">263</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE2Nw_0e1486c8-9494-475e-a56f-febf85ee512d">220</ix:nonFraction>, respectively.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 15</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_124"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90ZXh0cmVnaW9uOjkwMWIzMWZjOTU1OTQ0YjQ4YTYyNzU5ZTJiM2JiMWFkXzgw_1d40afcb-5930-4b56-994f-acc2c4b29b30" continuedAt="i0adbd4ba3585420f8be05bbe240c0c2f" escape="true">Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="i0adbd4ba3585420f8be05bbe240c0c2f"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90ZXh0cmVnaW9uOjkwMWIzMWZjOTU1OTQ0YjQ4YTYyNzU5ZTJiM2JiMWFkXzcw_5b42aa97-3d94-4957-b30b-25024f546038" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzItMS0xLTEtNTU2NzY_fe32139c-dfef-4d9d-ab91-d539b2b1a933">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzItMy0xLTEtNTU2NzY_e0f876f8-5c19-4919-9678-9f0a183113d7">452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccruedRentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzMtMS0xLTEtNTU2NzY_0fdf5f51-0fae-4dda-836b-b0aeca450d70">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccruedRentCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzMtMy0xLTEtNTU2NzY_258e8c86-97e8-4ebc-b220-25f360211bc5">71</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzQtMS0xLTEtNTU2NzY_8c9684e7-1314-45cb-8021-89dd36f9f5f4">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzQtMy0xLTEtNTU2NzY_b937fa32-a3f5-47c5-b7ff-5c164dfdf736">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field trials and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="yten:AccruedFieldTrialsAndRelatedExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzUtMS0xLTEtNTU2NzY_432bc759-93ca-453d-a761-4fe19d0478ef">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="yten:AccruedFieldTrialsAndRelatedExpensesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzUtMy0xLTEtNTU2NzY_da0e6a17-9746-4d8d-83c7-d658829344b5">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzYtMS0xLTEtNTU2NzY_37d3c6d4-f750-4691-bc7b-0c05193a8f86">269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzYtMy0xLTEtNTU2NzY_37a9ec51-3c32-4d6f-9b22-58360c217af9">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzctMS0xLTEtNTU2NzY_b892aa60-bcea-41cb-85e5-207cbd62cf32">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzctMy0xLTEtNTU2NzY_3b5c6bca-1150-4d5e-a8a9-9c0675643780">1,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="ic02604fb0219453aa54b246df7a39126_127"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU2NDU_8c28b0bb-9267-4d82-a1df-4df45dcc6132" continuedAt="i46fcaa8e73d3478ebda50fdd9113dba4" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i46fcaa8e73d3478ebda50fdd9113dba4" continuedAt="i40cbef5f79554078b2006719d8fe46dd"><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted&#8217;s program to develop omega-3 oils in Camelina sativa.  Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further EPA, DHA+EPA trait improvement, field testing and nutritional studies.  The Company will pay Rothamsted quarterly research funding and option fees of $<ix:nonFraction unitRef="usd" contextRef="i80f310cf5c534afebc48ec2031f27370_I20201112" decimals="-3" name="yten:CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU3Nw_7d0c97b4-28fe-42ce-bae4-5cfa2ae47f9b">31</ix:nonFraction> for <ix:nonNumeric contextRef="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112" name="yten:CollaborativeArrangementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU4NA_d3100559-4095-4551-b447-5cf8c2126067">two years</ix:nonNumeric> totaling $<ix:nonFraction unitRef="usd" contextRef="i80f310cf5c534afebc48ec2031f27370_I20201112" decimals="-3" name="yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU5Ng_8cd8e40b-b1d3-416a-9379-bdaee68ca9ef">250</ix:nonFraction>, of which $<ix:nonFraction unitRef="usd" contextRef="i78f5c017d62d4136be49a824fedd9fa5_I20221231" decimals="-3" name="yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzYwOQ_b89e77d8-c8f7-44f9-b4e6-5139b08cc3f4">31</ix:nonFraction> remains outstanding as of December&#160;31, 2022.  Included within the agreement, the Company had an exclusive <ix:nonNumeric contextRef="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112" name="yten:CollaborativeArrangementTermOfOptionForLicenseAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU2NTI_ffcf38a7-2fca-4757-913f-242ef28548a0">two-year</ix:nonNumeric> option to sign a global, exclusive or non-exclusive license agreement to the technology.  In November 2022, Yield10 and Rothamsted agreed to extend the collaboration agreement, including the license option, without additional funding support, through December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with the University of Missouri ("UM")</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops.  Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production.  The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market.  The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products.  The Company or UM may terminate the license agreement in accordance with the terms of the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranteed Minimum Payments to Growers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an incentive for growers located in Canada and the U.S. to enter into Camelina commercial grain production contracts with the Company for the 2022/2023 winter season, Yield10 offered minimum guaranteed payments per acre that </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i40cbef5f79554078b2006719d8fe46dd"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce the growers' risk of financial loss.  These minimum payments, which are being accrued on a straight-line basis over the expected winter growing season, are conditional upon each grower fulfilling their contractual responsibilities and are reduced by the price of Yield10's Camelina planting seed and the contractual price that the Company will pay for the actual amount of grain that is harvested.  Although the Company anticipates that the payment of these guaranteed amounts will not be required under normal growing conditions, for the 2022/2023 winter season the maximum amount of these grain production guarantees is approximately $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU0OTc1NTgyMjcyNA_f3df4ef8-efcf-41f1-9327-3b087f09dacf">320</ix:nonFraction>.  As of December&#160;31, 2022, the Company has recorded an accrual of approximately $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:GuarantyLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU0OTc1NTgyMjczMw_3976f472-1e84-4caa-bad7-ca7f48948d20">25</ix:nonFraction> for these minimum guaranteed payments, net of the growers' obligation to pay for the planting seed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Leases</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026.  See Note 11.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2022,&#160;and&#160;December&#160;31, 2021, the Company did not have significant liabilities recorded for guarantees.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers.  Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities.  These indemnification provisions generally survive termination of the underlying agreement.  The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited.  However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.  As a result, the estimated fair value of these agreements is minimal.  Accordingly, the Company has no liabilities recorded for these agreements as of&#160;December&#160;31, 2022&#160;and&#160;December&#160;31, 2021.</span></div></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_130"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzAvZnJhZzplMWExZDcwMzZiZGE0ZWQ3YjE5NDdlZTcwOWFhZmZkMC90ZXh0cmVnaW9uOmUxYTFkNzAzNmJkYTRlZDdiMTk0N2VlNzA5YWFmZmQwXzI1MjE_ff26420d-c312-4c2c-8384-87075f29a20a" continuedAt="iecb3d85c5603482fb272783734ae33ec" escape="true">License Agreements</ix:nonNumeric></span></div><ix:continuation id="iecb3d85c5603482fb272783734ae33ec" continuedAt="i41e58e57775a495c8e98fc077a83c9ae"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean.  Under this license, Bayer had the non-exclusive right to work with C3003 in its soybean program as a strategy to improve seed yield.  In December 2022, the Company and Bayer terminated the license in accordance with its terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company granted a <ix:nonNumeric contextRef="i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930" name="yten:LicenseAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzAvZnJhZzplMWExZDcwMzZiZGE0ZWQ3YjE5NDdlZTcwOWFhZmZkMC90ZXh0cmVnaW9uOmUxYTFkNzAzNmJkYTRlZDdiMTk0N2VlNzA5YWFmZmQwXzI3NDg3NzkwNzY4OTU_89adc7ca-e015-4e21-bbe1-deb738730777">four-year</ix:nonNumeric>, non-exclusive license, as amended, to Forage Genetics International, LLC, a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum.  The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform; C4001, C4002, C4003 and C4029.  In September 2022, the license terminated in accordance with its terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato.  Under the license agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability.  In September 2022, the Company and Simplot amended the license agreement in order to extend it for a fourth year.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i41e58e57775a495c8e98fc077a83c9ae"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specializing in plant genetics, to evaluate novel traits in soybean.  Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability.  The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.</span></div></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_133"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMTU_8d188194-b3d4-4222-91e0-d4716749b532" continuedAt="i371295bad6a54a9f80db4717c5d890a3" escape="true">Capital Stock and Warrants</ix:nonNumeric></span></div><ix:continuation id="i371295bad6a54a9f80db4717c5d890a3" continuedAt="i488520436c0d4c57abe4f02c62ebe517"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Public Offerings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2021, the Company completed a public offering of <ix:nonFraction unitRef="shares" contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzE0MA_e5154818-624f-498b-8da5-13ebb056c2db">1,040,000</ix:nonFraction> shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="icff22d25d26146d48d6decdae2cb0324_I20210203" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzIwMA_b99f7e71-9d92-40c3-a645-9ccd5eca46b6">12.25</ix:nonFraction> per share for total gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203" decimals="-3" name="yten:SaleofStockGrossConsiderationReceivedPerTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzI0MQ_573b9098-5f53-4562-8fb8-15deb2352f8c">12,740</ix:nonFraction> before issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzI2OQ_b850cfad-b8c4-4f89-96b3-f84a9d2717e1">747</ix:nonFraction>.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to <ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzQyODA_fb1c517c-5755-4bd4-bb2c-cc701afd0cb4">5,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="usdPerShare" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzQyOTM_718dcac4-c72f-49ca-9b9d-ae36e62f57c4">0.01</ix:nonFraction> par value preferred stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMDc_3e3b7c4b-f719-4367-ab5e-f65c8fac31b4" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information with regard to outstanding warrants to purchase common stock as of December&#160;31, 2022:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares Issuable Upon Exercise of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Public Offering - Series B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia723adea7be546caa73fa33c727a5588_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzItMi0xLTEtNTU2NzY_d6b3cf26-af85-4c81-a40c-26fade3c3f30">395,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia723adea7be546caa73fa33c727a5588_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzItNC0xLTEtNTU2NzY_bfee68ed-f100-4486-ae8d-5ce1a9a94dc5">8.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Private Placement - Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie858d5dd08b14a2188004834d4b1e502_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzQtMi0xLTEtNTU2NzY_c02430b1-6b04-4d02-87d7-8a5194c6ef85">718,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie858d5dd08b14a2188004834d4b1e502_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzQtNC0xLTEtNTU2NzY_f3121148-3309-4367-9738-a918e5381c31">8.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2017 Registered Direct Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7fc2e0c481974966a604c4a0215f7915_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzYtMi0xLTEtNTU2NzY_9a3d7630-2bcc-4763-80cb-08beee3c0472">14,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7fc2e0c481974966a604c4a0215f7915_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzYtNC0xLTEtNTU2NzY_1d6e7859-4a41-49e1-a7e9-6ffa0079a4b4">201.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5c1edd8e75c4550a03bf3e5051b199f_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzctMi0xLTEtNTU2NzY_95abb1fc-9333-41b1-80a9-e4c93e009973">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if5c1edd8e75c4550a03bf3e5051b199f_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzctNC0xLTEtNTU2NzY_92474f92-2b53-4b66-800d-73391796c03c">116.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzgtMi0xLTEtNTU2NzY_bc5f7793-5d1d-4884-bf62-4b26ff676dc3">1,129,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 19, 2022, <ix:nonFraction unitRef="shares" contextRef="i4c88b89cfb1647cd9d8bbb0a82bfcbc0_D20220519-20220519" decimals="0" name="yten:ClassOfWarrantOrRightExpired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzEwOTk1MTE2Mzk1ODE_71c41096-25b2-4e50-bc55-797db41c7dc5">1,071,453</ix:nonFraction> Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued.  In addition, <ix:nonFraction unitRef="shares" contextRef="i6251c05d326e4a9386219cd404a47d8a_D20220519-20220519" decimals="0" name="yten:ClassOfWarrantOrRightExpired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzEwOTk1MTE2Mzk4MDQ_f5ee2572-f90d-4c91-82eb-1a02cdac7036">160,975</ix:nonFraction> Series A warrants issued in the Company's December 2017 securities offering also expired in accordance with the terms of their securities purchase agreement.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, a combined total of <ix:nonFraction unitRef="shares" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="INF" name="yten:ClassOfWarrantOrRightExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzU3MjU_3b7e55f3-81bb-49ef-a8fe-3e3320325203">481,973</ix:nonFraction> Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing the Company with $<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzU4Nzk_e4a2e83f-24f5-43ca-97b6-78985ea3fbf3">3,856</ix:nonFraction> in cash proceeds.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:3pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMTQ_e9bd406e-1b31-4db4-9497-c0f765c55946" continuedAt="id0a074d7815145aab1babae7bab5a45a" escape="true">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><ix:continuation id="i488520436c0d4c57abe4f02c62ebe517"><ix:continuation id="id0a074d7815145aab1babae7bab5a45a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"></td><td style="width:67.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.922%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.925%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzEtMi0xLTEtNTU2NzY_e4e0a3bc-3211-4412-bc88-b4b9a37b6b2f">979,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i027dffbf78374212835464d3640c101d_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzEtNC0xLTEtNTU2NzY_642c6b05-b8a6-4524-8e1f-e8b9bcbb5dd1">722,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic0ad4c8865ec4c419c5b12e819189c76_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzItMi0xLTEtNTU2NzY_4a4bf53c-fc3d-4ff5-aff2-d41de1968a2f">27,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i260c3b3f20bf4f4681bc4a91f421bbe5_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzItNC0xLTEtNTU2NzY_776d9faf-c1a2-4b96-a91c-602a191c1a70">9,430</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2832ee80f63d460b8492d8bcc0b5909c_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzMtMi0xLTEtNTU2NzY_17e08a38-561e-4f99-ad71-3e717c45537c">1,129,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia0a7f5e745594f2dbf695fb7330eae73_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzMtNC0xLTEtNTU2NzY_3d6ddd0b-b31b-4849-89a2-d329791eb5e3">2,361,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of common shares reserved for future issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzQtMi0xLTEtNTU2NzY_6ca90c66-8953-41fc-afbe-186eba481d61">2,136,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzQtNC0xLTEtNTU2NzY_1bba7aa6-0237-4255-8363-360513a4aefc">3,093,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center"><span><br/></span></div><div id="ic02604fb0219453aa54b246df7a39126_139"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MTY_8326e095-ef30-435c-892c-5ca1fd25db23" continuedAt="id1a77c4d95c347eaa59583598b50c9b9" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="id1a77c4d95c347eaa59583598b50c9b9" continuedAt="i96c01209dd29484db4ce4aa60cc01651"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan").  No further grants or awards were subsequently made under the 2006 Plan.  A total of <ix:nonFraction unitRef="shares" contextRef="ic32cbf34fc774d82a6a93117e76c1b14_I20221231" decimals="INF" name="yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU0MQ_10037152-9bf1-4d6c-8a13-44f2f5c781b5">3,662</ix:nonFraction> options were awarded from the 2006 Plan and as of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ic32cbf34fc774d82a6a93117e76c1b14_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU5OA_17743ae4-fc9c-41a4-ae7c-3c3f7f0028c5">159</ix:nonFraction> of these options remain outstanding and eligible for future exercise.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan, which was amended in May 2020 (the "2018 Stock Plan").  A total of <ix:nonFraction unitRef="shares" contextRef="ic327f368a9714dc0a2557c36d8a5e3da_I20221231" decimals="0" name="yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk_5ebab5af-8cf8-48e3-b546-cb986d1e7ea7">16,896</ix:nonFraction> options were awarded from the 2014 Plan and as of December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ic327f368a9714dc0a2557c36d8a5e3da_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzExNTY_3cf8830b-653b-4ed1-94e0-895b31721305">15,990</ix:nonFraction> of these options remain outstanding and eligible for future exercise.  A total of <ix:nonFraction unitRef="shares" contextRef="i77415003bed3430f96c1e0adf0960a62_I20221231" decimals="INF" name="yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEyNDE_2479f6e8-d3f5-48af-9b13-46ecbfe348b1">3,619</ix:nonFraction> restricted stock awards were awarded from the 2014 Plan and as of December&#160;31, 2022, all of these restricted stock awards have vested.  No further stock awards may be issued from the 2014 Plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Stock Plan initially reserved for issuance <ix:nonFraction unitRef="shares" contextRef="ifd09c1537caf432ab0e3feb9155a01fd_I20181231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzE0NzU_e2eba01f-3ff5-4789-bc2f-353916c39a20">32,500</ix:nonFraction> shares of the Company's common stock for grants of incentive stock options, non-qualified stock options, stock grants and other stock-based awards.  In accordance with the terms of the 2018 Stock Plan, beginning on the first day in January 2019, the Company's Board of Directors has annually approved the addition of shares to the 2018 Stock Plan in amounts equal to <ix:nonFraction unitRef="number" contextRef="i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101" decimals="INF" name="yten:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzE4NDU_506945b5-587a-401d-a1fd-2637e2019165">5</ix:nonFraction>% of the outstanding shares of the Company's common stock on the day prior to the increase.  Effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of <ix:nonFraction unitRef="shares" contextRef="i30d73005a58b4b22bf596e5a6abcca81_D20220101-20220101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk1MTE2MzM3MjQ_de83bde9-8c29-4885-9ee5-a77fb726f239">247,210</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="if44b5193639a4f39b9593f64ec0b5853_D20210101-20210101" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk1MTE2MzM3MjA_03b78d78-ea46-42b3-8d3a-72e0802f6254">244,092</ix:nonFraction> shares, respectively.  At its annual meeting of stockholders held on May 24, 2021, stockholders approved an amendment to add <ix:nonFraction unitRef="shares" contextRef="i9337506ea45848f1ab5679c11ff6aeea_D20210524-20210524" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIxNzE_f4b0f08d-d8b6-426f-a8a9-51d8d99af6cd">300,000</ix:nonFraction> more shares to the Company's 2018 Stock Plan.  As of December&#160;31, 2022, a total of <ix:nonFraction unitRef="shares" contextRef="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231" decimals="INF" name="yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIyNDE_75109a17-d5db-4d58-8f00-1a2404f4d19b">1,059,719</ix:nonFraction> options and restricted stock awards have been issued from the 2018 Stock Plan, and as of that date, <ix:nonFraction unitRef="shares" contextRef="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231" decimals="INF" name="yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIzNDQ_327df441-6812-413e-a73a-ed7aa4b8ea22">990,243</ix:nonFraction> options and restricted stock awards remain outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense Information for Stock Awards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2MDc_6313a2a5-89f6-40eb-a0da-fc01ed884dc0">1,903</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2MTQ_521a4d2c-2c29-4b78-b069-5e496da5839b">1,675</ix:nonFraction> for the years ended December&#160;31, 2022 and 2021, respectively.  At December&#160;31, 2022, there was approximately $<ix:nonFraction unitRef="usd" contextRef="i1b5c8104784a476492d5c745748a9745_I20221231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2OTQ_d134100d-ef0e-4e31-a1df-6ad854c7eaa1">3,189</ix:nonFraction> of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="i0e337683c876475fbd6132b78b10119d_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI4NDg_6853a116-e8e9-411f-8930-d163997aa9e4">2.42</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5NzI_92e01ef7-0471-4c44-a8d1-ce238526654a">one</span> to <ix:nonNumeric contextRef="i7683e5fee18c49a889b650734cfda999_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5Nzg_e9de2017-b970-4878-b30a-e80f872a8420">four years</ix:nonNumeric> from the date of hire for new employees, the date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire <ix:nonNumeric contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" name="yten:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzMxNTc_cbf1c79f-dd8b-4b2a-bbef-4e49f3a22c62">ten years</ix:nonNumeric> from the date of issuance.  The Company's policy is to issue new shares upon the exercise of stock options.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i96c01209dd29484db4ce4aa60cc01651" continuedAt="i286b4a8d3db7480d904ce8b55e9ca97a"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MjQ_72da7b71-13b8-45af-a796-603dd46f8c45" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity related to the shares of common stock covered by outstanding options is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.036%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.040%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMS0xLTEtNjUwOTE_7625b56e-d2d8-4a82-9e97-c982d5473213">339,108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMy0xLTEtNjUwOTk_51870fd0-b8a6-4e81-a9a0-850f4cf5bc21">32.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iadffb97e562c40ab9d5c4ca96b69c01a_D20200101-20201231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtNS0xLTEtNjUxNDE_76668242-32c8-4e91-a765-08e343fa2787">9.02</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtNy0xLTEtNjUxMTQ_ab962fae-7df6-4372-aa0e-23e03b1cc43c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMS0xLTEtNjUwOTE_6c617e5a-21b0-4d53-8672-8f5b0a4e997d">386,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMy0xLTEtNjUwOTk_64e7c0eb-1c3b-4e03-8cfd-ff3bc876752b">10.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMS0xLTEtNjUwOTE_3cc89c3e-fbbf-415a-b908-af24bb70a3b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMy0xLTEtNjUwOTk_34661e82-1d27-48da-a610-17a6a96da118">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMS0xLTEtNjUwOTE_38876b99-73a9-4915-86ef-ec375dcf1106">1,509</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMy0xLTEtNjUwOTk_68ae7b0e-0fce-4a1d-bbf2-22b1b08d419e">12.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMS0xLTEtNjUwOTE_3c3a1685-c8f3-4007-be69-88aa8f223228">851</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMy0xLTEtNjUwOTk_62653547-4714-472a-9eea-ceb707e6c968">1,131.62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i027dffbf78374212835464d3640c101d_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMS0xLTEtNTU2NzY_0c780887-921f-438f-989e-5c7b6c2202a9">722,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i027dffbf78374212835464d3640c101d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMy0xLTEtNTU2NzY_4f55e67d-905a-4ac6-b578-a2ab1058aea9">19.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNS0xLTEtNjUxMzA_b5f0c6c9-5ee5-4c75-ab50-e0b2a8f1e307">8.79</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i027dffbf78374212835464d3640c101d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNy0xLTEtNjUxMjI_12144465-dff1-4ab7-be01-20465b18729f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMS0xLTEtNTU2NzY_85b86877-fa31-4411-a309-01bb848434c6">260,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMy0xLTEtNTU2NzY_941cf4d4-23bf-404e-a753-35320b64f32b">3.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMS0xLTEtNTU2NzY_c0025f19-69b6-4733-99b2-3b292baf3b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMy0xLTEtNTU2NzY_e7ffab94-38f4-4cd2-ac34-31cc5f7a1612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMS0xLTEtNTU2NzY_ff0f67ee-a747-4830-a8d7-ace08a7b0025">1,859</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMy0xLTEtNTU2NzY_7d7c0407-8424-4fb6-845f-ddbf693010ad">7.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMS0xLTEtNTU2NzY_3d26ae42-ea6f-41e1-9719-a6ea446b24f3">1,443</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMy0xLTEtNTU2NzY_779cb8ce-a4d3-4098-931a-bce7016bfd69">712.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtMS0xLTEtNTU2NzY_f2321115-1f77-4c54-bfb0-0e6726b17c9e">979,748</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtMy0xLTEtNTU2NzY_035eab20-9c30-4fdb-92d6-c468279aa226">14.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNS0xLTEtNTU2NzY_413ca947-efc6-4623-ad2f-9b18aa1cd9b7">8.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNy0xLTEtNTU2NzY_2d89a70b-74b1-4bce-99e3-585fb74f0797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctMS0xLTEtNTU2NzY_3ae98aa4-42a7-4331-acb6-757047665c7e">979,748</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctMy0xLTEtNTU2NzY_faa7adff-f1ee-47f3-bebc-692fa72d918f">14.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctNS0xLTEtNTU2NzY_54508340-0ac7-4780-91a4-f205d71797a2">8.15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctNy0xLTEtNTU2NzY_30492b62-9f39-4774-9cbb-eb1a6a8715cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtMS0xLTEtNTU2NzY_84899490-f6f5-4856-b1b2-657bdcde5e7b">437,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtMy0xLTEtNTU2NzY_8a848974-c9c6-4512-9df5-7b236274fec2">23.03</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtNS0xLTEtNTU2NzY_891787ec-cf20-4f09-8739-077fe97f1edd">7.69</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtNy0xLTEtNTU2NzY_9e0ba9d6-38f8-4024-8e79-5617b846e72a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of options granted during fiscal years 2022 and 2021, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM0ODY_8152e724-03bc-48b0-9566-b9fac74b955c">3.31</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM0OTM_444f1e2d-ba21-48d6-85dd-cb13315e3551">8.99</ix:nonFraction>, respectively.  <ix:nonFraction unitRef="shares" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM1MTI_77eab075-d744-4ee5-a8ed-4b07916654b4"><ix:nonFraction unitRef="shares" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM1MTI_aec2944a-258b-4030-ae67-b972b8fc90fe">No</ix:nonFraction></ix:nonFraction> options were exercised during 2022 and 2021, and therefore the intrinsic value for exercised options during the two years was not applicable.  The weighted average remaining contractual term for options outstanding as of December&#160;31, 2022 was <ix:nonNumeric contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM3Mzk_8a07b4d1-4862-4759-badc-9d532c4faa6b">8.15</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MjY_5aa0de91-b15a-4a0d-b297-045696c5119b" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, and 2021, the Company determined the fair value of stock options using the Black-Scholes option-pricing model with the following assumptions for option grants, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.316%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.949%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzItMi0xLTEtNTU2NzY_757d3171-35a9-41cc-b3d3-42d1260ed4a7">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzItNC0xLTEtNTU2NzY_781ded64-a545-43cc-8803-98e63fdf9cff">&#8212;</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo5MWMyOGZlMjFiZDM0ZTAyYWI4YzNiZmQ1ZDdjMzE2ZF80_b21294a9-347c-4261-b87b-e8e440e95f4e">1.6</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo5MWMyOGZlMjFiZDM0ZTAyYWI4YzNiZmQ1ZDdjMzE2ZF85_e37cedd8-4e30-49ec-bb11-5729a6ebd872">4.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpjOWYxOTNlNjdmMjY0ZDk3ODM4ZjkwNDk1Y2ZjY2JjMl80_955eb3e0-e524-40a9-8ad4-492288de483b">0.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpjOWYxOTNlNjdmMjY0ZDk3ODM4ZjkwNDk1Y2ZjY2JjMl85_fe4358d6-b091-495d-aa17-6fda3725377d">1.7</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiZWQ3NTZkMWY1MGY0Mjg2YTk1MjFhMThlMGZhY2MzMF80_a30458cf-acdb-4d93-87ed-338851125413">6.2</ix:nonNumeric> - <ix:nonNumeric contextRef="i7683e5fee18c49a889b650734cfda999_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiZWQ3NTZkMWY1MGY0Mjg2YTk1MjFhMThlMGZhY2MzMF85_38c28a45-04d0-4153-b559-b14df6f2fc1f">10.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i81e4afc9063e482c8ea9bcff80c5bc79_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiYzY2YzZjM2FjNDk0ZTc2OGUxN2Q2NzM2MzMyOGYwYV80_1cb14be1-090b-4f6e-a0c1-e0d37895b0ae">6.1</ix:nonNumeric> - <ix:nonNumeric contextRef="i115962649b404c9dad81db13df9ab327_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiYzY2YzZjM2FjNDk0ZTc2OGUxN2Q2NzM2MzMyOGYwYV85_b97d167c-89e4-428c-8cab-1dc1476866ab">10.0</ix:nonNumeric></span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo0YTEzZDUxNjI5Njg0Y2ZjYjE1ZTkwMWFmYzc2M2YxMl80_977ab803-3328-4346-b6fc-1a467b8e438c">116</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo0YTEzZDUxNjI5Njg0Y2ZjYjE1ZTkwMWFmYzc2M2YxMl85_742e5571-80cc-40ba-a63a-97b24842efcd">126</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjoxMzY3YzRlODlmZTA0NzY5ODczZGY2NWYzNGZmMGY4N180_11bbdf81-cca0-4509-9b81-d5037cb59e8d">118</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjoxMzY3YzRlODlmZTA0NzY5ODczZGY2NWYzNGZmMGY4N185_89fed527-67f5-483c-910f-d93387312e4c">128</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history.  The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option.  The expected term of the options is based upon evaluation of historical and expected future exercise behavior.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option.  The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest.  The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units ("RSUs")</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock compensation expense for RSUs on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value.  As RSUs vests, the Company </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i286b4a8d3db7480d904ce8b55e9ca97a"><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date.  The Company then pays the minimum required income tax for the employees.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, the Company withheld vested shares with a fair value of $<ix:nonFraction unitRef="usd" contextRef="iea7a2db667b9494c88b89ceeae9fafd9_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU2NTg_feb3003a-d5cd-4780-8227-43a37212ed6e">37</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie879a42901184b87a0029ddae2ba967e_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU2NjU_043ca67b-4293-464f-9439-2449381ab2a3">102</ix:nonFraction>, respectively, to pay for minimum tax withholding associated with RSU vesting.</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MzI_f895a8df-f11f-4683-ad88-c811bad21d65" escape="true"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.632%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.419%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzEtMS0xLTEtNTU2NzY_9a411595-6f7d-4160-833b-93502b39fe62">9,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzItMS0xLTEtNTU2NzY_efa5550e-d5bc-4282-8b74-8f7d45b359f6">54,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzMtMS0xLTEtNTU2NzY_08c4075f-b647-4197-baac-974b1817b364">36,557</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzQtMS0xLTEtNTU2NzY_33ab9e19-ab65-464c-99ad-cc4839a7aba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzUtMS0xLTEtNTU2NzY_e457e7b4-6afe-41e2-8734-30179283014a">27,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzUtMy0xLTEtNTU2NzY_0ad66d55-9609-47f6-80b7-665276b4d3a4">0.11</ix:nonNumeric></span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining recognition period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzctMS0xLTEtNTU2NzY_e5140278-c71a-402e-87bd-4a5777dbfa5a">0.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:center"><span><br/></span></div><div id="ic02604fb0219453aa54b246df7a39126_142"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNjc_e3fb8c2d-0633-4ffc-afc5-a21c36e46e0e" continuedAt="i3621e07b14f746c38b2297c2c0a6d265" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i3621e07b14f746c38b2297c2c0a6d265" continuedAt="icef0a3b130a74733b0191905c9c77e65"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity Analysis of Lease Liabilities</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities.  No other active real estate or equipment leases fall within the scope of ASC 842.  At December&#160;31, 2022, the Company's lease liability related to its Woburn facility will mature as follows:</span></div><div style="margin-bottom:12pt"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNjk_5fafad74-3ea3-4a1d-bd1a-0c3e473d01ff" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzEtMS0xLTEtNTU2NzY_1b91cf6f-9e9c-4e72-aa50-06212a1dfe7f">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzItMS0xLTEtNTU2NzY_e75b9e9a-07c4-42d7-8960-269324560490">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzMtMS0xLTEtNTU2NzY_fea35943-d6a9-4fd6-834e-473aa3a7246a">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzQtMS0xLTEtNTU2NzY_f76574b1-371d-49cd-b755-fd68394ccf42">747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzYtMS0xLTEtNTU2NzY_256d2290-8201-4adc-87d8-abbc9e0d5c7c">3,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzctMS0xLTEtNTU2NzY_f5438c52-4776-4aba-82aa-5485ac94675c">410</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzgtMS0xLTEtNTU2NzY_178656c8-112c-4a59-98bb-a7b9d21a8d6a">2,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Short-term lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzktMS0xLTEtNTU2NzY_dc9621cd-3336-4df3-89b8-3fdd1a4932c5">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Long-term lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzEwLTEtMS0xLTU1Njc2_4f64bb1a-d758-4c7c-8389-e5b8c17f4502">2,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNzI_31afba59-2731-48b2-8f53-04dfde836557" continuedAt="i804ae2c648f7420ea4ba245caec3c3a7" escape="true">Quantitative Disclosure of Lease Costs</ix:nonNumeric></span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="icef0a3b130a74733b0191905c9c77e65"><ix:continuation id="i804ae2c648f7420ea4ba245caec3c3a7"><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>&#160; &#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzMtMi0xLTEtNTU2NzY_bad4f238-55cf-45f5-a8b0-541c0f90dc6f">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzMtNC0xLTEtNTU2NzY_5c031392-18e9-427b-b151-72f1c4e04cd5">605</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzQtMi0xLTEtNTU2NzY_7ac0cbce-b3ea-469d-95da-0394ce671b15">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzQtNC0xLTEtNTU2NzY_5e35e602-c0c2-4f09-a1ae-e02364af7c26">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzUtMi0xLTEtNTU2NzY_de2036ea-0f52-42a0-abb5-de8a72415c1b">605</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzUtNC0xLTEtNTU2NzY_f16a3ade-ab4b-40c9-8d9d-01b2e559763e">616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzYtMi0xLTEtNTU2NzY_54c85b27-d9b5-4b9d-8272-c006570dc706">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzYtNC0xLTEtNTU2NzY_a9848e59-2f66-4a38-a529-19f4345775a0">644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:70.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.165%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information as of:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzEtMi0xLTEtNTU2NzY_b6ae6f1c-b13b-4875-8ae3-0366d4279a05">3.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzEtNC0xLTEtNTU2NzY_8c261732-a5a2-4a48-9788-cfdf70829a87">4.9</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzItMi0xLTEtNTU2NzY_739aceda-9dbf-47d9-a616-920f2e1c72b1">7.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzItNC0xLTEtNTU2NzY_61480977-cd2c-4a16-bd39-79d4e6366cc8">7.25</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2016, the Company entered into a lease agreement, as amended, for its headquarters, pursuant to which the Company leased <ix:nonFraction unitRef="sqft" contextRef="i119b882f71fe4a1082a3446bb15acbec_D20160101-20161231" decimals="0" name="yten:LesseeOperatingLeaseLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzE3Nzc_34ada14b-ed51-47e4-b337-bf89518961dd">22,213</ix:nonFraction> square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts.  The lease will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease.  Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease.  During the initial buildout of the rented space, the landlord paid for tenant improvements to the facility that resulted in increased rental payments by the Company.  As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset.  The Company has provided the landlord with a security deposit of $<ix:nonFraction unitRef="usd" contextRef="i91e719d6dc084b8eb65833dd9f3d826e_I20191130" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzI1NDc_02de9560-84c3-40ec-8bc5-e71dbca384b4">229</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of <ix:nonFraction unitRef="sqft" contextRef="i1669a5dd6ba54e94a94243d28e96c30c_D20161001-20161031" decimals="0" name="yten:LesseeOperatingSubleaseSubleasedArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzI3MDI_ca89951b-09fb-441e-a2a0-a903028b45d2">9,874</ix:nonFraction> square feet of its leased facility located in Woburn, Massachusetts.  The sublease space was determined to be in excess of the Company's needs.  The CJ sublease is coterminous with the Company's master lease and CJ will pay pro rata rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease.  Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $<ix:nonFraction unitRef="usd" contextRef="i9567ed174d68444dbf277b216ec8dcbb_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzMyMjg_c88a515f-9773-493f-bcdc-0ce3ee510881">3,060</ix:nonFraction> shown in the lease maturity analysis table above.  CJ provided the Company with a security deposit of $<ix:nonFraction unitRef="usd" contextRef="id253aebbd61b4ee5a2318fd621623370_I20161031" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzMzMzM_a83e609c-f8f7-4915-90d3-9a1f84e5c428">103</ix:nonFraction> in the form of an irrevocable letter of credit.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately <ix:nonFraction unitRef="sqft" contextRef="ifedea1c8eb9444c6bea044622e488712_D20220101-20221231" decimals="-2" name="yten:LesseeOperatingLeaseLeaseArea" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzM4MDg_b893735c-441f-4c74-9d12-54f38e2dbbc7">9,600</ix:nonFraction> square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place.  None of these leases contains renewal or early termination options.  YOI's leases for these facilities expire on various dates through September 2023.</span></div></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_148"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1OTM_da92f141-f5d5-4053-9450-f55376216286" continuedAt="iecbf5bb2dc6b42d78751af938e6c1b9d" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="iecbf5bb2dc6b42d78751af938e6c1b9d" continuedAt="i4c424360dc5d4e6293701c870c896288"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes and Deferred Tax Assets and Liabilities</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1OTA_90e97b9b-9cb6-4331-8350-677a530968b1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from operations before provision for income taxes consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzItMS0xLTEtNTU2NzY_c8c7ec50-35e2-4ce9-aab3-6a5d18516ed9">13,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzItMy0xLTEtNTU2NzY_b63f197c-2af1-4bb1-bb16-c568913f1378">11,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzMtMS0xLTEtNTU2NzY_26bf3234-7f3b-46a5-9626-098643e609ee">94</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzMtMy0xLTEtNTU2NzY_422389fb-8d8e-459b-84d3-8d111e106066">67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from operations before income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzQtMS0xLTEtNTU2NzY_d7cf969d-f39b-466a-a265-81c0aa7ed2dc">13,410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzQtMy0xLTEtNTU2NzY_29bd9447-2b67-495b-87e8-c04988648ee2">10,995</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="i4c424360dc5d4e6293701c870c896288" continuedAt="ic347cd588f8b49139f83934f1d25c299"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ2MTE_bf893b56-dcab-4218-9d0d-545964358c5f" continuedAt="id27153f94f70450784c2bf8b45fb5923" escape="true">The components of the income tax provision consisted of the following for the years ended December&#160;31, 2022 and 2021:</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="id27153f94f70450784c2bf8b45fb5923"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Tax Provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzMtMS0xLTEtNTU2NzY_850aa1e4-41d7-4a2d-9551-2f2692477fe2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzMtMy0xLTEtNTU2NzY_dcdcba93-810f-404b-b487-de8cd0fdbf0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzQtMS0xLTEtNTU2NzY_2df61983-e6ce-4009-b0ed-948c65cc0dfa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzQtMy0xLTEtNTU2NzY_dc1ef8ea-97ca-4b47-a378-ebf0b11d332f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzUtMS0xLTEtNTU2NzY_926ae3d3-61fb-4095-b040-5c4b6102f1f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzUtMy0xLTEtNTU2NzY_587cd9e5-adc8-4469-9eb8-940d06adbbc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzYtMS0xLTEtNTU2NzY_9e002406-0e71-410d-904d-14c8469b4d5d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzYtMy0xLTEtNTU2NzY_4f76f848-22f5-4093-84d4-585fac36f146">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzktMS0xLTEtNTU2NzY_7ae2daf5-52ab-44ba-b7de-a836423c9e2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzktMy0xLTEtNTU2NzY_bd819b3d-6b5d-402f-87ce-f8c4e84b96ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEwLTEtMS0xLTU1Njc2_5b4bca37-294f-4e86-a46a-75eb62095381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEwLTMtMS0xLTU1Njc2_9346b961-fd1f-42dd-9ec5-43c4ac303e6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzExLTEtMS0xLTU1Njc2_46890fb8-cc4f-438e-9e58-d9ddf5c65ae4">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzExLTMtMS0xLTU1Njc2_42a88cbb-338e-4a94-aec8-aedc77239f44">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEyLTEtMS0xLTU1Njc2_091b8390-1a74-453d-836a-f0b8c5c50ccf">156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEyLTMtMS0xLTU1Njc2_a96dbf1b-a0f4-42e7-9759-f5307f22d708">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEzLTEtMS0xLTU1Njc2_6bb7d9ec-bd41-46ec-aedd-68fffcea1ec8">156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEzLTMtMS0xLTU1Njc2_8392e43b-9912-44f9-af9a-64b0c700fa23">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ2MDU_e24c5b11-35e4-4253-a92f-e1fbaa47cd8d" escape="true"><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.114%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.996%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzMtMS0xLTEtNTU2NzY_534cf878-7428-480c-a8c4-aac9f761eb5c">6,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzMtMy0xLTEtNTU2NzY_4240bddd-0bb4-4c48-aac2-c86cfd533e5f">5,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzQtMS0xLTEtNTU2NzY_73053fec-6f73-4b1b-88e9-7cc0e9d0d93c">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzQtMy0xLTEtNTU2NzY_73661f81-d354-4b9a-85e2-8c7842e3241b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzUtMS0xLTEtNTU2NzY_f811c69f-589a-480b-a706-39864da6f910">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzUtMy0xLTEtNTU2NzY_40d452ca-aefb-40d6-92ec-3b83a235bcc5">565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzctMS0xLTEtNTU2NzY_c14efdf5-5bc5-41ea-a7d8-fda7a03a8ebe">1,043</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzctMy0xLTEtNTU2NzY_4f8e5281-84c2-4749-a11d-669c6be692e9">886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="yten:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzgtMS0xLTEtNTU2NzY_15d9fcb6-a5aa-47f8-88f5-a0940ea2cb0b">733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="yten:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzgtMy0xLTEtNTU2NzY_0705b921-5658-42a5-9da4-3149c42b0395">864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzktMS0xLTEtNTU2NzY_34b90d02-d46e-455c-bae4-de23c13c9a07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzktMy0xLTEtNTU2NzY_b65c4500-0bb2-4590-b198-3d15a9cdc5c0">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEwLTEtMS0xLTU1Njc2_5b495e80-26be-437e-8ae5-5cba46080c80">11,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEwLTMtMS0xLTU1Njc2_41955b3b-e03e-4234-9a29-f5a436d7ded5">7,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzExLTEtMS0xLTU1Njc2_ed913469-e0a9-464c-847a-c7e71b935e2e">10,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzExLTMtMS0xLTU1Njc2_170cd7f3-26a5-481d-9e87-52aaa78b1d02">6,961</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEyLTEtMS0xLTU1Njc2_4e87e95c-0c2d-42d1-a950-170697720988">630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEyLTMtMS0xLTU1Njc2_3f4524f2-1fc3-4ba1-8573-ff83d7418211">993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE0LTEtMS0xLTU1Njc2_8b57298a-0cd1-4b25-9252-bd7acc9dadf9">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE0LTMtMS0xLTU1Njc2_c489d3f3-000e-4798-beee-fb61054d1802">185</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="yten:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE1LTEtMS0xLTU1Njc2_675a76f0-21ce-499e-87a0-c8ad628e3556">536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="yten:DeferredTaxLiabilitiesRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE1LTMtMS0xLTU1Njc2_085e7197-f336-4731-a5c8-9e7647bb1acb">643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE2LTEtMS0xLTU1Njc2_29a0caea-6fa6-477a-b407-17002b9a8e33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE2LTMtMS0xLTU1Njc2_0e9b053f-9604-462b-8ea4-824aa8f6f41c">165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="ic347cd588f8b49139f83934f1d25c299" continuedAt="if3ccbb2225df4a76bbe37ecceeb35cd4"><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1ODc_63f88248-4ad7-4776-a3ad-de7ca3483dc3" escape="true"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of <ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ5Mg_3e0f2655-edc9-4474-8dda-770bb8cf45fc">21</ix:nonFraction>% and the provision for income taxes were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.965%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.995%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.996%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzItMS0xLTEtNTU2NzY_41ec03ce-e63a-4997-9896-5b530d0a2978">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzItMy0xLTEtNTU2NzY_8b835570-1558-4fa6-8933-52953ac88101">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzMtMS0xLTEtNTU2NzY_3d9593eb-8bad-4145-baf0-7a32ef0437cf">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzMtMy0xLTEtNTU2NzY_520b467f-0188-4a79-a21b-2ec559f9f106">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzQtMS0xLTEtNTU2NzY_5e55e26a-195d-44c5-909e-d91ec57d1efb">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzQtMy0xLTEtNTU2NzY_c5c43fea-2510-4b98-96fc-388833770645">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzUtMS0xLTEtNTU2NzY_fdb75593-b192-4262-8522-9f546ea202fa">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzUtMy0xLTEtNTU2NzY_1806fe64-b61a-4991-af30-e53f7f83eaca">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzYtMS0xLTEtNTU2NzY_f8fc6832-b7f0-49ca-b505-28d4f6d8a968">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzYtMy0xLTEtNTU2NzY_a0fb5ab7-4f98-4816-bbbc-ed04e349ff1c">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzctMS0xLTEtNTU2NzY_66ecf668-46cd-4486-abec-cc1cf5a06e7a">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzctMy0xLTEtNTU2NzY_17f71e9b-db79-48f9-a4ee-5ca40d5475d7">267.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible equity transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzgtMS0xLTEtNTU2NzY_5aa53273-3ae4-40d8-8d9c-e8e50d500fa7">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzgtMy0xLTEtNTU2NzY_a02cd97a-e0b9-4005-a7bf-b0a108007236">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzktMS0xLTEtNTU2NzY_579abc2e-3ed8-4c21-b701-7b551d3d2f2c">1.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzktMy0xLTEtNTU2NzY_edb6d11e-c38b-43b8-bb74-e6afae6836ef">2.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEwLTEtMS0xLTU1Njc2_5c1dbd4d-012c-4161-b4b9-db0013960591">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEwLTMtMS0xLTU1Njc2_2e4facd0-cfef-4994-bae6-23861886eace">0.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzExLTEtMS0xLTU1Njc2_e91cea6f-3d8a-4cc3-8152-5f22423cd13b">28.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzExLTMtMS0xLTU1Njc2_22b39fdf-653f-44ed-a183-909abe99c2c2">240.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEyLTEtMS0xLTU1Njc2_33927bbd-06e1-4f65-a003-da1e15091611">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEyLTMtMS0xLTU1Njc2_ac4d3348-12eb-49c9-acbc-fc6794cbdc5e">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Attributes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had U.S. net operating loss carryforwards ("NOLs") for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i29e3f12dc3c148188c3b9a72081bb52a_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzY5Mw_50d483c4-f2e0-426e-8a94-e6ee4763b42a">25,460</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i71199acae9bc42239b72a1e18ce921fd_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzcwMA_2b833a2e-ec4e-4e45-9d74-0bb283925e4e">25,414</ix:nonFraction>, respectively.  All of the $<ix:nonFraction unitRef="usd" contextRef="i29e3f12dc3c148188c3b9a72081bb52a_I20221231" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzczMA_50d483c4-f2e0-426e-8a94-e6ee4763b42a">25,460</ix:nonFraction> of federal NOLs will carry forward indefinitely.  The Company's state NOL carryforwards will begin to expire on various dates through 2042.  The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="i9695ea37c9b341f2b0c620593bc7e168_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzEwMTQ_de0db44c-0286-4ba2-ab22-5bd4f484b468">417</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i51098c3d74424991ace97eec86e2af91_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzEwMjE_974799fb-55f1-4710-b90b-fcaa2a084eba">312</ix:nonFraction>, respectively.  These federal and state credits will begin to expire on various dates through 2042.  In Canada, the Company has cumulative research tax credits totaling $<ix:nonFraction unitRef="usd" contextRef="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzExOTE_55cfb6f4-3da4-434e-ae72-18d3c6f9e5c7">132</ix:nonFraction> that will begin to expire on various dates through 2037.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets ("DTA"), which is comprised principally of NOL carryforwards.  Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state DTAs.  Accordingly, a full valuation allowance has been established against the U.S. net DTAs.  The Company has also concluded, based on its financial projections, that it is more likely than not the $<ix:nonFraction unitRef="usd" contextRef="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzU0OTc1NTgxODk3OQ_55cfb6f4-3da4-434e-ae72-18d3c6f9e5c7">132</ix:nonFraction> of DTAs of its wholly-owned Canadian subsidiary, YOI, may not be recognized in the future, resulting in the Company's recording of a full valuation allowance against the assets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOL and research and development credit ("R&amp;D Credit") carryforwards may be subject to a substantial annual limitation under Section&#160;382 of the U.S. Internal Revenue Code of 1986 (the "Code") due to ownership change limitations, as defined by the Code, that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of NOL and R&amp;D Credit carryforwards that can be utilized annually to offset future U.S. taxable income and tax, respectively.  The Company evaluated its Section 382 ownership changes through May 31, 2021 and has determined that the most recent change that occurred in November 2019 resulted in all NOL and R&amp;D Credit carryforwards outstanding as of that date becoming fully limited.  The Company has reduced its associated deferred tax assets accordingly.  To the extent an ownership change occurs in the future, the NOL, R&amp;D Credit carryforwards and other deferred tax assets recorded after the November 2019 ownership change may also be subject to limitations.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><ix:continuation id="if3ccbb2225df4a76bbe37ecceeb35cd4"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2019 through 2022 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S.  The statute of limitations for NOLs utilized in future years will remain open beginning in the year of utilization. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense.  As of December&#160;31, 2022 and 2021, the Company had <ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM1OTk_211215e2-846f-46ac-ada8-31b7bca1f2d9"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="INF" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM1OTk_5d4c4ff0-76f1-410a-954c-46d58e8212e7">no</ix:nonFraction></ix:nonFraction> accrued interest or penalties recorded related to uncertain tax positions.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="yten:ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM2Nzc_834b09bb-5a57-4d93-9d6a-4561061006ed">No</ix:nonFraction> additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant.  As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings.&#160; A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed.&#160; It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries.&#160; Unremitted earnings at December&#160;31, 2022 and December&#160;31, 2021 approximated $<ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1NTk_1d405195-2484-4ba1-a856-e13cc29dd1e2">1,081</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1NjY_30672211-33df-4b46-b4bf-e507979343ff">1,032</ix:nonFraction>, respectively.</span></div></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_151"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzc0NQ_093c5ca2-2422-42e7-bf31-42be80f66196" continuedAt="i6721b899169e40a9ac35fc5b044f561b" escape="true">Employee Benefits</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6721b899169e40a9ac35fc5b044f561b">The Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate.  Participants may contribute up to <ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzE5Mg_7a4502cc-9653-46b6-9ca0-6ddbc70ce7a9">60</ix:nonFraction>% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations.  The Company's plan provides for a matching contribution in common stock of up to <ix:nonFraction unitRef="number" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzM4Mw_2c2d654e-23fd-4270-8e40-5f3a10d9ebbb">4.5</ix:nonFraction>% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued <ix:nonFraction unitRef="shares" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzU0Nw_6ed26295-c24d-4c9a-a307-0ad9896e5c54">36,706</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzU1NQ_9ffc1c2a-09df-4cee-9c6a-078377abc4ca">13,611</ix:nonFraction> shares of common stock during the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively, and recorded $<ix:nonFraction unitRef="usd" contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzY0Mw_eebad91e-37ae-4771-922c-1e3543de8e26">133</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzY1MQ_3a3e31cc-3bd6-44be-b6bb-4fbc830744a1">112</ix:nonFraction>, respectively, of related expense.  Company contributions are fully vested upon issuance.</ix:continuation></span></div><div id="ic02604fb0219453aa54b246df7a39126_154"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="yten:EnergyGrantDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE5NzQ_35283d3d-918e-4df2-847c-41577afd83e0" continuedAt="i56a0b1bc915649e2bee55d6a6c809c20" escape="true">Government Research Grants</ix:nonNumeric></span></div><ix:continuation id="i56a0b1bc915649e2bee55d6a6c809c20"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Research Grant</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, YOI received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC").  The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises.  Under the terms of the agreement, NRC agreed to contribute up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i9843252c42d74447b91e88027db863ce_I20210226" decimals="-3" name="yten:ResearchGrantMaximumPayrollCostReimbursement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzQ0Ng_abbf6666-175a-4065-991f-9c6515bde59d">39</ix:nonFraction> for payroll costs incurred by YOI during the period December 20, 2020 - March 13, 2021.  During the first quarter of 2021, YOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Research Grants</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Systems Approach to Increasing Carbon Flux to Seed Oil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"  The Company's participation under this <ix:nonNumeric contextRef="i51fd40cc2e254ece8789b8a8cd184ae8_D20170915-20170915" name="yten:GovernmentGrantTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE5ODA_97271af6-270b-422f-b1b7-443642e2e692">five-year</ix:nonNumeric> grant has been awarded incrementally on an annual basis with the first year commencing September 15, 2017.  Total funding for this sub-award in the amount of $<ix:nonFraction unitRef="usd" contextRef="i65d3bb815986434388d03c0031f92093_I20220930" decimals="-3" name="yten:GovernmentGrantCumulativeAmountAwarded" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE0ODk_6de153cc-70af-43bc-918c-7706d967b48e">2,957</ix:nonFraction> was appropriated by the U.S. Congress through the final contractual year ending in September 2022.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, Yield10 recognized grant revenue of $<ix:nonFraction unitRef="usd" contextRef="i700069e2fa634d1189b702db4b2c4eaa_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE2Njc_38599f75-e43d-4e3d-a22f-7be3f35587de">450</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ie6dc4ad390504593af4a7847e1ed85a6_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE2NzQ_9b0e55a2-2e6f-4694-9134-5426e65807fa">575</ix:nonFraction>, respectively, from this sub-award.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, final proceeds of $<ix:nonFraction unitRef="usd" contextRef="i9f30c8f754de4a0f87018176ab9201bb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE3MzU_9815a21d-4fee-457c-911e-6ee2ff2c3c7b">60</ix:nonFraction> remain to be earned from the MSU sub-award.  During June 2022, the parties amended the sub-award to extend its termination date to September 14, 2023, allowing Yield10 time to utilize the remaining grant funds.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 25</span></div></div></div><div id="ic02604fb0219453aa54b246df7a39126_157"></div><hr style="page-break-after:always"/><div style="min-height:108pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ic02604fb0219453aa54b246df7a39126_7">Table of Contents</a></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">YIELD10 BIOSCIENCE,&#160;INC.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except for share and per share amounts)</span></div></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90ZXh0cmVnaW9uOmNlMzk2ZDdkZTU3NTRlNTNiNmI4NDRmOWY0MWJmMTU0XzI2Mw_d686a474-c1cf-4919-9ebd-b2d33ac89703" continuedAt="i8abe835339e34b1e9e6bb880f454a6ce" escape="true">Geographic Information</ix:nonNumeric></span></div><ix:continuation id="i8abe835339e34b1e9e6bb880f454a6ce"><ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90ZXh0cmVnaW9uOmNlMzk2ZDdkZTU3NTRlNTNiNmI4NDRmOWY0MWJmMTU0XzI1OA_9499fd8f-7216-4e8d-b926-4003b0b5b8c2" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below.  Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib809cccb2c294bd5843cf6785af9651f_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItMi0xLTEtNTU2NzY_670b3877-e131-4065-a656-65e0320cbe42">450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id239db0d46964587ab76bc81df6f1ee4_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItNC0xLTEtNTU2NzY_98d68e2c-4cd8-4003-a6ed-bb3beb9fedcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8ed864be1c04cbca5272439e51ebf52_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItNi0xLTEtNTU2NzY_4261c8e9-3b49-404e-8201-23e9c8615eed">450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3432e814c7b446a9bbe66a61846e2cde_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtMi0xLTEtNTU2NzY_49301d59-b292-4d96-8a8d-b60b29260cb0">671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd17402842448b7b9f9be98aca430e4_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtNC0xLTEtNTU2NzY_35eeeb78-a08e-441e-873a-e5348b7eef51">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i966a0b1f35af427492d1da0e13191558_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtNi0xLTEtNTU2NzY_6fa86461-2a86-4bd3-90e5-6ef967434493">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bc505e998514513905d81d0f376c451_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtMi0xLTEtNTU2NzY_2a2c1714-14bd-4c08-88b3-a9fefc553f0c">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4d4d7b016184bf3ab8c1d7180e6719f_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtNC0xLTEtNTU2NzY_fcda82dc-9d65-4004-8f58-4adfd4f44da6">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3182629b0bab4d00be6bc9a3a8bd468a_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtNi0xLTEtNTU2NzY_f8b99d64-0294-4a0f-b785-3a701b1c16e6">614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09214b6a6ff746c2aa27601f31735dc0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtMi0xLTEtNTU2NzY_9c916095-b6b7-423d-8605-a925301347b1">821</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629b7830786c41b6bda1598354d3a5b4_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtNC0xLTEtNTU2NzY_534964d7-58bd-48bd-938d-c378a7c97ff3">69</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtNi0xLTEtNTU2NzY_7ea57734-d789-44e9-9ca3-b6647a3ab7cd">890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ic02604fb0219453aa54b246df7a39126_160"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEzMjE_ad09d2a6-61ff-4fcf-bb80-9d08f3df81ee" continuedAt="i63c53e04360e4c079d0a6c6574e85dec" escape="true">Related Party Transaction</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i63c53e04360e4c079d0a6c6574e85dec">During 1999, Yield10 entered into a technology sublicense agreement with Tepha, Inc. ("Tepha"), a privately held related party engaged in the development of medical products.  Yield10 received <ix:nonFraction unitRef="shares" contextRef="i8415c21be2b24e3d8bf42091cf9a338e_I20021231" decimals="INF" name="us-gaap:InvestmentOwnedBalanceShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzA1Nzk_ac4cee36-4b61-46f6-a0dd-f0634cf9533d">648,149</ix:nonFraction> shares of Series A Convertible Preferred Stock of Tepha ("Tepha Shares") during 2002 as consideration for outstanding license payments due to Yield10 totaling $<ix:nonFraction unitRef="usd" contextRef="i8415c21be2b24e3d8bf42091cf9a338e_I20021231" decimals="-3" name="yten:LicensePaymentsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzA3NDI_046ac775-2f8c-4eb4-9573-563e3e674aae">700</ix:nonFraction>.  During 2005, the Company determined the value of the Tepha Shares was impaired resulting in their write off through a charge to other income (expense).  In May 2021, the board of directors of Tepha approved and authorized the merger of Tepha with Becton Dickinson Global Holdings, Inc. ("Becton Dickinson") and on July 26, 2021, Yield10 received cash consideration of $<ix:nonFraction unitRef="usd" contextRef="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231" decimals="-3" name="yten:GainOnRelatedPartyInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzExMTY_94cd11e2-da45-43f8-8af7-9673fe11ce21">700</ix:nonFraction> in exchange for the surrender of its Tepha Shares upon the closing of the sale of Tepha to Becton Dickinson.  As a result, the Company recorded the $<ix:nonFraction unitRef="usd" contextRef="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231" decimals="-3" name="yten:GainOnRelatedPartyInvestment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzEyNjg_94cd11e2-da45-43f8-8af7-9673fe11ce21">700</ix:nonFraction> as a gain on investment in related party within other income (expense) during the year ended December&#160;31, 2021.</ix:continuation></span></div><div id="ic02604fb0219453aa54b246df7a39126_1354"></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM18yNzQ4Nzc5MDcyOTYz_995724ce-7189-4ac0-ae4c-91388b1947fb" continuedAt="i43c65e74cf0a4b90a2f326f796e9d7da" escape="true">Subsequent Event</ix:nonNumeric></span></div><ix:continuation id="i43c65e74cf0a4b90a2f326f796e9d7da"><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market ("ATM") Program</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;24, 2023, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Maxim Group LLC ("Maxim") under which the Company may offer and sell shares of its common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i201dadb72c254a7c8f4f4491ef87c2ed_I20230124" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM18yNzQ4Nzc5MDcyOTY1_74a2357e-aa49-48db-83d2-812cc1f571a9">0.01</ix:nonFraction> par value per share, having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124" decimals="-3" name="yten:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4NTM_6ef693c2-37a0-4746-a63f-c0c923e70bf1">4,200</ix:nonFraction> from time to time through Maxim, acting exclusively as the Company's sales agent (the "Offering").  On January&#160;24, 2023, the Company filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering under its existing Registration Statement on Form S-3 (File No 333-254830), which was declared effective on April 2, 2021.  The Company intends to use the net proceeds of the Offering primarily for working capital and general corporate purposes.  Maxim will be entitled to compensation at a fixed commission rate of <ix:nonFraction unitRef="number" contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124" decimals="4" name="yten:SaleOfStockCommissionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4NzE_1fc62b1e-93d4-406c-a6b6-c5f6a9ce55fe">2.75</ix:nonFraction>% of the gross sales price per share sold.  In addition, the Company agreed to reimburse Maxim for its costs and out-of-pocket expenses incurred in connection with its services, including the fees and out-of-pocket expenses of its legal counsel.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not obligated to make any sales under the Sales Agreement and no assurance can be given that the Company will sell, or the dates on which any such sales will take place.  The Sales Agreement will continue until the earliest of (i) twelve (12) months following the date of the Sales Agreement, (ii) the sale of shares thereunder having an aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124" decimals="-3" name="yten:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4ODA_6ef693c2-37a0-4746-a63f-c0c923e70bf1">4,200</ix:nonFraction>, and (iii) the termination by the Company upon the provision of ten (10) days written notice or by Maxim immediately upon written notification to the Company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January&#160;24, 2023 through  March&#160;14, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314" decimals="0" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY5MjM_2ccbe65a-4b7f-431f-9b4d-c825d54754ce">94,665</ix:nonFraction> shares of common stock in connection with the ATM at per share prices between $<ix:nonFraction unitRef="usdPerShare" contextRef="ieb4322ccfe3e4eb29b27ffe467b4d129_I20230314" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcwOTI_c5bac214-b18a-44dc-8dc0-0a8e12a95817">3.03</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i9e7eed8de0164fab84eedcfec07eed0a_I20230314" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcxMDA_802858cd-0cbb-45af-b16c-05830c54098e">4.08</ix:nonFraction>, resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcyNDk_0bc0de33-e5bb-401d-9fac-5cdfb452a047">290</ix:nonFraction> after subtracting sales commissions.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F- 26</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>yten-20221231x10kexh41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i524c0ad7d8184faf9d3d7261f8ecfa23_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 4.1</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGISTERED PURSUANT TO SECTION 12 OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES EXCHANGE ACT OF 1934</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 Bioscience, Inc. (the &#8220;Company&#8221; or &#8220;we&#8221;) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended&#58; our common stock, par value $0.01 per share.</font></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF COMMON STOCK</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are authorized to issue 60,000,000 shares of common stock, par value $0.01 per share. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following description of our common stock is a summary and does not purport to be complete. You should refer to our amended and restated certificate of incorporation and our amended and restated by-laws, both of which are incorporated by reference as exhibits to the Company&#8217;s Annual Report on Form 10-K of which this exhibit is a part. The summary below is also qualified by provisions of applicable law. </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of our common stock are entitled to one vote per share on all matters submitted to a vote of our stockholders and do not have cumulative voting rights. Subject to preferences that may be applicable to any preferred stock outstanding at the time, the holders of outstanding shares of common stock are entitled to receive ratably any dividends declared by our board of directors out of assets legally available. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of liabilities and the liquidation preference of any then outstanding shares of preferred stock. Holders of common stock have no preemptive or conversion rights or other subscription rights. There are no redemption or sinking fund provisions applicable to our common stock.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Transfer Agent and Registrar</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transfer agent and registrar for our common stock is American Stock Transfer &#38; Trust Company, LLC, with offices at 6201 15th Avenue, Brooklyn, New York 11219.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Exchange Listing</font></div><div style="margin-bottom:15pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed for quotation on the Nasdaq Capital Market under the symbol &#8220;YTEN.&#8221;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:137%">CERTAIN PROVISIONS OF DELAWARE LAW AND</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:137%">OF THE COMPANY&#8217;S CERTIFICATE OF INCORPORATION AND BYLAWS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-Takeover Provisions</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 203 of the Delaware General Corporation Law. Subject to certain exceptions, Section 203 prevents a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the interested stockholder attained such status with the approval of our board of directors or unless the business combination is approved in a prescribed manner. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving us and the &#8220;interested stockholder&#8221; and the sale of more than 10% of our assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person affiliated with or controlling or controlled by such entity or person.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Charter Documents</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated by-laws include a number of provisions that may have the effect of delaying, deferring or discouraging another party from acquiring control of our company or preventing changes in our management, including the following&#58;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Issuance of Undesignated Preferred Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our board of directors has the authority, without further action by the stockholders, to issue up to 5,000,000 shares of undesignated preferred stock with rights, preferences and privileges designated from time to time by our board of directors without further action by stockholders. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences and sinking fund terms, any or all of which may be greater than the rights of common stock.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Size of the Board of Directors and Filling Vacancies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our entire board of directors. Any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the size of the board of directors, may only be filled by the affirmative vote of a majority of our directors then in office, even if less than a quorum.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Classified Board. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our board of directors is divided into three classes of directors, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">No Cumulative Voting.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation, as amended, and amended and restated by-laws do not permit cumulative voting in the election of directors. Cumulative voting allows a stockholder to vote a portion, or all of its shares for one or more candidates. The absence of cumulative voting makes it more difficult for a minority stockholder to gain a seat.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Removal of Directors.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Directors can only be removed by our stockholders for cause and removal of a director will require a 75% stockholder vote.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">No Written Consent of Stockholders.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stockholder actions are required to be taken by a vote of the stockholders at an annual or special meeting. Stockholders may not take action by written consent in lieu of a meeting. The inability of stockholders to take action by written consent means that a stockholder would need to wait until the next annual or special meeting to bring business before the stockholders for a vote.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Special Meetings of Stockholders.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Special meetings of our stockholders may be called only by our board of directors acting pursuant to a resolution approved by the affirmative vote of a majority of the directors then in office. Only those matters set forth in the notice of the special meeting may be considered or acted upon at a special meeting of our stockholders.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Advance Notice Requirements for Stockholder Proposals and Director Nominations.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated by-laws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. These procedures provide that notice must be given in writing not later than the close of business on the 90th day nor earlier than the close of business on the 120th day prior to the first anniversary of the preceding year&#8217;s annual meeting. These procedures may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempt to obtain control of us.</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Amendment to Amended and Restated Certificate of Incorporation and By-laws. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amendment, repeal or modification of certain provisions of our amended and restated certificate of incorporation or amended and restated by-laws requires a 75% stockholder vote. Provisions requiring such supermajority vote include, among other things, any amendment, repeal or modification of the provisions relating to the classification of our board of directors, the requirement that stockholder actions be effected at a duly called annual or special meeting of our stockholders and the designated parties entitled to call a special meeting of our stockholders.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>3
<FILENAME>yten-20221231x10kexh1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if156782af38142c9bb6d2f6d106885d7_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Exhibit 10.18</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY &#91;***&#93;, HAS BEEN OMITTED BECAUSE THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">ROTHAMSTED RESEARCH INSTITUTE</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">THIS OPTION AGREEMENT (&#8220;AGREEMENT&#8221;) is made and entered into on the day that the second PARTY signs it below (&#8220;EFFECTIVE DATE&#8221;) by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ROTHAMSTED RESEARCH LIMITED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> a company limited by guarantee incorporated and registered in England and Wales with company number 2393175 and a not for profit charity with charity number 802038, whose registered office is at West Common, Harpenden, Hertfordshire AL5 2JQ, United Kingdom (&#8220;ROTHAMSTED&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">YIELD10 BIOSCIENCE INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a corporation organized under the laws of the State of Delaware having offices at 19 Presidential Way, Woburn, MA 01801 (hereafter &#8220;COMPANY&#8221;).  ROTHAMSTED and COMPANY may sometimes be referred to herein as a &#8220;PARTY&#8221; or &#8220;PARTIES&#8221; as the case may be.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">WHEREAS, ROTHAMSTED has an ownership interest in the OPTION PATENT RIGHTS and OPTION KNOW-HOW (collectively, the &#8220;TECHNOLOGY&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">WHEREAS, COMPANY is desirous of obtaining an exclusive OPTION to research and develop the TECHNOLOGY to determine COMPANY&#8217;S interest in entering into good faith negotiations for (inter alia) an exclusive royalty-bearing license under the OPTION PATENT RIGHTS to research, develop and commercialize LICENSED PRODUCTS in the OPTION TERRITORY&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">WHEREAS, ROTHAMSTED is desirous of granting such an option to COMPANY in accordance with the terms of this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">NOW, THEREFORE, in consideration of the foregoing premises and the mutual promises contained herein and the payments specified hereunder, the PARTIES hereto agree as follows&#58;</font></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article I. DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.01</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;AFFILIATE&#8221; means (a) any business entity more than fifty percent (50%) owned by LICENSEE, (b) any business entity which owns more than fifty percent (50%) of LICENSEE, or (c) any business entity that is more than fifty percent (50%) owned by a (i) business entity that owns more than fifty percent (50%) of LICENSEE or (ii) business entity of which LICENSEE owns more than fifty percent (50%).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.02</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;CONTROLS&#8221; or &#8220;CONTROLLED BY&#8221; means, with respect to any KNOW-HOW or PATENT RIGHTS, the possession by a PARTY of the right to transfer or grant a license, sublicense or other rights to such KNOW-HOW or PATENT RIGHTS, as provided herein, without violating the terms of any agreement or arrangement with another party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.03</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;COVERED BY&#8221; means, when referring to an IMPROVEMENT or LICENSED PRODUCT&#58;  (a) with respect to a patent, that, in the absence of a license granted to a person under a </font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">claim included in such patent, the practice by such person of a specified activity with respect to such IMPROVEMENT or LICENSED PRODUCT would infringe such claim (without regard to the validity or enforceability of such claim), or (b) with respect to a patent application, that, in the absence of a license granted to a person under a claim included in such patent application, the practice by such person of a specified activity with respect to such IMPROVEMENT or LICENSED PRODUCT would infringe such claim if such patent application were to issue as a patent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.04</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;EXPLOIT&#8221; means to make, have made, import, use, sell, offer for sale, research, develop, have developed, commercialize or have commercialized, register, hold or keep (whether for disposal or otherwise), import, export, transport, distribute, promote, market or have sold or otherwise dispose of.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.05</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;IMPROVEMENTS&#8221; shall mean all additions, improvements, adaptations, modifications or enhancements to any part of the TECHNOLOGY.  For clarity, IMPROVEMENTS include, without limitation, &#8220;Improvements&#8221;, &#8220;Non-Severable Improvements&#8221; and &#8220;Severable Improvements&#8221; (as such terms are defined in the COLLABORATION AGREEMENT) including without limitation such Improvements deemed &#8220;Arising Intellectual Property&#8221; (as defined in the COLLABORATION AGREEMENT).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.06</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;KNOW-HOW&#8221; means, collectively, any knowledge, information, techniques, technology, trade secrets, inventions, discoveries, methods, know-how, data, results, analytical and quality control data and results, regulatory documents, and other information, compositions of matter, cells, cell lines, assays, plants and other physical, biological, genetic or chemical material (whether patentable or not).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.07</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;LICENSED PRODUCT&#8221; means a product that (i) is COVERED by a VALID CLAIM of the OPTION PATENT RIGHTS and&#47;or (ii) incorporates or uses the OPTION KNOW-HOW.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.08</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;NON-COMMERCIAL RESEARCH PURPOSES&#8221; means the use or practice of the OPTION PATENT RIGHTS and&#47;or OPTION KNOW-HOW for research, teaching, educational, or academic purposes in the OPTION FIELD which are undertaken at ROTHAMSTED or at a non-profit, academic, educational, or governmental institution, or with or funded by a commercial entity for such non-commercial purposes.  Without limiting the foregoing, subject to Section 2.01 and Section 6.02 NON-COMMERCIAL RESEARCH PURPOSES includes the use or practice of the TECHNOLOGY for research (including sponsored research) that leads, or may lead, to patentable or unpatentable inventions that may be licensed or otherwise transferred, either directly or indirectly, to third parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.09</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;OPTION KNOW-HOW&#8221; means KNOW-HOW owned or CONTROLLED BY ROTHAMSTED as of the Effective Date or developed during the Term relating to omega-3 oil traits including without limitation the production and applications of omega-3 fatty acid oils in plants including without limitation the KNOW-HOW listed in Appendix A.  For clarity, OPTION KNOW-HOW includes without limitation &#8220;Know-how&#8221; arising under and as defined in the COLLABORATION AGREEMENT.</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.10</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.03pt">&#8220;OPTION FIELD&#8221; means the evaluation and development of the production of plant seed oils contain</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ing omega-3 long chain polyunsaturated fatty acids as described in the OPTION PATENT RIGHTS defined herein and any IMPROVEMENTS.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.11    &#8220;OPTION PATENT RIGHTS&#8221; means ROTHAMSTED&#8217;s rights and interests in and to (a) issued patents and pending patent applications (which, for purposes of this AGREEMENT, include certificates of invention, applications for certificates of invention and priority rights) in any country or region listed in Appendix A including any divisionals, continuations, continuations-in-part, substitutions, patents of addition, reissues, revivals, extensions, re-examinations or renewal applications related to, or claiming priority to, the foregoing (including any supplemental patent certificates) or any confirmation patent or registration patent, and all patents issuing on, and all foreign counterparts of, any of the foregoing, (b) any PATENT RIGHTS COVERING IMPROVEMENTS developed during the TERM of this AGREEMENT and (c) any PATENT RIGHTS encompassed within &#8220;Arising Intellectual Property&#8221; as defined in the COLLABORATION AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;OPTION PERIOD&#8221; means the period commencing on the EFFECTIVE DATE of this AGREEMENT and ending on the later of (a) two (2) years thereafter, i.e., the second anniversary of the Effective Date, such period extendable by additional periods of up to one year with the prior written agreement of the PARTIES and (b) thirty (30) days after receipt of the FINAL REPORT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.13</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;OPTION TERRITORY&#8221; means worldwide.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.14</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;PATENT EXPENSES&#8221; means all reasonable out-of-pocket expenses, costs, and attorneys&#8217; fees ROTHAMSTED has incurred for the preparation, filing, prosecution and maintenance of the OPTION PATENT RIGHTS, including but not limited to interferences, derivation proceedings, re-examinations, reissues, oppositions, supplemental examinations, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">inter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">partes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> reviews, and post grant reviews.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;PATENT RIGHTS&#8221; means rights and interests in and to issued patents and pending patent applications (which, for purposes of this AGREEMENT, include certificates of invention, applications for certificates of invention and priority rights) in any country or region, including any divisionals, continuations, continuations-in-part, substitutions, patents of addition, reissues, revivals, extensions, re-examinations or renewal applications related to, or claiming priority to, the foregoing (including any supplemental patent certificates) or any confirmation patent or registration patent, and all patents issuing on, and all foreign counterparts of, any of the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.16</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;TAX&#8221; means value added tax (VAT) in the UK or any equivalent tax chargeable whether in the UK or elsewhere.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 1.17</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:12.03pt">&#8220;VALID CLAIM&#8221; means, with respect to any country or jurisdiction a claim of an issued and unexpired patent (as may be extended through supplementary protection certificate or patent term extension or the like) that has not been cancelled, revoked, held invalid or unenforceable by a decision of a patent office or other government authority of competent jurisdiction from which no appeal can be taken (or from which no appeal was taken within the allowable time period) and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination or disclaimer or otherwise.</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article II. OPTION GRANT, TECH TRANSFER</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.01    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Option Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  During the OPTION PERIOD, ROTHAMSTED hereby grants to COMPANY and COMPANY accepts, subject to the terms and conditions hereof, an (a) exclusive license to internally evaluate the TECHNOLOGY solely for purposes of determining its interest in licensing the TECHNOLOGY and (b) exclusive option to negotiate a license in the OPTION PATENT RIGHTS and&#47;or the OPTION KNOW-HOW in each case to research, develop, commercialize and otherwise EXPLOIT LICENSED PRODUCTS in the OPTION TERRITORY as set forth in Section 2.02 below (&#8220;OPTION&#8221;).  The OPTION PERIOD may be extended if mutually agreed to in writing by ROTHAMSTED and COMPANY.  During the OPTION PERIOD, and any extensions thereof, COMPANY shall have the right to use and shall use good faith efforts to evaluate the technical, economic, and commercial aspects of the TECHNOLOGY in accordance with (and at the locations set out in) the evaluation plan set out in Appendix C, but shall not have the right to use TECHNOLOGY for the sale, supply or commercialization of any products or services.  During the OPTION PERIOD, ROTHAMSTED will not grant (without the prior written consent of COMPANY) to any other third party any license or other rights under the TECHNOLOGY including without limitation for the sale or commercialization of products or services in the OPTION FIELD in the OPTION TERRITORY. COMPANY shall provide reports of progress and share data on the evaluation contemplated by this Section 2.01 in such detail as demonstrates said good faith efforts being applied by COMPANY &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.02    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exercise of Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  At any time during the OPTION PERIOD, and any extensions thereof, COMPANY may exercise its OPTION to begin good faith negotiations for a license agreement providing (a) a milestone and royalty-bearing, exclusive or nonexclusive license to OPTION PATENT RIGHTS and&#47;or (b) a royalty bearing exclusive or nonexclusive license to the OPTION KNOW-HOW to research, develop, commercialize and otherwise EXPLOIT LICENSED PRODUCTS in OPTION TERRITORY (&#8220;LICENSE AGREEMENT&#8221;) by giving ROTHAMSTED written notice of the same.  In the event that COMPANY does not timely exercise its OPTION, or if the PARTIES fail to execute a LICENSE AGREEMENT within the NEGOTIATION PERIOD, or if COMPANY fails to apply good faith efforts in accordance with Section 2.01 then the OPTION shall lapse, COMPANY shall forfeit its rights hereunder and ROTHAMSTED shall be free to negotiate with and to enter into exclusive or non-exclusive license agreements with third parties for the OPTION PATENT RIGHTS and&#47;or OPTION KNOW-HOW.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.03    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Separate Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Should COMPANY elect to exercise its OPTION to negotiate a license to TECHNOLOGY, all terms and conditions, license fees, and royalty rates of such license shall be negotiated as a separate agreement within the framework headline terms and conditions set forth in this AGREEMENT including Appendix B.  The LICENSE AGREEMENT if executed, will include other standard and customary terms normally contained in similar license agreements granted by ROTHAMSTED.  The PARTIES shall negotiate the LICENSE AGREEMENT in good faith.  Such LICENSE AGREEMENT shall be finalized &#91;***&#93; following COMPANY&#8217;s exercise of the option (&#8220;NEGOTIATION PERIOD&#8221;), and if not so finalized solely as a result of COMPANY&#8217;S actions or failures to act then the OPTION shall lapse as specified in Section 2.02.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.04    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Reserved Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  At all times during the OPTION PERIOD, NEGOTIATION PERIOD, and any extensions thereof, ROTHAMSTED reserves the right to make, use or otherwise practice the OPTION PATENT RIGHTS and OPTION KNOW-HOW for NON-COMMERCIAL RESEARCH PURPOSES. ROTHAMSTED also reserves the right to transfer tangible research </font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">materials and intangible materials incorporating the TECHNOLOGY to other non-profit, academic, educational, or governmental institutions for such NON-COMMERCIAL RESEARCH PURPOSES during the OPTION PERIOD, NEGOTIATION PERIOD, and any extensions thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.05    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">COMPANY Research</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  COMPANY shall from time to time during the OPTION PERIOD make available to ROTHAMSTED details of its research into camelina yield traits (&#8220;CAMELINA RESEARCH&#8221;), and COMPANY grants to ROTHAMSTED the right to use and practice such research solely for research, teaching, educational, or academic purposes which are undertaken at ROTHAMSTED or at a non-profit, academic, educational, or governmental institution, or with or funded by a commercial entity for such non-commercial purposes.  The PARTIES agree that CAMELINA RESEARCH shall be COMPANY CONFIDENTIAL INFORMATION.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 2.06    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Technology Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  At COMPANY&#8217;s request ROTHAMSTED will provide COMPANY with access to any OPTION KNOW-HOW that ROTHAMSTED owns or CONTROLS that is necessary or useful for the production or commercialization of omega-3 fatty acid oils in Camelina including without limitation the KNOW-HOW identified in Appendix A.  Where any materials are to be transferred between the Parties, the Parties acting reasonably and in good faith will negotiate and enter into a material transfer agreement consistent with this Agreement prior to any such transfer taking place.</font></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article III. PAYMENT AND FEES</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 3.01    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Option Fee and Research Funding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In consideration of the grant of the OPTION in accordance with Section 2.01, during the OPTION PERIOD COMPANY shall provide total non-refundable, non-creditable funding of &#91;***&#93; to be paid &#91;***&#93; installments as set forth in the table below to be used solely to support the research activities set forth in the separate sponsored research agreement by and between the PARTIES on or around the same date as this AGREEMENT (&#8220;COLLABORATION AGREEMENT&#8221;) materially in the form attached hereto as Appendix E.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.793%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Payment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Payment Due Date</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 3.02    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Patent Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 3.03    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">How Payments are Made</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All payments to ROTHAMSTED pursuant to this AGREEMENT shall be paid in US Dollars within &#91;***&#93; of receipt of an invoice therefor. Such payments shall be without deduction of exchange, collection or other charges.  Such payments shall be made payable to ROTHAMSTED. Invoices shall be submitted by UK mail to COMPANY at&#58;</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yield10 Bioscience</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19 Presidential Way</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Woburn, MA 01801</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">USA</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Or by e-mail to&#58;</font></div><div style="text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Payment shall be sent to the following bank account opened in the name of ROTHAMSTED at &#91;***&#93;&#58;</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of Account Holder</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Account number</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sort code</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IBAN</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SWIFT</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 3.04    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All amounts due under this AGREEMENT from COMPANY (a) shall be paid in full without any set-off, counterclaim, deduction or withholding (other than any deduction or withholding of tax as required by law) and (b) exclude amounts in respect of Tax, which COMPANY shall additionally be liable to pay to ROTHAMSTED at the prevailing rate (if applicable), subject to receipt of a valid Tax invoice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 3.05    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Late Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If COMPANY fails to make any payment due to ROTHAMSTED under this AGREEMENT by the due date for payment, then, without limiting ROTHAMSTED&#8217;s right to terminate under Section 5.02&#58;  (a) COMPANY shall pay interest on the overdue sum from the due date until payment of the overdue sum, whether before or after judgment at a rate of &#91;***&#93;&#59; and (b) ROTHAMSTED may suspend all research and development activities until payment has been made in full.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article IV. DOMESTIC AND FOREIGN PATENT FILING AND MAINTENANCE</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 4.01    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Ownership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  ROTHAMSTED shall have full, complete and sole ownership of any pending applications and issued patents included in the OPTION PATENT RIGHTS and subject to Section 4.02 ROTHAMSTED shall be responsible for their preparation, filing, prosecution (including any interferences, reissue proceedings, inter partes reviews and reexaminations) and maintenance (collectively, &#8220;PROSECUTION&#8221;).  All KNOW-HOW and IMPROVEMENTS and any intellectual property rights therein related to the TECHNOLOGY generated during the OPTION PERIOD&#58;  (a) by ROTHAMSTED shall be owned ROTHAMSTED&#59; (b) by COMPANY shall be owned by COMPANY but shall be the subject of an automatic irrevocable, payment-free license from COMPANY to ROTHAMSTED for NON-COMMERCIAL RESEARCH PURPOSES within the OPTION FIELD&#59; and (c) jointly by COMPANY and ROTHAMSTED shall be jointly owned by the PARTIES.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 4.02    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  As of the Effective Date, ROTHAMSTED has primary responsibility at the expense of COMPANY for the PROSECUTION of all OPTION PATENT RIGHTS, using patent counsel reasonably acceptable to COMPANY.  ROTHAMSTED shall consult with COMPANY as to the PROSECUTION of all OPTION PATENT RIGHTS reasonably prior to any deadline or action with the United States Patent &#38; Trademark Office or any foreign patent office and shall furnish COMPANY with copies of relevant documents reasonably in advance of consultation. COMPANY shall use its reasonable endeavours to revert to ROTHAMSTED at least &#91;***&#93; prior to any applicable, procedural, regulatory or statutory deadline, it being agreed that ROTHAMSTED may proceed at its discretion if COMPANY has not actively participated in the consultation by such time. ROTHAMSTED will instruct its counsel to communicate directly with patent counsel for </font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">COMPANY, and to fully consider any suggestions or revisions that would tend to support or expand the scope of claims sought, provided counsel was qualified to practice in the relevant jurisdiction (it being understood that the USA shall be considered a single jurisdiction for the purposes of this section).  However, any actions or revisions that would tend to narrow the scope of claims sought would be subject to approval by ROTHAMSTED.  If ROTHAMSTED wishes to abandon any patent or patent application within the OPTION PATENT RIGHTS, ROTHAMSTED shall provide COMPANY with reasonable prior notice of the intended abandonment, and assign such right to COMPANY, which may elect, at its expense, to PROSECUTE the relevant OPTION PATENT RIGHTS with no further license or royalty obligations to ROTHAMSTED with respect to such OPTION PATENT RIGHTS. COMPANY shall cooperate with ROTHAMSTED in such PROSECUTION. COMPANY agrees to hold any information provided to it under this Section 4.02 confidential in accordance with Section 6.05 and to use the information provided by ROTHAMSTED only for the purpose of advancing the OPTION PATENT RIGHTS and shall return all such information to ROTHAMSTED if the PARTIES do not complete the LICENSE AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 4.03    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Patent Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  For PATENT EXPENSES incurred after the EFFECTIVE DATE during the OPTION PERIOD or during the NEGOTIATION PERIOD (if any) set forth in Section 2.03 &#91;***&#93;.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article V. TERM and TERMINATION</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 5.01    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Unless earlier terminated as permitted by this AGREEMENT, the term of this AGREEMENT (the &#8220;TERM&#8221;) will commence upon the Effective Date and continue in full force and effect until (a) in the event COMPANY does not exercise its OPTION during the OPTION PERIOD, the expiration of the OPTION PERIOD and (b) in the event COMPANY does exercise its OPTION during the OPTION PERIOD, the earlier of (i) the execution of the LICENSE AGREEMENT and (ii) the expiration of the NEGOTIATION PERIOD.  For clarity, termination of this AGREEMENT shall cause the COLLABORATION AGREEMENT to terminate automatically</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 5.02    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Insolvency</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT may be terminated at any time prior to the expiration of the OPTION PERIOD by either PARTY upon the other PARTY&#8217;s filing or institution of bankruptcy, reorganization, liquidation or receivership proceedings, or upon an assignment of a substantial portion of the assets for the benefit of creditors by the other PARTY&#59; provided, that, in the case of any involuntary bankruptcy proceeding such right to terminate shall only become effective if the PARTY consents to the involuntary bankruptcy or such proceeding is not dismissed within &#91;***&#93; after the filing thereto.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 5.03    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Either PARTY may terminate this AGREEMENT by giving the other PARTY written notice if the other PARTY is in material breach of any provision hereof (including default on any payment due to ROTHAMSTED hereunder)&#59; provided, however, that if the other PARTY cures said default or breach within &#91;***&#93; after said notice shall have been given, this AGREEMENT shall continue in full force and effect.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 5.04    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination without Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  COMPANY may terminate this AGREEMENT at any time by providing ROTHAMSTED &#91;***&#93; advance written notice of termination. In the event COMPANY terminates this AGREEMENT without cause COMPANY will continue to reimburse ROTHAMSTED for any PATENT EXPENSES in Section 4.03 prior to the date of termination and for the &#91;***&#93; following the date of termination.</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 5.05    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Termination for Patent Challenge</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If COMPANY asserts the invalidity or unenforceability of any claim included in the OPTION PATENT RIGHTS, including by way of litigation or administrative proceedings, either directly or through any other party, then ROTHAMSTED shall have the right, but not the obligation, to terminate this AGREEMENT in accordance with Section 5.02. For clarity, COMPANY shall not be in breach of this Section 5.04 if it provides information or documents to a third party as required under a court order, judicial, administrative or similar process that are used by such third party in a patent challenge.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Article VI. GENERAL</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.01    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">ROTHAMSTED Representations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  ROTHAMSTED represents that the right, title and interest in the TECHNOLOGY developed by its employees during the course of their employment vests in ROTHAMSTED and that it has power to grant the OPTION and licenses set forth in this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.02    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Third Party Agreements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Each PARTY covenants it shall not, and shall cause its AFFILIATES not to, during the TERM enter into, any oral or written agreement or arrangement that would be intentionally and materially inconsistent with its obligations under this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.03    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Publicity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Each PARTY agrees not to (a) identify the other PARTY in any promotional advertising or other promotional materials to be disseminated to the public or any portion thereof, (b) use the name of any of the other PARTY&#8217;s faculty member, employees, agents, officers, directors, or students or (c) use any trademark, service mark, trade name, or symbol of the other PARTY or that is associated with either of them, without the other PARTY&#8217;S prior written consent.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.04    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Indemnity by COMPANY</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  COMPANY shall at all times during the Term of this AGREEMENT and thereafter, indemnify, defend and hold ROTHAMSTED, its current or former Trustees, officers, employees and affiliates, harmless from any third party claim, proceeding, suit, demand, expense, loss, penalty, judgment, or liability of any kind whatsoever, including but not limited to any product liability claims, such as those involving the death of or injury to any person or persons or damage to property, including costs, expenses and reasonable attorneys&#8217; fees, resulting from, related to, arising out of, or in connection with (a) COMPANY&#8217;s evaluation, production, use, EXPLOITATION or consumption of the TECHNOLOGY&#59; (b) a breach of any obligation, representation, or warranty by COMPANY hereunder&#59; (c) any violation of applicable law by COMPANY&#59; or (d) the exercise of COMPANY&#8217;s rights under this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.05    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  The confidentiality provisions described herein in Appendix D shall (a) govern any disclosure of Confidential Information (as defined in Appendix D) made under this AGREEMENT and (b) replace any prior confidentiality agreements between the PARTIES relating to the TECHNOLOGY including without limitation the Non-Disclosure Agreement dated 4 April 2019 (&#8220;PRIOR AGREEMENTS&#8221;) which are hereby terminated as of the Effective Date. For clarity, any information disclosed and defined as confidential information under the PRIOR AGREEMENTS shall be considered CONFIDENTIAL INFORMATION as defined in this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.06    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Disclaimer of Warranties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">.  THE TECHNOLOGY AND CAMELINA RESEARCH ARE DELIVERED &#8220;AS IS&#8221; IN EVERY RESPECT. NEITHER PARTY NOR ITS CURRENT OR FORMER CURATORS, OFFICERS, EMPLOYEES, AND AFFILIATES MAKE ANY REPRESENTATIONS OR EXTEND ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES </font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">OF COMMERCIAL UTILITY, MERCHANTABILITY, FITNESS FOR ANY PARTICULAR PURPOSE, THE ABSENCE OF LATENT OR OTHER DEFECTS, WHETHER OR NOT DISCOVERABLE, THE SCOPE, VALIDITY OR ENFORCEABILITY OF ANY PATENT RIGHTS, WHETHER ISSUED OR PENDING, OR THAT THE MANUFACTURE, USE, IMPORTATION OR SALE OF THE TECHNOLOGY OR THAT THE PRACTICE OF THE PATENT RIGHTS, KNOW-HOW OR CAMELINA RESEARCH WILL NOT INFRINGE OR MISAPPROPRIATE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS OF ANY THIRD PARTY.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.07    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Damages Exclusion &#47; Limitation of Remedies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">.  IN NO EVENT SHALL EITHER PARTY OR ITS CURRENT OR FORMER CURATORS, OFFICERS, EMPLOYEES, AND AFFILIATES BE LIABLE FOR INCIDENTAL, CONSEQUENTIAL, OR SPECIAL LOSS, EXEMPLARY, OR PUNITIVE DAMAGES OF ANY KIND, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT OR IN TORT, INCLUDING NEGLIGENCE OR OTHERWISE, AND INCLUDING ECONOMIC DAMAGE OR INJURY TO PROPERTY AND LOST PROFITS, ATTORNEYS&#8217; AND EXPERTS&#8217; FEES, REGARDLESS OF WHETHER IT MAY BE ADVISED, MAY HAVE OTHER REASON TO KNOW, OR IN FACT SHALL KNOW OF THE POSSIBILITY. COMPANY AGREES THAT ROTHAMSTED&#8217;S TOTAL LIABILITY FOR ANY DAMAGES OR CLAIMS ARISING OUT OF OR RELATED TO THIS AGREEMENT SHALL NOT EXCEED THE AMOUNT OF THE OPTION FEE PAID BY COMPANY TO ROTHAMSTED.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.08    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Consulting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event COMPANY wishes to engage the inventors as consultants, such an arrangement shall be separate and apart from this AGREEMENT but shall be in keeping with ROTHAMSTED&#8217;S policy on consulting and ownership of intellectual property developed by ROTHAMSTED employees.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.09    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Assignment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT is binding upon and shall enure to the benefit of ROTHAMSTED, its successors and assigns.  However, this AGREEMENT shall be personal to COMPANY, and it is not assignable by COMPANY to any other person or entity without the prior written consent of ROTHAMSTED, such consent to be in ROTHAMSTED&#8217;s sole discretion, but not to be unreasonably withheld, conditioned or delayed.  Any purported sale, transfer or assignment without ROTHAMSTED&#8217;s prior written consent shall be void ab initio, and this AGREEMENT shall immediately terminate.  For purposes of this Section 6.09, &#8220;transfer&#8221; shall include any transfer by operation of law or otherwise. Notwithstanding the foregoing, COMPANY may assign this AGREEMENT without ROTHAMSTED&#8217;S consent (a) to an AFFILIATE of the COMPANY, or (b) pursuant to an acquisition or sale of all or substantially all its business to which the TECHNOLOGY relates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.10    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All notices under this AGREEMENT shall be deemed to have been fully given when done in writing and deposited in the United Kingdom or United States mail (whichever is relevant), registered or certified, and addressed as follows&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to ROTHAMSTED&#58;            ROTHAMSTED RESEARCH LIMITED</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">West Common</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Harpenden</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Hertfordshire AL5 2JQ</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">United Kingdom</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If to COMPANY&#58;                   Yield10</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19 Presidential Way</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Woburn, MA 01801</font></div><div style="text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">USA</font></div><div style="margin-bottom:9pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">or such other address as either PARTY may request in writing.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.11    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  None of the terms, covenants, and conditions of this AGREEMENT can be waived except by the written consent of the PARTY waiving compliance.  A failure by one of the PARTIES to this AGREEMENT to assert its rights for or upon any breach or default of this AGREEMENT shall not be deemed a waiver of such rights nor shall any such waiver be implied from acceptance of any payment.  No such failure or waiver in writing by any one of the PARTIES hereto with respect to any rights, shall extend to or affect any subsequent breach or impair any right consequent thereon.  The failure on the part of either PARTY to exercise or enforce any right conferred upon it hereunder shall not be deemed to be a waiver of any such right nor operate to bar the exercise or enforcement thereof at any time or times thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.12    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amendments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT cannot be amended except in writing by mutual agreement of the PARTIES.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.13    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Choice of Law and Venue</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT shall be construed, interpreted, and applied in accordance with the laws of England and Wales.  The PARTIES agree that any action arising under this AGREEMENT shall be brought in the courts of London, England, and agree not to challenge personal jurisdiction in that forum.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.14    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  If any sentence, paragraph, clause or combination of the same is found by a court of competent jurisdiction to be in violation of any applicable law or regulation, or is unenforceable or void for any reason whatsoever, such sentence, paragraph, clause or combinations of the same shall be severed from the AGREEMENT and the remainder of the AGREEMENT shall remain binding upon the PARTIES.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.15    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute but one and the same instrument.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.16    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Survival</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Termination of this AGREEMENT for any reason shall not release either PARTY from any obligation theretofore accrued.  All provisions of this AGREEMENT that would reasonably be expected to survive the termination or expiration of this AGREEMENT shall do so, including Article III (Payment and Fees), Section 4.01 (Ownership), Article V (Termination), and Article VI (General) survive the termination of this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.17    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Entire Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  This AGREEMENT and the COLLABORATION AGREEMENT constitute the entire and only agreement between the PARTIES for TECHNOLOGY and all other prior negotiations, representations, agreements, and understandings including without limitation the PRIOR AGREEMENTS are superseded hereby. No agreements altering or supplementing the terms hereof may be made except by a written document signed by both PARTIES.</font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Section 6.18    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Precedence</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event of any conflict between the terms and provisions of this AGREEMENT and the terms and provisions of the COLLABORATION AGREEMENT the terms and provisions of this AGREEMENT will prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, the PARTIES hereto have executed this AGREEMENT in duplicate originals by their duly authorized officers or representatives.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.247%"><tr><td style="width:1.0%"></td><td style="width:43.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROTHMSTED RESEARCH LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YIELD10 BIOSCIENCE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DATE&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DATE&#58;  &#91;***&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:74.25pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</font></div></div></div><div id="if156782af38142c9bb6d2f6d106885d7_56"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">APPENDIX A. ROTHAMSTED TECHNOLOGY </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Patent Rights</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.200%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Case Ref.</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Reference</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Country</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Application No.</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Application Date</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Priority date</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Case Status</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Grant No.</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Next Renewal Date</font></div></td><td colspan="3" style="background-color:#c6d9f1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0033cc;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Outstanding deadlines</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" rowspan="7" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" rowspan="12" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.987%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.200%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.000%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#d9d9d9;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:62.987%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</font></div></div></div><div id="if156782af38142c9bb6d2f6d106885d7_64"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Know-How</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">At COMPANY&#8217;s request ROTHAMSTED will provide access to materials including but not limited to &#91;***&#93;. A non-exhaustive list of genetic parts (promoters, genes, terminators) and possible combinations is shown in Sections 12-14, Part A1.  Similarly, materials listed in &#91;***&#93; describe examples of additional gene combinations useful in Camelina.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Examples of proprietary know-how include, but not limited to, &#91;***&#93; &#8211; examples from the peer-reviewed literature are listed below, as are the key publications on the &#91;***&#93;.  A further component of such studies is the know-how associated with preparation, submission and revision of dossiers associated with the scientific and ethical approvals required.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_70"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Upon exercise of the OPTION by COMPANY in Section 2.02 of this AGREEMENT, COMPANY and ROTHAMSTED will negotiate in good faith to agree and execute a definitive licensing agreement for the TECHNOLOGY as set forth in Section 2.03 of this AGREEMENT. The intent of this Appendix B is to describe certain items of the proposed agreement between the PARTIES. The PARTIES recognize that the verbiage on the items listed below must be negotiated and is contingent upon legal review and approval.  This APPENDIX B does not contain all matters upon which agreement must be reached and is not intended to be a binding or enforceable agreement.  A binding and enforceable agreement will not occur unless and until all necessary management&#47;corporate approvals have been obtained and the PARTIES have negotiated, duly authorized, approved, executed and delivered the appropriate definitive agreements and all conditions therein have been satisfied or waived.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">License Execution fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sales&#47;Earned&#47;Running Royalties</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sub-Licensing Royalty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">A sublicensing royalty of &#91;***&#93; of all sublicensing revenue received by COMPANY.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Royalty Stacking and Combination Products language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Anti-stacking Deduction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  In the event that COMPANY is legally required to make running royalty payments to one or more third parties for license(s) of third party intellectual property rights necessary or useful to making, using, offering for sale, selling or importing a given LICENSED PRODUCT, COMPANY may deduct up to &#91;***&#93; of such third-party royalties from any running royalty payments that are due to ROTHAMSTED under Section 4.3 on Yield10 Net Sales of such Licensed Product in the same Royalty Period. However, in no event will royalties to ROTHAMSTED be reduced to less than &#91;***&#93; of the applicable amounts set forth under Section entitled &#8220;Sales&#47;Earned&#47;Running Royalties&#8221; above.  Upon request by ROTHAMSTED, COMPANY shall provide ROTHAMSTED with such records, information or access to personnel as are necessary to account for such third party royalties triggering the anti-stacking deduction, subject always to COMPANY remaining compliant with all applicable laws and obligations towards third parties.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Royalty Adjustment for Combination Product</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Royalties payable under the section entitled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sales&#47;Earned&#47;Running Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; above on COMPANY net sales of Combination Products will be reduced as follows.  The royalty shall &#91;***&#93; However, in no event will royalties to ROTHAMSTED be reduced to less than &#91;***&#93; of the applicable amounts set forth set forth under the section entitled &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Sales&#47;Earned&#47;Running Royalties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221; above for Combination Product Net Sales for any reason.  Such adjustment cannot be made together with an anti-stacking deduction under the Section entitled &#8220;Anti-stacking Deduction&#8221; above.  If the adjustment factor above cannot be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">calculated for any reason the PARTIES will negotiate in good faith an alternative mechanism for an equitable adjustment of the running royalties payable on COMPANY net sales of the Combination Products.  This provision does not apply to the royalty on Sublicensee net sales.  As used herein, &#8220;COMBINATION PRODUCT&#8221; means a LICENSED PRODUCT sold in combination with another product that is not a LICENSED PRODUCT.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.800%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minimum Annual Royalties&#58; Year</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Minimum Annual Royalty Payment</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In any given year, royalties paid to the ROTHAMSTED as Sales Royalties or Sublicensing Royalties will be fully deductible against minimum annual royalties paid in the same year, but there shall be no carry forward.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Milestone Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58;  A one-time milestone payment of &#91;***&#93; for the first regulatory filing for commercial production of a LICENSED PRODUCT in any country.  A one-time milestone payment of &#91;***&#93; on obtaining the first regulatory approval for a LICENSED PRODUCT in any country for the commercial production of a LICENSED PRODUCT.  A milestone payment of &#91;***&#93; on achieving cumulative net sales of LICENSED PRODUCTS of &#91;***&#93;.  For clarity, each milestone will be paid only paid once.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Patent Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  After the EFFECTIVE DATE, LICENSEE shall reimburse ROTHAMSTED for all PATENT EXPENSES.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The LICENSE AGREEMENT will contain additional customary terms and conditions agreed to by the PARTIES, including representations and warranties (for ROTHAMSTED limited as to ownership of the OPTION PATENT RIGHTS AND OPTION KNOW-HOW), indemnification provisions and dispute resolution provisions.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_76"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">APPENDIX C</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Evaluation Plan</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The following is an outline of the steps Yield10 will take, recognizing some of the challenges and competitive landscape, in developing a strategic plan to commercialize the technology in the shortest timeframe.</font></div><div style="margin-bottom:12pt;text-indent:90pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Yield10 will provide quarterly updates to Rothamsted on progress on each of these targets.</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_82"></div><div style="margin-bottom:9pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">APPENDIX D - CONFIDENTIALITY PROVISIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.         DEFINITIONS AND INTERPRETATION</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       The following definitions and rules of interpretation apply in this Appendix D&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Business Day&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  a day other than a Saturday, Sunday or public holiday in England when banks in London are open for business.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Confidential Information&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  has the meaning given in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Discloser&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  a PARTY to this AGREEMENT when it discloses its Confidential Information, directly or indirectly, to the other PARTY.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Holding company&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  has the meaning given in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 1.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Purpose&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  exercise of a PARTY&#8217;S rights and obligations under this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Recipient&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  a PARTY to this AGREEMENT when it receives Confidential Information, directly or indirectly, from the other PARTY.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Representative(s)&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> in relation to each PARTY and any AFFILIATE or member of its AFFILIATE&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)   its officers and employees that need to know the Confidential Information for the Purpose&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)  its professional advisers or consultants who are engaged to advise that PARTY and&#47;or any member of its AFFILIATE about the Purpose&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c) its contractors and sub-contractors engaged by that PARTY and&#47;or any member of its AFFILIATE about the Purpose&#59; and</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d)  any other person to whom the other PARTY agrees in writing that Confidential Information may be disclosed about the Purpose.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Subsidiary&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  has the meaning given in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 1.2(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. </font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Interpretation&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)   &#160;&#160;&#160;&#160;A reference to a statute or statutory provision is a reference to it as amended or re-enacted. A reference to a statute or statutory provision includes any subordinate legislation made under that statute or statutory provision, as amended or re-enacted.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)  &#160;&#160;&#160;&#160;Any words following the terms including, include for example or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)   &#160;&#160;&#160;&#160;A reference to writing or written includes email.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d) &#160;&#160;&#160;&#160;A reference to a company shall include any company, corporation or other body corporate, wherever and however incorporated or established.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e)   &#160;&#160;&#160;&#160;A reference to a holding company or a subsidiary means a holding company or a subsidiary as defined in section 1159 of the Companies Act 2006 and a company shall be treated, for the purposes only of the membership requirement contained in section 1159(1)(b) and (c), as a member of another company even if its shares in that other company are registered in the name of&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)         another person (or its nominee) by way of security or about the taking of security&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)        its nominee.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">f)   &#160;&#160;&#160;&#160;Any obligation on a PARTY not to do something includes an obligation not to allow that thing to be done.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.         CONFIDENTIAL INFORMATION</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.1    &#8220;Confidential Information&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> means all confidential information relating to the Purpose which the Discloser or its Representatives or any of its AFFILIATES, or their Representatives directly or indirectly discloses, or makes available, to the Recipient or its Representatives or any of its AFFILIATES, or their Representative, before, on or after the date of this AGREEMENT. This includes&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)  &#160;&#160;&#160;&#160;the fact that discussions and negotiations are taking place concerning the Purpose and the status of those discussions and negotiations&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)   &#160;&#160;&#160;&#160;the existence and terms of this AGREEMENT&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)   &#160;&#160;&#160;&#160;all confidential or proprietary information relating to&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i) the business, affairs, customers, clients, suppliers including plans, intentions, or market opportunities of the Discloser or of any of the Discloser&#8217;s AFFILIATES&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii) the operations, processes, product information, know-how, agricultural, mathematical scientific and technical information including materials, designs, trade secrets or software of the Discloser, or of any of the Discloser&#8217;s AFFILIATES&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d)         any information, findings, data or analysis derived from Confidential Information&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e)       any other information that is identified as being of a confidential or proprietary nature but excludes any information referred to in Clause 2.2.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Information is not Confidential Information if&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         it is, or becomes, generally available to the public other than as a direct or indirect result of the information being disclosed by the Recipient or its Representatives or by any of the Recipient&#8217;s AFFILIATES or their Representatives in breach of this AGREEMENT (except that any compilation of otherwise public information in a form not publicly known shall still be treated as Confidential Information)&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)     it was available to the Recipient on a non-confidential basis prior to disclosure by the Discloser&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)        it was, is, or becomes available to the Recipient on a non-confidential basis from a person who, to the Recipient&#8217;s knowledge, is not under any confidentiality obligation in respect of that information&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d)        it was lawfully in the possession of the Recipient before the information was disclosed by the Discloser&#59; or</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">e)        it is developed by or for the Recipient independently of the information disclosed by the Discloser&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">f)         the PARTIES agree in writing that the information is not confidential</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3.         CONFIDENTIALITY OBLIGATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       In return for the Discloser making Confidential Information available to the Recipient, the Recipient undertakes to the Discloser that it shall&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         keep the Confidential Information secret and confidential&#59;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         not use or exploit the Confidential Information in any way except for the Purpose&#59;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         not directly or indirectly disclose or make available any Confidential Information in whole or in part to any person, except as expressly permitted by, and in accordance with this AGREEMENT&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d)         not copy, reduce to writing or otherwise record the Confidential Information except as strictly necessary for the Purpose. Any such copies, reductions to writing and records shall be the property of the Discloser.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">3.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       The Recipient shall establish and maintain adequate security measures (including any reasonable security measures proposed by the Discloser from time to time) to safeguard the Confidential Information from unauthorised access or use.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.         PERMITTED DISCLOSURE</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Disclosure to Representatives</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         The Recipient may disclose the Confidential Information to its Representatives, any of its AFFILIATES, or their Representatives on the basis that it&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(i)   informs those Representatives, AFFILIATES or their Representatives of the confidential nature of the Confidential Information before it is disclosed&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(ii)       procures that those Representatives, AFFILIATES or their Representatives comply with the confidentiality obligations in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> as if they were the Recipient.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         The Recipient shall be liable for the actions or omissions of the Representatives, any of its AFFILIATES or their Representatives in relation to the Confidential Information as if they were the actions or omissions of the Recipient.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.2       The Recipient may, if it has reasonable grounds to believe that the Discloser is involved in activity that may constitute a criminal offence under the Bribery Act 2010, disclose the Discloser&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Confidential Information to the Serious Fraud Office without first notifying the Discloser of such disclosure.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.3       The PARTIES acknowledge that Rothamsted is a public authority for the purposes of either the Freedom of Information Act 2000 or the Freedom of Information (Scotland) Act 2002 (the &#8220;FOI Legislation&#8221;).  If a PARTY receives a request under the FOI Legislation to disclose any of the other PARTY&#8217;s Confidential Information, it will notify and consult with the other PARTY. The other PARTY will respond within &#91;***&#93; of receiving such notice if the notice requests assistance in determining whether an exemption applies to the disclosure of the Confidential Information requested under the FOI Legislation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.         MANDATORY DISCLOSURE</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Subject to the provisions of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 5</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a PARTY may disclose Confidential Information to the minimum extent required by&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         an order of any court of competent jurisdiction or any regulatory, judicial, governmental or similar body or any taxation authority of competent jurisdiction&#59;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         the rules of any listing authority or stock exchange on which its shares or those of any of its AFFILIATES are listed or traded&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         the laws or regulations of any country to which its affairs or those of any of its AFFILIATES are subject.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Before a PARTY discloses any Confidential Information pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> it shall, to the extent permitted by law, use all reasonable endeavours to give the other PARTY as much notice of this disclosure as possible. Where notice of such disclosure is not prohibited and is given in accordance with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, that PARTY shall consider the reasonable requests of the other PARTY in relation to the content of this disclosure.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.3       If a PARTY is unable to inform the other PARTY before Confidential Information is disclosed pursuant to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> it shall, to the extent permitted by law, inform the other PARTY of the full circumstances of the disclosure and the information that has been disclosed as soon as reasonably practicable after such disclosure has been made.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6.         RETURN OR DESTRUCTION OF CONFIDENTIAL INFORMATION</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Upon the expiration or termination of this AGREEMENT, if so requested by the Discloser at any time by notice in writing to the Recipient, the Recipient shall&#58;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         destroy or return to the Discloser all documents and materials (and any copies) containing, reflecting, incorporating or based on the Discloser&#8217;s Confidential Information&#59;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         erase all the Discloser&#8217;s Confidential Information from its computer and communications systems and devices used by it, or which is stored in electronic form&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)      to the extent technically and legally practicable, erase all the Discloser&#8217;s Confidential Information which is stored in electronic form on systems and data storage services provided by third parties so that such computer archive copies are incapable of being accessed by any employee </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">of the recipient or by any third party without permission provided by the recipients&#8217; IT systems administrator&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">d)         certify in writing to the Discloser that it has complied with the requirements of this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Nothing in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 6.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> shall require the Recipient to return or destroy any documents and materials containing or based on the Discloser&#8217;s Confidential Information that the Recipient is required to retain by applicable law, or to satisfy the requirements of a regulatory authority or body of competent jurisdiction or the rules of any listing authority or stock exchange, to which it is subject.  The provisions of this AGREEMENT shall continue to apply to any documents and materials retained by the Recipient pursuant to this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">Clause 6.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.         RESERVATION OF RIGHTS AND ACKNOWLEDGEMENT</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Each PARTY reserves all rights in its Confidential Information.  The disclosure of Confidential Information by one PARTY does not give the other PARTY or any other person any license or other right in respect of any Confidential Information beyond the rights expressly set out in this AGREEMENT.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       Except as expressly stated in this AGREEMENT, neither PARTY makes any express or implied warranty or representation concerning its Confidential Information, including but not limited to the accuracy or completeness of the Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       The disclosure of Confidential Information by the PARTIES shall not form any offer by, or representation or warranty on the part of, that PARTY to enter any further agreement with the other PARTY.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">8.         INADEQUACY OF DAMAGES</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Without prejudice to any other rights or remedies that each PARTY may have, each PARTY acknowledges and agrees that damages alone would not be an adequate remedy for any breach of the terms of this AGREEMENT by the other PARTY.  Accordingly, each PARTY shall be entitled to the remedies of injunctions, specific performance or other equitable relief for any threatened or actual breach of this AGREEMENT.  In the event of a breach or threatened breach by a PARTY, the offending PARTY shall reimburse the affected PARTY for any costs, expenses, claims, damages and settlement made, demands or liabilities arising directly out of a breach and finally awarded by a court of competent jurisdiction.  Nothing contained in this AGREEMENT shall be construed as prohibiting the affected PARTY from pursuing any other remedies available to them for a breach or threatened breach.</font></div><div id="if156782af38142c9bb6d2f6d106885d7_88"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Appendix E &#8211; Collaboration Agreement</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">&#91;remainder of page left blank on purpose&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_94"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;text-decoration:underline">DATED                                              2020</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font><br></font></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Rothamsted Research</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Confidential Yield10 Inc. Option Agreement</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">EXECUTION COPY</font></td></tr></table></div><div style="padding-left:27pt;padding-right:27pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:15pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Rothamsted Research Limited        (1)</font></div><div style="margin-bottom:15pt;text-indent:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">and</font></div><div style="margin-bottom:15pt;text-indent:144pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Yield10 Bioscience                            (2)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">_____________________________________</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">COLLABORATION AGREEMENT</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Legal Reference RRES 20202</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">_____________________________________</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_101"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:115%">Contents</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Interpretation.........................................................&#8230;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Commencement and duration..................................................................................9</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Project Management.................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Material Transfer.................................................................................................... 10</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Fees and Expenses................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Background Intellectual Property..........................&#8230;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Arising Intellectual Property......................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Not for Profit Knowledge Sharing...........................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">......... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Confidentiality...........................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Publication..............................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Limitation of Liability................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Term and Termination..........................................................................................19</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Consequences of Termination..................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Escalation and Dispute Resolution.......................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Force majeure..........................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Inadequacy of Damages.........................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Data Protection.........................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Anti-Bribery &#38; Corruption..........................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Variation..................................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Waiver.....................................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Rights and remedies.................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Severance............................................................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Entire agreement................................................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">24</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Assignment and other dealings.........................&#8230; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">25</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Subcontracting....................................................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">26</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">No partnership or agency...................................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">27</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Third party rights..................................................... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notices....................................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">29</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Counterparts &#38; Electronic Signature...............&#8230;    </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">30</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Brexit......................................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">31</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Governing law.........................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">32</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">....... </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Jurisdiction..............................................................</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Error! Bookmark not defined.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Schedule 1&#58; The Option Agreement&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;&#8230;  .29</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Annex 1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:112%">             </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Project Particulars................................................................................ 57</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_107"></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">THIS AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> is made on                                                     2020 </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BETWEEN</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rothamsted Research Limited</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, a company limited by guarantee incorporated and registered in England and Wales with company number 2393175 and a not for profit charity no. 802038, whose registered office is at West Common, Harpenden, Hertfordshire, AL5 2JQ, United Kingdom (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rothamsted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; and</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Yield10 Bioscience Inc</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> incorporated and registered in USA with company number CIK#&#58; 0001121702 whose registered office is at 19 Presidential Way, Woburn, Ma 01801 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Industry Partner</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and together, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">the Parties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;. </font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BACKGROUND&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(A)     The Parties wish to work together to carry out a collaborative research and development project on plant based Omega-3 fish oil development as more particularly defined in Annex 1 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(B)       The Parties are entering into the Option Agreement in conjunction with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IT IS AGREED&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Interpretation</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.1       The following definitions and rules of interpretation apply in this agreement&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADR Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 14.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Adverse Impact</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a substantial adverse impact on a Party&#8217;s ability to perform the Agreement in accordance with its terms or the law or a substantial increase in costs incurred by a Party in complying with its obligations under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affected Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 15.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affiliates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means in relation to a Party, any entity that controls, is controlled by or is under common control with that Party.  For the purpose of this Agreement an entity shall be deemed to &#8220;control&#8221; another entity if it owns, directly or indirectly, 50% or more of the outstanding voting securities or capital stock of such entity or any other comparable equity or ownership interest with respect to an entity other than a corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicable Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all laws, rules, regulations, codes of practice, research governance or ethical guidelines or other requirements of regulatory authorities as amended from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Arising Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all Intellectual Property Rights that arise or are obtained or developed by either Party, or by a contractor on behalf of either Party, in the course of or in connection with the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Background Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Intellectual Property Rights (other than Arising Intellectual Property) owned by or licensed to either Party before the Project Start Date or not created in the course of or in connection with the Project, including subsequent modifications and enhancements to such Intellectual Property Rights and including any such rights existing in the Materials.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Brexit Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 30.2. &#8220;Brexit Trigger Event&#8221; has the meaning given in clause 30.4.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means a day other than a Saturday, Sunday or public holiday in England when banks in London are open for business.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential Information</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all confidential information (however recorded or preserved) disclosed by a Party or its representative to the other Party, including but not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;the existence and terms of this Agreement&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;any information that would be regarded as confidential by a reasonable business      person relating to&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the business, finances, affairs, customers, clients, suppliers, plans, intentions or market opportunities of the Disclosing Party or any member of the group of companies to which the Disclosing Party belongs&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;the Intellectual Property Rights, technology, operations, processes, product information, Know-how, designs, trade secrets or software of the Disclosing Party (or of any member of the group of companies to which the Disclosing Party belongs)&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;any information developed by the Parties in the course of carrying out this Agreement (including but not limited to the Results and the subject matter of other Arising Intellectual Property).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means has the meaning given in section 1124 of the Corporation Tax Act 2010, and the expression &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be construed accordingly.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Data Protection Legislation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any data protection legislation from time to time in force in the UK including the Data Protection Act 2018 or any successor legislation and (for so long as and to the extent that the law of the European Union has legal effect in the UK) the General </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Data Protection Regulation ((EU) 2016&#47;679) and any other directly applicable European Union regulation relating to privacy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning set out in clause 9.2 in respect of the Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 14.1. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 14.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Force Majeure Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any circumstance not within a Party&#8217;s reasonable control including, without limitation acts of God, flood, drought, earthquake or other natural disaster, epidemic or pandemic, terrorist attack, civil war, civil commotion or riots, war, threat of or preparation for war, armed conflict, imposition of sanctions, embargo, or breaking off of diplomatic relations, nuclear, chemical or biological contamination, any law or any action taken by a government or public authority (including without limitation imposing an export or import restriction, quota or prohibition, or failing to grant a necessary licence or consent), any labour or trade dispute, strikes, industrial action or lockouts (other than in each case by the Party seeking to rely on this clause, or companies in the same group as that Party) and non-performance by suppliers or subcontractors (other than by companies in the same group as the Party seeking to rely on this clause) but for the avoidance of doubt excluding a Brexit Trigger Event.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all additions, improvements, adaptations, modifications or enhancements to any part of the subject matter in which a Party&#8217;s Background Intellectual Property exists.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Intellectual Property Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means all patents and patent applications, right to inventions, copyright and related rights, trademarks, trade names and domain names, rights in get up, rights in goodwill or to sue for passing off, rights in designs, rights in computer software, database rights, rights in confidential information (including Know-how) and any other intellectual property rights, in each case whether registered or unregistered and including all applications (or rights to apply) for, and renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection which may now or in the future subsist in any part of the world.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 7.2.2.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Know-how</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any unpatented technical and other information which is not in the public domain including any&#58;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;trade secrets, information comprising or relating to concepts, data, discoveries, formulae, ideas, inventions, research models or specifications&#59;</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;methods, research plans, procedures for experiments and tests and results of experimentation and testing&#59; and</font></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;information about biological or chemical structure or functions.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Materials</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the materials (including but not limited to any biological materials or any constructs, strains, derivatives, portions or progeny of the same) that Transferor may provide to the Transferee under or in connection with the Project and this Agreement as set out in Annex 1 and any Know-how relating to the same.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Non-Severable Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Improvement which if used or practised without licence from the Party who owns or controls the relevant Background Intellectual Property would infringe that Party&#8217;s Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in Background (A). </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project End Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date set out in Annex 1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the period from the Project Start Date to the Project End Date unless earlier terminated in accordance with clause 12 (Termination) or extended by written agreement between the Parties in accordance with clause 19 (Variation).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Project Start Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the date set out in Annex 1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication Restriction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 10.3.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means has the meaning set out in clause 9.2 in connection with Confidential Information.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Representatives</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means employees, officers, consultants, agents and any visiting workers (including for the avoidance of doubt, that Party&#8217;s Scientific Leader).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Resources</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, in relation to a Party, the information, Know-how, services, resources, manpower or other tangibles or intangibles that such Party provides in accordance with this agreement in relation to a Project including any Materials a Party is to provide as set out in Annex 1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Results</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the information, data, Know-how, results, inventions, software and other Intellectual Property Rights identified or first reduced to practice or writing within the scope of the Project and as a result of the delivery of the Project under this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Scientific Leader</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the individuals set out in Annex 1 (or their successors) appointed for the day to day management of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Severable Improvements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means any Improvement which if used or practised without licence from the Party who owns or controls the relevant Background Intellectual Property would not infringe that Party&#8217;s Intellectual Property Rights.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Solely Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 7.2.1.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 4.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; has the meaning given in clause 4.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.2       Any words following the terms </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">including</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">include</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">in particular</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">for example</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or any similar expression shall be construed as illustrative and shall not limit the sense of the words, description, definition, phrase or term preceding those terms.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.3       Unless the context otherwise requires, words in the singular shall include the plural and in the plural shall include the singular.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.4       References to clauses and Annexes are to the clauses and Annexes of this Agreement and references to paragraphs are to paragraphs of the relevant Annex.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.5       A reference to a statute or statutory provision is a reference to it as amended, extended or re-enacted from time to time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6       If there is any conflict, ambiguity or inconsistency between the terms of the documents listed below, the following order of priority shall apply&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.1    The License Agreement (as defined in the Option Agreement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.2    The Option Agreement entered into by the Parties on or around the date of this Agreement substantially in the form set out in Schedule 1&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.3    the main body of this Agreement&#59; then</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.6.4    the Annexes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Commencement and duration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.1       This Agreement shall commence on the Project Start Date and shall continue for the Project Period unless earlier terminated in accordance with clause 12.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Project Management</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.1       Annex 1 sets out details of the Project agreed between the Parties as at the date of this Agreement and details of the funding for the Project.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2       Each Party shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.1    use its reasonable endeavours to complete its part of the Project by such date as may be agreed and set out Annex 1&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.2&#160;&#160;&#160;&#160;perform the obligations allocated to it in Annex 1 including by providing the Resources in accordance with any agreed timeframes or milestones&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.3    use reasonable care and skill in performing its relevant obligations&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.4    comply with good industry practice&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.5    comply with all Applicable Laws&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.6&#160;&#160;&#160;&#160;obtain and maintain consents, licences and permissions (statutory, regulatory, contractual or otherwise) that are necessary to enable it to comply with such obligations&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.7 &#160;&#160;&#160;&#160;ensure that the Resources it provides conform with descriptions and specifications (if any) set out in this agreement or otherwise agreed between the Parties&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.8    if on the other Party&#8217;s premises, comply with that Party&#8217;s health and safety and site regulations made known to it&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.2.9    supply to the other Party information and assistance reasonably requested by it relating to the Project as is necessary to enable that other Party to perform its own obligations in relation to the Project.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.3       The Scientific Leaders at Rothamsted and Industry Partner named in Annex 1 have joint responsibility for the execution of the Project in a way that is compliant with the terms and conditions described in this Agreement and the Annexes.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.4       Each Party shall procure that its Scientific Leader signs the declaration set out in the signature clause to acknowledge that he or she has read and understood the terms of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Material Transfer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.1       Any Materials provided by one Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Transferee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) during the Project Period shall be supplied strictly for use in connection with the Project and shall only be transferred between Party&#8217;s Scientific Leaders when necessary for the purpose of the Project.  When transferring Materials, the terms set out in this clause 4 shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.2       Unless otherwise agreed between the Parties, Materials will be provided by the Transferor solely for use in the Project, at the premises of the Transferee only.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3       The Transferee undertakes that any Materials provided will be used&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.1    only by the Transferee&#8217;s Scientific Leader and such of its Representatives under the direct supervision of the Transferee&#8217;s Scientific Leader as are required to perform the Project.  The Materials will not be provided to any other scientist or institution (public or private) without the prior written permission from the Transferor&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.3.2    at all times in accordance with all Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.4       The Transferee acknowledges that the Materials are experimental in nature and will be provided by the Transferor without warranties of any kind expressed or implied.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.5       The Transferor and its Representatives and associated undertakings accept no liability for damages which might arise in connection with the use, storage or disposal by the Transferee of the Materials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6       The Transferee shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.1    keep accurate records as to the use of the Materials&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.2    save as provided for in this Agreement, not use, or cause or permit the use of, the Materials, directly or indirectly&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;in any human subject&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;in any manner that confers on any third party any Intellectual Property Rights in or to the Materials, or that creates obligations to disclose the Results to any third party&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;for any commercial purposes, including the incorporation of the Materials into products intended for commercial sale&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.3    not transfer or distribute any Materials to any third party without the prior written consent of the Transferor.  The Transferee shall refer third party requests for the Materials to the Transferor&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.6.4    not analyse, attempt to modify, reverse-engineer or otherwise seek to determine the structure or sequence of any Materials without the Transferor&#8217;s prior written consent save as expressly provided for in this Agreement or in accordance with the requirements of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.7       All experimental work within the Project and any destruction of Materials pursuant to clause 13.2 will be carried out in accordance with all applicable local, national and international legislation and any instructions from the Transferor relating to the safe handling, use and disposal of potentially hazardous materials.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.8       For the avoidance of doubt, the Parties acknowledge and agree that the Transferor shall retain all right, title and interest in and to the Materials and to any Intellectual Property Rights that exist in the same.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Fees and Expenses</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5.1       Funding for the Project will be provided as set forth in Article III of the Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Background Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.1       All Background Intellectual Property contributed by a Party is and shall remain the exclusive property of the Party owning it (or, where applicable, the third party from whom its right to use the Background Intellectual Property has derived).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2       The Parties agree that any Intellectual Property Rights in Improvements shall vest as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.1&#160;&#160;&#160;&#160;Non-Severable Improvements&#58; the Intellectual Property Rights in such Improvements shall vest in the Party that owns or controls the relevant Background Intellectual Property and each Party shall execute all such documents and do all things necessary to vest the title and interest in the aforesaid Non-Severable Improvement in the relevant Party and assist where reasonably required in the application for registration of the same provided always that where the sole purpose of the Project as set out in Annex 1 is expressed to be the Improvement of the subject matter of the relevant Background Intellectual Property, the Intellectual Property Rights in such Improvements shall be deemed to be Arising Intellectual Property and dealt with in accordance with clause 7.2&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.2.2&#160;&#160;&#160;&#160;Severable Improvements&#58; the Intellectual Property Rights in such Improvements shall be Arising Intellectual Property and dealt with in accordance with clause 7.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.3       Industry Partner shall have an option to acquire a license to Rothamsted&#8217;s Non-Severable Improvement as set forth in the Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.4       Each Party grants to the other for the Project Period, a royalty-free, worldwide, non-transferable (except to Affiliates), non-exclusive, irrevocable licence to use its Background Intellectual Property (including in any Non-Severable Improvements forming part of the Background Intellectual Property) for the sole purpose of the performance of the Project, such licence includes the right to sub licence to an Affiliate only where needed for the sole performance of the Project.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5       On expiry of the Project Period, each Party grants the other Party a royalty-free, worldwide, non-transferable (except to Affiliates), non-sub licensable, non-exclusive, irrevocable licence to use the other Party&#8217;s Background Intellectual Property (including in any Non-Severable Improvements forming part of the Background Intellectual Property) provided that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.1&#160;&#160;&#160;&#160;in the case of Industry Partner, the licence is limited to internal research and development only&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.5.2    in the case of Rothamsted, the licence is limited to teaching and academic research and development which is not commercially sponsored.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6.6       For the avoidance of doubt, the licences provided for in clauses 6.4 and 6.5 shall not permit use of the Background Intellectual Property by any Party for any commercial exploitation of the Arising Intellectual Property without prior written agreement of the Parties.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Arising Intellectual Property</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.1       Each Party shall promptly notify the other Parties of all Arising Intellectual Property that the notifying Party generates in the Project.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2       Arising Intellectual Property shall vest in and be owned as follows&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.1&#160;&#160;&#160;&#160;to the extent that the Arising Intellectual Property is generated or developed by a Party alone, then it shall vest in and be owned absolutely by that Party (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Solely Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.2.2&#160;&#160;&#160;&#160;to the extent that the Arising Intellectual Property is generated or developed jointly by the Parties, then it shall vest in and be owned jointly by both Parties in equal and indivisible shares (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Jointly Owned Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and the Parties shall execute all such documents and do all things necessary to vest the title and interest in the aforesaid Arising Intellectual Property in the manner specified in this clause 7.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3       In the event that it is or may be possible to obtain any registered Intellectual Property Rights in any Jointly Owned Intellectual Property, the Parties shall agree in writing a Party to be responsible for the filing and prosecution on behalf of the Parties in their joint names of applications for registration, and the maintenance and renewal of any registrations, in such countries as the Parties agree in writing, provided that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.1    if one Party wishes to apply for registration in any country or countries but the other does not, that Party may do so at its sole cost and expense on behalf of all Parties and in their joint names, and the Parties shall provide the applying Party with all necessary assistance, information, and instruction&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.2    no Party shall amend or abandon any registration in respect of which the Parties are jointly registered as owners unless, in the case of an amendment, a Party shall have given its prior written consent or, in the case of abandonment, the other Party shall be given the opportunity to maintain the registration at its own cost&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.3.3    the Party making an application for registration shall consult with the other Party at reasonable intervals concerning the application for and maintenance of such registration.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.4       Unless otherwise agreed in writing, the Parties agree that they shall each only be entitled to use its share of the Jointly Owned Intellectual Property to the other Party on the same terms as the licence set out in clause 7.5.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5       Each Party hereby grants to each of the other Party, a royalty-free, worldwide fully paid up, irrevocable, non-transferable (except to Affiliates), non-exclusive, right and licence in perpetuity, with the right to sublicense to Affiliates only, to use it&#8217;s the Solely Owned Intellectual Property for the purpose only of&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.1&#160;&#160;&#160;&#160;in the case of Industry Partner, its internal research and development&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.5.2in the case of Rothamsted, for teaching and academic research and development which is not commercially sponsored and so far as necessary to give effect to the provisions of clause 8&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that in each case, any commercial use of Arising Intellectual Property is explicitly excluded from the scope of such licences.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.6       Industry Partner shall have an option to acquire a license to Rothamsted&#8217;s Solely Owned Intellectual Property or its share of the Jointly Owned Intellectual Property as set forth in the Option Agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7.7       During the term of this Agreement Company shall be responsible for all costs and expenses for the preparation, filing, prosecution (including any interferences, reissue proceedings, inter partes reviews and reexaminations) and maintenance of Jointly Owned Intellectual Property.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Not for Profit Knowledge Sharing</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1       The Parties agree that Rothamsted may share the Results (including any Know-how or Arising Intellectual Property) with selected not-for-profit organisations on a case by case basis provided that prior to such information being shared&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.1&#160;&#160;&#160;&#160;Rothamsted notifies Industry Partner of the identity of the not-for-profit organisation and the nature of the information to be shared&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8.1.2    Rothamsted ensures that the information shared is marked as confidential and the not-for-profit organisation is required to enter into confidentiality obligations at least equivalent to those set out in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Confidentiality</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.1       Each Party undertakes that it shall not for the duration of the Agreement and for a period of &#91;***&#93; following the Project End Date, use or disclose to any person any Confidential Information other than as necessary to exercise its rights or perform its obligations under and in accordance with this Agreement and except as permitted by clause 9.2.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2       A Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosing Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">) may disclose or make available Confidential Information to the other Party (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Receiving Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).  The Receiving Party may disclose the Disclosing Party&#8217;s Confidential Information&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.1    to its Representatives and students who need to know such information for the purposes of exercising the Party&#8217;s rights or carrying out its obligations under or in connection with this Agreement. Each Party shall procure that its Representatives or students to whom it discloses the other Party&#8217;s Confidential Information&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;have been informed of the confidential nature of the Confidential Information and shall comply with the Receiving Party&#8217;s obligations under this clause 9&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;safeguard the Confidential Information from unauthorised use, access, or disclosure using at least the degree of care the relevant Party uses to protect its similarly sensitive information and in no event less than a reasonable degree of care&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.2    as may be required by law, a court of competent jurisdiction or any governmental or regulatory authority, and in these circumstances the Receiving Party shall&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;promptly, and before such disclosure (where reasonably practicable to do so and otherwise immediately afterwards), notify the Disclosing Party in writing of such requirement so that the Disclosing Party can seek a protective order or other remedy&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;disclose only that portion of the Confidential Information that the Receiving Party is legally required to disclose&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.2.3    in accordance with and subject to the provisions of clauses 8 and 10.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3       The prohibition in clause 9.1 shall cease to apply to information which&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.1&#160;&#160;&#160;&#160;is or becomes generally available to the public (other than as a result of its disclosure by the Receiving Party or its representatives in breach of this Agreement)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.2&#160;&#160;&#160;&#160;was available to the Receiving Party on a non-confidential basis before disclosure by the Disclosing Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.3&#160;&#160;&#160;&#160;was, is or becomes available to the Receiving Party on a non-confidential basis from a person who, to the Receiving Party&#8217;s knowledge, is not bound by a confidentiality obligation with the Disclosing Party or otherwise prohibited from disclosing the information to the Receiving Party&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.4    the Parties agree in writing is not confidential or may be disclosed&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.3.5&#160;&#160;&#160;&#160;is developed by or for the Receiving Party independently of the information disclosed by the Disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.4       Save as permitted by this Agreement, no Party shall use any other Party&#8217;s Confidential Information for any purpose other than to exercise its rights and perform its obligations under or in connection with this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9.5       For the avoidance of doubt, and save as expressly set out in this Agreement, the Confidential Information is proprietary to the Disclosing Party, and the Receiving Party acknowledges that no disclosure of the Confidential Information by the Disclosing Party gives the Receiving Party any Intellectual Property Rights of any kind in relation to the Confidential Information.  The Parties further agree that the Disclosing Party will own any copies of all or any part of the Confidential Information that the Receiving Party makes and the Receiving Party shall label any copies in a tangible medium with a notice that they are the property of the Disclosing Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Publication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.1     The Parties may publicise in general terms the fact that the Parties are collaborating on a project.  Nevertheless, neither Party shall use the name, logos or trade names or product trademarks owned by the other Party in any form of Publication or disclose any Confidential Information without prior written consent of that Party.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.2     Industry Partner acknowledges that the Project will form part of the actual carrying out of a primary charitable purpose at Rothamsted, that is the advancement of academic research. The Parties agree that any proposed Publication relating to the Project will be managed as per the following procedures.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.3     In accordance with normal academic practice, all Representatives of Rothamsted shall be permitted to publish or discuss in internal seminars any Arising Intellectual Property owned by any Party and to give advice internally or respond to queries on the same internally within Rothamsted provided that where such publication is intended during the Project Period and for a period of &#91;***&#93; following the Project End Date (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Publication Restriction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the procedures laid down in clause 10.4 shall be complied with.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4     During the Publication Restriction Period&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.1  all proposed publications (including, but not limited to, scientific publications, patent applications and non-confidential presentations) shall be submitted by Rothamsted in writing to Industry Partner for review at least &#91;***&#93; before submission for publication or before presentation, as the case may be&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.4.2  within &#91;***&#93; of receipt of the proposed publication from Rothamsted in accordance with clause 10.3, Industry Partner may (acting reasonably) require&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;the deletion from the publication of any Background Intellectual Property of Industry Partner&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;an amendment to the publication through which commercially sensitive Background Intellectual Property of Industry Partner is disguised, to the satisfaction of Industry Partner&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(iii) &#160;&#160;&#160;&#160;the delay of the publication if in Industry Partner&#8217;s reasonable opinion the delay is necessary in order for it to seek patent or similar protection for any Arising Intellectual Property in accordance with its respective rights in clause 6.  Any such delay imposed on publication shall not last longer than is reasonably necessary for Industry Partner to obtain the required protection&#59; and shall not exceed &#91;***&#93; from the date of receipt by Industry Partner of the proposed publication,</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provided that, where no response is received by Rothamsted from Industry Partner within the timescale specified in this clause 10.4, Rothamsted shall be free to assume that Industry Partner has no objection to the proposed publication.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10.5     Each Party agrees that any publication in a scientific&#47;academic journal shall give due acknowledgement to the financial and&#47;or intellectual contribution of the relevant Party in accordance with standard scientific practice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Limitation of Liability</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.1     To the fullest extent permitted by law, any warranties, representations, conditions and other terms implied by statute or common law are excluded from this Agreement, except as expressly provided in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.2     Without limiting the effect of clause 11.1, Rothamsted disclaims any express or implied warranties of merchantability or fitness for a particular purpose.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.3     Without limiting the effect of clause 11.1, COMPANY disclaims any express or implied warranties of merchantability or fitness for a particular purpose.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4     Nothing in this Agreement shall limit or exclude either Party&#8217;s liability for&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4.1&#160;&#160;&#160;&#160;death or personal injury caused by its negligence, or the negligence of its personnel, agents or subcontractors&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4.2  fraud or fraudulent misrepresentation&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.4.3  breach of the terms implied by section 2 of the Supply of Goods and Services Act 1982 (title and quiet possession) and any other liability which cannot be limited or excluded by Applicable Laws.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.5     Subject to clause 11.4, neither Party shall be liable to the other Party, whether in contract, tort (including negligence), for breach of statutory duty, or otherwise, arising under or in connection with this Agreement for loss of profits, loss of business, loss of agreements or contracts, loss of use or corruption of software, data or information or any indirect or consequential loss.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11.6     Subject to clause 11.4, each Party&#8217;s total liability to the other Party, whether in contract, tort (including negligence), breach of statutory duty, or otherwise, arising under or in connection with this Agreement shall be limited to the payments set forth in Section 3.01 of the Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Term and Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.1     Term.  Unless earlier terminated as permitted by this Agreement, the term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) will commence upon the Effective Date and continue in full force and effect until the later of (a) completion of the Project or (b) the expiration or termination of the Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12.2     This Agreement may be terminated as set forth in Sections 5.02, 5.03 and 5.05 of the Option Agreement it being agreed that all references to &#8220;this Agreement&#8221; shall be read as references to this Collaboration Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Consequences of Termination</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.1     Termination of this Agreement shall not affect any rights, remedies, obligations or liabilities of the Parties that have accrued up to the date of termination, including the right to claim </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">damages in respect of any breach of the Agreement which existed at or before the date of termination.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2     Upon termination or expiry of this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.1  each of the Parties shall within &#91;***&#93; return to the other Party, or if the other Party so requests by notice in writing, destroy (in accordance with all applicable local, national and international legislation relating to the safe handling, use and disposal of potentially hazardous materials), all of the other Party&#8217;s property, including all Confidential Information, Materials and copies thereof in its custody or control at the date of termination or expiry and shall certify that it has done so, and shall make no further use of such Confidential Information and Materials and copies thereof&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.2  the provisions of clauses 6, 7, 8, 9, 10, 13, 14, 16, 17, 19, 20, 21, 22, 23, 27, 28, 31 and 32 shall survive termination (for any reason) or expiry of this Agreement as shall any clauses which expressly or by implication are intended to remain in force on or after termination or expiry of this Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13.2.3  for the avoidance of doubt, where the Option Agreement remains in full force and effect, the Industry Partner shall remain bound to make the payments as set forth in Section 3.01 of the Option Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Escalation and Dispute Resolution</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1     If either Party has any issues, concerns or complaints arising under or in connection with this Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), that Party shall give written notice of the Dispute to the relevant contact of the other Party as set out below (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Dispute Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and those personal shall seek to resolve the Dispute by a process of consultation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1.1  For Rothamsted&#58; Dispute Notices shall be served on&#58; Head of Legal&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.1.2  For Yield10 Biosciences Dispute Notices shall be served on&#58; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Oliver Peoples, President and CEO</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.2     If the Dispute cannot be resolved by the persons named in clause 14.1 within &#91;***&#93;, the matter shall be escalated to the Chief Executive Officer of Rothamsted and the Chief Executive ROLE for Industry Partner.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.3     If the Chief Executive Officer of Rothamsted and the Chief Executive Officer for Industry Partner are for any reason unable to resolve the Dispute within&#91;***&#93; of it being referred to them, the parties agree to enter into mediation in good faith to settle the Dispute in accordance with the CEDR Model Mediation Procedure.  Unless otherwise agreed between the parties within &#91;***&#93; of service of the Dispute Notice, the mediator shall be nominated by CEDR.  To initiate the mediation, a party must serve notice in writing (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ADR notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other party to the Dispute, referring the dispute to mediation.  A copy of the ADR notice should be sent to CEDR. Unless </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">otherwise agreed between the parties, the mediation will start not later than &#91;***&#93; after the date of the ADR notice.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.4     No party may commence any court proceedings under clause 32 (Jurisdiction) in relation to the whole or part of the Dispute until &#91;***&#93; after service of the ADR notice, provided that the right to issue proceedings is not prejudiced by a delay.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">14.5     If the Dispute is not resolved within &#91;***&#93; after service of the ADR notice, or either party fails to participate or ceases to participate in the mediation before the expiry of that &#91;***&#93; or the mediation terminates without resolution before the expiry of that &#91;***&#93; period, the Dispute shall be finally resolved by the courts of England and Wales in accordance with clause 32 (Jurisdiction) in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15        Force majeure</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.1     Provided it has complied with clause 15.2, if a Party is prevented, hindered or delayed in or from performing any of its obligations, other than an obligation to make payments to the other Party, under this Agreement by a Force Majeure Event (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Affected Party</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), the Affected Party shall not be in breach of this Agreement or otherwise liable for any such failure or delay in the performance of such obligations.  The time for performance of such obligations shall be extended accordingly and the corresponding obligations of the other Party will be suspended, and its time for performance of such obligations extended, to the same extent as those of the Affected Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2     The Affected Party shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.1  as soon as reasonably practicable after the start of the Force Majeure Event but no later than &#91;***&#93; from its start, notify the other Party of the Force Majeure Event, the date on which it started, its likely or potential duration, and the effect of the Force Majeure Event on its ability to perform any of its obligations under the Agreement&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.2.2  use all reasonable endeavours to mitigate the effect of the Force Majeure Event on the performance of its obligations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">15.3     If the Force Majeure Event prevents, hinders or delays the Affected Party&#8217;s performance of its obligations for a continuous period of more than &#91;***&#93;, the Party not affected by the Force Majeure Event may terminate this Agreement by giving &#91;***&#93; written notice to the Affected Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Inadequacy of Damages</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16.1     Without prejudice to any other rights or remedies that each Party may have, each Party acknowledges and agrees that damages alone would not be an adequate remedy for any breach of this Agreement by the other Party.  Accordingly, each Party shall be entitled to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Data Protection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17.1     To the extent that the Parties process any Personal Data of the other Party in connection with this Agreement or a Project, each Party shall be acting as a Controller and shall comply with its obligations under the Data Protection Legislation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Anti-Bribery &#38; Corruption</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1     Each Party shall&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1.1  comply with all Applicable Laws, statutes, regulations, and codes relating to anti-bribery and anti-corruption including but not limited to the Bribery Act 2010&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1.2  not engage in any activity, practice or conduct which would constitute an offence under sections 1, 2 or 6 of the Bribery Act 2010 if such activity, practice or conduct had been carried out in the UK&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.1.3  promptly report to the representatives of the other Party any request or demand for any undue financial or other advantage of any kind received by it in connection with the performance of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">18.2     Each Party shall ensure that any person associated with it who is performing services in connection with this Agreement or any Project does so only on the basis of a written contract which imposes on and secures from such person terms equivalent to those imposed on the Parties in this clause 18 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Relevant Terms</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  The Party shall be responsible for the observance and performance by such persons of the Relevant Terms, and shall be directly liable to the other Party for any breach by such persons of any of the Relevant Terms.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Variation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">19.1     No variation of this Agreement shall be effective unless it is in writing and signed by the Parties (or their authorised representatives).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.1&#160;&#160;&#160;&#160;A waiver of any right or remedy under this Agreement or by law is only effective if given in writing and shall not be deemed a waiver of any subsequent right or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">20.2&#160;&#160;&#160;&#160;A failure or delay by a Party to exercise any right or remedy provided under this Agreement or by law shall not constitute a waiver of that or any other right or remedy, nor shall it prevent or restrict any further exercise of that or any other right or remedy. No single or partial exercise of any right or remedy provided under this Agreement or by law shall prevent or restrict the further exercise of that or any other right or remedy.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Rights and remedies</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">21.1     Except as expressly provided in this Agreement, the rights and remedies provided under this Agreement are in addition to, and not exclusive of, any rights or remedies provided by law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.1     If any provision or part-provision of this Agreement is or becomes invalid, illegal or unenforceable, it shall be deemed deleted, but that shall not affect the validity and enforceability of the rest of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">22.2     If any provision or part-provision of this Agreement is deemed deleted under clause 22.1 the Parties shall negotiate in good faith to agree a replacement provision that, to the greatest extent possible, achieves the intended commercial result of the original provision.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Entire agreement</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.1     This Agreement and the Option Agreement constitute the entire agreement between the Parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating to its subject matter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">23.2     Each Party agrees that it shall have no remedies in respect of any statement, representation, assurance or warranty (whether made innocently or negligently) under this Agreement that is not set out in this Agreement. Each Party agrees that it shall have no claim for innocent or negligent misrepresentation or negligent misstatement based on any statement in this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">24        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Assignment and other dealings</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">24.1     Save as otherwise set out in this Agreement, neither Party shall assign, transfer, mortgage, charge, subcontract, delegate, declare a trust over or deal in any other manner with any or all of its rights and obligations under this Agreement without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">25        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Subcontracting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">25.1     Rothamsted may, in its discretion, sub-contract the provision of any material part of the Project with the prior written consent of Industry Partner (such consent not to be unreasonably withheld, conditioned or delayed).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">26        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">No partnership or agency</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.1     Nothing in this Agreement is intended to, or shall be deemed to, establish any partnership or joint venture between any of the Parties, constitute any Party the agent of another Party, or authorise any Party to make or enter into any commitments for or on behalf of any other Party.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">26.2     Each Party confirms it is acting on its own behalf and not for the benefit of any other person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">27        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Third party rights</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.1     This Agreement does not give rise to any rights under the Contracts (Rights of Third Parties) Act 1999 to enforce any term of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">27.2     The rights or the Parties to rescind or vary this Agreement are not subject to the consent of any person.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">28        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Notices </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.1     Any notice or other communication given to a Party under or in connection with this Agreement shall be in writing and shall be delivered by hand or by pre-paid first-class post or other next working day delivery service at its registered office (if a company) or its principal place of business (in any other case).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.2     Any notice or communication shall be deemed to have been received&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.2.1  if delivered by hand, on signature of a delivery receipt or at the time the notice is left at the proper address&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.2.2  if sent by pre-paid first-class post or other next working day delivery service, at &#91;***&#93; after posting or at the time recorded by the delivery service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.3     This clause does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">28.4     A notice given under this Agreement is not valid if sent by email.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">29        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Counterparts &#38; Electronic Signature</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.1     This Agreement may be executed in any number of counterparts, each of which when executed and delivered shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.2     Transmission of an executed counterpart of this Agreement (but for the avoidance of doubt not just a signature page) by email (in PDF, JPEG or other agreed format) shall take effect as delivery of an executed counterpart of this Agreement.  If this method of delivery is adopted, without prejudice to the validity of the Agreement thus made, each Party shall provide the others with the original of such counterpart as soon as reasonably possible thereafter.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.3     No counterpart shall be effective until each Party has executed and delivered at least one counterpart.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">29.4     The Parties agree that this Agreement may be executed by electronic signature (whatever form the electronic signature takes) and that such method of signature is conclusive evidence of the each Party&#8217;s intention to be bound by this Agreement as if signed by each Party&#8217;s manuscript signature.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">30        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Brexit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.1     If a Brexit Trigger Event occurs which is or is likely to have an Adverse Impact on a Party, the impacted Party may&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.1.1  require the other Party to negotiate an amendment to this Agreement to alleviate the Adverse Impact, in accordance with clause 30.2&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.1.2  if renegotiation fails, terminate this Agreement in accordance with clause 30.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.2     An impacted Party may initiate a negotiation under clause 30.1 by a notice (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Brexit Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to the other Party giving details of the relevant Brexit Trigger Event and the Adverse Impact.  On delivery of a Brexit Notice&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.2.1  the Parties shall meet within &#91;***&#93; of the date of the Brexit Notice to discuss in good faith amendments to this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.2.2  the impacted Party shall provide any further information reasonable requested by the other Party on the Adverse Impact and Brexit Trigger Event relied on&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.2.3  the Parties shall record any amendments agreed to this Agreement in writing in accordance with clause 19.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.3     If the Parties fail to agree a variation within &#91;***&#93; of the date of the Brexit Notice, either Party may give the other Party &#91;***&#93; written notice to terminate this Agreement. On Termination of this Agreement under this clause 30, clause 13 (Consequences of Termination) shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.4     &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Brexit Trigger Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means one of the following events occurring within &#91;***&#93; after and caused by the UK ceasing to be a Member State of the European Union&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.4.1  a change in Law or new requirement to comply with any existing Law or exiting Law ceasing to apply to a Party.  For these purposes, &#8216;Law&#8217; means any legal provision a Party must comply with including any law, statute, subordinate legislation within the meaning of section 21(1) of the Interpretation Act 1978, enforceable EU right within the meaning of section 2 of the European Communities Act 1972, bye-law, regulation, order, mandatory guidance or code of practice, judgment of a court of law, or requirement of any regulatory body, whether in the UK or elsewhere&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.4.2  in any jurisdiction, the loss of, a change to or the imposition of a new requirement for any licence or consent required by a Party to perform its obligations under this Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.4.3  in any jurisdiction, the imposition of or a change to a duty, tax or levy imposed on a Party which affects its commercial ability to be comply with its obligations under this Agreement&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.4.4  any other change to the business or economic environment in which a Party operates other than as provided for in clauses 30.4.1, 30.4.2 or 30.4.3.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">30.5     Save as expressly provided in this clause 30, a Brexit Trigger Event shall not terminate or alter (or give any Party a right to terminate or alter) this contract, or invalidate any of its terms or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">discharge or excuse performance under it.  If there is an inconsistency between the provisions of this clause and any other provision of this Agreement, the provisions of this clause shall prevail.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">31        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Governing law</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">31.1     This Agreement and any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with it or its subject matter or formation shall be governed by and construed in accordance with the laws of England and Wales.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">32        </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">32.1     Subject to clause 14, each Party irrevocably agrees that the courts of London, England shall have exclusive jurisdiction to settle any dispute or claim (including non-contractual disputes or claims) arising out of or in connection with this Agreement or its subject matter or formation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Agreement has been entered into on the date stated at the beginning of it.</font></div><div id="if156782af38142c9bb6d2f6d106885d7_113"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXECUTION OF THIS AGREEMENT</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Authorised signatories</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Yield10 Bioscience Inc&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Rothamsted Research Limited&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POSITION&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEPARTMENT&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEPARTMENT&#58;  &#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">SCIENTIFIC LEADER DECLARATION</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Declaration by the Scientific Leaders for the purpose of clause 3.4</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I acknowledge that I have read and understood the terms and conditions of this Agreement and agree to use reasonable endeavours to comply with the terms and conditions.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Yield10 Bioscience Inc&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">For Rothamsted Research Limited&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POSITION&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">POSITION&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEPARTMENT&#58;  &#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_119"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Annex 1.  Project Particulars</font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">1.   Project title&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Camelina-based Omega-3 fish oil development</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">2.   Project Start Date&#58;                                     3.  Project End Date&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.798%"><tr><td style="width:1.0%"></td><td style="width:49.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">4.    Rothamsted Scientific Leaders&#58;               5.  Industry Partner Scientific Leaders&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.798%"><tr><td style="width:1.0%"></td><td style="width:49.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.936%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">6.   Location of work&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Rothamsted Research</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">7.   Technical objectives of the Project&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">8.   Work Plan and allocation of tasks by Party&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">See text below in </font><font style="color:#0070c0;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">blue</font></div></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">9.   Milestones (including delivery dates)&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">See attached<br></font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">10. Rothamsted Deliverables&#58;                         11.  Industry Partner Deliverables&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.798%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1. The Progress Reports and the Final Report, in each case as defined and set forth in the Option Agreement.<br>2. Quarterly meetings with Industry Partner to review each Progress Report and a meeting within &#91;***&#93; of Industry Partner&#8217;s receipt of the Final Report to review same.</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">None</font></td></tr></table></div><div><font><br></font></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">12. Background that each partner brings to the Project&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.641%"><tr><td style="width:1.0%"></td><td style="width:27.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.742%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top">Rothamsted</td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Industry Partner</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Know-How</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93; and a plan to commercialize the technology</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Materials</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">None</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Other</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">None</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">None</font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">13. Biological Materials&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.182%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If any Biological Material will be provided or exchanged for the Project,<br>please specify&#58;<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a) The exact type of Biological Material concerned (e.g. seeds, virus, fungi, bacteria)<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b) The origin of the material and its legal status if known (e.g. property of one of the Parties or of a third party, or freely accessible in the public domain)<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c) The material&#8217;s mode of protection (e.g. patent, variety rights) if known<br></font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">14. Total cost of the Project and breakdown by year&#58;</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.955%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Total project cost is &#91;***&#93; to be paid as set forth in the Option Agreement.<br></font></td></tr></table></div><div style="text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">15. Sources of funding for the Project&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Industry Partner</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Making Fish Oils in Plants&#58;  A new sustainable source of heart-healthy omega-3 oils </font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Omega-3 fish oils, or more precisely, omega-3 long chain polyunsaturated fatty acids such as EPA and DHA, are proven to be health-beneficial to humans, reducing the risk of cardiovascular disease (CVD) and other metabolic diseases such as obesity and type-2 diabetes.  These pathologies are now recognised as a global pandemic which threatens the health of hundreds of millions. Although omega-3 fish oils are recognised by health professionals as being crucial for correct human nutrition, the primary source of them is limited and finite.  As the global population continues to increase, so does demand, and oceanic sources of fish oils are even now insufficient to ensure every person on this planet receives the recommended daily amount of these vital nutrients. In an effort to solve this problem, &#91;***&#93; based at Rothamsted Research, has embarked on an ambitious programme to genetically engineer plants with the capacity to make these health-beneficial omega-3 fish oils, which no plants normally make. Perhaps surprisingly, fish don&#8217;t actually make omega-3 fish oils, instead it is marine microbes such as algae which make them (with fish just accumulating them through their diet). We identified the &#91;***&#93; and introduced them into plants.  By adding &#91;***&#93; it was possible to engineer plants to do something that they cannot normally do &#8211; make omega-3 fish oils.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a consequence of over fifteen years&#8217; dedicated effort, Rothamsted has now generated &#91;***&#93; &#8211; this is equivalent to (or better) than levels found in oceanically-sourced fish oils.  Our plant-based source of omega-3 fish oils can contribute to both better human nutrition (helping to reduce the risk of CVD) and also relieving pressure on global fish stocks. In addition, this new source of omega-3 oils can help solve the sustainability problems being faced by the aquaculture (fish-farming) industry, who use the vast majority of all oceanically sourced fish oils.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">The stage is now set to move this proven prototype out of a research phase and onto a commercialisation path.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Market Opportunity</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The omega-3 fish oils market is currently an approximate 1 million metric tonnes supplied almost exclusively from marine sources such as anchovy. Around 80% of annual supply is utilised as an ingredient in aquafeed, with the balance utilised for direct human consumption in markets that include dietary supplements, pharmaceuticals and infant nutrition.  Based on current commodity prices, the total revenue of global omega-3 fish oil businesses is in excess of $3 billion per annum.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Currently constraining growth in this sector, extraction of marine-sourced omega-3 fish oils are regulated by strict quotas to protect against over-fishing.  Furthermore, with the growing awareness of the negative impact of human activities on our oceans, alternatives with reduced environmental footprint compared to commercial fishing fleets are desirable, as are new sources of omega-3 fish oils which are more sustainable.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">From the consumer&#8217;s perspective, a product that is both health-beneficial and environmentally-responsible is becoming more and more important.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">As a result, there is a strong market need for new </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">non-marine</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> sources of omega-3 fish oils to meet growing supply requirements from both aquafeed and human consumption markets.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">The Rothamsted Omega-3 Programme</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Progress achieved by Rothamsted&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The project is ready for progression from late-stage research to a commercial development programme that includes both agricultural de-regulation and feed ingredient de-regulation.  It is assumed that the commercial development programme would be based in a geographic area that is more amenable to, and accepting of, GM crops most likely the &#91;***&#93;  The primary market for the resulting plant-derived omega-3 fish oils would be aquaculture, initially focussed on &#91;***&#93;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Rothamsted has investigated in some detail the development timelines and related budget to ready the project for commercial launch in the aquafeed market assuming agricultural development in N. America.  The timelines anticipate commercial launch in either &#91;***&#93; and a relatively modest development budget, which can be broken down into two phases&#58; 1) selection of lead event (i.e. best performing plant) 2) regulatory approval, with the bulk of costs being associated with the latter.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Programme of Research.</font></div><div><font><br></font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Purpose&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  &#91;***&#93;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Previously we have identified a &#91;***&#93; that direct the seed-specific accumulation of EPA and DHA in Camelina.  Whilst there are some possibilities that the resulting constructs and lines could be commercialised, this would require third party licenses.  However, we believe that we can improve on that benchmark (defined in our peer-reviewed publication Han et al., 2020) as well as avoiding third-party IP and have embarked on further rounds of iteration to elevate the levels of EPA and DHA. Additional enhancements are envisaged including &#91;***&#93;.  The current status of the programme is shown graphical in the attached Gannt chart and defined below.  For clarity, whilst the chart shows both past and future activities, the narrative below is for the next &#91;***&#93;, commencing &#91;***&#93;.  Several pre-existing resources have previously been generated, most notably a library of &#8220;parts&#8221; (i.e. genes and regulatory elements) which have also been assembled (via Golden Gate) into transformation-ready binary vectors for introduction into Camelina.  Please note that timings are considered to be realistic estimates, but subject to variation as a consequence of working with biological material and their interaction with environmental factors during field trials.  Also these timelines do not reflect current restrictions arising from Covis-19, though it is hoped that these will have been lifted by &#91;***&#93;.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Rothamsted Research (RRes) Camelina-based Omega-3 fish oil commercial development timeline &#8211; past &#38; future (to be read in conjunction with the associated Research Plan)</font></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_125"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">FIRST AMENDMENT TO OPTION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This First Amendment to Option Agreement (the &#8220;Amendment&#8221;), effective as of (&#8220;Amendment Effective Date&#8221;), is made by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ROTHAMSTED RESEARCH LIMITED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a company limited by guarantee incorporated and registered in England and Wales with company number 2393175 and a not for profit charity with charity number 802038, whose registered office is at West Common, Harpenden, Hertfordshire AL5 2JQ, United Kingdom (&#8220;ROTHAMSTED&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">YIELD10 BIOSCIENCE INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a corporation organized under the laws of the State of Delaware having offices at 19 Presidential Way, Woburn, MA 01801 (hereafter &#8220;COMPANY&#8221;).  ROTHAMSTED and COMPANY may sometimes be referred to herein as a &#8220;PARTY&#8221; or &#8220;PARTIES&#8221; as the case may be.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES entered into an Option Agreement effective as of November 12, 2020 (the &#8220;Option Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES entered into a Collaboration Agreement effective as of November 12, 2020 (the &#8220;Collaboration Agreement&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, due to a Force Majeure Event (as defined in the Collaboration Agreement) ROTHAMSTED was unable to complete the work plan outlined in Annex 1 of the Collaboration Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES are entering into a First Amendment to Collaboration Agreement on even date herewith&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES desire to amend the Option Agreement in accordance with Section 6.12 thereof.</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the PARTIES agree to amend the Option Agreement as follows.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">Capitalized terms not otherwise defined herein will have the meaning given to them in the Option Agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">Revision to Article 1 (DEFINITIONS).</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Section 1.12 is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;OPTION PERIOD&#8221; means the period commencing on the EFFECTIVE DATE of this AGREEMENT (i.e., November 12, 2020) and ending on the later of (a) three (3) years thereafter, i.e., the third anniversary of the Effective Date, such period extendable by additional periods of up to one year with the prior written agreement of the PARTIES and (b) thirty (30) days after receipt of all PART B PROGRESS REPORTS and the PART B FINAL REPORT (each as defined in the Collaboration Agreement).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:27pt">Revisions to Article III (PAYMENTS AND FEES)</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:18.3pt">Section 3.01 is hereby amended to add the following sentence at the end of the first sentence&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;The Parties acknowledge and agree that as of the Amendment Effective Date all payments other than Payment 8 due under this Section 3.01 have been paid in full and that no further payments under this Section 3.01 other than Payment 8 will be due to ROTHAMSTED upon completion of the Project.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">The fourth row of the table in Section 3.01 is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:27pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.264%"><tr><td style="width:1.0%"></td><td style="width:43.945%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.855%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;<br></font></td></tr></table></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Rothamsted Technology.  The Parties agree that Appendix A (Rothamsted Technology) to the Option Agreement shall be deleted in its entirety and replaced with Appendix A attached hereto.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revisions to Article VI (GENERAL).</font></div><div style="margin-bottom:12pt;padding-left:63pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Section 6.10 (Notices) is hereby deleted in its entirety and replaced with the following&#58;  &#8220;6.10.1 A notice given to a Party under or in connection with this Agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.1.1 shall be in writing and in English&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.1.2 shall be signed by or on behalf of the Party giving it&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.1.3 shall be sent to the party for the attention of the contact and at the address, email address listed in Section 6.10.2, or such other address, email address as that Party may notify in accordance with Section 6.10.2.3&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.1.4 shall be sent by a method listed in Section 6.10.3&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.1.5 unless proved otherwise is deemed received as set out in Section 6.10.3 if prepared and sent in accordance with this Section.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.2 The addresses and email addresses for service of notices are&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.2.1 Rothamsted Research Limited</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         Address&#58;  Rothamsted Research Limited, West Common, Harpenden, Hertfordshire, AL5 2JQ, United Kingdom</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         For the attention of&#58;  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         e-mail to</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93; and &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.2.2 Yield 10 Bioscience Inc.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         Address&#58;  19 Presidential Way, Woburn, 01801 MA, USA</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         For the attention of&#58;  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         Email address(es)&#58;  &#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.2.3 A party may change its details above by giving notice, the change taking effect for the Party notified of the change at 9.00 am on the later of&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         the date, if any, specified in the notice as the effective date for the change&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         the date five Business Days after deemed receipt of the notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.3 This Section 6.10.3 sets out the delivery methods for sending a notice to a Party under this Agreement and, for each delivery method, the date and time when the notice is deemed to have been received&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.3.1 if delivered by hand, at the time the notice is left at the address&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.3.2 if sent by pre-paid first class post or other next working day delivery service providing proof of postage, at 9.00 am on the second Business Day after posting&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.3.3 if sent by pre-paid airmail providing proof of postage at 9.00 am on the fifth Business Day after posting&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.3.4 if sent by email, at the time of transmission, provided that no &#8216;failed delivery&#8217; message has been issued by the recipient or received by the sender.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If deemed receipt under Section 6.10.3.4 would occur outside business hours in the place of receipt, it shall be deferred until business hours resume.  In this Section 6.10.3.4, business hours means 9.00 am to 5.00 pm on a Business Day in the place of receipt.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:63pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.10.4 Section 6.10 does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Upon its execution and delivery, this Amendment shall amend, modify and supersede, to the extent of any inconsistencies, the provisions of the Option Agreement.  Except as expressly modified by this Amendment, the Option Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">The Option Agreement, this Amendment, the Collaboration Agreement and the First Amendment to Collaboration Agreement embody the entire understanding of the PARTIES and there are no promises, terms, conditions or obligations, oral or written, expressed or implied, other than those contained in the Option Agreement and this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">This Amendment may be executed in one or more counterparts by the PARTIES by signature of a person having authority to bind the PARTY, each of which when executed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">and delivered by facsimile, electronic transmission or by mail delivery, will be an original and all of which shall constitute but one and the same instrument.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:26pt">General</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  All provisions of the Option Agreement regarding third party rights, signing by counterparts, amendments&#47;variations, governing law and jurisdiction and other general provisions shall apply to this Amendment as if set out in full and so that references in those provisions to &#8216;this agreement&#8217; shall be construed as references to this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Schedule to follow&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_135"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Appendex A Rothamsted Technology</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Patent Rights</font></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:6pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Case Ref.</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:6pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Reference</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:5.5pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:5.25pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Country</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center;text-indent:5.4pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Application No.</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Application Date</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Priority date</font></div></td><td colspan="3" style="background-color:#cddef1;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:5.05pt"><font style="color:#00156d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Case Status</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.25pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.5pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:7.2pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;text-indent:5.4pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;text-indent:5.05pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bebebe;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#bfbfbf;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Signature page follows.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_141"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROTHAMSTED RESEARCH LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YIELD10 BIOSCIENCE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_147"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">FIRST AMENDMENT TO COLLABORATION AGREEMENT</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This First Amendment to Collaboration Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), effective as of 09 November 2022 &#124; 07&#58;54&#58;32 PST</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Amendment Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;), is made by and between </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">ROTHAMSTED RESEARCH LIMITED </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a company limited by guarantee incorporated and registered in England and Wales with company number 2393175 and a not for profit charity with charity number 802038, whose registered office is at West Common, Harpenden, Hertfordshire AL5 2JQ, United Kingdom (&#8220;ROTHAMSTED&#8221;) and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">YIELD10 BIOSCIENCE INC.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, a corporation organized under the laws of the State of Delaware having offices at 19 Presidential Way, Woburn, MA 01801 (hereafter &#8220;COMPANY&#8221;).  ROTHAMSTED and COMPANY may sometimes be referred to herein as a &#8220;PARTY&#8221; or &#8220;PARTIES&#8221; as the case may be.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES entered into a Collaboration Agreement effective as of November 12, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Collaboration Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES entered into an Option Agreement effective as of November 12, 2020 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, due to a Force Majeure Event ROTHAMSTED was unable to complete the work plan outlined in Annex 1 of the Collaboration Agreement&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES are entering into a First Amendment to Option Agreement on even date herewith&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">WHEREAS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, the PARTIES desire to amend the Collaboration Agreement in accordance with Section 19 thereof.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NOW THEREFORE</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the PARTIES agree to amend the Collaboration Agreement as follows.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Capitalized terms not otherwise defined herein will have the meaning given to them in the Collaboration Agreement.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revision to Clause 3 (Project Management).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Clause 3.5 is hereby added as follows&#58;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;The Parties acknowledge and agree that as of the Amendment Effective Date all work on the Project has been completed other than as set forth in Annex 1 &#8211; Part B.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revision to Clause 5 (Fees and Expenses).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:31.8pt">Clause 5.2 is hereby added as follows.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;The Parties acknowledge and agree that as of the Amendment Effective Date the funding for the Project has been paid in full other than Payment 8 (as set forth in Section 3.01 of the Option Agreement) and that no payments will be due to Rothamsted for completing the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Project as set forth in Annex 1 &#8211; Part B other than Payment 8 (as set forth in Section 3.01 of the Option Agreement).&#8221;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revision to Clause 12 (Term and Termination).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Clause 12.1 is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Term.  Unless earlier terminated as permitted by this Agreement, the term of this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;) will commence upon the Effective Date and continue in full force and effect until the expiration or termination of the Option Agreement.&#8221;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revisions to Clause 13 (Consequences of Termination).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Clause 13.2.2 is hereby amended to include clauses 1.2-1.6 and 11 as surviving clauses.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Clause 13.2.3 is hereby deleted.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Annex 1 is hereby renamed &#8220;Annex 1 &#8211; Part A&#8221;.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt"> &#8220;Annex 1 &#8211; Part B&#8221; attached hereto is hereby added to the Collaboration Agreement following Annex 1 &#8211; Part A.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:26pt">Revisions to Clause 28 (Notices).</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Clause 28 is hereby deleted in its entirety and replaced with the following&#58;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;28.1 A notice given to a Party under or in connection with this Agreement&#58;</font></div><div style="margin-bottom:9pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.1.1 shall be in writing and in English&#59;</font></div><div style="margin-bottom:9pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.1.2 shall be signed by or on behalf of the Party giving it&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.1.3 shall be sent to the party for the attention of the contact and at the address, email address listed in clause 28.2, or such other address, email address as that Party may notify in accordance with clause 28.2.3&#59;</font></div><div style="margin-bottom:9pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.1.4 shall be sent by a method listed in clause 28.3&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.1.5 unless proved otherwise is deemed received as set out in clause 28.3 if prepared and sent in accordance with this clause.</font></div><div style="margin-bottom:9pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.2 The addresses and email addresses for service of notices are&#58;</font></div><div style="margin-bottom:9pt;text-indent:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.2.1 Rothamsted Research Limited</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         Address&#58; Rothamsted Research Limited, West Common, Harpenden, Hertfordshire, AL5 2JQ, United Kingdom</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         For the attention of&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         e-mail to &#91;***&#93; and &#91;***&#93;</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.2.2 Yield 10 Bioscience Inc.</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         Address&#58; 19 Presidential Way, Woburn, 01801 MA, USA</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         For the attention of&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">c)         Email address(es)&#58; &#91;***&#93;</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.2.3 A party may change its details above by giving notice, the change taking effect for the Party notified of the change at 9.00 am on the later of&#58;</font></div><div style="margin-bottom:9pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">a)         the date, if any, specified in the notice as the effective date for the change&#59; or</font></div><div style="margin-bottom:9pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">b)         the date five Business Days after deemed receipt of the notice.</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.3 This clause 28.3 sets out the delivery methods for sending a notice to a Party under this Agreement and, for each delivery method, the date and time when the notice is deemed to have been received&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.3.1 if delivered by hand, at the time the notice is left at the address&#59; or</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.3.2 if sent by pre-paid first class post or other next working day delivery service providing proof of postage, at 9.00 am on the second Business Day after posting&#59; or 28.3.3 if sent by pre-paid airmail providing proof of postage at 9.00 am on the fifth Business Day after posting&#59; or</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.3.4 if sent by email, at the time of transmission, provided that no &#8216;failed delivery&#8217; message has been issued by the recipient or received by the sender.</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If deemed receipt under clause 28.3.4 would occur outside business hours in the place of receipt, it shall be deferred until business hours resume.  In this clause 28.3.4, business hours means 9.00 am to 5.00 pm on a Business Day in the place of receipt.</font></div><div style="margin-bottom:9pt;padding-left:54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">28.4 Clause 28 does not apply to the service of any proceedings or other documents in any legal action or, where applicable, any arbitration or other method of dispute resolution.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:8pt">Upon its execution and delivery, this Amendment shall amend, modify and supersede, to the extent of any inconsistencies, the provisions of the Collaboration Agreement.  Except as expressly modified by this Amendment, the Collaboration Agreement shall remain in full force and effect.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:1.33pt">The Collaboration Agreement, this Amendment, the Option Agreement and the First Amendment to Option Agreement embody the entire understanding of the PARTIES and there are no promises, terms, conditions or obligations, oral or written, expressed or implied, other than those contained in the Collaboration Agreement and this Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:1.33pt">This Amendment may be executed in one or more counterparts by the PARTIES by signature of a person having authority to bind the PARTY, each of which when executed and delivered by facsimile, electronic transmission or by mail delivery, will be an original and all of which shall constitute but one and the same instrument.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:1.33pt">General.  All provisions of the Collaboration Agreement regarding third party rights, signing by counterparts, amendments&#47;variations, governing law and jurisdiction and other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">general provisions shall apply to this Amendment as if set out in full and so that references in those provisions to &#8216;this agreement&#8217; shall be construed as references to this Amendment.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;Signature page follows.&#93;</font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_155"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%">, the PARTIES have caused this Amendment to be executed by their duly authorized representatives as of the Amendment Effective Date.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.264%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.040%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ROTHAMSTED RESEARCH LIMITED</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">YIELD10 BIOSCIENCE, INC.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NAME&#58;  &#91;***&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TITLE&#58;  &#91;***&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><font><br></font></div><div id="if156782af38142c9bb6d2f6d106885d7_161"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Annex 1 &#8211; Part B</font></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.113%"><tr><td style="width:1.0%"></td><td style="width:45.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.688%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.690%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Project Title</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Camelina-based Omega-3 fish oil development</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Project Start Date</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment Effective Date</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Project End Date</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rothamsted Scientific Leaders</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Industry Partner Scientific</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Location of work</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rothamsted Research</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Technical objectives of the Project</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;***&#93;</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Work Plan and allocation of tasks by Party</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">See below.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Milestones (including delivery dates)</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">See below.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rothamsted Deliverables</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) On a quarterly basis (beginning on the &#91;***&#93; anniversary of the Amendment Effective Date and continuing until the completion of the Project) Rothamsted shall provide within &#91;***&#93; of the end of the applicable quarter a written progress report summarizing the studies performed and a copy of the results obtained during the immediately prior quarter (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART B PROGRESS REPORT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).                                 (b)Within &#91;***&#93; of the completion of the Project a written report summarizing all of the studies performed and a copy of all of the results of the Project (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART B FINAL REPORT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221;).</font></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Industry Partner Deliverables</font></td><td colspan="9" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">None</font></td></tr><tr style="height:15pt"><td colspan="3" rowspan="4" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Background that each partner brings to the Project</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rothamsted</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Industry Partner</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Know-How</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Materials</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">None</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Biological Materials</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">See below.</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cost of Part B of the Project to be paid as set forth in the Option Agreement</font></td><td colspan="9" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;***&#93;</font></td></tr></table></div><div style="margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Work Plan&#47;Milestones</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Purpose&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Previously we have identified &#91;***&#93; that direct the seed-specific accumulation of EPA and DHA in Camelina.  Whilst there are some possibilities that the resulting constructs and lines could be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">commercialised, this would require third party licenses.  However, we believe that we can improve on that benchmark (defined in our peer-reviewed publication Han et al., 2020) as well as avoiding third-party IP and have embarked on further rounds of iteration to elevate the levels of EPA and DHA.  Additional enhancements are envisaged including &#91;***&#93;.  The current status of the programme is shown graphical in the attached Gannt chart and defined below.  For clarity, whilst the chart shows both past and future activities, the narrative below is for the next &#91;***&#93;, commencing &#91;***&#93;.  Several pre-existing resources have previously been generated, most notably a library of &#8220;parts&#8221; (i.e.  genes and regulatory elements) which have also been assembled (via Golden Gate) into transformation-ready binary vectors for introduction into Camelina.  Please note that timings are considered to be realistic estimates, but subject to variation as a consequence of working with biological material and their interaction with environmental factors during field trials.  Also these timelines do not reflect current restrictions arising from Covid-19, though it is hoped that these will have been lifted by &#91;***&#93;.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Updated Programme &#8211; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Although potential problems resulting from the Covid19 pandemic were anticipated in the Original Programme of Work executed in &#91;***&#93;, the extent of this was significantly underestimated both in terms of direct access to Rothamsted infrastructure (laboratories etc) and provision of CRO services such as gene synthesis and construct assembly&#59; many of these companies (including our trusted supplier Genscript), are based in China and experienced significant interruption to normal business functions .  The latter particularly impacted on the generation of the &#91;***&#93;, which also encountered some technical challenges associated with the Golden Gate assembly &#8211; this activity was scheduled for completion by &#91;***&#93; but this was not delivered until &#91;***&#93;.  This had a knock-on delay for all the subsequent activities.  Consequently, the following revised work plan has been generated.  For clarity, this revised timeline starts from the delivery of the &#91;***&#93;.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></div><div style="text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:24pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Task</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Description</font></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="background-color:#000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f0bb91;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:center"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:470.25pt"><tr><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:40.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f0bb91;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f0bb91;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#f0bb91;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#91;***&#93;</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ea9b5b;border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>yten-20221231x10kexh231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0ab64096385a4c9785f138b778771bbe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 23.1</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the Registration Statements on Form S-1 (No. 333-237420 and 333-249388), Form S-3 (No.333-254830) and Form S-8 (No. 333-138631, 333-145232, 333-155115, 333-157869, 333-165405, 333-172724, 333-181268, 333-187589, 333-194858, 333-194859, 333-202983, 333-217052, 333-226731, 333-231474, 333-235858, 333-238764, 333-254826, 333-256849, and 333-264737) of Yield10 Bioscience, Inc. of our report dated March 14, 2023, relating to the consolidated financial statements of Yield10 Bioscience, Inc., appearing in this Annual Report on Form 10-K of Yield10 Bioscience, Inc., for the year ended December&#160;31, 2022.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;RSM US LLP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;14, 2023</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>yten-20221231x10kexh311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3e360989189f4da18266078e64981d45_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Oliver P. Peoples certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Yield10 Bioscience,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; OLIVER P. PEOPLES</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oliver P. Peoples</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>yten-20221231x10kexh312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i937cf1a3b4ec45769849cb6f53ebf5d3_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Charles B. Haaser, certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form&#160;10-K of Yield10 Bioscience,&#160;Inc.&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font><br></font></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.881%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHARLES B. HAASER</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles B. Haaser</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Accounting Officer<br>(Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>yten-20221231x10kexh321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ic57b2cbda95844d4a20777e42834c25d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION&#160;1350,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br></font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In connection with the annual report on Form&#160;10-K (the &#8220;Report&#8221;) of Yield10 Bioscience,&#160;Inc. (the &#8220;Company&#8221;) for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof, we, Oliver P. Peoples, President, Chief Executive Officer and Principal Executive Officer of the Company and Charles B. Haaser, Chief Accounting Officer and Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, to my knowledge that&#58;</font></div><div><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended, and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This certification is being provided pursuant to 18 U.S.C. 1350 and is not to be deemed a part of the Report, nor is it to be deemed to be &#8220;filed&#8221; for any purpose whatsoever.</font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:29.237%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.886%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.897%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">YIELD10 BIOSCIENCE, INC.</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; OLIVER P. PEOPLES</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oliver P. Peoples</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Executive Officer (Principal Executive Officer)</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 14, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; CHARLES B. HAASER</font></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles B. Haaser</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Accounting Officer (Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>yten-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:yten="http://www.yield10bio.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.yield10bio.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="yten-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="yten-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="yten-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="yten-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.yield10bio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.yield10bio.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>0000010 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.yield10bio.com/role/Investments">
        <link:definition>0000012 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.yield10bio.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNet" roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNet">
        <link:definition>0000014 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpenses" roleURI="http://www.yield10bio.com/role/AccruedExpenses">
        <link:definition>0000015 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.yield10bio.com/role/CommitmentsandContingencies">
        <link:definition>0000016 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreements" roleURI="http://www.yield10bio.com/role/LicenseAgreements">
        <link:definition>0000017 - Disclosure - License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockandWarrants" roleURI="http://www.yield10bio.com/role/CapitalStockandWarrants">
        <link:definition>0000018 - Disclosure - Capital Stock and Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.yield10bio.com/role/StockBasedCompensation">
        <link:definition>0000019 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.yield10bio.com/role/Leases">
        <link:definition>0000020 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.yield10bio.com/role/IncomeTaxes">
        <link:definition>0000021 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefits" roleURI="http://www.yield10bio.com/role/EmployeeBenefits">
        <link:definition>0000022 - Disclosure - Employee Benefits</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GovernmentResearchGrants" roleURI="http://www.yield10bio.com/role/GovernmentResearchGrants">
        <link:definition>0000023 - Disclosure - Government Research Grants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformation" roleURI="http://www.yield10bio.com/role/GeographicInformation">
        <link:definition>0000024 - Disclosure - Geographic Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransaction" roleURI="http://www.yield10bio.com/role/RelatedPartyTransaction">
        <link:definition>0000025 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvent" roleURI="http://www.yield10bio.com/role/SubsequentEvent">
        <link:definition>0000026 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.yield10bio.com/role/InvestmentsTables">
        <link:definition>0000029 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.yield10bio.com/role/FairValueMeasurementsTables">
        <link:definition>0000030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetTables" roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetTables">
        <link:definition>0000031 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesTables" roleURI="http://www.yield10bio.com/role/AccruedExpensesTables">
        <link:definition>0000032 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockandWarrantsTables" roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsTables">
        <link:definition>0000033 - Disclosure - Capital Stock and Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.yield10bio.com/role/StockBasedCompensationTables">
        <link:definition>0000034 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.yield10bio.com/role/LeasesTables">
        <link:definition>0000035 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.yield10bio.com/role/IncomeTaxesTables">
        <link:definition>0000036 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationTables" roleURI="http://www.yield10bio.com/role/GeographicInformationTables">
        <link:definition>0000037 - Disclosure - Geographic Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>0000038 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000039 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>0000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails">
        <link:definition>0000041 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000042 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsDetails" roleURI="http://www.yield10bio.com/role/InvestmentsDetails">
        <link:definition>0000043 - Disclosure - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" roleURI="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>0000044 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentNetDetails" roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails">
        <link:definition>0000045 - Disclosure - Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedExpensesDetails" roleURI="http://www.yield10bio.com/role/AccruedExpensesDetails">
        <link:definition>0000046 - Disclosure - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.yield10bio.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LicenseAgreementsDetails" roleURI="http://www.yield10bio.com/role/LicenseAgreementsDetails">
        <link:definition>0000048 - Disclosure - License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockandWarrantsNarrativeDetails" roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails">
        <link:definition>0000049 - Disclosure - Capital Stock and Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails" roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails">
        <link:definition>0000050 - Disclosure - Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails" roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails">
        <link:definition>0000051 - Disclosure - Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails" roleURI="http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails">
        <link:definition>0000054 - Disclosure - Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsRSUsDetails" roleURI="http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails">
        <link:definition>0000055 - Disclosure - Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityAnalysisofLeaseLiabilitiesDetails" roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails">
        <link:definition>0000056 - Disclosure - Leases - Maturity Analysis of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1" roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1">
        <link:definition>0000056 - Disclosure - Leases - Maturity Analysis of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesQuantitativeDisclosureofLeaseCostsDetails" roleURI="http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails">
        <link:definition>0000057 - Disclosure - Leases - Quantitative Disclosure of Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.yield10bio.com/role/LeasesNarrativeDetails">
        <link:definition>0000058 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.yield10bio.com/role/IncomeTaxesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextualDetails" roleURI="http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails">
        <link:definition>0000060 - Disclosure - Income Taxes - Details Textual (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitsDetails" roleURI="http://www.yield10bio.com/role/EmployeeBenefitsDetails">
        <link:definition>0000061 - Disclosure - Employee Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GovernmentResearchGrantsDetails" roleURI="http://www.yield10bio.com/role/GovernmentResearchGrantsDetails">
        <link:definition>0000062 - Disclosure - Government Research Grants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GeographicInformationDetails" roleURI="http://www.yield10bio.com/role/GeographicInformationDetails">
        <link:definition>0000063 - Disclosure - Geographic Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionDetails" roleURI="http://www.yield10bio.com/role/RelatedPartyTransactionDetails">
        <link:definition>0000064 - Disclosure - Related Party Transaction (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventDetails" roleURI="http://www.yield10bio.com/role/SubsequentEventDetails">
        <link:definition>0000065 - Disclosure - Subsequent Event (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="yten_GovernmentGrantTerm" abstract="false" name="GovernmentGrantTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="yten_CJCheilJedangCorporationMember" abstract="true" name="CJCheilJedangCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_LicenseAgreementTerm" abstract="false" name="LicenseAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="yten_CostOfRevenueResearchAndDevelopmentExpenses" abstract="false" name="CostOfRevenueResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_SaleofStockGrossConsiderationReceivedPerTransaction" abstract="false" name="SaleofStockGrossConsiderationReceivedPerTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" abstract="false" name="CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="yten_NoncashLeaseExpenseIncome" abstract="false" name="NoncashLeaseExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_LicensePaymentsReceivable" abstract="false" name="LicensePaymentsReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" abstract="false" name="ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_LesseeOperatingSubleaseSubleasedArea" abstract="false" name="LesseeOperatingSubleaseSubleasedArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="yten_IncreaseDecreaseInLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_SeriesAWarrantsIssuedNovember2019Member" abstract="true" name="SeriesAWarrantsIssuedNovember2019Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="yten_SaleOfStockCommissionRate" abstract="false" name="SaleOfStockCommissionRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="yten_ResearchGrantMaximumPayrollCostReimbursement" abstract="false" name="ResearchGrantMaximumPayrollCostReimbursement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_EmployeeAndDirectorMember" abstract="true" name="EmployeeAndDirectorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" abstract="true" name="SystemsApproachToIncreasingCarbonFluxToSeedOilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_WarrantExpiringJanuary2024Member" abstract="true" name="WarrantExpiringJanuary2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_SeriesAWarrantsIssuedDecember2017Member" abstract="true" name="SeriesAWarrantsIssuedDecember2017Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_LesseeOperatingLeaseLeaseArea" abstract="false" name="LesseeOperatingLeaseLeaseArea" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="yten_SeriesBWarrantExpiringMay2027Member" abstract="true" name="SeriesBWarrantExpiringMay2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_PresidentialWayWoburnMassachusettsMember" abstract="true" name="PresidentialWayWoburnMassachusettsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_IntellectualPropertyCostsPolicyPolicyTextBlock" abstract="false" name="IntellectualPropertyCostsPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" abstract="false" name="CollaborativeArrangementResearchFundingAndOptionFeesPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="yten_StockPlan2006Member" abstract="true" name="StockPlan2006Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_LeaseOtherInformationAbstract" abstract="true" name="LeaseOtherInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="yten_CollaborativeArrangementTerm" abstract="false" name="CollaborativeArrangementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="yten_ClassOfWarrantOrRightExpired" abstract="false" name="ClassOfWarrantOrRightExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="yten_A410DowneyRoadAnd110GymnasiumPlaceMember" abstract="true" name="A410DowneyRoadAnd110GymnasiumPlaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="yten_StockPlan2014Member" abstract="true" name="StockPlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_StockPlan2018Member" abstract="true" name="StockPlan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_AccountsReceivableTradeAndUnbilledReceivables" abstract="false" name="AccountsReceivableTradeAndUnbilledReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" abstract="false" name="CollaborativeArrangementTermOfOptionForLicenseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="yten_GovernmentGrantCumulativeAmountAwarded" abstract="false" name="GovernmentGrantCumulativeAmountAwarded" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_EnergyGrantDisclosureTextBlock" abstract="false" name="EnergyGrantDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="yten_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ChargeForCompanyCommonStockMatch" abstract="false" name="ChargeForCompanyCommonStockMatch" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="yten_AccruedFieldTrialsAndRelatedExpensesCurrent" abstract="false" name="AccruedFieldTrialsAndRelatedExpensesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_GainOnRelatedPartyInvestment" abstract="false" name="GainOnRelatedPartyInvestment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_WarrantExpiringSeptember2024Member" abstract="true" name="WarrantExpiringSeptember2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" abstract="false" name="SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" abstract="false" name="DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="yten_ClassOfWarrantOrRightExercised" abstract="false" name="ClassOfWarrantOrRightExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>yten-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_fc4f3829-f254-4b31-b528-220bfc839214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:to="loc_us-gaap_AssetsCurrent_fc4f3829-f254-4b31-b528-220bfc839214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4712cc00-1b6f-4834-bcd9-60ef78afd01b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_4712cc00-1b6f-4834-bcd9-60ef78afd01b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7aaf3050-01de-48b3-9993-81ffd09c8139" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7aaf3050-01de-48b3-9993-81ffd09c8139" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0cf4a206-6437-43fd-8dce-d1dd86d4ed51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0cf4a206-6437-43fd-8dce-d1dd86d4ed51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8dd05488-5fc6-4fde-8a07-d7e2c7b09272" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_e59958b4-81bf-4d1c-8049-3a96004d2bc6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8dd05488-5fc6-4fde-8a07-d7e2c7b09272" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_08a59399-3d69-439f-a766-e2e34d8a8e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b167348c-7787-4806-a2ac-9bcad368e133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a59399-3d69-439f-a766-e2e34d8a8e9f" xlink:to="loc_us-gaap_LiabilitiesCurrent_b167348c-7787-4806-a2ac-9bcad368e133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1965d464-1430-496b-b60d-d50bac80ae63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_08a59399-3d69-439f-a766-e2e34d8a8e9f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_1965d464-1430-496b-b60d-d50bac80ae63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_dfece92b-f7de-4ad1-8881-ca31f780d0de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eeecc206-3dbb-4027-ab77-37358833f6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfece92b-f7de-4ad1-8881-ca31f780d0de" xlink:to="loc_us-gaap_AccountsPayableCurrent_eeecc206-3dbb-4027-ab77-37358833f6ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_deb294d0-ff36-480f-b488-5831ea9f8c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfece92b-f7de-4ad1-8881-ca31f780d0de" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_deb294d0-ff36-480f-b488-5831ea9f8c3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c00e9e4b-e950-489a-84d3-c447c972fbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_dfece92b-f7de-4ad1-8881-ca31f780d0de" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c00e9e4b-e950-489a-84d3-c447c972fbf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a07b310-d97a-46ed-9648-a11bd3a4a895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2a07b310-d97a-46ed-9648-a11bd3a4a895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f537b955-f788-4b51-a2c3-0dda206f7ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f537b955-f788-4b51-a2c3-0dda206f7ad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_74d520ba-27cc-4dcf-a430-36db2362bb55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:to="loc_us-gaap_UnbilledContractsReceivable_74d520ba-27cc-4dcf-a430-36db2362bb55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27b198f5-024b-400f-9601-9c47ef6fad6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_27b198f5-024b-400f-9601-9c47ef6fad6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2be4e8d8-c40a-41d6-b04f-6a80449a9c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_63de64d1-ec61-4f74-9557-ee4663d4b0ab" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_2be4e8d8-c40a-41d6-b04f-6a80449a9c4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_329e899a-25ae-446a-9958-d3854e73538a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7eccaf57-14ac-4f57-9558-4268c933543c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_329e899a-25ae-446a-9958-d3854e73538a" xlink:to="loc_us-gaap_Liabilities_7eccaf57-14ac-4f57-9558-4268c933543c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f9db3ba9-2283-4a84-bc4e-840a423cd235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_329e899a-25ae-446a-9958-d3854e73538a" xlink:to="loc_us-gaap_StockholdersEquity_f9db3ba9-2283-4a84-bc4e-840a423cd235" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_00b57e86-6318-446d-b694-a2868515850f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_329e899a-25ae-446a-9958-d3854e73538a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_00b57e86-6318-446d-b694-a2868515850f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_eb670251-3aa3-4fcd-a303-4efcfb24f5ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:to="loc_us-gaap_CommonStockValue_eb670251-3aa3-4fcd-a303-4efcfb24f5ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a201552b-86b7-471c-afa0-b350b7206185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a201552b-86b7-471c-afa0-b350b7206185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_616f7e28-0b14-4a90-bcec-b6ef074347aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_616f7e28-0b14-4a90-bcec-b6ef074347aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2705bf51-53d6-47d2-8542-81a3a150f5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2705bf51-53d6-47d2-8542-81a3a150f5ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f5243f25-4bbb-4a4e-b4c1-993373268cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_05dc697c-d416-4888-9a09-8e8f7ee9556f" xlink:to="loc_us-gaap_PreferredStockValue_f5243f25-4bbb-4a4e-b4c1-993373268cdc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0b2eee13-87eb-4a38-8fcb-00ed544d25c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment_8c9d9114-d1ca-42fc-b364-7713b7445ff9" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0b2eee13-87eb-4a38-8fcb-00ed544d25c0" xlink:to="loc_yten_GainOnRelatedPartyInvestment_8c9d9114-d1ca-42fc-b364-7713b7445ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_8065f15c-d836-430e-acd7-8feea32bfad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0b2eee13-87eb-4a38-8fcb-00ed544d25c0" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_8065f15c-d836-430e-acd7-8feea32bfad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1039ce31-77d2-4292-9ba7-c2fdb21eaedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7df7286f-6201-4bac-abac-d5c2fda3d1b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1039ce31-77d2-4292-9ba7-c2fdb21eaedd" xlink:to="loc_us-gaap_OperatingIncomeLoss_7df7286f-6201-4bac-abac-d5c2fda3d1b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_d9bd5b80-56d5-4a11-9d0b-04169fcec6e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1039ce31-77d2-4292-9ba7-c2fdb21eaedd" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_d9bd5b80-56d5-4a11-9d0b-04169fcec6e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c2b8ed4d-321a-4edc-bea3-4f8107b52656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_006f8986-1db4-4ba3-bcd4-a9548c24cdc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2b8ed4d-321a-4edc-bea3-4f8107b52656" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_006f8986-1db4-4ba3-bcd4-a9548c24cdc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22010a88-5569-497b-b853-d2dc60d0bdff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c2b8ed4d-321a-4edc-bea3-4f8107b52656" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22010a88-5569-497b-b853-d2dc60d0bdff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e4890489-c6f5-4e12-b784-e8c08c58d076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_3bd57ece-ba6e-4a88-9cea-6f45ed56c8fb" xlink:href="yten-20221231.xsd#yten_CostOfRevenueResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e4890489-c6f5-4e12-b784-e8c08c58d076" xlink:to="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_3bd57ece-ba6e-4a88-9cea-6f45ed56c8fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61930caf-6fb3-447c-82a1-6867c5b59a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_e4890489-c6f5-4e12-b784-e8c08c58d076" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61930caf-6fb3-447c-82a1-6867c5b59a3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_df97e5a7-a8fc-4893-94c6-f84f328a2020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48e5628d-7b56-4467-b362-8a57024ad17e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_df97e5a7-a8fc-4893-94c6-f84f328a2020" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_48e5628d-7b56-4467-b362-8a57024ad17e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4b4b1ac1-0cf0-4e1d-ae71-d29b256df74d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_df97e5a7-a8fc-4893-94c6-f84f328a2020" xlink:to="loc_us-gaap_CostsAndExpenses_4b4b1ac1-0cf0-4e1d-ae71-d29b256df74d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_215232c6-6233-4312-abc3-efa2a4d138b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b2e6dda-cf0f-4f94-8a58-d0918db27181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_215232c6-6233-4312-abc3-efa2a4d138b0" xlink:to="loc_us-gaap_NetIncomeLoss_4b2e6dda-cf0f-4f94-8a58-d0918db27181" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d95f000-392e-4def-a6ad-821e5f9eeb90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_215232c6-6233-4312-abc3-efa2a4d138b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d95f000-392e-4def-a6ad-821e5f9eeb90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_016f426a-2d84-4d79-a51e-1ae1e2ccb0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_352c4e1d-9180-41b1-a3ec-39d3338f2125" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_016f426a-2d84-4d79-a51e-1ae1e2ccb0da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_352c4e1d-9180-41b1-a3ec-39d3338f2125" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_890bb9fe-fc74-40c4-b94e-6f6405136db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_016f426a-2d84-4d79-a51e-1ae1e2ccb0da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_890bb9fe-fc74-40c4-b94e-6f6405136db8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878dad65-d9d9-486c-8a05-7b6007a1948a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9d6cb4e-7c01-43bc-914a-5730d73b5897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878dad65-d9d9-486c-8a05-7b6007a1948a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9d6cb4e-7c01-43bc-914a-5730d73b5897" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fbae4035-404f-4e75-8c01-9cc50b936045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878dad65-d9d9-486c-8a05-7b6007a1948a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_fbae4035-404f-4e75-8c01-9cc50b936045" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fdf6961-80a2-4eae-a1b4-48a4a4330f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878dad65-d9d9-486c-8a05-7b6007a1948a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3fdf6961-80a2-4eae-a1b4-48a4a4330f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef0ad62a-b52c-4fbe-b30b-43958f8848ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_878dad65-d9d9-486c-8a05-7b6007a1948a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef0ad62a-b52c-4fbe-b30b-43958f8848ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b26c37fd-51b1-4c20-9baf-4a3035edecd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_b26c37fd-51b1-4c20-9baf-4a3035edecd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_71cc1bed-7fa9-44fa-bd0b-9232f9c39919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_71cc1bed-7fa9-44fa-bd0b-9232f9c39919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aebe2e87-2283-4e93-9728-683e11fd8bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_aebe2e87-2283-4e93-9728-683e11fd8bee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f416303-0e60-4fe4-98cb-f2e7118d9afc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_7f416303-0e60-4fe4-98cb-f2e7118d9afc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6a35e75b-26fc-4f53-ad47-bc787d356659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6a35e75b-26fc-4f53-ad47-bc787d356659" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_838895a0-8b91-4e6a-aeb5-98b52677f6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_ShareBasedCompensation_838895a0-8b91-4e6a-aeb5-98b52677f6b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_NoncashLeaseExpenseIncome_c090bea8-7555-4b68-8278-1e174fc88f46" xlink:href="yten-20221231.xsd#yten_NoncashLeaseExpenseIncome"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_yten_NoncashLeaseExpenseIncome_c090bea8-7555-4b68-8278-1e174fc88f46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4aa67956-c082-497c-8cec-459f65df2492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4aa67956-c082-497c-8cec-459f65df2492" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ChargeForCompanyCommonStockMatch_eb068479-33cd-4cb0-9197-e5c7c94e7a7e" xlink:href="yten-20221231.xsd#yten_ChargeForCompanyCommonStockMatch"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_yten_ChargeForCompanyCommonStockMatch_eb068479-33cd-4cb0-9197-e5c7c94e7a7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_17148bf6-6f3b-4336-ba28-34f95dad44d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_NetIncomeLoss_17148bf6-6f3b-4336-ba28-34f95dad44d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_046db60c-54fa-489b-903b-236353e37023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_046db60c-54fa-489b-903b-236353e37023" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_IncreaseDecreaseInLeaseLiabilities_1c4ebc64-6bdf-4928-bb5c-68ff2a740353" xlink:href="yten-20221231.xsd#yten_IncreaseDecreaseInLeaseLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2125b264-3818-4d23-8ae9-1e5279cc7cbb" xlink:to="loc_yten_IncreaseDecreaseInLeaseLiabilities_1c4ebc64-6bdf-4928-bb5c-68ff2a740353" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09915f46-1063-49cc-9922-c7ada9c093b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ac7ee3b-c1d8-4d9f-acf2-eb121817bf02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09915f46-1063-49cc-9922-c7ada9c093b4" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2ac7ee3b-c1d8-4d9f-acf2-eb121817bf02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c53dde7f-22d4-4ac2-915e-ce64ee9fad21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09915f46-1063-49cc-9922-c7ada9c093b4" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c53dde7f-22d4-4ac2-915e-ce64ee9fad21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_826f4c33-f2e0-48b4-92a6-c547566ba6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_09915f46-1063-49cc-9922-c7ada9c093b4" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_826f4c33-f2e0-48b4-92a6-c547566ba6e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c1ed9eb-1338-4656-b02d-04c6465c38a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4fa9c207-d98f-494f-baa4-4aab3231501a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c1ed9eb-1338-4656-b02d-04c6465c38a5" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_4fa9c207-d98f-494f-baa4-4aab3231501a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4e052b60-6f09-4877-a513-de4be0f31a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c1ed9eb-1338-4656-b02d-04c6465c38a5" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4e052b60-6f09-4877-a513-de4be0f31a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_623f8561-8c16-4f64-951f-3d3d228aa391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6c1ed9eb-1338-4656-b02d-04c6465c38a5" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_623f8561-8c16-4f64-951f-3d3d228aa391" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d19002a-b260-4999-8030-aaa93c1e980d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18051255-7a27-448b-a7d9-c88179c8fe8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d19002a-b260-4999-8030-aaa93c1e980d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18051255-7a27-448b-a7d9-c88179c8fe8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50ec8ae2-08dc-4321-b839-ce0085076676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6d19002a-b260-4999-8030-aaa93c1e980d" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_50ec8ae2-08dc-4321-b839-ce0085076676" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#InvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f6017d4a-58b3-4639-8241-2ad55fb12dfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf0e48b2-2fde-4d08-b991-1e5c06ccd2be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f6017d4a-58b3-4639-8241-2ad55fb12dfc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_cf0e48b2-2fde-4d08-b991-1e5c06ccd2be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7670de8d-a535-4ad0-aa60-cf5d956961d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f6017d4a-58b3-4639-8241-2ad55fb12dfc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7670de8d-a535-4ad0-aa60-cf5d956961d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e82bbc4-2d43-4d48-9df2-60b97edf5b15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_f6017d4a-58b3-4639-8241-2ad55fb12dfc" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4e82bbc4-2d43-4d48-9df2-60b97edf5b15" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f7f57558-c877-4c19-bf7e-e7c7d03e9282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff2c1e82-e4fb-4caf-82dd-ab9027ef96cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f7f57558-c877-4c19-bf7e-e7c7d03e9282" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ff2c1e82-e4fb-4caf-82dd-ab9027ef96cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddf5c813-43f4-42f9-b816-dfbb150b4560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_f7f57558-c877-4c19-bf7e-e7c7d03e9282" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddf5c813-43f4-42f9-b816-dfbb150b4560" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1eeea780-ffb2-41ee-a526-6931630476a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_542cd3af-458e-4bb6-98c6-0be322eccc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1eeea780-ffb2-41ee-a526-6931630476a0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_542cd3af-458e-4bb6-98c6-0be322eccc8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c52569d3-d5a7-42c5-9057-b07be23bd647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1eeea780-ffb2-41ee-a526-6931630476a0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_c52569d3-d5a7-42c5-9057-b07be23bd647" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#AccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0597611a-c9ae-4db6-b232-f610b71089dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0597611a-c9ae-4db6-b232-f610b71089dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1f201ee1-e1fa-4af1-b7b9-dcaec6ce9046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1f201ee1-e1fa-4af1-b7b9-dcaec6ce9046" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2fd8260a-f010-4dde-b458-326f86c65b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2fd8260a-f010-4dde-b458-326f86c65b97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_0b8638d7-2d18-41b1-b17f-547bf6999f12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:to="loc_us-gaap_AccruedRentCurrent_0b8638d7-2d18-41b1-b17f-547bf6999f12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_be813772-b041-4151-9956-e3e51be6d521" xlink:href="yten-20221231.xsd#yten_AccruedFieldTrialsAndRelatedExpensesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_a75dcf7e-ab87-4644-a1a2-8152958f3dec" xlink:to="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_be813772-b041-4151-9956-e3e51be6d521" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesMaturityAnalysisofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e2fd348-3efa-4544-8bf8-ed8feee25cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc622ada-0e8e-4389-a911-086411d0337a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e2fd348-3efa-4544-8bf8-ed8feee25cec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_dc622ada-0e8e-4389-a911-086411d0337a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad9a9263-7555-4860-b7fd-40aa2507cc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e2fd348-3efa-4544-8bf8-ed8feee25cec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ad9a9263-7555-4860-b7fd-40aa2507cc09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_59ce1b70-b213-435d-985e-97f29962831a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e2fd348-3efa-4544-8bf8-ed8feee25cec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_59ce1b70-b213-435d-985e-97f29962831a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a054179a-06fc-48b2-9950-2bde9bbb5992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5e2fd348-3efa-4544-8bf8-ed8feee25cec" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a054179a-06fc-48b2-9950-2bde9bbb5992" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5f612a38-c13d-4689-a6ce-c28591b75021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_87662ac6-bc70-4e75-a3bd-d4aefeeaa2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5f612a38-c13d-4689-a6ce-c28591b75021" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_87662ac6-bc70-4e75-a3bd-d4aefeeaa2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5033fcf2-2ce3-4d43-92aa-a2b39ab88245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_5f612a38-c13d-4689-a6ce-c28591b75021" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5033fcf2-2ce3-4d43-92aa-a2b39ab88245" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60684652-605a-4827-ae5c-71b9cd699e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ceb44397-00d2-4cd3-a07c-ce5165b5c226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60684652-605a-4827-ae5c-71b9cd699e2a" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ceb44397-00d2-4cd3-a07c-ce5165b5c226" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a189505f-3d5a-4071-9b9b-9b03148eb6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_60684652-605a-4827-ae5c-71b9cd699e2a" xlink:to="loc_us-gaap_OperatingLeaseLiability_a189505f-3d5a-4071-9b9b-9b03148eb6ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesQuantitativeDisclosureofLeaseCostsDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_dcc4ec79-04ac-4575-8c14-36b6100fd962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_133ced2d-afec-4895-a38f-8958559f7087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_dcc4ec79-04ac-4575-8c14-36b6100fd962" xlink:to="loc_us-gaap_OperatingLeaseCost_133ced2d-afec-4895-a38f-8958559f7087" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c0642b01-bd0f-4e99-a82e-b5f856e6a2a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_dcc4ec79-04ac-4575-8c14-36b6100fd962" xlink:to="loc_us-gaap_ShortTermLeaseCost_c0642b01-bd0f-4e99-a82e-b5f856e6a2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0aed5fb4-2b79-40ed-8e82-9fe0cbd56f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_dcc4ec79-04ac-4575-8c14-36b6100fd962" xlink:to="loc_us-gaap_SubleaseIncome_0aed5fb4-2b79-40ed-8e82-9fe0cbd56f93" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.yield10bio.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ed539038-2671-4ad8-8e81-a146443daa14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ed539038-2671-4ad8-8e81-a146443daa14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_292b9884-ef7c-44ff-a2d8-74a31ca5f0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_292b9884-ef7c-44ff-a2d8-74a31ca5f0e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_df86c196-0453-428b-83ec-06da66f5f2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_df86c196-0453-428b-83ec-06da66f5f2a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fe8d6aa7-9cc2-420f-9967-5f5cdc3bd6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_fe8d6aa7-9cc2-420f-9967-5f5cdc3bd6e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ca0ed93a-6249-4329-876d-f9b726e24ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ca0ed93a-6249-4329-876d-f9b726e24ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_cbe43997-ca44-4644-9b5b-1bdaf8ca4a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_cbe43997-ca44-4644-9b5b-1bdaf8ca4a01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a8f50056-2edd-4473-a90b-aa426f8938a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_a8f50056-2edd-4473-a90b-aa426f8938a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ce066bc-b419-454f-a88c-f7402501e58f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ce066bc-b419-454f-a88c-f7402501e58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d50b9213-c14a-4353-a9d4-b775cda0b593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_d50b9213-c14a-4353-a9d4-b775cda0b593" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_a4e5a73f-08c3-4035-8782-0b3544570d13" xlink:href="yten-20221231.xsd#yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_01ded767-70b8-41dc-a5c9-264cf9e57430" xlink:to="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_a4e5a73f-08c3-4035-8782-0b3544570d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7963b5b-7258-4d41-8f0c-47c0fef28fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f44e5baf-3e03-4f21-aff8-5d238adc15aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7963b5b-7258-4d41-8f0c-47c0fef28fe5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_f44e5baf-3e03-4f21-aff8-5d238adc15aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a36f667b-fe89-4fd3-b838-ae0718970491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7963b5b-7258-4d41-8f0c-47c0fef28fe5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_a36f667b-fe89-4fd3-b838-ae0718970491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_eddb6134-d7d2-4087-8e51-7bdf9ad36a58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7963b5b-7258-4d41-8f0c-47c0fef28fe5" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_eddb6134-d7d2-4087-8e51-7bdf9ad36a58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf748da6-cd7c-4ed5-8d1f-f2e4a47c21c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_2b0f44ad-4a09-43cf-a23b-45afa06d5418" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf748da6-cd7c-4ed5-8d1f-f2e4a47c21c5" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_2b0f44ad-4a09-43cf-a23b-45afa06d5418" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7cb750d4-2b82-4042-ae6b-f738df47994a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf748da6-cd7c-4ed5-8d1f-f2e4a47c21c5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_7cb750d4-2b82-4042-ae6b-f738df47994a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset_553f7b16-bed9-47ab-b67b-511af691256c" xlink:href="yten-20221231.xsd#yten_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_cf748da6-cd7c-4ed5-8d1f-f2e4a47c21c5" xlink:to="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset_553f7b16-bed9-47ab-b67b-511af691256c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_54a10e10-7c1d-416c-b78b-0bfb97bfefd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_54a10e10-7c1d-416c-b78b-0bfb97bfefd3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_5caa0a5d-b177-4b8b-a5b5-1a56f7bd49e5" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_5caa0a5d-b177-4b8b-a5b5-1a56f7bd49e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6ff8b8f1-7b34-4525-8061-cc353e8de3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_6ff8b8f1-7b34-4525-8061-cc353e8de3c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f6e357d5-3abb-42f4-a7f1-aacf35b30b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f6e357d5-3abb-42f4-a7f1-aacf35b30b0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_75fa4826-0971-4f29-8576-95293ef5feb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_75fa4826-0971-4f29-8576-95293ef5feb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsLeaseLiability_0d5083cb-9357-460c-b0c5-14cf63cc1a13" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cd9a7f67-6ae5-4e6c-b454-3fbfca77188d" xlink:to="loc_yten_DeferredTaxAssetsLeaseLiability_0d5083cb-9357-460c-b0c5-14cf63cc1a13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d054489e-de84-421d-b857-b3e3dc5e74bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0265e310-c2e2-4f9d-a7f8-e16e683baf63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d054489e-de84-421d-b857-b3e3dc5e74bc" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0265e310-c2e2-4f9d-a7f8-e16e683baf63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12a52b80-8dec-4b07-af99-ca566bc3d894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d054489e-de84-421d-b857-b3e3dc5e74bc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_12a52b80-8dec-4b07-af99-ca566bc3d894" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7e57a48-a08f-410a-90f7-8350c8402fda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0118cd37-e70a-448d-bb23-f6515aa7d52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7e57a48-a08f-410a-90f7-8350c8402fda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0118cd37-e70a-448d-bb23-f6515aa7d52f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b97b103a-f6c3-41eb-820c-8869ed063594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c7e57a48-a08f-410a-90f7-8350c8402fda" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_b97b103a-f6c3-41eb-820c-8869ed063594" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bd3e3965-3f1b-43f1-a60b-564d08368dec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6aab7a24-d91c-42bd-a3c9-636be95d338b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bd3e3965-3f1b-43f1-a60b-564d08368dec" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6aab7a24-d91c-42bd-a3c9-636be95d338b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83eeb193-8bf0-4fa0-94a8-93525c57e2a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bd3e3965-3f1b-43f1-a60b-564d08368dec" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_83eeb193-8bf0-4fa0-94a8-93525c57e2a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_03232335-fa1a-4698-8a3b-81569c96a825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_bd3e3965-3f1b-43f1-a60b-564d08368dec" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_03232335-fa1a-4698-8a3b-81569c96a825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ff2c4704-4f57-466a-a1f9-7a1b62ff80f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b893d997-3866-4870-bc3e-45988386beb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ff2c4704-4f57-466a-a1f9-7a1b62ff80f9" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_b893d997-3866-4870-bc3e-45988386beb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9945af08-4859-4a45-8565-8a5b30faf4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_ff2c4704-4f57-466a-a1f9-7a1b62ff80f9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9945af08-4859-4a45-8565-8a5b30faf4d8" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>yten-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended" id="i52d3140096e94747bb61289a96bd350e_CONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92dfb3be-ece8-4186-9883-01d373caba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92dfb3be-ece8-4186-9883-01d373caba75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_195a913b-1a9e-4dd4-bbf4-8eb0a7b493b1" xlink:href="yten-20221231.xsd#yten_CostOfRevenueResearchAndDevelopmentExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_195a913b-1a9e-4dd4-bbf4-8eb0a7b493b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11a113c-5a8e-44a3-9362-ed18c284eae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11a113c-5a8e-44a3-9362-ed18c284eae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eedc60e1-447f-4369-892f-d171c13c5391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_us-gaap_CostsAndExpenses_eedc60e1-447f-4369-892f-d171c13c5391" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1956a12b-39b3-4afe-ae5f-ceeedd92ba96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_OperatingIncomeLoss_1956a12b-39b3-4afe-ae5f-ceeedd92ba96" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment_3275cbb7-9d5b-4b78-a831-84523a39e245" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_yten_GainOnRelatedPartyInvestment_3275cbb7-9d5b-4b78-a831-84523a39e245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a674faf7-a897-4221-b29f-de63ac24694a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a674faf7-a897-4221-b29f-de63ac24694a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ca84850e-a8bf-4a87-a538-f53ef86dad59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ca84850e-a8bf-4a87-a538-f53ef86dad59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c42a389f-4d97-4023-83fc-c2d2ba76a174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c42a389f-4d97-4023-83fc-c2d2ba76a174" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_119ed344-3477-40f0-8d8c-2b8d1e853669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_119ed344-3477-40f0-8d8c-2b8d1e853669" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91e68839-e110-4989-91ac-0c135d0d3120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_NetIncomeLoss_91e68839-e110-4989-91ac-0c135d0d3120" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ac104593-4270-48d9-97f4-b6b19f6dd28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_EarningsPerShareBasic_ac104593-4270-48d9-97f4-b6b19f6dd28d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_24b7fc9f-a8d5-41bd-b2c9-c77385a3a31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_EarningsPerShareDiluted_24b7fc9f-a8d5-41bd-b2c9-c77385a3a31f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfd60c46-721c-4ea6-9c45-2a9af228a632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfd60c46-721c-4ea6-9c45-2a9af228a632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1247a9a-d892-403b-9d0c-864332f18fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1247a9a-d892-403b-9d0c-864332f18fa4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:to="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_52074cba-65e0-49c6-b922-672aae55aeed_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:to="loc_srt_ProductsAndServicesDomain_52074cba-65e0-49c6-b922-672aae55aeed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:to="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_bf936399-cf03-4424-a0b6-b8ec98f9ee14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:to="loc_us-gaap_GrantMember_bf936399-cf03-4424-a0b6-b8ec98f9ee14" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended" id="i53db1e5efb754bd5bce2da6f166f7377_CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e6fda82-b0e0-4b6c-a602-602abf2fa15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockholdersEquity_9e6fda82-b0e0-4b6c-a602-602abf2fa15f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98c9a779-3cb2-4214-8f78-2ab16a3dabde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_SharesOutstanding_98c9a779-3cb2-4214-8f78-2ab16a3dabde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e28c877c-9ae9-438b-8ea3-558eacd6fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e28c877c-9ae9-438b-8ea3-558eacd6fa4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_8dd38eaf-60bd-4376-89c2-12eb11c351ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_8dd38eaf-60bd-4376-89c2-12eb11c351ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_93310827-64d3-48fa-9c72-20daa1920621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_93310827-64d3-48fa-9c72-20daa1920621" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_fa81bbe2-a8f6-4067-938e-31516492652b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_fa81bbe2-a8f6-4067-938e-31516492652b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_891bf207-7277-44f3-89a6-d84fef8ee6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_891bf207-7277-44f3-89a6-d84fef8ee6a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8ff9a20d-7962-4d1a-8771-1591d19530f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8ff9a20d-7962-4d1a-8771-1591d19530f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f3bcaa3c-9fb1-41da-9341-8ebff007c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f3bcaa3c-9fb1-41da-9341-8ebff007c759" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_897cfe60-4a3a-4d21-99bc-59a472fc979c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_897cfe60-4a3a-4d21-99bc-59a472fc979c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_322e3955-c462-4f85-9a28-2f0000f74093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_322e3955-c462-4f85-9a28-2f0000f74093" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2082652e-c78e-4e4e-8309-20d2233966dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2082652e-c78e-4e4e-8309-20d2233966dc" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_c84fba7a-53e5-4527-9a7f-2a45c4995f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_c84fba7a-53e5-4527-9a7f-2a45c4995f95" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3dd29bd8-d056-4736-ab81-26cdfef5febd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_NetIncomeLoss_3dd29bd8-d056-4736-ab81-26cdfef5febd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c587455-7992-45f4-ac4e-b26d69ffde63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ba308b38-c9b3-4e8b-80d5-faddc36fe472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:to="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1a4cba7-41c5-4f80-b933-5c799e755c36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:to="loc_us-gaap_EquityComponentDomain_a1a4cba7-41c5-4f80-b933-5c799e755c36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:to="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e278c5dc-55a0-43b4-83cf-35a006698345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_CommonStockMember_e278c5dc-55a0-43b4-83cf-35a006698345" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c2c9cf55-89ca-451d-a66d-e2a0802b4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c2c9cf55-89ca-451d-a66d-e2a0802b4dea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61f1f6b9-3c3d-43a2-b3aa-f4a93c5c9d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61f1f6b9-3c3d-43a2-b3aa-f4a93c5c9d4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a2bb837b-e752-4441-b1c8-0fb448d23da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_RetainedEarningsMember_a2bb837b-e752-4441-b1c8-0fb448d23da3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8d859bdc-0275-454c-8078-51f2833632a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:to="loc_us-gaap_WarrantMember_8d859bdc-0275-454c-8078-51f2833632a9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" id="i8fb05715b4a94e60a1445dcb1464f5f3_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6e5b10c4-c7d0-46d5-8406-2b6b98c2cdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6e5b10c4-c7d0-46d5-8406-2b6b98c2cdc5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df448c3-bec9-490d-b39d-32e9d6b97719_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_7df448c3-bec9-490d-b39d-32e9d6b97719_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_50cc857f-0def-4c05-add7-c74d1e6168c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_EquipmentMember_50cc857f-0def-4c05-add7-c74d1e6168c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c9fed4d4-055f-49a9-b5cb-162314fc8da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c9fed4d4-055f-49a9-b5cb-162314fc8da4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9f332594-3c56-471b-b471-e665c486b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9f332594-3c56-471b-b471-e665c486b6bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails" xlink:type="extended" id="ib09d8eaa94074a788863aae3b58414cd_SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10a1c5d9-5bc8-48a3-93ae-3dd1936e61ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10a1c5d9-5bc8-48a3-93ae-3dd1936e61ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dce20f92-e499-42d5-86be-24a8bcb7e417_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_dce20f92-e499-42d5-86be-24a8bcb7e417_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_970a46f5-211f-4f24-a3b0-99f831b59207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_970a46f5-211f-4f24-a3b0-99f831b59207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eef87b01-f95e-4027-a56d-848b66ac0b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_RestrictedStockMember_eef87b01-f95e-4027-a56d-848b66ac0b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ae121854-77cb-4223-a10c-f65227c4c136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_WarrantMember_ae121854-77cb-4223-a10c-f65227c4c136" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#InvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="extended" id="i513809cd056e465dacfac3045f98d52e_InvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d808240-6097-41d6-b59a-536fa3457136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d808240-6097-41d6-b59a-536fa3457136" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6eb1391c-9873-42e7-b522-6d0bc568533f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6eb1391c-9873-42e7-b522-6d0bc568533f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6506e890-8b81-48d4-91da-0c435bf5ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6506e890-8b81-48d4-91da-0c435bf5ef6b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_016864c5-c767-452f-a222-ffd4d63a2c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_016864c5-c767-452f-a222-ffd4d63a2c96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_69d24e48-5a84-41dd-9933-495aa29c21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:to="loc_us-gaap_LongTermInvestments_69d24e48-5a84-41dd-9933-495aa29c21e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13166fd0-54c8-4c0c-8c22-88546437e992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_13166fd0-54c8-4c0c-8c22-88546437e992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d1bc3232-674f-46a9-a4d4-e38c93133687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d1bc3232-674f-46a9-a4d4-e38c93133687" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended" id="i5734ce1dd4d144db8b953a8245acead8_FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64ab1efe-647a-4e2b-86f0-a907e670b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64ab1efe-647a-4e2b-86f0-a907e670b09a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f81c15b-1820-476d-8a70-d5765ef95674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f81c15b-1820-476d-8a70-d5765ef95674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7a683a2-d301-4158-b0a4-069eef73cd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7a683a2-d301-4158-b0a4-069eef73cd3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0f4e937-77bb-4938-9863-c709d74bc686_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c0f4e937-77bb-4938-9863-c709d74bc686_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac1a2c26-ca26-4159-98df-28de6b01be85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac1a2c26-ca26-4159-98df-28de6b01be85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4be78393-1fce-47da-a250-a47b073a0c14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4be78393-1fce-47da-a250-a47b073a0c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_11beefe3-eb6a-470d-971b-a8ce66263766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_11beefe3-eb6a-470d-971b-a8ce66263766" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f7815708-f2dd-4d09-a664-be6e74b0ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f7815708-f2dd-4d09-a664-be6e74b0ff46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7c8a2c04-acc9-4c38-8fc7-f01aad5dd99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7c8a2c04-acc9-4c38-8fc7-f01aad5dd99c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a384b7af-c073-4812-9de8-643791d6ace0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a384b7af-c073-4812-9de8-643791d6ace0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5921b941-42a1-41c6-a1b0-625c191cc357_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5921b941-42a1-41c6-a1b0-625c191cc357_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6596f66a-9ec5-40f9-87cf-4d7445ce0580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6596f66a-9ec5-40f9-87cf-4d7445ce0580" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="extended" id="ia99819530cc24b57b5efe0360d242e98_PropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_346fcb5d-442c-4ef0-aa45-96bd393deee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_346fcb5d-442c-4ef0-aa45-96bd393deee8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6eab7366-4996-47e6-abbc-1dc6572efae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6eab7366-4996-47e6-abbc-1dc6572efae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eb176b5c-dacd-45ed-9785-4912eef77e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eb176b5c-dacd-45ed-9785-4912eef77e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f46c623-e222-4e36-aba6-5ec7e00727c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f46c623-e222-4e36-aba6-5ec7e00727c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31df40ea-33dd-4252-9d7a-01214aa6f8c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_31df40ea-33dd-4252-9d7a-01214aa6f8c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b9c65230-6b3a-4029-a6e5-7da6b7302c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_EquipmentMember_b9c65230-6b3a-4029-a6e5-7da6b7302c3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c5b14507-cfe7-4f92-b1ff-4801e2efe32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c5b14507-cfe7-4f92-b1ff-4801e2efe32d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_018cd205-6ecb-46c5-979b-48281cf5b316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_018cd205-6ecb-46c5-979b-48281cf5b316" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_6e7a798d-aae5-4721-8cec-3b79db84df32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_6e7a798d-aae5-4721-8cec-3b79db84df32" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i7b8e1288444549feabc329e696b836af_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_b9f7dede-644a-485c-8381-ed23d7f95a47" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_b9f7dede-644a-485c-8381-ed23d7f95a47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_a629b5c8-d042-49f7-bb07-a36c9d1b17af" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_a629b5c8-d042-49f7-bb07-a36c9d1b17af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTerm_85d3bac3-f5e7-404c-8915-a7e31e80ffce" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementTerm_85d3bac3-f5e7-404c-8915-a7e31e80ffce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_33a59598-fbef-4963-89f1-d118e340b292" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTermOfOptionForLicenseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_33a59598-fbef-4963-89f1-d118e340b292" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_3ee01cfd-81e3-451d-9ac7-513fdd0b6d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_3ee01cfd-81e3-451d-9ac7-513fdd0b6d77" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_14c5c23f-b221-466e-b09a-a17f27b9bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuarantyLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_us-gaap_GuarantyLiabilities_14c5c23f-b221-466e-b09a-a17f27b9bc49" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a790734e-7514-41f2-9fe0-371345343f58_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a790734e-7514-41f2-9fe0-371345343f58_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_45c3c53d-ea95-4b18-a144-49a0ee96279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_45c3c53d-ea95-4b18-a144-49a0ee96279e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails" xlink:type="extended" id="i48e7b7bd45ca47658e32c6135cd8fbcc_CapitalStockandWarrantsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e4fd7b80-67ec-4486-854e-39fe22c55c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e4fd7b80-67ec-4486-854e-39fe22c55c6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c845627d-ad41-4a0e-abc1-83e0b1f2f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c845627d-ad41-4a0e-abc1-83e0b1f2f690" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction_6447779e-8e90-4957-99e3-ab23a93c9437" xlink:href="yten-20221231.xsd#yten_SaleofStockGrossConsiderationReceivedPerTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction_6447779e-8e90-4957-99e3-ab23a93c9437" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b43690a8-6c36-4376-9cdd-8186aa7d9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b43690a8-6c36-4376-9cdd-8186aa7d9c23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d54065a4-e9de-44e3-a613-4f1f78f89f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d54065a4-e9de-44e3-a613-4f1f78f89f86" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f8ad0ca1-3197-40a9-9dd6-7b0b2c468d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f8ad0ca1-3197-40a9-9dd6-7b0b2c468d90" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExpired_4d626c13-f9ae-45e6-9bed-7c3a1b160af0" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExpired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_ClassOfWarrantOrRightExpired_4d626c13-f9ae-45e6-9bed-7c3a1b160af0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExercised_3b10cff8-2f1d-410f-a876-918ee2b41583" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_ClassOfWarrantOrRightExercised_3b10cff8-2f1d-410f-a876-918ee2b41583" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_791da106-541b-4e63-acd4-80fed15f8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_791da106-541b-4e63-acd4-80fed15f8cb0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PublicOfferingMember_25aa0140-2143-4abe-ad39-623d1ab4372f" xlink:href="yten-20221231.xsd#yten_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:to="loc_yten_PublicOfferingMember_25aa0140-2143-4abe-ad39-623d1ab4372f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6248b696-e741-497d-b563-cc1b6ce84795_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6248b696-e741-497d-b563-cc1b6ce84795_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedNovember2019Member_dc1c3121-c065-4323-aafb-c1f0d59866b4" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedNovember2019Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:to="loc_yten_SeriesAWarrantsIssuedNovember2019Member_dc1c3121-c065-4323-aafb-c1f0d59866b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedDecember2017Member_4d7be36d-f5da-49cf-a470-3e19f0492848" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedDecember2017Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:to="loc_yten_SeriesAWarrantsIssuedDecember2017Member_4d7be36d-f5da-49cf-a470-3e19f0492848" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails" xlink:type="extended" id="iffffb9b4e893476b8e4694152edf9108_CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7a0c48a9-6895-4428-b7c6-e01f34ca33d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7a0c48a9-6895-4428-b7c6-e01f34ca33d0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28c245f8-c0eb-4122-b980-b475c09a050e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28c245f8-c0eb-4122-b980-b475c09a050e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8029f57-3f85-4a76-b227-fed4985530a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a8029f57-3f85-4a76-b227-fed4985530a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PublicOfferingMember_8e3fd39c-6a85-4c08-b9cb-10f5cb119156" xlink:href="yten-20221231.xsd#yten_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:to="loc_yten_PublicOfferingMember_8e3fd39c-6a85-4c08-b9cb-10f5cb119156" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3025a314-c74e-4248-9959-70745723449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:to="loc_us-gaap_PrivatePlacementMember_3025a314-c74e-4248-9959-70745723449d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesBWarrantExpiringMay2027Member_20b22d10-16bf-424f-b1b1-0a5af1a6c443" xlink:href="yten-20221231.xsd#yten_SeriesBWarrantExpiringMay2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_SeriesBWarrantExpiringMay2027Member_20b22d10-16bf-424f-b1b1-0a5af1a6c443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringJanuary2024Member_b386c21d-c88b-4777-93ef-ed9fbf7ba172" xlink:href="yten-20221231.xsd#yten_WarrantExpiringJanuary2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_WarrantExpiringJanuary2024Member_b386c21d-c88b-4777-93ef-ed9fbf7ba172" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringSeptember2024Member_5d0dc8b7-46aa-493f-94c8-6d0ebb0324f1" xlink:href="yten-20221231.xsd#yten_WarrantExpiringSeptember2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_WarrantExpiringSeptember2024Member_5d0dc8b7-46aa-493f-94c8-6d0ebb0324f1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails" xlink:type="extended" id="i1d58b0e1594c4fcd9d3e09ffb1c4185b_CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d147ad1-4f06-498b-a85e-cbecd0443537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d147ad1-4f06-498b-a85e-cbecd0443537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_a9e0d707-4278-45e4-86ca-5d25be467efa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_a9e0d707-4278-45e4-86ca-5d25be467efa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_86065f1b-9f0e-495f-ac6e-c1c0e69fa65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:to="loc_us-gaap_WarrantMember_86065f1b-9f0e-495f-ac6e-c1c0e69fa65c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:to="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c72877c6-2395-4552-854c-2a136a8f778f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c72877c6-2395-4552-854c-2a136a8f778f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e617ca32-4584-43a5-9548-7cc981ecc8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e617ca32-4584-43a5-9548-7cc981ecc8be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e2e115b-8188-4e5b-9439-dc1111fa0157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e2e115b-8188-4e5b-9439-dc1111fa0157" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="idcd68155e9bb482bbba29a965371fce9_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_9f4aea97-4964-4e66-a6b3-203b5c8367b6" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_9f4aea97-4964-4e66-a6b3-203b5c8367b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a69b5fd-29b8-4dd3-a394-819e18b29fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a69b5fd-29b8-4dd3-a394-819e18b29fec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d996a383-5682-43c7-ae77-fb16868312df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d996a383-5682-43c7-ae77-fb16868312df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_70ed507a-c342-43f1-b18d-36e571cf249a" xlink:href="yten-20221231.xsd#yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_70ed507a-c342-43f1-b18d-36e571cf249a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c4460686-e55e-4b42-b015-dc0cc1201423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c4460686-e55e-4b42-b015-dc0cc1201423" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_6c14d0f7-3707-4037-bb25-b88c65765f31" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_6c14d0f7-3707-4037-bb25-b88c65765f31" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_ab5b50d5-30d3-4daf-ad90-bfd3992fd85a" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_ab5b50d5-30d3-4daf-ad90-bfd3992fd85a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bbc2be79-4f08-4b2b-b42b-513155d863a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensation_bbc2be79-4f08-4b2b-b42b-513155d863a0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bbb0e6a0-9ca7-4b05-a7ce-97f2c43641d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bbb0e6a0-9ca7-4b05-a7ce-97f2c43641d4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6131631-c92b-44e8-bf45-156b79c30c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6131631-c92b-44e8-bf45-156b79c30c8e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_83746279-50eb-417b-a83c-79263d547700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_83746279-50eb-417b-a83c-79263d547700" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_7d4599e4-ea6f-4cef-a41a-f2f9ee5a9f41" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_7d4599e4-ea6f-4cef-a41a-f2f9ee5a9f41" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd6dd820-28e6-4137-a321-45f3ca51e672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd6dd820-28e6-4137-a321-45f3ca51e672" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d61d7e49-3457-4692-b5ad-c510afe00464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d61d7e49-3457-4692-b5ad-c510afe00464" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_116ce2cb-e53a-4362-8c15-edb67be665f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_116ce2cb-e53a-4362-8c15-edb67be665f3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8eabf7dc-4f91-4898-9a23-58dc903ee25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8eabf7dc-4f91-4898-9a23-58dc903ee25c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d640d3-75da-4617-9262-e4cdeba719df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_75d640d3-75da-4617-9262-e4cdeba719df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44dd9d39-947a-46c8-9503-1575aef79858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44dd9d39-947a-46c8-9503-1575aef79858" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8d1c2b80-7637-4ada-a50b-a1bdef151269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_RestrictedStockMember_8d1c2b80-7637-4ada-a50b-a1bdef151269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e640283c-cc70-4ccf-9bff-90e73f4e140d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e640283c-cc70-4ccf-9bff-90e73f4e140d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e351033e-8c64-4e28-bd04-858e04814d8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:to="loc_us-gaap_PlanNameDomain_e351033e-8c64-4e28-bd04-858e04814d8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:to="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2006Member_1e49df5e-3715-4412-8b38-ee078cfa465d" xlink:href="yten-20221231.xsd#yten_StockPlan2006Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2006Member_1e49df5e-3715-4412-8b38-ee078cfa465d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2014Member_5ef55aab-e8d0-4c4e-8252-104d5c198a94" xlink:href="yten-20221231.xsd#yten_StockPlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2014Member_5ef55aab-e8d0-4c4e-8252-104d5c198a94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2018Member_23679b94-8f73-472a-aec5-79996cc613f9" xlink:href="yten-20221231.xsd#yten_StockPlan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2018Member_23679b94-8f73-472a-aec5-79996cc613f9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ed7cd6bf-857c-4b5c-a0b6-42b73346106e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:to="loc_srt_RangeMember_ed7cd6bf-857c-4b5c-a0b6-42b73346106e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:to="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8af1c19b-b601-4f26-9e28-f5011cad9f8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:to="loc_srt_MinimumMember_8af1c19b-b601-4f26-9e28-f5011cad9f8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e76e29d-7015-4719-8271-1615646bf06a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:to="loc_srt_MaximumMember_6e76e29d-7015-4719-8271-1615646bf06a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c9ddd429-edbd-4e68-8362-acca9b2f764d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_c9ddd429-edbd-4e68-8362-acca9b2f764d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EmployeeAndDirectorMember_0bb7f429-70ca-47c0-931a-dfb9ef9addaa" xlink:href="yten-20221231.xsd#yten_EmployeeAndDirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:to="loc_yten_EmployeeAndDirectorMember_0bb7f429-70ca-47c0-931a-dfb9ef9addaa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" id="i08c63479e49b4c0588b0baa2ffcf7a11_StockBasedCompensationStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9254631-33f5-47ad-9f8a-f442e96ffa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9254631-33f5-47ad-9f8a-f442e96ffa6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d02973c-9d88-4f61-9a05-f2ce0173aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d02973c-9d88-4f61-9a05-f2ce0173aff6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c2161f3-4346-4698-929c-56cac66b7d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c2161f3-4346-4698-929c-56cac66b7d74" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_92ed46d4-2418-47fd-9de9-548727eef7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_92ed46d4-2418-47fd-9de9-548727eef7a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_616ca067-0aad-4c91-b63f-627555c5c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_616ca067-0aad-4c91-b63f-627555c5c0da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_090384d5-5a04-4674-84c6-77564f67b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60b71988-ce91-41ed-94f1-b486b8958178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60b71988-ce91-41ed-94f1-b486b8958178" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f013377f-1e82-479f-bcb3-fac71d90058c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f013377f-1e82-479f-bcb3-fac71d90058c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_886181e0-dcec-4970-a6a7-4ce01b4cc578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_886181e0-dcec-4970-a6a7-4ce01b4cc578" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f01e6fc-a43b-47b1-b9e3-44d5908bc97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f01e6fc-a43b-47b1-b9e3-44d5908bc97b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4838958e-d304-427b-a9ff-4b79ef1212ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4838958e-d304-427b-a9ff-4b79ef1212ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_efc4fec3-ed58-4ed0-b687-0d0a454e3e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_efc4fec3-ed58-4ed0-b687-0d0a454e3e89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a0239581-7d70-47c9-a2fd-1320e689af29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a0239581-7d70-47c9-a2fd-1320e689af29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5421b96-25c2-4623-a12b-2016e8e40a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f84b647-4c2b-46c2-b975-d0d0d1556eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f84b647-4c2b-46c2-b975-d0d0d1556eeb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2175660b-5f87-40bf-a671-0821d800cea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2175660b-5f87-40bf-a671-0821d800cea5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcab4ee6-19dd-4758-91c3-38e5de2ff8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcab4ee6-19dd-4758-91c3-38e5de2ff8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4025c112-bae4-4f3c-88a2-06a2ae63f33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4025c112-bae4-4f3c-88a2-06a2ae63f33e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02acd77e-caca-4d65-9b75-26bdb47520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02acd77e-caca-4d65-9b75-26bdb47520e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_414ce377-2976-4b20-b66d-835a73aa2781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_414ce377-2976-4b20-b66d-835a73aa2781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_82164aa2-22a0-4c74-b9a5-5b997745a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_82164aa2-22a0-4c74-b9a5-5b997745a7ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ce2cf96-7260-4cff-876d-118da323da46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ce2cf96-7260-4cff-876d-118da323da46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:to="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92174a5a-46ff-4e7c-9e28-025637e98b48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_92174a5a-46ff-4e7c-9e28-025637e98b48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35ac1482-9cd9-4813-b762-6fdd1e221f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35ac1482-9cd9-4813-b762-6fdd1e221f43" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails" xlink:type="extended" id="i98295e7be52642e7b9a5e8de9dda38c2_StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e89a3d6-1df3-4b36-9a2c-1e9575b2b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e89a3d6-1df3-4b36-9a2c-1e9575b2b181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b6ff783b-cd93-497e-8934-3d5d2e4c20a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b6ff783b-cd93-497e-8934-3d5d2e4c20a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9c30c16a-d52a-46e4-bd22-77abe4888b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9c30c16a-d52a-46e4-bd22-77abe4888b66" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_feb7f75c-3d73-4889-92fa-deecc2e2ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_feb7f75c-3d73-4889-92fa-deecc2e2ad3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_cf0174b7-1ee8-43bb-9a45-d3e1c5ddaf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_cf0174b7-1ee8-43bb-9a45-d3e1c5ddaf3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f80cb12a-290c-4090-805b-e8a108e019ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f80cb12a-290c-4090-805b-e8a108e019ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:to="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2922bc2c-55ec-454f-86d1-97e030b888c2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:to="loc_srt_RangeMember_2922bc2c-55ec-454f-86d1-97e030b888c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:to="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc2903c3-fa09-4277-95b8-34f320530380" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:to="loc_srt_MinimumMember_bc2903c3-fa09-4277-95b8-34f320530380" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_68bf36a6-f856-4b4a-800d-08a100fc9647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:to="loc_srt_MaximumMember_68bf36a6-f856-4b4a-800d-08a100fc9647" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:to="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7f4e47d-3a70-4d94-b212-04f6fec60934_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e7f4e47d-3a70-4d94-b212-04f6fec60934_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_865d8c85-4744-446d-afe7-e09a41b454cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_865d8c85-4744-446d-afe7-e09a41b454cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ieb44739456254d2a89713dad50d51983_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingLeaseLeaseArea_db47af33-98af-4792-98ec-b6a89767ab30" xlink:href="yten-20221231.xsd#yten_LesseeOperatingLeaseLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_yten_LesseeOperatingLeaseLeaseArea_db47af33-98af-4792-98ec-b6a89767ab30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0570f6c3-35db-48c8-9e8f-992362140a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0570f6c3-35db-48c8-9e8f-992362140a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingSubleaseSubleasedArea_02e4f903-936f-4349-a08d-314d077fbd1a" xlink:href="yten-20221231.xsd#yten_LesseeOperatingSubleaseSubleasedArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_yten_LesseeOperatingSubleaseSubleasedArea_02e4f903-936f-4349-a08d-314d077fbd1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab830947-94ff-44a5-8829-c9c5102c9551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab830947-94ff-44a5-8829-c9c5102c9551" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:to="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:to="loc_dei_EntityDomain_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:to="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CJCheilJedangCorporationMember_572b81a5-0ee5-450c-bd8b-6543c1cfd967" xlink:href="yten-20221231.xsd#yten_CJCheilJedangCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:to="loc_yten_CJCheilJedangCorporationMember_572b81a5-0ee5-450c-bd8b-6543c1cfd967" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a829282a-a55a-4ca1-b4cb-6d7c49758bee_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_a829282a-a55a-4ca1-b4cb-6d7c49758bee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PresidentialWayWoburnMassachusettsMember_feae7b9e-dac5-4f24-9940-551621f5544c" xlink:href="yten-20221231.xsd#yten_PresidentialWayWoburnMassachusettsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:to="loc_yten_PresidentialWayWoburnMassachusettsMember_feae7b9e-dac5-4f24-9940-551621f5544c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_a020b940-cc50-415a-8592-29cdd428e71e" xlink:href="yten-20221231.xsd#yten_A410DowneyRoadAnd110GymnasiumPlaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:to="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_a020b940-cc50-415a-8592-29cdd428e71e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxesDetailsTextualDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails" xlink:type="extended" id="i2e180ea7f7bc4c89bd6ef3b6ec3cc9e8_IncomeTaxesDetailsTextualDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c4c0500d-7ff9-411e-9e06-8d71af9ea9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c4c0500d-7ff9-411e-9e06-8d71af9ea9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4a0c8ee2-92cc-485a-889d-fc4b443ecbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4a0c8ee2-92cc-485a-889d-fc4b443ecbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96825fe4-62e5-4904-9c29-8ea992773767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96825fe4-62e5-4904-9c29-8ea992773767" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_5a098285-2e6c-4571-8aa6-a6439442b51d" xlink:href="yten-20221231.xsd#yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_5a098285-2e6c-4571-8aa6-a6439442b51d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_92c58088-410c-4da7-8b25-b060f6aaa73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_92c58088-410c-4da7-8b25-b060f6aaa73b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6558a462-fd6f-4639-adb6-7bca8614586c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6558a462-fd6f-4639-adb6-7bca8614586c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_896af26c-7717-4412-9106-689428452791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:to="loc_us-gaap_ResearchMember_896af26c-7717-4412-9106-689428452791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_75ca7a18-4fda-4915-bea8-45a1b90220e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_75ca7a18-4fda-4915-bea8-45a1b90220e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_d207cb27-ad14-4725-b151-53dbca297450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_d207cb27-ad14-4725-b151-53dbca297450" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_422e0993-72f8-42be-9dfd-aab5915b1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_422e0993-72f8-42be-9dfd-aab5915b1bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e4c5b6c9-b7fa-4f4a-8bbb-9d5524eb616d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_ForeignCountryMember_e4c5b6c9-b7fa-4f4a-8bbb-9d5524eb616d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GovernmentResearchGrantsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#GovernmentResearchGrantsDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/GovernmentResearchGrantsDetails" xlink:type="extended" id="ib2fdddb0060c4385b4e25d3073ba864b_GovernmentResearchGrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ResearchGrantMaximumPayrollCostReimbursement_829e54f3-0160-4860-809c-c3f204a4369e" xlink:href="yten-20221231.xsd#yten_ResearchGrantMaximumPayrollCostReimbursement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_ResearchGrantMaximumPayrollCostReimbursement_829e54f3-0160-4860-809c-c3f204a4369e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantTerm_d8789810-3d0b-4f8d-a173-4f96f6880cf9" xlink:href="yten-20221231.xsd#yten_GovernmentGrantTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_GovernmentGrantTerm_d8789810-3d0b-4f8d-a173-4f96f6880cf9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantCumulativeAmountAwarded_ec4266e6-a213-41f7-a3c1-b113a6c7f5de" xlink:href="yten-20221231.xsd#yten_GovernmentGrantCumulativeAmountAwarded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_GovernmentGrantCumulativeAmountAwarded_ec4266e6-a213-41f7-a3c1-b113a6c7f5de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d3463c-53cb-4a82-b6d7-1f1729ac3b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d3463c-53cb-4a82-b6d7-1f1729ac3b59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fa75ea4f-f8c0-4ffa-8dfb-610462095034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fa75ea4f-f8c0-4ffa-8dfb-610462095034" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:to="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_462166a3-005e-421a-a299-d78f56d10005_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:to="loc_srt_ProductsAndServicesDomain_462166a3-005e-421a-a299-d78f56d10005_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:to="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a8985dc0-dc5f-4113-95af-80ab85def2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:to="loc_us-gaap_GrantMember_a8985dc0-dc5f-4113-95af-80ab85def2bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_dc8431d9-adfe-4ee0-900e-1c168ab3b41f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:to="loc_us-gaap_ProjectMember_dc8431d9-adfe-4ee0-900e-1c168ab3b41f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:to="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_3185e3e4-de38-44ca-ae13-f0ffca2e387c" xlink:href="yten-20221231.xsd#yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:to="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_3185e3e4-de38-44ca-ae13-f0ffca2e387c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#GeographicInformationDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/GeographicInformationDetails" xlink:type="extended" id="ifcbfd2e4bc424851837c96d86f47e078_GeographicInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38b0827d-c286-40d6-b6b8-77698ea6b805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38b0827d-c286-40d6-b6b8-77698ea6b805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1f3f5296-76af-498c-b485-dc9db472a231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1f3f5296-76af-498c-b485-dc9db472a231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:to="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_67cca926-2c5c-44d2-8028-2fd74f2b474d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:to="loc_srt_ConsolidationItemsDomain_67cca926-2c5c-44d2-8028-2fd74f2b474d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:to="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_b275d0bc-e788-4133-8925-c81ef347a34b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:to="loc_srt_ReportableGeographicalComponentsMember_b275d0bc-e788-4133-8925-c81ef347a34b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:to="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4c051412-905d-472b-8463-8a1e68180516_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:to="loc_srt_SegmentGeographicalDomain_4c051412-905d-472b-8463-8a1e68180516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:to="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_21b3e2c5-4429-42d2-8c48-b381c597307b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:to="loc_country_US_21b3e2c5-4429-42d2-8c48-b381c597307b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_df9f8a7e-47c9-4171-98bd-c9fc8408c7e3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:to="loc_country_CA_df9f8a7e-47c9-4171-98bd-c9fc8408c7e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/RelatedPartyTransactionDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#RelatedPartyTransactionDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/RelatedPartyTransactionDetails" xlink:type="extended" id="ife84527f2bb4481d89f5909832948f45_RelatedPartyTransactionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ac521ce6-dfc9-4213-bbb9-ceafac3cc97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ac521ce6-dfc9-4213-bbb9-ceafac3cc97f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LicensePaymentsReceivable_4d9589f8-952a-4462-8754-66710059d31d" xlink:href="yten-20221231.xsd#yten_LicensePaymentsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_yten_LicensePaymentsReceivable_4d9589f8-952a-4462-8754-66710059d31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment_5ad3641e-b009-4057-ac93-543a4e1178bc" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_yten_GainOnRelatedPartyInvestment_5ad3641e-b009-4057-ac93-543a4e1178bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c041e16c-bd47-46d3-be05-b9c6f85b1954_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:to="loc_us-gaap_RelatedPartyDomain_c041e16c-bd47-46d3-be05-b9c6f85b1954_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:to="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b153ecab-5ecb-4e94-9b32-409a0048ecdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:to="loc_srt_AffiliatedEntityMember_b153ecab-5ecb-4e94-9b32-409a0048ecdf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SubsequentEventDetails"/>
  <link:definitionLink xlink:role="http://www.yield10bio.com/role/SubsequentEventDetails" xlink:type="extended" id="i22c84f2824664056aa6b484286ffbf6c_SubsequentEventDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75cfe794-eb5f-4812-b027-03aef456f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75cfe794-eb5f-4812-b027-03aef456f4e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockMaximumAggregateOfferingPrice_618982e2-1fe1-4124-8e11-5370f1fdbdee" xlink:href="yten-20221231.xsd#yten_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_yten_SaleOfStockMaximumAggregateOfferingPrice_618982e2-1fe1-4124-8e11-5370f1fdbdee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockCommissionRate_685dcbff-e85f-4120-854e-6af270a4a199" xlink:href="yten-20221231.xsd#yten_SaleOfStockCommissionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_yten_SaleOfStockCommissionRate_685dcbff-e85f-4120-854e-6af270a4a199" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84922823-55ff-4a0f-8856-3b6ed9020ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84922823-55ff-4a0f-8856-3b6ed9020ff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3e302de2-6b6f-4c80-bbea-f724b0c21c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3e302de2-6b6f-4c80-bbea-f724b0c21c08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7c6a0bc4-9c9e-4463-82e6-61923ded4204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7c6a0bc4-9c9e-4463-82e6-61923ded4204" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_10cd4d6d-04be-4631-8f65-746be2f6dda8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_10cd4d6d-04be-4631-8f65-746be2f6dda8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_61b7857f-4313-4e9d-bd64-ea0af492183c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:to="loc_us-gaap_SubsequentEventMember_61b7857f-4313-4e9d-bd64-ea0af492183c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:to="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_526cd981-b98d-4ecf-840b-dc5d41853a49_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:to="loc_srt_RangeMember_526cd981-b98d-4ecf-840b-dc5d41853a49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:to="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8861a1d-b93d-437c-b737-27ac47956b3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:to="loc_srt_MinimumMember_b8861a1d-b93d-437c-b737-27ac47956b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_650b65f3-2b1a-4c6b-b013-b5ba1a51ee38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:to="loc_srt_MaximumMember_650b65f3-2b1a-4c6b-b013-b5ba1a51ee38" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>yten-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_yten_SeriesAWarrantsIssuedDecember2017Member_c5afe04a-020f-4e2a-a8ab-875a449e138e_terseLabel_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued December 2017</link:label>
    <link:label id="lab_yten_SeriesAWarrantsIssuedDecember2017Member_label_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued December 2017 [Member]</link:label>
    <link:label id="lab_yten_SeriesAWarrantsIssuedDecember2017Member_documentation_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued December 2017</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedDecember2017Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:to="lab_yten_SeriesAWarrantsIssuedDecember2017Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d4f15ce2-389f-4aca-8ec2-bf96b117ed01_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in stockholders' equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f17db303-edc5-4098-a5fd-c01ccda4bc2f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_bdba2375-4ea9-4cad-9844-85dd94c318b8_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9f6d5326-5c67-4d0a-86d6-38fdf5db523e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted future lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ClassOfWarrantOrRightExercised_436906be-e2d1-4321-9cfa-7f99476dc52f_terseLabel_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_yten_ClassOfWarrantOrRightExercised_label_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:label id="lab_yten_ClassOfWarrantOrRightExercised_documentation_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExercised" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ClassOfWarrantOrRightExercised" xlink:to="lab_yten_ClassOfWarrantOrRightExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a3d872a4-5f1b-4725-8ee3-0f19752ddf1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_444667fd-707d-4db4-a591-86264c1c6ec8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_e1fb0402-ed86-4d8d-aaf5-c6e30b0ff78e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_LesseeOperatingSubleaseSubleasedArea_beabebb0-a38b-4054-a29c-707db7e7dcfd_terseLabel_en-US" xlink:label="lab_yten_LesseeOperatingSubleaseSubleasedArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subleased area (in sqft)</link:label>
    <link:label id="lab_yten_LesseeOperatingSubleaseSubleasedArea_label_en-US" xlink:label="lab_yten_LesseeOperatingSubleaseSubleasedArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Subleased Area</link:label>
    <link:label id="lab_yten_LesseeOperatingSubleaseSubleasedArea_documentation_en-US" xlink:label="lab_yten_LesseeOperatingSubleaseSubleasedArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Sublease, Subleased Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingSubleaseSubleasedArea" xlink:href="yten-20221231.xsd#yten_LesseeOperatingSubleaseSubleasedArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_LesseeOperatingSubleaseSubleasedArea" xlink:to="lab_yten_LesseeOperatingSubleaseSubleasedArea" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_6838cc57-aeaa-440b-bfa7-b669de817e0d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_a89d23c0-e11a-484d-adfa-5f81fc0debfe_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d7b9a4f7-a2bc-4c09-acee-e989ef6a98cb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_04de2623-9f94-444e-a692-ea3180829a81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_13fca912-4498-42c3-b873-6df1a7369db4_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_74c3ac37-f271-4e96-949d-d0355148c7e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_5042d115-63d2-49c1-a8a3-b8555fe577a7_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_23b8d0c1-7f61-491e-8f36-8294fdd5746b_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27c7c0ca-138f-4652-9e11-eefaee0b380c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9563a43d-dd7d-4e38-95dc-5950ee374aec_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_5fbd4a5d-40bf-440c-b722-7d771f97060a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_1b34dd44-0580-4d57-87d2-59cd02b60b9c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d256d4ca-3706-4a7c-88fe-5491f40bd177_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_386d2759-c1a8-457c-a01e-80c38b7003f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the geographic distribution of revenues and long-lived assets from continuing operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59e7224e-d9b2-4c4f-9314-274e38c901e3_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_a29f9fa5-e142-4bbc-a6a6-d098534c9d86_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for warrant exercises</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_26f058d5-f3a2-42a6-bb39-259a8a093edd_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_088bafa2-2591-4c51-960b-c205206bff11_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5c1e1d44-c2cd-48a4-adee-dfb1b5d726fb_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3fa330b8-d7b8-4a91-8d06-de5480e77fbb_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_56f70323-a1b8-40fa-88be-387d647133ed_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ClassOfWarrantOrRightExpired_48e1428e-bb82-4cf8-94dd-5e4020f7a141_terseLabel_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired (in shares)</link:label>
    <link:label id="lab_yten_ClassOfWarrantOrRightExpired_label_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expired</link:label>
    <link:label id="lab_yten_ClassOfWarrantOrRightExpired_documentation_en-US" xlink:label="lab_yten_ClassOfWarrantOrRightExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExpired" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ClassOfWarrantOrRightExpired" xlink:to="lab_yten_ClassOfWarrantOrRightExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_20097591-688d-4072-bb84-3abad1f813a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a6936942-9c60-411f-a14b-d52d9ddead63_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive common stock excluded from the calculation of dilutive shares</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8e9c216b-b941-4465-86dd-f0c959c86a96_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_295b2092-602a-4db6-8d84-fc6cc7637f37_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b8e7faa3-84ab-47f0-8303-6a448e33949a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_590c07d3-08fc-40ad-9f4f-d0efcfc278a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b6648b64-fc06-4394-b789-abf458111c8f_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_fe5095e3-9cd8-470d-8103-b808ed72a79c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8233ee03-0619-4c7f-8d65-912c96aad1e0_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_330a9aba-20da-418e-9784-b2c00bd9f7ba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_91892b49-214a-4df4-b598-c4ecea0bc358_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_161b5419-d4da-45d2-88fa-5436261e833e_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0a64e05c-bc0e-4f3d-8dda-f5375afd0d0c_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b86172d2-656c-4386-a4ea-b2411c0b1ea7_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_2878025e-84ff-4609-beda-0d423d2bb64b_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b330a89d-8a68-4db7-bbd0-1c900631f186_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_64fffffc-2ad8-438f-be3a-4e796ae52a65_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_b9b748ea-058f-49d9-b34d-df89e5969f00_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_7ea05289-0856-4ccc-ae81-7cc1ab8a502a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Benefit:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_2cdca704-3a59-464a-86fc-b42ab60225cf_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d56f4031-6353-469a-9a98-cd85c4ddcf6d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4d34177f-50d9-4834-a53b-d7e5588e22cd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_7a33a108-e5f5-4c51-a3b4-355fa9df87eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted prices in active markets&#160;for identical assets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b56cef4a-8d59-4a0b-85a7-cfe962061749_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_62068da1-2230-4f88-8e8c-b6a46133971a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term for options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_ce532239-20e8-413f-a9f9-76631318ca95_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_aba3d262-6bac-479a-9bf9-9d81d429198b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_02ec9771-90fe-421b-a9e0-e440fc8cb91e_negatedTerseLabel_en-US" xlink:label="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact of ownership change</link:label>
    <link:label id="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_label_en-US" xlink:label="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Ownership Change, Percent</link:label>
    <link:label id="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_documentation_en-US" xlink:label="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Ownership Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:href="yten-20221231.xsd#yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:to="lab_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_477c4389-7228-45e8-b7e2-2c7bfb8a2970_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_54d7c10b-2a41-4d8d-88be-e7a0ec99c54c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_899c71c6-e541-4e5e-92e9-bd1560de64f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_66794d96-a025-4117-afe9-eb499836522c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_cc4078e2-0d73-4c72-98be-0fdb5096a795_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_2cc64448-b1d6-4cad-8a54-5cb7f08f0e26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1a322693-038f-4f3b-91ba-133a5a304ba5_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investment holdings</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_42a728e3-c9b4-4b61-b183-f08e3f325f9a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b864eb0d-de5b-479e-a6e4-9d6dd9518931_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_abe6cf30-62b1-4ac8-89e1-696225f31532_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent differences</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_37a1a8b9-a1da-4027-8980-dec9794319d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_04922f1f-915e-476d-bfa3-d4078bbdf059_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b467b368-5927-41e6-accc-b41855288498_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contribution by participants under the 401(k) savings plan (as a percent)</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_02bfa3f5-a3ca-4824-bb2c-9a6fbf17463d_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_79292db5-d264-47ef-a7cf-1d655ae0c586_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_d47dbfd9-1911-4e72-9f4c-ddc80c00441c_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_e07265bc-5b0b-4665-b820-d3ac2c070796_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_700cf33e-34bf-4e7f-9e11-4f9199264e95_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_65ecfe86-98b0-4b53-b92b-cadecf38d566_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6fa4e45c-6742-40b0-8d99-2c4500077759_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_GainOnRelatedPartyInvestment_8c273679-802e-4110-aa24-f76f967ded7f_terseLabel_en-US" xlink:label="lab_yten_GainOnRelatedPartyInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on investment in related party</link:label>
    <link:label id="lab_yten_GainOnRelatedPartyInvestment_label_en-US" xlink:label="lab_yten_GainOnRelatedPartyInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Related Party Investment</link:label>
    <link:label id="lab_yten_GainOnRelatedPartyInvestment_documentation_en-US" xlink:label="lab_yten_GainOnRelatedPartyInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Related Party Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_GainOnRelatedPartyInvestment" xlink:to="lab_yten_GainOnRelatedPartyInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8a52b6fe-b2cf-4385-b73b-8fe1329becff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_3748a82b-932b-41ae-98a1-b9b588932c4d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_cc7a5a48-c304-4268-9976-61cfda1c1e3d_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6167599a-3591-4fa5-88b9-9237badcf1c0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0373e155-6b75-4caf-9a96-add6e37de3d9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated useful life of assets used to compute depreciation using the straight-line method</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_31d0342c-39f7-4004-aeb5-a34b4ddfd16e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_0996e9ec-d133-46dd-9842-0847d5bd5e45_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_37495b77-96cb-4aa9-8962-b8a2ac3c9fe6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0db54da8-0128-406b-851f-d5d78a133fcd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_ac4bfaf6-ecd4-4c51-a8f3-9914a0bf2529_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_4a80efd7-7e97-4ea1-9dfe-c252a448064c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_a7fb7d24-ea48-4c7a-96f8-233482bdc330_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_2d4a84e5-7b17-447b-bbee-f37499529424_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_PublicOfferingMember_6d2f2aa6-1f61-4c99-8362-6cda3f48e55c_terseLabel_en-US" xlink:label="lab_yten_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_yten_PublicOfferingMember_label_en-US" xlink:label="lab_yten_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_yten_PublicOfferingMember_documentation_en-US" xlink:label="lab_yten_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PublicOfferingMember" xlink:href="yten-20221231.xsd#yten_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_PublicOfferingMember" xlink:to="lab_yten_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_LesseeOperatingLeaseLeaseArea_63a6ba6c-9249-4dc7-aa66-829b6fe88171_terseLabel_en-US" xlink:label="lab_yten_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased area (in sqft)</link:label>
    <link:label id="lab_yten_LesseeOperatingLeaseLeaseArea_label_en-US" xlink:label="lab_yten_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:label id="lab_yten_LesseeOperatingLeaseLeaseArea_documentation_en-US" xlink:label="lab_yten_LesseeOperatingLeaseLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingLeaseLeaseArea" xlink:href="yten-20221231.xsd#yten_LesseeOperatingLeaseLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_LesseeOperatingLeaseLeaseArea" xlink:to="lab_yten_LesseeOperatingLeaseLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_30e26ac4-ba17-4c78-af9f-cfa59424b2da_terseLabel_en-US" xlink:label="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems Approach to Increasing Carbon Flux to Seed Oil</link:label>
    <link:label id="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_label_en-US" xlink:label="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems Approach To Increasing Carbon Flux To Seed Oil [Member]</link:label>
    <link:label id="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_documentation_en-US" xlink:label="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Systems Approach To Increasing Carbon Flux To Seed Oil [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:href="yten-20221231.xsd#yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:to="lab_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_5916fad2-fce3-4376-a15b-b028d5324262_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_9f5f3456-e3de-43e2-bbb5-b35e13a80816_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_989d87f4-9dc9-47df-a8bc-17dabc045e21_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_e9057de5-6fa8-4870-a0a5-28ac77a80601_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_76249667-262f-4d13-8cbf-040dd688fd61_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_bee64e23-13a7-4cd8-b091-e95fda7ff082_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_d615e23c-0a96-4e06-9ac9-302791578a7c_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_6b5e918e-d0e4-4dbe-a4b7-ae6b6af267c3_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_9cfeb764-fc97-4242-aada-0ef0118d9655_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f4d27021-014d-4b49-8bca-053dff78b925_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_dbcf9296-e434-4669-9eda-530614f5bcbb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_90f83788-aa34-4865-87ac-c51fd7ef89e8_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_EmployeeAndDirectorMember_15210db8-1649-428a-90be-b47b527fe3e8_terseLabel_en-US" xlink:label="lab_yten_EmployeeAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and Director</link:label>
    <link:label id="lab_yten_EmployeeAndDirectorMember_label_en-US" xlink:label="lab_yten_EmployeeAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee and Director [Member]</link:label>
    <link:label id="lab_yten_EmployeeAndDirectorMember_documentation_en-US" xlink:label="lab_yten_EmployeeAndDirectorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the employee and members of the Board of Directors of the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EmployeeAndDirectorMember" xlink:href="yten-20221231.xsd#yten_EmployeeAndDirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_EmployeeAndDirectorMember" xlink:to="lab_yten_EmployeeAndDirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_62d86ba6-13e1-4381-a17a-f192a33dfa55_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_501b0c7c-c827-4d02-bb1a-26cc56708e03_terseLabel_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and restricted stock awards issued (in shares)</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_label_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards Issued, Number</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_documentation_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards Issued, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:to="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_97a3e38f-1b7f-4dd7-b412-ee9883bfe68f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_5fe1140e-bb8c-4e66-8bd6-4fa898563be6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_644f56ae-7eaf-4d91-b267-7aebd4788c81_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions used to determine fair value of stock options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_198209dc-eafa-4b7c-b624-cafa5f9fbf0c_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_322e5b98-b027-4785-8f03-9b08da965f51_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_524d3c8c-ffb5-469c-b705-eaf6a49bb158_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_e5094c40-798d-44bc-b3cf-a2714048b698_terseLabel_en-US" xlink:label="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalization of research and development expense</link:label>
    <link:label id="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Capitalized Research and Development Expenses</link:label>
    <link:label id="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalization of research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:to="lab_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_039499bf-2ab7-4a92-815a-9967ff46116d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_d6c44ec5-acbd-43a5-89b5-a20912c61407_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_fcd8a583-c127-4e5d-8c86-83e6b25dab00_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_fb5e33b2-f7bf-471e-87f0-9a2b34976829_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_abb32975-eb23-47ad-8c02-d3b3d45f6ea5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f8bae3a6-65a6-47b0-943e-02a8924b8269_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_c04df05a-ae8c-453b-af52-b11386549af0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5971555b-7b8f-4f1c-98c3-a00de4347668_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_7731b79f-16f7-4676-a94e-8414ba3430e5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_dee65549-0229-4e40-9120-8f80b3b87872_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_da7e1ad9-b78d-4b93-8b62-5073965a7092_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_b2ff4486-9bab-4575-aafd-c81d60949824_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_6dec5077-09e7-4092-8762-9386c85ca2f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of income tax benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_02e2c12b-b1f2-4cc7-b972-6066645ffe72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1b03d2c3-29cd-4c1b-a2af-8d084f87839d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_972a1e71-247e-46f9-88a9-69bcf606a762_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_d0201d49-8990-4e64-a430-9e8a5be7fafd_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a645b392-b43e-4af3-b716-708ba65b9bab_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period over which unrecognized compensation expense is expected to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2c02a159-a09c-4974-b271-8330029d0d6e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_c41f56d3-1c24-46cb-bc9c-a3fb8ca2b14e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f2647adb-ecd7-45e0-b7d8-dee8f7931952_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_67e42358-2981-4d26-821b-fe91e0c6aedd_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_dc9179db-544c-4bad-ac6a-200c1997a9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_12e6eaac-ba31-425e-89aa-cccb24ce74b1_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_db28664c-1f0e-4741-aa47-9c3a37e0ba66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_d8b4fd55-24e7-4291-90d9-2c59755c6453_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_a8cb14db-b147-45e8-87ca-0953a8b8c71f_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefits</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_358f5ea9-9b05-47b4-bb3c-292d499bf309_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_7fd6b8cc-2dc6-4696-9c4a-89fad239834b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_26f990b0-49a7-45bb-8954-8fd129e1f035_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_6434c5bd-052a-42b2-80aa-f79a569a3083_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_08f66be0-d46d-41fe-bf7a-eb1837babf1c_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_21f6fc28-517e-4cbe-9663-5a71e2162d12_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cdbb50b1-c9d3-412b-931f-faa5ebd75592_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1eb1287b-a800-426f-a622-eeb0ce08ed4d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2886a202-91b5-4e00-9c86-41ebc93899cc_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_16c88f5f-7f49-45f1-b00d-b3f9dfcf76f0_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_51093bec-b7d0-46cb-abf4-b29db5bfa464_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_fde454a9-d28d-4985-a7e3-382b70af8002_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRentCurrent_240b68bb-3fe6-44ae-bd93-95400b592c3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased facilities</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rent, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent" xlink:to="lab_us-gaap_AccruedRentCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1bd012e7-b11e-44bb-a608-20a481b7bbb2_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a41e3b2b-5e08-4edc-bcac-18313fca3408_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_LeaseOtherInformationAbstract_630acb78-b9da-4a64-9c30-8b4695cbbed3_terseLabel_en-US" xlink:label="lab_yten_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other information as of:</link:label>
    <link:label id="lab_yten_LeaseOtherInformationAbstract_label_en-US" xlink:label="lab_yten_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:label id="lab_yten_LeaseOtherInformationAbstract_documentation_en-US" xlink:label="lab_yten_LeaseOtherInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Other Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LeaseOtherInformationAbstract" xlink:href="yten-20221231.xsd#yten_LeaseOtherInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_LeaseOtherInformationAbstract" xlink:to="lab_yten_LeaseOtherInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_0e51c2f2-0156-4f42-96af-ea2a84e9fa75_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_ebafad4e-056a-454b-b2e9-c36161f26b1b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_29cbf133-6c24-4aa4-bf21-dd985729f4ba_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_2c780518-9ca1-42b9-86a8-dae9e4c0815c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_3a8baef8-8753-4ebd-991f-405463e90c0a_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_452d9b0c-9c42-4cf6-be63-2f7da48c0918_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_945402ba-ec86-4a62-b6af-721fa59e24be_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1aa57baa-7298-4dff-8b6d-e96ac47b2717_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6c11e0c5-4232-4918-9e17-cda703ebc452_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CJCheilJedangCorporationMember_6e1ee568-7de0-4024-be7b-b2fdf21f0472_verboseLabel_en-US" xlink:label="lab_yten_CJCheilJedangCorporationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CJ CheilJedang Corporation</link:label>
    <link:label id="lab_yten_CJCheilJedangCorporationMember_label_en-US" xlink:label="lab_yten_CJCheilJedangCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CJ CheilJedang Corporation [Member]</link:label>
    <link:label id="lab_yten_CJCheilJedangCorporationMember_documentation_en-US" xlink:label="lab_yten_CJCheilJedangCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CJ CheilJedang Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CJCheilJedangCorporationMember" xlink:href="yten-20221231.xsd#yten_CJCheilJedangCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CJCheilJedangCorporationMember" xlink:to="lab_yten_CJCheilJedangCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_435b739d-2b53-4c8b-9e50-fb4188083bc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a51e8051-0dfc-4658-9f23-f79c0ce30d31_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_EnergyGrantDisclosureTextBlock_71f56332-3d70-4b2c-97f1-a6bb3dc54c6c_terseLabel_en-US" xlink:label="lab_yten_EnergyGrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Research Grants</link:label>
    <link:label id="lab_yten_EnergyGrantDisclosureTextBlock_label_en-US" xlink:label="lab_yten_EnergyGrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Energy Grant Disclosure [Text Block]</link:label>
    <link:label id="lab_yten_EnergyGrantDisclosureTextBlock_documentation_en-US" xlink:label="lab_yten_EnergyGrantDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The entire disclosure regarding the grant agreement with the U.S. Department of Energy for the development of switchgrass.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EnergyGrantDisclosureTextBlock" xlink:href="yten-20221231.xsd#yten_EnergyGrantDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_EnergyGrantDisclosureTextBlock" xlink:to="lab_yten_EnergyGrantDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_952d4bb3-0eb3-4bd9-8954-1632b3f72f59_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_eecde1e4-d9bd-4ff9-91a1-8d0d8028cf6d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_a0d7463c-e0b0-4681-b9d4-2f4be4a2a662_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_2706f17d-9e32-47e6-b2a4-2e5c914e0254_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_9d399716-5c96-4056-a43d-9e04c9112f94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f86be656-1c87-4e83-91ff-99a33e27318d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_fb3217dd-5ee4-4bdc-8e57-eb175b86cf16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_baabfadd-6d2c-4e7f-9c10-5be559d6efe9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_6f52e242-ba8c-4af0-832b-f9b701d05ee1_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price (in USD per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_b0a9eb83-f7fa-45a1-9cee-4cc1f4e0c9f3_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_ea3408d7-0fac-4ab0-a1c4-6d4a4ee625ef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9084f378-e6db-44c2-9c65-c3224d444dca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_cfd35316-6fdd-4e28-b3b4-d3f4d3ae1ead_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Information</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_7d665c81-e3b0-4e4e-9eaf-407bb82a8677_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_f8e29429-5950-45a9-815b-1c4c64f96d5e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e38c6031-22d5-4cc4-a131-0f431293155c_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c9bb09bd-c823-496e-bc62-80a1f6b4e0c4_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_6f094787-4e0d-4a92-9d19-500d56c5feb9_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryforward, amount</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_cba8f3a8-c598-48dc-9f1f-ca9dc528f9e5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_5149e38f-8282-44a2-9101-3f880beff04b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other temporary differences</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5cc62efe-6499-4785-8bac-a42e88ac1e68_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_9cd926d9-2266-4da2-9032-93adbd82a57c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued in offering (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_b9a9b4c1-ecdb-485e-9e3d-5f0f1aa7646b_terseLabel_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_label_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangements by Share Based Payment Award, Options Expiration Term</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_documentation_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The period of time, from the grant date until the time at which the share-based (option) award expires.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="lab_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset_a41e728e-efa8-4580-b916-55848d5dbd8f_negatedTerseLabel_en-US" xlink:label="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:label id="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="yten-20221231.xsd#yten_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_yten_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_41f11440-9bb5-4182-a684-9a27fdad7710_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_404d3f57-f604-40a5-a746-0f86b8fb8eb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_53eb5f6d-7fb6-476a-881b-6da1f1d003eb_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_01d981c7-075e-472b-b54a-0e7972e7a927_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_e930df8e-d3c2-4cc1-97fc-8b3e3bc9d2b4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_b8d4552b-6d16-4885-afea-06cbfafebf89_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale and maturity of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_PresidentialWayWoburnMassachusettsMember_48302146-63ee-494e-9953-bf8cda66c543_terseLabel_en-US" xlink:label="lab_yten_PresidentialWayWoburnMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">19 Presidential Way, Woburn, Massachusetts</link:label>
    <link:label id="lab_yten_PresidentialWayWoburnMassachusettsMember_label_en-US" xlink:label="lab_yten_PresidentialWayWoburnMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presidential Way, Woburn, Massachusetts [Member]</link:label>
    <link:label id="lab_yten_PresidentialWayWoburnMassachusettsMember_documentation_en-US" xlink:label="lab_yten_PresidentialWayWoburnMassachusettsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Presidential Way, Woburn, Massachusetts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PresidentialWayWoburnMassachusettsMember" xlink:href="yten-20221231.xsd#yten_PresidentialWayWoburnMassachusettsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_PresidentialWayWoburnMassachusettsMember" xlink:to="lab_yten_PresidentialWayWoburnMassachusettsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_4d4650e4-9976-4085-a4dc-e22f3fda589a_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_7be0264a-7ad2-4f29-aed9-68c51c22dde4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_409568f8-8225-4c07-9ad6-fe4c4aaccbda_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProjectMember_8cff2e54-e0aa-4725-bb7e-f5df85b5fea6_terseLabel_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:label id="lab_us-gaap_ProjectMember_label_en-US" xlink:label="lab_us-gaap_ProjectMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProjectMember" xlink:to="lab_us-gaap_ProjectMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_6c76a096-c78d-4088-9a18-2f0f8b04ae1c_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quantitative disclosure of lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_4ddf84c0-5c4d-431f-bb78-be78dd151574_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_5b7399e7-92cb-4bcc-8c77-fddc76715f31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_61f30fd8-f144-42ac-b386-faf73cd6d666_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrestricted cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_b1b7e1b3-adcb-4858-ba12-b479766db64a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Tax Provision:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_6221a84f-178e-4a74-abc7-e1fe37396e3b_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_72fe078c-5668-4812-ace5-6e9ef081941c_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_68507ef9-5aa2-48c9-aa60-e17dc4ddedd5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2a955870-8917-4226-90cf-49e728a05289_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_a4c67126-7792-424f-9dc3-acd29b3991d9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related expense for common stock issued under the 401(k) savings plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d896c745-5a2b-4183-b91d-38fb3aee2644_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_0711e582-dab6-4127-ad79-466399d2b3c1_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_01afb956-dccb-482e-8d76-f7f95bec3357_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_28cf733c-ec4c-4f3d-a8f1-db7774e006e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_cc961161-5b44-4096-8549-f5ad72ae721c_terseLabel_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options awarded to date (in shares)</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_label_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options Grants to Date Gross</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_documentation_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative gross number of share options (or share units) granted under the stock based compensation plan as of the reporting date.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:to="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_b84b399f-7ea7-407d-bc61-f20010b1871e_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_8c9e89f8-2951-44ac-9bda-ef7e4d81cf58_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government and agency securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_03b22698-9f9f-42a8-b9f8-4776b455f191_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d441e9ac-bfb4-4c02-ba02-03aa0282340c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_370ad525-d519-4cdf-bf41-3b32e6c0fdc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_8c0489db-028d-4128-b2ce-4f9faaefda5f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_c2f554c5-590a-4640-9356-a55df2bd9182_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of profit (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_9cccd5dd-6e79-41cf-a0aa-ee02570a0d1f_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_80d7b15c-1735-4326-a8df-66096ca7ecd2_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_72a48c1a-e998-4bee-96d2-291a32092308_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_8d12b46b-4294-4a63-a4f6-90016a03b3e1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_b214ef85-4a6e-41f2-b5c8-36b4d9e74f66_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a2c44e1f-06ca-4e7a-9d89-8c83d00b1b08_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f4d1b6e6-40f6-4690-ab10-91cb4e23d4e2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_06c3f3a4-8237-40c7-815e-da567bf2584f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8828cdb9-ed61-49fc-a6fd-63e20f041617_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_687cfb6d-e164-48b8-b879-43f888fbee8d_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_87b6cdfe-9c3e-498d-849c-02952a5172ae_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_761141e2-39f9-4fe1-bb23-a89110386f2f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_fa8e0820-4391-4090-a16f-9acec1e6b764_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7717ed64-5c93-429d-9e11-5a471033eb7f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (Loss)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_05028fad-31aa-42ee-bde4-d718c0669b1b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_33353d47-df81-4a79-bb63-5b990f4487b3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_81fd534c-e887-4805-88e8-569818e7a7bd_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_dfe0f740-27be-4e59-ae58-03c45c1c7fd8_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1b1d504f-1adf-415c-b12a-fab26a15a88f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4544734c-fa7c-46d2-9e9e-6f0f606338df_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_7fc61b48-d5f2-4145-a094-35cf446550c5_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_bd895043-6232-4f69-978d-c4f8a751f2c5_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_LicensePaymentsReceivable_d2eb0d76-1561-44bb-ae29-b2fb5136471d_terseLabel_en-US" xlink:label="lab_yten_LicensePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding license payments</link:label>
    <link:label id="lab_yten_LicensePaymentsReceivable_label_en-US" xlink:label="lab_yten_LicensePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payments Receivable</link:label>
    <link:label id="lab_yten_LicensePaymentsReceivable_documentation_en-US" xlink:label="lab_yten_LicensePaymentsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Payments Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LicensePaymentsReceivable" xlink:href="yten-20221231.xsd#yten_LicensePaymentsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_LicensePaymentsReceivable" xlink:to="lab_yten_LicensePaymentsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d7aa916f-9d73-4a91-9e7d-e156fc1601e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the activity related to the shares of common stock covered by outstanding options under the plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_b40949af-f01c-4214-bbb4-8ee0c8fc2ead_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e32f5069-69d9-4247-9b66-5fe582acea4b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Standards Changes</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9171baeb-5765-4e93-a78b-3c80a2c85daa_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d153be6c-3b33-49c7-a429-24b6b615f38d_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_87738e72-067f-4785-a7b5-a752f47bcebd_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_7b753c30-2957-4111-acfc-17bbbd1b6a84_terseLabel_en-US" xlink:label="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Field trials and related expenses</link:label>
    <link:label id="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_label_en-US" xlink:label="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Field Trials And Related Expenses, Current</link:label>
    <link:label id="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_documentation_en-US" xlink:label="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Field Trials And Related Expenses, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:href="yten-20221231.xsd#yten_AccruedFieldTrialsAndRelatedExpensesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:to="lab_yten_AccruedFieldTrialsAndRelatedExpensesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2b278b9a-98cf-456d-886c-d979210f5136_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_WarrantExpiringJanuary2024Member_cb9828a4-5a50-4ef5-b7b5-93af7c0cd853_terseLabel_en-US" xlink:label="lab_yten_WarrantExpiringJanuary2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants - expiration January 2024</link:label>
    <link:label id="lab_yten_WarrantExpiringJanuary2024Member_label_en-US" xlink:label="lab_yten_WarrantExpiringJanuary2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Expiring January 2024 [Member]</link:label>
    <link:label id="lab_yten_WarrantExpiringJanuary2024Member_documentation_en-US" xlink:label="lab_yten_WarrantExpiringJanuary2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Expiring January 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringJanuary2024Member" xlink:href="yten-20221231.xsd#yten_WarrantExpiringJanuary2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_WarrantExpiringJanuary2024Member" xlink:to="lab_yten_WarrantExpiringJanuary2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_317dfd5e-5f18-4cce-a8ff-7cec30cecde3_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_cb365b19-5a3c-451d-9330-4da186403269_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f193a638-45fc-45a5-a1f7-8e7cfbe1a4a2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d099802d-276d-4fcc-9d52-ae7c9d2b5389_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_79a5685e-4b13-4b6c-b890-eb5a61a7fc80_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_a60a17dc-4f45-4b1b-9cb6-969c7485fccc_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_55b3b004-e430-4ef3-8a05-af7af51d6189_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_23c89297-5678-46b1-a65e-830f15926ba4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_e5348aba-bf34-404c-9e7d-04f5056ec015_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6f4d6ecf-3f61-4e77-8984-eb4ce778dab1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_a652e12c-2183-4c15-bee5-c879533128ef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_6aa933bc-e7bc-4130-b369-062e7fd3707c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_2bb81cb8-b9ad-4ab8-9eff-c68e76b9e8e5_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_54d35fb9-6e31-4bcd-abd4-780ac24d7c98_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7357ba99-e5f6-4ba3-b4dd-5e8eadeddb82_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_64bebebc-60a6-41e4-89c0-58dda084c3cf_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_0bcd2660-1ac5-4161-bfd7-4495f022d9d6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3289d591-7a79-42b5-9135-b085fc116457_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_8e6cf8bb-5428-423e-9625-421693329d6b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_52068bf2-a2e6-46e6-bd07-71617dc2dcb4_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_052d28d4-32e0-4191-af8b-b3c24d6094e8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected option term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e428dd30-cf4f-4692-9b85-4ad32a4cb357_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2ece3325-b902-4e20-8a97-f3ef1656a64d_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_cd2f05eb-0b56-41e0-9581-01674ed75ff1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_158eaff7-9b4e-4352-802e-c1e30d1fd0b1_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_f89b2268-1f35-4651-9612-cfa85c650015_terseLabel_en-US" xlink:label="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes for undistributed earnings of foreign subsidiaries</link:label>
    <link:label id="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes for Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:label id="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_documentation_en-US" xlink:label="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the provision that has been made for U.S. income taxes related to the undistributed earnings.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:href="yten-20221231.xsd#yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_9dcfd093-696a-45e2-b28d-2655a1df7aea_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock ($0.01 par value per share); 60,000,000 shares authorized at December&#160;31, 2022 and 2021, and 4,944,202 and 4,881,851 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_DeferredTaxAssetsLeaseLiability_0c73470e-6e89-49ec-b831-2bc4ba648f06_terseLabel_en-US" xlink:label="lab_yten_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_yten_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_yten_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_yten_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_yten_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsLeaseLiability" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_DeferredTaxAssetsLeaseLiability" xlink:to="lab_yten_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_713d69f4-3814-4a7f-8c95-611623c53eda_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and liabilities measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f7b170f0-8941-4692-9e8e-ddd09ab997a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_9de86a44-c7fc-4e9f-aeb9-34dd82ec49af_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_3c59a79c-1b3d-45f8-be44-973ef6dfbba7_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered direct offering</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_e7d735f7-bdab-439b-8eb3-8ab24f5a09bc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2ff936f1-b170-4fb8-b56f-3fad097b9552_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270f5db6-a006-4b22-9053-a9c25f1ae645_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of year</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aad1ef76-ad43-4b4c-84d6-eaba86c565df_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_346239ce-6c9c-4368-9033-c0ccfa07423d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment (in shares)</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedBalanceShares_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Owned, Balance, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedBalanceShares" xlink:to="lab_us-gaap_InvestmentOwnedBalanceShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c2e4d5af-b792-4f14-a744-2b616a65e677_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_acdcd2bc-1778-4839-bf5e-6ea649039eba_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_c1f199d0-49fe-4d44-9c8a-2480b3c6d3e0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_23f9acc0-a0af-47c7-8605-bde591fb0453_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_75edb25f-d432-4cef-bb8a-650f5d3cd1d7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_f23d7f72-d496-4c04-a60b-05cf41df8d22_terseLabel_en-US" xlink:label="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">410 Downey Road and 110 Gymnasium Place</link:label>
    <link:label id="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_label_en-US" xlink:label="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">410 Downey Road And 110 Gymnasium Place [Member]</link:label>
    <link:label id="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_documentation_en-US" xlink:label="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">410 Downey Road And 110 Gymnasium Place [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:href="yten-20221231.xsd#yten_A410DowneyRoadAnd110GymnasiumPlaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:to="lab_yten_A410DowneyRoadAnd110GymnasiumPlaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_c3ec1aa9-0515-4cc1-a3c8-25f4bff473b0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_3ff9c47b-9c59-4f1d-a76f-fdd75493a044_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual life</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_740633e2-f324-4d0a-9b2c-d68c9e9e5660_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_632a2330-78dd-48d2-83e9-c6af87be3b71_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_6e8b3792-aaff-45f6-a368-66493f003d61_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_1ba9f3c6-ac80-4ce5-a81e-1b5235d6a236_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_4baa42d5-808e-43a2-90cf-5399c38bc501_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_e263c32a-2dae-4271-9008-204012c21160_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_4b4c2399-a42c-404c-a0b9-d37b81107a3a_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2dccb9c8-ae13-4f04-964f-b7ef3738a88d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d5a7fb64-b25c-4c9e-a89f-c26a8aa335f6_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_5d672664-bb34-4042-be02-b7f87317a829_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SaleOfStockMaximumAggregateOfferingPrice_d12f79a7-886f-4e41-b2a3-77a433a32ec5_terseLabel_en-US" xlink:label="lab_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate maximum offering price</link:label>
    <link:label id="lab_yten_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_yten_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="yten-20221231.xsd#yten_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_yten_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1a78b0df-1164-4cc3-b2dc-df847afa87d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_IncreaseDecreaseInLeaseLiabilities_4bf8be7f-6f7a-4c57-ab48-606033a893bf_terseLabel_en-US" xlink:label="lab_yten_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_yten_IncreaseDecreaseInLeaseLiabilities_label_en-US" xlink:label="lab_yten_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities</link:label>
    <link:label id="lab_yten_IncreaseDecreaseInLeaseLiabilities_documentation_en-US" xlink:label="lab_yten_IncreaseDecreaseInLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_IncreaseDecreaseInLeaseLiabilities" xlink:href="yten-20221231.xsd#yten_IncreaseDecreaseInLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_IncreaseDecreaseInLeaseLiabilities" xlink:to="lab_yten_IncreaseDecreaseInLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9d38cebe-881f-41f9-a4a9-c01299a83db6_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_55a3665d-dc2a-4e72-99d1-6a63b9fd4c45_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal income tax at statutory federal rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_a9aa278c-e48c-42d0-bd8d-e6c8f2a16057_terseLabel_en-US" xlink:label="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in shares available for issuance, percent</link:label>
    <link:label id="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_label_en-US" xlink:label="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase Of Shares Authorized, Percent Of Outstanding Shares, Percent</link:label>
    <link:label id="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_documentation_en-US" xlink:label="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Increase Of Shares Authorized, Percent Of Outstanding Shares, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:href="yten-20221231.xsd#yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:to="lab_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_e53a317a-9a72-4a32-be52-2ec71a3039b5_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:label id="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_label_en-US" xlink:label="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="lab_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ee1c4a1f-0e96-4b73-8752-9e833f91a124_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested and outstanding options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cb31b840-5670-4026-a89d-600c9f460b3e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b532554b-56c0-4977-aad7-47350477191d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_31812634-0674-4f92-8d47-2e245a7aa961_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_948be22c-db5d-4338-a0fe-11c77c4ad948_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_b6f9c7a2-ec51-48be-82de-d62e814bd3f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_a3afe0bb-2769-4f31-a45b-354ff3563f82_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_65c20858-5abe-491d-8a96-cb61fc11e815_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_6f34f7b4-fe4a-4770-bdbc-fdede4951150_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of the net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_450837d4-6558-4d90-9f8e-72da7f584d06_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a827e61a-a583-4aed-906a-e41033a4533e_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4134837-4d03-442d-8433-0df109ff2086_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cf5ab69e-7277-413c-9c10-6ff1e3321e48_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_b047438d-f89e-40f4-b3df-ed55aa705e81_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_cc242eb5-13fd-4d40-b47e-aefef076b04a_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable long-lived assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e5612f00-c88d-461b-826a-05e85d06c299_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_672b7ebb-7928-41a2-8d76-ee096a1ab2fe_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f9b3584-3271-4189-b373-aaa4893248e4_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4c7113e3-c7b6-4890-9185-cc5b8bcfc18a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_43ef8c77-1937-4910-909f-b6324bdf253b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_a2aed70b-5a5d-4d5d-ba59-790fef01f3c8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_67411dd8-6120-4f27-a67a-1af19d67e275_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_906e3124-fb1f-4855-90b9-89beb06183e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock_0b196622-76b4-4b3d-ba98-46fdc1859282_terseLabel_en-US" xlink:label="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Costs</link:label>
    <link:label id="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intellectual Property Costs Policy [Policy Text Block]</link:label>
    <link:label id="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of accounting policy for intellectual property costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:href="yten-20221231.xsd#yten_IntellectualPropertyCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:to="lab_yten_IntellectualPropertyCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1d1ee1e4-d39a-42a0-bc02-92848eb0f3bb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_d5cbbb2a-5187-415b-9986-3b46c22c1f65_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2986f849-8310-4958-aaee-823f90890913_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7871edf4-a7e9-4e58-b59d-dd00926d4077_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_b40fe916-df32-40d7-ab4e-01e727fcc6b5_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses_511d6521-aaa6-498b-b6ff-15e418068709_terseLabel_en-US" xlink:label="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue Research and Development Expenses</link:label>
    <link:label id="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This element represents the expenses associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors; facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the company's research and development, which also includes the costs related to revenue-producing contracts, which are recorded as research and development expenses, during the period by the entity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:href="yten-20221231.xsd#yten_CostOfRevenueResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:to="lab_yten_CostOfRevenueResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_2fa6e028-365e-472b-8765-a4fbc996b56b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_NoncashLeaseExpenseIncome_218c719f-ba62-4b36-b06d-e9a8afbfd3fa_terseLabel_en-US" xlink:label="lab_yten_NoncashLeaseExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash lease expense</link:label>
    <link:label id="lab_yten_NoncashLeaseExpenseIncome_label_en-US" xlink:label="lab_yten_NoncashLeaseExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense (Income)</link:label>
    <link:label id="lab_yten_NoncashLeaseExpenseIncome_documentation_en-US" xlink:label="lab_yten_NoncashLeaseExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_NoncashLeaseExpenseIncome" xlink:href="yten-20221231.xsd#yten_NoncashLeaseExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_NoncashLeaseExpenseIncome" xlink:to="lab_yten_NoncashLeaseExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_70d2490f-efa0-49cb-bbad-3c1164206dd1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d6e3b119-520b-40b9-81a1-1ab1c18f6918_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_adfab4d2-a9d5-4a5c-8381-9c3041b95330_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_13ed5c09-f8c6-4021-a1e4-6e6642fc9d14_terseLabel_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components</link:label>
    <link:label id="lab_srt_ReportableGeographicalComponentsMember_label_en-US" xlink:label="lab_srt_ReportableGeographicalComponentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Geographical Components [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ReportableGeographicalComponentsMember" xlink:to="lab_srt_ReportableGeographicalComponentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_76ba5e13-5774-4654-a4d0-392df2d7a71e_terseLabel_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options and restricted stock awards outstanding (in shares)</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_label_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding, Number</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_documentation_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:to="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_70da096e-6bee-4430-b591-b56d90a366ba_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_08bec6da-7b07-49db-93cc-e8ca0a398bc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information with regard to outstanding warrants to purchase common stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_7faa526b-f152-432c-b7f3-2b717ca048d7_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_c9353b1c-7eaf-4b35-82d7-eea7fdafcff0_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_GovernmentGrantTerm_44f4a464-f900-4764-bbca-1a5174135c21_terseLabel_en-US" xlink:label="lab_yten_GovernmentGrantTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government grant term</link:label>
    <link:label id="lab_yten_GovernmentGrantTerm_label_en-US" xlink:label="lab_yten_GovernmentGrantTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Term</link:label>
    <link:label id="lab_yten_GovernmentGrantTerm_documentation_en-US" xlink:label="lab_yten_GovernmentGrantTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantTerm" xlink:href="yten-20221231.xsd#yten_GovernmentGrantTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_GovernmentGrantTerm" xlink:to="lab_yten_GovernmentGrantTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f883c8fe-c3f9-4212-9595-98a3a2a0b7d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_bcff3fcb-ac46-4a8f-b193-55b34e48871f_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Stock and Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_96af9820-104f-4d0a-acb1-66a98f671bf9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_4818ec5a-71b0-4323-bea5-aa5c62153594_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_6a202f47-46e7-406c-806c-42cadec2305b_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_17a7b911-3d06-4bee-b7c8-75cb2309a661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1ea832e4-101d-4d24-8d81-4c9c449a4d50_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_ef73bef4-5ddd-43aa-98b8-1b59788616a8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for 401k match (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_101b9dfa-91f9-40ad-b6f7-9913b735aeb1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued under the 401(k) savings plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_bf651c31-d7b3-4084-854e-9d708ba050f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_006f932f-0394-4b20-adf8-96d81bfb8fb0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_65b0403b-91a4-4568-b468-12307ad00a27_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f4cf4584-00af-4f0d-acc4-8a226f88dd51_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_431085f7-13b9-4165-a568-d4c9a825079e_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_2b457bbc-65bb-4f57-8c8a-dc13d1292af6_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_7b6a75af-43f2-4f48-b311-99fe56bc0993_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_061d1d5e-15b9-46fc-9fc3-feac44664606_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_7e10be76-eeff-43c8-b85f-0231ff886186_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3538e2ca-63e7-4ba3-b99a-7614b8fd17f0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_b2a10090-4b09-4556-97b6-2d57b4b0c6f7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b5905f1e-4ed4-4d90-8cae-01b2da909b75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2723bf5f-db8a-4437-b752-57e0b7edfddc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ChargeForCompanyCommonStockMatch_68430838-23b6-41e5-91ec-096488fed886_terseLabel_en-US" xlink:label="lab_yten_ChargeForCompanyCommonStockMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense for 401(k) company common stock match</link:label>
    <link:label id="lab_yten_ChargeForCompanyCommonStockMatch_label_en-US" xlink:label="lab_yten_ChargeForCompanyCommonStockMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charge for Company Common Stock Match</link:label>
    <link:label id="lab_yten_ChargeForCompanyCommonStockMatch_documentation_en-US" xlink:label="lab_yten_ChargeForCompanyCommonStockMatch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncash charge representing the fair value of Company common stock issued by the company to participants in the Company's 401(k) plan as a matching contribution during the reporting period. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ChargeForCompanyCommonStockMatch" xlink:href="yten-20221231.xsd#yten_ChargeForCompanyCommonStockMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ChargeForCompanyCommonStockMatch" xlink:to="lab_yten_ChargeForCompanyCommonStockMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5edb80cc-560e-486c-ad19-4cfd5b281d63_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_ad20c05f-f632-41e1-b330-aad6fde25a85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in foreign currency translation adjustment, net of income tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_24f221d2-3256-420c-8cf4-c2cab3f5636b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0e39d46f-7157-4cbb-9b19-9e99a3502763_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_56975473-363d-43f1-9d77-5b22d164030b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_99b251a3-8e9d-4a19-b01f-125c07d70e5c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government [Abstract]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement with Federal Government [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ResearchGrantMaximumPayrollCostReimbursement_c20d2aba-0034-49cf-bf55-716551d8b66a_terseLabel_en-US" xlink:label="lab_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum payroll cost reimbursement</link:label>
    <link:label id="lab_yten_ResearchGrantMaximumPayrollCostReimbursement_label_en-US" xlink:label="lab_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Grant, Maximum Payroll Cost Reimbursement</link:label>
    <link:label id="lab_yten_ResearchGrantMaximumPayrollCostReimbursement_documentation_en-US" xlink:label="lab_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Grant, Maximum Payroll Cost Reimbursement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:href="yten-20221231.xsd#yten_ResearchGrantMaximumPayrollCostReimbursement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:to="lab_yten_ResearchGrantMaximumPayrollCostReimbursement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_dbab3dc9-896f-46c0-b018-ccb78cfd3d00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares used in per share calculations:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_07994c92-0329-4bd1-ad34-7e0ac2c66990_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount received from offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_d8f0c7ed-de9a-4dbe-8220-82e54e29c914_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_debc7b3f-583c-42d6-b9bf-8be1de64b99d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_02606209-50e2-48a1-b614-4521f17245f9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_d47f3861-9f91-435b-953a-14890771dfa1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_8704c927-8214-41bd-aa16-be5f1cbc3cd7_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_8c0e1463-3274-4abe-b860-4087e41a2d9b_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_35b407a2-6dcc-4a5e-aee1-2c3b9bf05ec2_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3161375b-e315-4a5f-b83f-ce1ce5197f62_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from securities offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a2ad8635-19b0-487a-b229-42c0fc32bd6b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_2b56b575-c71f-48e2-b6d9-fe47f2a8fdfb_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_0c82e1f3-68fe-4e27-9b4a-083d016c5e51_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_9c031081-21e6-458e-96ef-62d2044970a3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_AuditInformationAbstract_label_en-US" xlink:label="lab_yten_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_yten_AuditInformationAbstract_documentation_en-US" xlink:label="lab_yten_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AuditInformationAbstract" xlink:href="yten-20221231.xsd#yten_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_AuditInformationAbstract" xlink:to="lab_yten_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_ceea06cd-97b8-4051-8616-656b72997f00_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fc3f8287-f9db-4a37-8679-b41f5a9a65c1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c9ff5eea-615e-469d-a462-30a99ac98691_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SaleOfStockCommissionRate_99621845-bfe4-4290-91e7-a2c567db6304_terseLabel_en-US" xlink:label="lab_yten_SaleOfStockCommissionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission rate</link:label>
    <link:label id="lab_yten_SaleOfStockCommissionRate_label_en-US" xlink:label="lab_yten_SaleOfStockCommissionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Rate</link:label>
    <link:label id="lab_yten_SaleOfStockCommissionRate_documentation_en-US" xlink:label="lab_yten_SaleOfStockCommissionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockCommissionRate" xlink:href="yten-20221231.xsd#yten_SaleOfStockCommissionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SaleOfStockCommissionRate" xlink:to="lab_yten_SaleOfStockCommissionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_072b10c5-56f0-4ace-aad1-b3097c2282bb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a1fe0bc9-a532-448c-be88-25893d03f4ff_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_7b4e4029-e438-4c33-9537-ebc7c8251b55_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security deposit - letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_55b35ff4-7ad9-476a-a380-b628320703d6_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_86b7be05-5320-4f31-a619-b1176bd95d3f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_330f86a2-2e73-467f-81b7-e59d5d23d641_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_297cbe8f-88b2-4028-8c05-e9dbede27f63_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_abc722ad-7acf-48be-871e-43bd0d37955f_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d758ec8-8c1d-4bee-a470-8f48de509227_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_347aa26f-0a36-4800-8eb7-598f3716f279_terseLabel_en-US" xlink:label="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option for license agreement</link:label>
    <link:label id="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_label_en-US" xlink:label="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term Of Option For License Agreement</link:label>
    <link:label id="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_documentation_en-US" xlink:label="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term Of Option For License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTermOfOptionForLicenseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:to="lab_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1351bd88-d71f-4ba4-a2d1-7dd67dc720dd_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for warrant exercises (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_094a48e3-8ea2-4067-ae8b-73e935587660_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction_4120a368-72c4-435f-809a-acc47d67884b_terseLabel_en-US" xlink:label="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction_label_en-US" xlink:label="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Gross Consideration Received Per Transaction</link:label>
    <link:label id="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction_documentation_en-US" xlink:label="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Gross Consideration Received Per Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:href="yten-20221231.xsd#yten_SaleofStockGrossConsiderationReceivedPerTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:to="lab_yten_SaleofStockGrossConsiderationReceivedPerTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_53308da8-281d-4668-ae4c-fdabfc379d44_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total number of common shares reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_293c1134-69b2-460b-b81f-3506e8343f60_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_a2126988-01e9-4d0a-8d6b-ebced3caf89d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Accounting</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_b31aa64f-f103-436f-bea6-6932fa551235_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant unobservable inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9c871859-9df5-421f-b557-a088223701bf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_5b0c8b17-7787-488c-a4cd-32d5c1e24af7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_cc7daf20-fd32-412e-81c9-ceb0a876989b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_4e87ab28-3013-402a-9d69-97430ab2ee22_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed earnings of foreign subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_c9a57120-c069-4b80-b8c8-21b2a3b55356_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_62bca81b-4994-48c3-8a1c-6d0d22f879b4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_73d6b953-d25a-4e1b-81d5-a53c1e36000f_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_5905b35d-41b5-45f0-b6d3-c53b1c9a40b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on employees' behalf related to vesting of stock awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_f0ee2023-3343-4580-8258-021588b6ce34_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of vested shares withheld for minimum tax withholding</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4ae8314a-a4d8-46a4-af1c-82bfc4b2aed7_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b64bb282-3287-490f-8220-2260b81b2430_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of significant components of the Company's net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b30a7713-e823-41a2-893b-6f34c8bd15a7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_191ed409-d2f9-4e3e-940b-112d0e7a824a_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8a62ec19-90c2-40b5-a806-e521fcfd4fb7_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7f0135ce-b5e6-4d45-a85d-1898dbaebdf3_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_45e375f6-881a-4cbd-8925-addd807664f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of components of profit (loss) before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_f623e618-574c-42ac-9f3c-2a5e9bc5685b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant&#160;other observable&#160;inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SeriesAWarrantsIssuedNovember2019Member_78485473-952b-4d6b-8559-f7362d9709be_terseLabel_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued November 2019</link:label>
    <link:label id="lab_yten_SeriesAWarrantsIssuedNovember2019Member_label_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued November 2019 [Member]</link:label>
    <link:label id="lab_yten_SeriesAWarrantsIssuedNovember2019Member_documentation_en-US" xlink:label="lab_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Warrants Issued November 2019</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedNovember2019Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:to="lab_yten_SeriesAWarrantsIssuedNovember2019Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f76c0a78-51d8-46a2-ae8f-89772de55a0f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_SeriesBWarrantExpiringMay2027Member_155922e8-47ec-4de2-8051-2aed8488713c_terseLabel_en-US" xlink:label="lab_yten_SeriesBWarrantExpiringMay2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrants - expiration May 2027</link:label>
    <link:label id="lab_yten_SeriesBWarrantExpiringMay2027Member_label_en-US" xlink:label="lab_yten_SeriesBWarrantExpiringMay2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrant Expiring May 2027 [Member]</link:label>
    <link:label id="lab_yten_SeriesBWarrantExpiringMay2027Member_documentation_en-US" xlink:label="lab_yten_SeriesBWarrantExpiringMay2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Warrant Expiring May 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesBWarrantExpiringMay2027Member" xlink:href="yten-20221231.xsd#yten_SeriesBWarrantExpiringMay2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_SeriesBWarrantExpiringMay2027Member" xlink:to="lab_yten_SeriesBWarrantExpiringMay2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_354b784d-9724-448b-9bee-42dbb17901e9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_3bebc38d-b872-4824-b85e-0d2d0a95c5f7_terseLabel_en-US" xlink:label="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly research funding and option fees</link:label>
    <link:label id="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_label_en-US" xlink:label="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable</link:label>
    <link:label id="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_documentation_en-US" xlink:label="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:to="lab_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_AccountsReceivableTradeAndUnbilledReceivables_21f1192e-df03-49d0-b344-a6dbeb7e74a1_terseLabel_en-US" xlink:label="lab_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and unbilled receivables</link:label>
    <link:label id="lab_yten_AccountsReceivableTradeAndUnbilledReceivables_label_en-US" xlink:label="lab_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Trade And Unbilled Receivables</link:label>
    <link:label id="lab_yten_AccountsReceivableTradeAndUnbilledReceivables_documentation_en-US" xlink:label="lab_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Trade And Unbilled Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:href="yten-20221231.xsd#yten_AccountsReceivableTradeAndUnbilledReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:to="lab_yten_AccountsReceivableTradeAndUnbilledReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_a92509a2-8a11-43ff-b5bb-32581fc85bbd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_258122f8-fae1-48e6-adf1-7cc36bb1f664_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of lease payments representing interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5cefc627-baf8-45e2-8466-8850e6dd2123_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net loss per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_92512793-d0f6-4731-9593-3c1e64eea105_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_15bf3e8a-25b1-4ef7-90c9-7261566c3cb8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period for options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_692e26ab-f1f0-4e85-85ed-6a05124cac4a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_d43dd39f-058f-452a-bf0a-a24fc88fc9f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_a5f17ee8-b5e0-42a7-8a60-980b140f2181_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_eb549733-c0d3-4b7b-8b80-40951d9032cc_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ab163f77-9d75-45f7-9df0-e5757417798b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_StockPlan2018Member_4b43a94a-511a-4453-9ae2-5163bd3e8ca5_terseLabel_en-US" xlink:label="lab_yten_StockPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Stock Plan</link:label>
    <link:label id="lab_yten_StockPlan2018Member_label_en-US" xlink:label="lab_yten_StockPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan 2018 [Member]</link:label>
    <link:label id="lab_yten_StockPlan2018Member_documentation_en-US" xlink:label="lab_yten_StockPlan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan 2018 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2018Member" xlink:href="yten-20221231.xsd#yten_StockPlan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_StockPlan2018Member" xlink:to="lab_yten_StockPlan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_dffdc028-2769-4f79-ace4-d6b69098e428_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_e49e3051-2e10-4778-9edc-05a18aeb48cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuarantyLiabilities_97b7c304-8ac3-4347-b2fe-abd0c2a76aad_terseLabel_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum guaranteed payments</link:label>
    <link:label id="lab_us-gaap_GuarantyLiabilities_label_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guaranty Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuarantyLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuarantyLiabilities" xlink:to="lab_us-gaap_GuarantyLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1c2a090c-d152-407b-a905-bd1e7b2626d6_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_03f173f2-f96e-4f51-9591-a613a83debaa_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c993796e-8b19-45c1-8753-f9e0935f24b9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_a0d97075-254c-4de4-994b-53c9d99f8f54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_cb8a1694-4fe5-4429-b476-764056b506b4_terseLabel_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Contractual Term</link:label>
    <link:label id="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement by Share based Payment Award, Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_StockPlan2006Member_f7b8e226-97c0-4610-8dcd-60a173f0a8e6_terseLabel_en-US" xlink:label="lab_yten_StockPlan2006Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2006 Plan</link:label>
    <link:label id="lab_yten_StockPlan2006Member_label_en-US" xlink:label="lab_yten_StockPlan2006Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan 2006 [Member]</link:label>
    <link:label id="lab_yten_StockPlan2006Member_documentation_en-US" xlink:label="lab_yten_StockPlan2006Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2006 Plan, which provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2006Member" xlink:href="yten-20221231.xsd#yten_StockPlan2006Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_StockPlan2006Member" xlink:to="lab_yten_StockPlan2006Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_272cef0b-9b20-43bd-bfbb-bfa7ab66f9eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_880aa86f-f9ed-4e78-846a-256b37cb6c1f_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_551a4bcc-a087-4b71-875a-bfa49900e29d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e9138700-d50a-455a-b444-c35ff527a6fd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity analysis of lease liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CollaborativeArrangementTerm_27b9f355-faf3-465e-afbf-d86afd22e42d_terseLabel_en-US" xlink:label="lab_yten_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_yten_CollaborativeArrangementTerm_label_en-US" xlink:label="lab_yten_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:label id="lab_yten_CollaborativeArrangementTerm_documentation_en-US" xlink:label="lab_yten_CollaborativeArrangementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTerm" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CollaborativeArrangementTerm" xlink:to="lab_yten_CollaborativeArrangementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d2d52039-fd37-4bc7-92fd-05c2f89e7b07_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_a7145ca6-ed51-4bb7-b780-0f42353b9325_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_56458d7c-0ecc-4dd2-94de-70b27941e0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining to be earned</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7d6c5964-2976-4f7d-8dca-bf61340f6756_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_cbce2821-3b70-45b5-b466-42a329909119_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_3d462129-038f-450e-af87-d0c512cfe693_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled receivables</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7e824ac5-24a9-4db1-a956-861e7bd0e984_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_f05a35ba-4fa8-4db2-8062-14159fab8137_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible equity transactions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_7e84e4fd-f653-4158-ab5f-19b05dfe441d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_73fadd75-5654-4300-b10d-ffa10e06deff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_WarrantExpiringSeptember2024Member_6918d2d9-d4ba-4c15-a7d5-87a3d7a7f7fc_terseLabel_en-US" xlink:label="lab_yten_WarrantExpiringSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants - expiration September 2024</link:label>
    <link:label id="lab_yten_WarrantExpiringSeptember2024Member_label_en-US" xlink:label="lab_yten_WarrantExpiringSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Expiring September 2024 [Member]</link:label>
    <link:label id="lab_yten_WarrantExpiringSeptember2024Member_documentation_en-US" xlink:label="lab_yten_WarrantExpiringSeptember2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Expiring September 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringSeptember2024Member" xlink:href="yten-20221231.xsd#yten_WarrantExpiringSeptember2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_WarrantExpiringSeptember2024Member" xlink:to="lab_yten_WarrantExpiringSeptember2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_614124ce-962d-4e33-a88e-b7c423abd98f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized gain (loss) on investments, net of income tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e4e575cf-2793-4b58-bb60-aad114dcd0eb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of accrued expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ce7f7ec6-de19-464d-86c7-991c51e89bf9_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ee3909e7-079e-4092-b323-e2b8c27cdedd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_77b6d10f-5405-44cd-97b9-845705de03ca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5de5274a-71e9-4edd-8b2b-54c6999491bd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_306f3d1e-40b9-41aa-b69f-e11277ef9622_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_a1b49dd0-34dc-4340-a5f6-0cb276a75cc4_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9dbf6f6f-27f8-4c78-b211-d38faf202560_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_6ac3b515-9c9d-4955-b8f6-e9bf2db9a66b_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor obligation, maximum</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsMaximumExposure_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="lab_us-gaap_GuaranteeObligationsMaximumExposure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_ac5a3010-a5f4-4ae4-acaa-a6ee06603bcc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_ad7ae676-e758-49a1-8457-b6f7b1167058_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for 401(k) match</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dd28551c-856d-4681-b64b-e6b217c93549_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_147d703b-ccf3-4ef8-8f9e-f54042f01974_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_StockPlan2014Member_c93a063f-87c6-4e9b-b7ca-86c18c2d8882_terseLabel_en-US" xlink:label="lab_yten_StockPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Plan</link:label>
    <link:label id="lab_yten_StockPlan2014Member_label_en-US" xlink:label="lab_yten_StockPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan, 2014 [Member]</link:label>
    <link:label id="lab_yten_StockPlan2014Member_documentation_en-US" xlink:label="lab_yten_StockPlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Plan, 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2014Member" xlink:href="yten-20221231.xsd#yten_StockPlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_StockPlan2014Member" xlink:to="lab_yten_StockPlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_ef992465-4faa-445b-a97d-147473b7c68b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_feb67112-d1f5-463a-a399-e800131b1a7e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_99468b46-957d-4a21-9fef-2f3889cd84b6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_5ae736cf-08ba-4542-858c-34102aa14727_terseLabel_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:label id="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_label_en-US" xlink:label="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name of Property [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:to="lab_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_ad8c236d-d4dd-444b-9ba7-13dd413f5cef_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid on employees' behalf related to vesting of stock awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cef94bb1-c810-4f8e-8989-1d8a4e23eb6e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_0ee6c8d0-87cb-4269-a7aa-77ed76372735_terseLabel_en-US" xlink:label="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total research funding and option fees</link:label>
    <link:label id="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_label_en-US" xlink:label="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Funding And Option Fees Payable</link:label>
    <link:label id="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_documentation_en-US" xlink:label="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Funding And Option Fees Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:to="lab_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_765d1146-8986-4f7c-a712-2b19eb5be04a_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_19354488-55e6-49bd-a01d-a7d0afa6a94c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_fc6b1fdd-5e2b-4987-8d19-77d4d8c9d89d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_57e9b5cd-9ba8-4d33-85a2-aca4d355ef91_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c70a4b07-d748-419c-a79b-6f59c5f5f103_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_b6966ac7-ac55-414b-b20f-e2ee4d9743ef_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_04a33bda-9baf-47e4-b775-702f21c6dee2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_31aaf81b-9a4b-43bf-97d5-a50236117af4_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General, and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_29edb1ae-0adf-451d-8847-da9dbdb0cf3f_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_6a22949a-de07-41cf-9dab-16ede826c048_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_11503e83-6cd6-4883-ad26-99e87f235de6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_35db06a5-5ba1-4078-9258-6004d1aeaa8a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_f001f830-a941-49a7-8a07-f7b153cf2350_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2eadc3d7-47cb-4e95-858d-3e5ffd292448_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_eb728fe6-723a-4de9-a421-06b6119d9cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_GovernmentGrantCumulativeAmountAwarded_771b4c9a-685d-4d4f-9db3-6c4b66e83138_terseLabel_en-US" xlink:label="lab_yten_GovernmentGrantCumulativeAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative amount awarded</link:label>
    <link:label id="lab_yten_GovernmentGrantCumulativeAmountAwarded_label_en-US" xlink:label="lab_yten_GovernmentGrantCumulativeAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Cumulative Amount Awarded</link:label>
    <link:label id="lab_yten_GovernmentGrantCumulativeAmountAwarded_documentation_en-US" xlink:label="lab_yten_GovernmentGrantCumulativeAmountAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Grant, Cumulative Amount Awarded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantCumulativeAmountAwarded" xlink:href="yten-20221231.xsd#yten_GovernmentGrantCumulativeAmountAwarded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_GovernmentGrantCumulativeAmountAwarded" xlink:to="lab_yten_GovernmentGrantCumulativeAmountAwarded" xlink:type="arc" order="1"/>
    <link:label id="lab_yten_LicenseAgreementTerm_5ee11fa2-c71e-4a22-829b-103e30581824_terseLabel_en-US" xlink:label="lab_yten_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement term</link:label>
    <link:label id="lab_yten_LicenseAgreementTerm_label_en-US" xlink:label="lab_yten_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Term</link:label>
    <link:label id="lab_yten_LicenseAgreementTerm_documentation_en-US" xlink:label="lab_yten_LicenseAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LicenseAgreementTerm" xlink:href="yten-20221231.xsd#yten_LicenseAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_yten_LicenseAgreementTerm" xlink:to="lab_yten_LicenseAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f48e454-7a14-4848-bdc2-7b6b8f7e53e6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_671c90b9-1e8b-4e0c-9509-ad56053c60b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of shares used to calculate diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_e31830f7-9b70-4922-a08a-9211e27c1ffa_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>yten-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:14c78308-2a14-44d9-b95d-a3670bf18406,g:160143dd-a301-4830-845b-0b87bde32c2e-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.yield10bio.com/role/Cover" xlink:type="simple" xlink:href="yten-20221231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_aafaa222-f05d-4e80-93c0-ddddb6046555" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentType_aafaa222-f05d-4e80-93c0-ddddb6046555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_28ebeaae-ab06-49d5-8c89-51570d8422c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentAnnualReport_28ebeaae-ab06-49d5-8c89-51570d8422c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_e24cd677-7b8e-4bd6-a687-488869eb8667" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentPeriodEndDate_e24cd677-7b8e-4bd6-a687-488869eb8667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_5be0fe21-0996-4a9c-91de-7269496036d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_CurrentFiscalYearEndDate_5be0fe21-0996-4a9c-91de-7269496036d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5a278e57-4c33-4629-b2e2-390bb0705346" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentTransitionReport_5a278e57-4c33-4629-b2e2-390bb0705346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e7db02e2-f916-47fa-aca4-3ebbf3eeff04" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityFileNumber_e7db02e2-f916-47fa-aca4-3ebbf3eeff04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bca5b842-038f-40ee-bf48-44834d9b84d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityRegistrantName_bca5b842-038f-40ee-bf48-44834d9b84d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_a4d5d2d8-5a19-460d-8da9-d0139e3fe028" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityIncorporationStateCountryCode_a4d5d2d8-5a19-460d-8da9-d0139e3fe028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_118993dd-c000-484b-86e1-c136919c30a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityTaxIdentificationNumber_118993dd-c000-484b-86e1-c136919c30a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_c6d31279-bdd2-485f-9aed-f62d874c0e23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityAddressAddressLine1_c6d31279-bdd2-485f-9aed-f62d874c0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6bead39c-3833-493e-8881-b091fb15d626" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityAddressCityOrTown_6bead39c-3833-493e-8881-b091fb15d626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_12c70f2f-686c-498e-bce2-5480128ecae7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityAddressStateOrProvince_12c70f2f-686c-498e-bce2-5480128ecae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3d5e4234-40a8-492c-bee5-2ef251c5ece0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityAddressPostalZipCode_3d5e4234-40a8-492c-bee5-2ef251c5ece0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fec4c694-71b8-4eb4-b49a-968021f09256" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_CityAreaCode_fec4c694-71b8-4eb4-b49a-968021f09256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_198fab85-3834-40eb-b88f-36d880773291" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_LocalPhoneNumber_198fab85-3834-40eb-b88f-36d880773291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_3820537b-7f19-4a75-a6c8-9aa3c4ebab90" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_Security12bTitle_3820537b-7f19-4a75-a6c8-9aa3c4ebab90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e41b3af8-380b-4edd-b221-cbd4f50ef21a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_TradingSymbol_e41b3af8-380b-4edd-b221-cbd4f50ef21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_888d0d6b-ae08-49ae-8694-7253a059d77d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_SecurityExchangeName_888d0d6b-ae08-49ae-8694-7253a059d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_c58a357f-21f9-4597-b0c8-83af2dc5bc93" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_c58a357f-21f9-4597-b0c8-83af2dc5bc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0d407ecc-4437-4ec2-8387-585fa89a8220" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityVoluntaryFilers_0d407ecc-4437-4ec2-8387-585fa89a8220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4e0117ab-3870-44d7-9b9f-33d990538799" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityCurrentReportingStatus_4e0117ab-3870-44d7-9b9f-33d990538799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_2eddf2ba-6295-459d-a502-2f8265ce91d0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityInteractiveDataCurrent_2eddf2ba-6295-459d-a502-2f8265ce91d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c8dc42f9-cd34-4836-a60f-51edd221ff74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityFilerCategory_c8dc42f9-cd34-4836-a60f-51edd221ff74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d32ec123-5c26-46db-bda6-8d67bd0e7d14" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntitySmallBusiness_d32ec123-5c26-46db-bda6-8d67bd0e7d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_cf1dd476-10fd-4e65-a504-946f00203bbc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityEmergingGrowthCompany_cf1dd476-10fd-4e65-a504-946f00203bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_445de276-81af-4087-990a-98fc2e35d0c9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_IcfrAuditorAttestationFlag_445de276-81af-4087-990a-98fc2e35d0c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8a7925cc-cf38-478e-a77a-17bc3f5f3a66" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityShellCompany_8a7925cc-cf38-478e-a77a-17bc3f5f3a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_34d9fe3a-812f-4b13-adf2-139c8b6e5f9a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityPublicFloat_34d9fe3a-812f-4b13-adf2-139c8b6e5f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_46fe32a8-89cd-4a04-a35f-c3e2429f5ec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_46fe32a8-89cd-4a04-a35f-c3e2429f5ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_11767452-9a72-4e81-b1c8-1b5a2fbd6b65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_11767452-9a72-4e81-b1c8-1b5a2fbd6b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_ffc83d33-c638-481d-8455-c4332795493a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentFiscalYearFocus_ffc83d33-c638-481d-8455-c4332795493a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_0add112d-269f-480e-b51f-d1b9de725387" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_DocumentFiscalPeriodFocus_0add112d-269f-480e-b51f-d1b9de725387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_0a34f443-55f5-49d4-a80f-2bfaf77ce6da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_AmendmentFlag_0a34f443-55f5-49d4-a80f-2bfaf77ce6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_2f00895f-7928-47f2-99e4-c667516281f5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_29699584-99fa-4009-adba-2db650d78848" xlink:to="loc_dei_EntityCentralIndexKey_2f00895f-7928-47f2-99e4-c667516281f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/AuditInformation" xlink:type="simple" xlink:href="yten-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_yten_AuditInformationAbstract_23e78351-8d6c-4e85-94ae-16403dd898f0" xlink:href="yten-20221231.xsd#yten_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_8f4c88a9-7e9b-47a1-9aa4-30c5b6132f19" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_AuditInformationAbstract_23e78351-8d6c-4e85-94ae-16403dd898f0" xlink:to="loc_dei_AuditorFirmId_8f4c88a9-7e9b-47a1-9aa4-30c5b6132f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9c8aabd7-1145-4d38-ae81-7b56d5ba693e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_AuditInformationAbstract_23e78351-8d6c-4e85-94ae-16403dd898f0" xlink:to="loc_dei_AuditorName_9c8aabd7-1145-4d38-ae81-7b56d5ba693e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_2200b0e8-d116-4d51-a508-4800710da889" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_AuditInformationAbstract_23e78351-8d6c-4e85-94ae-16403dd898f0" xlink:to="loc_dei_AuditorLocation_2200b0e8-d116-4d51-a508-4800710da889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_bf22343b-4005-4fc8-89b8-a42f60429fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf22343b-4005-4fc8-89b8-a42f60429fe1" xlink:to="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c70ac22-6d31-40b5-80d7-5ec31056b3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9c70ac22-6d31-40b5-80d7-5ec31056b3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5d68f324-a09e-4975-a5f6-e59825b2b6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5d68f324-a09e-4975-a5f6-e59825b2b6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_365dcfae-fda4-4e38-b617-b7809700f058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_365dcfae-fda4-4e38-b617-b7809700f058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_f2a296c5-d63c-4469-b737-5eab27d64480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_UnbilledContractsReceivable_f2a296c5-d63c-4469-b737-5eab27d64480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b75a5ddd-c799-4c82-8446-831d85033ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b75a5ddd-c799-4c82-8446-831d85033ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9f8ae57-bb28-4c58-9ffb-2feb45e6fe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_6767ddd7-d634-4704-97ba-032d7d201087" xlink:to="loc_us-gaap_AssetsCurrent_e9f8ae57-bb28-4c58-9ffb-2feb45e6fe4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_de3d928b-dce1-4129-affa-68da6e8368d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_de3d928b-dce1-4129-affa-68da6e8368d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c98845f1-bfde-40f9-9e2a-0e5ba6704f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c98845f1-bfde-40f9-9e2a-0e5ba6704f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_69f283d3-dc89-47a3-824a-bdecc5fb9f50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_69f283d3-dc89-47a3-824a-bdecc5fb9f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_0c9d6643-3600-469f-8c78-d01f962d5926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_0c9d6643-3600-469f-8c78-d01f962d5926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_3392bda9-6239-4524-bd87-dbf7e3c76490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_76de75ad-d4dc-4e81-a843-b568e99b4c6b" xlink:to="loc_us-gaap_Assets_3392bda9-6239-4524-bd87-dbf7e3c76490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_bf22343b-4005-4fc8-89b8-a42f60429fe1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5425dae6-3750-4c87-a289-ec9e05c609a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:to="loc_us-gaap_AccountsPayableCurrent_5425dae6-3750-4c87-a289-ec9e05c609a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_bc594b70-ada8-4799-bbcf-0a7d77ee8a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_bc594b70-ada8-4799-bbcf-0a7d77ee8a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_460ce935-01f6-447a-9c8a-f1fde46f960d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_460ce935-01f6-447a-9c8a-f1fde46f960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c1da1364-d1e8-4205-aa48-933a71cfcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_37dfdb59-60fd-497a-8e2d-111ddc37b8bb" xlink:to="loc_us-gaap_LiabilitiesCurrent_c1da1364-d1e8-4205-aa48-933a71cfcc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90960d50-7f0f-4502-9b20-751a1cfd0078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_90960d50-7f0f-4502-9b20-751a1cfd0078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6a21360a-fe1d-4565-8566-1b2e1c6b48bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_Liabilities_6a21360a-fe1d-4565-8566-1b2e1c6b48bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_330dc550-5812-4899-8366-391a2597a9e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_CommitmentsAndContingencies_330dc550-5812-4899-8366-391a2597a9e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a5ed13e2-df1a-464e-9714-a41b636f2015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_PreferredStockValue_a5ed13e2-df1a-464e-9714-a41b636f2015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d79f1b0f-219a-422a-9b5c-758eb5032210" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_CommonStockValue_d79f1b0f-219a-422a-9b5c-758eb5032210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_79ee7421-4299-4939-8c7f-46b0a215abd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_79ee7421-4299-4939-8c7f-46b0a215abd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa04a4eb-19f4-47ee-bfa8-656499215ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa04a4eb-19f4-47ee-bfa8-656499215ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9553af97-5388-47ea-921f-ebf1a3b417e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9553af97-5388-47ea-921f-ebf1a3b417e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ab765ced-72da-4b8d-ab4e-c50bb518de62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_c131111e-5fba-4313-ad96-b4ded78116a1" xlink:to="loc_us-gaap_StockholdersEquity_ab765ced-72da-4b8d-ab4e-c50bb518de62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_736d82d7-1240-4af1-a24b-74f9c67b871f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0c2dfb90-50f5-46c3-851a-50b1ab4d73ca" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_736d82d7-1240-4af1-a24b-74f9c67b871f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fb7f4203-eceb-414f-bae8-f70aca5131e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_fb7f4203-eceb-414f-bae8-f70aca5131e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9a1261ca-eb55-4614-9c95-cb58fdab8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9a1261ca-eb55-4614-9c95-cb58fdab8d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_5c1464cd-5636-4b72-8f9f-7be091932f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_5c1464cd-5636-4b72-8f9f-7be091932f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_65dd7b49-c9e2-4f2d-84ee-8dc5c1a74858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_65dd7b49-c9e2-4f2d-84ee-8dc5c1a74858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64e196d-7b45-4dc0-b9de-39839482ceab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_f64e196d-7b45-4dc0-b9de-39839482ceab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7b76df2b-0e89-4fef-b6dd-a5c2e132f1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7b76df2b-0e89-4fef-b6dd-a5c2e132f1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c229aaaf-9540-4e73-809f-ab112eadae69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_CommonStockSharesIssued_c229aaaf-9540-4e73-809f-ab112eadae69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5ed7ea67-4c82-4b27-b7e8-664d6d00c70a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8a203a47-cbdb-4f14-a607-3f49e3192e7d" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5ed7ea67-4c82-4b27-b7e8-664d6d00c70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_4eb6596b-5bf3-45e2-a0b7-7df67473913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_4eb6596b-5bf3-45e2-a0b7-7df67473913a" xlink:to="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:to="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_52074cba-65e0-49c6-b922-672aae55aeed" xlink:to="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_bf936399-cf03-4424-a0b6-b8ec98f9ee14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_20b0a724-5ccc-4109-a0d5-f7561d010451" xlink:to="loc_us-gaap_GrantMember_bf936399-cf03-4424-a0b6-b8ec98f9ee14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_420f0e19-a5ca-4a05-bb08-c7e17dd04514" xlink:to="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92dfb3be-ece8-4186-9883-01d373caba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c52e195f-68bb-4284-a366-49ee21dd5644" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_92dfb3be-ece8-4186-9883-01d373caba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_195a913b-1a9e-4dd4-bbf4-8eb0a7b493b1" xlink:href="yten-20221231.xsd#yten_CostOfRevenueResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_yten_CostOfRevenueResearchAndDevelopmentExpenses_195a913b-1a9e-4dd4-bbf4-8eb0a7b493b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11a113c-5a8e-44a3-9362-ed18c284eae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_d11a113c-5a8e-44a3-9362-ed18c284eae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_eedc60e1-447f-4369-892f-d171c13c5391" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c5f1f71f-e2ed-4c76-bda5-2a43aea92bae" xlink:to="loc_us-gaap_CostsAndExpenses_eedc60e1-447f-4369-892f-d171c13c5391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1956a12b-39b3-4afe-ae5f-ceeedd92ba96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_OperatingIncomeLoss_1956a12b-39b3-4afe-ae5f-ceeedd92ba96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment_3275cbb7-9d5b-4b78-a831-84523a39e245" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_yten_GainOnRelatedPartyInvestment_3275cbb7-9d5b-4b78-a831-84523a39e245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a674faf7-a897-4221-b29f-de63ac24694a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a674faf7-a897-4221-b29f-de63ac24694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ca84850e-a8bf-4a87-a538-f53ef86dad59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_3160b406-a242-45c1-9ed2-35bb163ba0b1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_ca84850e-a8bf-4a87-a538-f53ef86dad59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c42a389f-4d97-4023-83fc-c2d2ba76a174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c42a389f-4d97-4023-83fc-c2d2ba76a174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_119ed344-3477-40f0-8d8c-2b8d1e853669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_119ed344-3477-40f0-8d8c-2b8d1e853669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_91e68839-e110-4989-91ac-0c135d0d3120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_NetIncomeLoss_91e68839-e110-4989-91ac-0c135d0d3120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ac104593-4270-48d9-97f4-b6b19f6dd28d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_EarningsPerShareBasic_ac104593-4270-48d9-97f4-b6b19f6dd28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_24b7fc9f-a8d5-41bd-b2c9-c77385a3a31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_EarningsPerShareDiluted_24b7fc9f-a8d5-41bd-b2c9-c77385a3a31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ee086e45-6c48-4ca7-90cc-94cd5d008364" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfd60c46-721c-4ea6-9c45-2a9af228a632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfd60c46-721c-4ea6-9c45-2a9af228a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1247a9a-d892-403b-9d0c-864332f18fa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_73e4b912-f760-4e7e-81d5-38e5073003e7" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e1247a9a-d892-403b-9d0c-864332f18fa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ec35eef-b48d-4f56-bfad-c8e1ad15d087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a53d4e4e-281f-4412-9516-92fc6bc9489b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ec35eef-b48d-4f56-bfad-c8e1ad15d087" xlink:to="loc_us-gaap_NetIncomeLoss_a53d4e4e-281f-4412-9516-92fc6bc9489b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_44994010-42cb-4134-bb90-63bcdb365e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ec35eef-b48d-4f56-bfad-c8e1ad15d087" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_44994010-42cb-4134-bb90-63bcdb365e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0d3e4459-67c9-45f4-9c34-48cdce6a27f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_44994010-42cb-4134-bb90-63bcdb365e7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_0d3e4459-67c9-45f4-9c34-48cdce6a27f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e5074c5b-0ffc-416d-bfad-962c6071e707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_44994010-42cb-4134-bb90-63bcdb365e7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_e5074c5b-0ffc-416d-bfad-962c6071e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_da0e4122-01e0-4946-9188-9b675ee973b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_44994010-42cb-4134-bb90-63bcdb365e7d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_da0e4122-01e0-4946-9188-9b675ee973b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_b62012b0-bf8e-4492-bb51-3b08656339c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9ec35eef-b48d-4f56-bfad-c8e1ad15d087" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_b62012b0-bf8e-4492-bb51-3b08656339c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a123301-db9c-4fc7-a9cf-a36cc7a9b334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a123301-db9c-4fc7-a9cf-a36cc7a9b334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8ea4ce1f-3c14-438d-bf6a-87f11ca8bdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a123301-db9c-4fc7-a9cf-a36cc7a9b334" xlink:to="loc_us-gaap_NetIncomeLoss_8ea4ce1f-3c14-438d-bf6a-87f11ca8bdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a123301-db9c-4fc7-a9cf-a36cc7a9b334" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d8ca3dc0-2d3a-48aa-8ecd-5946db5358a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d8ca3dc0-2d3a-48aa-8ecd-5946db5358a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ChargeForCompanyCommonStockMatch_232869f1-a3b8-49e1-a343-8fd088a52f3b" xlink:href="yten-20221231.xsd#yten_ChargeForCompanyCommonStockMatch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_yten_ChargeForCompanyCommonStockMatch_232869f1-a3b8-49e1-a343-8fd088a52f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_d2661823-5c1f-4a62-8906-f5b9a64d04d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_us-gaap_ShareBasedCompensation_d2661823-5c1f-4a62-8906-f5b9a64d04d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_NoncashLeaseExpenseIncome_57b07bb9-4777-4f55-835a-116ae91e79e6" xlink:href="yten-20221231.xsd#yten_NoncashLeaseExpenseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_yten_NoncashLeaseExpenseIncome_57b07bb9-4777-4f55-835a-116ae91e79e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_57ef77da-2edc-46e2-bb41-a57b93c0ae77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_57ef77da-2edc-46e2-bb41-a57b93c0ae77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_715b6008-778d-46a0-a5c4-64a75fe9c92a" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27ae7746-d624-4826-a204-c3f055581da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_27ae7746-d624-4826-a204-c3f055581da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1aa7dc75-3fae-4fa6-891f-bac8533d7f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_1aa7dc75-3fae-4fa6-891f-bac8533d7f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ad09d7b0-e152-4421-9770-bd49869107ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ad09d7b0-e152-4421-9770-bd49869107ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_922b18ea-b9d0-4e2b-9983-3fed0fde2214" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_922b18ea-b9d0-4e2b-9983-3fed0fde2214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26b5ee61-8c9b-48d9-aa46-879d2df9c624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_26b5ee61-8c9b-48d9-aa46-879d2df9c624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_IncreaseDecreaseInLeaseLiabilities_0c716bb6-5123-441a-846b-94ad311c15eb" xlink:href="yten-20221231.xsd#yten_IncreaseDecreaseInLeaseLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3f435339-7915-4f99-a6d7-d3ed2842544b" xlink:to="loc_yten_IncreaseDecreaseInLeaseLiabilities_0c716bb6-5123-441a-846b-94ad311c15eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b259f7f7-03d4-462b-8491-95fc5d17caa2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_2a123301-db9c-4fc7-a9cf-a36cc7a9b334" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b259f7f7-03d4-462b-8491-95fc5d17caa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d342d3a2-fa56-4273-ba97-38962edce855" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d342d3a2-fa56-4273-ba97-38962edce855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2e46d509-59c9-4c87-b961-801d56348ddd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_2e46d509-59c9-4c87-b961-801d56348ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_b792ca1a-075e-4a2a-b225-dd1d19e82d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:to="loc_us-gaap_ProceedsFromSaleOfShortTermInvestments_b792ca1a-075e-4a2a-b225-dd1d19e82d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f377dc6c-1d88-474b-b485-c9e3e5d1e2c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_05616b31-7be0-461e-b362-add1c380a07a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f377dc6c-1d88-474b-b485-c9e3e5d1e2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7919a501-3e66-4952-9286-a1c5d8e35162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7919a501-3e66-4952-9286-a1c5d8e35162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09f78f02-7260-49da-a5fd-737a7cf6d022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_09f78f02-7260-49da-a5fd-737a7cf6d022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_732fd69c-0826-44c6-89be-c43a08cd7360" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_732fd69c-0826-44c6-89be-c43a08cd7360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad1abce2-4ffd-4e84-883f-4efb177a7bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6a4e7798-ef74-45d2-8b6c-eaa4f79145d6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ad1abce2-4ffd-4e84-883f-4efb177a7bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43093c12-0732-46eb-a8c1-869eff684942" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_43093c12-0732-46eb-a8c1-869eff684942" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_79a4acf5-3910-43ee-a470-5d8e7cae40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_79a4acf5-3910-43ee-a470-5d8e7cae40d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_623c2b6d-afd9-4270-8842-d59a969f43d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_623c2b6d-afd9-4270-8842-d59a969f43d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a5d2647-2995-4725-bf82-e0f555158d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a5d2647-2995-4725-bf82-e0f555158d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_71330678-f043-4eee-9c78-de705955c7f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0f16df47-6858-4e6b-a1f4-72d8a0341cbc" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_71330678-f043-4eee-9c78-de705955c7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_986f9eeb-5a3a-4c18-91e2-351d64351ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_71330678-f043-4eee-9c78-de705955c7f4" xlink:to="loc_us-gaap_InterestPaidNet_986f9eeb-5a3a-4c18-91e2-351d64351ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7cfe48e-aa7b-4356-a73a-8ea9e55d5b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e7cfe48e-aa7b-4356-a73a-8ea9e55d5b59" xlink:to="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a1a4cba7-41c5-4f80-b933-5c799e755c36" xlink:to="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e278c5dc-55a0-43b4-83cf-35a006698345" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_CommonStockMember_e278c5dc-55a0-43b4-83cf-35a006698345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c2c9cf55-89ca-451d-a66d-e2a0802b4dea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c2c9cf55-89ca-451d-a66d-e2a0802b4dea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61f1f6b9-3c3d-43a2-b3aa-f4a93c5c9d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_61f1f6b9-3c3d-43a2-b3aa-f4a93c5c9d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_a2bb837b-e752-4441-b1c8-0fb448d23da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_daadde02-d79f-4571-abec-1337bea994b5" xlink:to="loc_us-gaap_RetainedEarningsMember_a2bb837b-e752-4441-b1c8-0fb448d23da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_dd9d3f1a-0505-46d9-aa1d-48b9ef99e603" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8d859bdc-0275-454c-8078-51f2833632a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_23e539d9-6e78-4305-b242-c59ad4a643d0" xlink:to="loc_us-gaap_WarrantMember_8d859bdc-0275-454c-8078-51f2833632a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c73f1609-3a0f-4259-b11f-14586b8044e8" xlink:to="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_029586c8-2193-4179-95c9-a595c7bfbeb8" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9e6fda82-b0e0-4b6c-a602-602abf2fa15f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockholdersEquity_9e6fda82-b0e0-4b6c-a602-602abf2fa15f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_98c9a779-3cb2-4214-8f78-2ab16a3dabde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_SharesOutstanding_98c9a779-3cb2-4214-8f78-2ab16a3dabde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e28c877c-9ae9-438b-8ea3-558eacd6fa4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e28c877c-9ae9-438b-8ea3-558eacd6fa4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_8dd38eaf-60bd-4376-89c2-12eb11c351ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan_8dd38eaf-60bd-4376-89c2-12eb11c351ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_93310827-64d3-48fa-9c72-20daa1920621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_93310827-64d3-48fa-9c72-20daa1920621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_fa81bbe2-a8f6-4067-938e-31516492652b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_fa81bbe2-a8f6-4067-938e-31516492652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_891bf207-7277-44f3-89a6-d84fef8ee6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_891bf207-7277-44f3-89a6-d84fef8ee6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8ff9a20d-7962-4d1a-8771-1591d19530f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_8ff9a20d-7962-4d1a-8771-1591d19530f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f3bcaa3c-9fb1-41da-9341-8ebff007c759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_f3bcaa3c-9fb1-41da-9341-8ebff007c759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_897cfe60-4a3a-4d21-99bc-59a472fc979c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_897cfe60-4a3a-4d21-99bc-59a472fc979c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_322e3955-c462-4f85-9a28-2f0000f74093" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_322e3955-c462-4f85-9a28-2f0000f74093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2082652e-c78e-4e4e-8309-20d2233966dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2082652e-c78e-4e4e-8309-20d2233966dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_c84fba7a-53e5-4527-9a7f-2a45c4995f95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_c84fba7a-53e5-4527-9a7f-2a45c4995f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3dd29bd8-d056-4736-ab81-26cdfef5febd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_NetIncomeLoss_3dd29bd8-d056-4736-ab81-26cdfef5febd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6c587455-7992-45f4-ac4e-b26d69ffde63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_StockholdersEquity_6c587455-7992-45f4-ac4e-b26d69ffde63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ba308b38-c9b3-4e8b-80d5-faddc36fe472" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_93dbb5f7-78fd-401a-8dd0-7f9e302ef741" xlink:to="loc_us-gaap_SharesOutstanding_ba308b38-c9b3-4e8b-80d5-faddc36fe472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="yten-20221231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_3d0ea7b9-d257-4a69-aa48-78f08280a578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f5d5a9cc-83bd-403b-a768-86fbbacc1dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_3d0ea7b9-d257-4a69-aa48-78f08280a578" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f5d5a9cc-83bd-403b-a768-86fbbacc1dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="yten-20221231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f2958f7-30d0-4e00-94fc-fc52dbb24a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_976b5b4e-eebd-44e9-a660-c77ddb072c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f2958f7-30d0-4e00-94fc-fc52dbb24a50" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_976b5b4e-eebd-44e9-a660-c77ddb072c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3c98330c-7668-4656-84bf-551962989e60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5fd79115-3c8b-4665-b656-e9ea1dca66f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3c98330c-7668-4656-84bf-551962989e60" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5fd79115-3c8b-4665-b656-e9ea1dca66f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/Investments" xlink:type="simple" xlink:href="yten-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_675e3474-dacf-4251-893a-045f5bed3d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c01b8e42-facf-4062-8427-2a07aad18fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_675e3474-dacf-4251-893a-045f5bed3d58" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c01b8e42-facf-4062-8427-2a07aad18fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="yten-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_00a2d270-92f1-4fde-aa6b-19802c7643da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_57c6963b-a910-4081-9412-2a7623511239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_00a2d270-92f1-4fde-aa6b-19802c7643da" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_57c6963b-a910-4081-9412-2a7623511239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNet" xlink:type="simple" xlink:href="yten-20221231.xsd#PropertyandEquipmentNet"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/PropertyandEquipmentNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2fee4a30-6419-45b9-a639-cdf9441cd397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aafeac4e-86cb-4e9b-b3c4-0a396b027aba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2fee4a30-6419-45b9-a639-cdf9441cd397" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_aafeac4e-86cb-4e9b-b3c4-0a396b027aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/AccruedExpenses" xlink:type="simple" xlink:href="yten-20221231.xsd#AccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/AccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f4550377-ba63-4078-8875-69004e87e138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_90494c91-5d81-489f-831b-b3675f7ac637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f4550377-ba63-4078-8875-69004e87e138" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_90494c91-5d81-489f-831b-b3675f7ac637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="yten-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd34c93e-c39a-4a90-afff-ce4a3c295b92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55b95a9a-8df9-4e40-b377-885de48f7b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_dd34c93e-c39a-4a90-afff-ce4a3c295b92" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_55b95a9a-8df9-4e40-b377-885de48f7b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LicenseAgreements" xlink:type="simple" xlink:href="yten-20221231.xsd#LicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c79b4473-7785-4c5d-807b-6a53bd0823be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14103f03-ced7-4b33-af96-958ac4a36a90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c79b4473-7785-4c5d-807b-6a53bd0823be" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_14103f03-ced7-4b33-af96-958ac4a36a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrants" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrants"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ea5fc7af-6fa6-4429-9761-23eb56942d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_51ffe1a5-241f-4a16-8e0f-ea98f195f116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ea5fc7af-6fa6-4429-9761-23eb56942d39" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_51ffe1a5-241f-4a16-8e0f-ea98f195f116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bfba832-410c-4e3b-ace7-93b1fa75eda0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6cfb6ee1-3a61-4cf5-bbc9-9802f524c7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2bfba832-410c-4e3b-ace7-93b1fa75eda0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6cfb6ee1-3a61-4cf5-bbc9-9802f524c7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/Leases" xlink:type="simple" xlink:href="yten-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1a5cef56-309e-4aeb-baff-500241a362e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_f7cda043-e490-43d8-a96b-513f443b8f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1a5cef56-309e-4aeb-baff-500241a362e0" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_f7cda043-e490-43d8-a96b-513f443b8f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxes" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a3edd370-281d-4144-bc63-f45427d465e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_ecb8d112-e05b-443c-8126-3dce3426afa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a3edd370-281d-4144-bc63-f45427d465e2" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_ecb8d112-e05b-443c-8126-3dce3426afa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/EmployeeBenefits" xlink:type="simple" xlink:href="yten-20221231.xsd#EmployeeBenefits"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/EmployeeBenefits" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cda40767-37fa-4c41-8a86-69d7fafd351d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_07fe4d6d-62e6-40aa-812d-774a06fc3da5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_cda40767-37fa-4c41-8a86-69d7fafd351d" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_07fe4d6d-62e6-40aa-812d-774a06fc3da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GovernmentResearchGrants" xlink:type="simple" xlink:href="yten-20221231.xsd#GovernmentResearchGrants"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/GovernmentResearchGrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_0481d62a-2d97-4a61-bd39-7b2fb9525cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EnergyGrantDisclosureTextBlock_dfc5c74a-695c-4831-a197-67bc50fa043b" xlink:href="yten-20221231.xsd#yten_EnergyGrantDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_0481d62a-2d97-4a61-bd39-7b2fb9525cbc" xlink:to="loc_yten_EnergyGrantDisclosureTextBlock_dfc5c74a-695c-4831-a197-67bc50fa043b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GeographicInformation" xlink:type="simple" xlink:href="yten-20221231.xsd#GeographicInformation"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/GeographicInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_173479ad-8766-4efa-8f8c-eaafa723f8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_75e201e6-6dda-41b9-b345-a9b2b62d6a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_173479ad-8766-4efa-8f8c-eaafa723f8e7" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_75e201e6-6dda-41b9-b345-a9b2b62d6a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/RelatedPartyTransaction" xlink:type="simple" xlink:href="yten-20221231.xsd#RelatedPartyTransaction"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/RelatedPartyTransaction" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e9b62b98-3ae3-41d3-94cb-f045283b48d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_be44bd46-a1d5-4b34-a17f-736709fdc9da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e9b62b98-3ae3-41d3-94cb-f045283b48d7" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_be44bd46-a1d5-4b34-a17f-736709fdc9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SubsequentEvent" xlink:type="simple" xlink:href="yten-20221231.xsd#SubsequentEvent"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SubsequentEvent" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_dc1b3e33-a150-4293-9092-aed0422a09e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_c6f70770-2207-4837-8b3d-a3b62190c4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_dc1b3e33-a150-4293-9092-aed0422a09e8" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_c6f70770-2207-4837-8b3d-a3b62190c4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_21b1afc1-5064-480d-9f9d-34c94e56ddf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_21b1afc1-5064-480d-9f9d-34c94e56ddf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_1faf0126-354d-4adc-9855-615f9ff1a41c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_1faf0126-354d-4adc-9855-615f9ff1a41c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_eca9a803-9705-42ba-8e6b-2d4d8ec6b8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_UseOfEstimates_eca9a803-9705-42ba-8e6b-2d4d8ec6b8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_bd881201-3e74-4402-ab3d-1bad1d9355a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy_bd881201-3e74-4402-ab3d-1bad1d9355a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03778f4e-eddb-4f42-b5cb-2120f3fc4f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_03778f4e-eddb-4f42-b5cb-2120f3fc4f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_8e000563-11d4-42b0-a3d0-797e151bbb41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_8e000563-11d4-42b0-a3d0-797e151bbb41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9a4aff74-b747-45e7-ad66-249fa30a25cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_9a4aff74-b747-45e7-ad66-249fa30a25cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68594f80-8ec6-4c5c-b1c9-1015f0ee140b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_68594f80-8ec6-4c5c-b1c9-1015f0ee140b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fe8fb292-542a-4dca-964b-abef499d1841" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fe8fb292-542a-4dca-964b-abef499d1841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_26520322-8732-4624-ad1c-8b277d95c433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_26520322-8732-4624-ad1c-8b277d95c433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6bc2c795-05aa-4a0b-b41f-292584e8002e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6bc2c795-05aa-4a0b-b41f-292584e8002e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c50edddc-c96c-42b6-a37f-ea8567b4ffa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c50edddc-c96c-42b6-a37f-ea8567b4ffa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e24be2e9-ac83-4ee5-a83c-44a8aa5b96e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e24be2e9-ac83-4ee5-a83c-44a8aa5b96e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_73d6aa2a-12c5-4927-82df-bfce7ba5e47c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_73d6aa2a-12c5-4927-82df-bfce7ba5e47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5cd2bc5d-efa3-4202-b527-e6600e862721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5cd2bc5d-efa3-4202-b527-e6600e862721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e2c6f7cf-8609-4104-b4a1-15bf06921544" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_e2c6f7cf-8609-4104-b4a1-15bf06921544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_6715a24d-ee09-470e-b6b1-6a7b8aa14f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_6715a24d-ee09-470e-b6b1-6a7b8aa14f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_IntellectualPropertyCostsPolicyPolicyTextBlock_6faed974-3002-4bdf-8209-a67181d647c2" xlink:href="yten-20221231.xsd#yten_IntellectualPropertyCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_yten_IntellectualPropertyCostsPolicyPolicyTextBlock_6faed974-3002-4bdf-8209-a67181d647c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_791464fa-01cc-457d-9ad1-77543696fdf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_791464fa-01cc-457d-9ad1-77543696fdf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_e028ab58-f715-4797-824e-e4e566fd81ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_e028ab58-f715-4797-824e-e4e566fd81ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fc530f7d-a9fc-4b8f-81df-612ec5619e83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fc530f7d-a9fc-4b8f-81df-612ec5619e83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_feaadd1d-08a7-4e96-920b-487cab3e74e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fc8bc533-a95d-4c69-83db-ac2457520a95" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_feaadd1d-08a7-4e96-920b-487cab3e74e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d7cfbb2-7777-4c00-9fd2-78bbfa6f68ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5437cc4a-43dc-4b4a-aecb-04cb01bdf927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d7cfbb2-7777-4c00-9fd2-78bbfa6f68ad" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_5437cc4a-43dc-4b4a-aecb-04cb01bdf927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_41e300f7-3c41-4d3b-be1c-3f32e10073ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d7cfbb2-7777-4c00-9fd2-78bbfa6f68ad" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_41e300f7-3c41-4d3b-be1c-3f32e10073ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e7bc5eef-e73c-4c64-9e4c-b21f5ba1a907" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d7cfbb2-7777-4c00-9fd2-78bbfa6f68ad" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_e7bc5eef-e73c-4c64-9e4c-b21f5ba1a907" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/InvestmentsTables" xlink:type="simple" xlink:href="yten-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59e652d6-1f8a-42ef-a954-12460ff929e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_28c527cd-5f15-42f2-9678-7d3fa5cd9759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_59e652d6-1f8a-42ef-a954-12460ff929e6" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_28c527cd-5f15-42f2-9678-7d3fa5cd9759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="yten-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_603912cb-898d-49d9-825b-5491b50ab6b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_87940d35-d78d-402b-b977-41aa42cb88cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_603912cb-898d-49d9-825b-5491b50ab6b8" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_87940d35-d78d-402b-b977-41aa42cb88cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetTables" xlink:type="simple" xlink:href="yten-20221231.xsd#PropertyandEquipmentNetTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/PropertyandEquipmentNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_766c8e71-ae1b-495b-9f28-27a4e1669fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f329bd1f-6cc6-4c0a-a082-e7b5e3582777" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_766c8e71-ae1b-495b-9f28-27a4e1669fb5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_f329bd1f-6cc6-4c0a-a082-e7b5e3582777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/AccruedExpensesTables" xlink:type="simple" xlink:href="yten-20221231.xsd#AccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/AccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_e593e850-e158-4a29-815e-a45a2210c83e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948265b9-fb27-4def-8c43-7e730e395c82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_e593e850-e158-4a29-815e-a45a2210c83e" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_948265b9-fb27-4def-8c43-7e730e395c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsTables" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e9d66fa6-bf4d-4cb2-b722-f57d4e112d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_04f8ae46-f3de-4533-94f5-d9efc44c9f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9d66fa6-bf4d-4cb2-b722-f57d4e112d59" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_04f8ae46-f3de-4533-94f5-d9efc44c9f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_3369c1f1-fd36-4d5a-8f31-4c51fcb6a9df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e9d66fa6-bf4d-4cb2-b722-f57d4e112d59" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_3369c1f1-fd36-4d5a-8f31-4c51fcb6a9df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_609d9d65-f209-4261-9c86-87aee7305158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fd40bcca-818a-4941-8528-3e47e59a3acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_609d9d65-f209-4261-9c86-87aee7305158" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fd40bcca-818a-4941-8528-3e47e59a3acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cf580564-6943-4f50-ac96-baaacef5f27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_609d9d65-f209-4261-9c86-87aee7305158" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_cf580564-6943-4f50-ac96-baaacef5f27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5e3e87d6-6e42-4469-871c-e769a77a32e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_609d9d65-f209-4261-9c86-87aee7305158" xlink:to="loc_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_5e3e87d6-6e42-4469-871c-e769a77a32e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesTables" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_961f1540-4d28-4017-a344-a56f4b1ff021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b1218969-44e4-4183-ac9f-1ba00baf5e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_961f1540-4d28-4017-a344-a56f4b1ff021" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b1218969-44e4-4183-ac9f-1ba00baf5e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_e471b3ba-0827-4370-b203-1c4f8d05f66b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_961f1540-4d28-4017-a344-a56f4b1ff021" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_e471b3ba-0827-4370-b203-1c4f8d05f66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d29836-e388-40be-8f2c-f8b8a3ceda1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_602c4130-efe4-4b71-a5cf-cd05d303bc5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d29836-e388-40be-8f2c-f8b8a3ceda1a" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_602c4130-efe4-4b71-a5cf-cd05d303bc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a3658329-e90b-496b-ac80-ce959b5d793c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d29836-e388-40be-8f2c-f8b8a3ceda1a" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a3658329-e90b-496b-ac80-ce959b5d793c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6cf14a2d-eed5-4814-a919-c240257db0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d29836-e388-40be-8f2c-f8b8a3ceda1a" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6cf14a2d-eed5-4814-a919-c240257db0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1423fb07-7e2b-4b4a-ba7d-84e7307b01fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f3d29836-e388-40be-8f2c-f8b8a3ceda1a" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1423fb07-7e2b-4b4a-ba7d-84e7307b01fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GeographicInformationTables" xlink:type="simple" xlink:href="yten-20221231.xsd#GeographicInformationTables"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/GeographicInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8a9e865f-df7e-44d3-9b90-052bbdfc535d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d527d14f-4f39-4fcd-9338-c447fc9841cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8a9e865f-df7e-44d3-9b90-052bbdfc535d" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_d527d14f-4f39-4fcd-9338-c447fc9841cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95394328-9f00-4e91-b34e-8b8ea613470a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_743e444b-e20c-4a40-9d73-5f1875ad005f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95394328-9f00-4e91-b34e-8b8ea613470a" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_743e444b-e20c-4a40-9d73-5f1875ad005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_deac98c3-6753-4c71-943a-6ca33e160801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed2f69c5-c7d7-4f8f-a255-741a785f58e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_deac98c3-6753-4c71-943a-6ca33e160801" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_ed2f69c5-c7d7-4f8f-a255-741a785f58e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5d4e66a2-25be-4ffa-a91e-7d3e5aeb5675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_deac98c3-6753-4c71-943a-6ca33e160801" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_5d4e66a2-25be-4ffa-a91e-7d3e5aeb5675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c63f0742-74d9-47b8-9e67-8192388dea05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_deac98c3-6753-4c71-943a-6ca33e160801" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c63f0742-74d9-47b8-9e67-8192388dea05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12335eea-2dfa-4530-ba92-394feecd3f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ffd80b0d-60a8-4693-a7be-522d2b3ff3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12335eea-2dfa-4530-ba92-394feecd3f5e" xlink:to="loc_us-gaap_SegmentReportingAbstract_ffd80b0d-60a8-4693-a7be-522d2b3ff3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12335eea-2dfa-4530-ba92-394feecd3f5e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_7df448c3-bec9-490d-b39d-32e9d6b97719" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_50cc857f-0def-4c05-add7-c74d1e6168c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_EquipmentMember_50cc857f-0def-4c05-add7-c74d1e6168c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c9fed4d4-055f-49a9-b5cb-162314fc8da4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c9fed4d4-055f-49a9-b5cb-162314fc8da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9f332594-3c56-471b-b471-e665c486b6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d13b6501-1869-434b-ad5a-f0bac125a8b3" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_9f332594-3c56-471b-b471-e665c486b6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_b418f555-0d44-410e-a982-64f1926b4a60" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6e5b10c4-c7d0-46d5-8406-2b6b98c2cdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_126bc3b0-a71e-4c86-8434-6fed53f7dcdf" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6e5b10c4-c7d0-46d5-8406-2b6b98c2cdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7d9f632a-af3f-4f58-ac42-89d6bba15e68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7d9f632a-af3f-4f58-ac42-89d6bba15e68" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_dce20f92-e499-42d5-86be-24a8bcb7e417" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_970a46f5-211f-4f24-a3b0-99f831b59207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_970a46f5-211f-4f24-a3b0-99f831b59207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_eef87b01-f95e-4027-a56d-848b66ac0b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_RestrictedStockMember_eef87b01-f95e-4027-a56d-848b66ac0b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_ae121854-77cb-4223-a10c-f65227c4c136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_91d3ff46-2ac3-4a26-9220-fabdc393ccd3" xlink:to="loc_us-gaap_WarrantMember_ae121854-77cb-4223-a10c-f65227c4c136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a4f0ac46-4bdc-4d55-acf1-8d2808821fc1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10a1c5d9-5bc8-48a3-93ae-3dd1936e61ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f25c9178-5121-4f9b-9022-935c5358dccd" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_10a1c5d9-5bc8-48a3-93ae-3dd1936e61ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0fe0941e-f498-4729-b8ee-3c501a734058" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_0fe0941e-f498-4729-b8ee-3c501a734058" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_ca550e1d-80c0-4b73-9e78-0ad020d5ec00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:to="loc_us-gaap_LongTermInvestments_ca550e1d-80c0-4b73-9e78-0ad020d5ec00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AccountsReceivableTradeAndUnbilledReceivables_1eb0295d-f7c7-4d56-96de-3e90460cb1e8" xlink:href="yten-20221231.xsd#yten_AccountsReceivableTradeAndUnbilledReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:to="loc_yten_AccountsReceivableTradeAndUnbilledReceivables_1eb0295d-f7c7-4d56-96de-3e90460cb1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_71184826-1f01-40d2-b522-b95e4915ac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:to="loc_us-gaap_NumberOfOperatingSegments_71184826-1f01-40d2-b522-b95e4915ac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_ce985be2-829e-4685-85e6-3198ad257a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c2ba4c7-bc37-4179-b160-abe71a4c4470" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_ce985be2-829e-4685-85e6-3198ad257a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#InvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/InvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b3939d9b-50e4-49ea-ade8-456ca90d5e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b3939d9b-50e4-49ea-ade8-456ca90d5e23" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_13166fd0-54c8-4c0c-8c22-88546437e992" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_d1bc3232-674f-46a9-a4d4-e38c93133687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c915920-9084-495d-812b-974acadfb4ea" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_d1bc3232-674f-46a9-a4d4-e38c93133687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_77d8907a-1c61-4ef2-9ca5-f23de4ccb7d8" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d808240-6097-41d6-b59a-536fa3457136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_7d808240-6097-41d6-b59a-536fa3457136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6eb1391c-9873-42e7-b522-6d0bc568533f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6eb1391c-9873-42e7-b522-6d0bc568533f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6506e890-8b81-48d4-91da-0c435bf5ef6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6506e890-8b81-48d4-91da-0c435bf5ef6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_016864c5-c767-452f-a222-ffd4d63a2c96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_c879367e-27fa-45fd-a413-373b08287532" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_016864c5-c767-452f-a222-ffd4d63a2c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_69d24e48-5a84-41dd-9933-495aa29c21e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42ea87c8-b904-45a6-a7f6-72411236a815" xlink:to="loc_us-gaap_LongTermInvestments_69d24e48-5a84-41dd-9933-495aa29c21e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9e129253-d8e1-406d-a06f-2f0bef7a5f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9e129253-d8e1-406d-a06f-2f0bef7a5f4c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c0f4e937-77bb-4938-9863-c709d74bc686" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ac1a2c26-ca26-4159-98df-28de6b01be85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_6edf2902-540e-41a9-b87d-bba59fdca6fb" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ac1a2c26-ca26-4159-98df-28de6b01be85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_4be78393-1fce-47da-a250-a47b073a0c14" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_11beefe3-eb6a-470d-971b-a8ce66263766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_11beefe3-eb6a-470d-971b-a8ce66263766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_f7815708-f2dd-4d09-a664-be6e74b0ff46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_f7815708-f2dd-4d09-a664-be6e74b0ff46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7c8a2c04-acc9-4c38-8fc7-f01aad5dd99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3815cf74-b7b7-44f1-9a6f-00a13241327e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7c8a2c04-acc9-4c38-8fc7-f01aad5dd99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_750dc56b-1261-4c5c-8d5d-ecc308fdc1aa" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_a384b7af-c073-4812-9de8-643791d6ace0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f84b0a67-cf0b-401e-8ee9-1fb09cde405c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_a384b7af-c073-4812-9de8-643791d6ace0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_5921b941-42a1-41c6-a1b0-625c191cc357" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6596f66a-9ec5-40f9-87cf-4d7445ce0580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3ec5fb1b-7ed9-4403-afaf-a08e55ea548c" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6596f66a-9ec5-40f9-87cf-4d7445ce0580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ff9d970b-68da-46a5-b881-8bc7648eda0e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64ab1efe-647a-4e2b-86f0-a907e670b09a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_64ab1efe-647a-4e2b-86f0-a907e670b09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f81c15b-1820-476d-8a70-d5765ef95674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8f81c15b-1820-476d-8a70-d5765ef95674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c7a683a2-d301-4158-b0a4-069eef73cd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1cca1671-be6d-42e4-b66e-a13371144e77" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c7a683a2-d301-4158-b0a4-069eef73cd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#PropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/PropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_abf7d4d2-3c6e-4591-9b5e-db5a843e9e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_abf7d4d2-3c6e-4591-9b5e-db5a843e9e8a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_31df40ea-33dd-4252-9d7a-01214aa6f8c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_b9c65230-6b3a-4029-a6e5-7da6b7302c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_EquipmentMember_b9c65230-6b3a-4029-a6e5-7da6b7302c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_c5b14507-cfe7-4f92-b1ff-4801e2efe32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_c5b14507-cfe7-4f92-b1ff-4801e2efe32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_018cd205-6ecb-46c5-979b-48281cf5b316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_018cd205-6ecb-46c5-979b-48281cf5b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_6e7a798d-aae5-4721-8cec-3b79db84df32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dbde7f13-2441-43fa-a427-e3bf49fcc6b4" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_6e7a798d-aae5-4721-8cec-3b79db84df32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_9c6ad381-1569-4673-8d7e-ca354552de47" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_346fcb5d-442c-4ef0-aa45-96bd393deee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_346fcb5d-442c-4ef0-aa45-96bd393deee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6eab7366-4996-47e6-abbc-1dc6572efae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_6eab7366-4996-47e6-abbc-1dc6572efae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_eb176b5c-dacd-45ed-9785-4912eef77e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_eb176b5c-dacd-45ed-9785-4912eef77e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7f46c623-e222-4e36-aba6-5ec7e00727c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_2153d859-c9ab-408d-8af2-468b8c7ba667" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7f46c623-e222-4e36-aba6-5ec7e00727c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/AccruedExpensesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#AccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/AccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c0c5085a-4c9a-4b04-bd69-5a0440dd7bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_c0c5085a-4c9a-4b04-bd69-5a0440dd7bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRentCurrent_bc8288bf-188d-409c-8958-1e5d7b0c91bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedRentCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_us-gaap_AccruedRentCurrent_bc8288bf-188d-409c-8958-1e5d7b0c91bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e9805966-63d3-4961-bb95-a90a36b68adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e9805966-63d3-4961-bb95-a90a36b68adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_3fabdc53-5b51-4411-9f7d-3147e08f9a37" xlink:href="yten-20221231.xsd#yten_AccruedFieldTrialsAndRelatedExpensesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_yten_AccruedFieldTrialsAndRelatedExpensesCurrent_3fabdc53-5b51-4411-9f7d-3147e08f9a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_edf78621-df2e-406c-94f4-665a042c77f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_edf78621-df2e-406c-94f4-665a042c77f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_6cd08cfe-ff61-434c-bda0-7e07e8379074" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_511f5e42-a71c-4eb6-814d-ccfaef42555d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_6cd08cfe-ff61-434c-bda0-7e07e8379074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85ecf2b4-d9a7-46a2-a44c-805b324a2510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_85ecf2b4-d9a7-46a2-a44c-805b324a2510" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:to="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_a790734e-7514-41f2-9fe0-371345343f58" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_45c3c53d-ea95-4b18-a144-49a0ee96279e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_303e9aab-7a2c-4c0f-b006-21d6a582eac3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_45c3c53d-ea95-4b18-a144-49a0ee96279e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6f4f394c-fffe-475e-80fb-aa62ab82bb28" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_b9f7dede-644a-485c-8381-ed23d7f95a47" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable_b9f7dede-644a-485c-8381-ed23d7f95a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_a629b5c8-d042-49f7-bb07-a36c9d1b17af" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable_a629b5c8-d042-49f7-bb07-a36c9d1b17af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTerm_85d3bac3-f5e7-404c-8915-a7e31e80ffce" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementTerm_85d3bac3-f5e7-404c-8915-a7e31e80ffce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_33a59598-fbef-4963-89f1-d118e340b292" xlink:href="yten-20221231.xsd#yten_CollaborativeArrangementTermOfOptionForLicenseAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement_33a59598-fbef-4963-89f1-d118e340b292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsMaximumExposure_3ee01cfd-81e3-451d-9ac7-513fdd0b6d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuaranteeObligationsMaximumExposure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_us-gaap_GuaranteeObligationsMaximumExposure_3ee01cfd-81e3-451d-9ac7-513fdd0b6d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_14c5c23f-b221-466e-b09a-a17f27b9bc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GuarantyLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8332e53b-1a03-44eb-ae61-78fb387bd8a3" xlink:to="loc_us-gaap_GuarantyLiabilities_14c5c23f-b221-466e-b09a-a17f27b9bc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LicenseAgreementsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44b01337-e702-49ab-9565-8c0f2bf0d208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LicenseAgreementTerm_456c87c0-b644-4c6a-9655-8b8c6fa04052" xlink:href="yten-20221231.xsd#yten_LicenseAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_44b01337-e702-49ab-9565-8c0f2bf0d208" xlink:to="loc_yten_LicenseAgreementTerm_456c87c0-b644-4c6a-9655-8b8c6fa04052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2a29e05c-04c2-4c1b-8fc6-d8d0b5e1f401" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2a29e05c-04c2-4c1b-8fc6-d8d0b5e1f401" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_7846d43d-9ffe-4b66-8e63-4b13d7e3c17a" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PublicOfferingMember_25aa0140-2143-4abe-ad39-623d1ab4372f" xlink:href="yten-20221231.xsd#yten_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_3865ae77-c758-4ece-b436-426f8b3a59ba" xlink:to="loc_yten_PublicOfferingMember_25aa0140-2143-4abe-ad39-623d1ab4372f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6248b696-e741-497d-b563-cc1b6ce84795" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedNovember2019Member_dc1c3121-c065-4323-aafb-c1f0d59866b4" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedNovember2019Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:to="loc_yten_SeriesAWarrantsIssuedNovember2019Member_dc1c3121-c065-4323-aafb-c1f0d59866b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesAWarrantsIssuedDecember2017Member_4d7be36d-f5da-49cf-a470-3e19f0492848" xlink:href="yten-20221231.xsd#yten_SeriesAWarrantsIssuedDecember2017Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_b401d8b7-db42-4e86-b728-5df0ff3f8cc2" xlink:to="loc_yten_SeriesAWarrantsIssuedDecember2017Member_4d7be36d-f5da-49cf-a470-3e19f0492848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e36d1001-11ca-4795-80b7-606843296297" xlink:to="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e4fd7b80-67ec-4486-854e-39fe22c55c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e4fd7b80-67ec-4486-854e-39fe22c55c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_c845627d-ad41-4a0e-abc1-83e0b1f2f690" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_c845627d-ad41-4a0e-abc1-83e0b1f2f690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction_6447779e-8e90-4957-99e3-ab23a93c9437" xlink:href="yten-20221231.xsd#yten_SaleofStockGrossConsiderationReceivedPerTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_SaleofStockGrossConsiderationReceivedPerTransaction_6447779e-8e90-4957-99e3-ab23a93c9437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_b43690a8-6c36-4376-9cdd-8186aa7d9c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_b43690a8-6c36-4376-9cdd-8186aa7d9c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d54065a4-e9de-44e3-a613-4f1f78f89f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d54065a4-e9de-44e3-a613-4f1f78f89f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f8ad0ca1-3197-40a9-9dd6-7b0b2c468d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f8ad0ca1-3197-40a9-9dd6-7b0b2c468d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExpired_4d626c13-f9ae-45e6-9bed-7c3a1b160af0" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExpired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_ClassOfWarrantOrRightExpired_4d626c13-f9ae-45e6-9bed-7c3a1b160af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ClassOfWarrantOrRightExercised_3b10cff8-2f1d-410f-a876-918ee2b41583" xlink:href="yten-20221231.xsd#yten_ClassOfWarrantOrRightExercised"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_yten_ClassOfWarrantOrRightExercised_3b10cff8-2f1d-410f-a876-918ee2b41583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_791da106-541b-4e63-acd4-80fed15f8cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_72c1c721-8d5b-401c-8750-0bda532bacb7" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_791da106-541b-4e63-acd4-80fed15f8cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3c2e2b66-91de-4b0a-b80f-0d3f9d9eb75c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3c2e2b66-91de-4b0a-b80f-0d3f9d9eb75c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a8029f57-3f85-4a76-b227-fed4985530a6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PublicOfferingMember_8e3fd39c-6a85-4c08-b9cb-10f5cb119156" xlink:href="yten-20221231.xsd#yten_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:to="loc_yten_PublicOfferingMember_8e3fd39c-6a85-4c08-b9cb-10f5cb119156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_3025a314-c74e-4248-9959-70745723449d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1b52a332-6a7c-4fe6-bcac-1d98b503a929" xlink:to="loc_us-gaap_PrivatePlacementMember_3025a314-c74e-4248-9959-70745723449d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8b4c2d62-5ac0-4620-8e48-3d33cb9bff97" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SeriesBWarrantExpiringMay2027Member_20b22d10-16bf-424f-b1b1-0a5af1a6c443" xlink:href="yten-20221231.xsd#yten_SeriesBWarrantExpiringMay2027Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_SeriesBWarrantExpiringMay2027Member_20b22d10-16bf-424f-b1b1-0a5af1a6c443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringJanuary2024Member_b386c21d-c88b-4777-93ef-ed9fbf7ba172" xlink:href="yten-20221231.xsd#yten_WarrantExpiringJanuary2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_WarrantExpiringJanuary2024Member_b386c21d-c88b-4777-93ef-ed9fbf7ba172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_WarrantExpiringSeptember2024Member_5d0dc8b7-46aa-493f-94c8-6d0ebb0324f1" xlink:href="yten-20221231.xsd#yten_WarrantExpiringSeptember2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5f4aac79-16db-4310-b9a8-b1d002cfa450" xlink:to="loc_yten_WarrantExpiringSeptember2024Member_5d0dc8b7-46aa-493f-94c8-6d0ebb0324f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_696abe2b-c941-447a-a9c2-aa6ed621ca19" xlink:to="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7a0c48a9-6895-4428-b7c6-e01f34ca33d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7a0c48a9-6895-4428-b7c6-e01f34ca33d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28c245f8-c0eb-4122-b980-b475c09a050e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_73ab597f-a02c-47e8-9b8f-a4131244ede5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_28c245f8-c0eb-4122-b980-b475c09a050e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_71241e64-67b4-4be4-a505-1fd59409a138" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_71241e64-67b4-4be4-a505-1fd59409a138" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_a9e0d707-4278-45e4-86ca-5d25be467efa" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_86065f1b-9f0e-495f-ac6e-c1c0e69fa65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d1079ae-6450-4893-b9ee-e0fa94c94c72" xlink:to="loc_us-gaap_WarrantMember_86065f1b-9f0e-495f-ac6e-c1c0e69fa65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:to="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c72877c6-2395-4552-854c-2a136a8f778f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e617ca32-4584-43a5-9548-7cc981ecc8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e617ca32-4584-43a5-9548-7cc981ecc8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_6e2e115b-8188-4e5b-9439-dc1111fa0157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e10483b0-9c1a-4cff-abe6-8eabe83c216a" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_6e2e115b-8188-4e5b-9439-dc1111fa0157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_09391984-8563-4b82-a088-1d8c97e690de" xlink:to="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d147ad1-4f06-498b-a85e-cbecd0443537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_57989053-4896-45eb-ac7e-fc639d73aa2d" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_8d147ad1-4f06-498b-a85e-cbecd0443537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3ea9515-f168-4771-99e2-7a9391a8db3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c3ea9515-f168-4771-99e2-7a9391a8db3f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_75d640d3-75da-4617-9262-e4cdeba719df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44dd9d39-947a-46c8-9503-1575aef79858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44dd9d39-947a-46c8-9503-1575aef79858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8d1c2b80-7637-4ada-a50b-a1bdef151269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_RestrictedStockMember_8d1c2b80-7637-4ada-a50b-a1bdef151269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e640283c-cc70-4ccf-9bff-90e73f4e140d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_693cd814-996d-4711-99b9-5ee0bb869df9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e640283c-cc70-4ccf-9bff-90e73f4e140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_e351033e-8c64-4e28-bd04-858e04814d8f" xlink:to="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2006Member_1e49df5e-3715-4412-8b38-ee078cfa465d" xlink:href="yten-20221231.xsd#yten_StockPlan2006Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2006Member_1e49df5e-3715-4412-8b38-ee078cfa465d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2014Member_5ef55aab-e8d0-4c4e-8252-104d5c198a94" xlink:href="yten-20221231.xsd#yten_StockPlan2014Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2014Member_5ef55aab-e8d0-4c4e-8252-104d5c198a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_StockPlan2018Member_23679b94-8f73-472a-aec5-79996cc613f9" xlink:href="yten-20221231.xsd#yten_StockPlan2018Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a3c8a4c6-a248-4151-be1a-192c72301149" xlink:to="loc_yten_StockPlan2018Member_23679b94-8f73-472a-aec5-79996cc613f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ed7cd6bf-857c-4b5c-a0b6-42b73346106e" xlink:to="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8af1c19b-b601-4f26-9e28-f5011cad9f8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:to="loc_srt_MinimumMember_8af1c19b-b601-4f26-9e28-f5011cad9f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_6e76e29d-7015-4719-8271-1615646bf06a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_2d13f656-01c9-4570-99b0-02cfbfdbcba6" xlink:to="loc_srt_MaximumMember_6e76e29d-7015-4719-8271-1615646bf06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_c9ddd429-edbd-4e68-8362-acca9b2f764d" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EmployeeAndDirectorMember_0bb7f429-70ca-47c0-931a-dfb9ef9addaa" xlink:href="yten-20221231.xsd#yten_EmployeeAndDirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_52be227f-a5b8-4f76-9f9c-1c2a9d30cc31" xlink:to="loc_yten_EmployeeAndDirectorMember_0bb7f429-70ca-47c0-931a-dfb9ef9addaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70a17eaf-51e2-4620-9ba5-abcbb97b6905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_9f4aea97-4964-4e66-a6b3-203b5c8367b6" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross_9f4aea97-4964-4e66-a6b3-203b5c8367b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a69b5fd-29b8-4dd3-a394-819e18b29fec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8a69b5fd-29b8-4dd3-a394-819e18b29fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d996a383-5682-43c7-ae77-fb16868312df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d996a383-5682-43c7-ae77-fb16868312df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_70ed507a-c342-43f1-b18d-36e571cf249a" xlink:href="yten-20221231.xsd#yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent_70ed507a-c342-43f1-b18d-36e571cf249a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c4460686-e55e-4b42-b015-dc0cc1201423" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_c4460686-e55e-4b42-b015-dc0cc1201423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_6c14d0f7-3707-4037-bb25-b88c65765f31" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber_6c14d0f7-3707-4037-bb25-b88c65765f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_ab5b50d5-30d3-4daf-ad90-bfd3992fd85a" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber_ab5b50d5-30d3-4daf-ad90-bfd3992fd85a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bbc2be79-4f08-4b2b-b42b-513155d863a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensation_bbc2be79-4f08-4b2b-b42b-513155d863a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bbb0e6a0-9ca7-4b05-a7ce-97f2c43641d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_bbb0e6a0-9ca7-4b05-a7ce-97f2c43641d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6131631-c92b-44e8-bf45-156b79c30c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_b6131631-c92b-44e8-bf45-156b79c30c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_83746279-50eb-417b-a83c-79263d547700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_83746279-50eb-417b-a83c-79263d547700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_7d4599e4-ea6f-4cef-a41a-f2f9ee5a9f41" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm_7d4599e4-ea6f-4cef-a41a-f2f9ee5a9f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd6dd820-28e6-4137-a321-45f3ca51e672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bd6dd820-28e6-4137-a321-45f3ca51e672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d61d7e49-3457-4692-b5ad-c510afe00464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d61d7e49-3457-4692-b5ad-c510afe00464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_116ce2cb-e53a-4362-8c15-edb67be665f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_116ce2cb-e53a-4362-8c15-edb67be665f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8eabf7dc-4f91-4898-9a23-58dc903ee25c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f37d948e-c047-4adb-b767-49bc8e0fa905" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8eabf7dc-4f91-4898-9a23-58dc903ee25c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbc4df26-a4fc-46a1-a22d-39b6ecff6722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_bbc4df26-a4fc-46a1-a22d-39b6ecff6722" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:to="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_92174a5a-46ff-4e7c-9e28-025637e98b48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_35ac1482-9cd9-4813-b762-6fdd1e221f43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41462097-8658-4147-bb7a-b2fe1ab47090" xlink:to="loc_us-gaap_EmployeeStockOptionMember_35ac1482-9cd9-4813-b762-6fdd1e221f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ed31134c-2e7f-4f3c-9fc3-a3c035b8697d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9254631-33f5-47ad-9f8a-f442e96ffa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f9254631-33f5-47ad-9f8a-f442e96ffa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d02973c-9d88-4f61-9a05-f2ce0173aff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8d02973c-9d88-4f61-9a05-f2ce0173aff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c2161f3-4346-4698-929c-56cac66b7d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8c2161f3-4346-4698-929c-56cac66b7d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_92ed46d4-2418-47fd-9de9-548727eef7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_92ed46d4-2418-47fd-9de9-548727eef7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_616ca067-0aad-4c91-b63f-627555c5c0da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_616ca067-0aad-4c91-b63f-627555c5c0da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_090384d5-5a04-4674-84c6-77564f67b001" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_090384d5-5a04-4674-84c6-77564f67b001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60b71988-ce91-41ed-94f1-b486b8958178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_60b71988-ce91-41ed-94f1-b486b8958178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f013377f-1e82-479f-bcb3-fac71d90058c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9c42c11d-9f21-458e-918b-dd8d0122b7f0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f013377f-1e82-479f-bcb3-fac71d90058c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_886181e0-dcec-4970-a6a7-4ce01b4cc578" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_886181e0-dcec-4970-a6a7-4ce01b4cc578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f01e6fc-a43b-47b1-b9e3-44d5908bc97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6f01e6fc-a43b-47b1-b9e3-44d5908bc97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4838958e-d304-427b-a9ff-4b79ef1212ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_4838958e-d304-427b-a9ff-4b79ef1212ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_efc4fec3-ed58-4ed0-b687-0d0a454e3e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_efc4fec3-ed58-4ed0-b687-0d0a454e3e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a0239581-7d70-47c9-a2fd-1320e689af29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a0239581-7d70-47c9-a2fd-1320e689af29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5421b96-25c2-4623-a12b-2016e8e40a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a5421b96-25c2-4623-a12b-2016e8e40a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f84b647-4c2b-46c2-b975-d0d0d1556eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3f84b647-4c2b-46c2-b975-d0d0d1556eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2175660b-5f87-40bf-a671-0821d800cea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_82450616-6f81-495a-893d-9c8eda2cad1b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2175660b-5f87-40bf-a671-0821d800cea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:href="yten-20221231.xsd#yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcab4ee6-19dd-4758-91c3-38e5de2ff8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcab4ee6-19dd-4758-91c3-38e5de2ff8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4025c112-bae4-4f3c-88a2-06a2ae63f33e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4025c112-bae4-4f3c-88a2-06a2ae63f33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02acd77e-caca-4d65-9b75-26bdb47520e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_3ad4eade-5203-4102-9989-b6e8871b4d21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_02acd77e-caca-4d65-9b75-26bdb47520e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7e73fc8b-be74-4ba9-9451-852e4bad8b5c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_414ce377-2976-4b20-b66d-835a73aa2781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_414ce377-2976-4b20-b66d-835a73aa2781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_82164aa2-22a0-4c74-b9a5-5b997745a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_82164aa2-22a0-4c74-b9a5-5b997745a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ce2cf96-7260-4cff-876d-118da323da46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract_39d89e77-8862-4918-8cc9-c840e78f1464" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6ce2cf96-7260-4cff-876d-118da323da46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_febb38f5-75da-46e4-9d2d-e63a84cf00ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_febb38f5-75da-46e4-9d2d-e63a84cf00ea" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:to="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2922bc2c-55ec-454f-86d1-97e030b888c2" xlink:to="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bc2903c3-fa09-4277-95b8-34f320530380" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:to="loc_srt_MinimumMember_bc2903c3-fa09-4277-95b8-34f320530380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_68bf36a6-f856-4b4a-800d-08a100fc9647" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f9554191-cc45-4cca-a400-aa1750cfb90e" xlink:to="loc_srt_MaximumMember_68bf36a6-f856-4b4a-800d-08a100fc9647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:to="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_e7f4e47d-3a70-4d94-b212-04f6fec60934" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_865d8c85-4744-446d-afe7-e09a41b454cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_62a1db8b-810d-4938-848a-9449156313b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_865d8c85-4744-446d-afe7-e09a41b454cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_176cd95f-8f27-4530-9aca-a278bf506e55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_26a5d91f-4a36-45e5-947d-f9e95fbee35e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e89a3d6-1df3-4b36-9a2c-1e9575b2b181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6e89a3d6-1df3-4b36-9a2c-1e9575b2b181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b6ff783b-cd93-497e-8934-3d5d2e4c20a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_b6ff783b-cd93-497e-8934-3d5d2e4c20a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9c30c16a-d52a-46e4-bd22-77abe4888b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_9c30c16a-d52a-46e4-bd22-77abe4888b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_feb7f75c-3d73-4889-92fa-deecc2e2ad3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_feb7f75c-3d73-4889-92fa-deecc2e2ad3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_cf0174b7-1ee8-43bb-9a45-d3e1c5ddaf3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_cf0174b7-1ee8-43bb-9a45-d3e1c5ddaf3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f80cb12a-290c-4090-805b-e8a108e019ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_b99c68b5-7974-4bc5-bb22-596ac54ba796" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_f80cb12a-290c-4090-805b-e8a108e019ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#StockBasedCompensationRestrictedStockUnitsRSUsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5f3f93c-d7a7-4ef1-a05d-2be2d7938d38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d5f3f93c-d7a7-4ef1-a05d-2be2d7938d38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a0b1149-9f15-4994-8744-a0d4cc2e8814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8a0b1149-9f15-4994-8744-a0d4cc2e8814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_875e0903-4cc1-460d-a00d-70c8a18daed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_875e0903-4cc1-460d-a00d-70c8a18daed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18a088b9-26fc-42ca-933f-0cf345184800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_18a088b9-26fc-42ca-933f-0cf345184800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fd28786-6ada-4fbd-b385-c2fc501aba65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_8fd28786-6ada-4fbd-b385-c2fc501aba65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8c52e5d4-ae45-40d5-bde1-d0c7fa5725ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_8c52e5d4-ae45-40d5-bde1-d0c7fa5725ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_68aabebe-5499-42b3-b758-351a2130ce95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5a9a3fdc-b0c0-4229-9802-7ed839070991" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_68aabebe-5499-42b3-b758-351a2130ce95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesMaturityAnalysisofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_128dd4bb-6e51-414b-8e64-0a042d43af19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_128dd4bb-6e51-414b-8e64-0a042d43af19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2d5a50d7-c1ac-40c4-8bb1-0964ab4c5742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2d5a50d7-c1ac-40c4-8bb1-0964ab4c5742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2e9c9773-a79d-4ed0-b426-a11c0d655ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2e9c9773-a79d-4ed0-b426-a11c0d655ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8e3e1792-489b-41c8-8bf5-ad3c4442bab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8e3e1792-489b-41c8-8bf5-ad3c4442bab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d64f6fc1-ef46-40e4-99f9-a4ec8f871849" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d64f6fc1-ef46-40e4-99f9-a4ec8f871849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_821414e8-10c5-4d70-aa60-dd3641ef57fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_821414e8-10c5-4d70-aa60-dd3641ef57fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f76f5d5e-f9c5-4243-a2b3-b1688c3c04b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_OperatingLeaseLiability_f76f5d5e-f9c5-4243-a2b3-b1688c3c04b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_577e87be-18ba-4b71-855c-d2f540850479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_577e87be-18ba-4b71-855c-d2f540850479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a42f6c9-413d-4ea6-ba70-6889ed3ab104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_87977151-4392-420b-97e1-1b7a1d77dde5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4a42f6c9-413d-4ea6-ba70-6889ed3ab104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesQuantitativeDisclosureofLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_55f46f24-e9a7-4849-8957-ca7ca9228dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55f46f24-e9a7-4849-8957-ca7ca9228dc0" xlink:to="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9ac9b32f-7683-4396-bdba-8cfce62bda01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:to="loc_us-gaap_OperatingLeaseCost_9ac9b32f-7683-4396-bdba-8cfce62bda01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_f33af035-05c1-4755-93bb-b09ee7941680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:to="loc_us-gaap_ShortTermLeaseCost_f33af035-05c1-4755-93bb-b09ee7941680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_ad450c4d-ff39-4654-8daf-f34055c4f405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:to="loc_us-gaap_SubleaseIncome_ad450c4d-ff39-4654-8daf-f34055c4f405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_68947436-a725-4755-b613-91c278fb5077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_4a5ebe70-519d-48e8-b1c0-d8cc6c1dd15a" xlink:to="loc_us-gaap_LeaseCost_68947436-a725-4755-b613-91c278fb5077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LeaseOtherInformationAbstract_400950e4-3bc6-49ff-bc31-a822d902048c" xlink:href="yten-20221231.xsd#yten_LeaseOtherInformationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_55f46f24-e9a7-4849-8957-ca7ca9228dc0" xlink:to="loc_yten_LeaseOtherInformationAbstract_400950e4-3bc6-49ff-bc31-a822d902048c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e339b65b-fe6f-4d42-a666-4557d02f3621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_LeaseOtherInformationAbstract_400950e4-3bc6-49ff-bc31-a822d902048c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e339b65b-fe6f-4d42-a666-4557d02f3621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b417d45-0b47-46a8-a5f8-6b750092874a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_yten_LeaseOtherInformationAbstract_400950e4-3bc6-49ff-bc31-a822d902048c" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_1b417d45-0b47-46a8-a5f8-6b750092874a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7f64f172-44e6-4a78-8fd3-b934d11ae9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7f64f172-44e6-4a78-8fd3-b934d11ae9a4" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:to="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4f3b68bc-38dd-4ee3-8a66-36bdd03c73a8" xlink:to="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_CJCheilJedangCorporationMember_572b81a5-0ee5-450c-bd8b-6543c1cfd967" xlink:href="yten-20221231.xsd#yten_CJCheilJedangCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_96aeecf7-6c25-4b23-80de-e7953dc68aa5" xlink:to="loc_yten_CJCheilJedangCorporationMember_572b81a5-0ee5-450c-bd8b-6543c1cfd967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis_a829282a-a55a-4ca1-b4cb-6d7c49758bee" xlink:to="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_PresidentialWayWoburnMassachusettsMember_feae7b9e-dac5-4f24-9940-551621f5544c" xlink:href="yten-20221231.xsd#yten_PresidentialWayWoburnMassachusettsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:to="loc_yten_PresidentialWayWoburnMassachusettsMember_feae7b9e-dac5-4f24-9940-551621f5544c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_a020b940-cc50-415a-8592-29cdd428e71e" xlink:href="yten-20221231.xsd#yten_A410DowneyRoadAnd110GymnasiumPlaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain_b8bd325b-4d56-4caf-97a3-8afde664814c" xlink:to="loc_yten_A410DowneyRoadAnd110GymnasiumPlaceMember_a020b940-cc50-415a-8592-29cdd428e71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_292a2d85-000f-4122-8906-6665947903d3" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingLeaseLeaseArea_db47af33-98af-4792-98ec-b6a89767ab30" xlink:href="yten-20221231.xsd#yten_LesseeOperatingLeaseLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_yten_LesseeOperatingLeaseLeaseArea_db47af33-98af-4792-98ec-b6a89767ab30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0570f6c3-35db-48c8-9e8f-992362140a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0570f6c3-35db-48c8-9e8f-992362140a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LesseeOperatingSubleaseSubleasedArea_02e4f903-936f-4349-a08d-314d077fbd1a" xlink:href="yten-20221231.xsd#yten_LesseeOperatingSubleaseSubleasedArea"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_yten_LesseeOperatingSubleaseSubleasedArea_02e4f903-936f-4349-a08d-314d077fbd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab830947-94ff-44a5-8829-c9c5102c9551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_eaef6f77-c1fe-425a-a4ac-0ac4bc13293b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ab830947-94ff-44a5-8829-c9c5102c9551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_035d9fb8-8cee-4d8d-9212-694f631e45e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_01a1c832-d557-40b2-b88e-b5995247ccbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_035d9fb8-8cee-4d8d-9212-694f631e45e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_01a1c832-d557-40b2-b88e-b5995247ccbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8894f6ae-f525-41ee-a4ca-a6ad93209974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_01a1c832-d557-40b2-b88e-b5995247ccbc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8894f6ae-f525-41ee-a4ca-a6ad93209974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5c72eb4a-880e-4a35-9dab-7feec6b42eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_01a1c832-d557-40b2-b88e-b5995247ccbc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_5c72eb4a-880e-4a35-9dab-7feec6b42eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_876bd940-2440-4b07-8189-b8d81192f584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_01a1c832-d557-40b2-b88e-b5995247ccbc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_876bd940-2440-4b07-8189-b8d81192f584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_ac90df9f-8ee7-4a0b-aa27-9afca99b71dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_035d9fb8-8cee-4d8d-9212-694f631e45e8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_ac90df9f-8ee7-4a0b-aa27-9afca99b71dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_ac90df9f-8ee7-4a0b-aa27-9afca99b71dc" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3cfc4168-bb07-4448-afd0-dbc21076eb13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_3cfc4168-bb07-4448-afd0-dbc21076eb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8797a267-acc8-4310-8b56-c4a0bb509a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_8797a267-acc8-4310-8b56-c4a0bb509a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5eed5469-6382-44aa-b470-8b270e8132e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5eed5469-6382-44aa-b470-8b270e8132e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ddc10cb-92cf-4a03-9f00-ae5c8e70935a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_caa00d44-c240-464a-9add-c5cfa104ccd3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_6ddc10cb-92cf-4a03-9f00-ae5c8e70935a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_ac90df9f-8ee7-4a0b-aa27-9afca99b71dc" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7addacf1-9615-4277-9574-c306799f8762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7addacf1-9615-4277-9574-c306799f8762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_af697b34-67d3-4f83-95c1-c294598de647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_af697b34-67d3-4f83-95c1-c294598de647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0c71d9e5-e55e-491d-928c-298e9c1f7d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_0c71d9e5-e55e-491d-928c-298e9c1f7d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8e9d3b4-b22f-430a-a38e-b8557060d642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_086a1d4f-bef9-4dae-aec7-661b8ad47b68" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a8e9d3b4-b22f-430a-a38e-b8557060d642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_c4adb410-b987-41a8-a5c2-9a078527c276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_ac90df9f-8ee7-4a0b-aa27-9afca99b71dc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_c4adb410-b987-41a8-a5c2-9a078527c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_eb8199ca-f422-41ff-992f-a2572c0bff2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_035d9fb8-8cee-4d8d-9212-694f631e45e8" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_eb8199ca-f422-41ff-992f-a2572c0bff2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_eb8199ca-f422-41ff-992f-a2572c0bff2c" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_aaec60df-e595-49a2-8449-926606f4f9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_aaec60df-e595-49a2-8449-926606f4f9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_b3d720c5-20a7-481b-8b6b-3bc40ab24974" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses_b3d720c5-20a7-481b-8b6b-3bc40ab24974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_809b417d-07ba-4c4d-9f73-bc0303a46d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_809b417d-07ba-4c4d-9f73-bc0303a46d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7496840d-73a9-468f-9b56-241d3b47ec0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_7496840d-73a9-468f-9b56-241d3b47ec0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxAssetsLeaseLiability_b2ecdb8e-e6b5-4ba3-b38a-ed53d1721945" xlink:href="yten-20221231.xsd#yten_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_yten_DeferredTaxAssetsLeaseLiability_b2ecdb8e-e6b5-4ba3-b38a-ed53d1721945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_dcaacacd-e247-4723-ab92-06786ce7ec94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_dcaacacd-e247-4723-ab92-06786ce7ec94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_38347c7f-158e-498f-9d16-9d67842d3e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_38347c7f-158e-498f-9d16-9d67842d3e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61eefe07-ddc2-4d5e-9a42-a9de9f0138ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61eefe07-ddc2-4d5e-9a42-a9de9f0138ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_13d30fa7-b866-4b6e-b7c8-08ddafefffc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c8c5cb17-7e7d-4d32-ac07-440793d8fe2d" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_13d30fa7-b866-4b6e-b7c8-08ddafefffc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2b6f68fa-afe2-475b-9bad-a18e7027f689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_eb8199ca-f422-41ff-992f-a2572c0bff2c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2b6f68fa-afe2-475b-9bad-a18e7027f689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_451cf521-5330-4f64-8580-54beac3aae65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2b6f68fa-afe2-475b-9bad-a18e7027f689" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_451cf521-5330-4f64-8580-54beac3aae65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset_6d203d63-5c3c-42fb-9ebc-30680b17ed9c" xlink:href="yten-20221231.xsd#yten_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2b6f68fa-afe2-475b-9bad-a18e7027f689" xlink:to="loc_yten_DeferredTaxLiabilitiesRightOfUseAsset_6d203d63-5c3c-42fb-9ebc-30680b17ed9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_73429431-5dda-484c-b9f4-44f325640645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_2b6f68fa-afe2-475b-9bad-a18e7027f689" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_73429431-5dda-484c-b9f4-44f325640645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_035d9fb8-8cee-4d8d-9212-694f631e45e8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b59b722-4550-4dd2-8cd4-f7268d5891bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_7b59b722-4550-4dd2-8cd4-f7268d5891bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_60bb631e-315c-4810-841e-b7997ac8cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_60bb631e-315c-4810-841e-b7997ac8cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cf04b122-2666-4934-b050-5840cc281c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_cf04b122-2666-4934-b050-5840cc281c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bee6bf06-7371-4721-8b95-a8545bb00372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_bee6bf06-7371-4721-8b95-a8545bb00372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5863bdc3-52ac-4cff-bf52-400a2f209873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5863bdc3-52ac-4cff-bf52-400a2f209873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_64a0bf4d-005d-4e4a-908e-00ace5890766" xlink:href="yten-20221231.xsd#yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent_64a0bf4d-005d-4e4a-908e-00ace5890766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_e507b593-f20e-45a2-b5c3-833af16c40f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_e507b593-f20e-45a2-b5c3-833af16c40f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e1838b56-1f29-4f45-8426-7baea5d3b188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_e1838b56-1f29-4f45-8426-7baea5d3b188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f75a25c3-3fec-4374-96bf-d45edf88a633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_f75a25c3-3fec-4374-96bf-d45edf88a633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c6cfd66e-3abe-4425-93a7-cc73e348482a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c6cfd66e-3abe-4425-93a7-cc73e348482a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41f26014-38b8-43cd-8e46-dad049614d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_9cff8f2d-6ae2-499b-a065-40c38c2ff454" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_41f26014-38b8-43cd-8e46-dad049614d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#IncomeTaxesDetailsTextualDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_a6cfd7e2-35ea-4f66-8ec4-03ffb137f3de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_a6cfd7e2-35ea-4f66-8ec4-03ffb137f3de" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_6558a462-fd6f-4639-adb6-7bca8614586c" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_896af26c-7717-4412-9106-689428452791" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_ce19db9e-2b76-427d-8462-b24788c33e01" xlink:to="loc_us-gaap_ResearchMember_896af26c-7717-4412-9106-689428452791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_75ca7a18-4fda-4915-bea8-45a1b90220e5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_d207cb27-ad14-4725-b151-53dbca297450" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_d207cb27-ad14-4725-b151-53dbca297450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_422e0993-72f8-42be-9dfd-aab5915b1bac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_422e0993-72f8-42be-9dfd-aab5915b1bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e4c5b6c9-b7fa-4f4a-8bbb-9d5524eb616d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_0540a989-42d9-483a-babf-eb3ec12d8ed2" xlink:to="loc_us-gaap_ForeignCountryMember_e4c5b6c9-b7fa-4f4a-8bbb-9d5524eb616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_d2644db7-0afb-40a9-98cb-49dc1e9d1f54" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c4c0500d-7ff9-411e-9e06-8d71af9ea9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c4c0500d-7ff9-411e-9e06-8d71af9ea9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4a0c8ee2-92cc-485a-889d-fc4b443ecbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4a0c8ee2-92cc-485a-889d-fc4b443ecbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96825fe4-62e5-4904-9c29-8ea992773767" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_96825fe4-62e5-4904-9c29-8ea992773767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_5a098285-2e6c-4571-8aa6-a6439442b51d" xlink:href="yten-20221231.xsd#yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries_5a098285-2e6c-4571-8aa6-a6439442b51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_92c58088-410c-4da7-8b25-b060f6aaa73b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_0708717b-8c2a-41ac-91c0-79ad45aa5c15" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_92c58088-410c-4da7-8b25-b060f6aaa73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/EmployeeBenefitsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#EmployeeBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/EmployeeBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6b16d860-8af9-4c9b-8db7-bfc9fcf75bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f8ddc5fd-e941-49e1-86bb-3a3134b61c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6b16d860-8af9-4c9b-8db7-bfc9fcf75bd9" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_f8ddc5fd-e941-49e1-86bb-3a3134b61c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e54746d2-3582-4acb-9184-33c449aeb315" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6b16d860-8af9-4c9b-8db7-bfc9fcf75bd9" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_e54746d2-3582-4acb-9184-33c449aeb315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_9db16068-df57-4bb5-aeb6-ea05aeaf441c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6b16d860-8af9-4c9b-8db7-bfc9fcf75bd9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan_9db16068-df57-4bb5-aeb6-ea05aeaf441c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ae7f6603-033f-44be-b4b4-ab41cb732f93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_6b16d860-8af9-4c9b-8db7-bfc9fcf75bd9" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ae7f6603-033f-44be-b4b4-ab41cb732f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GovernmentResearchGrantsDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#GovernmentResearchGrantsDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/GovernmentResearchGrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_b7a578c7-9b99-4374-86de-503f1cc42a5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract_b7a578c7-9b99-4374-86de-503f1cc42a5c" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:to="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_462166a3-005e-421a-a299-d78f56d10005" xlink:to="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a8985dc0-dc5f-4113-95af-80ab85def2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c14a41d6-dfdf-470f-9f81-2bd0184c98c7" xlink:to="loc_us-gaap_GrantMember_a8985dc0-dc5f-4113-95af-80ab85def2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:to="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProjectMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_dc8431d9-adfe-4ee0-900e-1c168ab3b41f" xlink:to="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_3185e3e4-de38-44ca-ae13-f0ffca2e387c" xlink:href="yten-20221231.xsd#yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProjectMember_a6fbee81-2eff-42b8-b0c1-9fed4af29902" xlink:to="loc_yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember_3185e3e4-de38-44ca-ae13-f0ffca2e387c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_7a52953b-c356-4ed4-bcd4-b6b9cba12d16" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_ResearchGrantMaximumPayrollCostReimbursement_829e54f3-0160-4860-809c-c3f204a4369e" xlink:href="yten-20221231.xsd#yten_ResearchGrantMaximumPayrollCostReimbursement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_ResearchGrantMaximumPayrollCostReimbursement_829e54f3-0160-4860-809c-c3f204a4369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantTerm_d8789810-3d0b-4f8d-a173-4f96f6880cf9" xlink:href="yten-20221231.xsd#yten_GovernmentGrantTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_GovernmentGrantTerm_d8789810-3d0b-4f8d-a173-4f96f6880cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GovernmentGrantCumulativeAmountAwarded_ec4266e6-a213-41f7-a3c1-b113a6c7f5de" xlink:href="yten-20221231.xsd#yten_GovernmentGrantCumulativeAmountAwarded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_yten_GovernmentGrantCumulativeAmountAwarded_ec4266e6-a213-41f7-a3c1-b113a6c7f5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d3463c-53cb-4a82-b6d7-1f1729ac3b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_63d3463c-53cb-4a82-b6d7-1f1729ac3b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_fa75ea4f-f8c0-4ffa-8dfb-610462095034" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_51f5faa0-c9be-4b3f-ab6f-f01e7de7f7cc" xlink:to="loc_us-gaap_ContractWithCustomerLiability_fa75ea4f-f8c0-4ffa-8dfb-610462095034" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/GeographicInformationDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#GeographicInformationDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/GeographicInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_dcb45645-c276-47ac-b4e2-0e2f31a5e02c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_dcb45645-c276-47ac-b4e2-0e2f31a5e02c" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:to="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_67cca926-2c5c-44d2-8028-2fd74f2b474d" xlink:to="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ReportableGeographicalComponentsMember_b275d0bc-e788-4133-8925-c81ef347a34b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ReportableGeographicalComponentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_0f92e95a-3fed-48c6-81e9-166e61f7ca73" xlink:to="loc_srt_ReportableGeographicalComponentsMember_b275d0bc-e788-4133-8925-c81ef347a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:to="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4c051412-905d-472b-8463-8a1e68180516" xlink:to="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_21b3e2c5-4429-42d2-8c48-b381c597307b" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:to="loc_country_US_21b3e2c5-4429-42d2-8c48-b381c597307b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_df9f8a7e-47c9-4171-98bd-c9fc8408c7e3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_d94a2d64-3960-4fa0-8bae-f57c1b92504e" xlink:to="loc_country_CA_df9f8a7e-47c9-4171-98bd-c9fc8408c7e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_a82a2f31-d95f-4dc6-93cc-a984a2406e5a" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38b0827d-c286-40d6-b6b8-77698ea6b805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_38b0827d-c286-40d6-b6b8-77698ea6b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1f3f5296-76af-498c-b485-dc9db472a231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_f661924f-4841-440c-af7d-f1dab2a6af9d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1f3f5296-76af-498c-b485-dc9db472a231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/RelatedPartyTransactionDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#RelatedPartyTransactionDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/RelatedPartyTransactionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_1c87c353-d649-45a2-95ee-f9e60642d68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_1c87c353-d649-45a2-95ee-f9e60642d68e" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c041e16c-bd47-46d3-be05-b9c6f85b1954" xlink:to="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_b153ecab-5ecb-4e94-9b32-409a0048ecdf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_10a3adc5-fb96-45f7-bc19-36f22693f1e9" xlink:to="loc_srt_AffiliatedEntityMember_b153ecab-5ecb-4e94-9b32-409a0048ecdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_fdec9c22-67c6-4d5a-8ecf-092fabf47e37" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedBalanceShares_ac521ce6-dfc9-4213-bbb9-ceafac3cc97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentOwnedBalanceShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_us-gaap_InvestmentOwnedBalanceShares_ac521ce6-dfc9-4213-bbb9-ceafac3cc97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_LicensePaymentsReceivable_4d9589f8-952a-4462-8754-66710059d31d" xlink:href="yten-20221231.xsd#yten_LicensePaymentsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_yten_LicensePaymentsReceivable_4d9589f8-952a-4462-8754-66710059d31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_GainOnRelatedPartyInvestment_5ad3641e-b009-4057-ac93-543a4e1178bc" xlink:href="yten-20221231.xsd#yten_GainOnRelatedPartyInvestment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_521a0b11-cb89-4d5a-ace7-0b3ebd34060e" xlink:to="loc_yten_GainOnRelatedPartyInvestment_5ad3641e-b009-4057-ac93-543a4e1178bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.yield10bio.com/role/SubsequentEventDetails" xlink:type="simple" xlink:href="yten-20221231.xsd#SubsequentEventDetails"/>
  <link:presentationLink xlink:role="http://www.yield10bio.com/role/SubsequentEventDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_512d281a-48ec-4d7b-9ca5-be199d4ce387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_512d281a-48ec-4d7b-9ca5-be199d4ce387" xlink:to="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_10cd4d6d-04be-4631-8f65-746be2f6dda8" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_61b7857f-4313-4e9d-bd64-ea0af492183c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_cc497f7f-98d3-4e57-9bc3-9047d668b20f" xlink:to="loc_us-gaap_SubsequentEventMember_61b7857f-4313-4e9d-bd64-ea0af492183c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:to="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_526cd981-b98d-4ecf-840b-dc5d41853a49" xlink:to="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b8861a1d-b93d-437c-b737-27ac47956b3a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:to="loc_srt_MinimumMember_b8861a1d-b93d-437c-b737-27ac47956b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_650b65f3-2b1a-4c6b-b013-b5ba1a51ee38" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f2dd54a8-24d8-43b4-9ae3-900cec050780" xlink:to="loc_srt_MaximumMember_650b65f3-2b1a-4c6b-b013-b5ba1a51ee38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_fd897c62-a185-4005-af79-1cd9586c0479" xlink:to="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_75cfe794-eb5f-4812-b027-03aef456f4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_75cfe794-eb5f-4812-b027-03aef456f4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockMaximumAggregateOfferingPrice_618982e2-1fe1-4124-8e11-5370f1fdbdee" xlink:href="yten-20221231.xsd#yten_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_yten_SaleOfStockMaximumAggregateOfferingPrice_618982e2-1fe1-4124-8e11-5370f1fdbdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_yten_SaleOfStockCommissionRate_685dcbff-e85f-4120-854e-6af270a4a199" xlink:href="yten-20221231.xsd#yten_SaleOfStockCommissionRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_yten_SaleOfStockCommissionRate_685dcbff-e85f-4120-854e-6af270a4a199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84922823-55ff-4a0f-8856-3b6ed9020ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_84922823-55ff-4a0f-8856-3b6ed9020ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_3e302de2-6b6f-4c80-bbea-f724b0c21c08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_3e302de2-6b6f-4c80-bbea-f724b0c21c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7c6a0bc4-9c9e-4463-82e6-61923ded4204" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_5d0068b4-58e7-425b-bde4-dac6b97d8990" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_7c6a0bc4-9c9e-4463-82e6-61923ded4204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>yten-20221231_g1.jpg
<TEXT>
begin 644 yten-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#L17AI9@  34T *@    @ ! $[  (
M   +   (2H=I  0    !   (5IR=  $    6   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $QY;FYE($)R
M=6T    %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,U.0  DI(
M @    ,U.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*O_  !$( ,T"\P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MV:2_-"EAL'&/,UIZLS/^$@\8_P#01TG_ ,%[_P#QVC_A(/&/_01TG_P7O_\
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M%=-^G07U7!^7W_\ !(/^$@\8_P#01TG_ ,%[_P#QVC_A(/&/_01TG_P7O_\
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M+/9.R;Z_973?H#P^"2N[??W*/_"0>,?^@CI/_@O?_P".T?\ "0>,?^@CI/\
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M'_H(Z3_X+W_^.T?\)!XQ_P"@CI/_ (+W_P#CM,HH_P!8<S_Y^_@O\@^H8?\
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MV>2=^_'=O2N3\W5?^A8UG_ORG_Q='FZK_P!"QK/_ 'Y3_P"+KI4LW4G+ZO\
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MI_\ %T>;JO\ T+&L_P#?E/\ XNC^R,P_Y\R^X/K5#^=%JBJOFZK_ -"QK/\
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M!<VAW(L\@19-F1D?>XSU&#B@"A_PK.Y&GP1_VC&TUK#IXBP'C5WMHW0Y*L&
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MHV^I/.!S70IXKT62^DM$OE,L?F DHP1C&,N%?&UBO.0I)&#GH: -BN<\>_\
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MNJ7-Y=SFV!N"B(52"7S54*!CELY/4Y[5(?'.G+$-UK?B<W'V8VOV?]ZLFW<
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MR8:(P,S1NO'W@7.<Y!Z$5;A\/P1WUC>SW5U=75DDJI-.X);S-N[(  _A&
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MSG_"!>'_ /GVNO\ P87'_P 71_P@7A__ )]KK_P87'_Q=='10!SG_"!>'_\
MGVNO_!A<?_%T?\(%X?\ ^?:Z_P#!A<?_ !=='10!SG_"!>'_ /GVNO\ P87'
M_P 71_P@7A__ )]KK_P87'_Q=='10!SG_"!>'_\ GVNO_!A<?_%T?\(%X?\
M^?:Z_P#!A<?_ !=='10!SG_"!>'_ /GVNO\ P87'_P 71_P@7A__ )]KK_P8
M7'_Q=='10!SG_"!>'_\ GVNO_!A<?_%T?\(%X?\ ^?:Z_P#!A<?_ !=='10!
MSG_"!>'_ /GVNO\ P87'_P 71_P@7A__ )]KK_P87'_Q=='10!SG_"!>'_\
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M6PN PA:5II99)E6$#>N<L,+Z;CG/8 ZS_A O#_\ S[77_@PN/_BZ/^$"\/\
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M #[77_@PN/\ XNC_ (0+P_\ \^UU_P"#"X_^+KHZ* .<_P"$"\/_ //M=?\
M@PN/_BZ/^$"\/_\ /M=?^#"X_P#BZZ.B@#G/^$"\/_\ /M=?^#"X_P#BZ/\
MA O#_P#S[77_ (,+C_XNNCHH YS_ (0+P_\ \^UU_P"#"X_^+H_X0+P__P ^
MUU_X,+C_ .+KHZ* .<_X0+P__P ^UU_X,+C_ .+H_P"$"\/_ //M=?\ @PN/
M_BZZ.B@#G/\ A O#_P#S[77_ (,+C_XNL+QKX-T2Q\&W]S;07"RQ*K(6O9V
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M%C+H]J^HZG%IBP7:2Q37$'G0%P#A95. 5.3U(YQ@YQ0!OKJ%F]O!.+J'RK@
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MPFAZ3'+#(FEV:R0*$B86Z QJ#D!3C@ \\406^E"_G6VALQ=QN)IA&B^8KL"
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MWL_[0'FZC<M+;/:_N#"=QW[BO)SC'/X56>ROY=(F,EE/YCZ39*0MN5^87&2
M ."!SCM7K-%+V/F3]1TLY/K^)YW-=:M:F<?Z;9V<FL7 N+BSM TH0(NP@!3D
M$Y^;!J%+GQ;=VK&:\OK1X=+DN$V6ZYF=9#L# J<,5QE1S7I5%/V3[E?5'?XV
M5M.EEGTNUFN%*S20HTBD8(8J">/K5FBBMCN2LK!1110,**** "BBB@#G-%_Y
M'CQ-_P!NO_HHUT=<YHO_ "/'B;_MU_\ 11KHZ "BBB@ IDL,5Q$8YXTEC.,J
MZ@@X.>AI]% !1110 4444 %%%% !1110 4444 %<YX]_Y$ZX_P"OBV_]*(ZZ
M.N<\>_\ (G7'_7Q;?^E$= '1T5C>+]%NO$7A'4-)T[4'TVYNHMD=VF=T1R#D
M8(/;UJMX$\.7WA3P?:Z1JNK2:O=0ER]W)NW/EB1]XD\ XZT :TNL:9!J*:?-
MJ-I'>R8V6SSJ)&STPN<GI5RO/M2\,W^O^--?MV*6VFW"Z>[SO Q=S$SO^Z;(
M (( SSC-8LNJ^*Y+G6VM(]5A:32[YEB,4SF&X1U$.TLNS<020(Q@CUQF@#UN
MJ\]A;7-W:W,\*O-:,SP.>L992I(^JDC\:X*\T>XTWQE!>)-K$TCZ%-'#,99I
M UP#NPV/E!P20#@9''053D;Q;I^CL+*?5+B:XT6TN)WN4:1HYC*!-M 'RMY9
M8[%P?E&!F@#U&BO.-/M]<NKK1[9]4U.73IM0N#*\44\+)$(,JC/)\Y7S.C'!
MYV@X%:OB^>\CUJW2:75(-+^Q2LCZ8DC.UUD;0WE@G&W) /RD]>U '945YA/J
MWBNUL;FWOTU(ZG<PZ8\/V:V9T5OE%S\R@JO(;(ST/%)!INHV<FHV=C+K-O-<
M>)E:=D:4C[*YR65F!4 C@L.1ZC H ]0HKSFV/B,>-I8YKV[A6WO&6& P32)/
M:B/Y1O)\K)/)<_,&'IQ659ZMXJE@U!T354AEM;6653#,TMNQGQ.J&1>7$1/"
M #C*B@#U3[;;#4!8^<OVHQ&819^;9G&[Z9.*GKS+4=.NKO4YKW1KC7 EOH-R
M;6=Q(LCS"4,B$LNYN1PK=1USQ7HFFRS3Z3:2W:E)Y($:52N,,5!(QVYH LU7
ML["VL%F%G"L0GF:>3;_$['+-^)JQ10 4444 %%%% !1110 4444 %%%% !11
M10 4444 %<Y\0?\ D0M4_P"N:_\ H:UT=<Y\0?\ D0M4_P"N:_\ H:T ='11
M10!P?AC6=4M+*_AM?#EY>Q+JE[B>*>%5;_2'[,X/MTK:_P"$AUK_ *%#4/\
MP)M__CE'@G_D"WG_ &%+[_TIDKHJ .=_X2'6O^A0U#_P)M__ (Y1_P )#K7_
M $*&H?\ @3;_ /QRNBHH YW_ (2'6O\ H4-0_P# FW_^.4?\)#K7_0H:A_X$
MV_\ \<KHJ* .=_X2'6O^A0U#_P ";?\ ^.4?\)#K7_0H:A_X$V__ ,<KHJ*
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M@Y],5FKXP\/O8F\35;=H/,$88$_,Q&0 .IR.>.W- %?_ (2'6O\ H4-0_P#
MFW_^.4?\)#K7_0H:A_X$V_\ \<JQ<>,/#UK' ]QK%HB7$0FB8RC#1DXW_P"[
MGC/0=Z4>+_#YLWNAJ]KY$<HA9_,X#L,JOU/;U[4 5O\ A(=:_P"A0U#_ ,";
M?_XY1_PD.M?]"AJ'_@3;_P#QRK=CXLT'4KE8+'5K6>5D9PJR=E^]^([CJ.]-
M'B_P^;2:Z.K6RP0%!)(S[0N\X3KV8\ ]#VH K?\ "0ZU_P!"AJ'_ ($V_P#\
M<H_X2'6O^A0U#_P)M_\ XY5BY\5Z2BR16]_;-=BW,\<4KE 1L+#<<';D#/3.
M.<5+!XCTUYK2UGO;=;RZC1EB1]P8LNX -@9R,D="1SB@"E_PD.M?]"AJ'_@3
M;_\ QRC_ (2'6O\ H4-0_P# FW_^.5-HWB:"_P#",6O:AY=A P=I-\F50*Y7
MK@=<?K573O'.EWO]J2R3Q16EE=K:QSARWG,8ED^[C((W$8Y/RF@"3_A(=:_Z
M%#4/_ FW_P#CE'_"0ZU_T*&H?^!-O_\ '*T$\1Z/):S7*:E;-#!&DLL@D!"(
M_P!UC['!Q]*I:GXPTRSL=5:TN8;J\TZVFG:V#X+>6N6&<=CP<9QGF@!G_"0Z
MU_T*&H?^!-O_ /'*/^$AUK_H4-0_\";?_P".5;B\4:2;JVLY[Z"*]G2,BW+\
M@N,JI/8GL#R:(O%>@SW,EO#JMJ\L2NSJLG0)]_\ %>XZB@"I_P )#K7_ $*&
MH?\ @3;_ /QRC_A(=:_Z%#4/_ FW_P#CE2)XY\,2%1'KEFVYE Q)UW=#_NGL
MW3WJZ?$&DC5#IQOX1=KG,6[G(&XC/3..<=<4 9W_  D.M?\ 0H:A_P"!-O\
M_'*/^$AUK_H4-0_\";?_ ..4R[^(/AJUT6ZU1-3CNK>U1))/LWSL58X4@=P3
MWZ5T%M<Q7=M'<6[[XI%W(V",C\: ,+_A(=:_Z%#4/_ FW_\ CE'_  D.M?\
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MR;CS86&>HDP,C'? IS^*[*Y:U&FW<&7OH[69+J.6-QN0L JE<Y( ()PI&>:
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MX4444 %%%% !1110!SFB_P#(\>)O^W7_ -%&NCKG-%_Y'CQ-_P!NO_HHUT=
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MH *YSX@_\B%JG_7-?_0UKHZYSX@_\B%JG_7-?_0UH Z.BBB@#G?!/_(%O/\
ML*7W_I3)715R5I\/;"'[2T]]J,CW%U-<'R;^XA5?,<OM"K)CC.,]^M6/^$$T
MS_GZU;_P;W7_ ,=J.9]OR'9=SI:*YK_A!-,_Y^M6_P#!O=?_ !VC_A!-,_Y^
MM6_\&]U_\=HYGV_+_,++N=+17-?\()IG_/UJW_@WNO\ X[1_P@FF?\_6K?\
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M_P".T67\OY?YE+#TD[I+^M3I:*YK_A!-,_Y^M6_\&]U_\=H_X033/^?K5O\
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M]U_\=H_X033/^?K5O_!O=?\ QVCF?;\O\PLNYTM%<U_P@FF?\_6K?^#>Z_\
MCM'_  @FF?\ /UJW_@WNO_CM',^WY?YA9=SI:*YK_A!-,_Y^M6_\&]U_\=H_
MX033/^?K5O\ P;W7_P =HYGV_+_,++N=+17-?\()IG_/UJW_ (-[K_X[1_P@
MFF?\_6K?^#>Z_P#CM',^WY?YA9=SI:*YK_A!-,_Y^M6_\&]U_P#':/\ A!-,
M_P"?K5O_  ;W7_QVCF?;\O\ ,++N=+17-?\ "":9_P _6K?^#>Z_^.T?\()I
MG_/UJW_@WNO_ ([1S/M^7^867<Z6BN:_X033/^?K5O\ P;W7_P =H_X033/^
M?K5O_!O=?_':.9]OR_S"R[G2USGCW_D3KC_KXMO_ $HCIO\ P@FF?\_6K?\
M@WNO_CM1W'P\T:ZA,-S+J<L9()1]5NB"001QYG8@&CF?;\O\PLNYU-%<U_P@
MNF?\_6K?^#>Z_P#CM'_"":9_S]:M_P"#>Z_^.T<S[?E_F%EW.EHKFO\ A!-,
M_P"?K5O_  ;W7_QVC_A!-,_Y^M6_\&]U_P#':.9]OR_S"R[G2T5S7_"":9_S
M]:M_X-[K_P".T?\ "":9_P _6K?^#>Z_^.T<S[?E_F%EW.EHKFO^$$TS_GZU
M;_P;W7_QVC_A!-,_Y^M6_P#!O=?_ !VCF?;\O\PLNYTM%<U_P@FF?\_6K?\
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L535/AQI^H:9+;17^I1.^W:\FH7,R@A@>4:7#=.AHYGV_(++N=A1115B/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>yten-20221231_g2.jpg
<TEXT>
begin 644 yten-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0  D "0  #_X0">17AI9@  34T *@    @ !0$2  ,
M   !  $   $:  4    !    2@$;  4    !    4@$H  ,    !  (  (=I
M  0    !    6@        "0     0   )     !  .2A@ '    $@   (2@
M @ $     0  !?2@ P $     0   F      05-#24D   !38W)E96YS:&]T
M_^$)(6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E
M9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z
M>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB6$U0
M($-O<F4@-BXP+C B/B \<F1F.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N
M=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(B\^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TB=R(_/@#_
M[0 X4&AO=&]S:&]P(#,N,  X0DE-! 0        X0DE-!"4      !#4'8S9
MCP"R!.F "9CL^$)^_^(-($E#0U]04D]&24Q%  $!   -$&%P<&P"$   ;6YT
M<E)'0B!865H@!^<  0 1  < #  X86-S<$%04$P     05!03
M             /;6  $     TRUA<'!L
M                                   19&5S8P   5    !B9'-C;0
M ;0   'J8W!R=    Z     C=W1P=    \0    4<EA96@   ]@    49UA9
M6@   ^P    48EA96@  !      4<E120P  !!0   @,86%R9P  #"     @
M=F-G=   #$     P;F1I;@  #'     ^;6UO9   #+     H=F-G<   #-@
M   X8E120P  !!0   @,9U120P  !!0   @,86%B9P  #"     @86%G9P
M#"     @9&5S8P         (1&ES<&QA>0
M
M                     &UL=6,         )@    QH<DA2    $@   =AK
M;TM2    $@   =AN8DY/    $@   =AI9       $@   =AH=4A5    $@
M =AC<T-:    $@   =AD841+    $@   =AN;$Y,    $@   =AF:49)
M$@   =AI=$E4    $@   =AE<T53    $@   =AR;U)/    $@   =AF<D-!
M    $@   =AA<@      $@   =AU:U5!    $@   =AH94E,    $@   =AZ
M:%17    $@   =AV:59.    $@   =AS:U-+    $@   =AZ:$-.    $@
M =AR=5)5    $@   =AE;D="    $@   =AF<D92    $@   =AM<P
M$@   =AH:4E.    $@   =AT:%1(    $@   =AC8453    $@   =AE;D%5
M    $@   =AE<UA,    $@   =AD941%    $@   =AE;E53    $@   =AP
M=$)2    $@   =AP;%!,    $@   =AE;$=2    $@   =AS=E-%    $@
M =AT<E12    $@   =AP=%!4    $@   =AJ84I0    $@   =@ 0P!O &P
M;P!R "  3 !# $0  '1E>'0     0V]P>7)I9VAT($%P<&QE($EN8RXL(#(P
M,C,  %A96B        #S%@ !     1;*6%E:(        &][   XI@   GA8
M65H@        8,L  +<T   0ZUA96B         FD   $"8  +_*8W5R=@
M      0     !0 *  \ %  9 !X (P H "T ,@ V #L 0 !% $H 3P!4 %D
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M  #RIP  #5D  !/0   *6W9C9W0          0 !          $    !
M      $    !          $  &YD:6X         -@  I8   %4   !.0
MH$   ":    /0   4    %1   (S,P ",S,  C,S          !M;6]D
M    !A   *!!     -:FB8                      =F-G<        P
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M\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0        $" P0%!@<("0H+_\0
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MUCP]K\<DME>#X@6=KYJ1R/$3Y4UJ)%PR$?,.<9Z$5_5%\6?^25^)O^P5>_\
MHEZ_D"_X(B_\HLOA#_V#[W_TNN:_*_%KC;'\,971QN7PA*<ZB@^=-JW+)Z6E
M'6Z74^KX1R/#YIBIT,0VDHW]UI.]TNJ?<^O/^'R'_!83_HR+3?\ PY&G?_(U
M'_#Y#_@L)_T9%IO_ (<C3O\ Y&KZ9HK^?O\ B8OB;_GQ0_\  )__ "P_0O\
MB'&6?SU/OC_\@?,W_#Y#_@L)_P!&1:;_ .'(T[_Y&H_X?(?\%A/^C(M-_P##
MD:=_\C5],T4?\3%\3?\ /BA_X!/_ .6!_P 0XRS^>I]\?_D#YF_X?(?\%A/^
MC(M-_P##D:=_\C4?\/D/^"PG_1D6F_\ AR-._P#D:OIFBC_B8OB;_GQ0_P#
M)_\ RP/^(<99_/4^^/\ \@?,W_#Y#_@L)_T9%IO_ (<C3O\ Y&H_X?(?\%A/
M^C(M-_\ #D:=_P#(U?3-%'_$Q?$W_/BA_P" 3_\ E@?\0XRS^>I]\?\ Y ^9
MO^'R'_!83_HR+3?_  Y&G?\ R-1_P^0_X+"?]&1:;_X<C3O_ )&KZ9HH_P")
MB^)O^?%#_P  G_\ + _XAQEG\]3[X_\ R!\S?\/D/^"PG_1D6F_^'(T[_P"1
MJ/\ A\A_P6$_Z,BTW_PY&G?_ "-7TS11_P 3%\3?\^*'_@$__E@?\0XRS^>I
M]\?_ ) ^9O\ A\A_P6$_Z,BTW_PY&G?_ "-1_P /D/\ @L)_T9%IO_AR-._^
M1J^F:*/^)B^)O^?%#_P"?_RP/^(<99_/4^^/_P @?,W_  ^0_P""PG_1D6F_
M^'(T[_Y&H_X?(?\ !83_ *,BTW_PY&G?_(U?3-%'_$Q?$W_/BA_X!/\ ^6!_
MQ#C+/YZGWQ_^0/F;_A\A_P %A/\ HR+3?_#D:=_\C4?\/D/^"PG_ $9%IO\
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MQ?$W_/BA_P" 3_\ E@?\0XRS^>I]\?\ Y ^9O^'R'_!83_HR+3?_  Y&G?\
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M\/D/^"PG_1D6F_\ AR-._P#D:C_A\A_P6$_Z,BTW_P .1IW_ ,C5],T5XO\
MQ,7Q-_SXH?\ @$__ )8=O_$.,L_GJ??'_P"0/F;_ (?(?\%A/^C(M-_\.1IW
M_P C4?\ #Y#_ (+"?]&1:;_X<C3O_D:OIFBC_B8OB;_GQ0_\ G_\L#_B'&6?
MSU/OC_\ ('S-_P /D/\ @L)_T9%IO_AR-._^1J/^'R'_  6$_P"C(M-_\.1I
MW_R-7TS11_Q,7Q-_SXH?^ 3_ /E@?\0XRS^>I]\?_D#YF_X?(?\ !83_ *,B
MTW_PY&G?_(U'_#Y#_@L)_P!&1:;_ .'(T[_Y&KZ9HH_XF+XF_P"?%#_P"?\
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MR-._^1J/^'R'_!83_HR+3?\ PY&G?_(U?3-%'_$Q?$W_ #XH?^ 3_P#E@?\
M$.,L_GJ??'_Y ^9O^'R'_!83_HR+3?\ PY&G?_(U'_#Y#_@L)_T9%IO_ (<C
M3O\ Y&KZ9HH_XF+XF_Y\4/\ P"?_ ,L#_B'&6?SU/OC_ /('S-_P^0_X+"?]
M&1:;_P"'(T[_ .1J/^'R'_!83_HR+3?_  Y&G?\ R-7TS11_Q,7Q-_SXH?\
M@$__ )8'_$.,L_GJ??'_ .0/F;_A\A_P6$_Z,BTW_P .1IW_ ,C4?\/D/^"P
MG_1D6F_^'(T[_P"1J^F:*/\ B8OB;_GQ0_\  )__ "P/^(<99_/4^^/_ ,@?
M,W_#Y#_@L)_T9%IO_AR-._\ D:C_ (?(?\%A/^C(M-_\.1IW_P C5],T4?\
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M (AQEG\]3[X__('S-_P^0_X+"?\ 1D6F_P#AR-._^1J/^'R'_!83_HR+3?\
MPY&G?_(U?3-%'_$Q?$W_ #XH?^ 3_P#E@?\ $.,L_GJ??'_Y ^9O^'R'_!83
M_HR+3?\ PY&G?_(U'_#Y#_@L)_T9%IO_ (<C3O\ Y&KZ9HH_XF+XF_Y\4/\
MP"?_ ,L#_B'&6?SU/OC_ /('S-_P^0_X+"?]&1:;_P"'(T[_ .1J/^'R'_!8
M3_HR+3?_  Y&G?\ R-7TS11_Q,7Q-_SXH?\ @$__ )8'_$.,L_GJ??'_ .0/
MF;_A\A_P6$_Z,BTW_P .1IW_ ,C4?\/D/^"PG_1D6F_^'(T[_P"1J^F:*/\
MB8OB;_GQ0_\  )__ "P/^(<99_/4^^/_ ,@?,W_#Y#_@L)_T9%IO_AR-._\
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M (<C3O\ Y&H_X?(?\%A/^C(M-_\ #D:=_P#(U?3-%'_$Q?$W_/BA_P" 3_\
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M_P##D:=_\C4?\/D/^"PG_1D6F_\ AR-._P#D:OIFBC_B8OB;_GQ0_P# )_\
MRP/^(<99_/4^^/\ \@?,W_#Y#_@L)_T9%IO_ (<C3O\ Y&H_X?(?\%A/^C(M
M-_\ #D:=_P#(U?3-%'_$Q?$W_/BA_P" 3_\ E@?\0XRS^>I]\?\ Y ^9O^'R
M'_!83_HR+3?_  Y&G?\ R-1_P^0_X+"?]&1:;_X<C3O_ )&KZ9HH_P")B^)O
M^?%#_P  G_\ + _XAQEG\]3[X_\ R!\S?\/D/^"PG_1D6F_^'(T[_P"1J/\
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MY&G?_(U?3-%'_$Q?$W_/BA_X!/\ ^6!_Q#C+/YZGWQ_^0/F;_A\A_P %A/\
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M  Y&G?\ R-1_P^0_X+"?]&1:;_X<C3O_ )&KZ9HH_P")B^)O^?%#_P  G_\
M+ _XAQEG\]3[X_\ R!\S?\/D/^"PG_1D6F_^'(T[_P"1J/\ A\A_P6$_Z,BT
MW_PY&G?_ "-7TS11_P 3%\3?\^*'_@$__E@?\0XRS^>I]\?_ ) ^9O\ A\A_
MP6$_Z,BTW_PY&G?_ "-1_P /D/\ @L)_T9%IO_AR-._^1J^F:*/^)B^)O^?%
M#_P"?_RP/^(<99_/4^^/_P @?,W_  ^0_P""PG_1D6F_^'(T[_Y&H_X?(?\
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M (<C3O\ Y&H_X?(?\%A/^C(M-_\ #D:=_P#(U?3-%'_$Q?$W_/BA_P" 3_\
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M>_\ HEZ_D"_X(B_\HLOA#_V#[W_TNN:_GOZ1W_(@PO\ U_7_ *;J'Z)X;?\
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MS0C4BFW"3Y;IV3Z/8WAQ;@W3JSG"<7"*DXRC9N+=DTKZK5=4?(=%?I!H_P
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MS@?!/_MW7["5^/?_  5]_P";7O\ LX'P3_[=U]5P3_R.L/\ ]O?^D2/*SO\
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MT^>5DVK74=-+WLD].[1\E2XH5!XN>-^"G4Y%9:V=]]==CXKHK]'=/^ '[/\
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M++_\=?\ ]Q'E8;_?\1Z0_P#;COOAS\.M<^)VNR>'?#\D,=Q' \_[YBJD(0,
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MS2R3&?8A^>4$,=I&WD,>,8]*7Q'X]\7>*_$:^+=;O7?44"!)XP(F79]W&P*
M1ZCFO"R;Q,PF78)TZ=*4JGUWZRD[*+IN/*XMW;4]_LM+>[V._&<,5L364I32
MC[#V76_->][6V^=_(_2#Q]XS^+7AOQI+!X:\&0ZI =I@O4!9F!4 [F'W2#D<
MXX]J^)/VA/$/C7Q!XZC;QYIT6EWMM:QQ"")Q(-A+."6!8$G<>]6[7]I[XU6M
MJ+4:LLF!@.\$3,,>^WGZG->/>)?$^O>,-7DU[Q)<M=W<V TC8' &     !Z
M4O$#Q!P6<X.I0P6)Q+YZBFZ=2-&-.*U=DX7G)IVY;O;>[#A[AZO@JT9UZ5-<
ML;<T7-R>W?1*U[^>UC!K]'_B=_R:)IO_ %XZ9_[3K\X*]'U/XM_$'6?!\7@+
M4=0\S2H4CC2'RHQA8L;!N"[CC [_ %KY;@SBG"Y1@\UP^)C)O$T)4X\J32D[
MZRNU9:]+OR/6SK*JN,K82I3:2IS4G>^R[:/7[C[-_9(9D^$^O,AP1=RD$?\
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M:V;ZR4 P2\<,:.<<C)"Y^N,9[UQ>M_%7Q[XB\4V?C35[_P W4M/""WF$4:[
MC%A\H4*>23R#7TO$7BODF*P;PF$A6M[>E52E"E&,(PDFX14&MDM'*[;>K6[\
MS+N$L=2K>UK.'\.4':4VVVK*3YEYZVM;L?1/[8!(^*&C$=K*/_T<]=S^VQ_R
M"?#_ /UVN/\ T%*^+?&7Q \7>/\ 58M:\67?VJY@C$4;[$CVJ"6 P@4=2?>K
M_C?XI^._B-%;0>,;[[6MH6,0\N./!?&3\BKG.!UKY?-_$'+L52XAA3IS3QTJ
M+IW4=%3E>7/[VEUMR\WG8]3!\.XFE++I2E']PIJ6KUYE9<NFOG>Q]G_&AO\
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M.?%NF>*CXVL;^1-49VD:XX+,S=<@@@@]P1BNO\4_'+XF^,A9#7=0#C3[A+J
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M)N\7JVK6T?6[1YY\3-#TOPU\0-8T#12?LMI=R1Q G)55/W<]]O3UXKU;P_\
MM2?$_P -Z%9^'K 6;06,*01EX26V1C:,D,,\#TKYTDDDED:65BS,222<DD]S
M3*_'L)Q-CLOQE?%915EA_:-Z0=K1;NH^BZ'V57*Z&(HTZ6,BJG*EJUUM9OYG
MU+_PU]\6O[EC_P!^6_\ BZ^??%WBG5/&OB.Z\4:UL^U7C!I/+7:N0 HP.>PK
MG**,XXMSG-:4:&98N=6"=TI2;2=FK^MFPP>3X+"3=3#48QDU:Z70_1WX-_\
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M+A-QC:,N::<HW^TDMM%KJ6^$*T,74FH4YTYSYKR<^97=VK1T?E^/8^J? O\
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M&,_^#DK_ )__ -FG_O[XI_\ C-'_  QG_P ')7_/_P#LT_\ ?WQ3_P#&:/\
MB ?%G\E/_P #0?Z_Y1_-+_P%GV;17QE_PQG_ ,')7_/_ /LT_P#?WQ3_ /&:
M/^&,_P#@Y*_Y_P#]FG_O[XI_^,T?\0#XL_DI_P#@:#_7_*/YI?\ @+/LVBOC
M+_AC/_@Y*_Y__P!FG_O[XI_^,T?\,9_\')7_ #__ +-/_?WQ3_\ &:/^(!\6
M?R4__ T'^O\ E'\TO_ 6?9M%?&7_  QG_P ')7_/_P#LT_\ ?WQ3_P#&:/\
MAC/_ (.2O^?_ /9I_P"_OBG_ .,T?\0#XL_DI_\ @:#_ %_RC^:7_@+/LVBO
MC+_AC/\ X.2O^?\ _9I_[^^*?_C-'_#&?_!R5_S_ /[-/_?WQ3_\9H_X@'Q9
M_)3_ / T'^O^4?S2_P# 6?9M%?&7_#&?_!R5_P __P"S3_W]\4__ !FC_AC/
M_@Y*_P"?_P#9I_[^^*?_ (S1_P 0#XL_DI_^!H/]?\H_FE_X"S[-HKXR_P"&
M,_\ @Y*_Y_\ ]FG_ +^^*?\ XS1_PQG_ ,')7_/_ /LT_P#?WQ3_ /&:/^(!
M\6?R4_\ P-!_K_E'\TO_  %GV;17QE_PQG_P<E?\_P#^S3_W]\4__&:/^&,_
M^#DK_G__ &:?^_OBG_XS1_Q /BS^2G_X&@_U_P H_FE_X"S[-HKXR_X8S_X.
M2O\ G_\ V:?^_OBG_P",T?\ #&?_  <E?\__ .S3_P!_?%/_ ,9H_P"(!\6?
MR4__  -!_K_E'\TO_ 6?9M%?&7_#&?\ P<E?\_\ ^S3_ -_?%/\ \9H_X8S_
M .#DK_G_ /V:?^_OBG_XS1_Q /BS^2G_ .!H/]?\H_FE_P" L^S:*^,O^&,_
M^#DK_G__ &:?^_OBG_XS1_PQG_P<E?\ /_\ LT_]_?%/_P 9H_X@'Q9_)3_\
M#0?Z_P"4?S2_\!9]FT5\9?\ #&?_  <E?\__ .S3_P!_?%/_ ,9H_P"&,_\
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M_P 0#XL_DI_^!H/]?\H_FE_X"S[-HKXR_P"&,_\ @Y*_Y_\ ]FG_ +^^*?\
MXS1_PQG_ ,')7_/_ /LT_P#?WQ3_ /&:/^(!\6?R4_\ P-!_K_E'\TO_  %G
MV;17QE_PQG_P<E?\_P#^S3_W]\4__&:/^&,_^#DK_G__ &:?^_OBG_XS1_Q
M/BS^2G_X&@_U_P H_FE_X"S[-HKXR_X8S_X.2O\ G_\ V:?^_OBG_P",T?\
M#&?_  <E?\__ .S3_P!_?%/_ ,9H_P"(!\6?R4__  -!_K_E'\TO_ 6?9M%?
M&7_#&?\ P<E?\_\ ^S3_ -_?%/\ \9H_X8S_ .#DK_G_ /V:?^_OBG_XS1_Q
M /BS^2G_ .!H/]?\H_FE_P" L^S:*^,O^&,_^#DK_G__ &:?^_OBG_XS1_PQ
MG_P<E?\ /_\ LT_]_?%/_P 9H_X@'Q9_)3_\#0?Z_P"4?S2_\!9]FT5\9?\
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M_P"?_P#9I_[^^*?_ (S1_P 0#XL_DI_^!H/]?\H_FE_X"S[-HKXR_P"&,_\
M@Y*_Y_\ ]FG_ +^^*?\ XS1_PQG_ ,')7_/_ /LT_P#?WQ3_ /&:/^(!\6?R
M4_\ P-!_K_E'\TO_  %GV;17QE_PQG_P<E?\_P#^S3_W]\4__&:/^&,_^#DK
M_G__ &:?^_OBG_XS1_Q /BS^2G_X&@_U_P H_FE_X"S[-HKXR_X8S_X.2O\
MG_\ V:?^_OBG_P",T?\ #&?_  <E?\__ .S3_P!_?%/_ ,9H_P"(!\6?R4__
M  -!_K_E'\TO_ 6?9M%?&7_#&?\ P<E?\_\ ^S3_ -_?%/\ \9H_X8S_ .#D
MK_G_ /V:?^_OBG_XS1_Q /BS^2G_ .!H/]?\H_FE_P" L^S:*^,O^&,_^#DK
M_G__ &:?^_OBG_XS1_PQG_P<E?\ /_\ LT_]_?%/_P 9H_X@'Q9_)3_\#0?Z
M_P"4?S2_\!9]FT5\9?\ #&?_  <E?\__ .S3_P!_?%/_ ,9H_P"&,_\ @Y*_
MY_\ ]FG_ +^^*?\ XS1_Q /BS^2G_P"!H/\ 7_*/YI?^ L^S:*^,O^&,_P#@
MY*_Y_P#]FG_O[XI_^,T?\,9_\')7_/\ _LT_]_?%/_QFC_B ?%G\E/\ \#0?
MZ_Y1_-+_ ,!9]FT5\9?\,9_\')7_ #__ +-/_?WQ3_\ &:/^&,_^#DK_ )__
M -FG_O[XI_\ C-'_ ! /BS^2G_X&@_U_RC^:7_@+/LVBOC+_ (8S_P"#DK_G
M_P#V:?\ O[XI_P#C-'_#&?\ P<E?\_\ ^S3_ -_?%/\ \9H_X@'Q9_)3_P#
MT'^O^4?S2_\  6?9M%?&7_#&?_!R5_S_ /[-/_?WQ3_\9H_X8S_X.2O^?_\
M9I_[^^*?_C-'_$ ^+/Y*?_@:#_7_ "C^:7_@+/LVBOC+_AC/_@Y*_P"?_P#9
MI_[^^*?_ (S1_P ,9_\ !R5_S_\ [-/_ ']\4_\ QFC_ (@'Q9_)3_\  T'^
MO^4?S2_\!9]FT5\9?\,9_P#!R5_S_P#[-/\ W]\4_P#QFC_AC/\ X.2O^?\
M_9I_[^^*?_C-'_$ ^+/Y*?\ X&@_U_RC^:7_ ("S[-HKXR_X8S_X.2O^?_\
M9I_[^^*?_C-'_#&?_!R5_P __P"S3_W]\4__ !FC_B ?%G\E/_P-!_K_ )1_
M-+_P%GV;17QE_P ,9_\ !R5_S_\ [-/_ ']\4_\ QFC_ (8S_P"#DK_G_P#V
M:?\ O[XI_P#C-'_$ ^+/Y*?_ (&@_P!?\H_FE_X"S[-HKXR_X8S_ .#DK_G_
M /V:?^_OBG_XS1_PQG_P<E?\_P#^S3_W]\4__&:/^(!\6?R4_P#P-!_K_E'\
MTO\ P%GV;17QE_PQG_P<E?\ /_\ LT_]_?%/_P 9H_X8S_X.2O\ G_\ V:?^
M_OBG_P",T?\ $ ^+/Y*?_@:#_7_*/YI?^ L^S:*^,O\ AC/_ (.2O^?_ /9I
M_P"_OBG_ .,T?\,9_P#!R5_S_P#[-/\ W]\4_P#QFC_B ?%G\E/_ ,#0?Z_Y
M1_-+_P !9]FT5\9?\,9_\')7_/\ _LT_]_?%/_QFC_AC/_@Y*_Y__P!FG_O[
MXI_^,T?\0#XL_DI_^!H/]?\ */YI?^ L^S:*^,O^&,_^#DK_ )__ -FG_O[X
MI_\ C-'_  QG_P ')7_/_P#LT_\ ?WQ3_P#&:/\ B ?%G\E/_P #0?Z_Y1_-
M+_P%GV;17QE_PQG_ ,')7_/_ /LT_P#?WQ3_ /&:/^&,_P#@Y*_Y_P#]FG_O
M[XI_^,T?\0#XL_DI_P#@:#_7_*/YI?\ @+/LVBOC+_AC/_@Y*_Y__P!FG_O[
MXI_^,T?\,9_\')7_ #__ +-/_?WQ3_\ &:/^(!\6?R4__ T'^O\ E'\TO_ 6
M?9M%?&7_  QG_P ')7_/_P#LT_\ ?WQ3_P#&:/\ AC/_ (.2O^?_ /9I_P"_
MOBG_ .,T?\0#XL_DI_\ @:#_ %_RC^:7_@+/LVBOC+_AC/\ X.2O^?\ _9I_
M[^^*?_C-'_#&?_!R5_S_ /[-/_?WQ3_\9H_X@'Q9_)3_ / T'^O^4?S2_P#
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M9?\ #&?_  <E?\__ .S3_P!_?%/_ ,9H_P"&,_\ @Y*_Y_\ ]FG_ +^^*?\
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M?\,9_P#!R5_S_P#[-/\ W]\4_P#QFC_AC/\ X.2O^?\ _9I_[^^*?_C-'_$
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M/Y*?_@:#_7_*/YI?^ L^S:^,OV,_^5DJ_P#^S:9?_4HAH_X8S_X.2O\ G_\
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M4+#5K"#5-+FCN;6YC66&:)@\<D;C*LK#(*D$$$<$5_,7\0OCQ^WU_P %5O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.^ =/O'62Y@\/Z9;Z<EQ(@P'E\A$\Q@. SY..] '\OO_  0C_;5_98_X)Z?
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M4 %%%% !1110 4444 %?@#_P7T_YLK_[.J^''_M]7[_5^ /_  7T_P";*_\
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M>\6?\)K_ ,(M_8-G+:>5_9OV[S?,??NW?:8-N.F,'ZU^?G_$/-_U5[_R@?\
MWPKRL1B,=&HU2HIQZ.Z_S/A,US7B>EBZE/ Y=&I27PR=2*;T71R36MUL?MY_
MPV;^Q[_T5?P=_P"#VR_^/4?\-F_L>_\ 15_!W_@]LO\ X]7XA_\ $/-_U5[_
M ,H'_P!\*/\ B'F_ZJ]_Y0/_ +X5C]:S+_H'7_@2_P SS_[;XR_Z%4/_  ;#
M_P"3/V\_X;-_8]_Z*OX._P#![9?_ !ZC_ALW]CW_ **OX._\'ME_\>K\0_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X _\
M.TU_W:K_ .[=7[_5^ /_ #M-?]VJ_P#NW4 ?O]1110!__]7^[CXL_P#)*_$W
M_8*O?_1+U^0'_!MW_P H2O@)_P!@K4/_ $YW=?K_ /%G_DE?B;_L%7O_ *)>
MOR _X-N_^4)7P$_[!6H?^G.[H _;^BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
M^ /_ #M-?]VJ_P#NW5^_U?@#_P [37_=JO\ [MU '[_4444 ?__6_NX^+/\
MR2OQ-_V"KW_T2]?D!_P;=_\ *$KX"?\ 8*U#_P!.=W7Z_P#Q9_Y)7XF_[!5[
M_P"B7K\@/^#;O_E"5\!/^P5J'_ISNZ /V_HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /P _X.+_ /DT
M[X2_]EJ\"_\ I8U?O_7X ?\ !Q?_ ,FG?"7_ ++5X%_]+&K]_P"@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#X__ ."A7_)@GQQ_[)_XF_\ 3=<5X!_P12_Y1'_LY?\ 9/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5^ /_ #M-?]VJ_P#NW5^_U?@#
M_P [37_=JO\ [MU '[_4444 ?__7_NX^+/\ R2OQ-_V"KW_T2]?D!_P;=_\
M*$KX"?\ 8*U#_P!.=W7Z_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"5\!/^P5J
M'_ISNZ /V_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /P _X.+_ /DT[X2_]EJ\"_\ I8U?O_7X ?\
M!Q?_ ,FG?"7_ ++5X%_]+&K]_P"@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X__ ."A7_)@
MGQQ_[)_XF_\ 3=<5X!_P12_Y1'_LY?\ 9/\ 0_\ TF2O?_\ @H5_R8)\<?\
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M_;1S?<D:UU""VG,;<8D"%.0,Y(KR*V_X+3_\$O[SX]P_LTVGQ<TV3Q5<ZO\
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M]K'XG_$C2[/X?^+# FAZM;>;?#4WN59XTM8;5)9YW*JQ*1QLR[3D#!K\P?\
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MC3XO_%'4-(&@1>(_'.H17L]AI?F"5K6SBMX+:&"-Y '?"%BQ;Y@&8'RGP_\
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M_P"33OA+_P!EJ\"_^EC5^_\ 7X ?\'%__)IWPE_[+5X%_P#2QJ_?^@ HHHH
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M=0CA@55G@+RAC'(!N7(!P:_HN_X*%?\ )@GQQ_[)_P")O_3=<5X!_P $4O\
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M+9__ !ZOW_HH _ #_A\_^UC_ -&)_&K_ ,!;/_X]1_P^?_:Q_P"C$_C5_P"
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M ,>K]_Z* /P _P"'S_[6/_1B?QJ_\!;/_P"/4?\ #Y_]K'_HQ/XU?^ MG_\
M'J_?^B@#\ /^'S_[6/\ T8G\:O\ P%L__CU?F#_P4>_X*!_&[]J[XI_L=_#O
MXE?LU_$+X.6-E^TK\/=1CUKQ;#!'93S1S7$0M4,4C-YSK*TB@C&V-O:O[/:_
M '_@OI_S97_V=5\./_;Z@#]_J*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *_ '_G::_P"[5?\ W;J_?ZOP!_YVFO\ NU7_
M -VZ@#]_J*** /_2_NX^+/\ R2OQ-_V"KW_T2]?D!_P;=_\ *$KX"?\ 8*U#
M_P!.=W7Z_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"5\!/^P5J'_ISNZ /V_HH
MHH *_(3_ (+V_%?XF_!#_@D/\;OBC\'-?O\ PMXETO2;4V6JZ7</:WELTU];
M1.T4T95XV*.R[E(89X(-?KW7XB?\''__ "A,^/G_ &";#_TY6E '\QG_  2Q
M_P""8'_!6?\ X*:_L3^%OVR;'_@H#\3/!D7B:?48!I,FHZS?M#_9]W+:Y\\:
MQ &W^5NQY8QG'.,UH?\ !VY\/?%GPB^%?["?PH\>>);KQEKGABTU?2=1\07N
M[[3JMW90Z%#->2[WD;S+AT:5]TCG<QRS'D^1?\$6_P#@W._8V_;_ /\ @GWX
M*_:P^+GQ8\8^%M?UV[U2.?3M'O[&WM8A8WTUNA19K:20%DC#$EC\QR,"OK3_
M (/5GBDU[]D9X&WHVI>*"K YR"VC8.>^?6@#[A_X*M^#?V6-7_X.!?V6-:^*
MOQT\5>#/&UM'X?DT7P;INC2WFG:B1J]UY!DOEN8TM1=RA[>X!MYB8U&XA2,?
M%?[6?_!TYJ'PG_X+':5\-O _BMX_V<?"MP^C^,;9M"22^;4+-KF&[,+NOV@J
M)5BV%&4$#IUS7_X+C?\ *T]^Q7_U[>#/_4CU"O*O^"C'PQ^!NB_\'<OP2\+^
M)/#FAVWAOQ!:Z//J-G<64"V5[=7HOE+SQLGERR33%06<$L^,DF@#^I3XS_\
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M++QM9>$+/QA-H_B3Q%+JF@W$TA0FT6"X<J3(6"1"43!G(4J=U?U)_P#!;_\
MY1#_ +1?_8B:O_Z)-?RW_!+_ (-U_P!G?]J__@BOX&_:&\1_&;X@Z'K4_@-/
M$\5KJFM17?A6QN8K=IOFL98%\NV3:<[)E*+SN.,$ _9?]I#]HWPW^U;_ ,&Z
MN@?M2?MI>._$7P:MO%7AWPUJFO\ B#P=!(+^*XN+RVC!@@C.\PW<K+\@; BD
MR20.?U6\<_M@?LH_L)?L3>%_CO\ M"_$$Z=X&L-%TNVM-<UHR2ZAJA>V4P_N
MD4S7%W.BF1DCC+GYV( 5B/Y$/C1^V3\6OVW_ /@S?\8_%'XV0P#7M$O]&\-O
M=6MO':0W<&EZ_IT<$JPQ*D28B*QL(U5-Z$@*#M'T/_P4LM?"_C;]M;_@EC\*
M/C\L4WPQU*".XEM+P[K&\U:.VTY;:.>-OW<@\TP1A7R"LKJ1AF! /V<_96_X
M.'O^"6_[7?QJTO\ 9\\ >,[[1/%7B"18M%MO$>F7&E1ZF\A C6VFE7RF:4G$
M2,RO(WRJ"V!7\YW_  7S_P""@W["W[0W_!5[X(?LF_M/:CKE_P#!CX2ZCK3?
M$71X+.^A2?5!%_HRJL 26Y4-&B>9"3M223:P#$G]&_\ @\ T/P3#^P/\.O&V
MEQ1P_$S2OB'I4?@VYM@%U)9Y(IVECMV7]YL.R-V"_+YB1$_,%KM/^"@!O#_P
M<N?L(G4 HN#X<\6^:$^Z'_L^]W8SVSTH _0[]B_]K;_@F9^SM9? '_@GQ^R>
ME_X?L/BMX=O_ !7X T:6UOI$_LR8W6ISF6>[+R1,2)W5)GR.%'&T5]H?&/\
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M ,%"O^3!/CC_ -D_\3?^FZXKP#_@BE_RB/\ V<O^R?Z'_P"DR4 ?I_7Y<_\
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M)(I8I &5T=2596!!!!((.10!HT5\+> /^"D?[''CKPGXT^(5[XTT_P +^&O
MOC*^\!7VM>)+B'2-.GUK3E5IXK6XN9$CG4$LJLI^8H^W(4FO>O!W[37[-WQ#
M^'FJ_%[P!\0?#6N^$]!BFGU/6M/U:UNM.LHK=#+*\]S'(T42QQ@NY=@%49.!
MS0![?17F&L?&WX,>'OA0OQX\0>+M%L? SV<.HKXBN+^"+239W(4PSB[9Q!Y4
M@==DF_:VX8)R*N>,_B[\*/AQX%'Q0^(?B?2=!\,G[/C5]1O8;6Q_TME2#_2)
M76/]Z[HL?S?.S +DD4 >AT5\R_M7?M;?![]C7X=Z;\2?C--="UUK7=,\-Z;:
MV$!N;N\U/5YA!;P0Q @NQ)+'GA%8]L5:\=_MC_LB?"WXF6GP6^)OQ4\(>'?&
M-^8Q;:%J>N65IJ4QF_U>RUEF69M^?EPOS=J /I"BN*L?B5\.=4\>W_PKTS7]
M-N?%&E6L-[>Z/%=1/?VUM<$B*:6W#&5(Y"K!'90K$'!.*-,^)7PYUKQSJGPP
MT;7]-N_$NAP6]SJ.DPW44E]9P76[R))X%8R1I+M;RV=0'P<9Q0!VM%?)?Q+_
M &V_V?/A'^T;HW[+OCO5FLO$NK>&M4\8322*$L=-T/2"JSWE]<NRI;P[F*J[
M_*2K9(Q7I6L_M)_LZ>'+3PEJ'B'Q_P"'+"#Q]Y7_  C$EQJMK$FM>>$:/[ 6
MD NMZRQE?)W[@ZD9W#(![5161X@\0Z!X2T&]\5>*KZWTS2]-@DNKN\NY5A@M
MX(5+R222.0J(B@LS,0 !DG%>5V'[2G[.FJ^#?#GQ&TOQ_P"&[GP]XPU&+1]!
MU2+5;5[+5-1F=XX[6SG$ACN)WDC=%BB9G9D8 9!  /:Z**\\\&_%[X3_ !%^
M'D?Q=^'WBC2==\)RQSS)K6G7L-UIS1VK.DS"YC=HBL3QNLA#85E8'!!H ]#H
MKY/\4?MZ_L,^![32+_QK\:/ FCP>(;"/5=+DO?$>GVZ7UC*S(ES;F2=1+"S(
MZK(F4)4@'(-=?\'_ -K/]E;]H76+OP]\ OB9X4\<7]A"+BYMO#^LV>IS0PE@
MOF2);2R,J;B!N( R<4 ?0-%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 45YKX1^,?PL\>^)]9\$^$->L[[6?#T[6VI6$<@%S;2(<'?$<.%ST;&T]
MB:]*I1DI*Z9G3JPJ+FIR37D[[;A1113- HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ K\ ?^=IK_NU7_W;J_?ZOP!_YVFO^[5?_=NH
M _?ZBBB@#__3_NX^+/\ R2OQ-_V"KW_T2]?D!_P;=_\ *$KX"?\ 8*U#_P!.
M=W7Z_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"5\!/^P5J'_ISNZ /V_HHHH *
M^8_VS/V3OAC^W/\ LQ>,/V3OC)/?VWAKQK:+9WLVERI!>1K'*DR/"\D<J!E>
M-2-T;J<8((KZ<HH _D"_X@J?^"67_0_?%7_P:Z1_\IJ_37]L#_@@'^QU^VG\
M$_@'\!?B;XC\8:?HW[.VEIH_AV73;RS2YN[9(+.W_P!-:6SE5W*6,1+1)$,E
ML#! '[D44 ?DM^U5_P $;OV9?VO?V_OA;_P48^)&N>);+QI\)8].CTJQTZYM
MH],N!I=Y-?0?:(Y+669OWL[!]DR93 &""3XY_P %6O\ @@!^QE_P5M\?:#\7
MOC1J>O\ A;Q=H-@-*34_#\T"&YLED>5(KB.X@G5O+>20HR[&&\@EA@#]S**
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MN+9M7":V9&G9)$MD@#(9#Y>8"!@;@W.?U3HH _"G2O\ @WG_ &#K;_@FL?\
M@EWXBNO$FN>"(M;E\26>JWEW;C6;+59=P%Q!+%;1P HCO&%:!E*.P8-G(_/B
M+_@S<_X)OZCX'_X1?QO\0/B7K-_#) MEJ4FJV8DL;2'?_HT$1L7A6)]X+[D9
M@R+L* N&_K=HH QO#NAV?ACP_8>&M.+-;Z=;Q6T1<Y8I"H1<D  G YX%;-%%
M !1110!^ '_!Q?\ \FG?"7_LM7@7_P!+&K]_Z_ #_@XO_P"33OA+_P!EJ\"_
M^EC5^_\ 0!X3^T_^SSX%_:T_9W\:?LS?$Z6\@\/^.M(NM%OY=/D6*ZC@NT*,
M\+NDB+(N<J61UR.5(X/\_P#IG_!JK^QG#X/L_A=XE^-GQQU_P59I'"OAC4/%
MD!T=H(R"L1MX=/B"H,<!"N.V*_IVHH _-+X^?\$H/V2?C?\ \$ZKG_@EYHUC
M>> _A9)!8V\$'AN2.*ZMEL+V*_4I)=1W(9Y9XMTSRJ[R%W8MO;=5K]LG_@E/
M^R+^W?\ LJ^'OV2?VA-/OKS1O",5HNA:K:7 MM7TZ:SA$"3PSA"F]HQAU>)H
MGZE,JN/TCHH _ S]G3_@WB_92^#OQ\\,?M)_&GXA?$?X[>)? L@E\+CXBZ]_
M:UIH\D;*T4D$*PQ?O(RBE=S&,, P0,JD??/QF_X)U_!?XX_MU?";_@H%XJU3
M6K?QA\';/4[+1[*UF@73;B/5(98)#<QO \K,JRL4\N:,9QD$<'[ZHH _+W_@
MI9_P25_9G_X*AZ/X2F^,=]KOA;Q5X!NY+WPYXH\+7BV.K:?)+L9U21XY4*,\
M4;\IO5D!1D))/R3^S[_P;H?L4_L\_M(?#S]K[2O%7COQ)\3/ FHW^J7/B#Q#
MJ\>HW>O3W]NML!J+R6^62W0-Y @,)!=M[2<8_?BB@#\@OV^O^"+'[+O[>WQA
MT/\ :9OO$'BWX7?%?P[:_8K/QEX"U7^R=4:V7?LBE<QRJRKO8!E5)=IV[]H"
MCKOV#/\ @E-X _88^(^O?&NY^*7Q&^+?C7Q'IRZ5=:O\0->;5Y(K19%E\N!/
M+C5 753EM[#& 0"0?U/HH ^!O^">O_!.SX,?\$V?AQXQ^&'P0U36M6L/&OB[
M4?&=[)K<T$TL=]J4<$4D<1@@@40JMNFT,K/DMECD 6?^"CO_  3V^#G_  4Z
M_9DO/V5?CKJFLZ/H%[?V>HO<Z%+##>"6R?>@#7$%Q'M.2&!C)]"*^\** /C/
M]MG]@?\ 9H_X*#_LY7/[+W[3FC/J_AN1XKBVDAE,%Y97=NK)%<V\RCY)D#,
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M%+_E$?\ LY?]D_T/_P!)DKW_ /X*%?\ )@GQQ_[)_P")O_3=<5X!_P $4O\
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MA\6?$+>+-=^(^IZ%;7,<FJ221%PFD>:L"6QA1X5B$V8_-9E<$(% /P7\6?M
M_!/PY_P5@_90^(?[%W[/7C'X%WG]@>.M%UJVU[P@WA*WUBPLM%:[ALQ$=ANF
ML)HA(S!2BED^=NWG^F_LB?L^>)O^#5;5?VOM;T+3[GXNZGI5W\1KGQT\$?\
M;[>(H]6>=9Q?;1.K#;Y "N!LR,98D_T:?LW_ /!-?XL:3^U+#^VQ^WC\6?\
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MC_1OB#I.L2Z0NMQ_;M$2X$,;VK7-JK*7F#DF0CY,%2#QY1^S1_P3*^+?@_\
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M::)@R2PR3SLKH1U4@@@CCFM+]E,A_P#@X#_:S*\[? OP_#8[$QW1P?PKU?\
M:5_X)8^/=<_:&\+_ +7G[!7Q7D^"/Q"\/>%8O!%WYVD1>(-'U;0+9_,M[>XL
MYIH"LD#\I.LF\ !2"*\*\4_L:_M&?\$]_P!C?]I3]I+X<:_KW[0'[4/Q@LH(
MY]:M=.CL9I;Q$_L[3$LK"!W2VM=-2X:<CS&.U&9FP%"@'Q1;?\9:_!K_ (*1
M?\%/]1_TC2=6\%^+/A=X#F;YE'ASPGI=TMU/ W>&^U%I)?\ >BZ"O@S]N?\
M9.U']M[]GC_@EO\ LV>'KB2TUW6_@MXFN=#GBD,31:SIG@_2KW3VW@@J!=P1
M;CGA<U_4W\+/^"=.@?#?_@DJG_!,7P[J<>D)=?#J^\&W.K1P?:%2^U:SEAO+
MWR=T?F;[F>6<IO3<3C<,YKAO"'_!+<^%?'7[&GC3_A.//_X9(\*ZGX9,/]F[
M?[?_ +1T6VT?SMWVD_8]GV?SMF)]V[9N&-Q /R7^,?[<FI_\%:?V _V8/V.?
M"-Q):>,_VH=1CTSXA0P9AN-*T;PDPD\4D@8:$R2P""%7"^8DV!UKX'_9\M+;
M3_\ @BM_P3?L+-!'#!^UCHT:*.BJOB37P!^ K^C7]B__ ((T?"/]C/\ X*$?
M&?\ ;T\-:_+JDOQ/>5M'T)[7RH/#PU&9;K5!#)YSK)]LND20;8H?*1=GS@YK
MS/P'_P $3&\$_L7_ +./[(G_  LO[2?V?_BU9_%'^U?['V?VM]DU/4-1^P^1
M]K/V?=]N\OS_ #)<>7N\L[MJ@'WAX,_X*;_L1_$']J"?]C/PCXREN_B1;7U_
MILFDG2=2B476F)+)<I]JDM5M3L6&0[A-M;&%+$@'^5[_ ()2_MA_MI?#[_@@
M]I/PH^'/[+?B+QOX0AT'QI#'XQM/$.CVEG+%<:CJ;S2BUN)UN0+=G=&4IN<Q
MDKD%<_W*5^97[#__  3H_P"&-O\ @F7I_P#P3I;QA_PD?V'2_$&F_P#"0"P^
MR;O[=N[RYW_9?/EQY/VO;CSCOV9RN[  /Q;\(_L\_ 'XA?\ !K':_%GQ]X&\
M/ZYXJT']G[5O[,UG4-,MKG4++[/874L7D7$D;2Q>7(Q=-C#:Y+#!.:_:7_@D
M_P#L\_ 'X7_L-_!CXB?#/P-X?\.^(->^'7AEM3U/3-,MK2\O3+I]O*YGFBC6
M24M)\[;V.6Y/-5?!_P#P3B;PK_P2.E_X):'QB)VE^'M]X%_X2;^S]H!O;62V
M^U?8_//W?,W>5Y_.,;QG-?:G[-GP?_X9Z_9U\ _ +^T/[7_X0?PYI7A_[=Y7
MD?:O[,M8[;S?*W/Y?F>7NV;VVYQN.,T >U4444 ?RD_$#_@NC^UKX4\>:WX7
MT[P[X1>WTV_N;6)I+2\+E(9&12Q%Z 3@<X &>U<C_P /[_VPO^A;\'?^ =[_
M /)U?UR45XCR[%MW6*?_ (#_ ,$_-I\'Y^Y-K.YI=O9K_P"3/Y&_^']_[87_
M $+?@[_P#O?_ ).H_P"']_[87_0M^#O_  #O?_DZOZY**/[-Q?\ T%/_ ,!_
MX)/^IW$'_0\G_P""U_\ )G\C?_#^_P#;"_Z%OP=_X!WO_P G4?\ #^_]L+_H
M6_!W_@'>_P#R=7]<E%']FXO_ *"G_P" _P#!#_4[B#_H>3_\%K_Y,_D;_P"'
M]_[87_0M^#O_  #O?_DZC_A_?^V%_P!"WX._\ [W_P"3J_KDHH_LW%_]!3_\
M!_X(?ZG<0?\ 0\G_ ."U_P#)G\C?_#^_]L+_ *%OP=_X!WO_ ,G4?\/[_P!L
M+_H6_!W_ (!WO_R=7]<E%']FXO\ Z"G_ . _\$/]3N(/^AY/_P %K_Y,_D;_
M .']_P"V%_T+?@[_ , [W_Y.H_X?W_MA?]"WX._\ [W_ .3J_KDHH_LW%_\
M04__  '_ ((?ZG<0?]#R?_@M?_)G\C?_  _O_;"_Z%OP=_X!WO\ \G4?\/[_
M -L+_H6_!W_@'>__ "=7]<E%']FXO_H*?_@/_!#_ %.X@_Z'D_\ P6O_ ),_
MSS?B#^T%\2?'_P <]5_:(CN_[!\2ZK>M?F;2'EMA!,W7R6WM(H^KD^]?NS_P
M3O\ ^"I?[7OQ(\3VOPF\:>#+SXG0)L234],C2"^M4/ >X=MEJR\8!D:$D]78
MU]@:G_P1V^&7Q2_::\6_M!?'W6)M6L=<U26]M=$L=UO%Y;8P+B?(D;(ZK'LQ
M_?-?K'\/?AK\/_A/X8@\%_#/1K/0M*MO]7:V4*PQ@]V(4#+'NQR2>22:X\OR
MK%TZKJ2J<JO]_G;97/GN$^!L_P )CJF*JXQTH.3;2LW4UW<=8KFWUNUV1VBD
MLH8@J2.AZC\J=117TY^V!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !7X _P#.TU_W:K_[MU?O]7X _P#.TU_W:K_[MU '[_4444 ?
M_]3^[CXL_P#)*_$W_8*O?_1+U^0'_!MW_P H2O@)_P!@K4/_ $YW=?K_ /%G
M_DE?B;_L%7O_ *)>OR _X-N_^4)7P$_[!6H?^G.[H _;^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
M #_@XO\ ^33OA+_V6KP+_P"EC5^_]?@!_P '%_\ R:=\)?\ LM7@7_TL:OW_
M * /SA_X*_\ Q"\=?"C_ ()=_'GXC_#+5[SP_P"(-'\%ZK<V&I:?,UO=6LZP
MG;)#*A#QR+U5U(93R"#7\K'A+]C#_@H1H7_!&_2/^"M/P8_;3^+H\=Z7X&/C
MV\T+Q)KTVK:%/':0M<W%NL-P[+GRT;R_-68,P"D8;(_IW_X+?_\ *(?]HO\
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MU;P*DD9:.U9"58$95B/0T ?U<45^('_$2)_P1*_Z+WI7_@NU/_Y$H_XB1/\
M@B5_T7O2O_!=J?\ \B4 ?M_17X@?\1(G_!$K_HO>E?\ @NU/_P"1*/\ B)$_
MX(E?]%[TK_P7:G_\B4 ?M_17X@?\1(G_  1*_P"B]Z5_X+M3_P#D2C_B)$_X
M(E?]%[TK_P %VI__ ")0!^W]%?B!_P 1(G_!$K_HO>E?^"[4_P#Y$H_XB1/^
M")7_ $7O2O\ P7:G_P#(E '[?T5^('_$2)_P1*_Z+WI7_@NU/_Y$H_XB1/\
M@B5_T7O2O_!=J?\ \B4 ?M_17X@?\1(G_!$K_HO>E?\ @NU/_P"1*/\ B)$_
MX(E?]%[TK_P7:G_\B4 ?M_17X@?\1(G_  1*_P"B]Z5_X+M3_P#D2C_B)$_X
M(E?]%[TK_P %VI__ ")0!^W]%?B!_P 1(G_!$K_HO>E?^"[4_P#Y$H_XB1/^
M")7_ $7O2O\ P7:G_P#(E '[?T5^('_$2)_P1*_Z+WI7_@NU/_Y$H_XB1/\
M@B5_T7O2O_!=J?\ \B4 ?M_17X@?\1(G_!$K_HO>E?\ @NU/_P"1*/\ B)$_
MX(E?]%[TK_P7:G_\B4 ?M_17X@?\1(G_  1*_P"B]Z5_X+M3_P#D2C_B)$_X
M(E?]%[TK_P %VI__ ")0!^W]%?B!_P 1(G_!$K_HO>E?^"[4_P#Y$H_XB1/^
M")7_ $7O2O\ P7:G_P#(E '[?T5^('_$2)_P1*_Z+WI7_@NU/_Y$H_XB1/\
M@B5_T7O2O_!=J?\ \B4 ?M_17X@?\1(G_!$K_HO>E?\ @NU/_P"1*/\ B)$_
MX(E?]%[TK_P7:G_\B4 ?M_17X@?\1(G_  1*_P"B]Z5_X+M3_P#D2C_B)$_X
M(E?]%[TK_P %VI__ ")0!^W]%?B!_P 1(G_!$K_HO>E?^"[4_P#Y$H_XB1/^
M")7_ $7O2O\ P7:G_P#(E '[?U^ /_!?3_FRO_LZKX<?^WU=_P#\1(G_  1*
M_P"B]Z5_X+M3_P#D2ORI_P""G/\ P5J_X)W?MY_$G]CGX0?LD?$VR\:>)--_
M:7^'NL7-E;6MY \=C#+<P/*6N((D($D\2X#%OFZ8!P ?V*T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5\!/^P5J'_ISNZ /V_HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*_\  *'_ .)H_P"%3?"S_H6M*_\  *'_ .)KT"B@#S__ (5-\+/^A:TK_P
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MIXR75#/IUC(\MO"=/U&ZLEV-)\QW+;ASGH6(Z4 ?;?\ PJ;X6?\ 0M:5_P"
M4/\ \31_PJ;X6?\ 0M:5_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\
M\31_PJ;X6?\ 0M:5_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_
MPJ;X6?\ 0M:5_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_PJ;X
M6?\ 0M:5_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_PJ;X6?\
M0M:5_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_PJ;X6?\ 0M:5
M_P" 4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_PJ;X6?\ 0M:5_P"
M4/\ \37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \31_PJ;X6?\ 0M:5_P" 4/\
M\37H%% 'G_\ PJ;X6?\ 0M:5_P" 4/\ \37X,_\ !=GP/X+\-77[%M_X<TBR
MT^=_VI_AS&TEM;QQ.4)O25)4 XR <>U?T35^ /\ P7T_YLK_ .SJOAQ_[?4
M?O\ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML'Q7_8G$F-5DU/R_L/VWY>'\K=]H/(W8YVU^B?BK]@%O$W_!4_PO_P %+/\
MA*_)7PW\/[GP-_PCOV'<9C<7;W7VK[7YPV[?,*>5Y!SC._G% '\S_P"PE^QK
M\0/^"P_['WQ(_P""I_QG^-WQ \,_$_Q+KGB*3PB="UB:UTSPU8:8S1V]FM@"
M(Y(B4*S1L5,D>,D.7=ODKX?_ +6/QH^ W_!MM^Q?\"_@I?>)M(G^-/CO5/#&
ML7W@N'SO$?\ 8YU[4FN8-*&Y,7MQE$APZEL%<@,2/W;T?_@@A\>/A7J_Q ^#
M7[,?[4>O_#G]GCXFZS=ZSK'@;3]$M)=1MO[0*_:[;3]8DD\VTBF4; 4ARB
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MC[5]0\YVTE?%NH?9+&"W\J6-4NGABN+C]ZLB[ AVXSD _H@HK^>3XJ?MY_\
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M_P"?L?\ P)?YA_K3DO\ T'4O_!D/_DC](Z*_-S_A[M_P3P_Z*&O_ (*]2_\
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M$MO>:SXKL9-6*G0+6WGB9R)%8EU,@=L$L[ D\&@#^@VBOYI6_P""D'_!3/\
MX)U?M.?#?X,?\%;-"\$>(_AI\6-5B\.:)\1/ BW=HNGZQ/D0PZE;73,/WIQ@
MQK&JIN<-)L=5^;?V^O\ @NG^U;^Q1_P6?M_V>-4LM&F_9ZT%_"]OXKN7M&-]
M80^(U*?;6N!(-J0RL"?D*[5"8W.#0!_7917PC_P4Q_;5T+_@GO\ L-?$/]K/
M4XX;J[\-:8PTBSFR4O-6NF$%C 0I#%7N)$W[?F$>YATK\2/V O\ @K!^WO\
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M#@"HH[:WBEDN(HU627&]@ "V.!D]\#I0!_%Q_P %'_\ @JA^Q%^W)^W1J?\
MP3P_:;^)EE\-/V>_@WKB2>/$OX[C[;XVU[2YSMTF%(8G,>G6MQ%FZE?#3.H$
M8P$DK](_^"DOQ"\ ?\%"/B+^RA^P#\%KZ'6_ WQ@U.U^)GB.:V4BWG\#>&DC
MOH$D1@K+#J%TUO''E00R8P*_HJKY;T/]D'X1Z'^V%KW[<G^FW?CO7O#5IX1\
MRYF#VUGI-I.USY-M'M!C\V=O,ERS;F4$8YR ?S??\%N;S]BS2_\ @KO^S[?_
M +?_ (GN_!WPY?X?^*8Y-2M-2O\ 27^V?:+?RHQ<::Z3X;)R@;:>-PZ5M?\
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MC+.2QY->K6]C96DLL]K"D3SMND9%"EVZ98CJ?<T ?RZ_"/\ ;4_9\_X)1?\
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M/^?2/D_]1.'_ /H#A]S_ ,S\0_\ APA^Q[_T,GC'_P #++_Y!H_X<(?L>_\
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MXO\ _ JR_P#D.OW"HH_LG"?\^D'^H?#_ /T!P_'_ #/P]_X<&_LC?]#-XO\
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M** "BBB@#X__ ."A7_)@GQQ_[)_XF_\ 3=<5X!_P12_Y1'_LY?\ 9/\ 0_\
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M:/POLKOX5W^K3:X="N[N\N4M]0G^]/:SRSM<6K 9"_9Y8]@9@N S9QOV2O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ K\ ?\ G::_[M5_]VZOW^K\ ?\ G::_
M[M5_]VZ@#]_J*** /__1_NX^+/\ R2OQ-_V"KW_T2]?D!_P;=_\ *$KX"?\
M8*U#_P!.=W7Z_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"5\!/^P5J'_ISNZ /
MV_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%#_\31_PJ;X6?]"UI7_@%#_\30!^0'_$2)_P1*_Z+WI7_@NU/_Y$H_XB1/\
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M  J;X6?]"UI7_@%#_P#$T?\ "IOA9_T+6E?^ 4/_ ,30!^0'_$2)_P $2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ_M,>&/BKX@^(/Q(TWPO?_![2O#=A;*FF:A*XF:SGC>35 ;*,#?-.^S<P+X
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M[^T5\&FL/'>@V:LVIZE#?:%JCWEE:*8M[S7$6FM]E5(RQWX1=V!D ]H\/_\
M!6'X]77_  <+WO[$E_.K? JZL;GP;IL@MH!$?&MAIUOK5P3=!//WK!*;;RF?
MRRV"JE@37W9^P;^U+\</VH/VT?VJKW6=8CE^$/PR\3Z?X%\+62V\,?E:KI5H
M)-<DDN%02R'[1+&H5W*H!@ '-?AEK7[)_P"UIIG_  1_\.?M\Z=\.-;E_:(T
MWXVO^T#=>#H[.X.L2S7VJ-;RZ;Y B^T8.E-%YD?E A(\;?E KVR_B^.'[ G_
M  ;Q:9X!N[.>Q_:$_:2U Z8EK<HUM?-XO^)5Y(\BR(PWQ7%I:S/D,-R-;X89
M!H \>U3]NS]I/X<?L/\ [2W_  6C^%6H/&OQ@^(^G>&?!^HZC#+J.F>'?!&B
MW7]CPZP+(':2[FXE= -KRLC-O'!_4S1_%W[:'P-_X)_?'G]K!?VHM)_:$T6T
M^&^M>(_!6OVGA[2[%['5=.L+J?S VGE[.Z@+K&RI)&64J5;<,Y^J?'D'@S_@
MF5^P)X&^#/A/X3^(_C!X*\+6.G>$=3T;PMIL>JWYTT6KQS7LE@[ W2/(@^T1
MIN<^<6PP#5^$O['?[$FJ?'#X_?M3K^Q-\+?%OP _9T^+GP@U#PG_ &)XPL)]
M!M;_ ,;ZH'B&HV&F3%G@M8+1S$S+&J;F(1<$  '[*^)/VK?CKI__  07?]MR
MTUA4^)0^!<?C0:K]F@*C6FT);TS_ &<IY&/M!W^7Y?E_P[=O%:'Q1_;XU[]G
M?_@BM:?M_P#Q(N4O_%*?#/2-;5C$B+>^(-6LH%MD\N,!0)[Z>-=J+@!N!@8K
M\7[G]J3]KGQ/_P $A(_^"1%O^R_\4H/CF_@.'X5223Z(4\*HJ6@TQM3.N;_L
M?V4VZF4,&(,GR#*_/7UU^TS\*)OB)^T5^Q7_ ,$:(;E=4TCX;Z7I_P 1O'K1
MY*2:7X*@CLM+213C=#>ZGPRL!Q&#@]* &_L2ZQ^U)^Q1^TU^R3_P3@\:>*;K
M4;#Q!\*_$?B?QM#J"I=W5UXE-Q'=2N;N57N L,UQ+&BK(JE ,KP,>5?\$7_^
M"LG[7G[0/[;OC_\ 9I_;6U6TU/1_%DWB'4/AI>P6<%ELC\,ZK/87^G,843SI
M4B\F=2^YQ&I+.2V!^@?QV^%GQ.U?_@N[\ _BYI7AS4[KPIH_PW\6V5_K45I*
M^GVMS<36YBAFN IBCDD )1&8,P!P#BOP]A_9$_:_^%7_  3;T/\ ;&^#?P[U
MU_C=^SU\=/%?C/0_#TVFW,>HZSH&K:I);W]I% (_/>"]M724M&I+Q1$IG(R
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M2_Y]3^Y?YA_Q%#!?] 6(_P#!<?\ Y,_KDHK^1O\ X:N_X+I_] OQC_X1D/\
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M<O\ ,/\ B*&"_P"@+$?^"X__ "9_7)17\C?_  U=_P %T_\ H%^,?_",A_\
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M_P (R'_Y7T?\-7?\%T_^@7XQ_P#",A_^5]']NTO^?4_N7^8?\10P7_0%B/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /C_\
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MC_9V_:T^'^NQ>&M _9Z\-ZQX9T[PK#8^9'<6FI6?V*!4N?/7R%MHP,+Y4F\
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MX[\:3>(=)^/7B;Q3X@N-0MK$6,VFKXDCC18D1IIUE>V,0<2$J'/!0#K^S]%
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ME+0 4444 %?@#_P7T_YLK_[.J^''_M]7[_5^ /\ P7T_YLK_ .SJOAQ_[?4
M?O\ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (P#
M*5/?TXKQO]G_ /9[^#/[*_PETKX%?L_:!!X9\)Z)YYLM.MF=TC-S*\\K;I&=
MV9Y9'=F9B26/->RT4 %%%% !7C/Q-_9Z^#/QE\8>#/'OQ0T"#6=6^'NI/K'A
MZ:=GQ8W[Q-"9U16",XC=@I=6VDY7!YKV:B@ HHHH *\9T3]GKX,^'/CGKO[2
M^C:!!#X[\2Z;::/J.L%G>>:PL69X8 &8HB*SLQ"*NX\MD@8]FHH **** "BB
MB@ HHHH *\9^&/[/7P9^#?B_QGX_^&F@0:5K7Q"U-=8\17B,[S7]Y'$L*22,
M[-@)&H547:BC. "3GV:B@ HHHH **** "O&?@Y^SS\&/V?CXI;X.Z!!H;>-=
M?O?%.N/$SN]]J^HE3<7,C2,QWOL48!"J  H &*]FHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** /G[]J7]G[1_VI?@7K7P)
M\0:A-I=EKCV9GN;=5>54M;J*Y(0-\N7\K:"<A<YP<8/,_LW_ +%W[.7[*6E"
MS^#WAV&VOF39/JEQ^_U"<=]T[?, >I1-J9Z**^IZ*R="FZGM7'WMKG!/*\)/
M%+'3I)UDN52:NTDV[+MJWMJ%?@#_ ,[37_=JO_NW5^_U?@#_ ,[37_=JO_NW
M5J=Y^_U%%% '_]3^[CXL_P#)*_$W_8*O?_1+U^0'_!MW_P H2O@)_P!@K4/_
M $YW=?K_ /%G_DE?B;_L%7O_ *)>OR _X-N_^4)7P$_[!6H?^G.[H _;^BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH _ #_@XO\ ^33OA+_V6KP+_P"EC5^_]?@!_P '%_\ R:=\)?\
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MKLJ&96QG:]LRGD5^$S_\JB4W_953_P"I * /]&BOSU^,_P#P5B_X)L?L\?&
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MOGV8T](W$(@DW-OB"\(P8@KC!(Q0!_1L_P"TI\!HOV@T_91E\56"?$>31O\
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M\/[9"^'9;B#3KS]I?6;77)K7.]-,EU#31+R!]UG\M&!X(;!X.#^D?_!?_P"
M?_!.CX8_L[_LHZ]\ ] \)Z-XB_X6)X3MO"$^C)##=W?AQOFE,9APUQ;?\>[F
M1]X5V4@AI#N /[,J*** "BBB@ K\ ?\ @OI_S97_ -G5?#C_ -OJ_?ZOP!_X
M+Z?\V5_]G5?#C_V^H _?ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&ZW;S+<V=M<Q6TCL^7<F/]ZQ+2;B37%_\1(G_!$K_HO>E?\ @NU/_P"1*/\
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M&)9.6CC95DZ2!Q6?_P 1(G_!$K_HO>E?^"[4_P#Y$H_XB1/^")7_ $7O2O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MT+(]XP92549![CH:_>__ (5-\+/^A:TK_P  H?\ XFOQ _X.+_\ DT[X2_\
M9:O O_I8U?O_ $ >?_\ "IOA9_T+6E?^ 4/_ ,31_P *F^%G_0M:5_X!0_\
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M>/[.7_!1?X&_\-$?LN:E=:IX8_M&YTLS7=I)9RBYM-N\>7* V,.K ]P>QR
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M5_X!0_\ Q-'_  J;X6?]"UI7_@%#_P#$UZ!10!Y__P *F^%G_0M:5_X!0_\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^
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MOK<^'#'<6EC#%,@.O:<&VNB!AE20<'H3GB@"3_@@7\9_!W[.7_!N)\.?C_\
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MUX.TB?Q!JUG\;/#TUEI=L&::]N8[+46BMXPJNQ>5P$4!6.3P">* /)_VG?\
M@HW_ ,%__P#@F?X7\*?MT_MU^&OAQK'P?U[5[.R\1^$/#:W']K^&X+TMY:FZ
M<['E4 *7$EQ$9L)@*P<?HY_P40_;F\:?"7_@HU^P_P#"?X8Z=X?U?PW\9M4U
MQ;S4-1T\75]#;116+1/8SL5:V+K<$N0,L H/ Q7X:_\ !6O_ (+'_!S_ (+,
M_L>Z%_P30_80\*>)M6^,OQ0U[2K?6/#NH:7-;2>'5T^=;B?[5*5*'RY8U#NA
M9$B$CR%-H4_>/_!4[P*GPT_X*L_\$O/AQ;2&>/P]J.OZ:LF/OBTM]*BW?B%S
M0!]$?M?_ /!27_@H!\;O^"C^K?\ !*W_ ().:3X6L_$/@71H-9\<^-?&2SS6
M&EB[2.2*W@AA'S2[)H2"5EWNY78BQ2/5;]B+_@I5_P % ?A9_P %+8?^"3'_
M  5<TCPO=^*_%6@S>(?!/C#P>LT5CJL-LDDDL,L,H&&V6]P2VV(HT)78ZR))
M7PAXU_:,T+_@A_\ \%[OC?\ M#?MEZ3JNG_!3]I#2=+N-(\96=C/?VUGJ%A%
M&KV\_DHS@AQ.&CC#R!3"VS8Q*]1^SW\6X?\ @M)_P7X^'/[>?[,&AZL/@1^S
MQX6U+3O^$KU.REL8-:U?48;J'R;42JKG9]L1]K*K*L+%PH>,, .^"G_!2/\
MX+N_M_\ [37[0?[*G[&.D_#_ ,.:9\)/B%KVCMX[\2P7 M[?3[2YEM['3X[>
M(3&6Z80/)+,4==C<K&=F_P#1/_@CS_P4V_:4_:V\2?&[]C']N_P]I7A[XV?
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MJ:&.^>,S2_9'N58!A.]IY+2[P',A8O\ -FOTKH **** "BBB@ HHHH ^/_\
M@H5_R8)\<?\ LG_B;_TW7%> ?\$4O^41_P"SE_V3_0__ $F2O?\ _@H5_P F
M"?''_LG_ (F_]-UQ7@'_  12_P"41_[.7_9/]#_])DH _3^BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ K\ ?^"^G_-E?_9U7PX_]OJ_?ZOP!_P""^G_-E?\ V=5\./\
MV^H _?ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB[XV7V@Z]IOQM^)FH^,]&M]/:6X,%C=S32QI=K/!$JSKY@RL9D0$<.:_:(
M8'05\L_LQ_MO_LB_MH6NM7O[*7Q$T/Q]'X<EBAU/^Q[I;@VC7&_RO, Y42>6
M^QL;7V-M)P:^IZ (XHHH4\N%0BCLHP.:HVFC:181206-I#"DTAED6.-5#R'J
MQ '+''4\UI44 9NJZ-H^NVGV#7+2&\@R&\N=%D3(Z'# C(K01$B01Q@*JC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7X _P#.TU_W:K_[MU?O]7X
M_P#.TU_W:K_[MU '[_4444 ?_]'^[CXL_P#)*_$W_8*O?_1+U^0'_!MW_P H
M2O@)_P!@K4/_ $YW=?K_ /%G_DE?B;_L%7O_ *)>OR _X-N_^4)7P$_[!6H?
M^G.[H _;^BBB@ HHHH **** "OX>/^#H?]O+]J[QI^U?\*O^",_['&M77AR]
M^)4>GMKEW9SFVDOI=<NVLK.R>9,210)Y;2W !Q(DBALJI!_N'K_.W_X.1?\
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MO^3!/CC_ -D_\3?^FZXKP#_@BE_RB/\ V<O^R?Z'_P"DR4 ?I_1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM+B*-G./F<*KO_$S5^R5% 'YW?LQ?\$G_P#@GY^QIJWQ UC]F;X=6WA)OBA
M+3Q%#:W=VUM<6Z^;B**"2=XK9!YTF%MUC !P. H'0?LB?\$R_P!B7]A+X/\
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M8L/^/3S_ +)G[*!%GR<XY^]\U?>-% 'P?J/_  3-_8GU7]N6R_X*1W_@S?\
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MHPWMZURMSJ4207$EQ(]PQNR8T 07/FK%SY83)S^KM% 'YZ?MR?\ !*C]@/\
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M41_[.7_9/]#_ /29*]__ ."A7_)@GQQ_[)_XF_\ 3=<5X!_P12_Y1'_LY?\
M9/\ 0_\ TF2@#]/Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP!_P""^G_-E?\ V=5\
M./\ V^K]_J_ '_@OI_S97_V=5\./_;Z@#]_J*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** .;\8^,_!_P ._"U_XY^(&JV>A:)I4+7-[J&H3I:VMM"@
MRTDLLA5$11U9B *\%^&/[;?[&'QL\7P?#[X,_%WP5XNU^Y222'3=%U^QO[R1
M(E+.RPP3/(P502Q"X &3Q7Q?_P %Y/\ E#M^T/\ ]B?>?S6O$/\ @DUH;7\'
MA._U_P#8RL?@F;#PA:SV?CH-X=FEOYFB@B,:#39'O4:YBD>4M(H&U2KG<P!
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M%+32WUM]5AE66U.G1Q&<W"R(2KQ>4-X9205Y&17X6^,)HC_P:RO(&&T_LQP
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MKX)^.OC3]BC]IW]BW2[SXM16GQ8OXM/TJU5M&N-0NK?3IE>%&U-+81D9SOD
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M_P!#_P#29*]__P""A7_)@GQQ_P"R?^)O_3=<5X!_P12_Y1'_ +.7_9/]#_\
M29* /T_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M &AX'/C'XCZ_;1WE_=W80)"?LL+6\:6UNNY8+9'41JQ 8U^X-% 'X9?MH_\
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MGX777@&QUK1_$&C:-HL,5OXDTS58E$<,S0/;B)[:9?.20I+N. 1@"OU4HHH
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M_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"5\!/^P5J'_ISNZ /V_HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K\ ?^=IK_ +M5_P#=NK]_J_ '_G::_P"[5?\ W;J
M/W^HHHH _]7^ZSXTVTU[\'/%MG;S-;R2Z-?HLJ?>0M X##/<=17\?O\ P1,_
MX)=_M%?';_@EO\(OBSX-_:Y^*?P\TS6=/O)(/#N@SVR:=8A+ZYC*PAXV8!BI
M<Y)^9C7]AWQ9_P"25^)O^P5>_P#HEZ_(#_@V[_Y0E? 3_L%:A_Z<[N@#S_\
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M_&:/^','[6/_ $?9\:O_  *L_P#XS7[_ -% 'X ?\.8/VL?^C[/C5_X%6?\
M\9H_X<P?M8_]'V?&K_P*L_\ XS7[_P!% 'X ?\.8/VL?^C[/C5_X%6?_ ,9H
M_P"','[6/_1]GQJ_\"K/_P",U^_]% 'X ?\ #F#]K'_H^SXU?^!5G_\ &:/^
M','[6/\ T?9\:O\ P*L__C-?O_10!^ '_#F#]K'_ */L^-7_ (%6?_QFC_AS
M!^UC_P!'V?&K_P "K/\ ^,U^_P#10!^ '_#F#]K'_H^SXU?^!5G_ /&:/^',
M'[6/_1]GQJ_\"K/_ .,U^_\ 10!^ '_#F#]K'_H^SXU?^!5G_P#&:/\ AS!^
MUC_T?9\:O_ JS_\ C-?O_10!^ '_  Y@_:Q_Z/L^-7_@59__ !FC_AS!^UC_
M -'V?&K_ ,"K/_XS7[_T4 ?@!_PY@_:Q_P"C[/C5_P"!5G_\9H_X<P?M8_\
M1]GQJ_\  JS_ /C-?O\ T4 ?@!_PY@_:Q_Z/L^-7_@59_P#QFC_AS!^UC_T?
M9\:O_ JS_P#C-?O_ $4 ?@!_PY@_:Q_Z/L^-7_@59_\ QFC_ (<P?M8_]'V?
M&K_P*L__ (S7[_T4 ?@!_P .8/VL?^C[/C5_X%6?_P 9K\P?^"CW_!/SXW?L
MH_%/]COXB?$K]I3XA?&.QO?VE?A[IT>B^+9H)+*":2:XE%T@BC5O.18FC4DX
MVR-[5_9[7X _\%]/^;*_^SJOAQ_[?4 ?O]1110 4444 %%%% !1110 4444
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MG_AQ\4O#NI?#SPM<26NK^(1>I%864\21R,DTLA4(P26,@'KO4#)->2?LZ_\
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M3^S&GQ?\)ZCX5TS4[CQ 6F.=1N0_GP[89$"[ J'!&?FSG!% 'T[_ ,%=(?\
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MQSK,NQ0L;)N5T /]2*BBB@ HHHH _ #_ (.+_P#DT[X2_P#9:O O_I8U?O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX<?^WU?O]7X _P#!?3_FRO\ [.J^''_M]0!^_P!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **\U\*_&/X6>-_%NL> ?"NO6=[KGA^8P:CIZ2 7
M5NPP<O$</M.1AP"I[&O2J49)ZIF=.K"HN:G)-;:.^JW^X*_ '_G::_[M5_\
M=NK]_J_ '_G::_[M5_\ =NIFA^_U%%% '__0_NX^+/\ R2OQ-_V"KW_T2]?D
M!_P;=_\ *$KX"?\ 8*U#_P!.=W7Z_P#Q9_Y)7XF_[!5[_P"B7K\@/^#;O_E"
M5\!/^P5J'_ISNZ /V_HHHH **** "BBB@ K\I/\ @K'_ ,%??V9O^"1?P<L/
MB'\;TNM;\0>(WG@\.^'-.VB[U&6W"F1B[_)#!%O3S96SC< JNQ"U^K=?YVW_
M  75TG2/VA/^#HO]GKX"?'&'S_!>[P7I0LK@DV]W:WFHRRRH5SC$\DA@<]2
M >@H ^[?AO\ \';OQD'B?PSXN_:+_9%\4>"_A3XNO;:TL?%$5W<3QA+I@$DC
M>XT^VMKK(.[:DR9'0GO_ &N5AZMX8\-:]HC>&=<T^VO=-8(IM)XED@(C(* Q
ML"N%(!''! QTK^$K_@L)\&O^"?.J_MT_$+5?^"E/[?/BCP])<SQR^'_ 'A:U
MO;X>'K=H(S'%.ELEY#&S$[]GE0.ZD.6)?( /[T:*_@?_ .#7K]LWX\_$3]GS
M]K3]G+Q;X_U7QOX:^'VB?VEX2U*_FF:>VCGBOXW,)F8S0QRB&&5(<@1/N( 9
MFK\B_P#@E[^PK^WK_P %8_V!OBUX[UW]H[Q#X?\ !/PA.H7>D:!)<7-V-1UL
MVBW;_:&\Z/9#LCB578S,C.Q1%^;S #_54HK_ "U?^"=W[)'_  4:_P""S7[
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MD7Y7DGQYCL.&9B10!Z)1110 4444 %%%% !1110!\?\ _!0K_DP3XX_]D_\
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MS2^>GF$DG9M)^6OSK_:"_8'_ ."H7[.'_!-CX"_\$I_V2?!-WX]\"1Z?<?\
M"V]:\-Z_IFBZG=I=W+W=WI=A+JDUN8H;N:XF5[@1NQAPI49='^E?VF?VI?VA
M/V9?^"1/BOX3Z+^SU-^SQXFU/^R_A7\+?#B:[INLF\O_ !%_H4+6\FFRRB.2
MW5I)OWI+NR%CN))H _-+]HOXP?%/Q5_P3I_;J_X+8?"GQ'J/AG6/'OB71?"7
MP]US2KA[:YMO"'AC6K/3%GM)HR'B%],]T\H4\D=:^KOV"?VIO"0_X*]^#OV;
MOV$/VG?%G[1'POUWP=K6J>.+;Q?K(UU-(N;0H+"6QO)88I#))(VR2"-GVH2[
M#&-GW/\ \%$O^":7Q"N?^"!.K?\ !,_]CC1$\2>(M(\/^&M(TJR^T06/V^72
M]1L;FZE:6YDBA1Y1#-,Q=U!<D#D@5XW??LX_MS?MS?\ !0GX _M&_$C]G;3O
MV<-"^"6IW^LZAKESK^EZOK6LI=6Y@73H%TDR!8&)S*9Y "C': 1M< ^;/ G[
M=?[1/[-?_!(?]KKX1?$'Q=K7B+XQ_ OQGKOP\T'6-1O9;K6KL^([F.+0+P3R
M,97?-\&A+,2J0CHJUS&@?M]?M9^'?^#?3Q;\./$7BG4;K]IOPSXWNO@,VJB]
ME?4I?$\^JK:Q2QW1/GF9;&<2)-G>63>"">/H/]K_ /X)8_M6_$S_ (+:>$OC
M+\,-(BE^ 'CO5/"'C/XD7C75NA37? *7RZ?"UL\RS2QSAK56,<+@MRQ55.8?
M$O\ P2L_:MU'_@NVGQ;M=(A;]F+4?$VF_%V]F^U6X\KQII.DW&FPQK;^;]HW
MO.Z73OY)C/0.""* /KC_ (+,>)/'OPX_X)W>%?V#/AGKMWJ?Q#^/&H:)\)-,
MU.[D:>[EBU!5CU._N&)+N!8QSM-(6X:0$GGG\M_C[JO@KX3_ /!2?6/V%?VR
M/CQ\1_V9/@[X<\)>%M'^!=QX3UE_#>@7T5K9)%?M>WZ1-#+=0W"JB)=$1! 0
MWWH]WZ=Z#_QFK_P7IU3Q$W^E>#?V0/"2Z;:GK&?&?C--]PZ'[K>1ID:Q..3'
M(_)&<51_X*2>(/\ @H#\<?#?Q._8VD_8[TOXO>#O$MM-9^%O$TGB?3(-.3[3
M;A4N;VTO=ES;SV<K,X:#+-M'E,K?-0!T/[2'Q ^,?PF_X*=?\$^_@)I'C_6=
M5T/Q%IGQ!MO$DGVDQ0^))-)T"V>WNKZ&$K!,XFW3I\I5'<E *[G]L#XN_%/P
MI_P6;_8X^$GAGQ'J6G^%O%FD_$:76M(M[F2.RU%[#3[62V:YA4A)3 [,T1<'
M822N,FOCOQ__ ,$U_P!M[]G3]GW]BKXJ?L]0Z?\ %/XK_LD6MW8:CH%UJ TZ
M+7-/US3UL=0@L[RXQ'&\"HJ6S3A5V+N."HC;T3PKX=_:]^/?[=?AW_@I]^W9
M\-X?@!\,_P!G3P7XD_LK2[_6;36M5O;G5H5^WWL[6#/!!;0VL) 1G,A90<$,
M=@!VOQ*_XS4_X+N^#OA;'_I7@W]DOPM)XLU=1\T3>+_%:FWTV&5>FZWL$DNH
MFZJS].]?C_X]_:9_;"\7_P#!#_Q/XC\,_%CQ-HOC?5_V@[KPC:^)HM2N#J-G
MI]QK_P!E2&.<2"588T(58U=5V#8,+Q7[7_\ !!WP'XJUS]E;Q%^W5\5+1K7Q
MG^TWXHU#XAW<<O,EMI5VWE:1:!N\45C'&\?7 E/-?G3;_P#!,W]MM/\ @EM)
M^SHW@K'C)OVA!XV&G_VC8_\ (!_M\7GVKS?M'D_\>X\SR]_FXXV;N* /K_\
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MM_"RXC^$WACP7\6;7P3H>G^*]3L-.LAJDFJ)90+?K-?6ZLTQ:X5R[+*R.WS
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M<^(])U*6TM]-<R30:8; _;)FNB009$C0,B^8 <,@!_5E1110!R/Q U^\\*>
M];\4:<J/<:;87-U$L@)0O#&SJ& ()!(YP0<=Z_E)_P"']_[87_0M^#O_  #O
M?_DZOZY**X,9A:U5ITJKA;RO?\4?+\0Y+F./E3>!Q[PZC>Z4>;FO:WVE:WZG
M\C?_  _O_;"_Z%OP=_X!WO\ \G4?\/[_ -L+_H6_!W_@'>__ "=7]<E%<?\
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M_P!#R?\ X+7_ ,F?R-_\/[_VPO\ H6_!W_@'>_\ R=1_P_O_ &PO^A;\'?\
M@'>__)U?UR44?V;B_P#H*?\ X#_P0_U.X@_Z'D__  6O_DS^1O\ X?W_ +87
M_0M^#O\ P#O?_DZC_A_?^V%_T+?@[_P#O?\ Y.K^N2BC^S<7_P!!3_\  ?\
M@A_J=Q!_T/)_^"U_\F?R-_\ #^_]L+_H6_!W_@'>_P#R=1_P_O\ VPO^A;\'
M?^ =[_\ )U?UR44?V;B_^@I_^ _\$/\ 4[B#_H>3_P#!:_\ DS^1O_A_?^V%
M_P!"WX._\ [W_P"3J/\ A_?^V%_T+?@[_P  [W_Y.K^N2BC^S<7_ -!3_P#
M?^"'^IW$'_0\G_X+7_R9_(W_ ,/[_P!L+_H6_!W_ (!WO_R=1_P_O_;"_P"A
M;\'?^ =[_P#)U?UR44?V;B_^@I_^ _\ !#_4[B#_ *'D_P#P6O\ Y,_D;_X?
MW_MA?]"WX._\ [W_ .3J/^']_P"V%_T+?@[_ , [W_Y.K^N2BC^S<7_T%/\
M\!_X(?ZG<0?]#R?_ (+7_P F?R-_\/[_ -L+_H6_!W_@'>__ "=1_P /[_VP
MO^A;\'?^ =[_ /)U?UR44?V;B_\ H*?_ (#_ ,$/]3N(/^AY/_P6O_DS^1O_
M (?W_MA?]"WX._\  .]_^3J/^']_[87_ $+?@[_P#O?_ ).K^N2BC^S<7_T%
M/_P'_@A_J=Q!_P!#R?\ X+7_ ,F?R-_\/[_VPO\ H6_!W_@'>_\ R=1_P_O_
M &PO^A;\'?\ @'>__)U?UR44?V;B_P#H*?\ X#_P0_U.X@_Z'D__  6O_DS_
M #T/B;^T-\2?B;\=-4_:)>Y&A>)=4N_MIET=Y;802[0N86\QI$X']\GWK]Q_
M^">G_!4_]L#Q[XHM/A)XQ\'7GQ1@78CZAIL:PZA:QG@//(VRV91C ,K1$GDR
M$U]I^(_^"/?PV^+_ .U%XL_:$^/6LS:EIVMZB;JUT2PS;IY855 N)\B0YQRL
M03']\]*_5KX<_##X=_"+PO!X*^&&BV>@Z5;_ '+:RB6),]V.T99CW9LL>Y-<
M6 RK%TZTJDJG*KOY^=MM?F?.\*\"Y_A<?4Q57&.E!R;=K-U-7JXZQ7-OK=J^
MQW$;,\:NRE"0"5.,CV.,C\C7X"?\[37_ ':K_P"[=7[_ %?@#_SM-?\ =JO_
M +MU?4'[:?O]1110!__1_NX^+/\ R2OQ-_V"KW_T2]?D!_P;=_\ *$KX"?\
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ME\%X^#$VG*B>(?[0LL%QX933=OV7[1]KS]J!3_4XQ\WW>:_K2HH _DP\8_\
M!,[]MC5/^#J?PS_P4;L/!GF?!FPTUH[CQ#_:%D DG_".7&G[?LIG%V3]I=4X
MA(P=V=H)'Y-_"#_@EO\ \%L_^";W[<OQJ\0?LZ? +P5\;8/B??71T7QMXGFL
M)TTZ*:XFG2Z"W%U#+#(1*#<Q-&1(\:[2X4;O]#.B@#^4'_@UQ_X)A_MI_P#!
M-'0_COX:_;%\+P^'I/$NKZ0='N+>_M;V'4(K!;Q99H_L\KND9\U"HF2)R&^Z
M""!_5]110 4444 %%%% !1110!^ '_!Q?_R:=\)?^RU>!?\ TL:OW_K\ /\
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MK3-)N;33K6QM9F(^W/%/-$\H(ECE*P*[;K,97+#=1_X(41R?MW?\%!/VI_\
M@LIKBFXT?7=:_P"%=> 97' T+2!$99(P>@G6.T8E>/,\X9))K^I+Q/X;T7QE
MX:U'PAXD@^TZ=JMM-9W4.YD\R"="CKN4AAE21D$$=CFO(_V:/V8O@/\ L=_!
MK2OV??V:O#EOX4\'Z(9VL].MWDE5&N96FE8R3/)([-([,6=V/..@  !^%?\
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MX%\,Z=HUY>QEC%+/:PJC^7OPWE*P*QY .P#('2OKRB@ HHHH **** "BBB@
MHHHH ^/_ /@H5_R8)\<?^R?^)O\ TW7%> ?\$4O^41_[.7_9/]#_ /29*]__
M ."A7_)@GQQ_[)_XF_\ 3=<5X!_P12_Y1'_LY?\ 9/\ 0_\ TF2@#]/Z***
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M% &=I&D:3X?TFUT'0;6&QL;&%+>VMK=!%%#%$ J(B* JJJ@!5   &!6C110
M4444 %%%% !7+>,_ W@KXC^'IO"/Q"T>QU[2;AHGELM1MX[JW=H762,M'*K(
M2DBJZDCY64$<@5U-% !1110 4444 %<MXS\#>"OB/X>F\(_$+1['7M)N&B>6
MRU&WCNK=VA=9(RT<JLA*2*KJ2/E901R!74T4 %%%% !1110!RWAWP/X*\(7N
MJ:EX2T>QTNXURZ-]J,MI;QP/>73*J&:=D4&20JJJ7?+8 &< 5U-%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 5^ /_.TU_P!VJ_\ NW5^_P!7
MX _\[37_ ':K_P"[=0!^_P!1110!_]+^[CXL_P#)*_$W_8*O?_1+U^0'_!MW
M_P H2O@)_P!@K4/_ $YW=?K_ /%G_DE?B;_L%7O_ *)>OR _X-N_^4)7P$_[
M!6H?^G.[H _;^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!?@SPYXSN/'7P\@UBR37!)##INHS7UY'+J%W/&X9K2WM[7YH5VLS,-K,V$8
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\
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M6*_X*4%@1GQAX6_EJ]?U(5&D44;M(B@,_+$#DX]?6I* "BBB@ HHHH ****
M"BBB@ HHHH ^/_\ @H5_R8)\<?\ LG_B;_TW7%> ?\$4O^41_P"SE_V3_0__
M $F2O?\ _@H5_P F"?''_LG_ (F_]-UQ7@'_  12_P"41_[.7_9/]#_])DH
M_3^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ K\ ?^"^G_-E?_9U7PX_]OJ_?ZOP!_P""
M^G_-E?\ V=5\./\ V^H _?ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#\ /^'S_ .UC_P!&)_&K_P !;/\ ^/4?\/G_ -K'_HQ/XU?^ MG_ /'J_?\
MHH _ #_A\_\ M8_]&)_&K_P%L_\ X]1_P^?_ &L?^C$_C5_X"V?_ ,>K]_Z*
M /P _P"'S_[6/_1B?QJ_\!;/_P"/4?\ #Y_]K'_HQ/XU?^ MG_\ 'J_?^B@#
M\ /^'S_[6/\ T8G\:O\ P%L__CU'_#Y_]K'_ *,3^-7_ ("V?_QZOW_HH _
M#_A\_P#M8_\ 1B?QJ_\  6S_ /CU'_#Y_P#:Q_Z,3^-7_@+9_P#QZOW_ **
M/P _X?/_ +6/_1B?QJ_\!;/_ ./4?\/G_P!K'_HQ/XU?^ MG_P#'J_?^B@#\
M /\ A\_^UC_T8G\:O_ 6S_\ CU'_  ^?_:Q_Z,3^-7_@+9__ !ZOW_HH _ #
M_A\_^UC_ -&)_&K_ ,!;/_X]1_P^?_:Q_P"C$_C5_P" MG_\>K]_Z* /P _X
M?/\ [6/_ $8G\:O_  %L_P#X]1_P^?\ VL?^C$_C5_X"V?\ \>K]_P"B@#\
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M\_\ M8_]&)_&K_P%L_\ X]7[_P!% 'X ?\/G_P!K'_HQ/XU?^ MG_P#'J/\
MA\_^UC_T8G\:O_ 6S_\ CU?O_10!^ '_  ^?_:Q_Z,3^-7_@+9__ !ZC_A\_
M^UC_ -&)_&K_ ,!;/_X]7[_T4 ?@!_P^?_:Q_P"C$_C5_P" MG_\>H_X?/\
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M_P!&)_&K_P !;/\ ^/5^_P#10!^ '_#Y_P#:Q_Z,3^-7_@+9_P#QZC_A\_\
MM8_]&)_&K_P%L_\ X]7[_P!% 'X ?\/G_P!K'_HQ/XU?^ MG_P#'J_,G_@IA
M^VI^V[^V/_PS]_PBG[%/QBTG_A5?QG\*?$.\^T:=%/\ :;30_M/F6Z>0[[))
M/.&V23;$N/F89%?V:T4 ?@!_P^?_ &L?^C$_C5_X"V?_ ,>H_P"'S_[6/_1B
M?QJ_\!;/_P"/5^_]% 'X ?\ #Y_]K'_HQ/XU?^ MG_\ 'J/^'S_[6/\ T8G\
M:O\ P%L__CU?O_10!^ '_#Y_]K'_ *,3^-7_ ("V?_QZC_A\_P#M8_\ 1B?Q
MJ_\  6S_ /CU?O\ T4 ?@!_P^?\ VL?^C$_C5_X"V?\ \>H_X?/_ +6/_1B?
MQJ_\!;/_ ./5^_\ 10!^ '_#Y_\ :Q_Z,3^-7_@+9_\ QZC_ (?/_M8_]&)_
M&K_P%L__ (]7[_T4 ?@!_P /G_VL?^C$_C5_X"V?_P >H_X?/_M8_P#1B?QJ
M_P# 6S_^/5^_]% 'X ?\/G_VL?\ HQ/XU?\ @+9__'J/^'S_ .UC_P!&)_&K
M_P !;/\ ^/5^_P#10!^ '_#Y_P#:Q_Z,3^-7_@+9_P#QZC_A\_\ M8_]&)_&
MK_P%L_\ X]7[_P!% 'X ?\/G_P!K'_HQ/XU?^ MG_P#'J/\ A\_^UC_T8G\:
MO_ 6S_\ CU?O_10!^ '_  ^?_:Q_Z,3^-7_@+9__ !ZC_A\_^UC_ -&)_&K_
M ,!;/_X]7[_T4 ?@!_P^?_:Q_P"C$_C5_P" MG_\>H_X?/\ [6/_ $8G\:O_
M  %L_P#X]7[_ -% 'X ?\/G_ -K'_HQ/XU?^ MG_ /'J/^'S_P"UC_T8G\:O
M_ 6S_P#CU?O_ $4 ?@!_P^?_ &L?^C$_C5_X"V?_ ,>H_P"'S_[6/_1B?QJ_
M\!;/_P"/5^_]% 'X ?\ #Y_]K'_HQ/XU?^ MG_\ 'J/^'S_[6/\ T8G\:O\
MP%L__CU?O_10!^ '_#Y_]K'_ *,3^-7_ ("V?_QZC_A\_P#M8_\ 1B?QJ_\
M 6S_ /CU?O\ T4 ?@!_P^?\ VL?^C$_C5_X"V?\ \>H_X?/_ +6/_1B?QJ_\
M!;/_ ./5^_\ 10!^ '_#Y_\ :Q_Z,3^-7_@+9_\ QZC_ (?/_M8_]&)_&K_P
M%L__ (]7[_T4 ?@!_P /G_VL?^C$_C5_X"V?_P >H_X?/_M8_P#1B?QJ_P#
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M/5^_]% 'X ?\/G_VL?\ HQ/XU?\ @+9__'J/^'S_ .UC_P!&)_&K_P !;/\
M^/5^_P#10!^ '_#Y_P#:Q_Z,3^-7_@+9_P#QZC_A\_\ M8_]&)_&K_P%L_\
MX]7[_P!% 'X ?\/G_P!K'_HQ/XU?^ MG_P#'J/\ A\_^UC_T8G\:O_ 6S_\
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$* /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980464096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">YIELD10 BIOSCIENCE,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3158289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19 Presidential Way<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Woburn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">01801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">583-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">YTEN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,867,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,074,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference [Text Block]</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-bottom:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to General Instruction G to Form 10-K, the information required by Part III, Items 10, 11, 12, 13 and 14 is incorporated herein by reference from the Company's proxy statement for the Annual Meeting of Stockholders to be held on May 25, 2023, which is expected to be filed not later than 120 days after the fiscal year end covered by this Form 10-K.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001121702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980317568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">RSM US&#160;LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980549904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="nump">$ 5,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">10,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled receivables</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">641<span></span>
</td>
<td class="nump">436<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">5,018<span></span>
</td>
<td class="nump">16,624<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,961<span></span>
</td>
<td class="nump">2,354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">283<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">8,085<span></span>
</td>
<td class="nump">20,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">926<span></span>
</td>
<td class="nump">1,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">2,075<span></span>
</td>
<td class="nump">2,656<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,685<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note&#160;7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock ($0.01 par value per share); 60,000,000 shares authorized at December&#160;31, 2022 and 2021, and 4,944,202 and 4,881,851 shares issued and outstanding at December&#160;31, 2022 and 2021, respectively</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">404,277<span></span>
</td>
<td class="nump">402,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(399,697)<span></span>
</td>
<td class="num">(386,131)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">16,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 8,085<span></span>
</td>
<td class="nump">$ 20,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980481168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">4,944,202<span></span>
</td>
<td class="nump">4,881,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">4,944,202<span></span>
</td>
<td class="nump">4,881,851<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980518896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_CostOfRevenueResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">7,750<span></span>
</td>
<td class="nump">6,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,151<span></span>
</td>
<td class="nump">6,105<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">13,901<span></span>
</td>
<td class="nump">12,306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(13,451)<span></span>
</td>
<td class="num">(11,692)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_GainOnRelatedPartyInvestment', window );">Gain on investment in related party</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">41<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">697<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(13,410)<span></span>
</td>
<td class="num">(10,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(156)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,566)<span></span>
</td>
<td class="num">$ (11,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net loss per share (in dollars per share)</a></td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net loss per share (in dollars per share)</a></td>
<td class="num">$ (2.76)<span></span>
</td>
<td class="num">$ (2.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Number of shares used in per share calculations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">4,914,565<span></span>
</td>
<td class="nump">4,731,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">4,914,565<span></span>
</td>
<td class="nump">4,731,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_CostOfRevenueResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the expenses associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors; facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the company's research and development, which also includes the costs related to revenue-producing contracts, which are recorded as research and development expenses, during the period by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_CostOfRevenueResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_GainOnRelatedPartyInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Related Party Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_GainOnRelatedPartyInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980589648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,566)<span></span>
</td>
<td class="num">$ (11,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain (loss) on investments, net of income tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Change in foreign currency translation adjustment, net of income tax</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive loss</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (13,620)<span></span>
</td>
<td class="num">$ (11,047)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278981064128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,566)<span></span>
</td>
<td class="num">$ (11,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ChargeForCompanyCommonStockMatch', window );">Expense for 401(k) company common stock match</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">1,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_NoncashLeaseExpenseIncome', window );">Noncash lease expense</a></td>
<td class="nump">393<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax asset</a></td>
<td class="nump">165<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">164<span></span>
</td>
<td class="num">(78)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Unbilled receivables</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(160)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(209)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_IncreaseDecreaseInLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="num">(520)<span></span>
</td>
<td class="num">(463)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(11,404)<span></span>
</td>
<td class="num">(9,253)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(154)<span></span>
</td>
<td class="num">(189)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of investments</a></td>
<td class="num">(2,445)<span></span>
</td>
<td class="num">(10,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfShortTermInvestments', window );">Proceeds from sale and maturity of short-term investments</a></td>
<td class="nump">11,121<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="num">(4,578)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from securities offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on employees' behalf related to vesting of stock awards</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(37)<span></span>
</td>
<td class="nump">15,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,973)<span></span>
</td>
<td class="nump">1,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of year</a></td>
<td class="nump">5,593<span></span>
</td>
<td class="nump">3,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of year</a></td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">5,593<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ChargeForCompanyCommonStockMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncash charge representing the fair value of Company common stock issued by the company to participants in the Company's 401(k) plan as a matching contribution during the reporting period. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ChargeForCompanyCommonStockMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_NoncashLeaseExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_NoncashLeaseExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278979951888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 9,532<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 384,758<span></span>
</td>
<td class="num">$ (159)<span></span>
</td>
<td class="num">$ (375,100)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,334,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock for 401(k) match</a></td>
<td class="nump">$ 109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock for 401k match (in shares)</a></td>
<td class="nump">13,611<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on employees' behalf related to vesting of stock awards</a></td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for warrant exercises</a></td>
<td class="nump">3,856<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">3,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for warrant exercises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,973<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">11,993<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">11,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Effect of foreign currency translation</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,031)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,031)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">16,026<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">402,283<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(386,131)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,881,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (decrease) in stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,903<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan', window );">Issuance of common stock for 401(k) match</a></td>
<td class="nump">$ 128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Issuance of common stock for 401k match (in shares)</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">36,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid on employees' behalf related to vesting of stock awards</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax', window );">Effect of foreign currency translation</a></td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,566)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,566)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 404,277<span></span>
</td>
<td class="num">$ (229)<span></span>
</td>
<td class="num">$ (399,697)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,944,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a-c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983768384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs</a></td>
<td class="nump">$ 747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983828032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address 1) petroleum replacement markets: Camelina oil for use as a biofuel feedstock and PHA bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and 2) food and nutrition markets: omega-3 (EPA, DHA+EPA) oils produced in Camelina seed for aquaculture and nutraceuticals; and for protein meal for animal feed markets.  The commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from the Company's development pipeline which offer improved on-farm performance that will lead to increased acreage and seed product revenue.  Yield10 also plans to create additional value for its shareholders by licensing yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola.  Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.  Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December&#160;31, 2022.  The Company ended 2022 with unrestricted cash, cash equivalents and short-term investments of $4,347.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Presentation of Financial Statements-Going Concern</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its consolidated financial statements are issued.  The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given.  Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all.  If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment.  Based on its current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern.  This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company&#8217;s existing stockholders.  In addition, utilization of the Company&#8217;s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions.  If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ("COVID-19") and the risks to the international community as the virus spreads globally beyond its point of origin.  In March 2020, the WHO classified COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.  The full impact of the COVID-19 pandemic continues to evolve as of the </span></div>date of this report.  As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain.  While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce in future periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983969136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB").  The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported.  References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions were eliminated, including transactions with its subsidiaries, Yield10 Oilseeds Inc. and Yield10 Bioscience Securities Corp.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts included in restricted cash represent those required to be set aside by contractual agreement.  Restricted cash of $264 at December&#160;31, 2022 and December&#160;31, 2021, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy.  The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term. The Company held no long-term investments at December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred.  Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis.  Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense).  The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.  Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations.  The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date.  Revenues and expenses are translated at average exchange rates prevailing during the period.  Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet.  When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net  loss.  The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable.  The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes.  Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company's unbilled receivables of $30 were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor.  The Company believes these receivables have a low risk of default.  At December&#160;31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support of the DOE grant.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's financial instruments as of December&#160;31, 2022 and December&#160;31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.  See Note 4 for further discussion on fair value measurements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements.  The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops.&#160; The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization.  Repairs and maintenance are charged to operating expense as incurred.  Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lease Accounting</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a lessee, the Company follows the lease accounting guidance codified in ASC 842.  A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor.  These grants are considered an ongoing major and central operation of the Company's business.  Revenue is earned as research expenses related to the grants are incurred.  Revenue earned on </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December&#160;31, 2022 and December&#160;31, 2021.  Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs associated with internal research and development are expensed as incurred.  Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation.  Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory.  Costs incurred in connection with government research grants are recorded as research and development expense.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative and business development of the Company.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.  See Note&#160;10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding.  Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period.  Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced.  Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same.  Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions.  The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.  The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any.  The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;13 for further discussion of income taxes.  The Company had no amounts recorded for unrecognized tax expense or benefits as of December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Changes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU became effective for annual periods beginning after December 15, 2021.  The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.</span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement.  This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.  This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance is effective for fiscal years beginning after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC&#8217;s definition</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and interim periods within those fiscal years.  The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983969136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTSThe Company's investments consist of the following:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985797472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has certain financial assets recorded at fair value which have been classified as Level&#160;1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements.  Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date.  Fair values determined by Level&#160;1 inputs utilize observable data such as quoted prices in active markets for identical instruments.  Fair values determined by Level&#160;2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly.  Fair values determined by Level&#160;3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions.  The fair value hierarchy level is determined by the lowest level of significant input.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial assets classified as Level&#160;2 at December&#160;31, 2022 and December&#160;31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services.  Because the Company&#8217;s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities.  The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources.  After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December&#160;31, 2022 and December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2022 and December&#160;31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for &#160;identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for&#160; identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of financial assets or liabilities between category levels for the years ended December&#160;31, 2022 and December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982643840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text">Property and Equipment, Net<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Depreciation and amortization expense for the years ended December&#160;31, 2022 and December&#160;31, 2021, was $263 and $220, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983995072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text">Accrued Expenses<div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field trials and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982725552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted&#8217;s program to develop omega-3 oils in Camelina sativa.  Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further EPA, DHA+EPA trait improvement, field testing and nutritional studies.  The Company will pay Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $31 remains outstanding as of December&#160;31, 2022.  Included within the agreement, the Company had an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology.  In November 2022, Yield10 and Rothamsted agreed to extend the collaboration agreement, including the license option, without additional funding support, through December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with the University of Missouri ("UM")</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops.  Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production.  The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market.  The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products.  The Company or UM may terminate the license agreement in accordance with the terms of the agreement.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranteed Minimum Payments to Growers.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an incentive for growers located in Canada and the U.S. to enter into Camelina commercial grain production contracts with the Company for the 2022/2023 winter season, Yield10 offered minimum guaranteed payments per acre that </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce the growers' risk of financial loss.  These minimum payments, which are being accrued on a straight-line basis over the expected winter growing season, are conditional upon each grower fulfilling their contractual responsibilities and are reduced by the price of Yield10's Camelina planting seed and the contractual price that the Company will pay for the actual amount of grain that is harvested.  Although the Company anticipates that the payment of these guaranteed amounts will not be required under normal growing conditions, for the 2022/2023 winter season the maximum amount of these grain production guarantees is approximately $320.  As of December&#160;31, 2022, the Company has recorded an accrual of approximately $25 for these minimum guaranteed payments, net of the growers' obligation to pay for the planting seed.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Leases</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026.  See Note 11.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;December&#160;31, 2022,&#160;and&#160;December&#160;31, 2021, the Company did not have significant liabilities recorded for guarantees.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers.  Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities.  These indemnification provisions generally survive termination of the underlying agreement.  The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited.  However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.  As a result, the estimated fair value of these agreements is minimal.  Accordingly, the Company has no liabilities recorded for these agreements as of&#160;December&#160;31, 2022&#160;and&#160;December&#160;31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982643840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License Agreements</a></td>
<td class="text">License Agreements<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean.  Under this license, Bayer had the non-exclusive right to work with C3003 in its soybean program as a strategy to improve seed yield.  In December 2022, the Company and Bayer terminated the license in accordance with its terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company granted a four-year, non-exclusive license, as amended, to Forage Genetics International, LLC, a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum.  The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform; C4001, C4002, C4003 and C4029.  In September 2022, the license terminated in accordance with its terms.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato.  Under the license agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability.  In September 2022, the Company and Simplot amended the license agreement in order to extend it for a fourth year.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specializing in plant genetics, to evaluate novel traits in soybean.  Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability.  The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982725552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock and Warrants</a></td>
<td class="text">Capital Stock and Warrants<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Registered Public Offerings</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information with regard to outstanding warrants to purchase common stock as of December&#160;31, 2022:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares Issuable Upon Exercise of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Public Offering - Series B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Private Placement - Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2017 Registered Direct Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued.  In addition, 160,975 Series A warrants issued in the Company's December 2017 securities offering also expired in accordance with the terms of their securities purchase agreement.</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing the Company with $3,856 in cash proceeds.</span></div><div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:3pt;padding-right:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"/><td style="width:67.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of common shares reserved for future issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982640320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Option Plans</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan").  No further grants or awards were subsequently made under the 2006 Plan.  A total of 3,662 options were awarded from the 2006 Plan and as of December&#160;31, 2022, 159 of these options remain outstanding and eligible for future exercise.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2014 Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan, which was amended in May 2020 (the "2018 Stock Plan").  A total of 16,896 options were awarded from the 2014 Plan and as of December&#160;31, 2022, 15,990 of these options remain outstanding and eligible for future exercise.  A total of 3,619 restricted stock awards were awarded from the 2014 Plan and as of December&#160;31, 2022, all of these restricted stock awards have vested.  No further stock awards may be issued from the 2014 Plan.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2018 Stock Plan initially reserved for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, non-qualified stock options, stock grants and other stock-based awards.  In accordance with the terms of the 2018 Stock Plan, beginning on the first day in January 2019, the Company's Board of Directors has annually approved the addition of shares to the 2018 Stock Plan in amounts equal to 5% of the outstanding shares of the Company's common stock on the day prior to the increase.  Effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 247,210 and 244,092 shares, respectively.  At its annual meeting of stockholders held on May 24, 2021, stockholders approved an amendment to add 300,000 more shares to the Company's 2018 Stock Plan.  As of December&#160;31, 2022, a total of 1,059,719 options and restricted stock awards have been issued from the 2018 Stock Plan, and as of that date, 990,243 options and restricted stock awards remain outstanding.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense Information for Stock Awards</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $1,903 and $1,675 for the years ended December&#160;31, 2022 and 2021, respectively.  At December&#160;31, 2022, there was approximately $3,189 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 2.42 years.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5NzI_92e01ef7-0471-4c44-a8d1-ce238526654a">one</span> to four years from the date of hire for new employees, the date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance.  The Company's policy is to issue new shares upon the exercise of stock options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity related to the shares of common stock covered by outstanding options is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.040%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value per share of options granted during fiscal years 2022 and 2021, was $3.31 and $8.99, respectively.  No options were exercised during 2022 and 2021, and therefore the intrinsic value for exercised options during the two years was not applicable.  The weighted average remaining contractual term for options outstanding as of December&#160;31, 2022 was 8.15 years.</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, and 2021, the Company determined the fair value of stock options using the Black-Scholes option-pricing model with the following assumptions for option grants, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6% - 4.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7% - 1.7%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 - 10.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 - 10.0</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116% - 126%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118% - 128%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history.  The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option.  The expected term of the options is based upon evaluation of historical and expected future exercise behavior.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option.  The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest.  The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restricted Stock Units ("RSUs")</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records stock compensation expense for RSUs on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value.  As RSUs vests, the Company </span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date.  The Company then pays the minimum required income tax for the employees.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, the Company withheld vested shares with a fair value of $37 and $102, respectively, to pay for minimum tax withholding associated with RSU vesting.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining recognition period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977789312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Maturity Analysis of Lease Liabilities</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities.  No other active real estate or equipment leases fall within the scope of ASC 842.  At December&#160;31, 2022, the Company's lease liability related to its Woburn facility will mature as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Short-term lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Long-term lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Quantitative Disclosure of Lease Costs</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>&#160; &#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information as of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Real Estate Leases</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;During 2016, the Company entered into a lease agreement, as amended, for its headquarters, pursuant to which the Company leased 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts.  The lease will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease.  Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease.  During the initial buildout of the rented space, the landlord paid for tenant improvements to the facility that resulted in increased rental payments by the Company.  As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset.  The Company has provided the landlord with a security deposit of $229.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of 9,874 square feet of its leased facility located in Woburn, Massachusetts.  The sublease space was determined to be in excess of the Company's needs.  The CJ sublease is coterminous with the Company's master lease and CJ will pay pro rata rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease.  Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,060 shown in the lease maturity analysis table above.  CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 9,600 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place.  None of these leases contains renewal or early termination options.  YOI's leases for these facilities expire on various dates through September 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980644560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes and Deferred Tax Assets and Liabilities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from operations before provision for income taxes consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,062)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from operations before income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,410)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The components of the income tax provision consisted of the following for the years ended December&#160;31, 2022 and 2021:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Tax Provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Rate</span></div><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible equity transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Attributes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company had U.S. net operating loss carryforwards ("NOLs") for federal and state income tax purposes of approximately $25,460 and $25,414, respectively.  All of the $25,460 of federal NOLs will carry forward indefinitely.  The Company's state NOL carryforwards will begin to expire on various dates through 2042.  The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $417 and $312, respectively.  These federal and state credits will begin to expire on various dates through 2042.  In Canada, the Company has cumulative research tax credits totaling $132 that will begin to expire on various dates through 2037.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets ("DTA"), which is comprised principally of NOL carryforwards.  Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state DTAs.  Accordingly, a full valuation allowance has been established against the U.S. net DTAs.  The Company has also concluded, based on its financial projections, that it is more likely than not the $132 of DTAs of its wholly-owned Canadian subsidiary, YOI, may not be recognized in the future, resulting in the Company's recording of a full valuation allowance against the assets.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the NOL and research and development credit ("R&amp;D Credit") carryforwards may be subject to a substantial annual limitation under Section&#160;382 of the U.S. Internal Revenue Code of 1986 (the "Code") due to ownership change limitations, as defined by the Code, that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of NOL and R&amp;D Credit carryforwards that can be utilized annually to offset future U.S. taxable income and tax, respectively.  The Company evaluated its Section 382 ownership changes through May 31, 2021 and has determined that the most recent change that occurred in November 2019 resulted in all NOL and R&amp;D Credit carryforwards outstanding as of that date becoming fully limited.  The Company has reduced its associated deferred tax assets accordingly.  To the extent an ownership change occurs in the future, the NOL, R&amp;D Credit carryforwards and other deferred tax assets recorded after the November 2019 ownership change may also be subject to limitations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tax years 2019 through 2022 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S.  The statute of limitations for NOLs utilized in future years will remain open beginning in the year of utilization. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense.  As of December&#160;31, 2022 and 2021, the Company had no accrued interest or penalties recorded related to uncertain tax positions.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant.  As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings.&#160; A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed.&#160; It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries.&#160; Unremitted earnings at December&#160;31, 2022 and December&#160;31, 2021 approximated $1,081 and $1,032, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985696992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefits</a></td>
<td class="text">Employee BenefitsThe Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate.  Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations.  The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 36,706, and 13,611 shares of common stock during the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively, and recorded $133, and $112, respectively, of related expense.  Company contributions are fully vested upon issuance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985733248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Research Grants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract', window );"><strong>Research and Development Arrangement with Federal Government [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_EnergyGrantDisclosureTextBlock', window );">Government Research Grants</a></td>
<td class="text">Government Research Grants<div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Research Grant</span></div><div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 26, 2021, YOI received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC").  The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises.  Under the terms of the agreement, NRC agreed to contribute up to a maximum of $39 for payroll costs incurred by YOI during the period December 20, 2020 - March 13, 2021.  During the first quarter of 2021, YOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award.</span></div><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S. Research Grants</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2018, the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A Systems Approach to Increasing Carbon Flux to Seed Oil.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">"  The Company's participation under this five-year grant has been awarded incrementally on an annual basis with the first year commencing September 15, 2017.  Total funding for this sub-award in the amount of $2,957 was appropriated by the U.S. Congress through the final contractual year ending in September 2022.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, Yield10 recognized grant revenue of $450 and $575, respectively, from this sub-award.</span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, final proceeds of $60 remain to be earned from the MSU sub-award.  During June 2022, the parties amended the sub-award to extend its termination date to September 14, 2023, allowing Yield10 time to utilize the remaining grant funds.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_EnergyGrantDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure regarding the grant agreement with the U.S. Department of Energy for the development of switchgrass.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_EnergyGrantDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985780448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic Information</a></td>
<td class="text">Geographic Information<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below.  Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985680048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
<td class="text">Related Party TransactionDuring 1999, Yield10 entered into a technology sublicense agreement with Tepha, Inc. ("Tepha"), a privately held related party engaged in the development of medical products.  Yield10 received 648,149 shares of Series A Convertible Preferred Stock of Tepha ("Tepha Shares") during 2002 as consideration for outstanding license payments due to Yield10 totaling $700.  During 2005, the Company determined the value of the Tepha Shares was impaired resulting in their write off through a charge to other income (expense).  In May 2021, the board of directors of Tepha approved and authorized the merger of Tepha with Becton Dickinson Global Holdings, Inc. ("Becton Dickinson") and on July 26, 2021, Yield10 received cash consideration of $700 in exchange for the surrender of its Tepha Shares upon the closing of the sale of Tepha to Becton Dickinson.  As a result, the Company recorded the $700 as a gain on investment in related party within other income (expense) during the year ended December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985629040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text">Subsequent Event<div style="margin-bottom:9pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">At-The-Market ("ATM") Program</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January&#160;24, 2023, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Maxim Group LLC ("Maxim") under which the Company may offer and sell shares of its common stock, $0.01 par value per share, having an aggregate offering price of up to $4,200 from time to time through Maxim, acting exclusively as the Company's sales agent (the "Offering").  On January&#160;24, 2023, the Company filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering under its existing Registration Statement on Form S-3 (File No 333-254830), which was declared effective on April 2, 2021.  The Company intends to use the net proceeds of the Offering primarily for working capital and general corporate purposes.  Maxim will be entitled to compensation at a fixed commission rate of 2.75% of the gross sales price per share sold.  In addition, the Company agreed to reimburse Maxim for its costs and out-of-pocket expenses incurred in connection with its services, including the fees and out-of-pocket expenses of its legal counsel.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is not obligated to make any sales under the Sales Agreement and no assurance can be given that the Company will sell, or the dates on which any such sales will take place.  The Sales Agreement will continue until the earliest of (i) twelve (12) months following the date of the Sales Agreement, (ii) the sale of shares thereunder having an aggregate offering price of $4,200, and (iii) the termination by the Company upon the provision of ten (10) days written notice or by Maxim immediately upon written notification to the Company.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From January&#160;24, 2023 through  March&#160;14, 2023, the Company issued 94,665 shares of common stock in connection with the ATM at per share prices between $3.03 and $4.08, resulting in net proceeds to the Company of approximately $290 after subtracting sales commissions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980278944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB").  The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported.  References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions were eliminated, including transactions with its subsidiaries, Yield10 Oilseeds Inc. and Yield10 Bioscience Securities Corp.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">Amounts included in restricted cash represent those required to be set aside by contractual agreement.  Restricted cash of $264 at December&#160;31, 2022 and December&#160;31, 2021, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy.  The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term. The Company held no long-term investments at December&#160;31, 2022 and 2021.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred.  Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis.  Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense).  The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.  Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations.  The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date.  Revenues and expenses are translated at average exchange rates prevailing during the period.  Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet.  When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net  loss.  The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable.  The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes.  Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, the Company's unbilled receivables of $30 were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor.  The Company believes these receivables have a low risk of default.  At December&#160;31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support of the DOE grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company's financial instruments as of December&#160;31, 2022 and December&#160;31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.  See Note 4 for further discussion on fair value measurements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements.  The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops.&#160; The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost less accumulated depreciation and amortization.  Repairs and maintenance are charged to operating expense as incurred.  Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Accounting</a></td>
<td class="text">Lease Accounting<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a lessee, the Company follows the lease accounting guidance codified in ASC 842.  A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Leases</span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Impairment of Long-Lived Assets</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Grant Revenue</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grant Revenue</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor.  These grants are considered an ongoing major and central operation of the Company's business.  Revenue is earned as research expenses related to the grants are incurred.  Revenue earned on </span></div>government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December&#160;31, 2022 and December&#160;31, 2021.  Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs associated with internal research and development are expensed as incurred.  Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation.  Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory.  Costs incurred in connection with government research grants are recorded as research and development expense.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General, and Administrative Expenses</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative and business development of the Company.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_IntellectualPropertyCostsPolicyPolicyTextBlock', window );">Intellectual Property Costs</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property Costs</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.  See Note&#160;10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss per Share</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basic and Diluted Net Loss per Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding.  Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period.  Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced.  Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same.  Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions.  The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.  The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any.  The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.</span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;13 for further discussion of income taxes.  The Company had no amounts recorded for unrecognized tax expense or benefits as of December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards Changes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Standards Changes</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2021, the FASB issued </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2021-10,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU became effective for annual periods beginning after December 15, 2021.  The adoption of this standard did not materially impact the Company&#8217;s consolidated financial statements for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.</span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13,&#160;</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement.  This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.  This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.  </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance is effective for fiscal years beginning after</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC&#8217;s definition</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and interim periods within those fiscal years.  The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_IntellectualPropertyCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intellectual property costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_IntellectualPropertyCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278979891008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of cash, cash equivalents and restricted cash</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:</span></div><div style="margin-bottom:9pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,593&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of estimated useful life of assets used to compute depreciation using the straight-line method</a></td>
<td class="text">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of shares used to calculate diluted earnings per share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.847%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977770448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of investment holdings</a></td>
<td class="text">The Company's investments consist of the following:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2022</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,992&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.784%"/><td style="width:0.1%"/></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Cost at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Market Value at December 31, 2021</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gain</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Loss)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,669&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985629040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text">The tables below present information about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2022 and December&#160;31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for &#160;identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable&#160;inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,633&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,991&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:37.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted prices in active markets&#160;for&#160; identical<br/>assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;other<br/>observable inputs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>unobservable&#160; inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance&#160;as&#160;of</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level&#160;3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,661&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,539&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985780448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of components of property and equipment</a></td>
<td class="text">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:62.834%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:30.645%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Asset Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Useful Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of useful life or term of lease</span></td></tr></table><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,420&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, at cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,017&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,058&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,242)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980644560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.782%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased facilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Field trials and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">273&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985622880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Information with regard to outstanding warrants to purchase common stock</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes information with regard to outstanding warrants to purchase common stock as of December&#160;31, 2022:</span></div><div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Common Shares Issuable Upon Exercise of Outstanding Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Public Offering - Series B</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395,528&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 2019 Private Placement - Series B</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">718,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 19, 2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">July 2017 Registered Direct Offering</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 7, 2024</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consultant</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 11, 2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance</a></td>
<td class="text">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"><tr><td style="width:1.0%"/><td style="width:67.337%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.922%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.925%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,129,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total number of common shares reserved for future issuance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,136,169&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,093,921&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278986538016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the activity related to the shares of common stock covered by outstanding options under the plans</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the activity related to the shares of common stock covered by outstanding options is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.040%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Term<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.02</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,509)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(851)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131.62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722,765&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.79</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,859)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,443)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">712.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979,748&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.15</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">437,039&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.03&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2022, and 2021, the Company determined the fair value of stock options using the Black-Scholes option-pricing model with the following assumptions for option grants, respectively:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.316%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.949%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6% - 4.3%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7% - 1.7%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected option term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 - 10.0</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1 - 10.0</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116% - 126%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118% - 128%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of RSU activity for the year ended December&#160;31, 2022 is as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.632%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.419%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life (years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awarded</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,557)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining recognition period (years)</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977676816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturity analysis of lease liabilities</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.854%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year ended December 31,</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Undiscounted Cash Flows</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted future lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Short-term lease liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Long-term lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,075&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Quantitative disclosure of lease costs</a></td>
<td class="text">Quantitative Disclosure of Lease Costs<div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended<br/>&#160; &#160;December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">605&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(605)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(616)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"/><td style="width:70.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.165%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other information as of:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980432672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of profit (loss) before provision for income taxes</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss from operations before provision for income taxes consist of the following:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,062)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss from operations before income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,410)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,995)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of income tax benefit</a></td>
<td class="text">The components of the income tax provision consisted of the following for the years ended December&#160;31, 2022 and 2021:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Tax Provision:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Benefit:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the Company's net deferred tax asset</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company's deferred tax assets are as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.114%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforward</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalization of research and development expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit carryforwards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">565&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">886&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">864&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other temporary differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,961)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred Tax Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(185)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(643)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred taxes</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.965%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.995%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.996%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal income tax at statutory federal rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent differences</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impact of ownership change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(267.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible equity transactions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985665264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of the geographic distribution of revenues and long-lived assets from continuing operations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below.  Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.953%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Canada</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year Ended December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable long-lived assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278986550160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Unrestricted cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 4,347<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982400080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,356<span></span>
</td>
<td class="nump">$ 5,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 2,620<span></span>
</td>
<td class="nump">$ 5,593<span></span>
</td>
<td class="nump">$ 3,687<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278975830480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980280976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock excluded from the calculation of dilutive shares</a></td>
<td class="nump">2,136,169<span></span>
</td>
<td class="nump">3,093,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock excluded from the calculation of dilutive shares</a></td>
<td class="nump">979,748<span></span>
</td>
<td class="nump">722,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock excluded from the calculation of dilutive shares</a></td>
<td class="nump">27,123<span></span>
</td>
<td class="nump">9,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive common stock excluded from the calculation of dilutive shares</a></td>
<td class="nump">1,129,298<span></span>
</td>
<td class="nump">2,361,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977451872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">$ 264,000<span></span>
</td>
<td class="nump">$ 264,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_AccountsReceivableTradeAndUnbilledReceivables', window );">Accounts and unbilled receivables</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_AccountsReceivableTradeAndUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Trade And Unbilled Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_AccountsReceivableTradeAndUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278979940224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Accumulated Cost</a></td>
<td class="nump">$ 1,992,000<span></span>
</td>
<td class="nump">$ 10,669,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">1,991,000<span></span>
</td>
<td class="nump">10,661,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Accumulated Cost</a></td>
<td class="nump">1,992,000<span></span>
</td>
<td class="nump">10,669,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized (Loss)</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="num">(8,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Market Value</a></td>
<td class="nump">$ 1,991,000<span></span>
</td>
<td class="nump">$ 10,661,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977271344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">$ 1,991<span></span>
</td>
<td class="nump">$ 10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,624<span></span>
</td>
<td class="nump">15,539<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted prices in active markets&#160;for identical assets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted prices in active markets&#160;for identical assets (Level 1) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Quoted prices in active markets&#160;for identical assets (Level 1) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">1,633<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">10,661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant&#160;other observable&#160;inputs (Level 2) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | U.S. government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Significant unobservable inputs (Level 3) | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977411376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 2,017<span></span>
</td>
<td class="nump">$ 2,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(1,242)<span></span>
</td>
<td class="num">(1,168)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">1,425<span></span>
</td>
<td class="nump">1,420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property and equipment, net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment, at cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980515056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Leased facilities</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_AccruedFieldTrialsAndRelatedExpensesCurrent', window );">Field trials and related expenses</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">269<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 926<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_AccruedFieldTrialsAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Field Trials And Related Expenses, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_AccruedFieldTrialsAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278979926080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Nov. 12, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Guarantor obligation, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuarantyLiabilities', window );">Minimum guaranteed payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable', window );">Quarterly research funding and option fees</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable', window );">Total research funding and option fees</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_CollaborativeArrangementTerm', window );">Term of agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement', window );">Term of option for license agreement</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123422226&amp;loc=d3e11019-110243<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123422226&amp;loc=d3e11049-110243<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Funding And Option Fees Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_CollaborativeArrangementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_CollaborativeArrangementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_CollaborativeArrangementTermOfOptionForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Of Option For License Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_CollaborativeArrangementTermOfOptionForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278985782112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2018</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LicenseAgreementTerm', window );">License agreement term</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977343616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock and Warrants - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 19, 2022</div></th>
<th class="th"><div>Feb. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">481,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedNovember2019Member', window );">Series A Warrants Issued November 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="nump">1,071,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedDecember2017Member', window );">Series A Warrants Issued December 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ClassOfWarrantOrRightExpired', window );">Warrants expired (in shares)</a></td>
<td class="nump">160,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_SaleofStockGrossConsiderationReceivedPerTransaction', window );">Gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ClassOfWarrantOrRightExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ClassOfWarrantOrRightExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_SaleofStockGrossConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Gross Consideration Received Per Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_SaleofStockGrossConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedNovember2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedNovember2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedDecember2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesAWarrantsIssuedDecember2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278975776672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</a></td>
<td class="nump">1,129,298<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringJanuary2024Member', window );">Warrants - expiration January 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</a></td>
<td class="nump">14,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 201.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringSeptember2024Member', window );">Warrants - expiration September 2024</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</a></td>
<td class="nump">750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 116.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember', window );">Public offering | Series B Warrants - expiration May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</a></td>
<td class="nump">395,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Registered direct offering | Series B Warrants - expiration May 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)</a></td>
<td class="nump">718,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price (in USD per share) | $ / shares</a></td>
<td class="nump">$ 8.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringJanuary2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringJanuary2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringSeptember2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=yten_WarrantExpiringSeptember2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=yten_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesBWarrantExpiringMay2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=yten_SeriesBWarrantExpiringMay2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278975849872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of common shares reserved for future issuance</a></td>
<td class="nump">2,136,169<span></span>
</td>
<td class="nump">3,093,921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of common shares reserved for future issuance</a></td>
<td class="nump">979,748<span></span>
</td>
<td class="nump">722,765<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of common shares reserved for future issuance</a></td>
<td class="nump">27,123<span></span>
</td>
<td class="nump">9,430<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total number of common shares reserved for future issuance</a></td>
<td class="nump">1,129,298<span></span>
</td>
<td class="nump">2,361,726<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278976123888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 24, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent', window );">Increase in shares available for issuance, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,903<span></span>
</td>
<td class="nump">$ 1,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Fair value of vested shares withheld for minimum tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=yten_StockPlan2018Member', window );">2018 Stock Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional shares authorized</a></td>
<td class="nump">247,210<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">244,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber', window );">Options and restricted stock awards issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,059,719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber', window );">Options and restricted stock awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">990,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Unvested and outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979,748<span></span>
</td>
<td class="nump">722,765<span></span>
</td>
<td class="nump">339,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.31<span></span>
</td>
<td class="nump">$ 8.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term for options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">9 years 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Employee and Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period over which unrecognized compensation expense is expected to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period for options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2006 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross', window );">Options awarded to date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Unvested and outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross', window );">Options awarded to date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,896<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Unvested and outstanding options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards | 2014 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross', window );">Options awarded to date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Fair value of vested shares withheld for minimum tax withholding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Awards Issued, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding, Number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative gross number of share options (or share units) granted under the stock based compensation plan as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The period of time, from the grant date until the time at which the share-based (option) award expires.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Increase Of Shares Authorized, Percent Of Outstanding Shares, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=yten_StockPlan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=yten_StockPlan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=yten_EmployeeAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=yten_EmployeeAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=yten_StockPlan2006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=yten_StockPlan2006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=yten_StockPlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=yten_StockPlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977176448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">722,765<span></span>
</td>
<td class="nump">339,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">260,285<span></span>
</td>
<td class="nump">386,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,859)<span></span>
</td>
<td class="num">(1,509)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(1,443)<span></span>
</td>
<td class="num">(851)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">979,748<span></span>
</td>
<td class="nump">722,765<span></span>
</td>
<td class="nump">339,108<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest at the end of the period (in shares)</a></td>
<td class="nump">979,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at the end of the period (in shares)</a></td>
<td class="nump">437,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 19.22<span></span>
</td>
<td class="nump">$ 32.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.72<span></span>
</td>
<td class="nump">10.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">7.55<span></span>
</td>
<td class="nump">12.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">712.92<span></span>
</td>
<td class="nump">1,131.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">14.10<span></span>
</td>
<td class="nump">$ 19.22<span></span>
</td>
<td class="nump">$ 32.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest at the end of the period (in dollars per share)</a></td>
<td class="nump">14.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 23.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance</a></td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">8 years 9 months 14 days<span></span>
</td>
<td class="text">9 years 7 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest</a></td>
<td class="text">8 years 1 month 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable</a></td>
<td class="text">7 years 8 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278975855344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details) - Stock options<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free rate, minimum</a></td>
<td class="nump">1.60%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free rate, maximum</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="nump">116.00%<span></span>
</td>
<td class="nump">118.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="nump">126.00%<span></span>
</td>
<td class="nump">128.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Assumptions used to determine fair value of stock options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected option term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278983040976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">9,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares)</a></td>
<td class="nump">54,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(36,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding (in shares)</a></td>
<td class="nump">27,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">1 month 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977452096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturity Analysis of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted future lease payments</a></td>
<td class="nump">3,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Amount of lease payments representing interest</a></td>
<td class="num">(410)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">2,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short-term lease liabilities</a></td>
<td class="nump">575<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 2,075<span></span>
</td>
<td class="nump">$ 2,656<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278981036192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Quantitative Disclosure of Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 605<span></span>
</td>
<td class="nump">$ 605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">696<span></span>
</td>
<td class="nump">655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(605)<span></span>
</td>
<td class="num">(616)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost, net</a></td>
<td class="nump">$ 696<span></span>
</td>
<td class="nump">$ 644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LeaseOtherInformationAbstract', window );"><strong>Other information as of:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="nump">7.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_LeaseOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease, Other Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_LeaseOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977355008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted future lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_PresidentialWayWoburnMassachusettsMember', window );">19 Presidential Way, Woburn, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LesseeOperatingLeaseLeaseArea', window );">Leased area (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Security deposit - letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LesseeOperatingSubleaseSubleasedArea', window );">Subleased area (in sqft) | ft&#178;</a></td>
<td class="nump">9,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Undiscounted future lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_A410DowneyRoadAnd110GymnasiumPlaceMember', window );">410 Downey Road and 110 Gymnasium Place</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LesseeOperatingLeaseLeaseArea', window );">Leased area (in sqft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=yten_CJCheilJedangCorporationMember', window );">CJ CheilJedang Corporation | 19 Presidential Way, Woburn, Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Security deposit - letter of credit</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_LesseeOperatingLeaseLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_LesseeOperatingLeaseLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_LesseeOperatingSubleaseSubleasedArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Sublease, Subleased Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_LesseeOperatingSubleaseSubleasedArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_PresidentialWayWoburnMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_PresidentialWayWoburnMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_A410DowneyRoadAnd110GymnasiumPlaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis=yten_A410DowneyRoadAnd110GymnasiumPlaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=yten_CJCheilJedangCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=yten_CJCheilJedangCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977546176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Components of profit (loss) before provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (13,504)<span></span>
</td>
<td class="num">$ (11,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income taxes</a></td>
<td class="num">(13,410)<span></span>
</td>
<td class="num">(10,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current Tax Provision:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred Tax Benefit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total tax provision</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">6,953<span></span>
</td>
<td class="nump">5,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses', window );">Capitalization of research and development expense</a></td>
<td class="nump">1,841<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Credit carryforwards</a></td>
<td class="nump">799<span></span>
</td>
<td class="nump">565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">733<span></span>
</td>
<td class="nump">864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">11,369<span></span>
</td>
<td class="nump">7,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(10,739)<span></span>
</td>
<td class="num">(6,961)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">630<span></span>
</td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred Tax Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">(643)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal income tax at statutory federal rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">5.90%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Permanent differences</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent', window );">Impact of ownership change</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(267.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Non-deductible equity transactions</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(2.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(28.10%)<span></span>
</td>
<td class="nump">240.30%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalization of research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Ownership Change, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278981110304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Details Textual (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Interest and penalties accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries', window );">Provision for income taxes for undistributed earnings of foreign subsidiaries</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Undistributed earnings of foreign subsidiaries</a></td>
<td class="nump">1,081,000<span></span>
</td>
<td class="nump">$ 1,032,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">25,460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">25,414,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward | Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="nump">$ 132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126928070&amp;loc=d3e28200-109314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the provision that has been made for U.S. income taxes related to the undistributed earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278982421616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum contribution by participants under the 401(k) savings plan (as a percent)</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan', window );">Common stock issued under the 401(k) savings plan (in shares)</a></td>
<td class="nump">36,706<span></span>
</td>
<td class="nump">13,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Related expense for common stock issued under the 401(k) savings plan</a></td>
<td class="nump">$ 133<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977430400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Government Research Grants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2017</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Feb. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_ResearchGrantMaximumPayrollCostReimbursement', window );">Maximum payroll cost reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_GovernmentGrantTerm', window );">Government grant term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember', window );">Systems Approach to Increasing Carbon Flux to Seed Oil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_GovernmentGrantCumulativeAmountAwarded', window );">Cumulative amount awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,957<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant revenue | Systems Approach to Increasing Carbon Flux to Seed Oil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Amount remaining to be earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_GovernmentGrantCumulativeAmountAwarded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Grant, Cumulative Amount Awarded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_GovernmentGrantCumulativeAmountAwarded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_GovernmentGrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Government Grant, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_GovernmentGrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_ResearchGrantMaximumPayrollCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research Grant, Maximum Payroll Cost Reimbursement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_ResearchGrantMaximumPayrollCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278980394640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 450<span></span>
</td>
<td class="nump">$ 614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Identifiable long-lived assets</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Identifiable long-lived assets</a></td>
<td class="nump">671<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Identifiable long-lived assets</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">450<span></span>
</td>
<td class="nump">575<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember', window );">Reportable Geographical Components | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ReportableGeographicalComponentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977452096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2002</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_GainOnRelatedPartyInvestment', window );">Gain on investment in related party</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember', window );">Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedBalanceShares', window );">Investment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_LicensePaymentsReceivable', window );">Outstanding license payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_GainOnRelatedPartyInvestment', window );">Gain on investment in related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedBalanceShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Balance held at close of period in number of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column B))<br> -URI https://asc.fasb.org/extlink&amp;oid=122147990&amp;loc=d3e611197-123010<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedBalanceShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_GainOnRelatedPartyInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain On Related Party Investment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_GainOnRelatedPartyInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_LicensePaymentsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Payments Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_LicensePaymentsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140278977355968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 24, 2023</div></th>
<th class="th"><div>Mar. 14, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_SaleOfStockMaximumAggregateOfferingPrice', window );">Aggregate maximum offering price</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_yten_SaleOfStockCommissionRate', window );">Commission rate</a></td>
<td class="nump">2.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Common stock issued in offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Amount received from offering of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_SaleOfStockCommissionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_SaleOfStockCommissionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_yten_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">yten_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>yten_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>yten-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xmlns:yten="http://www.yield10bio.com/20221231">
    <link:schemaRef xlink:href="yten-20221231.xsd" xlink:type="simple"/>
    <context id="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac86a3d09d164b4a93df64e6e398cda3_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i0ec0531db504460d878e8a5b16adba16_I20230313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2023-03-13</instant>
        </period>
    </context>
    <context id="i966a0b1f35af427492d1da0e13191558_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if6e4e205f139470c9d01730aa2cae2bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0fa4f596e68b435cb25ae4cba2423590_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iee3c65cebf3e4b5cae9b882ffa69ba4b_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i97019bfe3e334d528406e95e102e2364_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3d3121e408a4cc2bbbbfbad11389e16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40955b8933394980b43a112a70cb81dd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if50f9d23f34d4f029330039500bd46fc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i684d6f37920d42318715b4946e6c8249_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia191e1112ea14abb840d58c60e120043_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i58fce4089bcb426e8039bc6cbfa6106c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7526ac612c264449a3e3ac301d55542f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ica80c64d92b04d749e752fded64ecc53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e6a79d372a4443d8d41d7ee23cabec4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic3efc24abbd6441ca82da51c9deb09b3_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iad8a0121d2bc47a58199c38a729c4349_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8b28bd8c03f94f9981d0b15e39eff5f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief1ac89ff5a2424396d026131c1fdf13_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i337d07789e89467e9cfd5f2c41ac49b3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i53f6338f531042b4a04410a3879ac996_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie14d20621fd74f3f903765f72c4cb378_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iceb9c616adc7405cb3808b71146eb760_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4648116206044ea1ab0d5587be0e4138_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4da9d58e3fa24edebed51009dfec4598_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibadc13ffe064427483b95cf9d059239f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icbc4ce7ce80f437bb07e269549f899be_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic119f79d77f64ab3b8eeebb87c15caa6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic77d372fcd3a4dc0b1f445bc7272f30c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if123f89aae974cfab1c6bc2456615632_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0987e598fd44b77bbed7faceb8e8bfd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id73e87c2e2c4452cb9bcdb46ea70f888_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i745a819a98b64320aa580b32fb4def9c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib708dd5f8a6f488982b1a6a8631cabc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04f100c5f4eb4b2fbb1336ee32b69ec2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb545bab60de47478b6320dbdab7d781_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9b04174d783444b5a91b08f126c073ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc0a6c75312c46e680b72b0b6f4f19e9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6aa5b795834d44dd8e3b1fcc2a74afad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ccbc1ced9aa46338a3306667ca0aff1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i94927ee7145149928eb35b6455abe6cd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ecc835c25a3427287cfa2313952f908_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0097ebc1457c424689098cd526fc4a70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie72dd2c270874bbd9c0f5786c80f1ce8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib4551191c4634001a933c43c11c34a07_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9c52dafa175b4fc68b9d93299520cd17_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i144df6c356284a69bdf5ec6b09bde5a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84682813ef2546fba512f9a3d6c563ad_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaf30edacde94c84a05341ca5dd0512f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iec9b06e45af54e8f9a8de5e18ac09e35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9ca1e9b355104bd08b48abb4bb45290e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i85e3db911982426a8a17792e40222a8f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3fec75a43493400b8c38e54079d13b02_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1479bec68b2c4d46978bb015eb204350_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib0041b2aac5540ffb18d839925fa734d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7d8c98f7a2c42188fb89171b9b7189a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia2c0fa82f93e4dbbbedf6619da265b98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0d96fc98eceb4bd6bec5c50fb28726ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd98a258635e48699f1a798857c5c38b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5eb1729532b6499587ce5b81b2cb2556_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7908f4e474c344729dd788b217be9fa9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd0d338183674907923554d81edf4952_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i80f310cf5c534afebc48ec2031f27370_I20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-12</instant>
        </period>
    </context>
    <context id="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-12</startDate>
            <endDate>2020-11-12</endDate>
        </period>
    </context>
    <context id="i78f5c017d62d4136be49a824fedd9fa5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-03</startDate>
            <endDate>2021-02-03</endDate>
        </period>
    </context>
    <context id="icff22d25d26146d48d6decdae2cb0324_I20210203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-03</instant>
        </period>
    </context>
    <context id="ia723adea7be546caa73fa33c727a5588_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesBWarrantExpiringMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">yten:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie858d5dd08b14a2188004834d4b1e502_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesBWarrantExpiringMay2027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7fc2e0c481974966a604c4a0215f7915_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:WarrantExpiringJanuary2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if5c1edd8e75c4550a03bf3e5051b199f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:WarrantExpiringSeptember2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c88b89cfb1647cd9d8bbb0a82bfcbc0_D20220519-20220519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesAWarrantsIssuedNovember2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-19</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="i6251c05d326e4a9386219cd404a47d8a_D20220519-20220519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">yten:SeriesAWarrantsIssuedDecember2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-19</startDate>
            <endDate>2022-05-19</endDate>
        </period>
    </context>
    <context id="i07391aec75484ead8a61a6df73afeff4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i027dffbf78374212835464d3640c101d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0ad4c8865ec4c419c5b12e819189c76_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i260c3b3f20bf4f4681bc4a91f421bbe5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2832ee80f63d460b8492d8bcc0b5909c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia0a7f5e745594f2dbf695fb7330eae73_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic32cbf34fc774d82a6a93117e76c1b14_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic327f368a9714dc0a2557c36d8a5e3da_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77415003bed3430f96c1e0adf0960a62_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd09c1537caf432ab0e3feb9155a01fd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="i30d73005a58b4b22bf596e5a6abcca81_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="if44b5193639a4f39b9593f64ec0b5853_D20210101-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i9337506ea45848f1ab5679c11ff6aeea_D20210524-20210524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-24</startDate>
            <endDate>2021-05-24</endDate>
        </period>
    </context>
    <context id="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">yten:StockPlan2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1b5c8104784a476492d5c745748a9745_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">yten:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0e337683c876475fbd6132b78b10119d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">yten:EmployeeAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7683e5fee18c49a889b650734cfda999_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d4fabacd1754b738011363e69731c36_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5cc722f803314436a9c7c6caad2c8578_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iadffb97e562c40ab9d5c4ca96b69c01a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i81e4afc9063e482c8ea9bcff80c5bc79_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i115962649b404c9dad81db13df9ab327_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iea7a2db667b9494c88b89ceeae9fafd9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie879a42901184b87a0029ddae2ba967e_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i119b882f71fe4a1082a3446bb15acbec_D20160101-20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="i91e719d6dc084b8eb65833dd9f3d826e_I20191130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-30</instant>
        </period>
    </context>
    <context id="i1669a5dd6ba54e94a94243d28e96c30c_D20161001-20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="i9567ed174d68444dbf277b216ec8dcbb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id253aebbd61b4ee5a2318fd621623370_I20161031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:PresidentialWayWoburnMassachusettsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">yten:CJCheilJedangCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-31</instant>
        </period>
    </context>
    <context id="ifedea1c8eb9444c6bea044622e488712_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis">yten:A410DowneyRoadAnd110GymnasiumPlaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i29e3f12dc3c148188c3b9a72081bb52a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i71199acae9bc42239b72a1e18ce921fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9695ea37c9b341f2b0c620593bc7e168_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i51098c3d74424991ace97eec86e2af91_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9843252c42d74447b91e88027db863ce_I20210226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <instant>2021-02-26</instant>
        </period>
    </context>
    <context id="i51fd40cc2e254ece8789b8a8cd184ae8_D20170915-20170915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
        </entity>
        <period>
            <startDate>2017-09-15</startDate>
            <endDate>2017-09-15</endDate>
        </period>
    </context>
    <context id="i65d3bb815986434388d03c0031f92093_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i700069e2fa634d1189b702db4b2c4eaa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie6dc4ad390504593af4a7847e1ed85a6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9f30c8f754de4a0f87018176ab9201bb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">yten:SystemsApproachToIncreasingCarbonFluxToSeedOilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib809cccb2c294bd5843cf6785af9651f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id239db0d46964587ab76bc81df6f1ee4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic8ed864be1c04cbca5272439e51ebf52_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3432e814c7b446a9bbe66a61846e2cde_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0bd17402842448b7b9f9be98aca430e4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5bc505e998514513905d81d0f376c451_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id4d4d7b016184bf3ab8c1d7180e6719f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3182629b0bab4d00be6bc9a3a8bd468a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ReportableGeographicalComponentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i09214b6a6ff746c2aa27601f31735dc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i629b7830786c41b6bda1598354d3a5b4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8415c21be2b24e3d8bf42091cf9a338e_I20021231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2002-12-31</instant>
        </period>
    </context>
    <context id="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i201dadb72c254a7c8f4f4491ef87c2ed_I20230124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-24</instant>
        </period>
    </context>
    <context id="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-01-24</endDate>
        </period>
    </context>
    <context id="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-24</startDate>
            <endDate>2023-03-14</endDate>
        </period>
    </context>
    <context id="ieb4322ccfe3e4eb29b27ffe467b4d129_I20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-14</instant>
        </period>
    </context>
    <context id="i9e7eed8de0164fab84eedcfec07eed0a_I20230314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001121702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-14</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>yten:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN18zLTEtMS0xLTU1Njc2_08a138b2-9824-4757-bf24-d832f5dd4a0f">0001121702</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN180LTEtMS0xLTU1Njc2_e7f8fc56-7243-43ba-a1e4-645ef5bcf331">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN181LTEtMS0xLTU1Njc2_21a0963b-c36e-4e4c-bb9e-fcfb192fc593">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl80L2ZyYWc6MjJjYTk0NjU1MjJkNGRhOThhNDIzYzA3NjJhZmM3YjgvdGFibGU6ZTQzMGFlMmE3NTRmNDY3NWExYjJmYzA2YjExODk0YjcvdGFibGVyYW5nZTplNDMwYWUyYTc1NGY0Njc1YTFiMmZjMDZiMTE4OTRiN182LTEtMS0xLTU1Njc2_c73f42fa-e3c8-4de7-8927-847ef40ef110">false</dei:AmendmentFlag>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5NzI_92e01ef7-0471-4c44-a8d1-ce238526654a">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <dei:DocumentType
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE1_c154591d-c113-434a-b35d-fe02f5b2e851">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZWRhNGU4ZTEwNTEwNDAxMGJiZGFlYjBjNWRlYWVlYmMvdGFibGVyYW5nZTplZGE0ZThlMTA1MTA0MDEwYmJkYWViMGM1ZGVhZWViY18wLTAtMS0xLTU1Njc2_3b63c279-5103-4794-92f5-95611f86f0be">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yMjc_91570595-e4b7-451a-8615-3a9ec744f132">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yMjc_a1a14724-8109-4aa7-a53b-e83323ac1060">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6NzcxNDNiYTUzY2RkNGI4ZWJjYjk0ZjhiNGU3MGQxOGEvdGFibGVyYW5nZTo3NzE0M2JhNTNjZGQ0YjhlYmNiOTRmOGI0ZTcwZDE4YV8wLTAtMS0xLTU1Njc2_089e2b4d-bb3f-4a83-bce5-240ae49efc3f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEx_147f0d75-cb17-45b6-9496-a1e0186aacc7">001-33133</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIw_f104e373-3bc3-44ab-b3f0-16bba2a9c479">YIELD10 BIOSCIENCE,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8wLTAtMS0xLTU1Njc2L3RleHRyZWdpb246NGQ4OTA5OGExNzZkNDE2MmJhYTRjZTNmMzQ5ODgwZmNfNA_d9ed6812-dd34-44f8-a7c8-ef96a06ebe59">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8wLTItMS0xLTU1Njc2L3RleHRyZWdpb246NjhhYzUxMTAwYWE4NDZkNThhOTU5OTIxMjI5MDA0ODJfNQ_41548169-5ec5-41d9-8e92-755241c83b16">04-3158289</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfNQ_59c35c4f-1ece-4b06-9de8-321a440678f3">19 Presidential Way</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfOQ_c397f76a-6064-4497-8e56-527dc611bc34">Woburn</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTAtMS0xLTU1Njc2L3RleHRyZWdpb246N2NkNzliOTMyMjllNGI0NWEwMTA3ZWNiY2JlZDY0Y2RfMTM_fff5b77c-d7f5-45bc-a65a-dae39624334b">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjFhNzk5MTJiNGQ2NGYwZTk4NDUzNjgxYzJhODYzZTAvdGFibGVyYW5nZTpmMWE3OTkxMmI0ZDY0ZjBlOTg0NTM2ODFjMmE4NjNlMF8yLTItMS0xLTU1Njc2L3RleHRyZWdpb246MjAzMzIwMzhmOWVhNDQyNDk5OTUzMjQ4ZTAwMDUwNDlfNQ_109e402a-e8f7-426e-8150-7d0b48651ab3">01801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIx_3f07ede2-3320-4df0-b6a2-ed26eb9e3cfe">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE3_04113618-072e-4e54-9989-8a2a1e682474">583-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTAtMS0xLTU1Njc2_013b75f2-bd73-42cd-aa3c-2c742041fb60">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTEtMS0xLTU1Njc2_c91c2380-80cd-4b76-b845-1e5cbe0cb441">YTEN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6ZjhlYmQzZjhmMDkzNDZhMDgxNWQwMDQ2NTk1MGFhMWYvdGFibGVyYW5nZTpmOGViZDNmOGYwOTM0NmEwODE1ZDAwNDY1OTUwYWExZl8xLTItMS0xLTU1Njc2L3RleHRyZWdpb246NzdiZDBiZjhjYmVlNDA5NWFkMmYxZmI0MmE0ZjVjNzJfOA_8c41c040-d7e4-414b-b641-0d01c52212af">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEy_c74d051f-0e6c-4995-bd14-def5d871c4c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEz_41e64033-7718-48c7-ac32-370e88c7d1fd">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE2_c328d597-0f22-4f36-9844-b40b3add2c69">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzIy_1ba82fa6-df23-4b63-810b-0a1d11858bfe">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8xLTAtMS0xLTU1Njc2_a42ac868-6603-497e-8fa1-2c15858db13a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8xLTMtMS0xLTU1Njc2_dc3dc77b-87b6-45f3-8af6-bc8a03edad75">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGFibGU6OTk3MGYyYmVlZTE4NDM1YWJjMmFjODE3YzI2ZTBjNWEvdGFibGVyYW5nZTo5OTcwZjJiZWVlMTg0MzVhYmMyYWM4MTdjMjZlMGM1YV8yLTMtMS0xLTU1Njc2_19a7b9e7-7034-4ebe-9a22-ac404fdf9d2f">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE5_4ed29849-30e6-4d2c-8ba1-ef0b1a9d6234">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzE0_8ba5202a-37f1-4135-880d-12bfe47552e6">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="iac86a3d09d164b4a93df64e6e398cda3_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yODI5_c419ae38-6870-4341-881d-1f942352b818"
      unitRef="usd">8867945</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i0ec0531db504460d878e8a5b16adba16_I20230313"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8yOTEz_e3b88f0f-be69-47f8-a9ac-2c17303e3cf2"
      unitRef="shares">5074085</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xL2ZyYWc6MTY4OWE1N2FkOWNiNGJkMzg2ZmMyOWVlNTAzNGU5ODgvdGV4dHJlZ2lvbjoxNjg5YTU3YWQ5Y2I0YmQzODZmYzI5ZWU1MDM0ZTk4OF8zMzEw_79dd8781-4ae3-4ac4-9a4b-97e315c89585">&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to General Instruction G to Form 10-K, the information required by Part III, Items 10, 11, 12, 13 and 14 is incorporated herein by reference from the Company's proxy statement for the Annual Meeting of Stockholders to be held on May 25, 2023, which is expected to be filed not later than 120 days after the fiscal year end covered by this Form 10-K.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl83OS9mcmFnOjMxNzc1OGVkMzY1ZjRkMTNiOWI1ODdkY2QwYWZkOWVmL3RhYmxlOmRjNGM2MWUxNjkyZTQzNjRiODIxNjNjYmM5MjM3ZjkxL3RhYmxlcmFuZ2U6ZGM0YzYxZTE2OTJlNDM2NGI4MjE2M2NiYzkyMzdmOTFfMi0wLTEtMS01NTY3Ni90ZXh0cmVnaW9uOjEyZWE3ZTFiMTk4YTRmMzU4YzU4YWY3NjYxNmI3NGE1Xzcx_2ca7b590-764e-492f-987c-190c52ab8759">49</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84Mi9mcmFnOjIwZGMzMzllYjlhZTQzNDlhMTk4YzQ1MjA3NjA0NThjL3RleHRyZWdpb246MjBkYzMzOWViOWFlNDM0OWExOThjNDUyMDc2MDQ1OGNfMzc0NQ_329a16b6-869f-454d-9001-c033793c11d8">RSM US&#160;LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84Mi9mcmFnOjIwZGMzMzllYjlhZTQzNDlhMTk4YzQ1MjA3NjA0NThjL3RleHRyZWdpb246MjBkYzMzOWViOWFlNDM0OWExOThjNDUyMDc2MDQ1OGNfMzc0Ng_0ebbad02-2e39-46f5-aad3-9de110fab5ac">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMy0xLTEtMS01NTY3Ng_b6a196e4-d9a5-44a6-8891-c16b840a0347"
      unitRef="usd">2356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMy0zLTEtMS01NTY3Ng_3e146b86-4582-4cd4-b5f2-40bc37b34bdb"
      unitRef="usd">5329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNC0xLTEtMS01NTY3Ng_55bc1030-10b2-4ced-bc9c-3b7d62212d60"
      unitRef="usd">1991000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNC0zLTEtMS01NTY3Ng_288a7aeb-2e66-42fd-a6f6-48a2f82d6c8a"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNS0xLTEtMS01NTY3Ng_a461c1ac-f92e-40bd-8f26-ae9ce9a38f74"
      unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNS0zLTEtMS01NTY3Ng_db44706a-b854-4ee4-bdbe-61eed31215b8"
      unitRef="usd">164000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNi0xLTEtMS01NTY3Ng_4920991e-023b-4ce9-a61e-a8facf7b672b"
      unitRef="usd">30000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNi0zLTEtMS01NTY3Ng_ea1899ec-95c3-4800-be36-a8cec2ad5bb3"
      unitRef="usd">34000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNy0xLTEtMS01NTY3Ng_7a0df96c-e802-4e19-b424-0f67f38446a2"
      unitRef="usd">641000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfNy0zLTEtMS01NTY3Ng_70c02a36-ab7a-4265-be72-d20dde673c17"
      unitRef="usd">436000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOC0xLTEtMS01NTY3Ng_97f01a4c-cfa5-493b-b1d8-52a04234912b"
      unitRef="usd">5018000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOC0zLTEtMS01NTY3Ng_360431ef-80b2-4b4d-9b48-f1e43bd22f3e"
      unitRef="usd">16624000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOS0xLTEtMS01NTY3Ng_2914b9d9-4a37-4ff5-bd84-858fde2c05e5"
      unitRef="usd">264000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfOS0zLTEtMS01NTY3Ng_d9f6ec3e-46aa-4568-844e-45239b5bf92d"
      unitRef="usd">264000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTAtMS0xLTEtNTU2NzY_95b91f3e-c3ed-45c4-a72a-acc8edea7d45"
      unitRef="usd">775000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTAtMy0xLTEtNTU2NzY_a9273a4c-5715-40ea-a152-b8de358aed68"
      unitRef="usd">890000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTEtMS0xLTEtNTU2NzY_6dc9f08f-17af-4d1d-873a-fd28b9f0301a"
      unitRef="usd">1961000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTEtMy0xLTEtNTU2NzY_78b9a9e5-b793-4bda-9df2-70ed7119e0f0"
      unitRef="usd">2354000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTItMS0xLTEtNTU2NzY_94e41408-ea26-432a-9bcb-a2dcdc53f553"
      unitRef="usd">67000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTItMy0xLTEtNTU2NzY_a250cc82-ead4-4619-b711-5635def155ef"
      unitRef="usd">283000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTMtMS0xLTEtNTU2NzY_a961c0ef-9659-490f-9c8d-106d985cf747"
      unitRef="usd">8085000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTMtMy0xLTEtNTU2NzY_3de859c5-bd36-4a94-858e-cdbaa692fc58"
      unitRef="usd">20415000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTctMS0xLTEtNTU2NzY_cca0adb7-ff1d-42b7-8b95-86821edede74"
      unitRef="usd">109000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTctMy0xLTEtNTU2NzY_17ba0128-6ede-4359-844e-4257a9b5d51f"
      unitRef="usd">83000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTgtMS0xLTEtNTU2NzY_95406552-80b9-48cf-94fe-25fed78890e1"
      unitRef="usd">926000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTgtMy0xLTEtNTU2NzY_bd7f81af-2e0f-4c08-8f62-f8739570374e"
      unitRef="usd">1136000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTktMS0xLTEtNTU2NzY_576d9aea-a9a2-4f67-bf86-e2b16bb9d5f6"
      unitRef="usd">575000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMTktMy0xLTEtNTU2NzY_079ce5da-078b-496f-8587-64c5c693f56b"
      unitRef="usd">514000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjAtMS0xLTEtNTU2NzY_b214a910-66be-40f2-9bbd-543e5e021d63"
      unitRef="usd">1610000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjAtMy0xLTEtNTU2NzY_b1d2ceb3-02ba-44f5-a531-11f544c8ff1c"
      unitRef="usd">1733000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjEtMS0xLTEtNTU2NzY_5f1c8c62-3f19-497b-9410-f4608d802f0b"
      unitRef="usd">2075000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjEtMy0xLTEtNTU2NzY_8e789675-4aae-4b15-9d92-0275bc087ed4"
      unitRef="usd">2656000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjMtMS0xLTEtNTU2NzY_868f6e8c-6453-4929-b047-ef9374604e7a"
      unitRef="usd">3685000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjMtMy0xLTEtNTU2NzY_89909940-bb6e-4a84-8d96-d3af27df3d92"
      unitRef="usd">4389000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjQtMS0xLTEtNTU2NzY_88d39459-ced3-49da-a740-165cafe6ea2e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjQtMy0xLTEtNTU2NzY_0f60ac53-1fe2-4c92-9fb8-15732f3f5549"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY18yMQ_2eba5c78-3654-402d-bd74-18cfed34b2d3"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY18yMQ_3a9aa73e-d0f7-46b7-ae63-1df8e20550fe"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY180Ng_0c950f6f-1e31-4d9a-be7e-59b93c9041ab"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY180Ng_6ba6deb5-f59b-45e9-86a3-e31feb427654"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_0c0463b4-5697-4ffb-a15b-9b47122de593"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_321e50f0-c66d-434d-a4f9-fc8eeb9f39e5"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_45f102dc-eed6-4dbd-8c07-ac8449707611"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjphMDcyM2FkMDE3MDc0MTkxYWVlMGQ4MGFiYjNlZGNkY182OA_b8585bc4-4cbb-4417-9c6b-160658918258"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMS0xLTEtNTU2NzY_f255064a-a0e3-4da9-9ded-8da57133f5c7"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjYtMy0xLTEtNTU2NzY_298a48ec-9390-46c1-9746-c972bcad1151"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV8xOA_7a004c6e-d316-4825-8aae-ea0749c2ed19"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV8xOA_a3a10b3d-dfe8-4056-966b-9c2e0218c476"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV80Mw_7938f41a-fc48-454f-a180-66a4922832f7"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV80Mw_c0537bd3-6674-4c76-88ef-d3e1142100fa"
      unitRef="shares">60000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84Mg_600b67f5-e4a0-410f-82f7-5a2cabb7c707"
      unitRef="shares">4944202</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84Mg_95bcd474-75a1-4902-b70f-803d70a217d9"
      unitRef="shares">4944202</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84OQ_827fdba9-96b5-4889-91a3-96cc985d84ff"
      unitRef="shares">4881851</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjozNGVhMzE0MmU5ZjE0MGI4YmVhYTEyZjY1MjhmODQzMV84OQ_94e83e86-3fdd-4d6d-a353-5551469854cd"
      unitRef="shares">4881851</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMS0xLTEtNTU2NzY_d4e11a4f-1e1d-4264-bdc4-8c0a45942d9c"
      unitRef="usd">49000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjctMy0xLTEtNTU2NzY_c836179b-bd33-4bed-8d91-2313a9e35d2c"
      unitRef="usd">49000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjgtMS0xLTEtNTU2NzY_829c852e-8551-4885-9bb7-d54201e0643b"
      unitRef="usd">404277000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjgtMy0xLTEtNTU2NzY_ff605d24-a041-4fb6-a849-9f7bc63188db"
      unitRef="usd">402283000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjktMS0xLTEtNTU2NzY_54a11c5f-8ae8-4586-8897-ff96733347b3"
      unitRef="usd">-229000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMjktMy0xLTEtNTU2NzY_66f96cd7-91e7-41a6-b496-5e22efa8a523"
      unitRef="usd">-175000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzAtMS0xLTEtNTU2NzY_3d7f713e-f513-4437-83f0-df46cbe6f4d6"
      unitRef="usd">-399697000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzAtMy0xLTEtNTU2NzY_e7b8baf5-887f-4b83-b9da-f9744687d68b"
      unitRef="usd">-386131000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzEtMS0xLTEtNTU2NzY_7203da47-a245-4a4c-b71c-97a39a5ff9e4"
      unitRef="usd">4400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzEtMy0xLTEtNTU2NzY_575ad9c0-6031-42c2-8e3f-07396494a073"
      unitRef="usd">16026000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzItMS0xLTEtNTU2NzY_fef15646-b175-4549-98d6-05b8ff685e67"
      unitRef="usd">8085000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84NS9mcmFnOmJiOGFlMDFiM2I3MzQxYWM4ZmZiNWE1OWRhZDM4NDdmL3RhYmxlOmJhZjhiMjM1ZThjZTQyMGI4OGVjNmMyYjAwMDFjOGQyL3RhYmxlcmFuZ2U6YmFmOGIyMzVlOGNlNDIwYjg4ZWM2YzJiMDAwMWM4ZDJfMzItMy0xLTEtNTU2NzY_f65406b8-7f2c-47c4-810a-3c7e9073836e"
      unitRef="usd">20415000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fa4f596e68b435cb25ae4cba2423590_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMy0yLTEtMS01NTY3Ng_6c1f4b5a-f078-4d02-849b-7e89ce40d251"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee3c65cebf3e4b5cae9b882ffa69ba4b_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMy00LTEtMS01NTY3Ng_8ed038ac-9f63-4f38-9460-8f86cf6027ac"
      unitRef="usd">614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfNi0yLTEtMS01NTY3Ng_9960cd7c-2db5-4878-81f5-df68a4880438"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfNi00LTEtMS01NTY3Ng_fc3f8586-590f-4e97-95df-dd56f258690c"
      unitRef="usd">614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <yten:CostOfRevenueResearchAndDevelopmentExpenses
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOC0yLTEtMS01NTY3Ng_8829cd46-2241-491a-b024-f7fc5dc6ed8f"
      unitRef="usd">7750000</yten:CostOfRevenueResearchAndDevelopmentExpenses>
    <yten:CostOfRevenueResearchAndDevelopmentExpenses
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOC00LTEtMS01NTY3Ng_5a0812bc-9b0d-458a-a343-2f908dd77dda"
      unitRef="usd">6201000</yten:CostOfRevenueResearchAndDevelopmentExpenses>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOS0yLTEtMS01NTY3Ng_c05acef6-4394-4510-a439-67f8a6d7319c"
      unitRef="usd">6151000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfOS00LTEtMS01NTY3Ng_d32ba628-a53c-456d-a902-d212f0db1e5a"
      unitRef="usd">6105000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTAtMi0xLTEtNTU2NzY_c35d9d89-bd76-4bc4-b02c-9214a437a893"
      unitRef="usd">13901000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTAtNC0xLTEtNTU2NzY_e8954ac3-ecb1-42c1-ad9c-fd386f00c722"
      unitRef="usd">12306000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTEtMi0xLTEtNTU2NzY_8c068dc8-5dc1-46bc-8afe-045332468c16"
      unitRef="usd">-13451000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTEtNC0xLTEtNTU2NzY_7d8f279b-c31d-4d09-886f-8cdd383f928a"
      unitRef="usd">-11692000</us-gaap:OperatingIncomeLoss>
    <yten:GainOnRelatedPartyInvestment
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTMtMi0xLTEtNTU2NzY_25a03573-6921-4a6f-a832-1d92b7b4ef7b"
      unitRef="usd">0</yten:GainOnRelatedPartyInvestment>
    <yten:GainOnRelatedPartyInvestment
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTMtNC0xLTEtNTU2NzY_ca9af1e2-1068-4047-b8e5-b30d72e84733"
      unitRef="usd">700000</yten:GainOnRelatedPartyInvestment>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTYtMi0xLTEtNTU2NzY_02c4b723-70e8-4e23-adde-d0e470304e20"
      unitRef="usd">41000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTYtNC0xLTEtNTU2NzY_6fdcb7bb-52b2-440c-9c61-d96885e36711"
      unitRef="usd">-3000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTctMi0xLTEtNTU2NzY_05de82fe-09a1-445c-a602-1e102ab90114"
      unitRef="usd">41000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTctNC0xLTEtNTU2NzY_a0086f11-9c44-4966-b5db-41120b64ab6a"
      unitRef="usd">697000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTgtMi0xLTEtNTU2NzY_a0f412b1-ca2c-4be3-99b5-4660c4b04e3b"
      unitRef="usd">-13410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTgtNC0xLTEtNTU2NzY_b6336791-bf64-44b4-bf97-21e866c9fd5d"
      unitRef="usd">-10995000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTktMi0xLTEtNTU2NzY_a830c9de-ac39-4f38-b695-33062c80cfdb"
      unitRef="usd">156000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMTktNC0xLTEtNTU2NzY_90fcca39-4edf-495e-9e5c-dac1de3aa90f"
      unitRef="usd">36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjAtMi0xLTEtNTU2NzY_d1a68092-da3b-4e9f-b777-924b387d0109"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjAtNC0xLTEtNTU2NzY_4d440f3d-7baf-445c-9f49-fa46d7c1583a"
      unitRef="usd">-11031000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctMi0xLTEtNTU2NzY_0e78ef97-f6c0-477d-b917-8c896668f0e0"
      unitRef="usdPerShare">-2.76</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctMi0xLTEtNTU2NzY_c2241853-297b-479b-9243-8f1a7deecc91"
      unitRef="usdPerShare">-2.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctNC0xLTEtNTU2NzY_12f50f85-9e63-41fb-bc80-1790ab0a5cb8"
      unitRef="usdPerShare">-2.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMjctNC0xLTEtNTU2NzY_9551abde-324a-4f13-990b-98bd1fa78e34"
      unitRef="usdPerShare">-2.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtMi0xLTEtNTU2NzY_0d46f57c-464c-46a7-a153-77787066d235"
      unitRef="shares">4914565</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtMi0xLTEtNTU2NzY_ae28ac7c-7613-4107-b753-4fad76e82523"
      unitRef="shares">4914565</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtNC0xLTEtNTU2NzY_22485454-c100-4a10-b9b3-0292dfa89895"
      unitRef="shares">4731833</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl84OC9mcmFnOmM4MjIzMTUzMDRiOTRlYzNiNWZkYTc5OWQ3YWQyYzdlL3RhYmxlOjcxYWI3ZDY3MTg2OTQyNDdhNDM0OTE5MzFjOWMzMjQ1L3RhYmxlcmFuZ2U6NzFhYjdkNjcxODY5NDI0N2E0MzQ5MTkzMWM5YzMyNDVfMzYtNC0xLTEtNTU2NzY_5f81c4ef-f852-4036-941e-9e6b553779ac"
      unitRef="shares">4731833</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi0yLTEtMS01NTY3Ng_9956a4a2-6857-4d1c-bf86-b6263c2b7fb5"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi0yLTEtMS01NTY3Ng_e637779e-261c-45ec-990b-f8c1a5041a51"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfMi00LTEtMS01NTY3Ng_57361f55-473b-4fcd-b476-b4b8ca441330"
      unitRef="usd">-11031000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNC0yLTEtMS01NTY3Ng_2e7d03e0-6436-4e07-a959-2e50a421b583"
      unitRef="usd">7000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNC00LTEtMS01NTY3Ng_21437fa6-3863-4b4e-b352-2d0d32476445"
      unitRef="usd">-8000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNS0yLTEtMS01NTY3Ng_43db437c-1b73-4f34-86f9-2402709a7b8f"
      unitRef="usd">-61000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNS00LTEtMS01NTY3Ng_4347cd7a-53ff-492b-af14-c66adef93c22"
      unitRef="usd">-8000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNi0yLTEtMS01NTY3Ng_253fa4f4-7399-4b00-be0c-2f394c623420"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNi00LTEtMS01NTY3Ng_4aac93ec-c13f-4242-9efd-76aa7b25e729"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNy0yLTEtMS01NTY3Ng_d1d0ebd6-02a2-4f40-97cc-e23995e2cba4"
      unitRef="usd">-13620000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85MS9mcmFnOjE1ODFhZTg2MDA2YTQ4Njg4ZTYxYWQ3NjI0MmEwNTlkL3RhYmxlOjkyN2FiYTFiY2Y2NTQ4MTRhZmNlMDA2YjA4YjVlNjNmL3RhYmxlcmFuZ2U6OTI3YWJhMWJjZjY1NDgxNGFmY2UwMDZiMDhiNWU2M2ZfNy00LTEtMS01NTY3Ng_a6808baf-7257-4a61-93a9-7fbc0c69899d"
      unitRef="usd">-11047000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMy0yLTEtMS01NTY3Ng_b4231ee5-84a4-498c-bdf4-f2486d4e4a19"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMy00LTEtMS01NTY3Ng_239bc190-86d9-41d5-a630-f4880901f549"
      unitRef="usd">-11031000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNS0yLTEtMS01NTY3Ng_a63b9951-1653-45d3-b762-04b0b6217fe8"
      unitRef="usd">263000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNS00LTEtMS01NTY3Ng_0e1486c8-9494-475e-a56f-febf85ee512d"
      unitRef="usd">220000</us-gaap:DepreciationDepletionAndAmortization>
    <yten:ChargeForCompanyCommonStockMatch
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfOS0yLTEtMS01NTY3Ng_e53bda09-abd2-4ba7-a83f-a1d48f1f02da"
      unitRef="usd">133000</yten:ChargeForCompanyCommonStockMatch>
    <yten:ChargeForCompanyCommonStockMatch
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfOS00LTEtMS01NTY3Ng_049104b5-885b-4954-ad2c-2a6b7024adaa"
      unitRef="usd">112000</yten:ChargeForCompanyCommonStockMatch>
    <us-gaap:ShareBasedCompensation
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTAtMi0xLTEtNTU2NzY_6313a2a5-89f6-40eb-a0da-fc01ed884dc0"
      unitRef="usd">1903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTAtNC0xLTEtNTU2NzY_521a4d2c-2c29-4b78-b069-5e496da5839b"
      unitRef="usd">1675000</us-gaap:ShareBasedCompensation>
    <yten:NoncashLeaseExpenseIncome
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTEtMi0xLTEtNTU2NzY_5ad0323d-56b7-48ba-a060-ad065449e608"
      unitRef="usd">393000</yten:NoncashLeaseExpenseIncome>
    <yten:NoncashLeaseExpenseIncome
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTEtNC0xLTEtNTU2NzY_127235bd-dcac-4d6e-89a1-0af5f5420664"
      unitRef="usd">358000</yten:NoncashLeaseExpenseIncome>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTItMi0xLTEtNTU2NzY_0ece706f-d110-41c8-99ec-2855d99df491"
      unitRef="usd">165000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTItNC0xLTEtNTU2NzY_8e3f5ed8-290c-4cc2-82dd-4bebfc34bacf"
      unitRef="usd">35000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTYtMi0xLTEtNTU2NzY_35907a85-4e95-4967-b31b-91bf23d295c9"
      unitRef="usd">-164000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTYtNC0xLTEtNTU2NzY_07c3b6df-6940-4e8c-956b-61d59cd4f201"
      unitRef="usd">78000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTgtMi0xLTEtNTU2NzY_1c3148e6-2f81-4767-a99c-ce05c7e2c590"
      unitRef="usd">-4000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMTgtNC0xLTEtNTU2NzY_b7a5df4d-84ad-42e8-8c2a-f99ca6fdc2c3"
      unitRef="usd">7000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjAtMi0xLTEtNTU2NzY_8c3d39d5-bc82-4fd0-bdb7-3815eec59a04"
      unitRef="usd">160000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjAtNC0xLTEtNTU2NzY_183e7b48-c07f-4545-ac90-d9d8a4dd6baa"
      unitRef="usd">-63000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjEtMi0xLTEtNTU2NzY_78a2122d-d921-48a5-bbeb-1aa75de4674d"
      unitRef="usd">26000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjEtNC0xLTEtNTU2NzY_ecdbde38-babb-4c47-a6c3-de2d0d92f7ef"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjItMi0xLTEtNTU2NzY_062a6645-7bfd-4889-b9a1-61d8a47793a4"
      unitRef="usd">-209000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjItNC0xLTEtNTU2NzY_87412476-45c0-41fd-9854-3d3eadc24aac"
      unitRef="usd">-160000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <yten:IncreaseDecreaseInLeaseLiabilities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjQtMi0xLTEtNTU2NzY_6c249f30-d529-40b2-8539-7bb62d00ccbb"
      unitRef="usd">-520000</yten:IncreaseDecreaseInLeaseLiabilities>
    <yten:IncreaseDecreaseInLeaseLiabilities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjQtNC0xLTEtNTU2NzY_66ed7f12-439a-4aa1-aa4c-1517c60663e3"
      unitRef="usd">-463000</yten:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtMi0xLTEtNTU2NzY_92fc0c65-06ea-43b3-bb28-77ddcf6b311f"
      unitRef="usd">-11404000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtMi0xLTEtNTU2NzY_b623e68b-c320-4540-9129-f5380dca5802"
      unitRef="usd">-11404000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtNC0xLTEtNTU2NzY_34a2e204-f9aa-47dd-962a-74d9f9e022cc"
      unitRef="usd">-9253000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMjgtNC0xLTEtNTU2NzY_502caa0b-2159-40bd-9a52-899635fc94a6"
      unitRef="usd">-9253000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzEtMi0xLTEtNTU2NzY_f65c04b6-0f9d-4171-bc05-17d84097324b"
      unitRef="usd">154000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzEtNC0xLTEtNTU2NzY_6690b3e3-8fc4-4c4f-96f8-7b9b8be71d05"
      unitRef="usd">189000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzQtMi0xLTEtNTU2NzY_bb29a477-6100-4629-a9ba-506277ade50b"
      unitRef="usd">2445000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzQtNC0xLTEtNTU2NzY_afc22f29-d746-4d89-9932-1272b3c2ad77"
      unitRef="usd">10639000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzUtMi0xLTEtNTU2NzY_5add4138-cc09-4f54-a3b6-edd992c0a82c"
      unitRef="usd">11121000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfShortTermInvestments
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzUtNC0xLTEtNTU2NzY_e8df0d5a-12ac-4574-bb27-caa56776c827"
      unitRef="usd">6250000</us-gaap:ProceedsFromSaleOfShortTermInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzYtMi0xLTEtNTU2NzY_d09b3e25-3a5d-4ef7-b0f3-6c60e1cf112e"
      unitRef="usd">8522000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfMzYtNC0xLTEtNTU2NzY_d8ef418f-6558-416b-97a0-80deaecc59b6"
      unitRef="usd">-4578000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDItMi0xLTEtNTU2NzY_92d4eec8-d663-4401-95c7-8ff0f758efdb"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDItNC0xLTEtNTU2NzY_eaf09f1d-194b-4f33-8e0e-503eb6485424"
      unitRef="usd">3856000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDQtMi0xLTEtNTU2NzY_f3f5f7de-5fbb-403f-9294-a4347c6753bd"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDQtNC0xLTEtNTU2NzY_ea16a785-56e6-4257-993a-b495fc631958"
      unitRef="usd">11993000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDUtMi0xLTEtNTU2NzY_6ae08b62-3d0b-4be1-8a7b-e8b1dd54ce24"
      unitRef="usd">37000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDUtNC0xLTEtNTU2NzY_abfde8be-d4df-419d-9e6c-ad3b4cab23ae"
      unitRef="usd">103000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtMi0xLTEtNTU2NzY_9dffc0b6-07f3-44cf-9a20-0f5b680c9138"
      unitRef="usd">-37000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtMi0xLTEtNTU2NzY_f9d53116-13b3-41d3-892d-be06486fa642"
      unitRef="usd">-37000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtNC0xLTEtNTU2NzY_1aad6679-44aa-46db-9b59-12456386658a"
      unitRef="usd">15746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDYtNC0xLTEtNTU2NzY_2e5234f4-73fe-4e26-b4df-a982aefe997b"
      unitRef="usd">15746000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDgtMi0xLTEtNTU2NzY_ea0c8993-cfd6-4020-b986-ab51ca681c91"
      unitRef="usd">-54000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDgtNC0xLTEtNTU2NzY_cfd7c50c-4e85-43e5-81f2-eb33c626da93"
      unitRef="usd">-9000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDktMi0xLTEtNTU2NzY_01fb210a-af88-407a-b616-0e279cf17b45"
      unitRef="usd">-2973000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNDktNC0xLTEtNTU2NzY_39c586d4-f863-4e1d-8a2c-b66f2a1ee386"
      unitRef="usd">1906000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTAtMi0xLTEtNTU2NzY_8d893a89-76b4-49ef-8dc4-7fd5d554e5b1"
      unitRef="usd">5593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTAtNC0xLTEtNTU2NzY_6ff29d1d-51e7-4c92-8443-a2439f37b0ec"
      unitRef="usd">3687000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTEtMi0xLTEtNTU2NzY_1243fe94-2b86-4bb6-ad22-7a6166019a78"
      unitRef="usd">2620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTEtNC0xLTEtNTU2NzY_52afff5f-b9e8-4980-a44a-bfcfa6508120"
      unitRef="usd">5593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTQtMi0xLTEtNTU2NzY_9ea84668-0af0-4064-b57d-2fa5ff6fcdca"
      unitRef="usd">10000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85NC9mcmFnOjRhYjU5NDk1Mzc2NTRiYzJiNGFiN2MwNTAzODA4ZTk4L3RhYmxlOjA5NWI3MzgxMWI5MTQyNzdhOWExZWU3M2RhMzE4NmY5L3RhYmxlcmFuZ2U6MDk1YjczODExYjkxNDI3N2E5YTFlZTczZGEzMTg2ZjlfNTQtNC0xLTEtNTU2NzY_94fe6a05-6fae-4deb-a0fa-c77ed48d39a6"
      unitRef="usd">9000</us-gaap:InterestPaidNet>
    <us-gaap:SharesOutstanding
      contextRef="i97019bfe3e334d528406e95e102e2364_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy04LTEtMS01NTY3Ng_d904f740-625c-41c3-8dd1-612c4b11de6e"
      unitRef="shares">3334048</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i97019bfe3e334d528406e95e102e2364_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xMC0xLTEtNTU2NzY_6001e2f2-a1ad-425d-ac44-05569c89a892"
      unitRef="usd">33000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3d3121e408a4cc2bbbbfbad11389e16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xMi0xLTEtNTU2NzY_3c8f8e5b-6d85-43aa-823c-88f0b585c7ad"
      unitRef="usd">384758000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i40955b8933394980b43a112a70cb81dd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xNC0xLTEtNTU2NzY_2aaee7fd-ca64-4ac9-b22b-3049e6ce965c"
      unitRef="usd">-159000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if50f9d23f34d4f029330039500bd46fc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xNi0xLTEtNTU2NzY_1fdd8497-51cf-4d16-a65f-649c9e92064c"
      unitRef="usd">-375100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i624d1c2db5334d9f8d1c42dd32837b1f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMy0xOC0xLTEtNTU2NzY_48ed6299-89f1-426e-8ba2-d18843c251b0"
      unitRef="usd">9532000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNC0xMi0xLTEtNTU2NzY_3da1deb8-9785-490d-b23b-3c53a8671a05"
      unitRef="usd">1685000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNC0xOC0xLTEtNTU2NzY_62883e3d-04c5-4726-a94b-41927f93db1f"
      unitRef="usd">1685000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS04LTEtMS01NTY3Ng_bfb3202b-a5ec-4d40-b64d-39b4db14274f"
      unitRef="shares">13611</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS0xMi0xLTEtNTU2NzY_220faa05-ad08-4849-a1c1-035ee774102a"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNS0xOC0xLTEtNTU2NzY_93e96e7e-3ece-4a85-834d-938ac999d43d"
      unitRef="usd">109000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi04LTEtMS01NTY3Ng_e9fbcf84-200f-48e2-8eb1-db779ee230df"
      unitRef="shares">12219</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi0xMi0xLTEtNTU2NzY_bb533cb0-31f9-4943-9398-cb9d64865293"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNi0xOC0xLTEtNTU2NzY_7e271572-ddce-4526-968a-4e7693ca6f03"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNy0xMi0xLTEtNTU2NzY_ba1bdecf-9a0b-4a9e-bd92-857098a1121e"
      unitRef="usd">102000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfNy0xOC0xLTEtNTU2NzY_a97c65a1-064c-46af-99f5-63e042d02091"
      unitRef="usd">102000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC04LTEtMS01NTY3Ng_84248a21-bce9-4c5c-91d6-3acefa7e9f88"
      unitRef="shares">481973</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xMC0xLTEtNTU2NzY_f41b3e0b-e3d5-4ac0-bb7e-2729450530ca"
      unitRef="usd">5000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xMi0xLTEtNTU2NzY_8ed1b2e2-666c-460e-a0aa-1933324db245"
      unitRef="usd">3851000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOC0xOC0xLTEtNTU2NzY_52a08387-e556-4e56-9992-9e77a32d9afc"
      unitRef="usd">3856000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0wLTEtMS01NTY3Ni90ZXh0cmVnaW9uOjBjM2JhOGQzNGM3YjQ0MDY5OWE0OTA4ZTFhZjY0YzM1XzMyOTg1MzQ4ODM0MjU_1c6b4b1d-46fa-4172-a21d-08a959c518aa"
      unitRef="usd">747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS04LTEtMS01NTY3Ng_3e638ca3-9bac-42de-83f5-c02525913349"
      unitRef="shares">1040000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7bbcb980d9044996a18be6d8aff9d2f4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xMC0xLTEtNTU2NzY_9773b83b-1333-45fc-a325-26c09c745d68"
      unitRef="usd">11000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i5160f76b6d7c4ca29727b7f120f38010_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xMi0xLTEtNTU2NzY_5950007e-7b65-4e43-9053-2755c43f4af9"
      unitRef="usd">11982000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfOS0xOC0xLTEtNTU2NzY_01cac995-64a4-45cb-b32c-22821fa16d03"
      unitRef="usd">11993000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i684d6f37920d42318715b4946e6c8249_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTMtMTQtMS0xLTU1Njc2_09387b84-e34f-4e9d-98fb-09d4f04e848a"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTMtMTgtMS0xLTU1Njc2_6ebec9e4-f477-40f4-b37b-318a45659396"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ia191e1112ea14abb840d58c60e120043_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTQtMTYtMS0xLTU1Njc2_1817a237-95ef-4605-8487-571d8dc9fa06"
      unitRef="usd">-11031000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTQtMTgtMS0xLTU1Njc2_4d9e9cb7-ae35-439c-a36b-0786554f48a5"
      unitRef="usd">-11031000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i58fce4089bcb426e8039bc6cbfa6106c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtOC0xLTEtNTU2NzY_2da733ed-d809-4c95-9ac3-994856cf7aa7"
      unitRef="shares">4881851</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i58fce4089bcb426e8039bc6cbfa6106c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTAtMS0xLTU1Njc2_715f725f-6f6e-4ab9-aad2-d69ad17770a3"
      unitRef="usd">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7526ac612c264449a3e3ac301d55542f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTItMS0xLTU1Njc2_de34d31c-48b3-431e-96cd-ff7b5a24cb64"
      unitRef="usd">402283000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ica80c64d92b04d749e752fded64ecc53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTQtMS0xLTU1Njc2_4b286ed6-a0ed-4497-9e0c-1aa20f7ee22c"
      unitRef="usd">-175000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2e6a79d372a4443d8d41d7ee23cabec4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTYtMS0xLTU1Njc2_16be69c7-4630-4d3d-9457-e0567f66f6c9"
      unitRef="usd">-386131000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTUtMTgtMS0xLTU1Njc2_f2b9a08c-f303-474d-8326-e5f6710c962c"
      unitRef="usd">16026000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTctMTItMS0xLTU1Njc2_ec1bd42c-dd2f-4230-b391-3ed460c60797"
      unitRef="usd">1903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTctMTgtMS0xLTU1Njc2_6f4b5198-73aa-4928-905f-e314f6552752"
      unitRef="usd">1903000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtOC0xLTEtNTU2NzY_7edf31c9-85db-4bef-b62a-55ddf270dbbe"
      unitRef="shares">36706</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtMTItMS0xLTU1Njc2_1a0d82bd-9994-4e72-99c5-04016cb308a0"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTgtMTgtMS0xLTU1Njc2_b13fd1a3-52f8-4961-8323-e973b95795b9"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="i27c22105dee446e8bdfabcad9354c59c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktOC0xLTEtNTU2NzY_848d5df3-8a5f-4606-bb8d-f89132754983"
      unitRef="shares">25645</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktMTItMS0xLTU1Njc2_63144e3d-6e7f-4b96-bd3a-c3ab2015e0e5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMTktMTgtMS0xLTU1Njc2_33f48ef3-8784-4898-b8d7-792a47c637be"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i003d2cbb804a440884d0ac319b2c54af_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjAtMTItMS0xLTU1Njc2_d7c3f340-01d4-4fed-b1d3-7ec142db27b5"
      unitRef="usd">37000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjAtMTgtMS0xLTU1Njc2_3290c9ec-c7dd-4fa2-87cd-c2a376494303"
      unitRef="usd">37000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="ic3efc24abbd6441ca82da51c9deb09b3_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjMtMTQtMS0xLTU1Njc2_cd796857-e1d4-4e4c-9c98-6624c1840aa9"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjMtMTgtMS0xLTU1Njc2_8b1b33ec-b055-4e5a-b945-0a93e57ecd37"
      unitRef="usd">-54000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iad8a0121d2bc47a58199c38a729c4349_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjQtMTYtMS0xLTU1Njc2_b173975c-894e-42f8-8593-7893ae5740f6"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjQtMTgtMS0xLTU1Njc2_39fffe93-a0c3-453d-bb3b-bfdc64494d59"
      unitRef="usd">-13566000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtOC0xLTEtNTU2NzY_dc9a4c84-3607-46d8-808c-adcdfd491e8b"
      unitRef="shares">4944202</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idcfc3c62ce2d4b0da45c7ba8184eb95b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTAtMS0xLTU1Njc2_17fd6086-8c2a-46fb-8076-9458736da59e"
      unitRef="usd">49000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b28bd8c03f94f9981d0b15e39eff5f3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTItMS0xLTU1Njc2_d45dadb2-af58-4a33-852f-068da84176a9"
      unitRef="usd">404277000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief1ac89ff5a2424396d026131c1fdf13_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTQtMS0xLTU1Njc2_8876dedd-811b-4854-9d87-cec02ed72247"
      unitRef="usd">-229000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i337d07789e89467e9cfd5f2c41ac49b3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTYtMS0xLTU1Njc2_c32b3a4c-050f-48bf-ae3b-bbb958bdf5e4"
      unitRef="usd">-399697000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl85Ny9mcmFnOjBiN2RjNGZiODM0MjQ0OTFhNWQxOTIxNGZkZDgwNDM4L3RhYmxlOjM3MWRkMWIyNzUwYjQwNTM4YzMyMGIyZWRmZGM0NjI0L3RhYmxlcmFuZ2U6MzcxZGQxYjI3NTBiNDA1MzhjMzIwYjJlZGZkYzQ2MjRfMjUtMTgtMS0xLTU1Njc2_4825336e-fa51-49ce-ae9d-7d7ad063f607"
      unitRef="usd">4400000</us-gaap:StockholdersEquity>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDMvZnJhZzplYmIwM2IzZWE1NGE0YTQxOWY1N2FlOWQzZjdlMjEzMS90ZXh0cmVnaW9uOmViYjAzYjNlYTU0YTRhNDE5ZjU3YWU5ZDNmN2UyMTMxXzU3ODg_32045abf-9cbc-4fd3-b1e3-f8c1c9c6df3f">Nature of Business and Basis of Presentation&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Yield10 Bioscience, Inc. ("Yield10" or the "Company") is an agricultural bioscience company that is developing the oilseed Camelina sativa ("Camelina") as a platform crop for large scale production of low carbon sustainable seed products to address 1) petroleum replacement markets: Camelina oil for use as a biofuel feedstock and PHA bioplastics produced in Camelina seed for use as a biodegradable bioplastic; and 2) food and nutrition markets: omega-3 (EPA, DHA+EPA) oils produced in Camelina seed for aquaculture and nutraceuticals; and for protein meal for animal feed markets.  The commercial plan is based on developing and releasing a series of proprietary elite Camelina seed varieties incorporating genetic traits from the Company's development pipeline which offer improved on-farm performance that will lead to increased acreage and seed product revenue.  Yield10 also plans to create additional value for its shareholders by licensing yield and seed oil traits from the Company's pipeline to large seed companies for commercialization in major food crops, including corn, soybean and canola.  Yield10 is headquartered in Woburn, Massachusetts and has an Oilseed Center of Excellence in Saskatoon, Saskatchewan, Canada.  Yield10's wholly-owned Canadian subsidiary, Metabolix Oilseeds Inc., changed its name to Yield10 Oilseeds Inc. ("YOI") effective July 12, 2022, in order to better align the name with the Company's branding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The accompanying consolidated financial statements have been prepared on a basis which assumes that the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  With the exception of a single year, the Company has recorded losses since its initial founding, including its fiscal year ending December&#160;31, 2022.  The Company ended 2022 with unrestricted cash, cash equivalents and short-term investments of $4,347.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the guidance of Accounting Standards Codification ("ASC") Topic 205-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Presentation of Financial Statements-Going Concern&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in order to determine whether there is substantial doubt about its ability to continue as a going concern for one year after the date its consolidated financial statements are issued.  The Company's ability to continue operations after its current cash resources are exhausted depends on its ability to obtain additional financing through, among other sources, public or private equity financing, secured or unsecured debt financing, equity or debt bridge financing, warrant holders' ability and willingness to exercise the Company's outstanding warrants, additional research grants or collaborative arrangements with third parties, as to which no assurance can be given.  Management does not know whether additional financing will be available on terms favorable or acceptable to the Company when needed, if at all.  If adequate additional funds are not available when required, management will be forced to curtail the Company's research efforts, explore strategic alternatives and/or wind down the Company's operations and pursue options for liquidating its remaining assets, including intellectual property and equipment.  Based on its current cash forecast, management has determined that the Company's present capital resources will not be sufficient to fund its planned operations for at least one year from when these consolidated financial statements are available to be issued, which raises substantial doubt as to the Company's ability to continue as a going concern.  This forecast of cash resource is forward-looking information that involves risks and uncertainties, and the actual amount of expenses could vary materially and adversely as a result of a number of factors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the Company issues equity or debt securities to raise additional funds, (i) the Company may incur fees associated with such issuance, (ii) its existing stockholders may experience dilution from the issuance of new equity securities, (iii) the Company may incur ongoing interest expense and be required to grant a security interest in Company assets in connection with any debt issuance, and (iv) the new equity or debt securities may have rights, preferences and privileges senior to those of the Company&#x2019;s existing stockholders.  In addition, utilization of the Company&#x2019;s net operating loss and research and development credit carryforwards may be subject to significant annual limitations under Section 382 of the Internal Revenue Code of 1986, as amended, (the "Internal Revenue Code") due to ownership changes resulting from equity financing transactions.  If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to its potential products or proprietary technologies or grant licenses on terms that are not favorable to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 30, 2020, the World Health Organization ("WHO") announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China ("COVID-19") and the risks to the international community as the virus spreads globally beyond its point of origin.  In March 2020, the WHO classified COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.  The full impact of the COVID-19 pandemic continues to evolve as of the &lt;/span&gt;&lt;/div&gt;date of this report.  As such, the full magnitude that the pandemic will have on the Company's financial condition, liquidity and future results of operations is uncertain.  While management currently expects the impact of COVID-19 to be temporary, there is uncertainty around the duration and its broader impact on the economy and therefore the effects it will have on Yield10's financial condition, liquidity, operations, suppliers, industry, and workforce in future periods.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDMvZnJhZzplYmIwM2IzZWE1NGE0YTQxOWY1N2FlOWQzZjdlMjEzMS90ZXh0cmVnaW9uOmViYjAzYjNlYTU0YTRhNDE5ZjU3YWU5ZDNmN2UyMTMxXzE4NzI_3796a455-c75b-4eea-ba87-ab022ffa4969"
      unitRef="usd">4347000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQ2_e2cba786-6f00-4a1a-81c1-a7b2607516d9">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB").  The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported.  References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions were eliminated, including transactions with its subsidiaries, Yield10 Oilseeds Inc. and Yield10 Bioscience Securities Corp.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts included in restricted cash represent those required to be set aside by contractual agreement.  Restricted cash of $264 at December&#160;31, 2022 and December&#160;31, 2021, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy.  The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term. The Company held no long-term investments at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred.  Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis.  Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense).  The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.  Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations.  The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date.  Revenues and expenses are translated at average exchange rates prevailing during the period.  Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet.  When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net  loss.  The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable.  The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes.  Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company's unbilled receivables of $30 were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor.  The Company believes these receivables have a low risk of default.  At December&#160;31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support of the DOE grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company's financial instruments as of December&#160;31, 2022 and December&#160;31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.  See Note 4 for further discussion on fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements.  The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops.&#160; The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization.  Repairs and maintenance are charged to operating expense as incurred.  Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Lease Accounting&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As a lessee, the Company follows the lease accounting guidance codified in ASC 842.  A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor.  These grants are considered an ongoing major and central operation of the Company's business.  Revenue is earned as research expenses related to the grants are incurred.  Revenue earned on &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December&#160;31, 2022 and December&#160;31, 2021.  Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs associated with internal research and development are expensed as incurred.  Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation.  Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory.  Costs incurred in connection with government research grants are recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative and business development of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.  See Note&#160;10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding.  Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period.  Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced.  Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same.  Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions.  The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.  The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any.  The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;13 for further discussion of income taxes.  The Company had no amounts recorded for unrecognized tax expense or benefits as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Standards Changes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2021-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU became effective for annual periods beginning after December 15, 2021.  The adoption of this standard did not materially impact the Company&#x2019;s consolidated financial statements for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.  &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement.  This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.  This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.  &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance is effective for fiscal years beginning after&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC&#x2019;s definition&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and interim periods within those fiscal years.  The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzg5_0be8b88a-ffff-4fd9-b079-4590180d1ec1">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are presented in U.S. dollars and are prepared in accordance with accounting standards set by the Financial Accounting Standards Board ("FASB").  The FASB sets generally accepted accounting principles ("GAAP") that the Company follows to ensure its financial condition, results of operations, and cash flows are consistently reported.  References to GAAP issued by the FASB in these notes to the consolidated financial statements are to the FASB Accounting Standards Codification ("ASC").&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODEx_c2275c8a-2700-4f95-a1ad-8b13d5988016">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States of America.  The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries.  All intercompany transactions were eliminated, including transactions with its subsidiaries, Yield10 Oilseeds Inc. and Yield10 Bioscience Securities Corp.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODY1_661969bb-5305-42e2-8b33-3fbd1d3c02e3">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods.  Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk5_ac1dfdae-b9b3-4a97-8353-1c7bc06898b0">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments purchased with an original maturity date of ninety days or less at the date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODkz_7a3871b7-60da-43dc-8764-eee20afe16c0">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Company's consolidated balance sheets included herein:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:11pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzEtMS0xLTEtNTU2NzY_b6a196e4-d9a5-44a6-8891-c16b840a0347"
      unitRef="usd">2356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzEtMy0xLTEtNTU2NzY_3e146b86-4582-4cd4-b5f2-40bc37b34bdb"
      unitRef="usd">5329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzItMS0xLTEtNTU2NzY_2914b9d9-4a37-4ff5-bd84-858fde2c05e5"
      unitRef="usd">264000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzItMy0xLTEtNTU2NzY_d9f6ec3e-46aa-4568-844e-45239b5bf92d"
      unitRef="usd">264000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzMtMS0xLTEtNTU2NzY_22952e24-e3fb-4c96-917b-fcfa6cfa8e10"
      unitRef="usd">2620000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpjMTFkMWM3OWFjMWE0YmI0OGFkYzliMDMzMGJhNzU1OC90YWJsZXJhbmdlOmMxMWQxYzc5YWMxYTRiYjQ4YWRjOWIwMzMwYmE3NTU4XzMtMy0xLTEtNTU2NzY_6824b80d-aad4-4003-ae83-be380f0af6b7"
      unitRef="usd">5593000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODYw_49ede043-7ee4-403d-8d24-5d78cacc46b3">Amounts included in restricted cash represent those required to be set aside by contractual agreement.  Restricted cash of $264 at December&#160;31, 2022 and December&#160;31, 2021, primarily consists of funds held in connection with the Company's lease agreement for its Woburn, Massachusetts facility.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzIzODk_2914b9d9-4a37-4ff5-bd84-858fde2c05e5"
      unitRef="usd">264000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc3_12b3cab8-5c13-4ff3-ae87-562a53ed04e4">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments represent holdings of available-for-sale marketable debt securities acquired in accordance with the Company's investment policy.  The Company considers all investments purchased with an original maturity date of ninety days or more at the date of purchase and a maturity date of one year or less at the balance sheet date to be short-term investments.  All other investments are classified as long-term. The Company held no long-term investments at December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments in marketable debt securities are recorded at fair value, with any unrealized gains and losses reported within accumulated other comprehensive income as a separate component of stockholders' equity until realized or until a determination is made that an other-than-temporary decline in market value has occurred.  Other-than-temporary impairments of equity investments are recognized in the Company's statements of operations if the Company has experienced a credit loss and has the intent to sell the investment or if it is more likely than not that the Company will be required to sell the investment before recovery of the amortized cost basis.  Realized gains and losses, dividends, interest income and declines in value judged to be other-than-temporary credit losses are included in other income (expense).  The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity.  Such amortization and accretion together with interest on securities are included in interest income on the Company's consolidated statements of operations.  The cost of marketable securities sold is determined based on the specific identification method and any realized gains or losses on the sale of investments are reflected as a component of other income (expense).&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:LongTermInvestments
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzI5NTg_11976bc5-7028-41d4-9cd5-d9ac0b0ce499"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzI5NTg_6f3f1f24-5063-4988-8987-08e8425b0f3f"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODgy_6da6dc1b-c11e-45b5-b36e-a5b7ff7f67a8">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign denominated assets and liabilities of the Company's wholly-owned foreign subsidiary are translated into U.S. dollars at the prevailing exchange rates in effect on the balance sheet date.  Revenues and expenses are translated at average exchange rates prevailing during the period.  Any resulting translation gains or losses are recorded in accumulated other comprehensive income (loss) in the consolidated balance sheet.  When the Company dissolves, sells or substantially sells all of the assets of a consolidated foreign subsidiary, the cumulative translation gain or loss of that subsidiary is released from comprehensive income (loss) and included within its consolidated statement of operations during the fiscal period when the dissolution or sale occurs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODkx_cefa1d9f-9ee1-4021-91cc-5a9aaa50ce24">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss is comprised of net loss and certain changes in stockholders' equity that are excluded from net  loss.  The Company includes unrealized gains and losses on debt securities and foreign currency translation adjustments in other comprehensive loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTMy_308090d6-2b54-420a-8d01-b4ca97b0805e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash and cash equivalents, restricted cash, short-term investments and accounts receivable.  The Company has historically invested its cash equivalents in highly rated money market funds, corporate debt, federal agency notes and U.S. treasury notes.  Investments are acquired in accordance with the Company's investment policy which establishes a concentration limit per issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company's unbilled receivables of $30 were due from Michigan State University ("MSU") for support to a Department of Energy funded grant under which the Company serves as a subcontractor.  The Company believes these receivables have a low risk of default.  At December&#160;31, 2021, all of the Company's accounts and unbilled receivables of $198 were due from MSU for support of the DOE grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <yten:AccountsReceivableTradeAndUnbilledReceivables
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzU5ODM_003e396b-8896-4c7b-8e5f-a79e0903d461"
      unitRef="usd">30000</yten:AccountsReceivableTradeAndUnbilledReceivables>
    <yten:AccountsReceivableTradeAndUnbilledReceivables
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzU0OTc1NTgzMjc0Ng_69e94215-987a-400c-a4e6-66fdb7ae0f37"
      unitRef="usd">198000</yten:AccountsReceivableTradeAndUnbilledReceivables>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk2_6229f83d-904f-47af-8b3c-0e01d32b6155">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company's financial instruments as of December&#160;31, 2022 and December&#160;31, 2021, which include cash equivalents, restricted cash, accounts receivable, unbilled receivables, accounts payable, and accrued expenses, approximate their fair values due to the short-term nature of these instruments.  See Note 4 for further discussion on fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODA1_ca8be478-115d-4c51-b683-585a93318672">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting guidance for segment reporting establishes standards for reporting information on operating segments in annual financial statements.  The Company is an agricultural bioscience company operating in one segment, which is the development of new technologies to enable step-change increases in crop yield to enhance global food security and production of specialty oils and niche crops.&#160; The Company's chief operating decision-maker does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company's consolidated operating results.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzcxNTE_bdb7227f-966c-4d66-b558-d019b8800354"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTMz_6e1817a4-16f1-4757-aab9-1777766f58e4">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization.  Repairs and maintenance are charged to operating expense as incurred.  Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODUz_94cbaa8d-a1ba-4d71-bbab-ad4d3f1c4e49">Depreciation and amortization is computed using the straight-line method over the estimated useful lives of the assets once they are placed in service as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.834%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Asset Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Useful Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shorter of useful life or term of lease&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i53f6338f531042b4a04410a3879ac996_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzEtMi0xLTEtNTU2NzY_822a562e-461c-4e6f-a8d1-1137593898c9">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie14d20621fd74f3f903765f72c4cb378_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzItMi0xLTEtNTU2NzY_525ce710-feaa-4d67-87b7-f549134081b1">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="iceb9c616adc7405cb3808b71146eb760_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTo1MjkyZjBkNjM0ZGY0ZTFjYThiYWRiYzQ5Zjc5YTcxZC90YWJsZXJhbmdlOjUyOTJmMGQ2MzRkZjRlMWNhOGJhZGJjNDlmNzlhNzFkXzMtMi0xLTEtNTU2NzY_717cfc55-59dd-4f2a-9ddf-1ad9ffbe2fa1">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzgy_f6bfbf3d-38ca-4042-a898-65188644aeae">Lease Accounting&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As a lessee, the Company follows the lease accounting guidance codified in ASC 842.  A lease is classified as a finance lease if any of five criteria described in the guidance apply to the lease and any lease not classified as a finance lease is classified as an operating lease with expense recognition occurring on a straight-line basis over the term of the lease.  Under ASC 842, the Company records a lease liability on the commencement date of a lease calculated as the present value of the lease payments, using the interest rate implicit in the lease, or if that rate is not readily determinable, using the Company's incremental borrowing rate.  A right-of-use asset equal to the lease liability is also recorded with adjustments made, as necessary, for lease prepayments, lease accruals, initial direct costs and lessor lease incentives that may be present within the terms of the lease.  The Company adopted the short-term lease exception that permits lessees to omit leases with terms of twelve months or less from the accounting requirements of ASC 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Leases&lt;/span&gt;.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODY2_eb2100d4-c134-445f-8801-86c532da5e33">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, such as property and equipment and right-of-use assets, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.  Accounting guidance further requires that companies recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and measure an impairment loss as the difference between the carrying amount and fair value of the asset.&lt;/span&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODU4_43186382-e807-4968-87b3-eafe2f84b992">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Grant Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's source of continuing revenue is from its government research grants in which it serves as either the primary contractor or as a subcontractor.  These grants are considered an ongoing major and central operation of the Company's business.  Revenue is earned as research expenses related to the grants are incurred.  Revenue earned on &lt;/span&gt;&lt;/div&gt;government grants, but not yet invoiced as of the balance sheet date, are recorded as unbilled receivables in the accompanying consolidated balance sheets for the years ended December&#160;31, 2022 and December&#160;31, 2021.  Funds received from government grants in advance of work being performed, if any, are recorded as deferred revenue until earned.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3Nzk1_0f918c46-72dd-4b3b-90bd-fa48ae14395c">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs associated with internal research and development are expensed as incurred.  Research and development expenses include, among others, direct costs for salaries, employee benefits, subcontractors, crop trials, regulatory activities, facility related expenses, depreciation, and stock-based compensation.  Costs incurred for seed multiplication and processing are included within research and development expense until the Company completes its transition to established commercial operations, at which time these costs are expected to be recorded within inventory.  Costs incurred in connection with government research grants are recorded as research and development expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQz_007c37fc-33e5-4aee-9322-3360ea0d77f7">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's general and administrative expense includes costs for salaries, employee benefits, facilities expenses, consulting and professional service fees, travel expenses, depreciation and amortization expenses and office related expenses incurred to support the administrative and business development of the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <yten:IntellectualPropertyCostsPolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODEz_ef4fb4ca-fb01-458b-8d8c-73db4f9be19d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intellectual Property Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company includes all costs associated with the prosecution and maintenance of patents within general and administrative expenses in the consolidated statement of operations.&lt;/span&gt;&lt;/div&gt;</yten:IntellectualPropertyCostsPolicyPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODQ4_dd104fa6-3b1a-49a1-aa9b-aef749c8013e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All stock-based payments to employees, members of the Board of Directors and non-employees are recognized within operating expense based on the straight-line recognition of their grant date fair value over the period during which the recipient is required to provide service in exchange for the award.  See Note&#160;10 for a description of the types of stock-based awards granted, the compensation expense related to such awards and detail of equity-based awards outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODcy_94008409-7aeb-454a-89ec-f668143a92be">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basic and Diluted Net Loss per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding.  Diluted net loss per share is computed by dividing net loss available to common shareholders by the weighted-average number of dilutive common shares outstanding during the period.  Diluted shares outstanding is calculated by adding to the weighted shares outstanding any potential (unissued) shares of common stock from outstanding stock options and warrants based on the treasury stock method, as well as weighted shares outstanding of any potential (unissued) shares of common stock from restricted stock units and the conversion of preferred stock.  In periods when a net loss is reported, all common stock equivalents are excluded from the calculation because they would have an anti-dilutive effect, meaning the loss per share would be reduced.  Therefore, in periods when a loss is reported, basic and dilutive loss per share are the same.  Common stock equivalents include stock options, restricted stock awards, convertible preferred stock and warrants.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc0_f21b5fcf-b684-4a59-aeb6-658a479640b7">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities were excluded from the calculation of diluted net loss per share due to their antidilutive effect:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.847%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4648116206044ea1ab0d5587be0e4138_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzItMi0xLTEtNTU2NzY_33423ce0-0529-45f2-a060-ac01eaf8983a"
      unitRef="shares">979748</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i4da9d58e3fa24edebed51009dfec4598_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzItNC0xLTEtNTU2NzY_aa38b39f-406b-4e2b-af05-2af4be995945"
      unitRef="shares">722765</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibadc13ffe064427483b95cf9d059239f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzMtMi0xLTEtNTU2NzY_f595317d-cf1d-4a94-8b34-930424f0e5c5"
      unitRef="shares">27123</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icbc4ce7ce80f437bb07e269549f899be_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzMtNC0xLTEtNTU2NzY_8c0eaa8b-b562-4bae-bca4-3966b2c0cc0d"
      unitRef="shares">9430</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic119f79d77f64ab3b8eeebb87c15caa6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzYtMi0xLTEtNTU2NzY_8df6b5e3-6c5a-4b67-8a1b-15c0793aecd8"
      unitRef="shares">1129298</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic77d372fcd3a4dc0b1f445bc7272f30c_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzYtNC0xLTEtNTU2NzY_d851d011-581b-417c-8361-99fdb253748b"
      unitRef="shares">2361726</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzctMi0xLTEtNTU2NzY_e8d169b4-9471-4b71-b76b-0112724e508f"
      unitRef="shares">2136169</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90YWJsZTpmYTkxZTdlZjlmNDY0NTczYmZlMzFjYjQ1NDMzN2JjYi90YWJsZXJhbmdlOmZhOTFlN2VmOWY0NjQ1NzNiZmUzMWNiNDU0MzM3YmNiXzctNC0xLTEtNTU2NzY_f0089ede-2188-4746-b66e-cc40e15ee410"
      unitRef="shares">3093921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3ODc1_31eb53aa-aa3c-4520-9292-8569df2b5ae3">&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the consolidated financial statements or in the Company's tax returns.  Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse.  A valuation allowance is provided to reduce deferred tax assets to a level which, more likely than not, will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for uncertain tax positions using a "more-likely-than-not" threshold for recognizing and resolving uncertain tax positions.  The evaluation of uncertain tax positions is based on factors that include, but are not limited to, changes in tax law, the measurement of tax positions taken or expected to be taken in tax returns, the effective settlement of matters subject to audit, new audit activity and changes in facts or circumstances related to a tax position.  The provision for income taxes includes the effects of any resulting tax reserves or unrecognized tax benefits that are considered appropriate as well as the related net interest and penalties, if any.  The Company evaluates uncertain tax positions on a quarterly basis and adjusts the level of the liability to reflect any subsequent changes in the relevant facts surrounding the uncertain positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;13 for further discussion of income taxes.  The Company had no amounts recorded for unrecognized tax expense or benefits as of December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE1NDUx_46e09ba9-f476-4618-909a-31860ee829a3"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE1NDUx_b6e00abe-8405-4aff-b2e7-e6e0adc6beb5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMDYvZnJhZzpjMDkyMTUwMGUxZDg0YmM2OTJlMzY5OThiNWM1MTY0NS90ZXh0cmVnaW9uOmMwOTIxNTAwZTFkODRiYzY5MmUzNjk5OGI1YzUxNjQ1XzE3OTQ3_b1ef0b83-3874-413d-9810-2ab688d6a286">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Standards Changes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") or other standard setting bodies that the Company adopts as of the specified effective date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In November 2021, the FASB issued &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2021-10,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt; Government Assistance (Topic 832) - Disclosures by Business Entities about Government Assistance&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. This ASU requires annual disclosures that are expected to increase the transparency of transactions with a government accounted for by applying a grant or contribution accounting model by analogy, including (1) the nature of the transactions and the form in which assistance has been received, (2) the accounting policy applied, and (3) the balance sheet and income statement line items that are affected by the transactions, and the amounts applicable to each financial statement line item. This ASU became effective for annual periods beginning after December 15, 2021.  The adoption of this standard did not materially impact the Company&#x2019;s consolidated financial statements for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following new pronouncement is not yet effective but may impact the Company's consolidated financial statements in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13,&#160;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.  &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date as the initial pronouncement.  This standard requires entities to estimate an expected lifetime credit loss on financial assets ranging from short-term trade accounts receivable to long-term financings and report credit losses using an expected losses model rather than the incurred losses model that was previously used, and establishes additional disclosures related to credit risks.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities with unrealized losses, this standard now requires allowances to be recorded instead of reducing the amortized cost of the investment.  This standard limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases.  &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The guidance is effective for fiscal years beginning after&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC&#x2019;s definition&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and interim periods within those fiscal years.  The Company does not expect the adoption of this guidance to have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzIxNw_31b12422-cc6c-4226-9545-f6f40f378ede">INVESTMENTSThe Company's investments consist of the following:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Cost at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Cost at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzIxOA_2314570c-110e-40e2-9573-148a9b068a75">The Company's investments consist of the following:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Cost at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market Value at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:27pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Cost at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Market Value at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtMS0xLTEtNTU2NzY_b1f9c98b-b419-4a7e-9ada-9f5d86b7f4df"
      unitRef="usd">1992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtMy0xLTEtNTU2NzY_d7553134-63ce-4e84-b68b-246a73b7c7c4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtNS0xLTEtNTU2NzY_448c9fa6-e455-45d3-b46a-194796f684ed"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5de44c0d37be40c9a28c2bd811fa6f36_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzMtNy0xLTEtNTU2NzY_227e275b-41a8-403d-aac7-c6da35788f0a"
      unitRef="usd">1991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtMS0xLTEtNTU2NzY_cb3434de-ee5f-4d5d-82cc-9a409ec801b8"
      unitRef="usd">1992000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtMy0xLTEtNTU2NzY_131a41b9-ccd7-4a7b-9b23-cdfdfb74d44b"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtNS0xLTEtNTU2NzY_ad5601e4-2083-4cfb-a551-135ec4b1501c"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo4NTJjZTg3MGFkYzM0MDJkYTZkNjU2YWMxNzg4NmFmOS90YWJsZXJhbmdlOjg1MmNlODcwYWRjMzQwMmRhNmQ2NTZhYzE3ODg2YWY5XzQtNy0xLTEtNTU2NzY_0d92af04-16e1-4d74-a7d8-ec690fdc994a"
      unitRef="usd">1991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if123f89aae974cfab1c6bc2456615632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtMS0xLTEtNTU2NzY_cc4397e3-e7e0-4ab4-b875-6769f3a8aab0"
      unitRef="usd">10669000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if123f89aae974cfab1c6bc2456615632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtMy0xLTEtNTU2NzY_d47436bd-d83f-4d1c-a547-9d3c3f661823"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if123f89aae974cfab1c6bc2456615632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtNS0xLTEtNTU2NzY_50ed3121-40fa-4f32-a4c9-e5357bc0c383"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if123f89aae974cfab1c6bc2456615632_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzMtNy0xLTEtNTU2NzY_be0016e9-9b66-4e78-aa3f-3921bf20c307"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtMS0xLTEtNTU2NzY_34e6b72c-d609-463e-921f-1bdb94404c55"
      unitRef="usd">10669000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtMy0xLTEtNTU2NzY_14bbd98b-3326-4ad0-9256-b124266a35d4"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtNS0xLTEtNTU2NzY_533f8237-0fff-41d7-adc8-976bec8ae457"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90YWJsZTo1ODAzMzUwOGJlYjk0NDI5OTRhMjMyMmM3NzVkZDE5OS90YWJsZXJhbmdlOjU4MDMzNTA4YmViOTQ0Mjk5NGEyMzIyYzc3NWRkMTk5XzQtNy0xLTEtNTU2NzY_dc5908d9-1a22-4746-8aa9-e4748583fdc4"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:LongTermInvestments
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzE3OA_8c6526fe-324f-4a43-8bcd-65d01b414cff"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTIvZnJhZzowMTQzOTQzZTEwNGE0MWJmODliZWMxOTNjZGY4ZmE1My90ZXh0cmVnaW9uOjAxNDM5NDNlMTA0YTQxYmY4OWJlYzE5M2NkZjhmYTUzXzE3OA_de2a2364-1c0d-4ef5-834d-8cddb446dc4c"
      unitRef="usd">0</us-gaap:LongTermInvestments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90ZXh0cmVnaW9uOjlkNDM2YzVlYmY4ODQ0N2ZhYzk2MjExZGExMTVhM2YzXzM3MDI_6a8f145b-640c-45ce-b082-b1b17d29087a">Fair Value Measurements&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has certain financial assets recorded at fair value which have been classified as Level&#160;1 and Level 2 within the fair value hierarchy as described in the accounting standards for fair value measurements.  Fair value is the price that would be received from the sale of an asset or the price paid to transfer a liability in an orderly transaction between independent market participants at the measurement date.  Fair values determined by Level&#160;1 inputs utilize observable data such as quoted prices in active markets for identical instruments.  Fair values determined by Level&#160;2 inputs utilize data points other than quoted prices in active markets that are observable either directly or indirectly.  Fair values determined by Level&#160;3 inputs utilize unobservable data points in which there is little or no market data, which require the reporting entity to develop its own assumptions.  The fair value hierarchy level is determined by the lowest level of significant input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial assets classified as Level&#160;2 at December&#160;31, 2022 and December&#160;31, 2021 were initially valued at the transaction price and subsequently valued utilizing third-party pricing services.  Because the Company&#x2019;s investment portfolio may include securities that do not always trade on a daily basis, the pricing services use many observable market inputs to determine value including reportable trades, benchmark yields and benchmarking of like securities.  The Company validates the prices provided by the third-party pricing services by reviewing their pricing methods and obtaining market values from other pricing sources.  After completing the validation procedures, the Company did not adjust or override any fair value measurements provided by these pricing services as of December&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2022 and December&#160;31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted prices in active markets&#160;for &#160;identical&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&#160; inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;as&#160;of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted prices in active markets&#160;for&#160; identical&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&#160; inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;as&#160;of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of financial assets or liabilities between category levels for the years ended December&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90ZXh0cmVnaW9uOjlkNDM2YzVlYmY4ODQ0N2ZhYzk2MjExZGExMTVhM2YzXzM3MDQ_3c83d2e8-fe7b-4656-8625-4595e9456ece">The tables below present information about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of December&#160;31, 2022 and December&#160;31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized to determine such fair value.&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted prices in active markets&#160;for &#160;identical&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable&#160;inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&#160; inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;as&#160;of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;value&#160;measurements&#160;at&#160;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted prices in active markets&#160;for&#160; identical&lt;br/&gt;assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;other&lt;br/&gt;observable inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;unobservable&#160; inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance&#160;as&#160;of&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:6.75pt;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;text-indent:9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie0987e598fd44b77bbed7faceb8e8bfd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtMS0xLTEtNTU2NzY_3251021a-1584-4d50-85a4-1830c6472e5e"
      unitRef="usd">1633000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id73e87c2e2c4452cb9bcdb46ea70f888_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtMy0xLTEtNTU2NzY_8379566f-ea7c-48c2-8179-e6fdce61d9e7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i745a819a98b64320aa580b32fb4def9c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtNS0xLTEtNTU2NzY_1badc4ec-5bf8-42a3-beff-95416e0d9b89"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib708dd5f8a6f488982b1a6a8631cabc2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzUtNy0xLTEtNTU2NzY_37b6e853-6a56-43c0-bb29-2f707b8fe8f9"
      unitRef="usd">1633000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04f100c5f4eb4b2fbb1336ee32b69ec2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtMS0xLTEtNTU2NzY_384ea03c-65c2-4b47-b64a-2da5bfe1e5cc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb545bab60de47478b6320dbdab7d781_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtMy0xLTEtNTU2NzY_2355050b-df09-49bf-94fe-7d4ee8b5a0ec"
      unitRef="usd">1991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b04174d783444b5a91b08f126c073ed_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtNS0xLTEtNTU2NzY_39b78a10-649f-42ad-9143-ce71b28f7ba6"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibc0a6c75312c46e680b72b0b6f4f19e9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzgtNy0xLTEtNTU2NzY_2fb729f4-e138-435b-a3bb-349b98e15346"
      unitRef="usd">1991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6aa5b795834d44dd8e3b1fcc2a74afad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktMS0xLTEtNTU2NzY_19f21075-b816-42d4-972d-f0cc56c7cbae"
      unitRef="usd">1633000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ccbc1ced9aa46338a3306667ca0aff1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktMy0xLTEtNTU2NzY_753f350b-e796-4246-b947-812e49499ce7"
      unitRef="usd">1991000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94927ee7145149928eb35b6455abe6cd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktNS0xLTEtNTU2NzY_aa4cbe1f-3035-4181-871f-45ac1c9966b8"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2ecc835c25a3427287cfa2313952f908_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo3YmY2MDhiZjg3Mzg0MTQxYjg4ZDY2N2JhYWY1MmZmMy90YWJsZXJhbmdlOjdiZjYwOGJmODczODQxNDFiODhkNjY3YmFhZjUyZmYzXzktNy0xLTEtNTU2NzY_2c833d9e-ab4a-46db-b413-91f6cc88dff7"
      unitRef="usd">3624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0097ebc1457c424689098cd526fc4a70_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtMS0xLTEtNTU2NzY_6ea96c73-2073-4651-9951-c788e352b14a"
      unitRef="usd">4878000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie72dd2c270874bbd9c0f5786c80f1ce8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtMy0xLTEtNTU2NzY_e91a485b-fba6-4f48-9896-9821f10953a2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib4551191c4634001a933c43c11c34a07_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtNS0xLTEtNTU2NzY_4f196551-d75c-4e8f-b78f-5817c8754845"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9c52dafa175b4fc68b9d93299520cd17_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzUtNy0xLTEtNTU2NzY_b189dc66-742c-4ca3-8c3e-211c88cb4e35"
      unitRef="usd">4878000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i144df6c356284a69bdf5ec6b09bde5a7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctMS0xLTEtNTU2NzY_a6fe35c8-bc75-4c52-b8c0-d736e41d26b7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i84682813ef2546fba512f9a3d6c563ad_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctMy0xLTEtNTU2NzY_63ff506c-ead4-424a-bebd-995b24d4ac76"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icaf30edacde94c84a05341ca5dd0512f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctNS0xLTEtNTU2NzY_39a5cf24-0cd4-4842-b7e9-edcf8fd310c2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iec9b06e45af54e8f9a8de5e18ac09e35_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzctNy0xLTEtNTU2NzY_2d9bed48-a261-4807-b95e-e8198b96d4e0"
      unitRef="usd">10661000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9ca1e9b355104bd08b48abb4bb45290e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtMS0xLTEtNTU2NzY_40b1ff15-19aa-4eb1-92cf-8933785dfd20"
      unitRef="usd">4878000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85e3db911982426a8a17792e40222a8f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtMy0xLTEtNTU2NzY_ab8c303f-e084-4308-9840-453164ab8a2a"
      unitRef="usd">10661000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3fec75a43493400b8c38e54079d13b02_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtNS0xLTEtNTU2NzY_63a831fe-49b4-4a78-82be-2c72430f246f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1479bec68b2c4d46978bb015eb204350_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMTUvZnJhZzo5ZDQzNmM1ZWJmODg0NDdmYWM5NjIxMWRhMTE1YTNmMy90YWJsZTo2NWZjYTg1OTc4ZDI0MjhkODM4MTgzMmRiYzJhNjIzMC90YWJsZXJhbmdlOjY1ZmNhODU5NzhkMjQyOGQ4MzgxODMyZGJjMmE2MjMwXzgtNy0xLTEtNTU2NzY_106b5968-c8b3-48e2-ab03-84fecbb6e766"
      unitRef="usd">15539000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE4Nw_3a4b9559-84bf-4933-bb1d-2f3fa03066cc">Property and Equipment, Net&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,420&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation and amortization expense for the years ended December&#160;31, 2022 and December&#160;31, 2021, was $263 and $220, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0041b2aac5540ffb18d839925fa734d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzItMi0xLTEtNTU2NzY_5b094ccd-4adf-4842-91e3-730ba825cc35"
      unitRef="usd">533000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id7d8c98f7a2c42188fb89171b9b7189a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzItNC0xLTEtNTU2NzY_a1c753c6-35f3-4fce-ad8b-0464504a0401"
      unitRef="usd">581000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia2c0fa82f93e4dbbbedf6619da265b98_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzMtMi0xLTEtNTU2NzY_f25b8cd5-91fc-4949-a346-3636ebf8a4ef"
      unitRef="usd">59000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0d96fc98eceb4bd6bec5c50fb28726ec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzMtNC0xLTEtNTU2NzY_d76fbc0c-c5cd-42f8-9e26-a12ed343a6cd"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="icd98a258635e48699f1a798857c5c38b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzQtMi0xLTEtNTU2NzY_cd5d7285-935a-4760-9dfe-c4f062c3c822"
      unitRef="usd">1425000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5eb1729532b6499587ce5b81b2cb2556_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzQtNC0xLTEtNTU2NzY_d1aa7679-d483-4744-a0a6-29dc8108780f"
      unitRef="usd">1420000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7908f4e474c344729dd788b217be9fa9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzUtMi0xLTEtNTU2NzY_a143680c-af00-4e63-bf02-1dea9ddfb96e"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd0d338183674907923554d81edf4952_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzUtNC0xLTEtNTU2NzY_3a5b1935-e077-4600-8164-b75f5da00889"
      unitRef="usd">14000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzYtMi0xLTEtNTU2NzY_318b4268-7348-44bf-9a06-f7754343b824"
      unitRef="usd">2017000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzYtNC0xLTEtNTU2NzY_ae1c4f1a-247e-4412-a36a-dcca3e7acaf0"
      unitRef="usd">2058000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzctMi0xLTEtNTU2NzY_8d48350c-8223-4827-ad47-6c1e58551ad2"
      unitRef="usd">1242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzctNC0xLTEtNTU2NzY_fd4d2834-eddd-40ab-b4af-ddcab299853a"
      unitRef="usd">1168000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzgtMi0xLTEtNTU2NzY_7b3d0702-6cf9-4bb3-8f17-4dc2f0dcd658"
      unitRef="usd">775000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90YWJsZTpiOWQ2MTdmMjZkNGY0Y2VmODM3Yjk4NTE3NzJkNzk1YS90YWJsZXJhbmdlOmI5ZDYxN2YyNmQ0ZjRjZWY4MzdiOTg1MTc3MmQ3OTVhXzgtNC0xLTEtNTU2NzY_f0340d2e-cdfc-45d7-b862-99c76d13de9d"
      unitRef="usd">890000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE2MA_a63b9951-1653-45d3-b762-04b0b6217fe8"
      unitRef="usd">263000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjEvZnJhZzo4MGIwZTI4NjgxNDc0Yjc5YTllM2Y0ZmNkNTU2NjEzZS90ZXh0cmVnaW9uOjgwYjBlMjg2ODE0NzRiNzlhOWUzZjRmY2Q1NTY2MTNlXzE2Nw_0e1486c8-9494-475e-a56f-febf85ee512d"
      unitRef="usd">220000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90ZXh0cmVnaW9uOjkwMWIzMWZjOTU1OTQ0YjQ4YTYyNzU5ZTJiM2JiMWFkXzgw_1d40afcb-5930-4b56-994f-acc2c4b29b30">Accrued Expenses&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field trials and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90ZXh0cmVnaW9uOjkwMWIzMWZjOTU1OTQ0YjQ4YTYyNzU5ZTJiM2JiMWFkXzcw_5b42aa97-3d94-4957-b30b-25024f546038">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:68.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.782%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Field trials and related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzItMS0xLTEtNTU2NzY_fe32139c-dfef-4d9d-ab91-d539b2b1a933"
      unitRef="usd">39000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzItMy0xLTEtNTU2NzY_e0f876f8-5c19-4919-9678-9f0a183113d7"
      unitRef="usd">452000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzMtMS0xLTEtNTU2NzY_0fdf5f51-0fae-4dda-836b-b0aeca450d70"
      unitRef="usd">81000</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzMtMy0xLTEtNTU2NzY_258e8c86-97e8-4ebc-b220-25f360211bc5"
      unitRef="usd">71000</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzQtMS0xLTEtNTU2NzY_8c9684e7-1314-45cb-8021-89dd36f9f5f4"
      unitRef="usd">264000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzQtMy0xLTEtNTU2NzY_b937fa32-a3f5-47c5-b7ff-5c164dfdf736"
      unitRef="usd">264000</us-gaap:AccruedProfessionalFeesCurrent>
    <yten:AccruedFieldTrialsAndRelatedExpensesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzUtMS0xLTEtNTU2NzY_432bc759-93ca-453d-a761-4fe19d0478ef"
      unitRef="usd">273000</yten:AccruedFieldTrialsAndRelatedExpensesCurrent>
    <yten:AccruedFieldTrialsAndRelatedExpensesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzUtMy0xLTEtNTU2NzY_da0e6a17-9746-4d8d-83c7-d658829344b5"
      unitRef="usd">97000</yten:AccruedFieldTrialsAndRelatedExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzYtMS0xLTEtNTU2NzY_37d3c6d4-f750-4691-bc7b-0c05193a8f86"
      unitRef="usd">269000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzYtMy0xLTEtNTU2NzY_37a9ec51-3c32-4d6f-9b22-58360c217af9"
      unitRef="usd">252000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzctMS0xLTEtNTU2NzY_b892aa60-bcea-41cb-85e5-207cbd62cf32"
      unitRef="usd">926000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjQvZnJhZzo5MDFiMzFmYzk1NTk0NGI0OGE2Mjc1OWUyYjNiYjFhZC90YWJsZTpmZjI5M2NkZGExYWQ0M2ViOWE3ZjhjNDRhZmEwYThmMC90YWJsZXJhbmdlOmZmMjkzY2RkYTFhZDQzZWI5YTdmOGM0NGFmYTBhOGYwXzctMy0xLTEtNTU2NzY_3b5c6bca-1150-4d5e-a8a9-9c0675643780"
      unitRef="usd">1136000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU2NDU_8c28b0bb-9267-4d82-a1df-4df45dcc6132">Commitments and Contingencies&lt;div style="margin-bottom:12pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exclusive Collaboration Agreement with Rothamsted Research ("Rothamsted")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 12, 2020, the Company signed an exclusive collaboration agreement with UK-based Rothamsted to support Rothamsted&#x2019;s program to develop omega-3 oils in Camelina sativa.  Under the agreement, Yield10 is providing Rothamsted with financial support for ongoing research including further EPA, DHA+EPA trait improvement, field testing and nutritional studies.  The Company will pay Rothamsted quarterly research funding and option fees of $31 for two years totaling $250, of which $31 remains outstanding as of December&#160;31, 2022.  Included within the agreement, the Company had an exclusive two-year option to sign a global, exclusive or non-exclusive license agreement to the technology.  In November 2022, Yield10 and Rothamsted agreed to extend the collaboration agreement, including the license option, without additional funding support, through December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with the University of Missouri ("UM")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to a license agreement with UM dated as of May 17, 2018, Yield10 has an exclusive, worldwide license to two novel gene technologies to boost oil content in crops.  Both technologies are based on significant new discoveries around the function and regulation of ACCase, a key rate-limiting enzyme involved in oil production.  The UM license was expanded during May 2019 to include an exclusive worldwide license to a third gene in the ACCase complex, that the Company has designated C3012, that may complement the activity of C3007 to boost oil content in crops.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the UM license agreement, the Company is required to use diligent efforts to develop licensed products throughout the licensed field and to introduce licensed products into the commercial market.  The Company's failure to achieve any milestone provided for under the license agreement would give UM the right to terminate the license agreement or render it nonexclusive, unless the Company is able to reach agreement with UM as to the potential adjustment of the applicable milestone.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is obligated to pay UM a license execution payment, milestone payments relating to any regulatory filings and approvals covered by the license agreement, royalties on any sales of licensed products following regulatory approval, as well as a percentage of any sublicense royalties, if any, related to the licensed products.  The Company or UM may terminate the license agreement in accordance with the terms of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Guaranteed Minimum Payments to Growers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As an incentive for growers located in Canada and the U.S. to enter into Camelina commercial grain production contracts with the Company for the 2022/2023 winter season, Yield10 offered minimum guaranteed payments per acre that &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reduce the growers' risk of financial loss.  These minimum payments, which are being accrued on a straight-line basis over the expected winter growing season, are conditional upon each grower fulfilling their contractual responsibilities and are reduced by the price of Yield10's Camelina planting seed and the contractual price that the Company will pay for the actual amount of grain that is harvested.  Although the Company anticipates that the payment of these guaranteed amounts will not be required under normal growing conditions, for the 2022/2023 winter season the maximum amount of these grain production guarantees is approximately $320.  As of December&#160;31, 2022, the Company has recorded an accrual of approximately $25 for these minimum guaranteed payments, net of the growers' obligation to pay for the planting seed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases facilities under non-cancelable leases expiring at various dates through November 30, 2026.  See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to legal proceedings and claims in the ordinary course of business. The Company is not currently aware of any such proceedings or claims that it believes will have, individually or in the aggregate, a material adverse effect on the business, financial condition or the results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Guarantees&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;December&#160;31, 2022,&#160;and&#160;December&#160;31, 2021, the Company did not have significant liabilities recorded for guarantees.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into indemnification provisions under various agreements with other companies in the ordinary course of business, typically with business partners, contractors, and customers.  Under these provisions, the Company generally indemnifies and holds harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of its activities.  These indemnification provisions generally survive termination of the underlying agreement.  The maximum potential amount of future payments the Company could be required to make under these indemnification provisions is unlimited.  However, to date Yield10 Bioscience has not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions.  As a result, the estimated fair value of these agreements is minimal.  Accordingly, the Company has no liabilities recorded for these agreements as of&#160;December&#160;31, 2022&#160;and&#160;December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <yten:CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable
      contextRef="i80f310cf5c534afebc48ec2031f27370_I20201112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU3Nw_7d0c97b4-28fe-42ce-bae4-5cfa2ae47f9b"
      unitRef="usd">31000</yten:CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable>
    <yten:CollaborativeArrangementTerm
      contextRef="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU4NA_d3100559-4095-4551-b447-5cf8c2126067">P2Y</yten:CollaborativeArrangementTerm>
    <yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable
      contextRef="i80f310cf5c534afebc48ec2031f27370_I20201112"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU5Ng_8cd8e40b-b1d3-416a-9379-bdaee68ca9ef"
      unitRef="usd">250000</yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable>
    <yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable
      contextRef="i78f5c017d62d4136be49a824fedd9fa5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzYwOQ_b89e77d8-c8f7-44f9-b4e6-5139b08cc3f4"
      unitRef="usd">31000</yten:CollaborativeArrangementResearchFundingAndOptionFeesPayable>
    <yten:CollaborativeArrangementTermOfOptionForLicenseAgreement
      contextRef="i2788bd19f3374dc9bb429ed458fbeab9_D20201112-20201112"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU2NTI_ffcf38a7-2fca-4757-913f-242ef28548a0">P2Y</yten:CollaborativeArrangementTermOfOptionForLicenseAgreement>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU0OTc1NTgyMjcyNA_f3df4ef8-efcf-41f1-9327-3b087f09dacf"
      unitRef="usd">320000</us-gaap:GuaranteeObligationsMaximumExposure>
    <us-gaap:GuarantyLiabilities
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMjcvZnJhZzoyNTRlMDBjZTdjODA0NWY0OGE1MTY4NjRjMmQ0ZGRhNC90ZXh0cmVnaW9uOjI1NGUwMGNlN2M4MDQ1ZjQ4YTUxNjg2NGMyZDRkZGE0XzU0OTc1NTgyMjczMw_3976f472-1e84-4caa-bad7-ca7f48948d20"
      unitRef="usd">25000</us-gaap:GuarantyLiabilities>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzAvZnJhZzplMWExZDcwMzZiZGE0ZWQ3YjE5NDdlZTcwOWFhZmZkMC90ZXh0cmVnaW9uOmUxYTFkNzAzNmJkYTRlZDdiMTk0N2VlNzA5YWFmZmQwXzI1MjE_ff26420d-c312-4c2c-8384-87075f29a20a">License Agreements&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2017, the Company granted a license to Bayer to evaluate the Company's novel C3003 and C3004 yield traits in soybean.  Under this license, Bayer had the non-exclusive right to work with C3003 in its soybean program as a strategy to improve seed yield.  In December 2022, the Company and Bayer terminated the license in accordance with its terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company granted a four-year, non-exclusive license, as amended, to Forage Genetics International, LLC, a subsidiary of Land O'Lakes, Inc., to evaluate five of the Company's novel traits in forage sorghum.  The traits included in the research license include C3003 as well as four traits from the Company's GRAIN platform; C4001, C4002, C4003 and C4029.  In September 2022, the license terminated in accordance with its terms.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company granted a non-exclusive license to J. R. Simplot ("Simplot"), to evaluate three of the Company's novel traits in potato.  Under the license agreement, Simplot plans to conduct research with the yield traits C3003, C3004 and C4001 within its research and development program as a strategy to improve crop performance and sustainability.  In September 2022, the Company and Simplot amended the license agreement in order to extend it for a fourth year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into a non-exclusive research agreement with GDM ("GDM"), a company specializing in plant genetics, to evaluate novel traits in soybean.  Under the terms of the agreement, GDM is working with the Company's yield traits within its research and development program as a strategy to improve soybean yield performance and sustainability.  The research agreement includes three novel yield traits in the first phase with the potential to expand the program to more traits in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;None of these research arrangements provide significant licensing revenue to the Company while the third parties perform trait evaluations.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <yten:LicenseAgreementTerm
      contextRef="i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzAvZnJhZzplMWExZDcwMzZiZGE0ZWQ3YjE5NDdlZTcwOWFhZmZkMC90ZXh0cmVnaW9uOmUxYTFkNzAzNmJkYTRlZDdiMTk0N2VlNzA5YWFmZmQwXzI3NDg3NzkwNzY4OTU_89adc7ca-e015-4e21-bbe1-deb738730777">P4Y</yten:LicenseAgreementTerm>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMTU_8d188194-b3d4-4222-91e0-d4716749b532">Capital Stock and Warrants&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Registered Public Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 3, 2021, the Company completed a public offering of 1,040,000 shares of its common stock at a public offering price of $12.25 per share for total gross proceeds of $12,740 before issuance costs of $747.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's certificate of incorporation, as amended and restated, authorizes it to issue up to 5,000,000 shares of $0.01 par value preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information with regard to outstanding warrants to purchase common stock as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Common Shares Issuable Upon Exercise of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019 Public Offering - Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 19, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019 Private Placement - Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 19, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2017 Registered Direct Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consultant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 11, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective May 19, 2022, 1,071,453 Series A warrants issued in the Company's November 2019 public and private securities offerings expired in accordance with the terms of the respective purchase agreement under which the securities had been issued.  In addition, 160,975 Series A warrants issued in the Company's December 2017 securities offering also expired in accordance with the terms of their securities purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2021, a combined total of 481,973 Series A and Series B warrants issued in the Company's November 2019 securities offering were exercised by warrant holders, providing the Company with $3,856 in cash proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;padding-right:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reserved Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-right:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzE0MA_e5154818-624f-498b-8da5-13ebb056c2db"
      unitRef="shares">1040000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="icff22d25d26146d48d6decdae2cb0324_I20210203"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzIwMA_b99f7e71-9d92-40c3-a645-9ccd5eca46b6"
      unitRef="usdPerShare">12.25</us-gaap:SaleOfStockPricePerShare>
    <yten:SaleofStockGrossConsiderationReceivedPerTransaction
      contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzI0MQ_573b9098-5f53-4562-8fb8-15deb2352f8c"
      unitRef="usd">12740000</yten:SaleofStockGrossConsiderationReceivedPerTransaction>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ida28ffa9536b416f9e25193865f6b4f6_D20210203-20210203"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzI2OQ_b850cfad-b8c4-4f89-96b3-f84a9d2717e1"
      unitRef="usd">747000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzQyODA_fb1c517c-5755-4bd4-bb2c-cc701afd0cb4"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzQyOTM_718dcac4-c72f-49ca-9b9d-ae36e62f57c4"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMDc_3e3b7c4b-f719-4367-ab5e-f65c8fac31b4">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes information with regard to outstanding warrants to purchase common stock as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.828%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Common Shares Issuable Upon Exercise of Outstanding Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration Date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019 Public Offering - Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 19, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;November 2019 Private Placement - Series B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;718,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May 19, 2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;July 2017 Registered Direct Offering&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 7, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consultant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;September 11, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ia723adea7be546caa73fa33c727a5588_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzItMi0xLTEtNTU2NzY_d6b3cf26-af85-4c81-a40c-26fade3c3f30"
      unitRef="shares">395528</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ia723adea7be546caa73fa33c727a5588_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzItNC0xLTEtNTU2NzY_bfee68ed-f100-4486-ae8d-5ce1a9a94dc5"
      unitRef="usdPerShare">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ie858d5dd08b14a2188004834d4b1e502_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzQtMi0xLTEtNTU2NzY_c02430b1-6b04-4d02-87d7-8a5194c6ef85"
      unitRef="shares">718750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ie858d5dd08b14a2188004834d4b1e502_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzQtNC0xLTEtNTU2NzY_f3121148-3309-4367-9738-a918e5381c31"
      unitRef="usdPerShare">8.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i7fc2e0c481974966a604c4a0215f7915_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzYtMi0xLTEtNTU2NzY_9a3d7630-2bcc-4763-80cb-08beee3c0472"
      unitRef="shares">14270</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7fc2e0c481974966a604c4a0215f7915_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzYtNC0xLTEtNTU2NzY_1d6e7859-4a41-49e1-a7e9-6ffa0079a4b4"
      unitRef="usdPerShare">201.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="if5c1edd8e75c4550a03bf3e5051b199f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzctMi0xLTEtNTU2NzY_95abb1fc-9333-41b1-80a9-e4c93e009973"
      unitRef="shares">750</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="if5c1edd8e75c4550a03bf3e5051b199f_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzctNC0xLTEtNTU2NzY_92474f92-2b53-4b66-800d-73391796c03c"
      unitRef="usdPerShare">116.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTo0YzIyMDEwYmM0NjU0ZDNjYmVmZjQ1NTY2YmJkNWU2Zi90YWJsZXJhbmdlOjRjMjIwMTBiYzQ2NTRkM2NiZWZmNDU1NjZiYmQ1ZTZmXzgtMi0xLTEtNTU2NzY_bc5f7793-5d1d-4884-bf62-4b26ff676dc3"
      unitRef="shares">1129298</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <yten:ClassOfWarrantOrRightExpired
      contextRef="i4c88b89cfb1647cd9d8bbb0a82bfcbc0_D20220519-20220519"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzEwOTk1MTE2Mzk1ODE_71c41096-25b2-4e50-bc55-797db41c7dc5"
      unitRef="shares">1071453</yten:ClassOfWarrantOrRightExpired>
    <yten:ClassOfWarrantOrRightExpired
      contextRef="i6251c05d326e4a9386219cd404a47d8a_D20220519-20220519"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzEwOTk1MTE2Mzk4MDQ_f5ee2572-f90d-4c91-82eb-1a02cdac7036"
      unitRef="shares">160975</yten:ClassOfWarrantOrRightExpired>
    <yten:ClassOfWarrantOrRightExercised
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzU3MjU_3b7e55f3-81bb-49ef-a8fe-3e3320325203"
      unitRef="shares">481973</yten:ClassOfWarrantOrRightExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzU4Nzk_e4a2e83f-24f5-43ca-97b6-78985ea3fbf3"
      unitRef="usd">3856000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90ZXh0cmVnaW9uOmQzNTcyYzczZGUyMjRlNGRhZWEwYzBiM2M2Nzc3Y2YwXzYxMTQ_e9bd406e-1b31-4db4-9497-c0f765c55946">The following shares of common stock were reserved for future issuance upon exercise of stock options, vesting of Restricted Stock Units ("RSUs") and conversion of outstanding warrants:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.065%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.337%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.922%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.925%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,129,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total number of common shares reserved for future issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,136,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,093,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzEtMi0xLTEtNTU2NzY_e4e0a3bc-3211-4412-bc88-b4b9a37b6b2f"
      unitRef="shares">979748</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i027dffbf78374212835464d3640c101d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzEtNC0xLTEtNTU2NzY_642c6b05-b8a6-4524-8e1f-e8b9bcbb5dd1"
      unitRef="shares">722765</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ic0ad4c8865ec4c419c5b12e819189c76_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzItMi0xLTEtNTU2NzY_4a4bf53c-fc3d-4ff5-aff2-d41de1968a2f"
      unitRef="shares">27123</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i260c3b3f20bf4f4681bc4a91f421bbe5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzItNC0xLTEtNTU2NzY_776d9faf-c1a2-4b96-a91c-602a191c1a70"
      unitRef="shares">9430</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2832ee80f63d460b8492d8bcc0b5909c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzMtMi0xLTEtNTU2NzY_17e08a38-561e-4f99-ad71-3e717c45537c"
      unitRef="shares">1129298</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia0a7f5e745594f2dbf695fb7330eae73_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzMtNC0xLTEtNTU2NzY_3d6ddd0b-b31b-4849-89a2-d329791eb5e3"
      unitRef="shares">2361726</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzQtMi0xLTEtNTU2NzY_6ca90c66-8953-41fc-afbe-186eba481d61"
      unitRef="shares">2136169</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzMvZnJhZzpkMzU3MmM3M2RlMjI0ZTRkYWVhMGMwYjNjNjc3N2NmMC90YWJsZTpiNzhlNzM4YmI5Y2M0OTFiODFkNGNkNDE2MjQ5Y2NiZS90YWJsZXJhbmdlOmI3OGU3MzhiYjljYzQ5MWI4MWQ0Y2Q0MTYyNDljY2JlXzQtNC0xLTEtNTU2NzY_1bba7aa6-0237-4255-8363-360513a4aefc"
      unitRef="shares">3093921</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MTY_8326e095-ef30-435c-892c-5ca1fd25db23">Stock-Based Compensation&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Option Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted a stock plan in 2006 (the "2006 Plan"), which provided for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In October 2014, the 2006 Plan was terminated, and the Company adopted a new plan (the "2014 Plan").  No further grants or awards were subsequently made under the 2006 Plan.  A total of 3,662 options were awarded from the 2006 Plan and as of December&#160;31, 2022, 159 of these options remain outstanding and eligible for future exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2014 Plan provides for the granting of incentive stock options, non-qualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.  In May 2018, the 2014 Plan was terminated, and the Company adopted a new 2018 Stock Option and Incentive Plan, which was amended in May 2020 (the "2018 Stock Plan").  A total of 16,896 options were awarded from the 2014 Plan and as of December&#160;31, 2022, 15,990 of these options remain outstanding and eligible for future exercise.  A total of 3,619 restricted stock awards were awarded from the 2014 Plan and as of December&#160;31, 2022, all of these restricted stock awards have vested.  No further stock awards may be issued from the 2014 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2018 Stock Plan initially reserved for issuance 32,500 shares of the Company's common stock for grants of incentive stock options, non-qualified stock options, stock grants and other stock-based awards.  In accordance with the terms of the 2018 Stock Plan, beginning on the first day in January 2019, the Company's Board of Directors has annually approved the addition of shares to the 2018 Stock Plan in amounts equal to 5% of the outstanding shares of the Company's common stock on the day prior to the increase.  Effective January 1, 2022 and January 1, 2021, Yield10's Board of Directors approved the addition of 247,210 and 244,092 shares, respectively.  At its annual meeting of stockholders held on May 24, 2021, stockholders approved an amendment to add 300,000 more shares to the Company's 2018 Stock Plan.  As of December&#160;31, 2022, a total of 1,059,719 options and restricted stock awards have been issued from the 2018 Stock Plan, and as of that date, 990,243 options and restricted stock awards remain outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expense Information for Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized stock-based compensation expense, related to employee stock awards, including awards to non-employees and members of the Board of Directors, of $1,903 and $1,675 for the years ended December&#160;31, 2022 and 2021, respectively.  At December&#160;31, 2022, there was approximately $3,189 of stock-based compensation expense related to unvested awards not yet recognized which is expected to be recognized over a weighted average period of 2.42 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:8pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted under the 2006 Plan, 2014 Plan and 2018 Stock Plan generally vest ratably over periods of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5NzI_92e01ef7-0471-4c44-a8d1-ce238526654a"&gt;one&lt;/span&gt; to four years from the date of hire for new employees, the date of award for existing employees, or date of commencement of services with the Company for non-employees, and generally expire ten years from the date of issuance.  The Company's policy is to issue new shares upon the exercise of stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity related to the shares of common stock covered by outstanding options is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value per share of options granted during fiscal years 2022 and 2021, was $3.31 and $8.99, respectively.  No options were exercised during 2022 and 2021, and therefore the intrinsic value for exercised options during the two years was not applicable.  The weighted average remaining contractual term for options outstanding as of December&#160;31, 2022 was 8.15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, and 2021, the Company determined the fair value of stock options using the Black-Scholes option-pricing model with the following assumptions for option grants, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6% - 4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7% - 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 - 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 - 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116% - 126%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118% - 128%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined its volatility assumption based on actual market price fluctuations experienced during its trading history.  The risk-free interest rate used for each grant is equal to the U.S. Treasury yield curve in effect at the time of grant for instruments with a term similar to the expected life of the related option.  The expected term of the options is based upon evaluation of historical and expected future exercise behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock price volatility and expected terms utilized in the calculation involve management's best estimates at that time, both of which impact the fair value of the option calculated under the Black-Scholes methodology and, ultimately, the expense that will be recognized over the life of the option.  The accounting standard for stock-based compensation requires that the Company recognize compensation expense for only the portion of options that vest.  The Company recognizes stock option forfeitures resulting from award terminations in the period in which the forfeiture occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restricted Stock Units ("RSUs")&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records stock compensation expense for RSUs on a straight-line basis over their requisite service period, which approximates the vesting period, based on each RSU's award date market value.  As RSUs vests, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;withholds a number of shares from its employees with an aggregate fair market value equal to the minimum tax withholding amount (unless the employee makes other arrangements for payment of the tax withholding) from the common stock issuable at the vest date.  The Company then pays the minimum required income tax for the employees.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, the Company withheld vested shares with a fair value of $37 and $102, respectively, to pay for minimum tax withholding associated with RSU vesting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining recognition period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross
      contextRef="ic32cbf34fc774d82a6a93117e76c1b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU0MQ_10037152-9bf1-4d6c-8a13-44f2f5c781b5"
      unitRef="shares">3662</yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic32cbf34fc774d82a6a93117e76c1b14_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU5OA_17743ae4-fc9c-41a4-ae7c-3c3f7f0028c5"
      unitRef="shares">159</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross
      contextRef="ic327f368a9714dc0a2557c36d8a5e3da_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk_5ebab5af-8cf8-48e3-b546-cb986d1e7ea7"
      unitRef="shares">16896</yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic327f368a9714dc0a2557c36d8a5e3da_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzExNTY_3cf8830b-653b-4ed1-94e0-895b31721305"
      unitRef="shares">15990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross
      contextRef="i77415003bed3430f96c1e0adf0960a62_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEyNDE_2479f6e8-d3f5-48af-9b13-46ecbfe348b1"
      unitRef="shares">3619</yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ifd09c1537caf432ab0e3feb9155a01fd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzE0NzU_e2eba01f-3ff5-4789-bc2f-353916c39a20"
      unitRef="shares">32500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <yten:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent
      contextRef="i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzE4NDU_506945b5-587a-401d-a1fd-2637e2019165"
      unitRef="number">0.05</yten:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i30d73005a58b4b22bf596e5a6abcca81_D20220101-20220101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk1MTE2MzM3MjQ_de83bde9-8c29-4885-9ee5-a77fb726f239"
      unitRef="shares">247210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="if44b5193639a4f39b9593f64ec0b5853_D20210101-20210101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzEwOTk1MTE2MzM3MjA_03b78d78-ea46-42b3-8d3a-72e0802f6254"
      unitRef="shares">244092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="i9337506ea45848f1ab5679c11ff6aeea_D20210524-20210524"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIxNzE_f4b0f08d-d8b6-426f-a8a9-51d8d99af6cd"
      unitRef="shares">300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber
      contextRef="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIyNDE_75109a17-d5db-4d58-8f00-1a2404f4d19b"
      unitRef="shares">1059719</yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber>
    <yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber
      contextRef="i12b74c3bbaaf44c9ba3b1fde69a12387_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzIzNDQ_327df441-6812-413e-a73a-ed7aa4b8ea22"
      unitRef="shares">990243</yten:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber>
    <us-gaap:ShareBasedCompensation
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2MDc_6313a2a5-89f6-40eb-a0da-fc01ed884dc0"
      unitRef="usd">1903000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2MTQ_521a4d2c-2c29-4b78-b069-5e496da5839b"
      unitRef="usd">1675000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i1b5c8104784a476492d5c745748a9745_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI2OTQ_d134100d-ef0e-4e31-a1df-6ad854c7eaa1"
      unitRef="usd">3189000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0e337683c876475fbd6132b78b10119d_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI4NDg_6853a116-e8e9-411f-8930-d163997aa9e4">P2Y5M1D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i7683e5fee18c49a889b650734cfda999_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzI5Nzg_e9de2017-b970-4878-b30a-e80f872a8420">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <yten:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzMxNTc_cbf1c79f-dd8b-4b2a-bbef-4e49f3a22c62">P10Y</yten:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MjQ_72da7b71-13b8-45af-a796-603dd46f8c45">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the activity related to the shares of common stock covered by outstanding options is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.036%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Term&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.02&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,509)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(851)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;260,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,859)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,443)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;712.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979,748&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;437,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.69&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMS0xLTEtNjUwOTE_7625b56e-d2d8-4a82-9e97-c982d5473213"
      unitRef="shares">339108</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMy0xLTEtNjUwOTk_51870fd0-b8a6-4e81-a9a0-850f4cf5bc21"
      unitRef="usdPerShare">32.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="iadffb97e562c40ab9d5c4ca96b69c01a_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtNS0xLTEtNjUxNDE_76668242-32c8-4e91-a765-08e343fa2787">P9Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i5cc722f803314436a9c7c6caad2c8578_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtNy0xLTEtNjUxMTQ_ab962fae-7df6-4372-aa0e-23e03b1cc43c"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMS0xLTEtNjUwOTE_6c617e5a-21b0-4d53-8672-8f5b0a4e997d"
      unitRef="shares">386017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMy0xLTEtNjUwOTk_64e7c0eb-1c3b-4e03-8cfd-ff3bc876752b"
      unitRef="usdPerShare">10.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMS0xLTEtNjUwOTE_3cc89c3e-fbbf-415a-b908-af24bb70a3b6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMy0xLTEtNjUwOTk_34661e82-1d27-48da-a610-17a6a96da118"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMS0xLTEtNjUwOTE_38876b99-73a9-4915-86ef-ec375dcf1106"
      unitRef="shares">1509</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMy0xLTEtNjUwOTk_68ae7b0e-0fce-4a1d-bbf2-22b1b08d419e"
      unitRef="usdPerShare">12.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMS0xLTEtNjUwOTE_3c3a1685-c8f3-4007-be69-88aa8f223228"
      unitRef="shares">851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMy0xLTEtNjUwOTk_62653547-4714-472a-9eea-ceb707e6c968"
      unitRef="usdPerShare">1131.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i027dffbf78374212835464d3640c101d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMS0xLTEtNTU2NzY_0c780887-921f-438f-989e-5c7b6c2202a9"
      unitRef="shares">722765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i027dffbf78374212835464d3640c101d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzEtMy0xLTEtNTU2NzY_4f55e67d-905a-4ac6-b578-a2ab1058aea9"
      unitRef="usdPerShare">19.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNS0xLTEtNjUxMzA_b5f0c6c9-5ee5-4c75-ab50-e0b2a8f1e307">P8Y9M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i027dffbf78374212835464d3640c101d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNy0xLTEtNjUxMjI_12144465-dff1-4ab7-be01-20465b18729f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMS0xLTEtNTU2NzY_85b86877-fa31-4411-a309-01bb848434c6"
      unitRef="shares">260285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzItMy0xLTEtNTU2NzY_941cf4d4-23bf-404e-a753-35320b64f32b"
      unitRef="usdPerShare">3.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMS0xLTEtNTU2NzY_c0025f19-69b6-4733-99b2-3b292baf3b11"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzMtMy0xLTEtNTU2NzY_e7ffab94-38f4-4cd2-ac34-31cc5f7a1612"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMS0xLTEtNTU2NzY_ff0f67ee-a747-4830-a8d7-ace08a7b0025"
      unitRef="shares">1859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzQtMy0xLTEtNTU2NzY_7d7c0407-8424-4fb6-845f-ddbf693010ad"
      unitRef="usdPerShare">7.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMS0xLTEtNTU2NzY_3d26ae42-ea6f-41e1-9719-a6ea446b24f3"
      unitRef="shares">1443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzUtMy0xLTEtNTU2NzY_779cb8ce-a4d3-4098-931a-bce7016bfd69"
      unitRef="usdPerShare">712.92</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtMS0xLTEtNTU2NzY_f2321115-1f77-4c54-bfb0-0e6726b17c9e"
      unitRef="shares">979748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtMy0xLTEtNTU2NzY_035eab20-9c30-4fdb-92d6-c468279aa226"
      unitRef="usdPerShare">14.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNS0xLTEtNTU2NzY_413ca947-efc6-4623-ad2f-9b18aa1cd9b7">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzYtNy0xLTEtNTU2NzY_2d89a70b-74b1-4bce-99e3-585fb74f0797"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctMS0xLTEtNTU2NzY_3ae98aa4-42a7-4331-acb6-757047665c7e"
      unitRef="shares">979748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctMy0xLTEtNTU2NzY_faa7adff-f1ee-47f3-bebc-692fa72d918f"
      unitRef="usdPerShare">14.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctNS0xLTEtNTU2NzY_54508340-0ac7-4780-91a4-f205d71797a2">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzctNy0xLTEtNTU2NzY_30492b62-9f39-4774-9cbb-eb1a6a8715cc"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtMS0xLTEtNTU2NzY_84899490-f6f5-4856-b1b2-657bdcde5e7b"
      unitRef="shares">437039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtMy0xLTEtNTU2NzY_8a848974-c9c6-4512-9df5-7b236274fec2"
      unitRef="usdPerShare">23.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtNS0xLTEtNTU2NzY_891787ec-cf20-4f09-8739-077fe97f1edd">P7Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i07391aec75484ead8a61a6df73afeff4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTplM2M1NWVmMjZiM2I0MzBhODE4MmUxZDQ1MTYyOTg4Ni90YWJsZXJhbmdlOmUzYzU1ZWYyNmIzYjQzMGE4MTgyZTFkNDUxNjI5ODg2XzgtNy0xLTEtNTU2NzY_9e0ba9d6-38f8-4024-8e79-5617b846e72a"
      unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM0ODY_8152e724-03bc-48b0-9566-b9fac74b955c"
      unitRef="usdPerShare">3.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM0OTM_444f1e2d-ba21-48d6-85dd-cb13315e3551"
      unitRef="usdPerShare">8.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM1MTI_77eab075-d744-4ee5-a8ed-4b07916654b4"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM1MTI_aec2944a-258b-4030-ae67-b972b8fc90fe"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzM3Mzk_8a07b4d1-4862-4759-badc-9d532c4faa6b">P8Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MjY_5aa0de91-b15a-4a0d-b297-045696c5119b">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2022, and 2021, the Company determined the fair value of stock options using the Black-Scholes option-pricing model with the following assumptions for option grants, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.316%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.947%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6% - 4.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7% - 1.7%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected option term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 - 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1 - 10.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116% - 126%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118% - 128%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzItMi0xLTEtNTU2NzY_757d3171-35a9-41cc-b3d3-42d1260ed4a7"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzItNC0xLTEtNTU2NzY_781ded64-a545-43cc-8803-98e63fdf9cff"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo5MWMyOGZlMjFiZDM0ZTAyYWI4YzNiZmQ1ZDdjMzE2ZF80_b21294a9-347c-4261-b87b-e8e440e95f4e"
      unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo5MWMyOGZlMjFiZDM0ZTAyYWI4YzNiZmQ1ZDdjMzE2ZF85_e37cedd8-4e30-49ec-bb11-5729a6ebd872"
      unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpjOWYxOTNlNjdmMjY0ZDk3ODM4ZjkwNDk1Y2ZjY2JjMl80_955eb3e0-e524-40a9-8ad4-492288de483b"
      unitRef="number">0.007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzMtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpjOWYxOTNlNjdmMjY0ZDk3ODM4ZjkwNDk1Y2ZjY2JjMl85_fe4358d6-b091-495d-aa17-6fda3725377d"
      unitRef="number">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i635ada1b5dce4d25ad57b6a85d3a5a62_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiZWQ3NTZkMWY1MGY0Mjg2YTk1MjFhMThlMGZhY2MzMF80_a30458cf-acdb-4d93-87ed-338851125413">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i7683e5fee18c49a889b650734cfda999_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiZWQ3NTZkMWY1MGY0Mjg2YTk1MjFhMThlMGZhY2MzMF85_38c28a45-04d0-4153-b559-b14df6f2fc1f">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i81e4afc9063e482c8ea9bcff80c5bc79_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiYzY2YzZjM2FjNDk0ZTc2OGUxN2Q2NzM2MzMyOGYwYV80_1cb14be1-090b-4f6e-a0c1-e0d37895b0ae">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i115962649b404c9dad81db13df9ab327_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzQtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjpiYzY2YzZjM2FjNDk0ZTc2OGUxN2Q2NzM2MzMyOGYwYV85_b97d167c-89e4-428c-8cab-1dc1476866ab">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo0YTEzZDUxNjI5Njg0Y2ZjYjE1ZTkwMWFmYzc2M2YxMl80_977ab803-3328-4346-b6fc-1a467b8e438c"
      unitRef="number">1.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="i7d4fabacd1754b738011363e69731c36_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtMi0xLTEtNTU2NzYvdGV4dHJlZ2lvbjo0YTEzZDUxNjI5Njg0Y2ZjYjE1ZTkwMWFmYzc2M2YxMl85_742e5571-80cc-40ba-a63a-97b24842efcd"
      unitRef="number">1.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjoxMzY3YzRlODlmZTA0NzY5ODczZGY2NWYzNGZmMGY4N180_11bbdf81-cca0-4509-9b81-d5037cb59e8d"
      unitRef="number">1.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="ic6d3bb9de732443095be33ea4d776c16_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTpkMDBjNThmYTAwYjE0ZDk1OWVmNjY0NGRiNTEyYTQyZS90YWJsZXJhbmdlOmQwMGM1OGZhMDBiMTRkOTU5ZWY2NjQ0ZGI1MTJhNDJlXzUtNC0xLTEtNTU2NzYvdGV4dHJlZ2lvbjoxMzY3YzRlODlmZTA0NzY5ODczZGY2NWYzNGZmMGY4N185_89fed527-67f5-483c-910f-d93387312e4c"
      unitRef="number">1.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iea7a2db667b9494c88b89ceeae9fafd9_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU2NTg_feb3003a-d5cd-4780-8227-43a37212ed6e"
      unitRef="usd">37000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ie879a42901184b87a0029ddae2ba967e_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU2NjU_043ca67b-4293-464f-9439-2449381ab2a3"
      unitRef="usd">102000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90ZXh0cmVnaW9uOjYyZWEwMTFkOTc1ZDQ0ZmM4N2NjODM3OTU0ZTY0YTkwXzU4MzI_f895a8df-f11f-4683-ad88-c811bad21d65">&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of RSU activity for the year ended December&#160;31, 2022 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.419%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number of RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual Life (years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36,557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining recognition period (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzEtMS0xLTEtNTU2NzY_9a411595-6f7d-4160-833b-93502b39fe62"
      unitRef="shares">9430</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzItMS0xLTEtNTU2NzY_efa5550e-d5bc-4282-8b74-8f7d45b359f6"
      unitRef="shares">54250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzMtMS0xLTEtNTU2NzY_08c4075f-b647-4197-baac-974b1817b364"
      unitRef="shares">36557</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzQtMS0xLTEtNTU2NzY_33ab9e19-ab65-464c-99ad-cc4839a7aba0"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzUtMS0xLTEtNTU2NzY_e457e7b4-6afe-41e2-8734-30179283014a"
      unitRef="shares">27123</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzUtMy0xLTEtNTU2NzY_0ad66d55-9609-47f6-80b7-665276b4d3a4">P0Y1M9D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzkvZnJhZzo2MmVhMDExZDk3NWQ0NGZjODdjYzgzNzk1NGU2NGE5MC90YWJsZTo3ZjY2MjQwNmJjZTk0OGQ4ODRkZWNiMzdhNWNiNmVmOC90YWJsZXJhbmdlOjdmNjYyNDA2YmNlOTQ4ZDg4NGRlY2IzN2E1Y2I2ZWY4XzctMS0xLTEtNTU2NzY_e5140278-c71a-402e-87bd-4a5777dbfa5a">P0Y1M9D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNjc_e3fb8c2d-0633-4ffc-afc5-a21c36e46e0e">LEASES&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Maturity Analysis of Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Woburn, Massachusetts facility is the only lease included in the Company's right-of-use assets and corresponding lease liabilities.  No other active real estate or equipment leases fall within the scope of ASC 842.  At December&#160;31, 2022, the Company's lease liability related to its Woburn facility will mature as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Quantitative Disclosure of Lease Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;&#160; &#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information as of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Real Estate Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;During 2016, the Company entered into a lease agreement, as amended, for its headquarters, pursuant to which the Company leased 22,213 square feet of office and research and development space located at 19 Presidential Way, Woburn, Massachusetts.  The lease will terminate on November 30, 2026 and does not include options for an early termination or for an extension of the lease.  Pursuant to the lease, the Company is required to pay certain pro rata taxes and operating costs associated with the premises throughout the term of the lease.  During the initial buildout of the rented space, the landlord paid for tenant improvements to the facility that resulted in increased rental payments by the Company.  As required by ASC 842, these improvements were recorded as a reduction in the valuation of the associated right-of-use asset.  The Company has provided the landlord with a security deposit of $229.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2016, the Company entered into a sublease agreement with a subsidiary of CJ CheilJedang Corporation ("CJ") with respect to CJ's sublease of 9,874 square feet of its leased facility located in Woburn, Massachusetts.  The sublease space was determined to be in excess of the Company's needs.  The CJ sublease is coterminous with the Company's master lease and CJ will pay pro rata rent and operating expenses proportionate to the amounts payable to the landlord by the Company, as adjusted from time to time in accordance with the terms of the master lease.  Future CJ sublease payments have not been presented as an offset to total undiscounted future lease payments of $3,060 shown in the lease maturity analysis table above.  CJ provided the Company with a security deposit of $103 in the form of an irrevocable letter of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's wholly-owned subsidiary, YOI, located in Saskatoon, Saskatchewan, Canada, leases approximately 9,600 square feet of office, laboratory and greenhouse space located within Innovation Place at 410 Downey Road and within the research facility of National Research Council Canada located at 110 Gymnasium Place.  None of these leases contains renewal or early termination options.  YOI's leases for these facilities expire on various dates through September 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNjk_5fafad74-3ea3-4a1d-bd1a-0c3e473d01ff">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.854%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Short-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Long-term lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzEtMS0xLTEtNTU2NzY_1b91cf6f-9e9c-4e72-aa50-06212a1dfe7f"
      unitRef="usd">749000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzItMS0xLTEtNTU2NzY_e75b9e9a-07c4-42d7-8960-269324560490"
      unitRef="usd">771000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzMtMS0xLTEtNTU2NzY_fea35943-d6a9-4fd6-834e-473aa3a7246a"
      unitRef="usd">793000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzQtMS0xLTEtNTU2NzY_f76574b1-371d-49cd-b755-fd68394ccf42"
      unitRef="usd">747000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzYtMS0xLTEtNTU2NzY_256d2290-8201-4adc-87d8-abbc9e0d5c7c"
      unitRef="usd">3060000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzctMS0xLTEtNTU2NzY_f5438c52-4776-4aba-82aa-5485ac94675c"
      unitRef="usd">410000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzgtMS0xLTEtNTU2NzY_178656c8-112c-4a59-98bb-a7b9d21a8d6a"
      unitRef="usd">2650000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzktMS0xLTEtNTU2NzY_dc9621cd-3336-4df3-89b8-3fdd1a4932c5"
      unitRef="usd">575000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpmNTVkMzU1NDI2OWY0OWFhOGUzOTQwNzBlZDQ2NjNlNi90YWJsZXJhbmdlOmY1NWQzNTU0MjY5ZjQ5YWE4ZTM5NDA3MGVkNDY2M2U2XzEwLTEtMS0xLTU1Njc2_4f64bb1a-d758-4c7c-8389-e5b8c17f4502"
      unitRef="usd">2075000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzQxNzI_31afba59-2731-48b2-8f53-04dfde836557">Quantitative Disclosure of Lease Costs&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended&lt;br/&gt;&#160; &#160;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;605&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(605)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.165%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other information as of:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzMtMi0xLTEtNTU2NzY_bad4f238-55cf-45f5-a8b0-541c0f90dc6f"
      unitRef="usd">605000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzMtNC0xLTEtNTU2NzY_5c031392-18e9-427b-b151-72f1c4e04cd5"
      unitRef="usd">605000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzQtMi0xLTEtNTU2NzY_7ac0cbce-b3ea-469d-95da-0394ce671b15"
      unitRef="usd">696000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzQtNC0xLTEtNTU2NzY_5e35e602-c0c2-4f09-a1ae-e02364af7c26"
      unitRef="usd">655000</us-gaap:ShortTermLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzUtMi0xLTEtNTU2NzY_de2036ea-0f52-42a0-abb5-de8a72415c1b"
      unitRef="usd">605000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzUtNC0xLTEtNTU2NzY_f16a3ade-ab4b-40c9-8d9d-01b2e559763e"
      unitRef="usd">616000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzYtMi0xLTEtNTU2NzY_54c85b27-d9b5-4b9d-8272-c006570dc706"
      unitRef="usd">696000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTphYzNkZDhhYjliODE0OWE4YmE5NDljYmI5OTM3N2Q3ZC90YWJsZXJhbmdlOmFjM2RkOGFiOWI4MTQ5YThiYTk0OWNiYjk5Mzc3ZDdkXzYtNC0xLTEtNTU2NzY_a9848e59-2f66-4a38-a529-19f4345775a0"
      unitRef="usd">644000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzEtMi0xLTEtNTU2NzY_b6ae6f1c-b13b-4875-8ae3-0366d4279a05">P3Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzEtNC0xLTEtNTU2NzY_8c261732-a5a2-4a48-9788-cfdf70829a87">P4Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzItMi0xLTEtNTU2NzY_739aceda-9dbf-47d9-a616-920f2e1c72b1"
      unitRef="number">0.0725</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90YWJsZTpkYTU1NmM4MTEyODE0YTBiYjJmZWZjODllNWVhNWUyYS90YWJsZXJhbmdlOmRhNTU2YzgxMTI4MTRhMGJiMmZlZmM4OWU1ZWE1ZTJhXzItNC0xLTEtNTU2NzY_61480977-cd2c-4a16-bd39-79d4e6366cc8"
      unitRef="number">0.0725</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <yten:LesseeOperatingLeaseLeaseArea
      contextRef="i119b882f71fe4a1082a3446bb15acbec_D20160101-20161231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzE3Nzc_34ada14b-ed51-47e4-b337-bf89518961dd"
      unitRef="sqft">22213</yten:LesseeOperatingLeaseLeaseArea>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i91e719d6dc084b8eb65833dd9f3d826e_I20191130"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzI1NDc_02de9560-84c3-40ec-8bc5-e71dbca384b4"
      unitRef="usd">229000</us-gaap:LettersOfCreditOutstandingAmount>
    <yten:LesseeOperatingSubleaseSubleasedArea
      contextRef="i1669a5dd6ba54e94a94243d28e96c30c_D20161001-20161031"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzI3MDI_ca89951b-09fb-441e-a2a0-a903028b45d2"
      unitRef="sqft">9874</yten:LesseeOperatingSubleaseSubleasedArea>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i9567ed174d68444dbf277b216ec8dcbb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzMyMjg_c88a515f-9773-493f-bcdc-0ce3ee510881"
      unitRef="usd">3060000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id253aebbd61b4ee5a2318fd621623370_I20161031"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzMzMzM_a83e609c-f8f7-4915-90d3-9a1f84e5c428"
      unitRef="usd">103000</us-gaap:LettersOfCreditOutstandingAmount>
    <yten:LesseeOperatingLeaseLeaseArea
      contextRef="ifedea1c8eb9444c6bea044622e488712_D20220101-20221231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDIvZnJhZzo2ZDllMzMyY2E5ZDc0NGJjYTIyOWE1OTNiMTgzZjIyZS90ZXh0cmVnaW9uOjZkOWUzMzJjYTlkNzQ0YmNhMjI5YTU5M2IxODNmMjJlXzM4MDg_b893735c-441f-4c74-9d12-54f38e2dbbc7"
      unitRef="sqft">9600</yten:LesseeOperatingLeaseLeaseArea>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1OTM_da92f141-f5d5-4053-9450-f55376216286">Income Taxes&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes and Deferred Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss from operations before provision for income taxes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from operations before income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The components of the income tax provision consisted of the following for the years ended December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Tax Provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible equity transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Tax Attributes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, the Company had U.S. net operating loss carryforwards ("NOLs") for federal and state income tax purposes of approximately $25,460 and $25,414, respectively.  All of the $25,460 of federal NOLs will carry forward indefinitely.  The Company's state NOL carryforwards will begin to expire on various dates through 2042.  The Company also had available research and development and investment tax credits for federal and state income tax purposes of approximately $417 and $312, respectively.  These federal and state credits will begin to expire on various dates through 2042.  In Canada, the Company has cumulative research tax credits totaling $132 that will begin to expire on various dates through 2037.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management of the Company has evaluated the positive and negative evidence bearing upon the realizability of its deferred tax assets ("DTA"), which is comprised principally of NOL carryforwards.  Under the applicable accounting standards, management has considered the Company's history of losses and concluded that it is more likely than not that the Company will not recognize the benefits of U.S. federal and state DTAs.  Accordingly, a full valuation allowance has been established against the U.S. net DTAs.  The Company has also concluded, based on its financial projections, that it is more likely than not the $132 of DTAs of its wholly-owned Canadian subsidiary, YOI, may not be recognized in the future, resulting in the Company's recording of a full valuation allowance against the assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Utilization of the NOL and research and development credit ("R&amp;amp;D Credit") carryforwards may be subject to a substantial annual limitation under Section&#160;382 of the U.S. Internal Revenue Code of 1986 (the "Code") due to ownership change limitations, as defined by the Code, that have occurred previously or that could occur in the future.  These ownership changes may limit the amount of NOL and R&amp;amp;D Credit carryforwards that can be utilized annually to offset future U.S. taxable income and tax, respectively.  The Company evaluated its Section 382 ownership changes through May 31, 2021 and has determined that the most recent change that occurred in November 2019 resulted in all NOL and R&amp;amp;D Credit carryforwards outstanding as of that date becoming fully limited.  The Company has reduced its associated deferred tax assets accordingly.  To the extent an ownership change occurs in the future, the NOL, R&amp;amp;D Credit carryforwards and other deferred tax assets recorded after the November 2019 ownership change may also be subject to limitations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tax years 2019 through 2022 remain open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the U.S.  The statute of limitations for NOLs utilized in future years will remain open beginning in the year of utilization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's policy is to record estimated interest and penalties related to uncertain tax positions as income tax expense.  As of December&#160;31, 2022 and 2021, the Company had no accrued interest or penalties recorded related to uncertain tax positions.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No additional provision has been made for U.S. income taxes related to the undistributed earnings of the wholly-owned subsidiaries of Yield10 or for unrecognized deferred tax liabilities for temporary differences related to investments in subsidiaries as the amounts are not significant.  As such, earnings are expected to be permanently reinvested, the investments are essentially permanent in duration, or the Company has concluded that no additional tax liability will arise as a result of the distribution of such earnings.&#160; A liability could arise if amounts are distributed by such subsidiaries or if such subsidiaries are ultimately disposed.&#160; It is not practical to estimate the additional income taxes related to permanently reinvested earnings or the basis differences related to investment in subsidiaries.&#160; Unremitted earnings at December&#160;31, 2022 and December&#160;31, 2021 approximated $1,081 and $1,032, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1OTA_90e97b9b-9cb6-4331-8350-677a530968b1">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss from operations before provision for income taxes consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,062)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss from operations before income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,995)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzItMS0xLTEtNTU2NzY_c8c7ec50-35e2-4ce9-aab3-6a5d18516ed9"
      unitRef="usd">-13504000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzItMy0xLTEtNTU2NzY_b63f197c-2af1-4bb1-bb16-c568913f1378"
      unitRef="usd">-11062000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzMtMS0xLTEtNTU2NzY_26bf3234-7f3b-46a5-9626-098643e609ee"
      unitRef="usd">94000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzMtMy0xLTEtNTU2NzY_422389fb-8d8e-459b-84d3-8d111e106066"
      unitRef="usd">67000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzQtMS0xLTEtNTU2NzY_d7cf969d-f39b-466a-a265-81c0aa7ed2dc"
      unitRef="usd">-13410000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3MmE3ZjE5Y2Q3YWQ0MWMxYmVlYWMwMTNjZDNhOGY5NC90YWJsZXJhbmdlOjcyYTdmMTljZDdhZDQxYzFiZWVhYzAxM2NkM2E4Zjk0XzQtMy0xLTEtNTU2NzY_29bd9447-2b67-495b-87e8-c04988648ee2"
      unitRef="usd">-10995000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ2MTE_bf893b56-dcab-4218-9d0d-545964358c5f">The components of the income tax provision consisted of the following for the years ended December&#160;31, 2022 and 2021:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current Tax Provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Benefit:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzMtMS0xLTEtNTU2NzY_850aa1e4-41d7-4a2d-9551-2f2692477fe2"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzMtMy0xLTEtNTU2NzY_dcdcba93-810f-404b-b487-de8cd0fdbf0e"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzQtMS0xLTEtNTU2NzY_2df61983-e6ce-4009-b0ed-948c65cc0dfa"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzQtMy0xLTEtNTU2NzY_dc1ef8ea-97ca-4b47-a378-ebf0b11d332f"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzUtMS0xLTEtNTU2NzY_926ae3d3-61fb-4095-b040-5c4b6102f1f8"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzUtMy0xLTEtNTU2NzY_587cd9e5-adc8-4469-9eb8-940d06adbbc0"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzYtMS0xLTEtNTU2NzY_9e002406-0e71-410d-904d-14c8469b4d5d"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzYtMy0xLTEtNTU2NzY_4f76f848-22f5-4093-84d4-585fac36f146"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzktMS0xLTEtNTU2NzY_7ae2daf5-52ab-44ba-b7de-a836423c9e2b"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzktMy0xLTEtNTU2NzY_bd819b3d-6b5d-402f-87ce-f8c4e84b96ec"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEwLTEtMS0xLTU1Njc2_5b4bca37-294f-4e86-a46a-75eb62095381"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEwLTMtMS0xLTU1Njc2_9346b961-fd1f-42dd-9ec5-43c4ac303e6b"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzExLTEtMS0xLTU1Njc2_46890fb8-cc4f-438e-9e58-d9ddf5c65ae4"
      unitRef="usd">156000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzExLTMtMS0xLTU1Njc2_42a88cbb-338e-4a94-aec8-aedc77239f44"
      unitRef="usd">36000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEyLTEtMS0xLTU1Njc2_091b8390-1a74-453d-836a-f0b8c5c50ccf"
      unitRef="usd">156000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEyLTMtMS0xLTU1Njc2_a96dbf1b-a0f4-42e7-9759-f5307f22d708"
      unitRef="usd">36000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEzLTEtMS0xLTU1Njc2_6bb7d9ec-bd41-46ec-aedd-68fffcea1ec8"
      unitRef="usd">156000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo2ODRhNzI2YTVhMjU0Mjc5ODkxN2VjMGJmY2EyZTQ2MS90YWJsZXJhbmdlOjY4NGE3MjZhNWEyNTQyNzk4OTE3ZWMwYmZjYTJlNDYxXzEzLTMtMS0xLTU1Njc2_8392e43b-9912-44f9-af9a-64b0c700fa23"
      unitRef="usd">36000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ2MDU_e24c5b11-35e4-4253-a92f-e1fbaa47cd8d">&lt;div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company's deferred tax assets are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforward&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalization of research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other temporary differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,739)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,961)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred Tax Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(185)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(643)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzMtMS0xLTEtNTU2NzY_534cf878-7428-480c-a8c4-aac9f761eb5c"
      unitRef="usd">6953000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzMtMy0xLTEtNTU2NzY_4240bddd-0bb4-4c48-aac2-c86cfd533e5f"
      unitRef="usd">5533000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzQtMS0xLTEtNTU2NzY_73053fec-6f73-4b1b-88e9-7cc0e9d0d93c"
      unitRef="usd">1841000</yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzQtMy0xLTEtNTU2NzY_73661f81-d354-4b9a-85e2-8c7842e3241b"
      unitRef="usd">0</yten:DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzUtMS0xLTEtNTU2NzY_f811c69f-589a-480b-a706-39864da6f910"
      unitRef="usd">799000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzUtMy0xLTEtNTU2NzY_40d452ca-aefb-40d6-92ec-3b83a235bcc5"
      unitRef="usd">565000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzctMS0xLTEtNTU2NzY_c14efdf5-5bc5-41ea-a7d8-fda7a03a8ebe"
      unitRef="usd">1043000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzctMy0xLTEtNTU2NzY_4f8e5281-84c2-4749-a11d-669c6be692e9"
      unitRef="usd">886000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <yten:DeferredTaxAssetsLeaseLiability
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzgtMS0xLTEtNTU2NzY_15d9fcb6-a5aa-47f8-88f5-a0940ea2cb0b"
      unitRef="usd">733000</yten:DeferredTaxAssetsLeaseLiability>
    <yten:DeferredTaxAssetsLeaseLiability
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzgtMy0xLTEtNTU2NzY_0705b921-5658-42a5-9da4-3149c42b0395"
      unitRef="usd">864000</yten:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzktMS0xLTEtNTU2NzY_34b90d02-d46e-455c-bae4-de23c13c9a07"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzktMy0xLTEtNTU2NzY_b65c4500-0bb2-4590-b198-3d15a9cdc5c0"
      unitRef="usd">106000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEwLTEtMS0xLTU1Njc2_5b495e80-26be-437e-8ae5-5cba46080c80"
      unitRef="usd">11369000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEwLTMtMS0xLTU1Njc2_41955b3b-e03e-4234-9a29-f5a436d7ded5"
      unitRef="usd">7954000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzExLTEtMS0xLTU1Njc2_ed913469-e0a9-464c-847a-c7e71b935e2e"
      unitRef="usd">10739000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzExLTMtMS0xLTU1Njc2_170cd7f3-26a5-481d-9e87-52aaa78b1d02"
      unitRef="usd">6961000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEyLTEtMS0xLTU1Njc2_4e87e95c-0c2d-42d1-a950-170697720988"
      unitRef="usd">630000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzEyLTMtMS0xLTU1Njc2_3f4524f2-1fc3-4ba1-8573-ff83d7418211"
      unitRef="usd">993000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE0LTEtMS0xLTU1Njc2_8b57298a-0cd1-4b25-9252-bd7acc9dadf9"
      unitRef="usd">94000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE0LTMtMS0xLTU1Njc2_c489d3f3-000e-4798-beee-fb61054d1802"
      unitRef="usd">185000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <yten:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE1LTEtMS0xLTU1Njc2_675a76f0-21ce-499e-87a0-c8ad628e3556"
      unitRef="usd">536000</yten:DeferredTaxLiabilitiesRightOfUseAsset>
    <yten:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE1LTMtMS0xLTU1Njc2_085e7197-f336-4731-a5c8-9e7647bb1acb"
      unitRef="usd">643000</yten:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE2LTEtMS0xLTU1Njc2_29a0caea-6fa6-477a-b407-17002b9a8e33"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTphMmRmMmEzMDFlODM0OGYxODRjZGQ2MjQwMzc5NzBjYi90YWJsZXJhbmdlOmEyZGYyYTMwMWU4MzQ4ZjE4NGNkZDYyNDAzNzk3MGNiXzE2LTMtMS0xLTU1Njc2_0e9b053f-9604-462b-8ea4-824aa8f6f41c"
      unitRef="usd">165000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1ODc_63f88248-4ad7-4776-a3ad-de7ca3483dc3">&lt;div style="margin-bottom:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The items accounting for the difference between the income tax (provision) benefit computed at the federal statutory rate of 21% and the provision for income taxes were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.965%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.996%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal income tax at statutory federal rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent differences&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impact of ownership change&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(267.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible equity transactions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ5Mg_3e0f2655-edc9-4474-8dda-770bb8cf45fc"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzItMS0xLTEtNTU2NzY_41ec03ce-e63a-4997-9896-5b530d0a2978"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzItMy0xLTEtNTU2NzY_8b835570-1558-4fa6-8933-52953ac88101"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzMtMS0xLTEtNTU2NzY_3d9593eb-8bad-4145-baf0-7a32ef0437cf"
      unitRef="number">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzMtMy0xLTEtNTU2NzY_520b467f-0188-4a79-a21b-2ec559f9f106"
      unitRef="number">0.059</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzQtMS0xLTEtNTU2NzY_5e55e26a-195d-44c5-909e-d91ec57d1efb"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzQtMy0xLTEtNTU2NzY_c5c43fea-2510-4b98-96fc-388833770645"
      unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzUtMS0xLTEtNTU2NzY_fdb75593-b192-4262-8522-9f546ea202fa"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzUtMy0xLTEtNTU2NzY_1806fe64-b61a-4991-af30-e53f7f83eaca"
      unitRef="number">-0.020</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzYtMS0xLTEtNTU2NzY_f8fc6832-b7f0-49ca-b505-28d4f6d8a968"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzYtMy0xLTEtNTU2NzY_a0fb5ab7-4f98-4816-bbbc-ed04e349ff1c"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzctMS0xLTEtNTU2NzY_66ecf668-46cd-4486-abec-cc1cf5a06e7a"
      unitRef="number">-0.000</yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent>
    <yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzctMy0xLTEtNTU2NzY_17f71e9b-db79-48f9-a4ee-5ca40d5475d7"
      unitRef="number">2.670</yten:EffectiveIncomeTaxRateReconciliationOwnershipChangePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzgtMS0xLTEtNTU2NzY_5aa53273-3ae4-40d8-8d9c-e8e50d500fa7"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzgtMy0xLTEtNTU2NzY_a02cd97a-e0b9-4005-a7bf-b0a108007236"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzktMS0xLTEtNTU2NzY_579abc2e-3ed8-4c21-b701-7b551d3d2f2c"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzktMy0xLTEtNTU2NzY_edb6d11e-c38b-43b8-bb74-e6afae6836ef"
      unitRef="number">0.021</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEwLTEtMS0xLTU1Njc2_5c1dbd4d-012c-4161-b4b9-db0013960591"
      unitRef="number">0.000</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEwLTMtMS0xLTU1Njc2_2e4facd0-cfef-4994-bae6-23861886eace"
      unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzExLTEtMS0xLTU1Njc2_e91cea6f-3d8a-4cc3-8152-5f22423cd13b"
      unitRef="number">-0.281</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzExLTMtMS0xLTU1Njc2_22b39fdf-653f-44ed-a183-909abe99c2c2"
      unitRef="number">2.403</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEyLTEtMS0xLTU1Njc2_33927bbd-06e1-4f65-a003-da1e15091611"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90YWJsZTo3ZWEzZDA4NmY1ZjA0YjU0OWIzZjliN2IyMjQ3M2IxYy90YWJsZXJhbmdlOjdlYTNkMDg2ZjVmMDRiNTQ5YjNmOWI3YjIyNDczYjFjXzEyLTMtMS0xLTU1Njc2_ac4d3348-12eb-49c9-acbc-fc6794cbdc5e"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i29e3f12dc3c148188c3b9a72081bb52a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzY5Mw_50d483c4-f2e0-426e-8a94-e6ee4763b42a"
      unitRef="usd">25460000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i71199acae9bc42239b72a1e18ce921fd_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzcwMA_2b833a2e-ec4e-4e45-9d74-0bb283925e4e"
      unitRef="usd">25414000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i29e3f12dc3c148188c3b9a72081bb52a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzczMA_50d483c4-f2e0-426e-8a94-e6ee4763b42a"
      unitRef="usd">25460000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i9695ea37c9b341f2b0c620593bc7e168_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzEwMTQ_de0db44c-0286-4ba2-ab22-5bd4f484b468"
      unitRef="usd">417000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i51098c3d74424991ace97eec86e2af91_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzEwMjE_974799fb-55f1-4710-b90b-fcaa2a084eba"
      unitRef="usd">312000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzExOTE_55cfb6f4-3da4-434e-ae72-18d3c6f9e5c7"
      unitRef="usd">132000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ic2ea7b0f73f04c4e8da1cb74fe36b35c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzU0OTc1NTgxODk3OQ_55cfb6f4-3da4-434e-ae72-18d3c6f9e5c7"
      unitRef="usd">132000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM1OTk_211215e2-846f-46ac-ada8-31b7bca1f2d9"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM1OTk_5d4c4ff0-76f1-410a-954c-46d58e8212e7"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <yten:ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzM2Nzc_834b09bb-5a57-4d93-9d6a-4561061006ed"
      unitRef="usd">0</yten:ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1NTk_1d405195-2484-4ba1-a856-e13cc29dd1e2"
      unitRef="usd">1081000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNDgvZnJhZzo2NzcyZmI2MjUyYjQ0ZmRhODk4NzQwZmQ1NmFiZjg3OS90ZXh0cmVnaW9uOjY3NzJmYjYyNTJiNDRmZGE4OTg3NDBmZDU2YWJmODc5XzQ1NjY_30672211-33df-4b46-b4bf-e507979343ff"
      unitRef="usd">1032000</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzc0NQ_093c5ca2-2422-42e7-bf31-42be80f66196">Employee BenefitsThe Company maintains a 401(k) savings plan in which substantially all of its regular U.S. employees are eligible to participate.  Participants may contribute up to 60% of their annual compensation to the plan, subject to eligibility requirements and annual IRS limitations.  The Company's plan provides for a matching contribution in common stock of up to 4.5% of a participant's total compensation dependent upon the level of participant contributions made during the plan year. Pursuant to this plan, the Company issued 36,706, and 13,611 shares of common stock during the years ended December&#160;31, 2022, and December&#160;31, 2021, respectively, and recorded $133, and $112, respectively, of related expense.  Company contributions are fully vested upon issuance.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzE5Mg_7a4502cc-9653-46b6-9ca0-6ddbc70ce7a9"
      unitRef="number">0.60</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzM4Mw_2c2d654e-23fd-4270-8e40-5f3a10d9ebbb"
      unitRef="number">0.045</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzU0Nw_6ed26295-c24d-4c9a-a307-0ad9896e5c54"
      unitRef="shares">36706</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzU1NQ_9ffc1c2a-09df-4cee-9c6a-078377abc4ca"
      unitRef="shares">13611</us-gaap:StockIssuedDuringPeriodSharesEmployeeBenefitPlan>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzY0Mw_eebad91e-37ae-4771-922c-1e3543de8e26"
      unitRef="usd">133000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTEvZnJhZzpjZTNkODE0MjU5ZTk0Zjg1YjYyMjE4OTVlZGU2MWJjZC90ZXh0cmVnaW9uOmNlM2Q4MTQyNTllOTRmODViNjIyMTg5NWVkZTYxYmNkXzY1MQ_3a3e31cc-3bd6-44be-b6bb-4fbc830744a1"
      unitRef="usd">112000</us-gaap:DefinedContributionPlanCostRecognized>
    <yten:EnergyGrantDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE5NzQ_35283d3d-918e-4df2-847c-41577afd83e0">Government Research Grants&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Research Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 26, 2021, YOI received a research grant through the Industrial Research Assistance Program ("IRAP") administered by National Research Council Canada ("NRC").  The objective of the grant was to provide financial research assistance to innovative, early-stage small and medium-sized enterprises.  Under the terms of the agreement, NRC agreed to contribute up to a maximum of $39 for payroll costs incurred by YOI during the period December 20, 2020 - March 13, 2021.  During the first quarter of 2021, YOI submitted claims for eligible payroll costs and recognized grant revenue for the full amount of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;U.S. Research Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2018, the Company entered into a sub-award with Michigan State University ("MSU") to support a Department of Energy ("DOE") funded grant entitled "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;A Systems Approach to Increasing Carbon Flux to Seed Oil.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;"  The Company's participation under this five-year grant has been awarded incrementally on an annual basis with the first year commencing September 15, 2017.  Total funding for this sub-award in the amount of $2,957 was appropriated by the U.S. Congress through the final contractual year ending in September 2022.  During the years ended December&#160;31, 2022 and December&#160;31, 2021, Yield10 recognized grant revenue of $450 and $575, respectively, from this sub-award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, final proceeds of $60 remain to be earned from the MSU sub-award.  During June 2022, the parties amended the sub-award to extend its termination date to September 14, 2023, allowing Yield10 time to utilize the remaining grant funds.&lt;/span&gt;&lt;/div&gt;</yten:EnergyGrantDisclosureTextBlock>
    <yten:ResearchGrantMaximumPayrollCostReimbursement
      contextRef="i9843252c42d74447b91e88027db863ce_I20210226"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzQ0Ng_abbf6666-175a-4065-991f-9c6515bde59d"
      unitRef="usd">39000</yten:ResearchGrantMaximumPayrollCostReimbursement>
    <yten:GovernmentGrantTerm
      contextRef="i51fd40cc2e254ece8789b8a8cd184ae8_D20170915-20170915"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE5ODA_97271af6-270b-422f-b1b7-443642e2e692">P5Y</yten:GovernmentGrantTerm>
    <yten:GovernmentGrantCumulativeAmountAwarded
      contextRef="i65d3bb815986434388d03c0031f92093_I20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE0ODk_6de153cc-70af-43bc-918c-7706d967b48e"
      unitRef="usd">2957000</yten:GovernmentGrantCumulativeAmountAwarded>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i700069e2fa634d1189b702db4b2c4eaa_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE2Njc_38599f75-e43d-4e3d-a22f-7be3f35587de"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6dc4ad390504593af4a7847e1ed85a6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE2NzQ_9b0e55a2-2e6f-4694-9134-5426e65807fa"
      unitRef="usd">575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i9f30c8f754de4a0f87018176ab9201bb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTQvZnJhZzo0ZDVjMDU4MWZjN2E0MzY2YTMxZmQyMGM2NmNmMTg1Ny90ZXh0cmVnaW9uOjRkNWMwNTgxZmM3YTQzNjZhMzFmZDIwYzY2Y2YxODU3XzE3MzU_9815a21d-4fee-457c-911e-6ee2ff2c3c7b"
      unitRef="usd">60000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90ZXh0cmVnaW9uOmNlMzk2ZDdkZTU3NTRlNTNiNmI4NDRmOWY0MWJmMTU0XzI2Mw_d686a474-c1cf-4919-9ebd-b2d33ac89703">Geographic Information&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below.  Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90ZXh0cmVnaW9uOmNlMzk2ZDdkZTU3NTRlNTNiNmI4NDRmOWY0MWJmMTU0XzI1OA_9499fd8f-7216-4e8d-b926-4003b0b5b8c2">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The geographic distribution of the Company's revenues and long-lived assets are summarized in the table below.  Foreign revenue is based on the country in which the Company's subsidiary that earned the revenue is domiciled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Identifiable long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib809cccb2c294bd5843cf6785af9651f_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItMi0xLTEtNTU2NzY_670b3877-e131-4065-a656-65e0320cbe42"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id239db0d46964587ab76bc81df6f1ee4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItNC0xLTEtNTU2NzY_98d68e2c-4cd8-4003-a6ed-bb3beb9fedcb"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic8ed864be1c04cbca5272439e51ebf52_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzItNi0xLTEtNTU2NzY_4261c8e9-3b49-404e-8201-23e9c8615eed"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i3432e814c7b446a9bbe66a61846e2cde_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtMi0xLTEtNTU2NzY_49301d59-b292-4d96-8a8d-b60b29260cb0"
      unitRef="usd">671000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0bd17402842448b7b9f9be98aca430e4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtNC0xLTEtNTU2NzY_35eeeb78-a08e-441e-873a-e5348b7eef51"
      unitRef="usd">104000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i966a0b1f35af427492d1da0e13191558_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzMtNi0xLTEtNTU2NzY_6fa86461-2a86-4bd3-90e5-6ef967434493"
      unitRef="usd">775000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bc505e998514513905d81d0f376c451_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtMi0xLTEtNTU2NzY_2a2c1714-14bd-4c08-88b3-a9fefc553f0c"
      unitRef="usd">575000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4d4d7b016184bf3ab8c1d7180e6719f_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtNC0xLTEtNTU2NzY_fcda82dc-9d65-4004-8f58-4adfd4f44da6"
      unitRef="usd">39000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3182629b0bab4d00be6bc9a3a8bd468a_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzUtNi0xLTEtNTU2NzY_f8b99d64-0294-4a0f-b785-3a701b1c16e6"
      unitRef="usd">614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i09214b6a6ff746c2aa27601f31735dc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtMi0xLTEtNTU2NzY_9c916095-b6b7-423d-8605-a925301347b1"
      unitRef="usd">821000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i629b7830786c41b6bda1598354d3a5b4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtNC0xLTEtNTU2NzY_534964d7-58bd-48bd-938d-c378a7c97ff3"
      unitRef="usd">69000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="if6e4e205f139470c9d01730aa2cae2bc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNTcvZnJhZzpjZTM5NmQ3ZGU1NzU0ZTUzYjZiODQ0ZjlmNDFiZjE1NC90YWJsZTo1OWIzN2FhZTFkN2Q0Y2NiYTJhNGQ2M2RjMGViMDYxNi90YWJsZXJhbmdlOjU5YjM3YWFlMWQ3ZDRjY2JhMmE0ZDYzZGMwZWIwNjE2XzYtNi0xLTEtNTU2NzY_7ea57734-d789-44e9-9ca3-b6647a3ab7cd"
      unitRef="usd">890000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEzMjE_ad09d2a6-61ff-4fcf-bb80-9d08f3df81ee">Related Party TransactionDuring 1999, Yield10 entered into a technology sublicense agreement with Tepha, Inc. ("Tepha"), a privately held related party engaged in the development of medical products.  Yield10 received 648,149 shares of Series A Convertible Preferred Stock of Tepha ("Tepha Shares") during 2002 as consideration for outstanding license payments due to Yield10 totaling $700.  During 2005, the Company determined the value of the Tepha Shares was impaired resulting in their write off through a charge to other income (expense).  In May 2021, the board of directors of Tepha approved and authorized the merger of Tepha with Becton Dickinson Global Holdings, Inc. ("Becton Dickinson") and on July 26, 2021, Yield10 received cash consideration of $700 in exchange for the surrender of its Tepha Shares upon the closing of the sale of Tepha to Becton Dickinson.  As a result, the Company recorded the $700 as a gain on investment in related party within other income (expense) during the year ended December&#160;31, 2021.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InvestmentOwnedBalanceShares
      contextRef="i8415c21be2b24e3d8bf42091cf9a338e_I20021231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzA1Nzk_ac4cee36-4b61-46f6-a0dd-f0634cf9533d"
      unitRef="shares">648149</us-gaap:InvestmentOwnedBalanceShares>
    <yten:LicensePaymentsReceivable
      contextRef="i8415c21be2b24e3d8bf42091cf9a338e_I20021231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzA3NDI_046ac775-2f8c-4eb4-9573-563e3e674aae"
      unitRef="usd">700000</yten:LicensePaymentsReceivable>
    <yten:GainOnRelatedPartyInvestment
      contextRef="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzExMTY_94cd11e2-da45-43f8-8af7-9673fe11ce21"
      unitRef="usd">700000</yten:GainOnRelatedPartyInvestment>
    <yten:GainOnRelatedPartyInvestment
      contextRef="ifa8a3a89635641c697f91acc24140d39_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xNjAvZnJhZzpkNjRiMzVhYmFiY2M0MDY0ODE0MTRmNjUzMjEzYTA1My90ZXh0cmVnaW9uOmQ2NGIzNWFiYWJjYzQwNjQ4MTQxNGY2NTMyMTNhMDUzXzEwOTk1MTE2MzEyNjg_94cd11e2-da45-43f8-8af7-9673fe11ce21"
      unitRef="usd">700000</yten:GainOnRelatedPartyInvestment>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i153a6dac627346fbada7e736d265bdcf_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM18yNzQ4Nzc5MDcyOTYz_995724ce-7189-4ac0-ae4c-91388b1947fb">Subsequent Event&lt;div style="margin-bottom:9pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;At-The-Market ("ATM") Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January&#160;24, 2023, the Company entered into an Equity Distribution Agreement (the "Sales Agreement") with Maxim Group LLC ("Maxim") under which the Company may offer and sell shares of its common stock, $0.01 par value per share, having an aggregate offering price of up to $4,200 from time to time through Maxim, acting exclusively as the Company's sales agent (the "Offering").  On January&#160;24, 2023, the Company filed a prospectus supplement with the Securities and Exchange Commission in connection with the Offering under its existing Registration Statement on Form S-3 (File No 333-254830), which was declared effective on April 2, 2021.  The Company intends to use the net proceeds of the Offering primarily for working capital and general corporate purposes.  Maxim will be entitled to compensation at a fixed commission rate of 2.75% of the gross sales price per share sold.  In addition, the Company agreed to reimburse Maxim for its costs and out-of-pocket expenses incurred in connection with its services, including the fees and out-of-pocket expenses of its legal counsel.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is not obligated to make any sales under the Sales Agreement and no assurance can be given that the Company will sell, or the dates on which any such sales will take place.  The Sales Agreement will continue until the earliest of (i) twelve (12) months following the date of the Sales Agreement, (ii) the sale of shares thereunder having an aggregate offering price of $4,200, and (iii) the termination by the Company upon the provision of ten (10) days written notice or by Maxim immediately upon written notification to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From January&#160;24, 2023 through  March&#160;14, 2023, the Company issued 94,665 shares of common stock in connection with the ATM at per share prices between $3.03 and $4.08, resulting in net proceeds to the Company of approximately $290 after subtracting sales commissions.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i201dadb72c254a7c8f4f4491ef87c2ed_I20230124"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM18yNzQ4Nzc5MDcyOTY1_74a2357e-aa49-48db-83d2-812cc1f571a9"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <yten:SaleOfStockMaximumAggregateOfferingPrice
      contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4NTM_6ef693c2-37a0-4746-a63f-c0c923e70bf1"
      unitRef="usd">4200000</yten:SaleOfStockMaximumAggregateOfferingPrice>
    <yten:SaleOfStockCommissionRate
      contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4NzE_1fc62b1e-93d4-406c-a6b6-c5f6a9ce55fe"
      unitRef="number">0.0275</yten:SaleOfStockCommissionRate>
    <yten:SaleOfStockMaximumAggregateOfferingPrice
      contextRef="ia76d15d3af394786b55ad1ebd2e4f0c2_D20230124-20230124"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY4ODA_6ef693c2-37a0-4746-a63f-c0c923e70bf1"
      unitRef="usd">4200000</yten:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTY5MjM_2ccbe65a-4b7f-431f-9b4d-c825d54754ce"
      unitRef="shares">94665</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="ieb4322ccfe3e4eb29b27ffe467b4d129_I20230314"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcwOTI_c5bac214-b18a-44dc-8dc0-0a8e12a95817"
      unitRef="usdPerShare">3.03</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i9e7eed8de0164fab84eedcfec07eed0a_I20230314"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcxMDA_802858cd-0cbb-45af-b16c-05830c54098e"
      unitRef="usdPerShare">4.08</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i3778a066508e4c11b57303c9c650a62a_D20230124-20230314"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmMwMjYwNGZiMDIxOTQ1M2FhNTRiMjQ2ZGY3YTM5MTI2L3NlYzpjMDI2MDRmYjAyMTk0NTNhYTU0YjI0NmRmN2EzOTEyNl8xMzU0L2ZyYWc6MzE4OTgxZGE3MTA1NGMwMDgxOWQ4YjUxODhlOTk0MTMvdGV4dHJlZ2lvbjozMTg5ODFkYTcxMDU0YzAwODE5ZDhiNTE4OGU5OTQxM181NDk3NTU4MTcyNDk_0bc0de33-e5bb-401d-9fac-5cdfb452a047"
      unitRef="usd">290000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>81
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MP\)T5I VP.P?A-"GB3V@Z]7I7U!+ P04    " "U@6Y6GE5%Y\@%  #D%P
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MO'K<T 0P:P'XON; XON!ONAM+O;G_P)02P,$%     @ M8%N5IOAM$T  P
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M_$22-R3+S*8^85(=$<QMK$YQP'6 >CYE3#XW]#FA/!<&_P%02P,$%     @
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M++B@6>TL&61)7EWQ6YV( P?H]SB@V@&=.@QZ'-S:P2T#K9B58<VQP-,QHSO
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MH5&DIO<-0;!A=)NH+W,M44]#P/-/:6JLW)[^!UNE@V:I>Y0;F50F6<O+[WQ
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MDF_EDL]4*/ "O%]X8+S<L(+Q=Z2+_P)02P,$%     @ M8%N5@HTAFC&&
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M"$^R01R@)+'\"I$D:?B134(+$%H-O^'!(.;(DX(P G402T!O-!PQ1S!PL(V
M<$2?&B(B76*1%52J1,+0DT8PSD@N,D/P6XL(]+>IK9JXHZU0EF#UT(TY#(I2
MUO'//C+K%2'QKH/@.-/#. O P*M:CF0@JR6!I5LF/', *[ #H99$'4Z1T,FC
MJ&VP$DLR%$P:*$2MOZH:,321A\+F_3#_3M,IBZ&EG#IYH9;&(WNK)-GBP'$#
MKP_<2^-:%!FT@PT]($$Y^7^X/S*$N42-='X4$UKFN<62+'SZHZM6T8!/<C@A
ME1?RU$4$M>0K'OG0Q2=,(^@)I['*$!V+ZH_.<=!$U/4[HL<F8=_H;N.#OI)
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MTI1@"C37E)HI) C!GE^+E_FDW=>D-D<@M;:3\QC#K8%_]N+7+?X(27_ C&Q
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MN.>T'1;!C.<)WJOE-UCK.;-\H4I,\63+,O>,*H:Y096NP31/A2S?_&6]#UN
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M?Q70-H'69TKA9F(+5/^I_A]02P,$%     @ M8%N5KMG5\,:!@  QQ   !D
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M!(?*A O@_4*IVM_@!NUW]*O_ E!+ P04    " "U@6Y6EMHB"FD'   F$0
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M-1,@5W=HBYN24%</:+1.B61X-DU:W*Y@@?8])4Z<+A9B-I\!:I-]82BP,VA
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M>&]*_KE6J :6%N#YRAC?7)""]E^^B_\"4$L#!!0    ( +6!;E;EU@>$<@,
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M4?1BP/L;Y^@XD0"G=WGY+U!+ P04    " "U@6Y6FE%SL"8%   C"P  &0
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M'0]/CA)AXY4LOGC3A&M09CPN5>%QB5LL63; ^L(8OWGA!/V]^/Q?4$L#!!0
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MMVNRYVUO>7%O._0UTP67!@0N"1KU1L, =-OUVH55M>\TJ;+4M_RTI!\%:N=
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M1J>]X>B,0J60 ?&Z9Z^QNJ K9U?LHYX;IAE:GKT$=1]=\2!VB>..*]TG_^R
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M_'B<D>_>QVX379/>I+F+>.'2LL)?"O9B@-\7SL7=1B[8_TF9_@M02P,$%
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MU;2N?7DCW,C,*KO1ZUJO=)'7;795%*:K6UVOLP^FTH563?; _W7Z_&%+6P/
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MC]?$KMN\PNG&I.?KH&8'<!CX1\*9U!TTXM\3<R16OU1PC*2=&XH;R7Y4FB#
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M;FBE[9V& \J*!(4"-YAFDBI3KWEYGR LDK6)/_?!1!7(>M(/63_OL9DX,\5
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MO5;>YR<?6K/C=^@M3=N:+?^Y(251%@_0[RM#&83[@ W"6Q5?_B]02P,$%
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M<FMS:&5E=',O<VAE970S-RYX;6R-56UOTS 0_BNG,/$B0?/2=ANCK;2-MWU
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MS^\-<Y)3!4$I"HG5(#P%/+9J*W50[VUB91U](' U_Z<M0X*QU]QT_2Y"/W^
MM_EX-+[*XNVAROA@OOQ1_2K=1AD4&M8,2\ZO&.^Z\>\"LDT8N94E'N"PK/C&
M .<+>']M+3T'?HKW=U#^'U!+ P04    " "U@6Y6ZP$<V;$"   M"   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6RM5EUOVC 4_2M65DVMU#4A7_T8
M1&K)INUA$BKM]C#MP9@;8M6QJ6V@^_>SG30+(V6HZDOBCWL.]YP;7S/<"/F@
M2@"-GBK&U<@KM5Y>^;XB)518G8DE<+-3"%EA;:9RX:NE!#QWH(KY81"D?H4I
M][*A6YO(;"A6FE$.$XG4JJJP_'T#3&Q&WL![7KBEBU+;!3\;+O$"IJ#OEQ-I
M9G[+,J<5<$4%1Q**D7<]N,H3&^\"OE/8J,X8624S(1[LY.M\Y 4V(6! M&7
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M=HGTTXS0"V A/8*F3M#4RW35"D94*\#FK2#/9BQW*?+RO#-M,Z=R=J#BSCY
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MRF@),9'G? 6)_C+G(B9*3\7"E2L!9):!8N;ZGA>X,:&)$PZR=_<B'/!4,9K
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M#<($Z.]SSM7KQ/1W93\?_@502P,$%     @ M8%N5A]Q$>:T!0  VRT  !D
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MG!I006UW- KL I/2BB,SMN!QQ-:2DA(6'(EU46#^>@V4;:>68[T-W)-5+O6
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M/%1X7K]'=4>RRESI2R;5 V&:N7K"@>L -9\Q)M\Z^I5H_Q3$_P!02P,$%
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M!ZP/H/W*&#P8_H#Q*<O_ E!+ P04    " "U@6Y64/FYG,X$  !#'@  &0
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M5303M38?5+ZM9_&\R97*-_7B6L8K650%]/>W>:Z>/U05[*?+O?X?4$L#!!0
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M6-)8+B>.TPFY!.DE\&V;GMZH^0G%&_CH$8'#B%\4$32-X/+\QZ,'/GZX !^
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M&X(#PE2 O+ZB5.Q/U V*'T<L_@=02P,$%     @ M8%N5C-:H-IJ P  . X
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M>[Q*A7I@1J,U7*$Y$H_K.R9;9NV2X!P1CBD!#"W'QL2^FMI:H$?\P&C+&_=
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MBY@:(/N7E(J7AJJ:ZBHY^@M02P,$%     @ M8%N5DJ;]:$F P  , H  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3<N>&ULK59M;]HP$/XK5E9-K53("Q!:
M!I$*;-JD5>U*NWXVR4&L)C:S'6C__6PGI%#<C$G]DMC.W>/G.>=\-]PP_B12
M (F>\XR*D9-*N1JXKHA3R+%HLQ50]67!>(ZEFO*E*U8<<&*<\LP-/"]T<TRH
M$PW-VBV/AJR0&:%PRY$H\ASSES%D;#-R?&>[<$>6J=0+;C1<X27,0#ZL;KF:
MN35*0G*@@C"*."Q&SI4_F/B>=C 6OPELQ,X8:2ESQI[TY$<R<CS-"#*(I8;
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M5/V"&::JI0.N#=3W!6-R.]$;U$UB]!=02P,$%     @ M8%N5LF.L?N!!
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M\^("]?N<,;D]*1(TNW&3[U!+ P04    " "U@6Y66?Z"/]P&   H(0  &0
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M JX?4/<?&)//)[J =B=\]@]02P,$%     @ M8%N5N7+O82A P  ^A(  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULK5A=CYLX%/TK%JU6K=0&3!*2
MS"9(G4QW.P^51C.=]MD#-P$5;-9VDEEI?WQM8/A(B#M9^27!YM[C<^P#OGAY
M8/RG2  D>LXS*E9.(F5QY;HB2B G8L0*H.K.AO&<2-7D6U<4'$A<)N69ZWM>
MX.8DI4ZX+/ON>+AD.YFE%.XX$KL\)_S?:\C88>5@YZ7C/MTF4G>XX;(@6W@
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M=$Y[*CU>-,?%1+*%:1?OF53-IQFFZG\"N#90SV>,R<U$.ZC^4,*_4$L#!!0
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M] LLJL.BZD;QO#P->>9*\;2\W *+0)@.^O<UY^KUQ@S0'-DM_P-02P,$%
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M-ZR&>0,&E@<R_=Y:X[N-5\C+=8#MZ4L5@LT4KT1LIOA: Q)>-V!D67BWL3S
MP'8!JQW('\X#-17F) GL*N8->X)Q),LP!&HQ7*-IBJQ."I_P_F!/29)D61@!
M+.P@23 $GD8<P1R !PQ)$G<.[IU'\?J<BC>_[XR> %!+ P04    " "U@6Y6
MEXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S
M9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X
M 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO
M3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)
MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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MU-TAGPW__YJ] 5!+ 0(4 Q0    ( +6!;E8'04UB@0   +$    0
M      "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ M8%N5@=
M@;GN    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ M8%N5IE<G",0!@  G"<  !,              ( !S $
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "U@6Y6SN.I @<(  #
M+P  &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ M8%N5IQEUNPU @  MP4  !@              ("!2A
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( +6!;E:>547G
MR 4  .07   8              " @;42  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " "U@6Y6F^&T30 #   C"@  &
M@(&S&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ M8%N
M5OV#^F?!!   5A0  !@              ("!Z1L  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( +6!;E:M=\,Z.P,  )0)   8
M      " @> @  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" "U@6Y6&H?FA+\&  "8'   &               @(%1)   >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ M8%N5C<"8Z(J!P  03,  !@
M             ("!1BL  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4
M Q0    ( +6!;E96C,]27 (  -$$   8              " @:8R  !X;"]W
M;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " "U@6Y6_4[R@2L+  !3
M&@  &0              @($X-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM
M;%!+ 0(4 Q0    ( +6!;E8*-(9HQA@  *I)   9              " @9I
M  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ M8%N5H&T
M&VRY @  LP8  !D              ("!EUD  'AL+W=O<FMS:&5E=',O<VAE
M970Q,BYX;6Q02P$"% ,4    " "U@6Y6NV=7PQH&  #'$   &0
M    @(&'7   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M +6!;E897(ZGO@(  #4&   9              " @=AB  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ M8%N5HS^" *8 @  P@4  !D
M             ("!S64  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " "U@6Y69N^G/^@)   P&0  &0              @(&<:   >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( +6!;E8XRN0'Y 0
M &8,   9              " @;MR  !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ M8%N5O0\>QY,!0  F@P  !D              ("!
MUG<  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " "U@6Y6
M]28\W1@+  !3'P  &0              @(%9?0  >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( +6!;E:6VB(*:0<  "81   9
M      " @:B(  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ M8%N5IKD[HQV"@  \1L  !D              ("!2)   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " "U@6Y6Y=8'A'(#  "C!P
M&0              @('UF@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( +6!;E::47.P)@4  ",+   9              " @9Z>  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ M8%N5N"3-=#8
M @  A@8  !D              ("!^Z,  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " "U@6Y6XAKHO>X#  "P"   &0
M@($*IP  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( +6!
M;E83V][-;@4  "(,   9              " @2^K  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ M8%N5F56LM\4&0  85$  !D
M         ("!U+   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " "U@6Y6;.1%\< $  "Y"P  &0              @($?R@  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( +6!;E9J3\4)Q0(  ,4&
M   9              " @1;/  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ M8%N5@,;BQN- P  10D  !D              ("!$M(
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " "U@6Y6EK _
MAE4#  !Y!P  &0              @('6U0  >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( +6!;E;A)U9LJ0(  ,8%   9
M  " @6+9  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MM8%N5BAN8A[P P  5@D  !D              ("!0MP  'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " "U@6Y61<@5D_ $  "?#   &0
M            @(%IX   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( +6!;E;78CPF1@,  ,@'   9              " @9#E  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ M8%N5A]I9,)/!0
MJ X  !D              ("!#>D  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " "U@6Y6VU^V&_,"  #&!@  &0              @(&3
M[@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( +6!;E9>
M$#C!10(  (\$   9              " @;WQ  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ M8%N5NL!'-FQ @  +0@  !D
M     ("!.?0  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( +6!;E8?<1'FM 4  -LM   9              "
M@=\# 0!X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ M8%N
M5N?+-SW! P  /1(  !D              ("!R@D! 'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " "U@6Y6&&@9H= "   @"   &0
M        @('"#0$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( +6!;E:R[,3J&@,  +,+   9              " @<D0 0!X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ M8%N5N><V_LO @  U@0
M !D              ("!&A0! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " "U@6Y64/FYG,X$  !#'@  &0              @(& %@$
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( +6!;E9#C6@4
M=0,  &0/   9              " @84; 0!X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ M8%N5FE^7 \I P  ;PT  !D
M ("!,1\! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " "U
M@6Y614H.1$\*   Z=P  &0              @(&1(@$ >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( +6!;E9<--_GL 4  "@A   9
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M970U-RYX;6Q02P$"% ,4    " "U@6Y6R8ZQ^X$$  "9&P  &0
M    @($P0 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M +6!;E99_H(_W 8  "@A   9              " @>A$ 0!X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ M8%N5HRM."HU!   ^14  !D
M             ("!^TL! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " "U@6Y6%YY)&" #  #("   &0              @(%G4 $ >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( +6!;E;7%P(5I 0
M !4?   9              " @;Y3 0!X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ M8%N5N7+O82A P  ^A(  !D              ("!
MF5@! 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " "U@6Y6
M"E"[\0\#  "M#   &0              @(%Q7 $ >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( +6!;E; %!N#6@0  +X;   9
M      " @;=? 0!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ M8%N5MIE7Z,E P  [!$   T              ( !2&0! 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " "U@6Y6EXJ[',     3 @  "P
M@ &89P$ 7W)E;',O+G)E;'-02P$"% ,4    " "U@6Y6*D.NS",%  #'*@
M#P              @ &!: $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MM8%N5K5Q8'P6 @  JB8  !H              ( !T6T! 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ M8%N5M(T9!3L 0  !R8  !,
M             ( !'W ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     $D
,20#V$P  /'(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>145</ContextCount>
  <ElementCount>327</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/PropertyandEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LicenseAgreements</Role>
      <ShortName>License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Capital Stock and Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CapitalStockandWarrants</Role>
      <ShortName>Capital Stock and Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Government Research Grants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/GovernmentResearchGrants</Role>
      <ShortName>Government Research Grants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/GeographicInformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/RelatedPartyTransaction</Role>
      <ShortName>Related Party Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/Investments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/PropertyandEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/PropertyandEquipmentNet</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/AccruedExpenses</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Capital Stock and Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CapitalStockandWarrantsTables</Role>
      <ShortName>Capital Stock and Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/CapitalStockandWarrants</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/StockBasedCompensation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/GeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/GeographicInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/InvestmentsDetails</Role>
      <ShortName>Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/InvestmentsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/PropertyandEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/PropertyandEquipmentNetTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/AccruedExpensesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/CommitmentsandContingencies</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - License Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LicenseAgreementsDetails</Role>
      <ShortName>License Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/LicenseAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Capital Stock and Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails</Role>
      <ShortName>Capital Stock and Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails</Role>
      <ShortName>Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Leases - Maturity Analysis of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturity Analysis of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Leases - Quantitative Disclosure of Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails</Role>
      <ShortName>Leases - Quantitative Disclosure of Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/IncomeTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Income Taxes - Details Textual (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails</Role>
      <ShortName>Income Taxes - Details Textual (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/EmployeeBenefits</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Government Research Grants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/GovernmentResearchGrantsDetails</Role>
      <ShortName>Government Research Grants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/GovernmentResearchGrants</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/GeographicInformationDetails</Role>
      <ShortName>Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/GeographicInformationTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Related Party Transaction (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/RelatedPartyTransactionDetails</Role>
      <ShortName>Related Party Transaction (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/RelatedPartyTransaction</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="yten-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Subsequent Event (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.yield10bio.com/role/SubsequentEventDetails</Role>
      <ShortName>Subsequent Event (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.yield10bio.com/role/SubsequentEvent</ParentRole>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 -  yten-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="yten-20221231.htm">yten-20221231.htm</File>
    <File>yten-20221231.xsd</File>
    <File>yten-20221231_cal.xml</File>
    <File>yten-20221231_def.xml</File>
    <File>yten-20221231_lab.xml</File>
    <File>yten-20221231_pre.xml</File>
    <File>yten-20221231x10kexh1018.htm</File>
    <File>yten-20221231x10kexh231.htm</File>
    <File>yten-20221231x10kexh311.htm</File>
    <File>yten-20221231x10kexh312.htm</File>
    <File>yten-20221231x10kexh321.htm</File>
    <File>yten-20221231x10kexh41.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>yten-20221231_g1.jpg</File>
    <File>yten-20221231_g2.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="583">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>87
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "yten-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 583,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 145,
   "dts": {
    "calculationLink": {
     "local": [
      "yten-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "yten-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "yten-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "yten-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "yten-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "yten-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 506,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 5
   },
   "keyCustom": 35,
   "keyStandard": 292,
   "memberCustom": 14,
   "memberStandard": 32,
   "nsprefix": "yten",
   "nsuri": "http://www.yield10bio.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.yield10bio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Nature of Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.yield10bio.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.yield10bio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.yield10bio.com/role/PropertyandEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Accrued Expenses",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.yield10bio.com/role/AccruedExpenses",
     "shortName": "Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.yield10bio.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - License Agreements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.yield10bio.com/role/LicenseAgreements",
     "shortName": "License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Capital Stock and Warrants",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.yield10bio.com/role/CapitalStockandWarrants",
     "shortName": "Capital Stock and Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.yield10bio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.yield10bio.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.yield10bio.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.yield10bio.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Employee Benefits",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.yield10bio.com/role/EmployeeBenefits",
     "shortName": "Employee Benefits",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "yten:EnergyGrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Government Research Grants",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.yield10bio.com/role/GovernmentResearchGrants",
     "shortName": "Government Research Grants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "yten:EnergyGrantDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Geographic Information",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.yield10bio.com/role/GeographicInformation",
     "shortName": "Geographic Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Related Party Transaction",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.yield10bio.com/role/RelatedPartyTransaction",
     "shortName": "Related Party Transaction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Subsequent Event",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.yield10bio.com/role/SubsequentEvent",
     "shortName": "Subsequent Event",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "27",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.yield10bio.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.yield10bio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.yield10bio.com/role/PropertyandEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Accrued Expenses (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.yield10bio.com/role/AccruedExpensesTables",
     "shortName": "Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Capital Stock and Warrants (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.yield10bio.com/role/CapitalStockandWarrantsTables",
     "shortName": "Capital Stock and Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.yield10bio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.yield10bio.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.yield10bio.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Geographic Information (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.yield10bio.com/role/GeographicInformationTables",
     "shortName": "Geographic Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Reconciliation of Cash, Cash Equivalents and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i53f6338f531042b4a04410a3879ac996_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i53f6338f531042b4a04410a3879ac996_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Common Stock Excluded From Calculation of Dilutive Shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "yten:AccountsReceivableTradeAndUnbilledReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Investments (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.yield10bio.com/role/InvestmentsDetails",
     "shortName": "Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i2ecc835c25a3427287cfa2313952f908_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
     "shortName": "Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.yield10bio.com/role/AccruedExpensesDetails",
     "shortName": "Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GuaranteeObligationsMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "yten:LicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - License Agreements (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.yield10bio.com/role/LicenseAgreementsDetails",
     "shortName": "License Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i862cdb1a954e4ab887a3e4c49698e99c_D20180901-20180930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "yten:LicenseAgreementTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Capital Stock and Warrants - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
     "shortName": "Capital Stock and Warrants - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "yten:ClassOfWarrantOrRightExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "yten:CostOfRevenueResearchAndDevelopmentExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails",
     "shortName": "Capital Stock and Warrants - Schedule Of Warrants Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Capital Stock and Warrants - Schedule of Common Stock Reserved For Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "yten:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i8c15250f4a98403bb394595ac0b4d6cd_D20190101-20190101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "yten:SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i027dffbf78374212835464d3640c101d_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i7d4fabacd1754b738011363e69731c36_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i7d4fabacd1754b738011363e69731c36_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions Used for Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i7d4fabacd1754b738011363e69731c36_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "if6e4e205f139470c9d01730aa2cae2bc_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units (RSUs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "if6e4e205f139470c9d01730aa2cae2bc_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Leases - Maturity Analysis of Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturity Analysis of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Leases - Quantitative Disclosure of Lease Costs (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails",
     "shortName": "Leases - Quantitative Disclosure of Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.yield10bio.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i119b882f71fe4a1082a3446bb15acbec_D20160101-20161231",
      "decimals": "0",
      "lang": "en-US",
      "name": "yten:LesseeOperatingLeaseLeaseArea",
      "reportCount": 1,
      "unique": true,
      "unitRef": "sqft",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.yield10bio.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Income Taxes - Details Textual (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails",
     "shortName": "Income Taxes - Details Textual (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Employee Benefits (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.yield10bio.com/role/EmployeeBenefitsDetails",
     "shortName": "Employee Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i9843252c42d74447b91e88027db863ce_I20210226",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "yten:ResearchGrantMaximumPayrollCostReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Government Research Grants (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails",
     "shortName": "Government Research Grants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i9843252c42d74447b91e88027db863ce_I20210226",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "yten:ResearchGrantMaximumPayrollCostReimbursement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Geographic Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.yield10bio.com/role/GeographicInformationDetails",
     "shortName": "Geographic Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i3432e814c7b446a9bbe66a61846e2cde_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "yten:GainOnRelatedPartyInvestment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Related Party Transaction (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.yield10bio.com/role/RelatedPartyTransactionDetails",
     "shortName": "Related Party Transaction (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i8415c21be2b24e3d8bf42091cf9a338e_I20021231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:InvestmentOwnedBalanceShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i966a0b1f35af427492d1da0e13191558_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Subsequent Event (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.yield10bio.com/role/SubsequentEventDetails",
     "shortName": "Subsequent Event (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i201dadb72c254a7c8f4f4491ef87c2ed_I20230124",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i153a6dac627346fbada7e736d265bdcf_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "yten:ChargeForCompanyCommonStockMatch",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i624d1c2db5334d9f8d1c42dd32837b1f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i624d1c2db5334d9f8d1c42dd32837b1f_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "yten-20221231.htm",
      "contextRef": "i856d8c2dac0145bd9218bf6d4cff0e24_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 49,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r640"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r635"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r637",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r633"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r603",
      "r676",
      "r716",
      "r717",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r188",
      "r226",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r247",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r295",
      "r297",
      "r298",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r188",
      "r226",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r243",
      "r247",
      "r287",
      "r288",
      "r289",
      "r290",
      "r292",
      "r293",
      "r295",
      "r297",
      "r298",
      "r670",
      "r671"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r353",
      "r546",
      "r574",
      "r605",
      "r606",
      "r618",
      "r624",
      "r632",
      "r672",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r353",
      "r546",
      "r574",
      "r605",
      "r606",
      "r618",
      "r624",
      "r632",
      "r672",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r249",
      "r548",
      "r619",
      "r630",
      "r667",
      "r668",
      "r673",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r249",
      "r548",
      "r619",
      "r630",
      "r667",
      "r668",
      "r673",
      "r729"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r335",
      "r353",
      "r384",
      "r385",
      "r386",
      "r522",
      "r546",
      "r574",
      "r605",
      "r606",
      "r618",
      "r624",
      "r632",
      "r666",
      "r672",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r335",
      "r353",
      "r384",
      "r385",
      "r386",
      "r522",
      "r546",
      "r574",
      "r605",
      "r606",
      "r618",
      "r624",
      "r632",
      "r666",
      "r672",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": {
     "auth_ref": [
      "r604",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Axis]",
        "terseLabel": "Name of Property [Axis]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": {
     "auth_ref": [
      "r604",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Name of Property [Domain]",
        "terseLabel": "Name of Property [Domain]"
       }
      }
     },
     "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ReportableGeographicalComponentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reportable Geographical Components [Member]",
        "terseLabel": "Reportable Geographical Components"
       }
      }
     },
     "localname": "ReportableGeographicalComponentsMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r250",
      "r251",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r620",
      "r631",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Segment, Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r250",
      "r251",
      "r588",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r620",
      "r631",
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r658",
      "r718"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r9",
      "r629"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails",
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRentCurrent": {
     "auth_ref": [
      "r12",
      "r609"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Rent, Current",
        "terseLabel": "Leased facilities"
       }
      }
     },
     "localname": "AccruedRentCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r62",
      "r156"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r162",
      "r570",
      "r582",
      "r586"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r19",
      "r22",
      "r113",
      "r506",
      "r577",
      "r578",
      "r645",
      "r646",
      "r647",
      "r653",
      "r654",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r4"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r394",
      "r653",
      "r654",
      "r655",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Taxes paid on employees' behalf related to vesting of stock awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r91",
      "r92",
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Offering costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive common stock excluded from the calculation of dilutive shares"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r125",
      "r134",
      "r158",
      "r184",
      "r229",
      "r239",
      "r245",
      "r265",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r298",
      "r299",
      "r438",
      "r440",
      "r463",
      "r629",
      "r670",
      "r671",
      "r720"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r151",
      "r163",
      "r184",
      "r265",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r298",
      "r299",
      "r438",
      "r440",
      "r463",
      "r629",
      "r670",
      "r671",
      "r720"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/InvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/InvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized (Loss)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r260",
      "r277"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/InvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Accumulated Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r56",
      "r259",
      "r277",
      "r564"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/InvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Market Value",
        "verboseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r55",
      "r277"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r45",
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Nature of Business and Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": {
     "auth_ref": [
      "r118",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by project.",
        "label": "Project [Axis]",
        "terseLabel": "Project [Axis]"
       }
      }
     },
     "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r42",
      "r153",
      "r608"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r43",
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.",
        "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "verboseLabel": "Unrestricted cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r37",
      "r42",
      "r44"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of year",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of year",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r37",
      "r115"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise Price (in USD per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of Shares Issuable Upon Exercise of Outstanding Warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r434",
      "r435",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r14",
      "r128",
      "r138"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note\u00a07)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r281",
      "r282",
      "r590",
      "r669"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Total number of common shares reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r653",
      "r654",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r3",
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r3",
      "r629"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock ($0.01 par value per share); 60,000,000 shares authorized at December\u00a031, 2022 and 2021, and 4,944,202 and 4,881,851 shares issued and outstanding at December\u00a031, 2022 and 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Significant components of the net deferred tax asset"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r23",
      "r168",
      "r170",
      "r175",
      "r565",
      "r571"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r627",
      "r664",
      "r665"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r133",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r321",
      "r322",
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Amount remaining to be earned"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current Tax Provision:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r652",
      "r707",
      "r709"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r652",
      "r707"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r412",
      "r422",
      "r652"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r652",
      "r707",
      "r709"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Schedule of investment holdings"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r652",
      "r708",
      "r709"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred Tax Benefit:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r652",
      "r708"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r40",
      "r108",
      "r413",
      "r421",
      "r422",
      "r652"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r652",
      "r708",
      "r709"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r408"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r705"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r105",
      "r706"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r105",
      "r706"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other temporary differences"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r103",
      "r105",
      "r706"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r105",
      "r706"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r409"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred Tax Liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r105",
      "r706"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Depreciation"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r352"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Related expense for common stock issued under the 401(k) savings plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer's matching contribution in common stock as a percentage of a participant's total compensation, percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum contribution by participants under the 401(k) savings plan (as a percent)"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r40",
      "r227"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r358",
      "r388",
      "r389",
      "r391",
      "r396",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r206",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r453",
      "r454",
      "r566",
      "r572",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r176",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r208",
      "r210",
      "r211",
      "r212",
      "r214",
      "r453",
      "r454",
      "r566",
      "r572",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net loss per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r47",
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and Diluted Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Difference between income tax benefit computed at the federal statutory rate and the provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r186",
      "r402",
      "r424"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal income tax at statutory federal rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": {
     "auth_ref": [
      "r424",
      "r704"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent",
        "terseLabel": "Non-deductible equity transactions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "negatedTerseLabel": "Stock compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r704",
      "r710"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Tax credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employee compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period over which unrecognized compensation expense is expected to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r703"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Stock-based compensation expense, net of estimated forfeitures, related to unvested awards not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r74",
      "r147",
      "r172",
      "r173",
      "r174",
      "r189",
      "r190",
      "r191",
      "r194",
      "r202",
      "r204",
      "r215",
      "r269",
      "r320",
      "r392",
      "r393",
      "r394",
      "r417",
      "r418",
      "r452",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r506",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r456",
      "r457",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r300",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r457",
      "r519",
      "r520",
      "r521",
      "r616",
      "r617",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r456",
      "r457",
      "r458",
      "r459",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r300",
      "r337",
      "r342",
      "r457",
      "r519",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted prices in active markets\u00a0for identical assets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r300",
      "r337",
      "r342",
      "r457",
      "r520",
      "r616",
      "r617",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant\u00a0other observable\u00a0inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r300",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r457",
      "r521",
      "r616",
      "r617",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant unobservable inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r300",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r519",
      "r520",
      "r521",
      "r616",
      "r617",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r460",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r261",
      "r262",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r278",
      "r279",
      "r280",
      "r302",
      "r316",
      "r442",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r615",
      "r660",
      "r661",
      "r662",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.",
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "terseLabel": "Guarantor obligation, maximum"
       }
      }
     },
     "localname": "GuaranteeObligationsMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuarantyLiabilities": {
     "auth_ref": [
      "r67",
      "r68",
      "r127",
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.",
        "label": "Guaranty Liabilities",
        "terseLabel": "Minimum guaranteed payments"
       }
      }
     },
     "localname": "GuarantyLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r185",
      "r423"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r25",
      "r122",
      "r129",
      "r141",
      "r229",
      "r238",
      "r244",
      "r247",
      "r567",
      "r614"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss from operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r185",
      "r423"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest [Abstract]",
        "terseLabel": "Components of profit (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r99",
      "r100",
      "r101",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r403",
      "r406",
      "r411",
      "r419",
      "r425",
      "r427",
      "r428",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r187",
      "r203",
      "r204",
      "r228",
      "r401",
      "r420",
      "r426",
      "r573"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax provision",
        "totalLabel": "Total tax provision"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Components of the income tax benefit"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r171",
      "r399",
      "r400",
      "r406",
      "r407",
      "r410",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r649"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (decrease) in stockholders' equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r178",
      "r180",
      "r181"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentOwnedBalanceShares": {
     "auth_ref": [
      "r143",
      "r587"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Balance held at close of period in number of shares.",
        "label": "Investment Owned, Balance, Shares",
        "terseLabel": "Investment (in shares)"
       }
      }
     },
     "localname": "InvestmentOwnedBalanceShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r264",
      "r728"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r59",
      "r123",
      "r131",
      "r144",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r498",
      "r628"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease cost:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Quantitative disclosure of lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Lease Accounting"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturity analysis of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Undiscounted future lease payments",
        "totalLabel": "Total undiscounted future lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails",
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r499"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Amount of lease payments representing interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Security deposit - letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r11",
      "r184",
      "r265",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r298",
      "r299",
      "r439",
      "r440",
      "r441",
      "r463",
      "r613",
      "r670",
      "r720",
      "r721"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r8",
      "r126",
      "r136",
      "r629",
      "r651",
      "r663",
      "r713"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r152",
      "r184",
      "r265",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r298",
      "r299",
      "r439",
      "r440",
      "r441",
      "r463",
      "r629",
      "r670",
      "r720",
      "r721"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-Term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r675"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r37",
      "r38",
      "r41"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r41",
      "r130",
      "r140",
      "r150",
      "r166",
      "r169",
      "r174",
      "r184",
      "r193",
      "r197",
      "r198",
      "r199",
      "r200",
      "r203",
      "r204",
      "r209",
      "r229",
      "r238",
      "r244",
      "r247",
      "r265",
      "r287",
      "r288",
      "r290",
      "r291",
      "r292",
      "r294",
      "r296",
      "r298",
      "r299",
      "r454",
      "r463",
      "r614",
      "r670"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r46",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r199",
      "r205",
      "r214",
      "r257",
      "r258",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r392",
      "r393",
      "r394",
      "r415",
      "r416",
      "r417",
      "r418",
      "r431",
      "r432",
      "r433",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r549",
      "r550",
      "r551",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards Changes"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r657"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r229",
      "r238",
      "r244",
      "r247",
      "r614"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r493",
      "r628"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities",
        "verboseLabel": "Short-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities, net of current portion",
        "verboseLabel": "Long-term lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/LeasesMaturityAnalysisofLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r490"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r497",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r496",
      "r628"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r157"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r109",
      "r110",
      "r112"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Change in foreign currency translation adjustment, net of income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r18",
      "r20",
      "r472",
      "r473",
      "r475"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax",
        "terseLabel": "Effect of foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r109",
      "r110",
      "r112",
      "r167",
      "r170"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized gain (loss) on investments, net of income tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid on employees' behalf related to vesting of stock awards",
        "terseLabel": "Fair value of vested shares withheld for minimum tax withholding"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r335",
      "r336",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r354",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefits"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/EmployeeBenefits"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r2",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r2",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r2",
      "r629"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock ($0.01 par value per share); 5,000,000 shares authorized; no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r644"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Registered direct offering"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from securities offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfShortTermInvestments": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from sales of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale of Short-Term Investments",
        "terseLabel": "Proceeds from sale and maturity of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r648"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProjectMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Planned program of work.",
        "label": "Project [Domain]",
        "terseLabel": "Project [Domain]"
       }
      }
     },
     "localname": "ProjectMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r65",
      "r591",
      "r592",
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r61",
      "r155"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment, at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property and Equipment",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r63",
      "r137",
      "r569",
      "r629"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "verboseLabel": "Identifiable long-lived assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/GeographicInformationDetails",
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r63",
      "r591",
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of estimated useful life of assets used to compute depreciation using the straight-line method",
        "verboseLabel": "Schedule of components of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetTables",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated Useful Life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r344",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r344",
      "r509",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r507",
      "r508",
      "r510",
      "r511",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransaction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Arrangement with Federal Government [Abstract]",
        "terseLabel": "Research and Development Arrangement with Federal Government [Abstract]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementWithFederalGovernmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "Research Tax Credit Carryforward"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r42",
      "r44",
      "r589"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r5",
      "r81",
      "r135",
      "r581",
      "r586",
      "r629"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r147",
      "r189",
      "r190",
      "r191",
      "r194",
      "r202",
      "r204",
      "r269",
      "r392",
      "r393",
      "r394",
      "r417",
      "r418",
      "r452",
      "r577",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r225",
      "r226",
      "r237",
      "r242",
      "r243",
      "r249",
      "r250",
      "r253",
      "r331",
      "r332",
      "r548"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/GeographicInformationDetails",
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r334",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Geographic Information"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Amount received from offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Common stock issued in offering (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Common stock price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of accrued expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of income tax benefit"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of significant components of the Company's net deferred tax asset"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r656"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of shares used to calculate diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of items accounting for the difference between the income tax benefit computed at the federal statutory rate and the provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of components of profit (loss) before provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/PropertyandEquipmentNetDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r28",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of the geographic distribution of revenues and long-lived assets from continuing operations"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r24",
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r355",
      "r357",
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the activity related to the shares of common stock covered by outstanding options under the plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of assumptions used in determining fair value of stock options granted using the Black-Scholes option pricing model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r70",
      "r72",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81",
      "r159",
      "r160",
      "r161",
      "r216",
      "r303",
      "r304",
      "r305",
      "r307",
      "r311",
      "r316",
      "r318",
      "r618",
      "r643",
      "r650"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r71",
      "r72",
      "r73",
      "r75",
      "r76",
      "r77",
      "r78",
      "r79",
      "r80",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of primary rights of convertible preferred stockholders, and common stock shares reserved for future issuance"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r82",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Information with regard to outstanding warrants to purchase common stock"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r229",
      "r230",
      "r241",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Geographic Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/GeographicInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General, and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Additional General Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period for options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationRestrictedStockUnitsRSUsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Assumptions used to determine fair value of stock options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "verboseLabel": "Shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Unvested and outstanding options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest at the end of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest at the end of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]",
        "verboseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r362",
      "r381",
      "r382",
      "r383",
      "r384",
      "r387",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected option term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationAssumptionsUsedforFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term for options outstanding",
        "verboseLabel": "Balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investments [Abstract]",
        "terseLabel": "Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r494",
      "r628"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r45",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r74",
      "r147",
      "r172",
      "r173",
      "r174",
      "r189",
      "r190",
      "r191",
      "r194",
      "r202",
      "r204",
      "r215",
      "r269",
      "r320",
      "r392",
      "r393",
      "r394",
      "r417",
      "r418",
      "r452",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r506",
      "r577",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r215",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r16",
      "r74",
      "r75",
      "r81",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Issuance of common stock for warrant exercises (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Shares, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock for 401k match (in shares)",
        "verboseLabel": "Common stock issued under the 401(k) savings plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.yield10bio.com/role/EmployeeBenefitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r2",
      "r3",
      "r74",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r2",
      "r3",
      "r74",
      "r81",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock for warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan.",
        "label": "Stock Issued During Period, Value, Employee Benefit Plan",
        "terseLabel": "Issuance of common stock for 401(k) match"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r2",
      "r3",
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r74",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "terseLabel": "Issuance of stock for restricted stock unit vesting, net of shares withheld for employee taxes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r3",
      "r6",
      "r7",
      "r54",
      "r629",
      "r651",
      "r663",
      "r713"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r83",
      "r183",
      "r304",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r320",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Capital Stock and Warrants"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r495",
      "r628"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r482",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r513",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEvent"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r261",
      "r262",
      "r302",
      "r316",
      "r442",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r660",
      "r661",
      "r662",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r568",
      "r621",
      "r730"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "Government securities",
        "verboseLabel": "U.S. government and agency securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/FairValueMeasurementsAssetsandLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://www.yield10bio.com/role/InvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r547"
     ],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled receivables"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r132",
      "r142",
      "r397",
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Undistributed earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r398",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Interest and penalties accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r217",
      "r218",
      "r220",
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleofCommonStockReservedForFutureIssuanceDetails",
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveCommonStockExcludedFromCalculationofDilutiveSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r207",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Number of shares used in per share calculations:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_A410DowneyRoadAnd110GymnasiumPlaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "410 Downey Road And 110 Gymnasium Place [Member]",
        "label": "410 Downey Road And 110 Gymnasium Place [Member]",
        "terseLabel": "410 Downey Road and 110 Gymnasium Place"
       }
      }
     },
     "localname": "A410DowneyRoadAnd110GymnasiumPlaceMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_AccountsReceivableTradeAndUnbilledReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Trade And Unbilled Receivables",
        "label": "Accounts Receivable, Trade And Unbilled Receivables",
        "terseLabel": "Accounts and unbilled receivables"
       }
      }
     },
     "localname": "AccountsReceivableTradeAndUnbilledReceivables",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_AccruedFieldTrialsAndRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/AccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Field Trials And Related Expenses, Current",
        "label": "Accrued Field Trials And Related Expenses, Current",
        "terseLabel": "Field trials and related expenses"
       }
      }
     },
     "localname": "AccruedFieldTrialsAndRelatedExpensesCurrent",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/AccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.yield10bio.com/20221231",
     "xbrltype": "stringItemType"
    },
    "yten_CJCheilJedangCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CJ CheilJedang Corporation [Member]",
        "label": "CJ CheilJedang Corporation [Member]",
        "verboseLabel": "CJ CheilJedang Corporation"
       }
      }
     },
     "localname": "CJCheilJedangCorporationMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_ChargeForCompanyCommonStockMatch": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The noncash charge representing the fair value of Company common stock issued by the company to participants in the Company's 401(k) plan as a matching contribution during the reporting period. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.",
        "label": "Charge for Company Common Stock Match",
        "terseLabel": "Expense for 401(k) company common stock match"
       }
      }
     },
     "localname": "ChargeForCompanyCommonStockMatch",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_ClassOfWarrantOrRightExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercised",
        "label": "Class of Warrant or Right, Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercised",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_ClassOfWarrantOrRightExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expired",
        "label": "Class Of Warrant Or Right, Expired",
        "terseLabel": "Warrants expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpired",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable",
        "label": "Collaborative Arrangement, Quarterly Research Funding And Option Fees Payable",
        "terseLabel": "Quarterly research funding and option fees"
       }
      }
     },
     "localname": "CollaborativeArrangementQuarterlyResearchFundingAndOptionFeesPayable",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_CollaborativeArrangementResearchFundingAndOptionFeesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Funding And Option Fees Payable",
        "label": "Collaborative Arrangement, Research Funding And Option Fees Payable",
        "terseLabel": "Total research funding and option fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchFundingAndOptionFeesPayable",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_CollaborativeArrangementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term",
        "label": "Collaborative Arrangement, Term",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTerm",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "yten_CollaborativeArrangementTermOfOptionForLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Term Of Option For License Agreement",
        "label": "Collaborative Arrangement, Term Of Option For License Agreement",
        "terseLabel": "Term of option for license agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementTermOfOptionForLicenseAgreement",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "yten_CostOfRevenueResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the expenses associated with internal research and development as well as research and development services conducted for others are expensed as incurred. Research and development expenses include direct costs for salaries, employee benefits, subcontractors; facility related expenses, depreciation and stock-based compensation related to employees and non-employees involved in the company's research and development, which also includes the costs related to revenue-producing contracts, which are recorded as research and development expenses, during the period by the entity.",
        "label": "Cost of Revenue Research and Development Expenses",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "CostOfRevenueResearchAndDevelopmentExpenses",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from capitalization of research and development expenses.",
        "label": "Deferred Tax Assets Capitalized Research and Development Expenses",
        "terseLabel": "Capitalization of research and development expense"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Right-Of-Use Asset",
        "label": "Deferred Tax Liabilities, Right-Of-Use Asset",
        "negatedTerseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_EffectiveIncomeTaxRateReconciliationOwnershipChangePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Ownership Change, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Ownership Change, Percent",
        "negatedTerseLabel": "Impact of ownership change"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOwnershipChangePercent",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "yten_EmployeeAndDirectorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the employee and members of the Board of Directors of the entity.",
        "label": "Employee and Director [Member]",
        "terseLabel": "Employee and Director"
       }
      }
     },
     "localname": "EmployeeAndDirectorMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_EnergyGrantDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure regarding the grant agreement with the U.S. Department of Energy for the development of switchgrass.",
        "label": "Energy Grant Disclosure [Text Block]",
        "terseLabel": "Government Research Grants"
       }
      }
     },
     "localname": "EnergyGrantDisclosureTextBlock",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "yten_GainOnRelatedPartyInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Related Party Investment",
        "label": "Gain On Related Party Investment",
        "terseLabel": "Gain on investment in related party"
       }
      }
     },
     "localname": "GainOnRelatedPartyInvestment",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_GovernmentGrantCumulativeAmountAwarded": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Grant, Cumulative Amount Awarded",
        "label": "Government Grant, Cumulative Amount Awarded",
        "terseLabel": "Cumulative amount awarded"
       }
      }
     },
     "localname": "GovernmentGrantCumulativeAmountAwarded",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_GovernmentGrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Grant, Term",
        "label": "Government Grant, Term",
        "terseLabel": "Government grant term"
       }
      }
     },
     "localname": "GovernmentGrantTerm",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "yten_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Liabilities",
        "label": "Increase (Decrease) In Lease Liabilities",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_IntellectualPropertyCostsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intellectual property costs.",
        "label": "Intellectual Property Costs Policy [Policy Text Block]",
        "terseLabel": "Intellectual Property Costs"
       }
      }
     },
     "localname": "IntellectualPropertyCostsPolicyPolicyTextBlock",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "yten_LeaseOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease, Other Information [Abstract]",
        "label": "Lease, Other Information [Abstract]",
        "terseLabel": "Other information as of:"
       }
      }
     },
     "localname": "LeaseOtherInformationAbstract",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesQuantitativeDisclosureofLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "yten_LesseeOperatingLeaseLeaseArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Lease Area",
        "label": "Lessee, Operating Lease, Lease Area",
        "terseLabel": "Leased area (in sqft)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseArea",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "yten_LesseeOperatingSubleaseSubleasedArea": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Sublease, Subleased Area",
        "label": "Lessee, Operating Sublease, Subleased Area",
        "terseLabel": "Subleased area (in sqft)"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseSubleasedArea",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "yten_LicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Term",
        "label": "License Agreement, Term",
        "terseLabel": "License agreement term"
       }
      }
     },
     "localname": "LicenseAgreementTerm",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LicenseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "yten_LicensePaymentsReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Payments Receivable",
        "label": "License Payments Receivable",
        "terseLabel": "Outstanding license payments"
       }
      }
     },
     "localname": "LicensePaymentsReceivable",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/RelatedPartyTransactionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_NoncashLeaseExpenseIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense (Income)",
        "label": "Noncash Lease Expense (Income)",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpenseIncome",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_PresidentialWayWoburnMassachusettsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Presidential Way, Woburn, Massachusetts [Member]",
        "label": "Presidential Way, Woburn, Massachusetts [Member]",
        "terseLabel": "19 Presidential Way, Woburn, Massachusetts"
       }
      }
     },
     "localname": "PresidentialWayWoburnMassachusettsMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the provision that has been made for U.S. income taxes related to the undistributed earnings.",
        "label": "Provision for Income Taxes for Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Provision for income taxes for undistributed earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "ProvisionForIncomeTaxesForUndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/IncomeTaxesDetailsTextualDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Public Offering [Member]",
        "label": "Public Offering [Member]",
        "terseLabel": "Public offering"
       }
      }
     },
     "localname": "PublicOfferingMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails",
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_ResearchGrantMaximumPayrollCostReimbursement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research Grant, Maximum Payroll Cost Reimbursement",
        "label": "Research Grant, Maximum Payroll Cost Reimbursement",
        "terseLabel": "Maximum payroll cost reimbursement"
       }
      }
     },
     "localname": "ResearchGrantMaximumPayrollCostReimbursement",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_SaleOfStockCommissionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Rate",
        "label": "Sale Of Stock, Commission Rate",
        "terseLabel": "Commission rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionRate",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "yten_SaleOfStockMaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "terseLabel": "Aggregate maximum offering price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/SubsequentEventDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_SaleofStockGrossConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Gross Consideration Received Per Transaction",
        "label": "Sale of Stock, Gross Consideration Received Per Transaction",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "SaleofStockGrossConsiderationReceivedPerTransaction",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "yten_SeriesAWarrantsIssuedDecember2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Warrants Issued December 2017",
        "label": "Series A Warrants Issued December 2017 [Member]",
        "terseLabel": "Series A Warrants Issued December 2017"
       }
      }
     },
     "localname": "SeriesAWarrantsIssuedDecember2017Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_SeriesAWarrantsIssuedNovember2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Warrants Issued November 2019",
        "label": "Series A Warrants Issued November 2019 [Member]",
        "terseLabel": "Series A Warrants Issued November 2019"
       }
      }
     },
     "localname": "SeriesAWarrantsIssuedNovember2019Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_SeriesBWarrantExpiringMay2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Warrant Expiring May 2027 [Member]",
        "label": "Series B Warrant Expiring May 2027 [Member]",
        "terseLabel": "Series B Warrants - expiration May 2027"
       }
      }
     },
     "localname": "SeriesBWarrantExpiringMay2027Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Issued, Number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Issued, Number",
        "terseLabel": "Options and restricted stock awards issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsIssuedNumber",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding, Number",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Awards Outstanding, Number",
        "terseLabel": "Options and restricted stock awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsOutstandingNumber",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative gross number of share options (or share units) granted under the stock based compensation plan as of the reporting date.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options Grants to Date Gross",
        "terseLabel": "Options awarded to date (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsToDateGross",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "yten_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based Compensation Arrangement by Share based Payment Award, Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "yten_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of time, from the grant date until the time at which the share-based (option) award expires.",
        "label": "Share Based Compensation Arrangements by Share Based Payment Award, Options Expiration Term",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationTerm",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "yten_SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase Of Shares Authorized, Percent Of Outstanding Shares, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase Of Shares Authorized, Percent Of Outstanding Shares, Percent",
        "terseLabel": "Increase in shares available for issuance, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardIncreaseOfSharesAuthorizedPercentOfOutstandingSharesPercent",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "yten_StockPlan2006Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2006 Plan, which provides for the granting of incentive stock options, nonqualified stock options, stock appreciation rights, deferred stock awards, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights.",
        "label": "Stock Plan 2006 [Member]",
        "terseLabel": "2006 Plan"
       }
      }
     },
     "localname": "StockPlan2006Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_StockPlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Plan, 2014 [Member]",
        "label": "Stock Plan, 2014 [Member]",
        "terseLabel": "2014 Plan"
       }
      }
     },
     "localname": "StockPlan2014Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_StockPlan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Plan 2018 [Member]",
        "label": "Stock Plan 2018 [Member]",
        "terseLabel": "2018 Stock Plan"
       }
      }
     },
     "localname": "StockPlan2018Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_SystemsApproachToIncreasingCarbonFluxToSeedOilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Systems Approach To Increasing Carbon Flux To Seed Oil [Member]",
        "label": "Systems Approach To Increasing Carbon Flux To Seed Oil [Member]",
        "terseLabel": "Systems Approach to Increasing Carbon Flux to Seed Oil"
       }
      }
     },
     "localname": "SystemsApproachToIncreasingCarbonFluxToSeedOilMember",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/GovernmentResearchGrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_WarrantExpiringJanuary2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Expiring January 2024 [Member]",
        "label": "Warrant Expiring January 2024 [Member]",
        "terseLabel": "Warrants - expiration January 2024"
       }
      }
     },
     "localname": "WarrantExpiringJanuary2024Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "yten_WarrantExpiringSeptember2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Expiring September 2024 [Member]",
        "label": "Warrant Expiring September 2024 [Member]",
        "terseLabel": "Warrants - expiration September 2024"
       }
      }
     },
     "localname": "WarrantExpiringSeptember2024Member",
     "nsuri": "http://www.yield10bio.com/20221231",
     "presentation": [
      "http://www.yield10bio.com/role/CapitalStockandWarrantsScheduleOfWarrantsIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126976462&loc=d3e36027-109320",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(a)(32))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6806780-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=99383244&loc=d3e12121-115841",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a-c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126928070&loc=d3e28200-109314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092918&loc=SL128093175-196984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL120254526-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL122642865-165497",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "832",
   "URI": "https://asc.fasb.org/extlink&oid=128342835&loc=SL128342857-244232",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 5))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r633": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r634": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r635": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r636": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r637": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r638": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r639": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r641": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r642": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=123422226&loc=d3e11019-110243",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=123422226&loc=d3e11049-110243",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001121702-23-000012-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001121702-23-000012-xbrl.zip
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M8"\ISET1:>HJX['(]X+ YV+E[0=ZDY3?S*I>A4E,84!E+6_1&%'M7"^M:@O
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M*24554;'0G!,.A:,D2 (0B6(2)*EVC>O:M^\(%#,8R\T)J3<ISR.O<A(YLN
M^[Z0)E"OA ,MH-HU+PCD&:4BYBO/%XQ[H1>%*A& +BSVO20FRQC'',*,D#@T
M(#>X'RKN\2"*"9YIX'M!HK@(R0)$O5^GVG'O*<V=J_81,P)"3VM/>2&)0BZE
MCA5)_# *5$02T(2BA4+>><&7N?)TO6#DE:!841I3!<HZ!^02,6.*,T6I8ER0
M<*&0]S6I6TOD!5M!^9X6B:"A+WFB@DC&.F9>#)H>49HN%O(N\>7)\85RKI-
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M+;',.PD"&FOA!;Z,%R"-9 Z[*CY-\HB.@P0HR2@LE=(!R"E?^2217A1Z@5F
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MR CQA1_A"2B>3/PX,#ZH0& EB(A>.\#V1T!A<>CB[Q\Z^QW(,,O-\,P$&K.
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M2]C<K]+PWK1%'HVV5*#!9(ZU"9D'M$5B7X+B;@37(09<@VL^JR4@']M[]5B
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MV<.=,B/BS//Q/!OD$#R4,351A,U*9!0P99HNF%XP!P53UQM.>L&C,,A$<Z*
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M3_,#<(WQ82$&I;#I'.7OX_:5*;?;2)(T2_'"MEW(4[H3R2,VK!41"ITX8'[
MJ0KB,,&,(.5QRHEFBU1E/7\0>WYYY!&JA9:AISR?BU!%>'X&CZE)HE!YIDK1
M9(3.;^='/)K0_'<$#VU?P)^;)9/7;GA2-SY#&$Z;.W[7H::!IMC^*V$Q!TDE
M?5]H:J3V#$^(JEQJ%C#N$D(/HK-K,/H:G5V[]7O4^3",! D"GT2&*TJE'S+"
M5*S@%Q%XXCHX&5V"\RG R5SZ&. TDC//4RHQS' C0:'TPB0Q/ C!6*->7+/-
MUP/%>ZFN/ZKQR"Q#;H/\>](>36B,CK0A-, V:Q&'KX  BN#O1"Q!?A^0/U4C
MD>\'^9OT:KTP93XJE"FKKSTCM)V/3B_>_@I_FD/@O(#P1((>%G.?">%S,&+P
MK$3!8NH%GU$#GCY3#L<9P+J?#MR>P<.*UEEP/OSE,M7#WCHEY']6['UO?RW/
MQ>#MK[)X T]7GZM!)D-5MS0#JCS+B_5_$/N_7Q)8AYN(?IJ-U_]Y"$ HG:ZY
M=/;SOAC\<[4$;=<M8>5)=6.9?C'P;IB&_7I9S8O#.%DZ,,T\J8>3X^1C:9QA
MS\!?N'I6.L/< <,SU=G8*<Q%"J^!JX[.U0CA-3OYKTT[29YLVK\@4%UM5%U^
MN3X: "CQ+MAM,3=S<7J%27Y;^<>W<2I<>7NX\?O[;6=OQ]G<ZQYN=P\/?GTC
MWBYW^TEV.UYYNPO/72&N3WV81CL[Z4 ,5"HR9^*(*;\"A]OHN<T41'$"?&&8
MGZ_[L#8[=9&E)X-U9;!P";;/.DB;^V5>P&)<V,E,G)=FO?GPBT[+\TR,@=O9
M_; /_5*/+O/A,._;%UQ@NI026?T2^[[J\I0?K9&*)PV!\PUU\^;Z\IJ]]&:H
M;UZ+H[68W'V9K-')M3=V[**YH88>3'#%/@>KPOWZ;86M7%MXO13O?.A8D#@-
M^SL76J>#DW7B4#O*]#5O[%[<LO>W;?;C\E=^#5W#6_GKQ^[NX?:6<W"X<;A]
M<">FS,ML#[8W/^[O'NYN'S@;W2UG^S^;_]KHOML&GM3I[!X<[.YUOX7L-0R#
M._#]:47<[8OZ),H>8,\P'ZPZ6VN;:XY'?![?<R'LARSD?M#9V=OO.+^"ZC+(
M!UV0QD6JG%K#V4?6EU+@=H$6*O!"QH-$"BU"$[) >X$O09V]+5/'&0A45K'G
MP58MXU%W7*E#G.ROL=S*+]Y[^Q='K#/2I]L7Q^_BT[U^Y[)S>G39?7><=K9V
MK_8._Z0=;Z?7/=Q/.Z=_>L?OCMC18<?O'.YZ[UDW._IR?@KW>9VM_?[1Z<:X
M<WA&NH?=WM'A1W)TNDNZ_?U^U]O^LG>X/>YFT=5[[WA\]$D%G<,COO=IFW:]
MG;.]3]VT^^Z/L\Z7$^^XWQGO??HKZQYN?.F^^^CO;9U<Z'=_<?VO/[)C+[N0
MI_E5]_3$A_'9T:<__2-OEQSU__RRMW7</_JRZQ]_^D@[6QUR?'C&]W:B+YTO
MV_2SHC[W8ZI=,.&9RQD7KF2^=A-#O,27GHE\4/XH<?]M%<@I%!9(!/B$@PBH
M>/'M(F#*86]<9,VCMU_^ZK-?OQCZ3S$NC]B:=]^1;Q=;2)IWRJU&+GGG5RB9
MVN#-3'(3&OGYRM?9?C5".D![<-T+[:OOR6D^P41P,N4=/";^EG952?>GYRX;
M@\$(*[8Q/+SB)'G1%T,8_6JXGJ171KO#8K28W&<GE>\^!L>?]GOP&S\^W+[L
MXG];&U>==W^DQ^]VLJ/3WT^[G_:S(WCVJ-^IG_D+WN4/C@_/L^-WV\"1>EGG
M<(/"?Z2SM7UYU/_C#.Y/.^\Z]/C=7[UC^'Q$H\OWAQO#S@&Y>G_XD79/E?>9
MR8 I+XQ=GX*)S,.8NS&P+3?V TJ3*$B(!(7]?_\1ASSXY>L,K"&6KZ#\C"KV
MB-3QJ'+U.L[?$*L6YS>ZW8\;[YW][0][^X?.AX_[!Q\WNH?.X9X#ZM AZ#S_
M^P\:D%\H<_;V'>K_I']&,^WP7]M.2UV:J$H;FX=PN7XD9GRRL]_669]#\[B?
M"K63%]8+D*0E ,P9&U$X!KB4_A'JR ?KT]FN_+FS' .M-K</[^SA8ZX68Q?G
MYIK!0G*0OZV_C#NGZG-,_9#XL>\:+D.7^U2X44!]EXG8J)#SA#+O23G\YJ@H
M %X[%DF.  [WA=FK!)>@@O+0XVY$2>QR(4)7^$RZ)F+,8T)1$I"5MUM&6;]I
MQ5 P*CS+N%<=A,1#]=$Y9#%Y\0#3<JE6OU*UNE:3OT=U6!A%V6:QI.CEO%M9
M3D16+K*VW/VBKKI;W13&_G+D[9]UW^WRXT]_G!Z=GI'CTQZ,\9%UWOUYM?=N
M^YJVG+/NEVW2\?Z =71/C]_]"7/K@5;=3?<.]_M[[W:!V:K+XZUM?O37+=HR
MB6+C2:Y=*5D"W#=BKE0&S^XDPO#8)(HEM;;,[]:67Y6>?+B_T3W8185X[G3E
M:S)AGKR/FWF_GY88,W5V4I!(W=%4G#\A$ZF2VO"-U0L7DD=\ES_OZC.H5PG1
MH>\J25$AEH$;\SAP!36$1H$02H48CJ<N8Y2Q>RM1\^(/?G+TV3<G:3G$<G\\
MQ_?5H=#NY>>$$FY8R%PF%7,Y%](%>4%<&D@I/!$KCL'$H]WM]UN4.+_O[AUL
M[FYW-[=7*P+?[6ZNS0]:?5.SL5CUT_:54$.+"TZ>.,4$!QQ1.N6Y49BHHIUT
MX*3#TE$]4<!4?UX<#SCSOT-5#^G]-=^YT-5IZ-_?NKA=5V=?"]T^4'FI(/$-
M+_B/E]1/K=)7[!1[%$Y:AML$@[H=X6:N9YTDL 2U;OM&8R\4'&=!722U3_P4
MYO'E#-[]!]S_I]=]=W2);+:[]?$+L.2KHR]_]/:VCKX<'VY<]XGW.Y^VV=[A
MV56G#QK]UA%8!;]G>X<G,->.M[>U<]KI;_/N:3?K[-S4\M^S_<S\:W]\_$F?
M8PH(O)OO'6[X8$U<=;\<GW6WMKU._P]8\_[I\6&WW_GR)\[[\KC?3;H;GW5L
M=!!1S]6:<6#^2>1B$KUKDC@0)##2^#%Z:#)Q*0HS/WS^VYDT%M]_LBCHY(63
M#WNF<$Y;?4N!\\_]_-,V.=EE%"=B4/<&^GD.(AJOFMD=BJO=.JU568@LL!WR
MH[G8[M>YV&FO=_3EXU7G<./RZ!,\MP6<[+#7VSN$^1[N7G5.=_W.U@;9V_HC
MZ?[YF5.?1S2(7=\HW^54QVYD8L\-?=_C5$5,T@"L(.XRZD=>%"\>']M=VU\[
M6'/JTQ+O]B//RX1GZ<+IYFNW<:L[E+%[Z&(/X&1_]];;)^<]8K+$JV:>&UH7
MIBSK?][#!.B2<7Z+<8Z_J?YYW;/NERS=.^R,.Z=9UGT'Z_RT?0F,E!W#6HZ\
M/S)\QY&WCXS3CQ7S%4]<:I1QN22!&VL3N<RC@G,2A%'"5M[2V&F?NN-\$N.;
M,;H?A3";*?9"/,POE];"CT67O3\_*Q:'21@(-R !6@MQ"'+6#US?"[4**)6*
M\96WU9%,SX<A5N>W[3(O0']>3)_>XJ))Y[#S.4D27X:A<G68^.B55JX(?.%J
M85@<>)PQ+E?>=C863P^K40R]AN<%8%=Z#OS07!DU&J87Z$P$E<>42\ML/I2+
M#WDY%-EQ>EYYGY9\X)M\X.MF6>=TP\8,.E]Z?9AKK[OUY[B[=08FV<<OL$<<
MWG_9V?IXV=W*4+N@)#:<>,(U41*ZW N,&U&?N*$FDD>!3X4$[8+0B-S(^9E_
M3@!8Y2!:W6G7/+ANYWZE5O,4#KXCNC*-J?VS=(8F,^>]?&"<@?6.K#K -K,1
MLC)'%$8 ]<,FKCO-NI\C@/W34V8,(CN"=2XL"_JN\.+59Y:0T&CCN8QYQ.4Z
M(:X,A.<:V#\C8\-48E;>!C2\S@)^?O($ GN4U0?$S05VW'U7 @'[3#BE+*"1
M2T(/+$#C<S>.H]B-!)YT&$0>#T&E]R/F4J"=16+3EK(_?]?_'KR\![/PQRR/
M>=2-.P"5MDCQ:((Z/&X*HYWS45&.,$X^S!VX WU[=6J3]Y/\&;5B3*'?4,/U
M^P3+Z:V9CS\\6LYCOXE,/SQ:SL.GBI9S_E0CQ]%WY[;^S7CY[;FM$U/E.12Y
MPW28V2P0(U3/49DHRP?D/B[(&@MA]:V#<5_FV4\M^_2EK+!;I_)8()HKU<.V
M+4X^<"Y[*?PR96$W\R]?,G(_H?)4"X@Q]:0EH854GAKS&K.J__P"__8[6V=?
MNEO'O<[6R57WTY]@SH*Y?7A&.^]V>IU/1S?,Z[UW?Z7'6UWX]^AR[[ #\]J^
MW-O:IL=;&V &'U$PC3&">76,<[R1H4V9#/W$<Z4.&1C(2KM",.5Z*N0>:&:)
MQ/H83*\%3#X8YNKL.]*T7SW&UERP8H)+=+T'NF[/HJN*J?)81-R( *9R&0:N
MC+CO4N,K:8B2G-.5MT>'V]W'1=/Y=6_>(6Y!!_X!G'>[%G-5XO+UU#H4@B\@
MJ^Y'H?HW\E&^:!CK]Q3F<7K4A[EN;?C=3SMGG?[1U7%_EW3ZV^3X]*_3[I<_
MDKV-SY'B>) 0<75HN,LIEZX,.'6))E3Y"%&1H,Y2:O'?ZZ3BU,?%.1U1G)GA
M@[V+LP80]6;]A/;["S(Z3V:,SF=U(G;S@7D)EO_N0&/:CG'DV%$]H\X<F/R9
MDU;;W,J53TM'.)<FR]RS07X)\S2BA#W0<*$<H:-7E(XV23JH4NGW1YFIX,:)
MWT"M!7$ X)IS9,KJGKHLK?ER_>^31Y ^P;K^C<LZJ%>U:Q>UD+STNUR$X\^@
MC&KBT\0E)E NCV,?]%7*78"MKZ.0*JX(HO]U3M8")';C>!AE+!8=#/(A_/+?
M48K\"MA4@F5PA2UI+;_"OQBF],[^9.L)IRQMCBCBKSP;#8:BL!5W1?GZ*.'+
M9TY-P EC;AC2R.61"EVAF.>RD)@(OFF:Z-=#"9<]8Y/JKY'#3_1GIP>L'VE
M.R++)H30IA!IZAM@S)H"G(H>9DB@)1\:=1?) B]C-:VCX>K@Q-YZ7AAEK)N+
M>HYMOE$Z/\%XH!@[Y4CUG+*78QV74S70A6?$\/K<+T5YDX[MP_4:?@:I-M#.
M3UZU1@GJ-5R7>"XOWF]OQ4,78!;U.+;!IIV$G:0HATY,'"W&Y=K39T35[4JJ
MXGJT?8=B.'J%I NV*_,B[<>A2Q+/<WG" C>..'<E)Y*!Z>FI *L<3?E5VKV+
M^7;S&1[]TDD<41^POI\.L:.LR0#[BWR UGDV=@Q8ZF-G%U5:/)_DPCA;8BBJ
MRO!K'& Z1EM&WE 4]\W)*!-3(7G@'CH_X<>PWGZ/>6L3I3*U%9OG6+%Y%WNH
MGGHD'E$M8D+ZIOSY!Q!V:WMQ=VLZ?W6$O3O^3*6(O$0$KDX\YG(9,.PV)%TB
MJ*8T\B.)^05+PKX785N3+H.U&$<H!81=V)[1B-9HSPUN_16TWX%[ZX6R#QP!
MWE(T\@<HH0^;,%Y%00_#@73$?3MQ3HK\<MAK+J^!W#=53W:T'VV#&)MSN7+7
MW%:<E5M_O'L&*U:0K]PQ@Y59BY5ZTO4:G:2MB'PSSMUJ0_6RRL3]^*G"T\%3
MU8G[X5.-['UW0-W[>S'' I^^#NE^JG5FGLGY_?YV"GW"",!SK/*Z//A;JYH_
MX&T\/=B>=7VW@>VE$^0/Z<!4; +.G.3%^)9 E+W)8I.J;UKHF-3>X1GKO#L:
M8QSH^!!KDSOTZ-,?IYW^SNG>UC8#3=4[/L0NR#?ZN?E[V*_M](_T&,;N')Z0
MSI>_>D?PKJ-/'=XYU*>=T^,,NR ?_75+MH#@GE!1$+E!@-V/X]"X42( ,HKZ
MH.=J29FP88B;RM@/C,<^&UD'+XX;']REO+XPKOSD',INY.^C$MY<EB^P(?N/
M8TF=69:D%=,J#*4;A3)PN9^ \2V2P)4J$H09+73H?[LA^W=*X:?I!; 0'&+[
M=NOUA;'W)^</S3:^L[NXV;@ 7EXOVA_$*,8W& 6-12AC$[HAP3Y31AHW%IX'
MF@HG/-%)K+U[]J+]>O9+^X#"\[QJ+;Q>X.G8Z86Y<63AU--BG29D^HB099Z-
MAC<?^=8IA]7?7C&ELQ/CRL*(,U<D0U.LB^Q2C,N5-X]]MN+#R@1KQR2-GL\Q
MF7S% 8A%@O>,OMOH ^BY&((?YLZH.NK1@456IS<,)RVF&Z<^.OOQ/=D87WR9
MPFOAE<X UI47]D#(TNK-S3EYH$UC#SN\&4_BU*+0I8--ZU)]>W:20]E/XN?;
MW(5KSBMQ)+<"P+7ZBLGXZ'$5PZ'!MG^X3[!EV& 3Y@94@H'2__U'Y-'PE](1
M90FJ&O[4;*-)$F/C'8.Z_AZ?3-%O.@ 8H4PH\LS)06ZU0#?5G.TABA,  =-I
MU2L=B$(*&-;=N\K,V,:7?Z*^\W'M (]2"[T BYM^QH5/5UEGILD,!%(+09*T
MZ%=1HW-XM\"; *=L0I2V,Q8CG0[K>3UIG&A7)<4&OBPO-J9;OI.)DY<EV+XK
M+NQ_YD9[<<1CEQ$#&JSVE!M),*I-0B05L0X\;&GR+<&T"%1,O8KKEM.4"L#/
M;R1:.M<+^^[DS&U&,"7 <G+&:#-&.]ID"\&K[,#JL3IQ(LEL/@7\I/*B,$V[
M1BLPB@)3*7*DKXLT'Y79N"&OV]ZZ]M"4T(T"!OB^/;[&XI\#S,Y"8>9]Y M*
M:(M!.0CX"@FFN-%@<@O;+ ^>A.E1"*G<)B: K,G&95J)D %&WD"FN%*@S$>M
MP S*2CAAO@!<LAE*D[>W\7<BK*[W?RG*=N(!:)_F M%],H5:#VF36Y7-X'&R
M1LF62X'F?C#F>K>YQU\*\MP6Y2Y[)LL:?=/YZ:Y<Y9G(+_"_G^^?D=GD#CP0
MCM\ZO.6>6_+T3C7<P!=I*W^72D$^@_[@>]CVAH4)=3EEOAM%1+N 2HGAV)/4
M!$AKGL\66Z/PFF(G<7("Y(7TU[=%*\Z%R$:FH9J+W*K&J/QCIDC]5555C<BA
MAV,'<,DR6IM*DJ B *.5ECQ'PXH'@UH 6@IP;.275487\%JP)^H:WTI=: ^*
MF5H9)ER"+:_1_L!;JJJ;:U4V>/&/T:"F>4:J(\?L /]O34@[-MT*[AL-THJ,
M1J5>F:4K#,\(IDFL:< E%S'32<!-8%@<*2W8YUU+5P$C*\!M5-H'$OEMA=RD
MK0_6L-C)<G'M2*3!J._JW!X/CT^O.'@.G;%CO"9"&^]M[?J?%:>Q,"QR@R@D
M>)@Q!4*C0&A)S#WF>S*BT<K;:#4*PM68^PVM-9!\NW9/:HOGB]JJ/DI(764/
M]![09$9#ZYA LKJAI?RS;*BBQ )B+,J!>P#M5:^I0K#8SBRVWXGLU:NNX3LQ
MBOB,:ND3S@.BHS RD? E#80&(RJP^,X(HZR-[[O=G5LRE>T<;8WS@7W5WG11
M2Q*XE00.M[]\-DQ&44(25YH@=GF(_?MC@17D-(2-Q^Y*WLI;?Y6$?)5$WR2!
MIS_QK9R>$&'T[^/]AJD?PHM^SP#ZKPN*J#%<?@YCC;0#R@*P,_BCN!L++MTX
M-(SZ*HK]R%]Q#"#Z.98Y8[#R/NQJ#HX&V]K;_-C9[AX>.+O=S;W]#WO[&X?;
M6\[O1\[^]L[V/IXCM'@JSX>6X?;.#$P!>L3N -CMJ&*:[_#"#K LAQ+WWZN6
M(:>#BH=5EF5MEH)6\T$40V=W=W?5V073M80G5AU*X3]O%>MA4&FB'"V6M$4W
MH"X5!LR4&:TH*?*^?56MD__3.JFOQE-OR*0*I3J?W.D8,ZQEAF6\/5"3T'BM
MDO.M2@:S[8BQX_F5C%BM=:T4C=[SRO'>+N9!)WPFAM;D$N@\JBI='!OZN.UX
M9<>:Q-56V-3]R;9=XTS7]>3YB_G@V)9U*>(%A">2>!2T#B:$S[&&7">A8#'U
M@L_ARB/$B7Q^2YSH[B+PNTDE2?X.J=SGH*V*7D%.UP>8K%LG/-X%LQ'S,A6G
M5Z" ^\>]X'9H$[2!8#91-H(X^_6-^%9$;EYX\3>.<)N;3GZWSW[V"/N]KK.S
MM]^QG&+NI]X<+8_GA3O;-BIY_<SKYHSK.5_);G=K^S^+<PX>,,8U4C''.PH<
M_N>NG/U@+6#1G5?)&KWSVM=&C?@:#<)'']9? Q7Q7J-^1\>S'W?DRMPD?/W(
M_EC1O3JG?P UX;:\N87K+__W1/V]^LO_(+7C>^=R?[V#,@#\!DB]W;5;U(V[
M(5KS5]OWY]QZ05/M-"CZ/03XH&.\)PKTT^W\;6F#SX4%#YS+ [ @ /D+AIQ#
M'X0$2Y@],\R:O/.GA-HWF+%-7'YR7OQJ(,KO .62>\XQW.*&>VXLV><B 6T_
M+<^<':&&>;%DH2\&JEZTY*%S,I?[ \[S&A[Z^Y*'+A+0/@X* ]8?)C,>#$6"
MWNM^_P[O]9*ASLE<'@9B3&]9,M2YF,L# .?7#-5;\M-%@MF'(C_'/39+!OIB
M8+IDH',SEP< +JH9*%LRT$6"V7MS(C('V*@RMB?GDH^^&-#R8,E'YV0N]P<<
MHS4?O<NUO8397,*L X\X!R(QP[&SE98JR\M1L=1*7PZ OY>;/FW>QQ+,CY+=
M$:%?M94?+F0^&CI[HP)H&BN<\Z*TB>![=77QDKQ?#MSGF\"7B5U/FMB%K46J
MQ*X'9G8MD[?F8BX/@'18*]AW>9F6,)M+F-7EX5@XM=\NJ:W/Y-VVA>:K<"VS
M=5FM,BJG@YVN:LE='1[G?!@5JB=*8TMPJV=;)QPMQ?I+P1J^S&Z8E[G<'W"<
MU"SZ+HUL";.YA-F^@?=?&+UDGR\%HDOV.3=S>0#@6,T^PR7[7"28=2;-5T&M
M11_RJ"S3NE?K1JM7WLZDN^)F/M!50UV\!]CO**O:.^Z=FVHR2U7VQ:#'DA?/
MS5P> +BF5"Q<%CLL%-#^Q+8RZ=!V+K'<%7[(FN^M )^S84,$M7<"2R26'/>E
MX("_3$2;E[D\ '!->=E=XG()L[F$V52K/9CVCD;&>S Z/\_L=U&,[0G62P[[
M4H"^Y+!S,Y?[ \YOBL_B)8==))AMVL-OL'^AY:N@Q(J3PM2<UAZ^LU$=GR+L
M(1&#YFO3,GK*H:?Z[Y(5OQ3L6++BN9G+ P#7E*W%2_?"0@$-FU86 !?+6&WU
MA5ZF"[\D "_9Z=S,Y0& :XK8XF5;A84"VIX]7*B5N;UDI"\%M/Z/J6);%E,\
M,NR"II MWOQ1Q+B$VR/!;6K?8ZZM*.QY-CMY :_"TYF*M-1I?=R?/=WO0V$N
M\%2#W4%Y7I\#N&3 +P$9'H,!+^MB7D9=S+(P9BY _72,GS<]Y<C2^%DDH$U*
M4U>=[<GYMTV%JG4P;3;G%3GO\) ?=.,O/?<O!OX_R$):$N[3<-ME$_F% MJ4
MQ6ZVSBA?<M.7 M\E-YV;N?P=;KKLW[E00*MKKL?.WN4 M-5>>FZ/](-M%^G
M^=T,#*BQF')27;?:[+1.IBY[N;/B>\F57PJ>++GRW,SE[W#E95/0A0):PW\M
M:T5O/O#E<H;9'A8PR^KD\G*U3B>LO!#.+KP4]&)MEDZ&%X022P8\-W/Y.PQX
MV4UTH8#VH4@'*CT'O;>5@[UC3%T18XJ+5"VS!5\.O)<QUE<<8PW")L;ZUS+$
M.@^0?C)2#YO&5G39?'"A@+9]U4ME6A>DWE*IZARHGM&C;"F37P[,EQ;/W,SE
M 8!K>E_19>_ A0+:3EY@YI'[;^=@U.^+8KQDI"\%M,%=^63/9MPLR?=181RL
MO#W8?=?=./RXOWVPI-N7 M.OT^V;H9"9:7Z_AY?@[:^R>'-MN-9C]0I\#DL\
MSTO;UG"]L &("_/+9:J'/;N\6>A7&+%.IH\(6>;9:'CW(P_P8L#N/@F4/)P3
MN[:SK;\XVU3_MG*/HRO(2O-0KYA2U8EQ96'$F2L26."ZR"[%N%QY,[,/_73@
MMC?]KOT"87P"M]8[3;WS1R>Q^![[]8,H[#NG\@ "6WE[B 1DTQW@A7>< =V@
MPY.AJ!UQ/1T"0:BON[LLTH*:=BD*[;[/\S/T24][-=T@['M1_2QRQ8T(2#%\
M.%QGP=>0[4FI\["7EL[&8# ",W_?G.?%$#NBH);ZO_^@ ?G%JJH*AA'IH'16
MDGI?LGI?RLF^K-C6*NG &?:,TS=B@)<!Z%ZX@?_@K].#!YP--<1?:<S8JB-*
M1_0QDJJ=G_"^E=D;5WY>K<,!-@Y;S<NCV[<,NWVE;/.7UOC\EO';MZW\O.8X
MASU3FM9B',N0C3/,G7Q4.,EHB#5BYYG *' N3W$F%P8^FRLL!*N"QW:2J47Q
MR=>^&#O2 )/#'Y,49B#'SF5>Z-(I1ZJ'4P/<&*^N."N7:9;AOV4O'V4:/U6#
ME_BQ>C5\P&Z-&#$9&OQFWZ;MA2%@F!G:>XO\M'D.(6?ZY[@8^UV:+#47]EE3
M#M-^\_MY8;#4K?J<VR4(G VNP0Z2#D;X5 [,-P4T%$6UBK7%P_B-; @[?-)S
M+HU3;T=5W8>0GH4GP%R*$H &) %BILP'EI6)LASUSZM[6DB?P<94;8EQI+-!
M?ID9?6*:'^2HA+F4%5[DD\;%J_;9N^FJ(3Z#N 7W KGJ7(VJM#"8X,"DMB@<
MH-Y/\:"/ <#H9"3PV!!C2D#NO?;+4T0\B\"(W"5H!X"6"NYUBK0\JR8W&J@J
M,<+2%/Z";S .W(;(/,CM#A1873'=.:&&R$.*NCDS8C/<.71TFB0P/<2T G J
M&SL)S/3&9D^(\"L[D0Y4-M)F%593KQW&M[L.FS/,5Z_M&BRB8D+M]5M"LFO"
MDU6&Y@26^$L]$QBEIO1DXOILUH-/*%'VX(?_CM*B>LLO]7!X6$LN<<=L#RE=
M-:N&IQ,0F?#3+ZW7SF"8W;TJC01QS.ZC3#-,% 3H-'1G&9ASDN/@];I^L6--
MWZX!B[/\?)(LJ/)^WQ2X@O1+=<1;C86JR,^=<6HRV+%" +X"_AG5&P#QG330
M1JZ29:8"Z'EU\O@8 '2 '.LK\$&0M)!+.(-17P+LX=5W(9?= (4,#W9W!."_
MAD8PS!T(!$2,MT_8H:[1 ^:T:JD2V]5:Y+#K7ZVG4-2)/35G;["G!FT)ORGD
MZ]-9CNO#\:[!ID2A8VZ!]2TO0@(W53K]%!!?Q<AF$*"S'("(X]C&93@2 &18
M2<(*G[ 9A*J\\_70M\+/L59C::7A)5S&?W/+.>Z"35D=0P2O!3:97SI6_;-3
M4,)R/V<%^P [.\)69:T@?_H@BF$EH'=7'710UEK$QFHEK5/<&-0R%E!P''Z=
M3^,&XE8Z2;4?L// SP;#NQAW7VB0#0/ 9U$VJHQ&I0-Y+7S'\4!$Z=RRN4K2
M(S:-SNU=8C"NGP(RF'DOL .X[7PD0=7%T0>#?%2Q:C.A*SL^X(2Y2,N*$^7-
MB%;AN7N9%<X W0YPWC4WU"WD2 Q\ L0KIVI9)BZ_HBG,"7@_#C(D1XO?J#5=
M#:NU7J:XP=4ZD7PRY$[ D3#OKYR ]ELJ-.SORA&R74J<W].\5"D^C^I6_:M5
M >T/  #\9U367Y"9PWZ,K?:U4LVO_L%.!,>^9>B:# =J#2;M; $[ND2T4W6-
M9,,_4&4!IEVF.A4% .L6.-W31&<K=U/S,#^?DO(/=4K<;M]5>0A_>ZG!5Y;:
M<B#\\GRKO]/>O1WY?_K4B!=SI<QY(ZA*K#4 1H996)6T$5:G N8&>%?V$*'T
MM$E\11TZS] ^$'U,Z$*"*E#=1AG:XO^5LM#++P<5">4C6!!81:.*"J>4!XP!
M]%/@HFL_WU-DW++SSX1ENX?;'8>N591X\^_O'P]VN]L'!_<7A<^TCKT+S,0S
MEXLGLV_ABPZR1.>GAN]:KFJ] ILU5_T9C204;R> ]R M1RC-Y&2 AON"D%2C
MVCBTYA\:X&ZI1&9U-#U2#16A\J1$(>%;.2I1O[)F9'U36>FSY]@<L2Q1VFZ*
M/MBE P$B%"6K_0W?D*>9_65Z'9W& M;2_ )SM[8"&OS8(\RJ^VN->P.?G;RT
M-J;6'P#3.HKA8LBB\J6VH>S2Z"%@WD!E_B[@>O<"[O_^(_*\X)=F!3\>OV9W
MA+(UNP,3\ "\K'%F[1H$2PL1 )^2D8'K !3+99\+#H]*;O,&$;[FXU[L]<V)
M<)DE( N1P6A85 =*+;?]Z;;]P[\VD/$",RK!2J]V'O!>FY-":,L"OY@B=R[A
M,G!#H<[$B34V,*Y5]=9ZBO7<C[<X#\",9[1'5>[6''TB1>!++3!N\OQR*COZ
M!J3:92]5/:=7R0ST*X NIJHHC34%0>X[G/Q/92B4#AAT8/8,T:@\A]LOT&%6
M\S=LMNX4UJEN;<NT+RKFYM1^S@4T^/<JVZMVI%E'#>["Q"5<.]V:OO&%R8RP
MPAHE-]I2N!7H?X'/]E /V'G ]%GQ?H%6E[6202(WMAF,<6(&\+.JO713IVG;
MTW>>GN-(IH:C]5<;?%@;].S6;B[K/DO[-<#R 6P6: :@P-LNHA,G[F7;FU;Y
M;V$]=@B8&;J_X6F!'T[0[Y6?3TS(-I(YMD7>R*PY$YL4MJP' _UW) HP>2IW
MR*=<CHK!JM,192E4#S!H6+M0*F3<% ,!!NE@:IJ.5R<#[E5Z4.E4QFV6J]K_
MYQR(\DP,<W3W51]5SUP*^&;'$PN(@PVRK%J-M'(R-'H@(N30:4)NJ%D60)!V
M%JO(50$P6>761@\3X,Z,6CC%8\2OT2#]+WJ:AR 8Y0BC0E-_JKT![<(LL\ZK
MDR(?Y/TI;C:1+%1O+M%-:P&98$Y+!DM%A^3Y:+CJ:&L((HJ4*4P6,<^B3P_M
MP2Q-@)V-508:>E^<5:^%H=-A'7-!_I)7SMQJ_JW0R\>U@S6GB[[*2U,.:VH\
ML8XMC#M;X,]X/H7USXY1]U>6R]D1ETD;#=KQNY,VEOD7SS^5)\N_F#<=QT8]
M8 -J09./I1$#ITWUG50CS:_-A[+X''OTR3A-++\.U*:5&WL2R*\"E,CF&'%@
M!IF5W*HP-7NL]9&6UP)VV+)39P.TGU2)5[R]4PF<E@WFE?!;+7ZK=Z),46*0
M9\(BZD!8KQ'\7NVI:20.R@N\6P(MX],]45R@Q$)E.\W<.M:/PJ]6Q]T"-3NK
M[H!*-0$5ZE0P1QP*-$%+X!C!T1<H5?5$>30#H&(#ZZY55/@][QO78- 2;816
MY/=Y(?R< ';0O5F[\  40] 1+HPS-@([38)6W!,7J%>;&85_HD_?I<W7;N])
MZH^:AERT.<_R<3MBB_"JM"GK3D=2Q3&2/ .=JDH::NOKYD)D(]$0:E)%\P&-
MGAF(SPI%--8&,-2,,5(KJ+6OT\(8G1)RXI1H-KT";+73HTG.BY/7CJ.?MC]L
MK#I;_]KX_^##S]:Q5P\-(*B,KTM3YP1@B@>\KL36>57,O4J&:%F260K*'1C-
MM0T%,/2(1Q;0.K$6LCC',!,L"G7[25I#/]<FFS&7D;D5V$L%R,?*=; C+K'9
M%4:K*S8YI::3 ANS5+YO:[JTS.@9DFL9FM9FM=1:![+:4*ABXH4"^[*Z7K->
MY);V7756"7I-FHG9S)K\<E .0<F=<=';#)!S4521>#2!X=56,EQSLM?I'U42
M"U)\WYZ@W.1EM9%"C : 1XV7 1[, "L+M+9Q!)R3]0MDN82[M>E;(ZMRJ:$K
MN4J6,95_&6!HGQIB_QJ,MU7<HK2M:U;K+!\'%C#$$(<H5NOL * @*TPTL!\
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M[P9CWP@<!]-$-5F8DD8<>(2R'Q:^3\BEH8AQQ*#V$\K00H&W:,AT8R8U(6G
M[ZT5_8PB5 *6#>4R3@4[>Z>,-JL5]E@WZS+BG3%QY01B!9??VX(978EE"!L-
MRFPH'JXC!CT5NX,*X9G3.]6R,:ZSX<@Z=EO,*DAQ$A\=@]$5:IJB-:)Z!<>M
M"LP8-OC!/?\\?T^!6W6R*("<O0PSV@@* ZB&[196V:WKJLF"V*TPJ9NT]KK8
MCGFY$YN5*'\SG$T=T :8LFWI9WAZ"]XKE%^I$B9*@KA@HJRMTS;Y$M(@BH/G
ML9PIO7(NU1*6@J^8V#6T)!)G*\#_83>[RIL-@&H;0]0Q US@CYNF@(8!B>?C
M28C\?$W>XU&G?7"RPKV[&9@1X)9<0<.MN-8]/.]>:']!5=C7V()N*G>!I-G+
M7:?+NKS4L3U3:C$(EZ%7#U"K(][5'PJ,PK&?P@W#'B;KANVRAD02MJ1YJ*7;
M?+/--#>Y' HVKE(0415SC4"5-(\NM !9!H++ 68^/$848^=J*8>FW.[@,'3$
M^_F+$MRYF4;>$Y06>O#390VF9/E;DWN&-BU<H7:2TVW^\T>6@[Y&K0$U[VIU
M4N9+S9Y]@>CD]-M/2<S.T?7\YW:#,<M??_?YMB1=D=/'#WD%HD>"SFEOK'S&
M;# ZH<Q 8754L)':<_W.I5KX%2<U<@.5M;7GKN61CV]_W//?>\\-%WW]WL/@
M,3;S^:OSQ#$R/52B2#[<B?\./_N$QLYQZSYNZU[_9[;9?O<L&,;KTX<OF =,
M4H?;7_A_BQ'6CNF!_VB-WQN?XU_E,Z]9A;6HLB'ZL,MY]SH@P:P @"<,Y/1@
M:$5=YH+'>KZC?<ZGD]>[MBTRD:+(46XL)^?XAQ;JFY,-0."70&WPTRE!L^=G
MIFBOXT]1N#?K8P!!"Z$_G9MNLFW."ZKQ.[S.Z9,O'[4/_Z"M_LC@[%8 #H U
M$'Y-QXF+Q32RUX.8%Q-"365D\R*-:BO,'B$!&&#G\/&1.$-?3X&$9\V83N@8
MKX4KK6+<H(;72:(_XFCZ39>)TK<F&J=/OGZD\)P XF"N\(%MT=AM631M9\-U
MS!*<27,1JU[FV*X=G8&2WOO;,X629([R1')ENT(6#!S"FN\C LSILLV-UZZH
M!)L9,^Z0"'N!''[AJMS-:[K_-20DV@?7R-J,^"0P=!8;(UF3V#RREW6SK94+
M9ITW,UK]!<H=N(DPIEC[]7[6T'8D=#7A/#UY-.9L]2V(:+V&1E#..-#*"!(9
M<IX]=ZT?7LT:H)@G_^OLJR V8V4$?GE!7U(X1O8#<-VG\B!/Z3WF=-.X=)C(
M<MS!<&"M]H;!;>UN]JO6SU!WX>! 2+>C0<N7M&(=CPKWZ- 3FF@T]W1&&;V0
MX,H87@PY%+S6/GR?ZP-@5(9<VYA-R84.SUOA2[CAL/()I7=11;F^:RA0'2V5
M&I1>V, S <K\_C-MZGIRSB2<8^["BB6OF_<)#?D PWX+)F50\G'3CWL:T! K
M*/K-VS\H1?W8!2P^YPHRCHI6JC*HG+,007,EZBJ(=9^R;><"L]A,6D[,_;:B
M%1% K0L>K>M4W %@2'.F4[]AK0[7;Y@W,91%@BS\,@=;5U%M=\+/9F@]@[2/
MO4X<3KH-G"@!):N+MT5K"+F@JR&$;<+\K_[:M(J761L%0)AW7(7WHA]H=X5P
M,3,$;MM8:^&*C6"4?5 SQK8*JA11-)&+H18!M)SQ.";MH,'!GR;*!S*'((@W
M-"+X-I>#>B5* \;TC2)U%D4-F-QMOJ:7YA4X&Q].7BCHNJUWS,7$Y5>FL;//
MZ+V[?JO=%G-#FV)QPE^MJU<YOP]# 0XT$0>?\QI!0UU&.]S+(*G#B**^1D-?
M?B2L'B7GYU&VX7 IVCG=^::H<6B"N@1]HHX8 ?Y*WPMK<0)"/Q<4I#T];O:J
M6%-LU I&:"M8"_Z'!D"73KBP!(^H7TYTC_L<-*9\9V-T^QN.$_Z&C/C.QG=
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M5_II._S,]W(*T4&"_Z,T=:,$8;2+Y!>WV'%U1=K[G=S'X!RD9AYH%_C:1"K
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M;""E1&(Q85FM>A%9/9B!39F!A)BMG=Q?EMD'^&UHT>YG.>+6>4;):J:^UE5
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M663\OE*RRV5:16(-49%X^.RP2NV(-\;V(YS_H?3IFBQ(-(258 /^@BLA:&;
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M4*BV^_&(M^)=KD/0/'34YC$>MC5DMU4C#6QV[=HFVI>[AEND!U45!(86^"6
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MLZ45T6'^F\^!G?DX.WKQ\ZM?WD[>OCZ_>/OFUAO]'\-5?)M<Q6?U504 ;[G
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M:9DIZ7/:+FWL$ZGHX90^"CB2:]H\=W!E#[IRHA35Y3H(H\F'RG)Y,J*A%MP
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M]$N)^2*]0@?Y6X_%+Q9QI0!25V;$![XM/;F,;H'V4$MQ=76"P8WW G1(RCQ
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M<"0Y<%KD2U\'9U$69*7:S)5QI _%9K=QYS6+89F<9ZG>ZP84C+Y$@LPL.-8
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M0[0$X?^P]VY-;AQ)EO!?@?4WMB.997%XD=12R[Z'$B6UN--J<DEJ:/N8A0P
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MU/,ATC" JTT^%'2RT['R11@SXG<A4(@2N?EOR+GR]$>EC'\)QY__E4PDTAX
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MFD(%T-06!STWQ50W'(U;6O_)(/_G&^3;U(!<?5FV#?M:&(FP;Q/675FV@Z2
MMY9_#&W9%>62/7(S]* 4OM[V+EG9G,2>*AE&[ !L39]%R,FM3W]Q6?ODA-D'
MK/\7U#^LBTPK&%8PJ]_#?D^&^;EB29]9;ED-K 3T:4D.\5J#9##=.A>U$:G
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M@NXNF5:?5*"R/3"R4%<K!,)X4I6B%NE"9=)*\$XGOO1X^),>5+KWJ[RLR!U
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M!]LF.%"@YLEK.XLY76NA6(QN;M=12#VI,C?CU8WYK-6_ IE&XA_4NJT7R:2
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MS*M?S@%BBDQP2J7LEX.HY2<>?Y4 @D;+C <\??S58R")US2X4V00F_7^J0U
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M=M##11\BAD&.*Y33O0>P2VZ@&W%! B=-%IT1XB5Z\(U-\#4,F:KC:B=V-)&
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M _'H=!;' \6S5#WL&T8SB^6U;#;C<6#2%211B8_ZN2Z0M.LLSI?&3\ J:'Z
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M/9#7 #4_GP_H$NP'HHJ6U45&+RJO*[&:5G<&CCS'\6Y0D!&;,@H"B6/)LT_
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MQ#$S+2F<3:T4Y\S$%%[Q#(XPXPRI'H7@Z$AW "(G,;)7KHXGF*80J9G7 O'
M%+>)6:=\0![SEO#M)0<6L@?&,6)ZRDK((:I)K,;TYP-[W _/3Z6.A5/)P.H!
M>%A^R@],!K#J;K(C(N.<#A0@T@3>H2,F> %K@C-H<%H-C\1-10R9(&&?)66P
M<!X8:QG!0K:;IGI!YKKY) Y,3<AN)?#$D@W1P=.5;(J[/[32$3O*4S'TBD*N
M^+!.%.^X+ 79:(ZT;1R_R.Q5;-F6R%1F[F#VZ#;QB.EHL/1$^[ F%[RPIV>
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M&O#8L,,UU B$[4%R.BG?#+N$0("GJ)7]:[K>Q;XOIR!4LLNH)Z$S*V2Y%5[
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M]7UNF?;+,I6K1]5ZHUPOJUKCN'RHPR>52J/RP[HMJN6_*Z7P%K98*Y?K]TT
MR\W1<\9((+'['"25V2*5'QG$9X=(@$&26JD=U<NOUR3E1BDW2LN,DKJ^52HH
MR7F4_'WF*S$V7FZ_GMM^[75,E5NPO;!@6F[!<@NV:,&TAUBPCN<6_XA@2T>V
M;/7,K=C+6[%];@#-K=A>6+%*;L5R*[9HQ3;(#B963,Y-S\W9=IJS/*V8F[/E
MYNR0)K?]FH_U7C'6^VA.4>5CO?.QWG>.]<Y'*^:C%?/1BOEHQ9<>K;A](6>>
M-MW/@%/42=9P[17MD.),FM91#3 ^_-NC^/!6=[E.$C^X/_+L6==V, =7E >6
M3QI89CNA,8>TOU'E\:%:P>K)YROZWC8*O/[J22TO5<DM5EG%%"F8) 0W^EN\
MFUJNJ)L8J_O*56YT/S=>3VZ\?L\K5>*,X*%6R\W7:S=?><"5FZ\5YDM[B/FZ
MZW O-V$O8<+VN$PE-V'[8,+R(I7<A*TP896'F#!,%?JV$<;VZ[,+NC2W7B]B
MO?:X*B6W7J_?>N6V:Y]M%P_;J-8.8XNEWC%H ^=]Y\W8+VV@\N.MY'A+S6=N
MO'+SE!]O[;6!8N"J\M&AF-^A'F<#+*WVD_8JB;KR/H!M"+BT4FU_+1H$7,<Y
MW-5KMVCYB=<^6S2>M:(V8HO62$VD H-63TZ]-C!>*U*&N15[*2M6WVLK5LL'
ML+QN*U;-;=@>VS#X/_RG56,;5I\[]F(3UII,'6^&]B>Q1,K0"F\LRZ5Q82?>
M!/9M1I:MZ\!S?>6RI%Q:WM0!*I@4Q%WHL"1%.RY@.'>4&[)G/O_:9S-6*>\W
M'/[K-V.UW(SE9FRE&:L^P(R=C'4?C=>'DO))U^&-<S.V!6:LFINQW(R]7C-6
MS\U8;L96FK'Z \S8^<QU+>532?G@1Y/<A&V!"=OKA&)NPEZ["3O*35ANPE::
ML.,'F+#??3L(;:7O6HZ36[ ML&#'N07++=CKM6#'N07++=A*"];(SM=D2V99
MV*YL@-&R0@(B+2"6X\@VL<8#-C2<B:*/:_R%YP9KF#T[#.*[YQ;N>2U<([=P
MN85[O1:ND5NXO;1P=X/QJU4&XT_PHTQKXMHCV+-L*7W&9/6L*PC/<)IT;+4D
M/G_ ]2 CN(/E![D->U(;UC^<!^)7]_BP+,?AWXNQ,L]7F9I;L*VP8&#"ZK6&
M6BM7:XV:>JBKM2+8,JWR=]6Z5<NF:'KNAV!X@M!VG)31XLSA;Y%K*6J#$H>U
ME;'7;[KQ7?E24OK&.'(L'P& 7?BZ_#==@]^1_SXC\BEG'KPCO6QN[)[4V!W/
MQ6M[W#Q=/U2/<FR/UQVOJ<_7&9_;N6VR<_5R0ZU6C\'.U8M:757_UM)F[MS2
M VN-3&*SUU(NFA2I01C7\4I@_ K*^?F)M(FZ&^G^C'Z+"4]EY/ETDZEO3>P
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M7H% I/[WT<&O Q0*C"U.X(' ?\$2]3DO,&*'0+^]JRU3A$ ADK5$5'Q86]%
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M)[ XO$LXFQ+63?J@.ASK8::G/O0M'=:A!\K4MZ_A5LS$R4.7,.S#K$<./$7
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M1<C*&GM2S8V79FMQE&?5NY:)/'9@Y*GM+#PF0RGP-A]X\]/D1(2H:=XR-)8
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M6GU8^^KYB1)76RZ&69^\G[9/M5R+=;JK=?ISNE08&""3&$9!Y/I"V%&D!3/
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ME33,6YEP(ZWG,TB^V;=?X%JYC7F5S]",XYZ#?U4N'ME.COJ,BEL.>U=C0:,
MD,U*=+<(T+..>I>]B2*E(J6'KTBPR!,W;T8XN=\#0'W7'A[E<[PPD\ NZL#J
M;Y,9P853S,(IKJDJY2QQ()N$C,4.<6LBRA02::&PT;ED#HEY.VGZ[.[,E0F*
M,A?(+5(J4EHJ*<UB&!=Y4J88Q@4;QDEGVQKEI; $Y?H\B$L+)M(D@22+F-.
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M*;11)6HE/,S/UC!Z%4W1G805,'-R3)_DIZ,/8U-V8=[T\(HKFP@[WV *"][
MF2Z-L :4G2&A'X"P=P1?57CVQ?PF[UPK'UT:CO )+/:^C99.Z+C_-@SKO//^
M):^*;[%QE=:OF #?Y& <AY ,OT$/K;.>3+(T0_TV773MD9=5VR\&PRB=@VB
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MF=IP!AW-7S^WS^\P9$YA#I()@Q[%*HCZK-Z?5TZF]18K AZ+M\['(B@7I2_
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MB[*:1R5/W<3#LV%(,I\3DV_Z?+J2^P_64DD_4:Z"<D[U>%8$9>&4*=3^\%Y
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MD[,%5 GJG)W6Q4"1>&,TN,:RZ,XKCRX^>C 9!\XSZ/N3HN*.'/9]W?*_[3
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MRT0W*<-)BB7"C%-$#4L09Y(BS$FB,YJGEEE?#RXCY(%2UYY1;F\#4NO4MSN
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MXP'G&+H/[_NC.]"G3XV2_CT1)6G[_>[YX?XN[9P<?>]L:[A>LX/];K>='B2
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M^,2E(@<3;,(93F/[U&)(P4]8QO1=BF_/V>R3P^8Q?2@_7DA6O%O!0=(784Y
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MQAZEQ]D@Y54B'/0N-^X5JZ$L\WI;5=F9S; ..QZV;C?9245EP;S5'PQK'L
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M1/V8:MKIS4V8N4\P<:47?,6MEOW_/<*N\W?7[.G1SG'S?']OZZP.D+"SZPA
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M"4@[EPF,2K;QCK3.'#T6EJ?V\P6BFD<$("21X=*@0@0K*=:"I;:ZJY<J4:=
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M_6 ^(!-AO'^8SJ6Y&JS]/MO4L]V=P(J"$<R__V??,L9'>\M2A@")>OV\XG^
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M+15N]8\QE#B[V]WIPA!SO<GZ!-G= ?=D,07.&,%@'1$S@2/ 6(64U^ LJR
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MYY/7S;K=ZPY@]/WJ!2=,Y[0]R#W/X1N3EPWSG=XY;6-W1CY?#0+2'J:AGO=
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M/92"]3X'SR+MQ5?!(1A$MUP^8*CGYBR13_,IL9>S4;\]\.W254X7ET&.Z>
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MWJZO$Z6>-/)B3<&_D4;&6'#IJ#&TD)A$1@HFO,.W;0=:1YP?#%D/%UQ1[30
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MZ*]."./'"AUK;>\>8RZ-*PJ!:%0.\6 YTJ)@2$@66) %-P9L!U"'!8&;=&2
MQ1"S;?E\*%LM5+5//YK.Z*;'Z;2TY?Y+;;BGG003_C#J#*LV2G!IN]^X[+>'
MZ<YXTX/)-!S<>I*%K <7]5/SL-YY:#RK>F&GYJJ[W4;37%5=D]*7VE[J!@$C
M\/!-;MCK#R8*D/L_Y0W5+OQ_-#SME05BTWU@$4_*;I3EM1G=_TQ/Z#:VV^Y#
MNSN GUYV>A:0^=^]3M*)P0WPSU^8.L9V<RW9OT:=F0ZU\T#NS.!T3O/NV/HD
M&I62,[1D0G+BI"ZB)L8YR@G'GNE;YVN4C<I,N[O7G29R$\RO]2GKT\ZGYL'A
ML>;.$Q(H\H8+Q%E42)E8("T+%@,A+E"R7)^2T(=/(-S=DTFCTD%JLIH;(,+R
MIQ8F,]J3F[GGLL1 HY/>5"HV,&7GA?)B4)1Y0005V1R4K9!!XV9U-S47ZX\[
MJ=02M\H2=]4Z.[F/Q*7F=XV3U($G<>2;Z4V2.,M,$^REJY;B[73OWW$OO,_U
MMR//E_C6"_[&+1UM)OB3\K2+QV_&,+*#\-\1K.'.QT1Z5L6O;EZ_PZ_HT=7A
M>R=!;OE>ZB[U<H<U01]:+^&[MT\^[;U_PP_/WGW:VS[M@(R#WC0_^I=_<__O
MOSI'M//1GO6NFP<G8F_[Q8?# _<)] $?7F]>@HZ)H^W3=NL GOORG8"Q?VH2
M==6Z?L-;UTXTM]W5WL'A];$&8D.!8J."I)T7XS RX BF[FM*61"R(MIY)YLS
M<!!# ?0;&VXU-C0R*F.A9="^\&;>R9XL0".OP#>T8OCJ5ZZ*L.<GWJ$W\1 =
MG ;4-/T/80CD:/.@"7SH=3\5]S]_\AVJ]X#3&5C'_E6)=_2FF=CGVU5W&VEG
M%>!U>[JMP>9-*.%9NG5M'RS=8/)7F+.RMW7J==]X":3XHO'JU5;J:)W^ A^7
M#9,7VA,TSH$1 Y.&SQ()'81.9\IG3-PB-=3MI9D#P%C_LNE_'?J9@\Q1 $ G
M;[PMJ*."F\*IF)+=-0E1%8X&GW>@&2:43UM^NMAN+PTD^ZE@^??ZN7VW_SMY
M$9,O7I'(P0I &SD&-XTR401D3"K#I;Q%BGF*%*'.D2@*8O3:!GZ.%]//DH6O
M'+2;MD?KC5/S,9GTU(;Y!"3OQ)1>6,B&_@*0+/-+$#V0X[MP1%-(3X1G)J84
M!26M$,:38#T-/&)7%GW+ H*62<H<1TRJL1>SG&3A'YUOCD>[5PWV=1KKTVB@
M_ ,DB;2V/[#6P3L@FX<<B.:Q#%%JYBABA<&(%UPB(UE$#CM-62BPC4 F^3I=
M1B?+SHU5J\3RWY73GE=GO9$N!/D)*;5_D)N8)@HZUT(EPYTYF0#@>"G7DF=_
M.YR-J;M*#K?V<L/446K-<G'1F0K1ILOW@P/J6K:/!$C<&7M?"7_:@T$VR=TD
MP-U02O;-G>,Q56";T#-\ A1/?WH;3A*>ER8]0U<9PNVF[C+GC7W$&L]>P  ;
MK5Z#,88 *A7#OZU7D)U"(B":'9,,18#OR?U>T^V;H'B=!JV(=*-Q,/7&[=1C
MSP]RD\I!V:"R"V9VNG'JS+CA4:D1#JQ <C4O>_T/Z:] 99(]S[,!*Q#ZN=5U
M_R*U @1\&,%/@Y BSZ7UN6R##4F=.X'##-.,P[>#$4EN0?GV9@B+D.NT9N-2
MS6F_1)//1ZM!0\%Q>%CHX)]#CLEBOX5QW: !HK\Z'%SO'),(WH@E 6GF>2HR
M[0 .K$1.1&FT"T+$U%O]^9(3MO\8B]P)Z.!8K4O+,6FO-^AU?!FN2^E+Z;Y9
M/<[;*EFL^J%];D=]$.U2])+4EIQE,"RUMS<:HEY$%["D(/B5<SI(WNJH7W*N
M!4U.#P"^]Q$&-5A/5Y8GCLH^[R%\\;D59^J M>GDME! J&[;?7EU:>P,I P:
MW1[@ENVT3W(L );AW'Q(+1*OJO4LT2]#Z2Q+S3/7[:4S*J-^V@P":.DFJ#@!
M+.N6S;&F%SHC2:*DZXTJ\I7Z\PX2ZI6HF+]S!#^47YRO'Z;!7'2,"Q48S@\B
M7S5VZ&"P0X#/].Q@^AT _;RM]JS]6V-X&3H L<\(_:T!Q'-X.@#Y&O< '@]F
M+,]S7[(.3TB/F J[5:PZ!4M".4.WHU,UD?HYD'-O>_->1&H]:P^(5257TVVK
M[=6,WMQ$@-,61GLP;HL'*O:,X-] ;J\&>0\E_064.0M:/SVD1-'V>=I5+C>D
M\Z.FKXUM5WYG8G.3[WSZ()>.G"YGD3>$%>:G[T[+#\E2B@F4873G'7=6%,I@
M*056@3M"K"@89DX[^(N1U,QK+2,S6HL7XGT3O6UES@2_Y._=S:/;[4ZE>3R-
MC?@?K+NB>=8\!I_9!BD,XK:(B#,2D;;<(Z>H\((7@J>&J)JOPT)^:1]^.I[R
M.4=B\Z"96/*$$F5K, !3"48)%/%;HC#!<D;A)6)@@0=+M:4%H#B7!;P%H;J*
MPLP)UT(49DJX,OC7H9<967&7>P>[QTY8XRCAR!(% L.]0\H[C+!1@5"CA2+%
MV@9[CMF2[1= ^6]97QT*8,7*!TPDC\8J#K_":CN<_HY-O;X/LKYP[>:QPE0)
MY3S"SEK$A8FPTN &80$^NQ,<:P58P)]CM<2,SR0TS+CCLR8U@47.0@";7!KC
MNU#!>QJ5Q?,_,\[Q5 K"VRH[86_6K-2L+TG+%?Q\C*W#/C"&@DC2@HE'.AJ'
MA//1<D$-YH &=,GAGH:)PV0#1C97PD@R4WHZD[C)8(YY+4]2KKA417@$!T9T
MT1MDW_J/O*D+*SCI\ON/V=VDBKKAR2W&@H\^&G[^EH5FF#^*U*$&E7,3-/U/
MV_-7\*_3X7EGX_\#4$L#!!0    ( +6!;E;0*8AW"!   )2M   1    >71E
M;BTR,#(R,3(S,2YX<V3M76USVK@6_MY?H<N7VYU9&B!IFV2:[E!"VNQ-0A;(
M=N^GCK %:&HL5K+3<'_]/9+M8)!M600V[#J=*0%;YY%TGJ.7<R3+'WYYF'GH
MGG!!F7]6:[YIU!#Q'>92?W)6NQM>U(]KOWQ\]>K#O^KU/S[UK] Y<\(9\0/4
MX00'Q$4_:#!%7UTBOJ,Q9S/TE?'O]![7ZQ^54(?-%YQ.I@%J-5J'ZW?Y:?/(
M>7]\V#BNMW#SJ'YTY)[41R=OW3H^?/>^,1HWCX\:[WZ>G#;?-9I'AZZ\WFC6
MCT"B?GST=E1OC([?CUQRV'):1($^B%/A3,D,(ZB8+TX?Q%EM&@3STX.#'S]^
MO/EQ^(;QR4&KT6@>_'%]-5!):W%:C_K?5U(_C+B7I#\\D+='6) D^2(@_DKR
M!26>VVR,*'OCL!D(M5K-UF$S22_1: $^]46 ?><1WPUX/5C,B<B6@=L'\K;,
MIU$'K;0@)QP$G(["@%PP/CLG8QQZP5DM]/\,L4?'E+A KT<D@2L)4K<#S"<D
MN,$S(N;8(:4J^/$50E+S=#9G/$"^)CS&8J0*+7B@Q&HH8NF*.3A0IB=3"DBJ
MZJ>E/R!>(.2ONOSUYD&XM8/RN8:B/L%X;I5S6B;*/;YB4X*4R35/3DX.'J0-
M99<@TR14^KK\6F^VZH=-BVSS;*M\WO"KGLAMHPS+]F-7AD3NB67(;"]YMF"2
M5+]%R6(H($&<-Q-V?^"PT _XHHPM9HDD/VRL< 7,)=0F[R2Y_)*1)_9]%BAY
M>26^-I]3?\RB"W!)\G>:D-@GXZ0[U+K;C):B_IQB[G#F&9K5P9RS.>$!)2+=
M52N *2?CLYKLL.M)I_7-PZ,W4)(DB9;!JB7*VP<@0KRK94T266D,9S4!!'@D
MTLT^5WS.B6W%043 F*&(_MO7W\&>;?U!Q F]?T;U73*VK3Z(4)]N4'LI/83[
MB+IGM0Z#>68-R6MW_<NBB87*-$J>X"6(RZ)\;*A_351?3DKK2$E].%A/NX82
M"N+V_(_J^[IMQ\)QD@+!-:,H+;>JS4RQ^&*BO@*EMD.7!I?0W?*9*DEY_6J2
M1E6W5E6M % *H4)J[_1N!KVKR_/VL'O^J7W5ONET!U^ZW>' PKYS(8Q$'(+V
M!Z ZDAA]"@K%6"@">^%D.+C%'&HU)0&%<FZ!H%4\(UM'Y=E"KU>P?ZHH>X,A
M?%YW;X:#WD7OMMMO#R_A[F;,Y6 967M;Q-H2%/4NT!+VA:^+3N_ZMM_]TKT9
M7/[>O>H-MD";#FED[UUY]E;0D81_8?&BTQY\N;CJ?=T&>X]01M;>6[ &J$C!
MOK!U,1CV.O_YTKLZ[_8'W=_N+H?_?3IM&9A&_H[+\Y>&_S>*,GAA,D/K6YB\
MV&1@Y/CD:1Q7>(9S@X.0$S;^% KJ$R&P[W["@@HVODW5JSS%)?%,C#8;TJVC
MPO&8 #SX$0$C-D8)- )LI,#EU31\A?@;A+,9Y@LV'M")3\=@OG[0=E0\EOJ3
M6^91AQ)1GK^2>$;^FNO\Q<"2JA0T6F*C!+Q"[%WZ]T0$LM.RH"@M9.2AM<Y#
M2KI"BK[ E/^.O9!<$RP58:GR;'&C\@_7E2]QD )"::0*$7$;Q847T'=W_PSI
M7-;_A@3EJ<@#,))QM$Y&@J3&D4>LGQ&@58@0Z(!Y2-SNPYSXPF:D6!<T$O!V
MG8 8 240%=)ZA\UF-.J%P?HZ3(V Q+<;JXM C&R\6V<CA:9:Q I>A:BYHHZT
MQO:$$]MA0A<UTO!^G888 RU!*J3[#I[3 'N#@#G?P0:_8LZQ%0-Y $8>CK7F
M$"$A!:4:1 )6(3Y4Y<'%(M"[S&0G;>D-YL@;V3C1O <)5%=(* U5(2ZN8,)H
M,SK$Z4VZ;FF>=B18(<U>^J T,L0/-NI-"QEUK'G#D312XA72='<V]]B"D$_$
M!UB;CEV3-.I<\WP3")1@5$CQG^4.%%].)_I0#<R=Z6?+D347P4B$Y@4OH5""
MA3Y7;6C]3-B$X_F4.AMME,D6-W*A.<%+G(INFND33SXR<(MYL!B"$0KLV#&1
M!V#D0O.'8R2DH% *JT)T#,*1('^&4('N/7S8!*Y7!8WJUQS@)0)2$)72>IFH
M_ZY6$TJO*K0T;[G\J@)ZG7RKTO)>.0*&>.1MG]88U4BJYGK;D!IE4B5*4PLX
MMKSIHD9R-$\\A5%%[6>N!-GR4 1B8N10\]=S%I6JR$[.XI M/\4P1H8T;[]@
MI:F*+*VM'-FRDRUN9$6+!ZPO/U61BIQXN2TEQ3!&:K0(07[PO8HD94?1K2=M
M12A&BK3 05Y$OHH$11%S6T)6I(P$:-&"2+R*ZDZ%WNUGP.NB1L5K<8)T[+Z*
MZL\,/=H2401BI$0+ V1',:M(3KG]M^<DP-2SH,L.UDB@YO+;[.Y%K^-\JL1K
MN9!+GSC,=ZA'56G9N(/%5/Z7/L<]]N*=0GUPX#EU I@)P#UK6]A]48SVH^\/
M*!\RDG'V=-&DC,S\9_6)4N53)K@L873_Q?CR&.^*@,[D L:=(./0NZ+W1.S(
MN(JR,AG/D19 L3*>QZQ1E#=2F;^812Y7;?CE4B\,0$]RCR'SE>O0?7"\T"7N
M!6>SSK(V;'P>IQU,,=^9 6VG4$93>\)3$#) D2HDBDH9>\1).9$L*$J55 (G
M945185],,]<*;F100:IJ1U:FX1L-1@M261G,8WZ5Y#RU,F'-9X:LD2LM:K6R
M-%)! C*7-=I"$#75NZ)X!',N>210?-_%P:,(\S%,RT+.P:35K-^:PIWD;C0"
M+2Z6MQH#W;DJBYI4IDJ3I'(1#M+"T)=C]%BHV!.JHE7E+,98VX<!Q\BT%H K
M7-6I(%%KZS+6!.7(&XG1 G3ZPDX%V2AX.,B:F1)81I:TF%WA\T:5I$Q[?,B:
MJ%P$(SU:1$Y_#JF2G.2L;&[N.90%-#*FQ< *%DVK[AKD*%V>M.V&'NF-DRN7
M0H3R:.%MT6K.P<3S6RU<5<ASDB'JC9>7DSQ?N->98>-4_$<^CL#OB7O!^$4H
M5R1V90]VN1IM1(LSE;,1&?E.AY62@B H"8J*4FW;R=XS\82P43D\(]]ZF"AO
M-T;5>_YLC:NKO;G\VG9 -S18;(G+ F0CJUI J8#5J,%&&:$DIQ>&'U74AFYK
MIK0C[N#6&+K6QV#/.$72!@L,V\G/: WE=URIT%*2NUR6<M%8=N"I8-)XQ6"J
M.97/)FZYOJONWT%VHC^XVY9=F."-9J"%G0K,(+56'=&MLD.O988_59+S:)/<
MM=Q= OUCV\?>0NU:4==345A[3]L2V,BS%L6*]_?549()2G*1S5G=78DCO]!K
M9.%;<V<$?VN^4+Q#BG\#'R2@031+?E1AS$:'B4UB99; 1GKUHWP2>M.9I),\
MDJPRJC"]FWM4.?)&LO1X9T)6M?VEU ;I#1;1-5DC#QG/%Z9W5[\P +4?DH<@
MQ-X6^%A#,K'S3HL]KK #]R(@%.-6DJ_UDVFL:<H#,+*C1?VT$VXJ24C>2376
MQ)B C 1I8;K\DV^JR5360R#V-!6A&#G23R?*>9:D@OSD'&UCS9 !Q\B1%@K+
M/2FGDC2M'7VSP6;63'DC+7IH:NT$G7\Z&Q\.5M\L&OU>>?NH?/=H_')CQ95\
M[>&WY3"@.O\AX;,:PB,1<+#BL]H8>_)MB?*=J>G1+)76IYXG'VT[JP4\E"]6
ME&]Q/IT33IDKBW=6<T.NRE!# D@!YS.4OSYS%L[/:E%R&A" "E3RZ$HB= EW
M),SRE:I:%3J_=J:$>K\2%_N3#N-S%HE>D]E(OE!Q69NHA%%E3%);K]?CZZI/
M73;#M$S-UO?0%+*3G?CYZ5%;__5%"KD$/%%)/RV626[Q0EYJ_\#<51^B%P;R
M%<ORA>LWX3JA*PK8?D9FY47O?PZL="?4LQ!E#)N)H#?N$^B_0I),TMJ^>PY7
M/*:V>"[/2L]1BA6&C;%$]T;8DROR<(.,J)T:9LR''IDORI@0]I*E*P 5HL-\
M05W"XV4-A]![8)3PE4/S\JQD$ZQ]54R'R7*Q*$B4LO3?0IB-$.XM$L8O0F78
M0'RT['9!B( F(.M48#K; +=H0VN:<SAQ=VA3F_86\;IEY"L-V3G,_I0A;;]?
MRL_IF3NF&^8[6$Q5G#+N/:)H3*X."B3VM6W%XVE,B(BZAL(&4R"Q>2O8:1UO
M.;NG0C99QE,A.OAU!TU:KN".0G!NNIC[T,!%;PQW")WX<G9-78HY+1AZM@.^
MM^9!A""D-U<CAS^!0GO2N)._;IL3G&\II81W. 6%AHY+5!)HX[) YR3Z>^FO
MKSGF5K&,Z+YR>T[&A,/H _8:/2FU4O1%;IV-<GO:#0R(;&OM]+Y@XMZ MR>G
MP:U&\Z38E2HMO@\^E7$T%H;A&(8O&A6RT!W;>CY[X,EAN7M<39W5$S-"=NY]
MF)443K9S)'9H"P " W%0HD8KP?1K_$!GX0RHX##SE8Y3G]#9*.1"2>56T@YD
M3[N 9+U&NH:4$R=@O+C1%PCL13-?"$@DVO,Y9]B9#ED\'L%HV\%\!),2+WP8
ML@$A;H]ZAOYM(ZR]T,*R_<6&V9Y,.)E "^R-8:R2!P1PF+66:< &@">,Y;MU
M].)A276G4-Q?L0_^ZZ+5:!T5LVZ6VPN&L\9>F',E8^_[#8;N+/%]J.O:K#F:
M7,D/F[GVNM3S3[(C#CZMV=LUEK96BCZ#Z#Y0)P]-HRY<HMC[BA=?&8R(_C46
M OK3$&;*@2BN:'GY?:CMI1\0SX,Q,<1>\FB^VE>G#DA91)]RH\HG#SK6 A?*
M#F:'50^27,I,)6!@D$^!D$>G7\[X5D\ZZ_WP"1=3.N],Y7SX-IJQY6KB*9![
M,=',BZ7N(CY;S;!LM(@3^YX[72A:S>.90[%J:G8+U+0:C7>&P2(KZ3YTEVHT
M[@53PE.[7-IQ'?)J8Q#:D;<LHY;^Y D-OC!F4"ST_ & C@<C[N/SXSW>IY-I
M-.L@;GZE"H5VQ5/9]M,^:C;.&0P=BS[#+O25S6;C\V+F@W<'7KR''5+<J,K+
M[T-+:X?0=5LTLOSTS]V^4IU9T^#(92;=!S;2!3LN7X?C?:I#?/I?:K%KR+$K
MHT)W_@C*1]SEG?S% DN4/8VAW88CF)$G<1&#0Y.9=A\8+1J$>N-X*LGX^G:C
MC0:U0KSG'^_6-KQUPIG:T@?5F$ES5=/!@I&OK/B>FG,7_*G)0A5]N;72[+6:
MQ/;$2TVMU:76)-7DI#>^ T.4"WAE5OJ*I/?5RP(7F4\(M#KI &%_D3H!YAH'
MSC2_,1L%]W5-]ZF[<+X222YQV]"F\83TB>Q.Y0H \Y6B0NS)'LTTH_K+B_'<
M$[7X!,0+N=E[R"D84UN>M:\VS2<[#SLAM*6"(<0*8U_;W&<@JN>GGS]8'M*;
M/X04"OU=UEP&9![$*PJ6JRZ9DOLP2U*-=%30CD>+99)T.T[VQ?3&T9GH[3"8
M,D[_IS:=RF@BS(F6.Y&C-*;PZ/,49B\"J]J6F_BX,5F'#;=,/P5R3Z=R.3$8
MT#(5]J&;1[&_+'BCGF81SA1&NX^O_@]02P,$%     @ M8%N5A/R>Q=B(
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M:7":M( +]7RLA*)R5\FX/T#-0Q<L:2F1+5M+KCZO?\0PP[_]Y7\ 4$L#!!0
M   ( +6!;E8*\=*R@$H  'P] P 5    >71E;BTR,#(R,3(S,5]D968N>&UL
M[;U9=UM'LB;Z?GZ%K_OU1CGGH5;7Z25K<.M<VU1+<KG["2N'2 I=(* #@+)X
M?OV-W #%$21 Y 9 4K5<$@=H[R\COLR,R(SAO_^/KR>C'[[@=#:<C/_Q(_\;
M^_$''*=)'HZ/__'C'Q_?@/OQ?_S[O_W;?_]_ /[WS^]__>'5))V>X'C^P\LI
MACGF'_X:SC_]\&?&V;]^*-/)R0]_3J;_&GX) /_>_:.7D\]GT^'QI_D/@@EY
M_;?3OW.5K)/,@0A<@5+90_0Z0Y#&LEBX4\S\O\=_YX9Q)7/].>.@Z%^ 4SH"
MB\[&C%(D@=U#1\/QO_Y>_XAAAC_0X,:S[MM__/AI/O_\]Y]^^NNOO_[V-4Y'
M?YM,CW\2C,F?SC_]X_+C7V]\_B_9?9I[[W_J?OOMH[/A;1^DQ_*?_O=OOWY(
MG_ DP' \FX=QNG@!O3[/O_W#RVCT3XM?TD=GP[_/NG__ZR2%>:>>>X?PP\I/
MU._@_&-0?P1<@.1_^SK+/_[[O_WPPT)R89JFDQ&^Q_+#\LL_WK^]B70XGO^4
MAR<_+3_S4QB-"''WA/G99_S'C[/AR><1GO_LTQ3+2O3G0ZZ@=(7SW^K3?MH:
MTR<",DVG$8%^BN-*\(88;WOZ]IB_/0LREG ZFC=$?//93?%.3L*PI8!O/+H!
MVNY!<((G$:<MH5YY[B6<YR"O(ZR//!OB*',6AY._I<G)3QW ET>_?SCZ]>VK
M%Q]?O_KPD?[\[?7O'S\<O3EZ]_K]BX]OZ;?WHSZ;XYB@"<'%8G;_MS6>>@DS
MD6,X'M;UYE?Z=OGHBJXY>OQ*4#/F'W\8YG_\.-0B2ZX8\P:]LLK&:+AP/G@3
ML]0,!VL\OP[C?""C2;KRNE%=1B??]#X*$4?=3P>G,S@.X?/@PYQVM+JYT<CQ
M+7TY&R R9U!I,$DY4"E8\"PE\"IEG1ESTJB;K)F=L["$6>QXLWS%3U4Q/^%H
M/CO_2:>J3DVK42S4\_!QO<<O.#[%V8LXFT]#F@^2%LB]+F!<C*"$4W6_-: \
MHN Y:Z-:C^HZAJMCNB#=B^GYZ):S]H'3NMHB3;4[GS04ZD)S-( ??YA,,T[_
M\2-KI.0W-.Z7DW$'Z4\RS5Z>SN:3$YR^_II&I]6J>S&;(?V7/X:O R]RB9+V
M,$Q(X^?.@'=. N-96IE"#%;WPX--8.Z>*MOI]G:B]*:8FUSBVW+IY60VG[T8
MY]=?/],>?$4.A1?+"Z# 3!/&&H@Y:#+>E0P8O(CAEDUT*\*LPO+H%Y F0FZH
M_&HX=*".RI*R[W&&].A/!/(5_60T^5Q'?XYW0!,B>"XC\. 15,X*8BP*'$86
M;%1>1GZ?;;+I2W>O]39JFNQ QCTL!!]P1+\Z_@7'. TCPO@BGY#$JP3FPR^X
MA#G(G ?.90(='*%408*71@!F[A(MEAA0MK:2UD+VR.G2HQINDD6TWC5H=<S)
M,.0$Q190TGAP7A3(W/)$.+7TO.?=XHD08"O1WE2UW%;51Y^Q4F]\_'9,[A_^
M.IEU2Y4)7$20/DI0H2 $)),I(8'-=7C>--;V+3 >O5FPK6A[F-B_3\:3JZB6
M//S&;<D-BXH9"$()4#IQ\)@%2!TC-S(&=MT4V%KW]X)Z]$QH*_:&JT!GQ?Q"
M$CD:O\=1O05X%Z;SL[?C+SB;U_$/I+ ZQ4B#S9K\I6@=!"=Y/;,7,DB/0NFU
M3,.[WK)[!3?6R*0/<?9@!1[-/^%TY=@'P5A50K&$R5MRC@6'*#SM16AD2$(9
MKT+KA?].1$^%&#W(?Y>[PR %IYQFM%FY2$9*< 112P=%2RS.Y)"UW]6N\-0X
MT4;J/9B&%V;+^8G7<'Q*()=VS60\^QG+9(J+SWT,7W'V^BO)@]X_'(?I6;=O
MTNA2/2N;='[/V_$<I[06#I(203JBMLJ5Z4Q(<+(D2"*3#63)1K*MSZU[',ZC
M-U .1=4W6:S:L)@@+V?5S^1ZE^%\P#G-4*D42&4KK,+ 99= 1)<Y.BV-:;VD
MK8#R1-BSG8AO:EYOO9WA_)+GY3D:YZ0'Y)R!\LZ#YR$!(R>;!I@E%ZSU%G89
MP*/7\L/%>5.W9EO=O@[3,2TRLW<X_? I3/'G,!NF04B<*>W)L1:60+E,H&Q1
M$$WDOIB<A<N-=7PKD$>OZ^W%>U/GMK7.7PU'I^1B#02Y4271!A-<UJ!XS&0U
M)P_)6NET(+>*EYZUOH3RY/3^$!'?U+S;5O-_8HT[Q/SB"YDCQ_C[:17*4>D@
MSHY.YS4HK[MX/;?'K405/1=0K"&FHD5PG)!+AYI9R9A$VY@2FV)\]%SI52DW
M2>1W1:+%6I=*-BPI U;P1&"# 9]4/>/WH0CA@I%B3PS:TQ;3K[X?2*[-E=7#
MJ=H*L,O%\P;F 7*A+$&#[+P@NUA&\)DE<$9)*0IW);1V?C>$^#S9U41A/9S+
M?5NX/X8XPH$2Y$DA]Q!T"J "TQ C<[09([<YDXG&>XMD[! T9,>E<//>-ZPM
MQ'C;HO'#(GCX[VDTF6'^QX_SZ2E>_' RGN/7^>M1]\)__#C#XYL7'>LS83:=
M#]Y-)_DTS8^F'W#Z99CPQ=?A;* %LRK% $9C=<.2@>B% &-%"*AU0%S+XZ$7
M7.(!?7?!@57O;LB".P+\[V#% ]0X:2C.AAO))3PU-F"):/:J6SK7 C6XEF6P
MO:YO FFY*:S*CKA0=QL=W51X(P'O3/N"U?@PH4 G6N<49\1T1OM<L=KPS*I'
MOM:%_&%I_4J.R5Z4OHE<>[ 9?YF&\?RWSB@:Q.*ED9[<Z<(D*$6@ HLT0H?)
MN^(1FV_HEUZ_.UNOH4(F;:2Y,GK_O_]T31ID@ORK?3K0AX]'+_^__WGTZZO7
M[S^\_E]_O/WX?UJF!=WR]%[3@^X;S?4T(9DC1XTE6JUBUC&AR,$4;DRQTMJ5
M:4*WO*=YNA 37CN3' A>#SRY]>!UJE8&_65CB1C=P:<+O1VG*889OL+%WV_'
M'^:3]*]/DQ%Q??;Z/T^'\[/WD]'HS63Z5YCF@2>-1%TL6%<R^3D\@",3"BS-
M&LD$%JM:!W]M"/$@3LTVX<8M=V6]J:2'7*2;X 8>3<G!"8BL;L71) B&T5;,
M1(A%E,!UZ^/VFRAVSX->%7?#4]U*ZGVD#]PX$_$N^6")^C)% 4IP!:[8FOT?
MN0DRAYA;)Q =P#'53EFPE<Q[.(=ZD?_OZ2*.<?9Q\B+G3M9A]"X,\]OQR_!Y
M. ^C#G2M3)!?3DYJ-$ 7/O(>23*SX1R7-M\[G XG^3VFR?%"8_\,HU,<H'#)
M69O !_2@I(O@,$C0FOY*V92@8F-.]3VFITW1@V)$#R%PG>3>SF:GF%^=3FD*
M+F!VV%Z3:3XYP_-HEW>C,!Z0X"0!*[0L1Y*EM :<3P*XP,AYDIICZF-O7!_B
MT^9CG_KJ(39M!=S%PG\;7B\E9TY8,"J3Y>E* )^L(%;D$+@7S(C6!OJF&)\E
MP=IHK(<8N+LFQ'N<S:?#5&^\ZJ=>5.'\CO.C0H(J.)R?TI &)3@>(PH(KA@2
MEK'@:<J Y)H;Y871HO66O"WF9\G ?C3:0^3>G3-HK0$XS\GC820]4<-*59&T
M: <#V:F"Q2&:T#HT8VO0SY*3/>FTA]#"2W;L,G'KX^1C^%JK>U2!T8@(['DD
MY%5#=N!*\8&6<[#>D%.6J^"LY<"UYYE[+5EIO2=O ?=I$W%7>NPAQO&N=?WE
M9+PL['A4%E_/AW%$KE.B3\Z'=5&7,84@R4\JD8/BF<P,J7BM+E$*8S;9Y@E:
M6P%^VC3<G2Y[B).\<S&_'[WS-A6L(5E!!II&@H/W,8'V05E1DK=^1R[PFHB?
M)17[T.8MQ\YM[A]6S*3?\:_N-[.!% *EUQJ2JDMW<1IH*7<@:+HP1N)AOGG5
MFG6 /4MJ;:&;6QBT_<W%71/@ J8@)YT\'X1D:\4=5 A.,E_]="&D],;DG2Y;
MSYM#VVCG%A)M??/1Y>U7:W&*GVH(TY=E)BR) (?'XY>GTRF.T]G':2!K,G7J
M&>?NNU%G7-::$#5M[L5T.*-!7AYJYPK52H&)7)T8;  M48/2@OSR8$NM*J23
M\EX7W[J$XPZ&];3I>VB\N(7[6]^!7,W[E#D+'[.#S+0!9:6!$!T'85(F3UT7
MC*U3+/><1KM+/CU<UK=HOLWUQ-4P!).TLXIV<^MK)H0N"D*BU3@*DXTOI58J
MV7'P1XM@AA@D<U$Z2%U9+JS7C%WL8<@Y25.0C-W=!C-LG262K"S<T!XI RN@
MA/80.2_ E78F.J9HE$\U2V2; *TMQ+CO+)$;0UA,E[H_3<;U3*P+I0X\U$AJ
M2W))NAKD#**7$D@RWJ/5F@C?%S%N W0@>20;*7H59[86> ^A6]<P+:.MUP&U
M25+)!FRX%=!NDTMZ4-SU3/IF4M\9)7*@W0Z9@&QKM1YM.9D;F(!+:2,&[U5L
M[8#LD HK,D[VQ81-A-U+7?B3D\G"D%VF3:"P+NF<0.O 0,FHR,5.!21]RXSQ
M3EXO]-B@Q.\U$+LW[ALHYT:!WVTDVT,(]XJPO"6X)))/A0QZYVOZI.89@C$9
M4 3FF(@J8^N2CW<">@H4:"?Q'F;^BY1.3TZ[N]%5IQ=+H(877DRLT<:R!L<%
M 5&& $4%+Q/9TUFU#O1?&]R3H$DOFN@A[OL]SFFLF,^K RU1!1&CHV$";8 "
ME%*<+&9RNEB)2KDL9 ZMSP)N1_(4R-! QCW$/[\<A=GLJ/P9IC7!\FCZOM;-
MZ"RBG'TFARD TXPL(I/)NPZTE"D7/18RB@QKK?R58)Z !]E&T'VT@K@-V#G?
MUX#6DP]Y!ZS]>)*-%+@.+;:0?A^>Q!T0A40M/0$S:!WM6[4V1RV0G+0/606C
M9&Y=<W/GQ+C'K]P]+S81>A_%L!:8EON7RT[[2+X/$[9>7JD$CA$LS8MP4AHI
M0NNXM"L ]M UII5JKM>L>K!<=U7DX,/IR4F8GDW*A^'Q>%B&B>"2C3LYK=6D
MC]]-1L,TQ-GKV7QX4FW>/V983D>_DJT[>U6-G]'L*N#U:A]L_](F)1$:C_U:
MI017(B-K4D>R]Q6M"X$KI7.*7!E5=)&#[5^_W:1_-ZTE[.=G->5E7KL;D7W\
M^>J=#!<F)AD9!,L15'(&G)(*3,&L9;$YY=;>Y/VHMEWL5K[A7,(%!P9UY"PI
M2#:SNLZ3YU];!8A('IU+(N74^F!M#5B[7Q@;<^3Z^MA:%7T44TB?,)^.\*BL
M!+OP)*+BKFBM@66E:BD<A."= )KMW).,:*MH;3>MBVU7M[H]LZ4751S*_>_*
M(?U\]I$>T5F?-A>E7)(0,7E0GF6(9)J %.@SS09K>6O#; U8>_/D>Z'#NBO4
M ]72@_&^>O3T@*41NP[$GKS^->#MQ_MOKMIUJ;.E7O9$H<QE-)IQX,[4J@XJ
M0L@Z0&$Q)"YT<+'UX>'>J'//^< A,&<3=?04C=!!6OJVFJ7DM"VTQF*A?9V\
MY)"S):--98Z&&Y=:;TW7(!R0<?Q0-=T2A/!0&?=@";\YG8Z[S%\:ZIOAURX'
M^/QZU)/YIK("IC4A\\%#U"D"-^3RJY)<;EX<?36:IT>$1I+O)R3E\^D<IQ\F
M9?Y7J+W&YF%\7//17LQF>$Y<7Z04VBN0J8N)YA$B_0EHC$[*&?+D6N?IK 7L
MZ3&EO3Y67D_MY2#R!7V7:\7_X1>\%+3S^FL:G6;,72.\,$JGBTR-R:([ 'UV
M$;C=^Y%E&W@[/-SL09[7CD$C\]EA"%XQJX)USAD9 LJHG>(JY36/0=L W3(*
MYQ*&BW3;*Q"ZZ==!."K7^S)='((4H9/GW<F_X*"*C^");."E3EIJEU-JG8_3
M"OO6D4S;X7AQ4GDQX"SPI+,''9,#Y8(DV04$F3/WTI M5)I'.;4 OOL-9R^<
MO1$TM7.E]WH0O.5P%H=20146:OLC56\$5=9DS*?"P67AF'."E]2\*ES3$>SJ
M4/D@&+Q'Y1_* ?66 __Y[/8'+,(J$@I6O !4GDQ>4>]X3$00BHS=%"TJWKKU
M7X_#V?^!^.Y)VG;%;T:6/F*Q;T7V>SCYYK^M@:^GL_;[L.WGH/U@R+ 62;?4
MY#X8YWF6I=!,%2%)4$$8\$(P*(%FKO22-K;61_/[8=H]Y_*/EFB;*+"/P_QE
M#=S.I3[Z7*5S?E)D65"F:! U*%J5VI>GWMY[7YSD47O!6F_,*\$<BO/T4+U=
M/]UO(O0>')UKM3_/$^*P.!L9A^(U@F+"0M F@U,N&A,2BZIU:8);@3PQ%FPO
M[-[#@0.2O^2T FM3I)5/2 B<)2A&"V&32KQY[8$]AP/WJO&'"W=71_%OQU]P
M69!UBQ/S6Y[2Y&#[/G37&Y9QZ9A/M1H/*J,SN3"D,Z9T\2YK@8-;GM?LH.@+
M/:[Z4K6 ;;A<H_'B5$()#,XF!]$S!4H' \&6VA5;<9*E"8ZWCC3=".#V=7LF
MT_E'G)Y<DO.W?M#)62^-)2O*EII66S($Q25(2_N=$\[JY@W;[\*SAT9EO7'E
M9F.B1GKH(]O]VMA?89Q?,K]/"/GPOVKEY]F\]HZOP36.8"D&AOE:WR$;(+.H
M5ELS)<B:Q-E\2]H4XQZXU$S#U]V7/M73A[]\-]Z+#.Y?II/9[(_Q%,.H#J 6
M]OL9RZ0>@'T=&(Q<>I[ .TM[O$!+@ZC=:S.+21NGI6Q^Q]0"^/,A7@^*[*,!
MVP,'4:L)7AJ$9@:=9^!J,4'EL@)?BXRSI*2.16,QS;NLM0#^G8U;*+*'X@"K
MS8RKPQDP;IQ124.RQM8*I@6"H%E32E;9R""2[WN+787M"7.JB3IZ:'KVZV1\
M?&W\ ^.S4*@<Z.!J6D7.X&M]+>5U",(GP;&U\7X+C*=LLV\K]1YLJVN+WC4!
M+"X.+=E_GMD /!E:XK (\"EH*$)F5"E%^GUC8JP!:V>E37=&C]:Z.)1(@S?#
M<1BG81B]'=,2>UH?V5W!<%F[S&<&6M4 H,02N$1KH'-:&24M>M]ZP5D!95\W
M_,TU?CW0O('D>UATNN+K!:>S%^.\:#T['!\?E5O0SFH<]>SV7RW/;M<92T_7
M\RW'L9^K_"8$F1R8=@^=L2YY7B_]P+.ZY7N=P7$1P5L54L@EJN;E'@^?J?>$
M AP\43=1:@\$_>/#Q]H8X71Z1H/Y9?(%I^-+F6:9QR2%%&"L*J!,\.32D*>*
MDF!++J5QK:_][P2T>R-_?[J>]*6H7944>A.&TZZ?U&\=;EQXRS7]:!;&^==A
MB,-19[\L?Y_#_-L_F8S#^VK?U)8JW5GR%A>0O>!H<H79OX2N7X):J1*2KZ@R
M5RI'%[V6P0GR-Q*&[ :](-K2"SA__@+&BUMA'(V_O9H^\/MD/+V"Y,+/XBD%
M;BR'B";70V %T1B$4.M\<A(*VM8K6M,!;)VH&6:?Z 7UKYIS^(7<!=+P-XBO
MAK/JX1&B@5$A<BP(1I$3H9#6*6<*@T!.!1K+(O.MK8VUP>U^']@?"V^D=O:B
MP1W<YJX\TW3%\<1U!.YH;U2V!C@%RR!K:S06KVE3>S9'S(=#M%[TU\<U;R>H
MVR9 LL&X6G [2U:;\6H'D04%S'C$8F7*LGE]_%5@GC63FFBHASO9%B):G+:5
MXK.G)16,RZ$:X!JB<QQ<3-8H1X82PP.T*W9Z(GXXA-R/W@_F7/U\]#^?73+S
MWTSQ/T]KP\ON?"2QHM!+"];&2*ZJ=."=D9 L\]FJF(QK?>V[!JQ]G;?OB2^K
M6-M(;SWLQ;?YC]\ +D]!UH'8T\'[&O#V=)[>6K6KJ--8+WNBD,%<A&<"M&)(
M9D.M=N1LAAB#]B6G8$KK**B]4>>^ ^X#8,XFZM@18V;?UN+S!(O$@TC"0*I9
M&F1I>I)!+B!<1A,9C^A:Q]>O@VN/;D$KA:Y!F*VTT4<)NXM)\^W+_SG$*;WD
MT]FO^ 5'W;Q1$:V37@(OB<1@:<<.0C,(RD9F96")-R]GMQ:R[W908^WUZ5M>
MG@<W\2YGW#I@=V@4K02Z=_.HF<;76;::JFM7.]]*T-)QG8HE/]E&"TH5#IY6
M<F",?&:AZ/^VMS.*_7%K??OI,*BUB9;ZI-3;\>?3^:R3 %_NVISV92PH :.A
M1=NR#+X6C0PNH3'"2&MZ.Q2X"><P3*=&BEQ%F2VUT*?M= F:6$(KEL9LF8,B
M<@:5F:_M454]HD/R,UC-E=X!0<3S),A#M+"C%40NH=GDR.YG"D*JU= 3>:*N
M) N%\1"RSMG[UA6 [X#SW CR$"WTT9;RUAOL1;5\S7+2)@(7-6@YZ02.  &F
M))DCSY, [B3HX+N7U4A+/>2N7=1*N1WC[3\]Y_X:V'MRM+;!O:?&J(TXL++8
MS8X4V,,NM]48BJ-M.!@+J=#D5(PC.$1/SD6L-4I0,=UZ&SP\\MW7?/4 N;>)
MWGK@W&^3,9[]%J;_POF;TW'^UF=<$BP;"B3R1$$Y+L!G=%#CV#W/)B1LW7'N
M=B2[MZ=VI\U)<U7TX9NMR';07O#H%<T5$6J833(0>&1@A$[<<YHVNGG4ZV%E
MS!V&3=5"/SUD=3=-<EAG+-_SZE;1M 5!^DQ7>HAV#SVO3F+2)?((%C.YPXI)
M"(76\, <:HU!*]?:&CM\ICXPK^Y@B+J)4G>>5V>T-\68 )Y0DN51/#B;"JAL
ME=)D(VC7VF)[RGEU&^EZH[RZ312UJ[RZ\]YAX5+;L-]QOD6&W#U/;)+KM@GJ
M:UEKP7O'O98L):&BME%C028-RT()]&YPS[-[ZHGZZ[=09,&US$Y[2#Y41\+5
M!(@BR#ATT24;@S&MS>O[4?76"[8K:S60RI04R>E62J1:7H)!"$J#-S%++S,B
MMB[N<C>B VKB]S!FK-W]=7,%])'==5'G[!5^)D=IV%73IZ]'V(E]G)<5(;N?
MKQS,P&"(5AH#ROO:A!#)8H@Q <_):"O(E,36#9!:87]RE-N+4G?9QYIVA0%&
M;DW4"7)(-'LTUOMS1[N[YZ(F'5GDK<-@[L+SY$C43/@]7#VNP^J!+<HD(R1@
MK:RG4%;R!@,:DT7&K+#-6[*M@^O)$:6Y,GJX:[RHXK:Z96]W+.B3"5DZ#ES7
M;KW&2G#9(J0@M=):9%2M;<!UL>TJOZ]GNO2BBD/)R5LYI)_/JO_;G:U(GHMB
M&$#*&M<C=+U<L $8%UR%8(I+K=L[K0%K_UWN6M)AW;WL@6K9I:USJ97X.A![
M.I-? ]Y^CMJ;JW9=ZFRIESU1*,>,MG )0M7375D"!"4LH(Q%^9*2B:US8?9&
MG7O.O@^!.9NHHX].<>>0EN>DD199+20#$V6HC:IJR"EJL#D8<@292+*U3W4-
MP@%9QP]5T_7&<%O(N(_8@M,I2?1TBC34-\.O]:OSJ(>D(U>:U4 *M+6CLH#(
M2P'E&$=18]5%ZS[VJ]$\/2(TDGP/R\"O&&;X:3+*;T\^3R=?%N',2VB,NY0%
MTV"P=C0S29.G[^DK)QQ/14?)6^<"W 'GZ;&BE>S["/#NNJOB],.DS/\*4WP[
MGH?Q\9",\2[ZYOQN#6VPGCS $&@54U9P< D3R&A]CD[ETKSIUUK GAY5VNMC
MY4E+X[M.0GXR7'0\"./\DGSOX?@8QZDK0O;@^\XUGMKDSG-3]-?N/6UTR(5S
M2BE-*L90:[QZ--Y$)TTH@S6>O^U$'M%/)]-0.V"^J/TJCY<E0;OPN+3BU]WE
M?DA59)<*-CDI!6H9@0<F02F,$-!PL*Y$Z6S,+K0^OFB)_Z&+8J7?2B#_ZS1,
M:6*.SM[C#&OJ3PTF780?+EH!OT&<O0MGW4%&],42.VH]1T4&H*MAS_5< [.0
MV1:OP_4CQIO4;X9F]ZODWLAXOISN1Y,-3?D[![ .[F"$CSHYR$P)H#7)0HQD
M?09IDL\\<AO*5@S\3KR-B==:;PW=A#MQUX9& Z>SC+5W<M'5?V&*)H+G&H)%
MR=&Q4M*]N_F];_G.F"TEW]!%N!?845G2=S+]=9AP/,,7QU/L?CV0,FBOO8,2
MD7Q<;R1A+APRYPZE8E%<;_SS +;< > [D?K35P]WM[_0EDP.%>)1' V/N^OD
MV6_AZ_#D].3UU\^+ K02D9%'7!LQ(,E$\PP^) N:RY(SBR8WKP>_!JQG2+2^
ME-9#NLP2XMFE#*(!KUF(0A:(M-: JH5H:WEU"-P68:./2?E^>'09QG?>/%@I
M-WFBV\6.-)#2XB[;%%6DI[VZE%++$&D$VJI)3&3AA>A$C*)UU&W[4>PJ'N5@
MN+EG(AQ*C$L]S3PJEX;5W90&ZYF5"L%J7AN9UCZ%!1E(RZ724LFB6U/Z5B#[
MCV/9#SFN)V%MK:0^6CS<$$:X??SG:=AKP.TIWF5#J/N)?6F@Y.N1XSO0T $0
M2S*)/H0(-M2DB\3(MF#,@*BY_=H)#,U#\ Z"4/=$Q.R?3YLHI@<>K5JZE^B4
M3C)IF0&#UZ B=V2#JMH",#!$;X3UK<-C[D:T>T>A5X7>N.]LIHU=)76^#)^'
M\S#Z,)^D?X5Q_K,3SGSV>_V[CF*;V\XU']WFRO,AX[AV[ZD<VD@6->DI*&NT
M0RF2X5*G3,9V2H-U7[+EG!Z%V>RH=&^Y\ .L2#QU=^-9=T5C$CBK&;"8@Y8B
MAA1;'QC="F1KYS14D[-[YN^G=5K0-Y_"%&=O9[-3S&_'E^;D %7)-CH&QB)-
M1N4,.$T+NZ3U7(BD=3*MR_)M@F\/QQY;<^.&C]B7/GH(!;R$]=UTF/ =3CNL
M@^24IN4S0\@U2(664P@QD3PDLDC[?S&^=5V#55B>&"<>+N?6]WD5U&0!JDM$
M?DE[]I">VQW5OL>$M !G0GJ9KT8I:VE7!8>>U<;'%KQ'2:"%#%XFK^1ZD0L/
M>/EC)L).!-Y# ."[<-89>DLAU"4LC!.^G,SFLT%4DN@9')@D#1 0 S[E>ICO
M3 @V^R2:IS'=@><Q\Z.YO'NXA7M'*L3I%',';;&GO3B=?YI,A_^%>9"U8D8'
M!>@SUG-5(BG9>J *+]85YTOS1G-W(WH2?&@G\Q[NSZZB>Q>F1],/\UISH"O0
M]VV3*RYDE@('R7V-4 @>?,X&;&11)&5<;FY,K(?LZ3&DB0X:WJ MH@X6@UYZ
M=T?3]\/C3_/77S\/"?5 92-,(LX6'[#6$:!%+6(&FV3@D1L6"EO+HKCK+8]9
MT6U%>%.WI@_=XC0-9P1-1LY2*0Y$X1D49P6"J_L6=X@BUC[!<AOM+M_S5/7[
M$#'>U+!MD%::$//L#8EA"?$<&XW9\QPX,Z 5IS&CH3TH954OJC!S75R*[5?W
MU7@>,Q6:R_LF%UR[6(ANP#^?=<-?7%>B-)DSQH'S5!O:>$VHH@7#C%-2>"-\
M?Z4S;L#9671"^^."1C(^E'B!#Z>1'-UAF)Y=.@A9%(!WRF0E,_CN@CL:0XXN
M,5I%+K-%F;AM?AZY"LS^XP:VU/9U%C61>@]W;)=/2,,)?7GIP&.9)+<.PI[N
M_>]'MY^K_D;JO..TNJ$N]L,:Z<@91FLA6>UH:TP(]<P$E##%Q1K#'/N\W=@E
M6^ZYQ]\;63910>L#[7>G<31,1S2N2PV*A0Z!<<5 <$6CI'\"(4L/1LC, V&S
M8KU,I]N>OGMCL[4*)BWEU\,-U:V.44=D(Y2+QAM 6Z].?.UJK6LO],2C2>CJ
M9MG/_>U-,$_-=&@C]3X*$MP&[+S7^1K0>K(9[H"UIWY?;12X#BVVD'X?\5MW
M0(SDA65'4R#'FCR)SD"TPH'.A94BR7-.S>M4[)H8]_7BVCDO-A%Z\QMNVLAP
M]N(\K&@1@/%[+;%".YM@W"_WN$RNNN3DJR=F--#B*"&$$B'QPK+VSMPHB;;J
M5GN]%^[MC&I[#4UZ%F_K)/E;,;XBFVB)T9Z'$F8;ZXX)1==F4#Z5VA&<@43N
M"U->..4>3H&;+WS*%-A2O"M7@=U$:E[85)='56_AVX=NWO^N/F,Y-QSIM>#.
M0O^+/A)9O%361(?*>,6UP%P\9VY5<.?];^TEVE.&J+VMK61J%+)%!SZZRD).
M2Y-2F+$G;Z%MM.>ML_A;G&'M<M=E3+X,HQ'FG\_.1;S\(,DAL*1<(/_-U9!I
M19,\VD2[/N-%JA2DS*UO:[:$?# 7.ALP:"T#J2>M[<H)/[^1Z@(:+R;S.68^
M$"X)I8NC;1\C*"X$1.\81&5U8CXPS9KG2CP$Z),E6%,-]7&B>\?I!7DB] \$
M&8E=#SIE P2?1,U\Q&P$3X&W3L,_W*O$+8C12L:'?Y48'!.^: MDKM(:&:RI
MU0(L%,S*.ZTE"ZWC#Q_55>)&VE[[*G$3J>_G4F@=A-^O$A^BSLUOAQZBB_VP
MAD<MR*P28(*E-;<@(4VA]KWR+FHF@Q?-]Y_'=I78,UDV4<%.KA(=RI*E3P2H
MCC<QLL)]BL!9T2ER[KF^ML,\]JO$C51P[U7B)O+KP8LA,_A+F..[44B7DX@E
M$SI(KB!9A:"$(NO*:P^66:6MD$KYUC7O;T?R9!C04."[NB'JUC,751)D"H$.
MB8$R@H%#0B>SE"GZ6$KS\,5'=:.\C0791NH[OE%>!]KW&^6-%+C!S>%#I+_C
M&V5=5 C)>N F1U"2,]K1 FUK/#/RU4M0>B>GJ0=YH]P7+S81>C\WRC]_"\K_
M/.SLFW!&>CJ_ZQ*,K.!,J+B)I>YOA:!%#BSH4'@P2:GU<E[6>-EA72-NI)F;
MUXCMQ-KZ%OD:L/\(XU/RAPB<.F_I))U)@F=(SM'(K;7@)1; [$LL-@9NURMH
M?-^;GHC"FPJT]22_!NX#?IXO[[._P=.9Y50OS)4)]3Y;%O J.3"988Q,$COY
M0_1]R[N>IL:W%>I*2W"W00*34ENW3,;=[VL!_^D7S&\FTS>GM;E7_X$#F[U_
M%\$$6TCD6H !S]I%AEP3"51)V6>)S)<2>5+<Z7A?@,%F2/H(.M#6.\^T!.6\
MJ8FY$6CN()1DI,]6AM"\G5X_00<7<CR7>5>)8*50!RYS<@\S>8F%T<@]K>'!
M:804,65&.[6^7B>F14NPS4 >RKWO)BRYI2%8CYKIH^+4'><+S$O/O5/@=)>0
MX@0$YASP[)*W:#S+K0,&#O;.=QM2M)+QH=SYKG8Q@T>6+2.+05A7I43C,BF
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MW42U/=#U]<GGT>0,L=M1%CTBEUL^&FY3D(*$1-N*DD&#U\J!3<D[CBFYV/K
M9B68/41/[5W7DSX4U8-M]AYG\^DPS9=%2O\@S<S>?_AC"<Z@0,YUK'6,:[T2
M^LHKZ2$G3O\K@7'=^JSX3D#?F=108;M*YEV8N]=%V*+KRII/;G*W]I!17+LU
MRRD;Q[5&'Z.J'>)B$#YXHZ7E):$?K/F.GDV<582^. $OTF:O'#F03%E0(4>(
MUM!7/B;7N:>L=<;N]JBW"RYZZ.L7:_WLE^[Z\^/D59ACUV!@X(L*&&K!9V]4
MK15J()@H:>2R=I&7QL;U(M:;0SO 1;8M):_&-^U5LWU<XVTYH*/3^6P>QGDX
M/EZD00]<,#[JDD'X2)M*SA*"](KV&(_<1>$+MCZ6:SZ(9T/JPZ#!/ESS50.Z
MVNKI<HL&[TV03H(VCNQOF2QTQ?E*Y,89)[G(K4\BFP_B.Z]W2H.&1Z87NT^\
M8S3Q[.(CET?S=IRF2#^\.9YW.$WTJ:-R:08O/K/\S< RS)K9 $G6DD*R<(C<
M99 &M>6I".7#^J;'CM$_&\(_#G[TT,QHZQG^(N>.$N<15Y?F>E*J%MDT@.2&
M@:HEM2+YQ.0?LY2X8%PU[XO5XW">S5PX-&HT;-BTG1/2_7%>WF]AIIG$56;%
M@NS"!9BT$*/0$)U+1ENCBUPO_KTAJ&=#U+UJLW5SJ"W'<=.#"%%'S;(&R<AY
M4#D4"-DSB#7WW(N2G=[ \&B([#L_=Z;7AEVN[I;E(,8D(EI?PZG)7XV"Y*/H
M#\TEUSH[(T/S1KFW(GDV[&JHD!Y:97V[@\/IEV'"VT'^/AE_P=D<EUS_.)F'
MT>7?UW:?OT_F_P?G[S%-CL?5=+ATJ3>C04:&)M2[G4#2BDQ#L G!VR*2DD;Q
MK!JS;B<#>W8D/CRZ]- RK+=!DB\YG-0<E^6/ZN?X(!J:ZD9R2)[FO5+H:(]0
M&K@VT?HD&6GEL4R.6T?X?98<#H%N3A>_MZ.)[H]_D@S(:%J,C ^<M,H(V@[U
MHL2GK>E>,H'UPLBLE;5L-_;)P_ _.ZKO3?FW7*9L67G_P4$MRVVK2Q7O_M%'
MG)X,;%;:>U2 P110";L"J &**!Y1!U]4HR.'S8 ]&XKN7:NW4'1_%WY7;N;?
MCA=3[D^LJ16T!7W!:3C&[I?USOY-&$Z[?MR#F$W.3C 0#@U-26DA2,%!Z2)3
MT!Q-\_RC'0_QV<R'QT"A6Z;,]ND7U;58=OHXG7[;;A9GW9?]CHO^U=GP;%%Y
MD$K7\AY>0-0A0]*<A8*,*=/:7]T<Y?,C;K^*O(5[;:[M[KJJ_'G%5>7-@)-K
M$^T]5I71SU].QO-I2//3,*H[E!AP;A**% &U#$#NL@"7N ;,T=B(IAZ/][%D
M[W:8SX_]!TZE6Z;/@^__SL>\',;L/8YH2\D?)Q_#US^'\T^?)J,Z#G*$5YRJ
MUJ#Q8G.M .MY31-UX(.0H%U.GDE$T3QI]J%8GQV1=Z+46]CXX'N_6Y)5'^Q5
M+%);+0O<8BA UH]8E)KT,6@(,<7H;30]Q(JW K^K.C/[7F[WHNQ#*6%S-</0
MZFQ4O<6T73<\PRUX07L!JI1IO['<-X\)/;3L]%URX,Y<]DUT\5AR@=<9T_=<
M]HURV3>BR2Z2@A^BX\?"7^-ERHXK\-YD4)9S^BIZT(@L1F=H:,V;KSP:WFZ4
MRWYPM-U$M3O-95<JUPJC'GSM:Z!,(F-8,PE<6QVP6.^T:\RYIY[+OI&NU\YE
MWT11_>>RGQ<_RCR)Z!A8(SO+.$#0+$+@D=3'-1>F]8IU*Y#OS&F@H![6G;L3
MZI'6:%$O9E.R#%1*!6I[!/ ,K2P*.2WAWRL@[)-%6RBLAP)8Y^/LMGB4FC,I
M$5SJ,H%K;^#,:I4O<LD5#3\W+W5V^?W/VY=\L"9Z9,5Y_8\UT/3D!!Z"^_9P
MS:Q0\19B[6%#N88JR.2"2@9";:>F:#^#B#P ]R)9(1GGJK7]<0"^3E\ZWD2:
MS3L,U>VFXA&,F>5VPU'17J41I.6U_3L7X*)T0/N8=;7GAM'7[(-5H4\W'[[[
MO7X;84\:2JIUDZ!+>/BWEB98M XA KI<#05%]!1: &<JZ\2]"UYMJCF^M\8P
M/6CN09+J<<YQ=]YN2AI+QB*M'\5*,AX%.0R8-%A/UF1*ALOK9U!K:,X])<T]
M1%(-S9[9=#YX7TV\Q>J?;<JU,9C3M4]IU D"BP:4B%9*93@S:P7]TU,O;7[T
MW<7&=^6%S]/L?;C,&Z;P?P-Q[HRM 6,30W<="K2?Q_=;MEL(_[KZMI!<P[7W
M.AR1::DPV@#CR8/2Y%J3O\Z@]A6+)1,O@WD,"EQAM;;7WR8":ZRWWTA2)Z<G
MYZ=KH7#:HR-$PVIG(6' 5P.\:-I*4LB^N+6*#]^CN2LOW=TFNI78)RUDUM!4
M[8"$KY> &+0&A<]@:R4*9;DGR\MRX(9KHXBB;+W*T?<I[_)+'Z'R'BRSQC/O
MXW!>M_^WXSS\,LRG8;0H6NUSSDKX&DJ8:SU !ZZ&%X:4@H^B6*/6.D*^1XFW
MOOSYVD+;ZZ)AD9=; =5 P"XPL(:L?AI^_CAY/9X/YV?G%?'7@-K0=MH0WN[M
MJP8*O8L>/6BC[]7E'LA:1!3"%@BZUFLDB."+3\"3"#Y+EM+U0D"/ESAWV'7[
MY<TF2FA]=G)^4?]BG%\-IYCHH\L]DL5H2QV]92G0'IEH494\0"[18_$AY[!>
M(9Z5K]BM%=&K5B;-1;K29MQ)Y?5+<1LOTIP$1F)I78/]CG?T6(U]W9%=J\O.
M7#)268_*1Y68=BZR&((H)14;.%]1E_V.M^V]0KNME]W)D0>#5I$+&VI,CN;D
MT0JD[[*+S9-"MD>][X3A2VE#[R>CT9O)M/YRX),2B?-,2T27RND0/"?1YNPR
MXT+0O#^8.@UWCN0 8T?:,KG'&M@/)<2C*/!>O-"J5E61LE27.=2AN0!%*8'>
ME!),/%R&/[H2?@W9U7O1]TVH<4A%WV]-X%_T9R Q"F]E I]KCYQB./C -!21
MD'$K0REKG67OK<[#8^O2<;A\WY8>?730W#SSW]6&4;Q(4%*9FOGOP OR9K1)
M(1D3;;;?2S@<!E_[5>XA%6-?#H2D5G X/Z7QG4^S@1>8E<D*A.(TPVPA66;T
MH)6SPB*2T[7S'*+-A_&=T = CX9G]*V&=%%%ZV)(AM-L9<8""V1 J>0Y1",+
M&&&UUDDGEG?> 7;S87QG_ '0HV&1]_Z\!N:9="IKT(&1TV[(<W<UILU:;<BB
MLI&QM:X>#L>AW+U4_[FHF#K.Q!A,7?60^J.;PC8L6N[)5DU8:X5P)%ZKVK-%
M.1.=UX[;UNF1NQK;]Q7G4(G40WWV[5?6SF:N40/GAQ>,2VEM 8ZULY?U!6**
M$DI(EF?/F'8'<PJ^:A#?I\#>J=%#W?6&,KY6X>S<<WPW'2:L\B]+^3NA-"-+
M TQQ)'^O S@O21W)80XBA<P/^)!WS5$^HMER<%<<?1#I (^$UQSQP#G#'4<&
M.6&B85H&P=0>#?48,*J4],&956L.[1%-DAVQ=#^3:B.*'52!H'7*(U\=JJ$-
M%TU)$)2,M-]&,BL]2E#D)7KF8O)VY[M/N^%]GU';SJ@]4:V/"YQMAWH^FO5&
MJYRLKAE"EO6H1=1&$KX4,B.LQ\(%%[MOSMYTA-_G5M]SJS_"[>-"ZK[1WG+E
M<.=XL215,$G K!THS RB<1989D%IA1+=X52\>]@8OT^QOJ=8GZ3;QQW8^JUD
MUAMO8$+6 T:PN59MLLE#$"4#EX*A<3X4<7"3;,,Q?I]D_>]C_9'NL*_=[AZF
M5H)';T#HU&7020A<1)H1W*!#Q8(]X/CE]:?4(5[1W:D869R*II9K3[69H2'M
M1&\U9%KE,]?:(![:B>QV(_Z^!/9\\+1#0A[V!>"=PQ3<:F-8!%W(I%(L%@C&
M<F!.\.P82QB:MZ38S="^3[">)U@?%&MXO;A>'\A[QKAFRZ07<=9].Y A*PP9
M00LF07$FP'OGR6%!YRR/*HM&W3_; G]$DV6[N\*#9T5?I[#Q_N'&C=>EU2W$
M2@I1(1K@/M>BQN2Y>TX^O'2H,XI27&@>A[_[8>YNVAP^;P^@;]TFI.OK#G&+
M(6]LL:Z2!!\H1@XNYV2S!J2EL<@$S@4!S 01T,@BY5IU!G<X_=J-_ONL[&U6
M[HFB![@IKK9^5P^9B9"RM0@IU+H8V6CPD7Q*86*.M%P)AH?6HO4!P_P^_7J;
M?GV3[I"2YE[DW-$FC'[!,8UQ]&HXJ[T0Z[W1A3)\=AZMI:7#"/)_N0.7DH?D
M%$/K"N^A8W>? WHV?MCAT>.0N'_W;GMI%7AQ?#S%XS#'MS3KA^/9,/TSC$YQ
MH+A**&G@PEM#*A'USM1D<%('*T,0UAU:TM&#!_N(YDQ[TN[FT+PQXPXP$OI^
MPW;5P)W@1M'X0(A0.P+0$AA]T*"C]]8J&CVV[HJUM\%^GVJ/C7&'[3E='1@?
MF(0B%6_ "E-'5@HX2XL(YRX'*60.JI=R-+V,YOMD.3C.]&'C-:ONC%ER+E4"
M@;8L#D1\21*"3$SJV@C0-M](6H%OR/4P&AVNM[(79=]F+OU0Y9?G?Z^S%/,_
M?IQ/3_'BAY/Q'+_.7X\Z)/_X<8;']8MMJ7ZU9[,7W*J@:V_;&O&,-BT: S"A
MC;3H752M<\*N 'C\Y=PWXL"DE2X.*GGJCK:HZXRII\:0?8QG/^TEMZ#)+MJL
M/T3'CX6_Y! ;P3R92Z:&K7-E(48;((J"/$1EF=]YJ.G!\/:>CID'3MM-5-L#
M75<WG9<Z)*Z< )^R!^6XA&C)6#<E9XY"\*):7S"M!'. [D_ONI[TH:C]5LA_
M,9N=GBR<L#_H5V4R?1.&T\[WFI3+91J;U\W?^,T]5M/?3@K7:NQ[)[Q&&U$+
MH\CVJX<WZ#+Z3 ZK2V)%C?V-,>R]\KXP06?/:<T.TH#2J,G5LAF*1Z]+1)2Z
MERB4K5#O[23ZFS8O*9K6H]]P_FF2)Z/)\=FWHYCH?3+DJ(+UG0^;-"U*0H#V
M)B1-7JSU!U.V>?UA'>".T9;CS8Z0>Z+*(17HOVV(YR?EKVIG&UI1WX<Y#@PZ
M'V0VP'.M#!Q)"SZ(!)SD;W44D1_.5>>Z@WI$,Z$O*O8Y5;;FT2%=8-XVP/?#
MV;_>3+&>E>,49_,ZP&5;ST$D)\HZ&8$L3UD+[6!-&5$@L\X"51(L'/1\N6-L
MWZ=-K].F%:OV46AFZW$N^JH.?)(L<1,@:U$/)%!!S*0,:PF4<LY%<]"6UQUC
M^SY[=C]['L"JON+4'G([>]?FNH@^+1AML3K10F!I77#.@Q>%!HJ8DD 1LNRE
M)%,OH_D^0YK=Z[=ESB&U/KAK9/^<U#:<H^'\[/+>F0KC5D5+IB8Z4#)&LCR5
MABR1)YUS*/W,D9V,[ON<V8DKLSVS#JFJRP8C7>Z@Q;$4.6V>PK,$BGD&CND(
MZ )G#AGWI3S".?3=,MO?''H LV[.(7,X\67<&G+.= %7A 6E):/%( 6HH=FQ
M:&90-R_U\0SCR[8Z$-Z+LO<=7U:[EK^OX^IN^X47(B:10.M:"%HK&H/)'+Q%
M)EDD9RB)=6A*3[U$4?KN@IY77OCXX\@VTO5D6YDW//O\!F)Y*[X.C$U"OM:A
M0/M@A?NCL[80_G7U;2&Y'A59O-:*>PXID;6I4B6C8@Q"X%:S5*)G:UW\[EN!
M*\*4VNMO$X$UUMO25U@"H8%X)E-M_L)\K6ALP>OH0*HB!:.E1;JUHM;NT=R5
ME^[.O-U*[),6,FMXQ=H!61BI2R!D31=I@H'B=,W!4X%,59:!55.5E>2-LBV4
M=_FECU!Y#Y99#]=^5R,=T1:%U5B4H59AS5Y!%%P 4\443(9YV3J=_8G%U#_$
M%MI>%P?5.N&.8,9UQO0]IGZCF/J-:+*+X.2'Z/BQQ-0;$7B.+H+CM$0K+QTX
MY0(YV,IS;227\7M,_>.D[2:JW6E,O3,ZN^3(PK!*@5(F0RAH 9D/BD>R]U/K
MRM1//:9^(UVO'5._B:)V%5/_*Y)89K^'::W%_P6WB)%?\:0F,>_KH+P6PXY1
M*2N]TD9HE45PWG*90]8L:^Z='*QXYG:S]'?\ZT5*D]/Q?#@^?C>=C.G+M*#A
MT?3EI\K)M^/+GQB.TY"$>W$ZBP%I@2,/+?&"Y*OIZC2$!"PD%1.7PLO6LWEK
MT%M50/X59S/$(S+&0WUZIY;NCQ=3#(-: 2P4*<&[4&KK5T%?88)HJD:-#5&R
M^YAY_VMVOVSMEBA7B@NW$W@/X=B_XGR.T]E1>3G%/+Q2;.2DRF+ M&7%U)JI
M.D=0M)Z"1U? >R&-X(J%YO%M]V%Z+NSI14<-3:7;V/WAE)QNXO;YW[DC.1.H
MBF=$<FF(Y%)Y",R1K<E59M:6F'EXR*IRZ]N>"SWZ$7\/)Q>W+H##$+N;]:6%
M.'MUBH,0G61>6;+[:EZO"AJ<$QZ23YHSD;S6K2/1U\7V7$C5J\YZB%1]J)06
MAX/"BR R>0B,,0+/A0#GF0%CC*8QT93)K=.CMP*\JZB'_7)O=SK==Z!#QB'-
MM.,P>DTCF9]U!S&JR&A<3"!=K5F/*,'1_@W2Q)R93%:&N\KHS##][7CRY2=Z
M](*.],4%"V]YX;Z.^'>HY4D;:3<TG2J4!8KSJ@)KX%CC(/Y^[5]^ZVZ/R[<6
M_Z2A[/K4I3<!,14+)@E=*Y\2'I81T'HM<S(NW-E"ZQ!TN.+HN#<5;B*RUA[,
MR_]X^0F'H__ '&JU].GGR:)/YO(445L1'2>SAB$2-,W(-\\N@M%*)IY*]L:N
MY;O<_9[=&9C;"7_2C^0:AT&\1^(H><GS>MA,F\CIR>DHU 1?_#S%-.Q0OL)9
MF@Z[ ^.C0AL0[5U+2@<R8(439++H6F0H!0Y1)0*>;5+>:A>Q2;32-B"?S[:]
M6WTV]'_7!5XO0BX0+R?E.IA;ACX^$.<>XB1W1X4-"=A,CZT#,1^*/;J8I= 1
M5*ZA4"D4\#;4_;UD-$8YKM;*0WM4W+LKQ/-Q46\3];4VJMY-<59+:<R'8?1G
M./MS$D^GX]_";!;2I],9SN>S\Z ]#+7@%>T](9&14(0"[Q4#K;D1O&BMKG-L
MA7FU[AMW')^X$^5-^I9\0_.L _E"<?9J\M<8S]Y/0JUYSSG[Y>QD'&;#TY-W
MHY#.8SH#$RQ65"EI1@9#[6>KO0#A4\Y*.+3\WIORC=[XU.G1B^17KAZ-HR?>
MCNE+,B6_XGE-NX_XM7:VVB*.XMYG-HFHV SYM=@*@=PQ#+;8F%1R/F:#U>O&
M)%/RZ ;W/GV[0_9OCZ^]Q,BHQW$ZNSCJ998YRVT$EVJM"AY2;;+)P/J0E2;?
M,?'6:81W MKV2N'BTF,RF[T,T^G9LKGV;$#29[H&@]M2/ V5(W@D]\5ERT/Q
M&'QI/=35:'9_)=6.!]>/_!O)O(< B3K:[MK],JKEO;L*+#E$ 5ZD!,K5)=+Y
M#"6IJ)3$%'/K'/,[X#PE/K22>@^!H7^,:6>>'(^'_X698/Z,8Y+T?/9-%N]P
M'$;S(=8L]_/2/K2S3T\Q#[QQ0A=48$0]$?.,3*XD/#ABL1?62GO]+'%KPFP!
M]RD1:E=::WA\M+3F)U^&U3%],YE>VN7INS_&>3B;3X?QE.S%UV%:>WW.C@K]
M!H?'XP^GD;R 89C2D 8Z,.^$TR#0U(1$R\E.# :"4=(K):+F>4T?:WLT3X%5
M^U%-#^$3&R"EU58[YFK)\UKV(@<++@H-D1E63 C!-@^4?5ZDZEDG/93$NDT&
MBW/^+(Q2.5I@H9"/RFI/)9?H*Y\31Y]YT:WS%E>"V5703'^,:"/G?0>[W&W;
MU1-2H[4+R@@HN<8I&NDAY&B W-[@#%?:F=9USU:"V=?]6B-=KV5/;RKS'JSI
M6X%=S@Q: UY/":KW0-M/KFDC1:Y#CRVUL >R).0^UQ-M$6O+86$SN(HZ"F6=
M2U(B:QT_O!>2W)/8N1^.;"+\'KCQ'F=(#_QTGOOG32B"3&I+FRXHQ05MMS70
MP'DEG-+"^M94N(I@]Q9I4P5-FDFWAS.Y;WODB]/YI\GT/!+-ZA1LX&0-EQQJ
M/UHRA#'0MSKPZ$E=#'L[B+Z"Y&G9#@VDW4-2R4U42YJO@ZLGBV$5IOV8"BWT
M=B\5MA!Z#YO 2GQ,5\Z[6HRI:Z\F \00"V"4F+C(#O-:-00/E@SWF 2[Y,(F
MLNZ% W.<CL/H/7[!\2E^P.F78<*W[S\L]ZXLF$U16+)\N )EZW$)UQRTS&0%
M"6^5;ETRY!Y(>SR\VDIW-PC13O!]-)Y:1EG\2I\<_<?I=#C+PW0I6ED)@<Q[
M"584F@&"MER?2X80HJ:)$7D,S8NNWPWIB?"BI>![6"^6YZHOZ]WB]&R)"572
MT20/T19:&$LM A=KL?2LM5 8#3>Y,1ENP_%$&+"UB%?:CXWCBWZ9?*$EK!YR
MGCL\OTQ#371]>'C1?8]L$EVT$>YKP451E)QS9,RPI*334:'063(K8W!&Q<%]
M#V_CM],"\8HVCM'D<U<PZ**>4/5E:GGXCY-W."6O]H38=#3_A-/9Q>&Z)O^E
MA, @>5H]5)0%0C0%"N-H,]IB4^NUNP7NK6Z&KRAC6<+R73@C/HQ>3F:DJ^%)
M/)W..BP#)SQJ520P;AC-7E-KUOL$21;!5%#2^/7"*#=YZ^Y7KYV3Z<J%<&\:
M:1U]>S&C.ZBUO<X@.^N\XPQD9I&68T<;,+>2OO*F&.=8*GXMAMSR\.=&A&WE
MVSH8_QJ>EXLHX^$77$14=879, \P*6$,&@B"$S!>R%27B9.5SF4PR1:=UULD
MUGO?,V=%"RWT<*ZV]-[>D/#.I?'G</[IY>EL3H;A]/77-#KM2@_-9K5$2 VF
M&AB9I3(RD2M7SQ2#$Q!-ML +M\*'),F0;[[];@SS&?%M5\KL(2+I-IS?"L\,
M2K :@Z+1NT2[9B'/P>42P7"FC&!>L^;UL.\$] PYU4Y!?33I^U8W? LY+:Y,
M;-#"Z]K 5M8,&\P*8JI_F.A3#.3R\N:-79NAWU7,T][9N">%[SN6JN:.O9M.
M\FF:'TV7)ZV+:AQ&<&,"N15,U[I+O%:Z]QZR=46;S!G]?!W6WI.R>]N[]]\K
M8+<4F#141>.,[R6>&LR^1#0[KY6S!JB&9056 ME]W8#M=713X8T$O#/M)ZZ"
MXME +KD6FV4%?'$<1,R,.Y6\2RWZP>Q8ZW=D[.](Z9O(M8<KC,6!TS)MUWFG
M,]E>.>E:885\2*]# <="I%]@$;%U3MJEU^\V>[J10B9MI-G#G>7+\'DX#Z.:
MM%1/$&='Y8_QY^GD"^9E.O@09PLG#G-U\EZ<3.AG_]6EC?]\=IXR?C2EK_XO
MIGG'_IR<DCS7R+]:F1&1@6<,@2=N7(@R*MZ:(#T,XYD:&X="C!X.GI90SH,%
MU@#34Q37%2#["=W:NWHGK773PZYW%50PM95N7>*QUB$6T4%DB=.R3Q,K%-K?
M6>L(KQT0Y9ZPKL/FR28J:7WE\>%L5L\67GPF<83TZ>/D[3A-,<R&X^.781HG
MXS>CTZ\?)Q\0\]%PM 0LN=,H4=$$E0Z4JFWBD+;\PDI)0= /[7JUB![R]MT?
M)6ZAK<DN1;VKWCR_X.1X&CY_&J:WX[I?+^MY/3STXZ[GM8G[6!OQM:"/DF+)
M E5,2BBGN9,V>9.=*<HBLVYPYY.;W##-ZH+T^NLB9O#\('G6Q8F-CW\=TAI6
M;R7FE\X)BS'<"T7D=(H39UB"4&HC=9Y#%,&$XEL'93T4ZSYNX:2+S-6LCB0<
MV9.,O!\R)1U8:[S#0%^N=_3W]&[A=L"W%C=OFRBP!V?SW!RHO=GF))?7_WDZ
M['R:WW$^X$46<E<,6%/;%)'_#)$6#O*+?>U@) (M>NW-JY5XG@F+FJFDCWZ>
MESSAC42S\'Z#(X!%<NB:\ZJ<#'B92#;>J2!4[<L;&A-J.\2[NU+; ]%VJ,Q#
MN#JC)7DV&0US9]5TTENDQ]J4@A<&1-*)))@%."8<B)*M*H(FE5K+P+CG>/SV
MMQ_"B5;?JI\T54'C:Y.;B,ZSW]? U/#.;!6.W5^9M=#1G2K?0L"[4CXK7J#7
M 23YP;6WG@''T0.O,7J\V!3L6BVB#DKI=]R8[4KGF\BU>3WTSY/IO*Y>%UXN
MK723D\^3<>UCL#RBB,+JS&("M%V%)2G!>:$A$<XBE0U2K57PZM[JY^N@V>W%
M6ANM37H5>>..(5V66A><>PG@XKHX,<V[$@=,YYJW&&O=A%IJF:-QG)RR]0+!
M[N'!2@#/S#!HHXC&;3P^+&S.RY#.XSW6 -70.%@)9/?602-%3?J2<N-=8S6X
M[(G0V2B0OJ;RE,# Q8!0M$T\TOK%5(MV03M6_1TVPBXUOXEP&VH\+7)5!W]\
M& @>)8K:(D&)+OV53)^D'$3I>-+>2F;OL@/.V[DMG[C0\/*;"P5?O&^W.WTC
MP4^VDEK#K?P<P<L7@UQ\<<$BT3#5PN&6@W<Q0_(E.<5<LGB7Y;Z9WEZ^> IZ
MVU!JNVK[\!Z[IACOPG1^]G$:QK.0MKR:N^>)32[G-D%]_7H.NR):Y%=%I1S/
MSA?MF7=2>.6*TH-[GKWMY=.M#[\X:=2"!Q8YAQ1K08!<F_LFM,!HRL<LR;9C
M:VUX&]TTW8UI^ZHQ7W VKU/JZ*\QYI_#*(P3?O@4IC@;A$0C3EBC">N<J'EY
M,48/"4,)70\.VSID[BX\^[C\:,B(FW5C&HF^=9KTK\-$QA">=SM_CPF'7SK?
M1I%/0W/2@=>UF&^MHN>L5F",Y8QIG^6:!=57ON*)Z+BA')LG19-0CL:71WU!
MQ($.61K%$2)C-%:F+8W52]!*!H6<6Q?7BP2ZZRU/2<?-I-E#9.GE@XQ;QS_[
M^>S*;SINEHS))R' V&06HG"8"C O2H@U3D:V[M7Q(*"[NY?L<0_H7T7[OG:\
M1XS7QM<YTXG1G.&F=DU6%I3)M/<ATQ!],L7IR'WS(OKKHSN$4\F>F'(CE*<7
MC?52 _D"SWDBS!J(>HJCOXEF/\'T?>GO#IIL(?S=T(*S($-.&DKT-!]TL1 3
M]R!-$<)X63BVK]BQ&SK<$S*_/S9L(O/&9]<O2AF.AA70Z_%\.#\OP1>YEIA"
M!(VUU =Z!3Y*01::#XPI6B'7ZU]WS\'U[6_?K_7[$)U,F@IT5U'MM6$0_N<I
MF2ZOO] ?6QR:K7A2D\.R=5!>[XHJDE-%.*&,(9_"A&"B<DHX4THL)@U6/'-+
M9^+J0R^9OYDQXZ("[<CH5;4W;\PUP2$D$[W-SOO6=8578=F^!L_)R63\83Y)
M_Z+)<C3M[GOR/\/H%-_AM#N9J:6C"UHB.,9ZO>NX(.].D+4O Q:E35'-B^VO
M 6OWBTH3/MRLL=-6 :U/QCZ$:H!W^)9U#E\<'T_QF% >E8+3X?CXW728<&"X
M\TZ@ %Z0@^)"D=W-:\UGRPHOF22R7DFY==_XR G0GW2;)]A=@*QL'<ZJ]?6>
M( Y,S9B/I0"Z+F=>,'!:(=26(98%%;A?KY+DRE<\,25O(;\^3LLN@/U^6J5"
MWW1G\6]GLU/,;\>7K.:!4U[0#BQ!ZYHT&%@!Y[2!VIP\>R98*<V+9&V [Y$3
MI7>5]%"_[Q+6;I'ZME])E$QD6JQ,K>VEDF,0(P8H5JC(DN")N?ZH<@7+TZ/%
MPT7=1Q&^RTL;>>6YZ^U.JUMW\8/YZ I?;3*!Q51[*GNL=T 2:$\S4)-9)%G[
M2K#6IYP; 7QZ9&FLE)L,TELSZ*H$SL]PG2=< @)WFEQJIFM^DP>>ZBVB24S9
MUF=6M^'8U7U+/RS85K"'<HUR?2#TS[HS.\Y25MED8*K6DC22@RM&@U4FHB@F
MY]!\E[D=RMXN2+96\3V<>8BH^\@_O0GKVZ'>_<!ZNO-8"6H_5Q]-5'<_';:0
M^TZ)D9+RMM@"WF4)"K4%'Y,$3_3/AM94,HX?-R'NN?S8+1\V$7?_/%@>T1L>
MK=,$2LE:7A]]IMW3*,# 0B'7B3O9O,W7;4#V;E8^5%%WJ_\!4FZ<R/6^UM_K
M6*V%H>W-<8@T+@*1R!-6+-9:CEG1/BB#6LM@O"^![_R%CW['?[CX&J=;=2"6
M5%H'1L,$JTNOWGU*U0.%?UU]6TBN=:KM)3A%Y*Q5<"!4=K0PD ?C ]95AB5,
M3#/KUKH@V[<"[TB,:JN_30366&^_D:1.3D_.K[6=,SQP6L.]I,%(FR!::4'8
MD&@9T2;*M6JUW*.Y*R_=;3K-@\4^:2&SQCO@\M+H?"O6+!I=)(C( ZAD(D16
MP^AU##QHCBC7\HCO4][EESY"Y3U89ILF02U_7/^(88;__F__/U!+ P04
M" "U@6Y6M.3-5SMQ  #-J0  %    'ET96XM,C R,C$R,S%?9S$N:G!G[+H%
M6%W+LBXZ< D2".X)$ CNKB$X!$EP""'HQ-UA @D0" Z!X.ZN$R>X0_#@#@&"
MN\WYR#Y;EIRULL]YY]UW[W=7\?5'CS&[J[JJ_JZN[M&PK[ EX+Z<E*P4  <'
M![R^^P-@R_>_2[J"3 ! 41%@    %4"$$P3@[VKW[A[D D$ XET=[JZNGI3\
MXS]   #WA[;) )2[=QAWSR)W!2#;_EO?O^@O^HO^HK_H+_J+_B\E!3=K:V.J
MI_9.5G</2!$(?\LF\.ZRAJP(Q'_6:Z,B_U9'X.8'@*BH?]7_E5F@?OK![:_,
MXB_ZB_ZBO^@O^HO^[R8.-@Y. 39. 78V*G8> 2YV 4ZN__3=70X"N '6=W_&
M !7P%+ 'G( ?R0AL^1ZYF:.CK0 KJ[4#BX&1S1MC%D,;*U97 UM6=A8V5D!(
MU-76P-#"V)'JC;$IR%J8;K^AA8X*9"1,I\&MR*9H*V%L!I)QMS=^X?[\I:&[
MA2&_$9VH"":ZD*N JY6ME;&C 96KE:6U@X"K\*._<1>XJ_]XS?I(1,C>R$1
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M;#^['?5*:V;Z\V8'FG>4%'S%[.5#8BD4Q)K]N/3>TS2L91MFK6RUNG>?GM/
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MH8&S'3%2%XK'([LV-%4)IT@=K_?$LFY:7? 1,0AF."$E@FI6A%T)CQMR)=Q
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MF!HQPIW,J< E!0@X5YT@D2]E:;N:U!R=X3LP2-!\IRJ'!:Y-@PM#,UQ(JSQ
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M2?7Y\DY'73B*EW+Q"$\FT$A:S$Z*HMG2[85]"ZV5,Y#^(1XCT0:F-;;4JS"
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MO<>/@6Z[(_#VX2!:^M ;51O(4L<0366T[FCM^O[T%EBB[]%]-O(")"56CS#
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M<)L2VH?CB?CA<?=II]KJ4!)C^1GBDEV  *H]C_Q3>:%O#PU_9\2O+.<8_>X
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M)9 F:.S"F87B0_]R\PW/"+_G4U8ETVH9R03J*,N'].V,T]0OW2*\N4?X$.*
M"].GX]&O1POSD[QWG$83:0+\?-A?D*$J"J\+WS [JB)YFV[W.=%45/F)5NWF
MKS@P0P5BBNE03A$%BV;0Z&!N/RR_84L:[HO%]ZUE.L(^DLV*QQ2EL;Y],QM7
MU*9 +_##5IK".N8.@#T;W[\[_4/=X)D%?EN]'7FJ01QH\2R64O=0!;VS0\9@
MAP"A:=Y#HA8(G*9@/.P>;K]EU8C$JL%_X&^)*/DU@$8>36B] %B;^J]B=OWO
M/=C4X.8#EP]D+?!G]LU%'W<S]"S-JJ-[_!X;V1[68S\.5U%$JK=$<@Y>63\P
M3W]7#,_XC#*>1I0T<68=^]4$-Y!%K&+2A:B)^E$:4A2+IT4[[N8MV?#))R':
M>*SG"AJD:]ZT0M!G;!23K$8 [I'L;]C0X'4G;WR!Q 6,<-QG;.O<>A<M795'
M;]\FI;[ #'%IS)0,_E&@.VH%LS7;2RN/XTB#"I)%%#U,=X@"4"<PDZSYB#QD
M]1_Q\'3QMK&A+];1O:C0A#&L6K!@PM@?O$$0)S"9.6ISS%W*)RQ_7*(W/T]7
M"SE,[K&0CI6-)M/QZ7^-]R=<Y$1JB:,W_L;E=0#?UP'QVL^)#F09YY,1%"X(
M5?;HG9T#A/E_.=SP2XW\?GWYJ=]L$+4].WT*J*M_Z9S[+E;3!:-"VY2*-60=
M[3##$L[X=7&'0UQ0MC2LOY_VN<RCY@(5U2UK6'"M+&B1$\-P&S:DQ%\7XF4:
MV8QZ2H(4$B%Z.4KY\, I.<R#%51H5:2*4M=D5#P#( <99PK1.Y]\0V]8Q"Y-
M;CN#SZ5F.ZWG-T1C@*?)9&LPY9R+>Q ?D./JP+P0HSQ)65UWEP4? ?&M[:#8
M6;<FBH?<<EC-G1"T+*KGX6\.ZDZCEUBOM%^V+10+F/SHU];7O]A]_:'?+C+$
MMVQ]U"G?ZMHI#:YO_6CV)I6HJ *ZI7S@>9Y&+:R&[=JYX*,BQRN%R^E;=N$A
M-OX8G3I>@?%CTK".!D%/C=W#7A>JA,,I^J..Y_ZWN'V>#27@U=H1Y=/H*AH-
MW]:7='*X,(\IK'8Y$<=U?A;7+8&)$55/*K5@HI&YZYEN7^?4"F']]<SE3N+,
ME@.D9]!N8+;R6)[=M*QCLJ5/2CPSF34/T@1[.S:VPLDWS._G#BQ6L>/S<-RR
MV.H7IQRWZ@BF4*W(!,R;F7K$D\9M+7 M/GM[-6?;BG7J4KL-9X_DX2XY[D3]
MK3BW)NW!;:20+W78KEY<P9M!W0[L32)952Y__S*L(&>'$)=\+,-6:+QXK^:P
MC).3 [VR8#3P\9<NTF6'R$E3WRW%!5) 4_+B137LD;)'+DG=* <],R5Q_K!"
M)?F)(6^AQVNB9!RS<)4PDKDN,!VT]R:5_S-<82%&L6S/(61A 1M!?-OE%E^9
M,)\#G):XXC>CQZL0&85>.;T:N9W8LOD:=$NM^\7&M&Z$<R>@(L-QLC%$P2):
MR.";6W*CVR#2VGY[*H?39#XGNVQ@V1M%L<DO/61EM&R(V ^O<SRK"+]X(&15
M%&<,,.:20\=YX;W!S2^R KD""&7>(7Q@CWJP3EB6)#PTK1/^@IU%F;YYWN$)
MO!0TNTI.OMM1P=ONH"#FDA9>D==@&:S$+V>9Q)DDM:LND$6_4C3M[Y_T30W%
M:=]Q<X',$X63[DHYK\N.O)U'K5IU+<NLWRX"8:T4+(:0-3O;E:T_KUMW9&T(
MPDWM(M<66,*+T\1*P P<&'70W/-P=KP#/*(UT)Y+_S!B6A,O61+-QD#_L'=F
MV5(_B3=IJJ"9^:7K2VUM,?LG9F\'_3OY$#IQ$.A==)7TQ.O*RZM9YO5DR=Y5
M/N!,I.1I#5%0%.Z7(4T#[8]]*ZHOYM7MC-*;E0':+VE")25=Z!]/<E?ZO<:\
MTOIVGXWHN=*>]28-<=XGX:7@O?LEL%>^'^\9W<7K=3+%  @='1.\E*\0%4@:
M"(W8BFJR0*D;3^/#_: :KVL>1U \ZU=CRM[!Q"+4(1$N"[#3\D*$KJO45NA-
MCLY8VEH]GU._>&'6?UN'O9LTJNN*/@V$"7*,3Q =&O1 \)76XF@B1\-0;Q+P
M;"?_0*;Z P9&N)Y"F2/(QH@??2QET+O$_T(>I84.K=W-3,3]I&!N>N"*S?O=
MX?5-6N]A*<S%PR+A==E_0=T]8Z.Z/[^@MCHTJ_23HE(V:)@I%&ZE*6@)5UXL
MDC 3,LCTG4BB^.F-S)9%(5 !AVQ!FCM6Z&@A6P5ZU^ICCSWJG;EO42I("-%2
M!!VMRF1=]<Y*$:?*Z%$$KR,GE9B@[Y%-QBJI%X-L691L**U&YMAK*UQ.@W:4
MS>AC'_E$JA T0%NYNUAX/W<?(E G:  E ^&@/$:!^OHO$,VB;!MF9X;:>E-K
MQ&\4KO2'\@W\:4S^QYL&<$4FH\ODTZ_,;_V98E=W-L_LI@OK $;6DOCO.(Y%
MI\3$!2]-;3L<$*)-\HK*.@,:->D]%UM 8'G"=*J0A8IX/2NBHU?548>[3XPK
MRC58:.CL#R>%,"6,Y?9>++Q:W*=(T,6,%]UZ7*+#9]>&)QB#J1!"(F7D YM%
M8H\.A@$7,3"4=?B)5RMY\B9>H9@;U!0\C-T9?$=\[3:(XAY.N3&^F?&\_95-
M=IXJYAV )0LO C_0J",* 4X&AK0YCK53!8JH!8\3[Q4N!Z+GIYJB\JY]<IDG
MH4^A2ZI10!NN$?E7^LPQZI^,34OO%Z1EM_JNPGSC&< A-P14Y[B$_@Z%Y\%D
M.]9DKS)[JQGR\!7)BZKKABQ[A+"I'IRI2&AN&Z!]= S?V</<(M6M#-TU,I47
M)[S,OD9'+>40([M)LX,X.66_F:9XB9XZR@Y*%*L2R'Z9$FP#\).31MN4(IZ0
MQ-])*9[(9$=6MC C''MO'S@K& =F0#C8M6MGE7EYD-@'K<N8[K#!F#1&R.Y5
MG$72QRO:V0EM61LPUQWQ1M_LL\J;IHE_XO2!:,XTQ(=6]E,W@M#RZLD __.]
MQ8F@$PQ/69O\@+:V6UX("TT2)FT.^KQ-#\R2;I[1AU/PDV/AN0+34%HM#%CY
M[>CIQ68/V.SP(&&7#$)YTJ-S?J:>O+AY@#-]'&=N6L[(4!Z)-]J]E0GA26Q$
M%1<X+AAR9$7P.FM_-&$#\%VC-LVB7Q\1-NDSG3ZG):X5B"?LS_=VR6PM8E/O
M+O(G_C@68V9"TC^([= &,)JYEAXS'@'+AM9!TR$@%Y:\0=1'LWHRQ%%:(6!Z
MKAFZ]C6RJ],"*)9GQH%9XG=[^FJO] RR&DVDB,Z>FJ2%O"S/BF1=Z%&SB$!Z
M;JC,J^+ X_2&J46_-7K7%(.V+SF136 >3P(-]L?-='+C[W0?Z!S?<*H"E?@C
M84+SC&MH $R6[];U4\<K2%E_0S7XI3+DJ-&_176H7B9YN5]W!QC\]@VKYY,H
ML*[A/IKP#&)=HP8UO!@=O?=W$>=.Z<S[5WEGM :H+_<[2:3C%)E,$^RKJ,.?
MBO?KV>SO]I/+,Z:[\W]WA@G8Z@DT%LL*]P">KD3Z(#"EZQQ4Y&99006VC9KA
MPC-Y9WWX"NP^),@!Z]'M[AKL)NTNFI%6VQGYZ:-A18H0EJBAU,XF*9D(>T5Z
MBZ*\V6=?7ZPE,2:0O=RPGG35%56*J8J_7%IS&@E,,AC3LD=E(P,@U"2X:2#L
MWPZQT9<$WVZRKPU-*,39ON\BS66IMVO!VAGQWU0]0 O-9V,/<7LQ./OF)AND
M(U#ZX<LZPV>($-R5/!ZT_I'#>]%@9ILHEDO1Z5%'' %;#K$"06AXI] /]Z$=
MNBPQ97JXRJD68W03T1Z$YLIS>'+ B7#E5(JQBS'<?"0!C,2=0DV.)]ZG_'81
M0UQ"F7FI,C$LCJ$W$DRWSANEYT(!LPO.$[,@;&LKK^56!MG:T,*26'/MR;"_
M^W'-6)!3>GW^:+8L_NH'JX.3F"E'K/B(.4#NY*NE$#(>]S1M="[!B^*8:'&\
MX'7#]GB/QWYSV@5?Z#HP)YAQ=HTC&YNC$\+2BMM$50Z2DK.WU'7:;" D<2MA
MS&9!N#5R7F9HXJY]6F(VP'A/X\\[?=F#ZK*$YHO_&./H'QS$-0>>7B;V?WDE
MYRXI:3M+\2?TT?M'Z'03A>]<\D6>( 65GT,$8H&DEI?5>L]/H^#ZI7#PTR@%
MTYMA-,HWPS\(/!H1$= (8:BA.585S!9I6]#]:;T\==TV.W,SW-;('RRM(E#Z
MQ=+($)/XV50?X<!]72J _KD99QQ69V32=C>Y6!0)B9\CD@,Y=@N%->Y"]BZ_
MV1@_A3IC[16HKH<XO[:,^:%(#@J; E.OL9ZD3T%%,&")^MRV2$<:S/_4XRM0
M6Q!"X?$I6L+KS&.G UQ[G,N\ -%4,/)4UE,NKTDZA". /A(IRJSP?2WJQBR0
M>HCS(CK,;>L)4N*0QQ,^]QV!A3<D]4W?"^)@/=,-F)G>;R3V5+W*A_Y6KG<]
MNWVV'7YY7G$'&/ZPG?9+C84"N5A>3)G\("^RJ(6N0/H:ZU$38=E35M>H)QW/
M9!^B+3 ?JZ&^IJ0L\6^-K9XRY-G:H7U1G7WX_JT/W"XRL4-L0J0!XWAAXFWA
M;K"^KCX<@,>EP634JX32PT7GUSIA(PMX.W]NS+KSDG6L)IZ(B$>[^P/!1V,/
MI\Y.ZA _EM#YEAN!PV%12 ''P[9,&:.@52%<H4@J9*.*530T_TT##0*$@:GS
MYV3N^2)K>E4,\<U6YD^+.O"*7:]+'J;Z^@B?]"GEN=I<J:J'W4ZH58X4C,_N
MO-$F)/-X(<TB@XB ;(K;N5:Q\0U;PCM(@"U)-BD%8F$^I-O!4*:''OVC%6(*
M?2D/0/+O1S&X [P7F-]YV74Z'<YPPC=&1,Z(ISZ*%/*9*8&J^<^V*O\F*!2^
MTY]B8[M),=IGQT;YPH*'9_%#-'@?1Q]I(MU,UX-S9(=]CCMK]O&5&)<,;0<>
MWYL72:8VA]]FFGRZWJW7N=PKLCC3^ZC-]5BUT8(", ??A>,% \NG0X4I>D E
MLB/5>$5>OF:'*JPL-"X*'<K /AI O'Z8O?%_AEKY"79EX(/D(8UU\DF?]S'_
M'XA._^GG7]!:L'^]6,9>,QGG'<V5DJIG5N?9XU?Z5(RW2X2&W#T[#TM,0I;%
M+\?"SZ7Y!BXNQQKV;9S^N%]:.-FFT]F@'QJ\UK"(/"*YOJUY!VBJF_CSHN1'
MRKRW7N4VUV2SW@?P^P=[KIM[JH:']">NJ>,MKF^LY\\%J_]R'^N##.^!\?MH
MU-^]\%94GG?GPON+CHN(+FO\O?CQ7]P!DO/U[@"H9X9_W'#]T_<MUSP;.(\P
M.-:59!T,]_VLDH].<KT7YK;_<F<K.F/<'4!2%W:+M=MPOD,^ %N]?6LVLPG\
M.;Y@;OCYQ5$7*AP^O1H7ORT#%4O]M\O1&M4L+3.0& >)^=B+@%B'[-2JPG-I
MQY8[ .=?25/]\NG>*R_#-:)_,[%8%@!_YDWR5];C3J\;>MEJ$ME_:OIA3OY%
M?J#](SGW+[ND!B_Z2$N^!VE4SZ041^#$#2YX/0VSF#Z\ W"5[#KQ:?'_RLD_
MD&+/Y>F'RU%;-MV OH^AMPY(G_\$!G+W;=IY#?:B.K??ZF=U&1GR2)?5T=K[
M_,8G>I0R:%OQ-[1'^;[6A*_>FO.T#'\%*XK&QQ=\!.9.R=IP1U'1RD:14'N&
MXW,^S=S4N ,L$HTT+)+%/KLYF\I@2/?FY1$EFM&&9?.K_G-99=;7-L1>Q&R,
M@"J@U7C3Y[S*?HX)?2Y\V_:Q$N]&P.9/T#68J!P17;,Z?!TCS4'^,Q?FPTHR
M5TV)85<#X*KOOYM@*QUOSM5;4T_=<%,E)K_C+B<DQV$#%"L\'?;W\]6?1\AT
M8JL6W%^/UQ,5E;HS?LQD[+;*_.3@#XT5+>V@BP[._IWDS:[_8+[H.+I:Z7+T
M]XJ1^Z>Z\9?L.I;]R[/ZWV(;%+\$!*O1BVNAY(=]Y-7Q/0)B':3Y@YR^OM%K
M#KXO_P<;%V'?K\S],OB_.J+T/QW13ZS]'>]_,[C_IJGYY0JIC#O S[RKSWB(
M#16D<,WT9/>04,=X:F[X22/;K3E3D_Z5Q.B?LUO];^+Y_JTFY]]J3?D?(-F?
M(J2_4V4-?M4@4J^4#"40X6TZ?OUL(6.* X\?,:5Z>HOCQA_2H2[9=;Z/J[7#
M[Z;^%U!+ P04    " "U@6Y6K^;]ISD# @!)N ( %    'ET96XM,C R,C$R
M,S%?9S(N:G!G[+IW6%--NSZZZ%VD@W2I$BF"]*8@78JTT".]20?IH((@7;IT
M!0$!(4IO@G0! >D"4D+O)" 0)"0G^GZOWV[G[&^?<UW[C_/S2>9:]YK,,VN>
M6?>:N9\DF*^8)>"RIJJ&*H"# P#/L2\  P/R50*<'0! 6QL0  " &"# H0;P
ML @'^P)PK@ $OS  :.(P_\;Z./S_:(,+ -'. /X_ZLV O^SY/\[_.N*E1 %$
M6$2-+9$O<?]N3?#])=[?&/?^3[?;!LH:&MBC@:VWO;V[CY.'+P9&PNGDZ^LI
M(RSL[B-D;>=A8R]DZ^$F'&#M*7Q#2$08D%,,\+2V=;7WY;"Q=W1VE[]ZT-)^
ME</93OXJ6%Q;1-M3V=[)63W(V]X@2,?0-LC55MKNJJ("AUR 3(";IYN]KS5'
M@-L#=Q^9 /FKOSJ7P>*?U<)7.7XU\765OVJBK<>A[.%MSR$A)"(D<A7K[6WG
M(*-_1_4?OM@S^:O_&*2_O[^0OYB0A[>C\ UI:6EA$5%A45%!; M!GT!W7^L
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M;,(5\,^Z^X, T' 3NT#L_+..%YNZ7<;RJ7W UL_[X5]UOYXE H 4H 1H 2:
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MP/[-;O DA,4& T3VG=B/M8(#0@;C MZZ9XU8'I;W8H"LL+#T#7L6SLB*](T
M@<0\"YTKERM):]>&&&BA-_,S+=K ^A].WH_&#X/4Z!Y#Z?C'RZXIZ:74M(P)
MS1X?3;+G^F*EH5+HLWLJM,"_+>"5113=*=HM&#U,U*%X[@]YEX[$)N0$H1@@
MQPH#U#R&ZZ+GIR<]=5&)[[#4.44G<PT,8X!OY2'M-\,Z#9*OJ!(_JKGQ$2]%
MHV1Z-+QZ.NHZ2@OA,G.P0MU7JG3Z6%=[TTBOH$B$ZQLXI^M,_NZ<:-=:;5ZQ
ML5?"N>4V6LN@]$9O'TE464QV\Q/W^;WQ=7/XR&XQPKS;F&I;DL2MY&U<D_[>
MC%W'5KJAC4(T8>O*LFXG.Q,*U/A$F%:-*7;#,]8)$N(.9F)Y]#$^\64P>#2\
MCJA7D<EY0<:#(, &[2:ST"DU:]S@P]S/'<N>H7\)]SEP/ *#.:_,AR]7O7H5
M(+FL6LZ@^V2#PI]W,IGZ+N'UC8A'4H+C;:[?K00&&I5)P%3):Z-O$6FK+\LU
M[YUX9Z?$3V3DOK<ZSMZN&P<?!>H(2U60!NQJ1;]/\?;2..*?J9TZ#7:>^XS(
M!AW,4W8L5O.65G4M)<B8"D/7%<RTUT>BPF_MU(OJ/B!GFUQ9N(X4+$2JK?2F
M+A&E:"4(&Z20,'AU/[G&6*;_\=)M@T^L-Q9:0_JZY/K(HDMCBY^],LLM5TWU
M+?<YU#&_MEEYV#03M1PB;I92+. 3F68QENLV1-=BAGZH8%O8KB$>_DBQ9B1"
M_),=PG+P3G;$=>/ZE.$!,E\^ ?_<%&EN_G(TYT5N&&$ &UJ7#MG\P]R-L[[0
MK)^3;)UEXU)[ZWTU%99X:@U6^=DVXHV)B6\[>E9#L_[EF37&S;G['[[6E9\;
MAU_:P)?:P!&R,C$\S6S9#]&M]9N$MGQ&K12V=5\4AA$B%3L4KM0@^AX-\KP>
M>ZM_QV+@J9W^I\T^/I;[J[FK-LVL?$O1G1Y1:-Q:1%)O&6_V\JF#X&B64DU"
M!Y!$;D*>(?MHY0CA"'/P(1^DRC1.EQ(0,<@SU9E(XX$/9D]/&V8*[N=GLP[&
MPO6[#+H[-(X:Z&BA$E/;TUO;(>(0=90:DLQU23$JVS')>F)V7>L(MU;PL@I$
M1A0EL3+.6-6R OZX2.B$QFM %L.'G2_E<<2\CE6]+M?4"-9?%)%]1J 3=-*G
M4'1^!YNU-@4$7YRS7UR>/+@?(F]"+N1'OI!K;YQ.;%0LU=]8Q[LG53N6\K"^
MHNC+$8+E#H+.4[^C_\UP4?RXY@^>H@^[QYLA:PB?D_!)!9J H$%(ZX1-*X/^
M,R8JTC3OXD;NO*Z($;JCM=#WY]HA"F-R/$NAU!A M^E#WJPU_5Q.9A[NB_XS
MHWZR\7K06!T&F!E<@D3YGD-HD2GKYF3$-#2@SUYB;1)'@UX1AR_[1^K<\@-,
M8WH<D)\5C#3S2 ,"]-,FMNM3RIB/? 9 *@YKP::"PH5<>#V^9?<W)WH&C'CN
M#?$Q<B^"YM(5;V:&?1@9F@7M)246X+;B%*+D=6,@%%DI,W=UMM9OON^G[1:H
MSAC$2Y']+IX*4Z0(&VPFBJR=U^W+CG.12=@EN?ZNCSMAM88\'72)=&_3/S?[
M+%<W*C"1633?,JY;KWB0P&!6IS!!6DFGOU?;<G[>/.-'$%NQ E^74==U[2M^
M/(%2AV\6-"K-7$[, @O8IA:COC./T.Z<A+&,SU ';Z4P?HYV<?=YG()SL.NZ
M#4U2Q ^A@(W@FX5H('VX*M.[5%[,Q!6IB0S(9)Q%/WBB:_5U8U6+>2Y/YH15
M:2A6&^]M\KMM)IW;*(H )@Q 82-*/BQU?>B:\$-P9%4IT91H@Y%OCOEW>?)V
ML=(7UI8A@N.3P0-#&KZNG[XGQ2P2MX+A^>MCB]V]) 3;+7=.=DUU/KL3>9=]
M^K2W\ KI""_J4:2K(\M3[.*EE4B.X0[\6D[1!]@;)>I*K;R'-H0[@<P]8A9Q
M'K0&E[P4?L#Y ?!64I?XU ZG]@Z??]L^,TL6'M6.>PR)D7GRZ%3!K7,CH1^X
M=@4#?"QXJ%#WHU*77'2R9P>_6'AW6FV'97IZQOM@R&/C$ GQ65WI8<Q,;3Z!
MF&Z</*S/G=Y#LW<C*;O-6!>C_'9&+BU6RYV(R5$S#J]>CR8BPHM/TNR%0N68
M"]'#>@'Z<SV+M'62[9-UHH=#[BG2_&O#WN]0 [H631MU#T+LD%SPY3E8"LH0
M:76HYM)F\&*PIJ@'A/]I\:B"D(LC/VM%'.$G)]5K]''J,]QO<T DNLXWW4C@
MR^MI4>]8XS%!B/F9Q0FLN];:BM%L8CTG\VI.PLNUNM0/Q\%.(6"K#K@/C.Z@
M9\_F0*ON@Q9=;:3F\$XK-FVFI4+F(B!@I-K)0Z1*.'Q#!5'Z['/]TFQ/8""7
MCK$D>=9]GU,P-YM(0*\K%VSC$9K>M9U)G$PX^M2?:LO+.4:@+GWB?<&-7$*"
M0W;&O@%=LQ_D19WQ#LS,F1-#\NF:?FO,^D86COP#E\!CDO>,:[-W"D>_';W/
M-5<M)K_CV8I(OWD@=&<YV]D\6.)'(#M=0'M7*E*YAP'-V)SLD-+I']G\W:V4
MZ62DV"?]F/)I&XD:@FC%Z@,LJ5:+/JMX_J[CB_HSS1ABHV\S@Y**-T:4 L7W
MS/Z%# ?AJ<"X;II6:DXI8.@\\'9K+$$SPX^'?CS^IKMQ7=5NSI%L!4*5F;R(
M--8@)=Z>CW%>1;RU;NQ\S@ F3!E@WATF^,%-MDO" *+SS,[NJ=;EEX]3$R.X
M20NTX545H<L['@3SG+6M^5N"3 X$(0T/R8XNM=(,A46@A]N(X4F/6L&5 =ZN
M$<(Q;V?57[.+&-?P2B1\[!UM$=#ECE]N[5I1> KW/ETFR&N(KBKVN&SE^KSG
MS=6;$3;2G ,I$D^8W4GS09.5,,?):AFFRI [\C5O5F1T"LUEI51FVEWR)HK&
MPZ*YI:"S*^76U\8S^017>.A/P>M!*/D"@ZXPL1#&#TAY/VN"R4,(SP_U@4]1
MHB6BHL3<&"#@_GJK?MNGB]=M3'V.*\*7G!18LK>W-XPH2"^J8!NR#>553/T"
M"N[!8+=R%-=%;AM=950$XLIR\ ?5,[4#2?67/D_.;3D$-A[G+292..8%N%K5
M^[W0[^C-9Z"XW2%I7+$:EVLS83B[GIKJ/Z?U>F'Z+0.-0109I<"PD<N$OK,J
MVY%&2YOA;LKQ!)(P]L?!<OCNG"MLY)D,6PRL)=-2UJJ@WT"(:<F^PSW@FT0N
M-$PDU'5<SA0^<G(?Z1'H"O-@[/-G[9DPG]J;M;F1TL2C<'?5&Q>QB-LZ$$:[
M05HBQ#B0]D8ULHA$\^W9_37N7$,S7=_QENI)RU*?<@OS)U[% C?RU.Y)I-GZ
MV^WN5]4[GWY%(0MKC]_X[K@Y["^J/1]R9AF[3BT)CK]!JHOWIF,3]/H]TAG!
M8%"3I#=>RZH4P*N'Z&>MC8\O?84O1*Q0V*Y8G+D,,DP7H/WVS7]-QPH\7IKU
M7:S;(-)P6T-%X4>8(Y5*$"5*P",6\EW()1Q))HP!:"P<BDM<9.2_9SM4>O!4
M?N:CI"V_-W&\>IEX.9]/L >V7/JLB)^O>(T^'>UD^/ZFBZQ!MD=_25!#%)H0
M.=C#AM.$C"OI=ZFG+[L97RU+HOZ(^BN.^EZO.I09.KH8$7[HTMQ^$;0-^8$'
MS@DA1U(LA<= R!VGCFNN2_:NJV?X>N,*$"CZ[^>75H9!X^ ]*YQIH_WA"<^Z
M9,8WTE-=IN^-:RWTR\O6AJ0+\1NR"04L/LG34;&OS#N=MDR*W82.SO\K/V8>
M%7S4?7(9I8D01%EQ^\=V:7 ZF@Q?T3!Y?IFM:XT[_T/+>NM=CZ>!D^0.9$0:
MX^4(BX5APXTA2I^5UK>5 W7!E:Q5DXG;+.#'9:H?G'V49\RS-$QWZM)_?$?I
MRB.5X8?"L6PWXSI3+9G% UX__U36BHJ0ZE6#5 ;1%>P>>96'V$R@Z4Q<8BM*
M/C90^'"'5%?W?B5FKK+#@SXX!W]5)$=1P-FU$1/3X13[X<O.Q=S/1W _#U\Z
M2(^A=I22L[^$ Q5F8WR/@.QY0;]"AKQP>QQ97E4Z.+%?921:4+HDHLL$_;(9
M (GH6,L*G]H:AUI5W3#P+C6VJ"Z!R79E.=.7,O@/?LZN&\DKH)V"QG8',VGF
M28UZ:^J!]=?-YBK'Q\W9&4)NP?U&'LE9A\+(FC)@NUF&GR)P(OCO>\T]$95W
M3826,R]5!TR?1$RV4CIZW7PHD;3Q39<KRX%JS^ T)\/! :#)]=N@VS6#=F(%
MBFJ?4>9'R8;U$:-XZ^+ 5?V$^,.]\]QS-E<8)RQ#D1G,\*Q(P"2(JE)&[Z0N
M,+"82=&;VG71U;46ZC@SMQ!R+_H5Z<WU4OVB2'LA]87^X@/Q4-DY\]"^C4JZ
M8W!7$AEZN%[A4EQW.XVXLD^@7$KIUY6' P(W2#55CA(^N@]>EEYNP7(+OXUN
M.YST-;((7KP:RV\P1&PYSZWB5D6<*O2V5![1I^-C(>5!44.N:BD7QDZEY)V@
MZ+*E6NYG) O)Z@&!>&N]V\K,]KB"6K6C2F-,@M+64_^QB6%32SRX@D8-7#+>
MCY50E_;K5B;UUI<H8<_WJ5<BS_L4(IKV+*$=(Y'@=H:ZN ]"4\?7C<>H0+)5
MA]Z>@)[:LD]/6$R S"!,+IS W>TF*#J<0OQ#7P&(X1MMQ/HQ3K7TID+Z45)G
M.#[J!H*AE\*X[Z-_0X1&PSNU1*W M<>?GZ:)S!\VL?7%3W_# -U\7???-RG*
MNP0\6Q8<T3:ZY^TNZA\1V_*Z$E%5;ZE+=N%6814E^B5=4N<DDV<W57-,>R['
MLOT3\KP'S5+0R<;?#N^9B+N90=/*,UWD)C52'PK*A;:&L830(>U7DJ@#NI2G
MIM;-AX3U,Z16Q21@9"FT!0<2:P]2\V>@7$A6N-5TKR*UN"(YLE-2HEGT4P,.
M8XD]^&M%,E;8P['\0GIDZ])$FICTI3+HO[XVJWW8J%%VK0U2XUB9-V$NWVRA
M]31!8+C"OYBQR2G]+,6Y!P(=] V95 FMA$%F=CK0HLB\9?RZ#',/BDV?RD:<
MP\.[Y7(]"SY/C8GXJHC[WFQ_AT0JUI3VY,@KWT5ZW#R9K@?P)+88J6=FS^T^
MV7/[Q+.7THU'P%-ENOOFRU0T]<NN>*5K:=:\GDU]75D^.M-F*3Y3XF@>!S?,
M?Y^CH=+_9EXYQVBH*LDJ<S<L'%P=0+/D$=_&B30[Z)DESZAP=3A@OCX\L#OZ
MQN<1;6*\3+(5N&++/XBWPJ]P\5'-K"9<G8A#SJ[L0B4L"CV  0Z5ZZ _SILQ
MP"C5-'L42OCIL$^9_4QL2NQ3U;&'+O?,0D=\W;J;*BWH"6P\ARP'0)9&66<]
M*G2G= U1BG;"9&H>Q3NSV/5.7R SBSL]6<O_,^,M^6KU RO*2YX?[L(FUKI'
MBQC-#BOOW;8"5YM)+"39EYJSGF4XLUQ)V-)Q!U='!N;G++JZA\BJA&J=JZ-H
MOR@P?HAJ@*D]-X74](ZJSZ$:](AGY]6YY+U598YZI_=8X3X?L7JX]4:Q2QA]
ME,EZTXL^SD"R*&:Q+]^EOT/-V6'#'D_08R:)1L?BVA.G#48*#!3B;?LG#571
MO.PQ(G[HRMV#\WU[5@FOA1];R *.>Q"(JR)1")7CN7@?0H#8_LK[*!+R*"7#
M+%Y#1>&[;N*;"VP7>6W4BRC1T5;G99*U=P9N=/.[O1:@"E[-H^<OW[,2!GQ<
MG7[U%%XDVVV<0.I=ZJ_$F.!H5S946S5;[3(T6*CUT&=R^1N=E$R*?G5.:6'+
M>FS;],QW5-)(,^C @QU%B-1^&R+8A,  G65,8?UDWT Q;.IKZC[KA)0IC$"0
M;?)8H_"C11PYV15*BF\AMY$1LLK%G19J5QHRF&S895N.2:49&>5HQM\:PRMD
MHYS5!$IWU[>[9E5?.P99C;QM>EMKE3UO=JH<37_?BCJ@R4=%U:)*,/C;?&4H
M.I3I4#R4"U&P) CM+*!PGCUN*SFM#.2/22XD)C2LOTT>*F-\T ,A1P\?(:]X
M4(> VLB"76]ZY?APK=_JP]_-V5CR:0J UJ!!2$?80CN,F6PDID%U6ON=7V;T
M5]89TJ=2!$D6L,#EMI9H.9$B<Z(<V,YDD7'MM;$\@?<50??TT\Y>K[ZM=)(]
MXG-U;EIUL#"0,NZ8+&7JI4Z;6((=M/#/F%O],"UX;@B>8V=5( C 4T$&%5"W
M,8OQ5+_(&__L;)MR[9F1O6 &$;?_INMR$*HAMA',W(6<?-PGU215UJL7,IIF
M'ZPI-*A54J=ENUV=.QMEK3SWI5FC=MS8N2KI0"$*+KP[B #UF<F9730VO*O+
M)8JIRDM_K3SZI/Q]QUZNG;<H* F9!_?I92=9;X!0GXFJ^#>J"+9DJ%Z+3U1Z
MQ\7U!CIZ0+=Y&DZ/IIGAZ]*VV,JWZ;DN>F>W?"!6+6U-P1[(#WH.3H84A-/X
MCB1(G,YZ/ Z[*G=Z-X7NO:C(<_6QYZ4//IC+>?:!-L4@95Z+./;2O&#*<ICK
M1!J,B/R./9-^VNO)Y>7,YNQV/N,SX^::-6\6#,"4V*/H:DRET2_C)GXSY:'S
ML?]B(?@K_ ?H(%1Y:>.C<.05^<AP>K[L0_0Y%_\8 ;ZMEU$2OL"J=W?JUM?
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MTZ6O-:H6JS!-Z"$_Y ;-SIN=9WO4MU/!RFP6*%2]4ZI3XST8C]P^_PCCZYD
MS[%=0K+#1SH5*?;0W"C'#+!YG0;U/%.:0/^ </^1F,CJX0TDC6&;0 @E,ERX
M2P4)A1>:JF2_288EQX%4S:VYPC\S,;_AAE.N3!IT[JXSDMC:"X0@2O?RA,(7
M!2##,+?*C;",MJ@;RV]IWY,^T:_)O%H@W+B&:C@X;/B$'(OEAPY3%O_](^ZO
M@AP\$<, Z2E8O;4[:X\!)@JOG$NTB5[$8X UNPH,<"Z1%7[,']7N#*=$:WX*
MGVXN2%$ )6& U7O""+4CQ0HS_L+VII%.2LSH_]8?F2_ B(P8]CTRN,04A'*X
MW3G9INE94^<9 K<J89HH P*5!QT6MB01HC00?5UGW*F=5^(S;"!MCX@2DLK4
M"'P.XJ>/V@&O*!K>'^MD8D4"+^X:2@OPU[ZN#-:4K':SW/+[<%!<L-EZ.]6X
M]_S*5],W4\6@WG/YJKP/5-OTX=48H.=A?6O;5*7-^/V:* TM+8&FT$>Y_/%-
M_7TAI#^*.MM(X:>/%,B<%P3@?5$V"-X*?P_\?2:\3T-2Y.H\)D_OKK@D?CL5
M1S3$A#L)QUF!QNU&CRU-,V;M05>58NB/Y2YK\C^@FG D+$<JKT![*/&<\93@
M)Z_U1\6JI;DTE!P+TMYQDQ\EYD]^/Z.D\W303BB[3D"Z+UK*7U['I>G'*3%9
MS*@X/R,HW*YEMI&9-%#SUHWQK8JFO[YNBI!77*Q9*<^!2^@*(LK2.'RF'!WJ
MWBDON@5[U.]*16##ZWNF*K4UO="H&P,Y= J"7 1M88 AUU5!_Q7_'G8:)TD%
MINDZQ^;JUOMC17UL&N2,0(<_0(P/W&+7')K ;J;G)O 0!=P)#]20 $$"-:7
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ME6^RM=BZ+IO?]O]B[[VCFNJ^=M$H*BHJTJ6K]"Z]"$3E!00$I'>"(B!$ND"
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MS5C/#\XXWWA-"Q/]1<]A.'(];.>WWDH67VL]23*LYO0%%=!GT(DZ'-@X+@A
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MZQ@-+8=@*MQ)HE-[,D@W.TZ2@/N%@E"PUU/VY$R!?A;2P%*<[I#\0L+4,16
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M*%M[9\F<31RP_?=S03*7*,,9]4D8XZNS4#U9H?8*A0YL'K1Q7T#.TQ64OBY
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MRV!A>U 5 =X31=/Y-KB#!F#3A-XH?/'R42(_D6;)<BR0!4*G&]$E 4R72=X
M-@<(REU;?7;EF@]X?]N66(%!72>:SG=P=5,!686V%Z=%H<4S9V_575A[W$LW
M20;K=N1P:PH3+W>Y._),SDJ=Z8OZR\;$G[RXG,HWH*MXJ *ZX??+&=RN_RW/
M,I++R\2<G"]B\-F"4YF#8^@H:%^]M)7[7>I%,+V*>6;Y0I.]FR>WGL*?S:,<
M;9(],1*?:$&DZ3PTB$$[S]V*D57JU@LUK-,6N]Q]GDKY!K9?L#'@OI<C'Q4
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M5DF*0K^%A''#U\6CL7>+;8GT*TKO<#7Z,.&+\0G*6AX7]/C*UXPGN8AY'8Y
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MW6=7@KU562]X/^U;F(IE? ODEZK34ZA0_LZ.T\LJWUJR-TR@N#Y(VAR&A4)
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MN>.5/,'BE1*3=#G]_6C%N1K8;K.RVVJBUNV!K>6\M_$Z.1IZAK:G=VV/#!R
MRSF@W_!+5( [Z$WS?E%X;PY#HV"'>%UMSEY^I.]F\I>$GO9/1'*%.Y=TRHJ#
M5E>A8&.T;75FW,;S1&%3^9&?:CF%X)5%&4(:<;C 1NJ-;=.GQYZ6&:*KOE3
M69=^*N"U:RNR&R:/-TY0E,%ZLRWUAVK>8<@43]0VB339 ; =O<=SW!KP@QJ!
MDG291.S2?E8N;X[7M*RN>;:<2,PJ[=;AA#H_DAR5T@3X-@L8EAX;Z@=93I_
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MT?_*Q:^@-J0/5 !.@7^;8D(:IP*^VQ \:77B7QO]K[U\G3$6F)Q#N1!!A@\
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MH!AYZ&7B7=SYBMI1-F*.P;>8/?OI@/DZ/T_/)7C:C:^R?04I8+$'PZT/7P.
M12<2^)9EW9WHO\<@\N(ZT0T_'$"$U#KBFY.>+ \D(]08+75-H.RYU9"+75XP
M#[RY-=Z\"_>)\YV/EOB73MA?4-@4W'N/*&2%Q9Y*$95&"85XQE[W=D5BSWQG
MNQC.[2U6ZHRG&MHZKW'RQ<H;]MHHP$[GN7,NG('&LL_I3B_F(C/@"4@6*L"3
MD2BZ06(+1<N06.8)/L2&$A(3T07'WWEBL1%SF'C-3DNXKG1;;0?LZ^W-<Q!U
MO9/GW/XKWM\K$;L@F5ZX&X(H#L)JG3(3Z0C3Y!RX)_*Z2#?C#5A_?>#<:'3K
M?5^/-']P,ZS!:\*]:DGPO/F=I(II7=!'R7ROIY]N\D]-L9$<2=8U-!_^I(R
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MWI(KJ'.=_&!D0[;B]UK#<;(P=3 "MU*3N,WIN/%:^8%M?]WJP)>F[Q*\>##
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M(DPI[:,(W1AI8#P;VH++G+!G85EDCE*J;P +;3@'/>C>2CUR,S-H98!ZCJ/
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M+SVN>';I6.$UQDI&BI=?\I(YY-X!,%HP)8O<78D" "VF_>\5@6Y_VP168P1
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MD1(P$:)MO(_:8#>&=@_9S/?BC('(3<)JY]- S5[@YUS\1Y]=?%PBT'",3*O
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M?XJV-;+[@JKN/>O+#GE""% N5*C;+<NZ]*'E5*I0D]0A]N0!XC7Q'$<TIT1
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M^]>M+ZVJE>_O_OKK^C&/EI3(<\%:UJ?_.GF2<5C&>H N3AO&R@'4;70 ^NH
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M:M";546UHU]^O8*K\OQ!0=HA+@^V"'XFMH#.#$ >H_X*D 1HXJRR^*JO2L?
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M[/:->19LO=:F.RD1]UHNI3)@. 1&FR/!+R3*8,WX\>A63]I+OP V5,/.!)(
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M/WR]%NH+BT8I]:Q%AI*(#VK;:Z:#Q-?05SN9],]GJ8CP6CL$>A+E$WZB;]@
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M&U[!88.P/AM,8;BFO%3G- S^T+&(EK%;'W[A$7#*QR7X>6F'F]XGRY:J0HW
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M<5P_>=4Z359!TFR^V8[QAX.6ETSZ32+N/!PO\-$9STTRS+!>J#LLXJ1R6"3
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M_:YY7<?7=^_94P-J&8\^\-I5E:=?DGHQ9G7OP@6IV5NG?[D-4^K]&9YL,V@
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MW2BZHA<NO >KY YA>U)*\[.RA@ARE!I4S[ <B()$]CPE=)ZV/O'\-2# \%U
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M.E2QTJHGJ\_#[Y2/%Q4\'SZ19;[.*E6O^><!\D\IV="5:EL8?@]/F/C3/-J
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M^.&S:]X,50%;_2E[4C>["33ZS4[?L]_\260LJ8#B\ROS4.;"WG7G-O%/_A?
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MK<T VBD(/"F645?^NI.DTL(]O0KKY0CSW367( 4F]KQ]<1P(^Q0RP4%(*=P
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M"LPH'157Z=?/6)[F;_Z&]Y]R?;\C%MFT"J/0>&&(BNEV9>+H]9^61DGE.+P
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M7Y"_.8&!/*$)/F+1'P7R^(AQ,5X469A(4UC@(]3MEMX<AA/T13C=?=L%+PL
M8N[S$:?K(GDQ&;"2<(>: :21(2*1$<5''*1&DL&-<->7\?@?2K:3UP/[\P>X
MIWA-I,6L/&A#_33.XXEA.?<X27Q$*YN/N()>D>$H\!%A@63. TL.0&;!=;$
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M#M-[*9)3PY7ZCTJ\;\;55_?MV>N;:W_VA)9Z5^I7^6<'M+D_^LFV3?*<WZ!
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M;)_UA-ORVNYS[JQCHP*O$J=+53HDR[;NKU\ 9%6Q5&\ "Z38N_W!;4LDD/F
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MF[?D7@Y=CYS3RQV4_51>/=KHQVG&+G2SK+;I\F!,\AB)!#!,(8 TB]2>&B5
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M\J?80S7080[UKRUKG&Y[%&JP4F\]_^T>'MG=\VZ3"SJ3! J8,I#E, 8P5+2
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M=$?)*5?Y610NR%5^O.W1<I6?5:^;J_S\PWUS!WVZ%_.Y-I^2Q=,,RU0F,,V
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M,L+:=#8UBNLD5^E(:W-%S!UG.X[SA=[0KCD#W.<>P/4(TCV/B+>0VA-=C1P
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M\:^_L_F*"ZYO/&C)5XT=Z%:^)N6B6-Q5'T39"/YTN %S;R_"* XQ9T M;01
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MD888,AB"'",.(*2*-A(F 8GS"(80T0S;!S'WEV-J++T1O+$?+*4.^##R&U,
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M B.1T)B"5*C9!@57QW5&&(A0$B62D02&R"TN8=OXU*9>ZV#7 K9U-ET#$#K
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MG$'8;M+[QVU@+MCD=FDE#CH%7%NA@Q];L8_?#NF=U\4.)\\I7<YT^B+97.R
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M=RY+B/NI5EM:15'OU*C-CR5MI810211Y9#QF:D^9J^TDBT*04I&FF&>J+:?
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MW6G6<94M _4?"P9MJ$WQZQ4:=V,[&(!'F]/AGGQE@/^^W^.<HY@BRC30,10
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M?#@+0]#(AV,I+Q#Y<-;4TY$/YR]_F;ZROU>91>^7GZNFI+^O;?E;S!A-4RZ
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MRCBE.?,JUC.<JE.;/UJ:CI0^<'DT'6>%28S1T%-$P$+Q+8-GT<[D>M*90/J
M\["\=/K 947_'ND#SH '2Q]PE]AWAEFM-S8/H5K=O%Z5FSF5BF"&$!"Y%@ I
MJ@%3G((424D2)1!E7NV'CD5,C=$K#8'-!XL6U6I:&"5]N?T(1U=.O@:=P;G4
M F.UVW8\>]V%3 _F.V=\,,8Z$C RTYPS\)@ASE[9M^-K\<@VZO/"#&TK_CH5
M&64Y%0#R5 *4:0*X,A\[S5.EL=2<,Z_\G]-BIO:%?U$_BM((LJG_A5G-;\P"
M4BOKM/LV;#T)JMNG?CU4@P<X5 I&.PT'"&+O!B%8L]630D9NKMIEZ'$SU<ZK
M0S1]K@MYW>Q.2.<JEWF:Z1QPR3A *>6 *)X"PGB"=,9BRKW:@W6+FQHE'#5Y
M/CI"OJ:7\Q'8KA01"L+!J>)9[^:F%N#-9?2N[-=\#I1!^C0?"7O!_LSG#._N
MRWSVKOXEHI]5/?WRO"KJX0]:5\X3K6F*-01V[PD@;7M69=CV:F8RICFG69;,
M[ZMZUE\W;+UQXYVK=/+YIIYK-F"XA%%R%@E;C%CM=:WVMUM5BZO?LTW$C7>S
MM$%)=EO\2;'S?8>'&-,\UIGD&+ XMKU$D@30.$L!HR+)-&0*HZP9T[=+QU)4
M(X_H5J^IC*>RP4;CCR1C$BJ=FY&4*#4CB00@2&*@&&<$BPQGTBS\5QNVF-@H
M[G4:;@2_61G5"+F-XY@#Y^9;C#8< [L>];=T7*A]KWM47V)'Y=D/G>KN]RK?
M?C6R :NW]]=E].+M5\-VJG;[]0_MV]#]T3S9+M\^_;54\C=FWENA:@]LGB*<
MI%0H@ 459K6%B9DGTQ2(6 C-XAPEJ5=Q@2YA4UMK[77M7Y>]$UPW!@P%V< $
MUT*KTG,6-9IN5UDAN[Q?1B18J_<.42/W>[]L]''3=X=[^K*&S37XL"K+=T;5
MUZOEIE@^&&?^DW%.JV.B\C=E$[X.<Q)LYL%<) K)C&G <YJ8]11$@.4(@81C
MB!G.%,Z]-G/[JS(UQFG4\J68WB/A2D!CX#LX/54I4:^L&;]$]O.*]I9$>U/,
MLM3:<I H-XLN#4P/"KL6TV $UUN1D>GO6L".R?'J)_;/ERHVV^)1M> ?:BD*
M5;XI2K%8V1"M?>PD$U+(A L \YP 1%(*N,YL]@+#R#AC5'&O,%D_\5.CR);V
M=>NKMO[^^4H>X^"X7AT,W:$7J%W 1GO=H^_#-!/KA5O '"D/X:-G4/D#<RJ_
MJL=3^A%<*^#T]<-Z;:."N%F[,K&9"ZC-FRAC@*A6 $E[AB\( PDB,4\%EJF*
M?<CLO*C)$5>M7CO2^]_]^*H#5C=N"@/6P#S44G(6;4'[OE4T(.-<1B,0NW0(
M&I5)+AO\G#4<[K@Z9;Q>C=9)M?,DU90)$0,6F_4ARD4."(XSP*7**-0\1EGJ
MZ^N<D#,Y;F@EC\\.<[A[IV ?X.KNNUR)U@A.RCXANU9RT(SL4SB$3\P^D/)2
M^=FG3.U(TSYY^<LDC/Q3E;81X%+N2I2O[(]:W?^>-0O\HFS)9?-SZPA9.GM@
MB[JC09XIR9-, XG2!""A-.#<^"<XL^?%J9!0>NU-3<>TJ7%>;5FUU%#;!@>;
M560W+,=-4 GX]KC1['04GA"SATR :;U:;UNOEOWQ[+#OZU&;V!U440NKJ33>
M&&S\)Y)I$]"POU5F3O@!#9W),X"&/0J[W" 8OUG]M51/7U;,:@-A_/O3W9*5
MQ<-=%83<1+;K))6YSA,SBU-L9O$8 89C#N),: 2E)C))G"N\N$J=V@1KU(YJ
MO2.K>$6'1O5HIWL=,>]1QL09_^YY<#!4!YZBG@-Z<QK0R^D'5R#K42EF"(1'
M*AD3#&F_\C&^B'76D7%^V'@%97SM.Z@LXWUSO[7@&Z6+I:IVJ*O2A;;?H7DW
MWM[=+U9/:OT'VXC;[;2R_;TRK]UR,Q>I$I Q:F@>9H;U!00L%028Y1SB6J,\
MY5Y[R_U5F=I4L%7YW\KHKM$Z$BVUHV)I_MTJ8,C*B-FBA=88ZQ:OM/TW6V\*
M4=RSY<8\:%.'EK;<B=GV#K_UVQ4C[K;>&F<<!YY\&B.BMI95#]E9M#4DVEIR
M<-$L:HRQ@]A<JLI_BWY?K\K2+J'"+6RN!SK00N0*149=.%P/V'-'/\ 3K]C#
MZ]/+W :R;I[>+\O-NG(MRJI3VK=;MFS6'OZ+C'*>:DT%RCF@(J,VQ$P"EF,-
MM)1YAFC*8H2\M_&F8MW49I?=)@IK-E'6NTT4T=I$612Z3^F9J:#NL[DW%9TG
M-'\%V-^K$8I:$+6[*NYV__IN\ 4,4)[D2Q!RDV\RMHV_SS<9T[NV^B:G9#^G
MPK>67=V+<WU0VN[#KFU:CF*<IBH!.DT00#)F@/)$ (F)H(JJ#&.O]6%0[:8V
MJ?>N4VFO:INY+5SYH6]OO+ O@=LL_F)#._ L_"*CZCU]#H)^H.DOK&ZC3E^#
MP/I\^AE&B'\?P!LSA4D[C54MZG":L"1-8Y 3*0$B,@$D510(S#3)N4IY[MSZ
M[^#)4Z/MG7*>[?T.X>HFR:M &)C@'.WWZMIWTM9>C?H.GS1:;[Z3!K3;\9V^
MH)_/]E%M;'YRU9=(*OG;TY_&SWR_K%,1[0=O>\M4;##'BO#4Y@ RIK6MZH8!
MLQG&&".::F.DQ-"G=(.[:*_/=H0Z#4;SNC[#?:.[70J_>K"+X&+YB_E_8T'$
M=B;X.5$>H^+F(0V#]<#L8&&N"BI\;L/\YQ;FG?+1S668O;T:?\0"N2P>@D?U
M1_P!>>YL]'A"/U)K<@*7/_:%4B%G5*?"4)8@L8T4S0 C4 '(LR3-)#;^AE<I
M\F,14_,M=AKVKC=[ D8WMKD.G(%998_+(.5FS]L>B!]."!B5!\X;^/Q[[[BR
M;Q4#\^$LV>*+>E3+!_55K1\+H=Y_^=J$VR#.&$ID!DA,;,MP9LN$"0VRE%*1
M$BZRV&G=X"AO:E_\5MVHT3=J%(Y>&96]*Z%T0^U&! $!')@5NK$;H$:M(S3!
MZ@9T2QNY.("3Z<<5 -QNN[:NTN?5HA!/^TQRE>!4I D#B62&59(<&E:)B0$9
MQ3 1"81^&]%G)4V/3[:*>BY?SF/I2AL!$!J<,+8ZSJ):R^A[\]]!,NXO8A*\
MA-)S.2]4/^F,N>>+)YV[H7?NZ_U:W:IE63PVQ47,.N:3_L9^SFWYRL3X%L!X
M'0*@& G 8DZ!3'-.((QSEC*O8I;G94UM"^1 U6BQ*OVK>9R%U8TD H$U,$T<
MXG10UF@6V0V.E;95BV;1S:8.\:H:QFU6T6>V[HK-[),E>PFN<)FR9R6-G2U[
MR>03&;,7;^G'(S>/K%C8P7VW6G]E"_5&\<U7>XY2;7C<"/%P][!@&R6K2,\_
MEVO%%K:6]N^L6-:5C>RGD4@A.!4$, 53@'2, ,7(UF93.LU3P@CQ*O 81*NI
M^2U[-2.KIQ\QA1DG-PH;'?V!R<[J'^T-,*2V-1 898$UT?QL;U83U?QLO&;;
MHF[&N'#\%Q3K0$P91J=1.34HC,_9-^S#_4^AWRXWQ>:IJ9WR1=VOUG;WZNN&
M;1[*N<Q8KCE&@">9<?8$58 1JH%(,".,I6FFG7:0+PF:&IO6NNYJ^^RTC6IU
MW0^M.]'M)LR0F W,@7WA\CKC=L&BUY%WYX-'.P%W,:]](.YT?<^C)!M560?'
M?#2*UR+FF<1Y@BT7\!39A5\"N(K-'[DF>0IS1A+J=9IT2LK4B*".WF:5EIX'
M22=!=#Q+NA::H8^3*E1J!6?17L6 )TI="(0Z5#HI8]QSI2XSCXZ6.B_N4:S
MNAN?=%4JZ0_VL[A[N+OY\6.M?AAOXU/3Q>_SNA!J+F&B<\IR0 C6 "D$C4/
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M/6\4NKA@S/:#OW39M24 JP*#MZN%N;>LJZ=_7&U4D^];-@F_9:N2%>%*8,E
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MMR1OMT?UW<E]5.7&OD?E&\6WL:6;IR9^I&C5\$OR).4ZTT!RPFSSM!P8JDM
MEJN8YTIJ*87?MJZKZ*GQ74OS661UWP6CV]9B._5[GR1[#(KK_N\04 ^^&1P,
MY1Y[P[Z !=LH=A8\\JZQ+R#'6\C>3^C1H>.U8= ?ZMUJ;0F4+9_J7-?*0?G#
MIA[/,4%I3%("#)EA@*#* (5*@)AB1(A6DKCM*SM)FQIQ->%$VW1LF^<K:LT/
MT[6K+&V/[A474>^FJ>!8#KT#7:E:H=@H&S4YU?66]!^AX?/H!!(2QI':@GR[
M5='2T! K;R-10[M6]T:"J@MFVJQTS8IU]&BKT]N=_]>G7MHFDYT_53=LWVO;
MS)"9Y:,H[JL6>L6R^G7SA'\KM]]!E>?.RHC5+[^5:ZAQLR[X0U7M2=:IVO;>
M]6X#H6Z?]6MT4VX-F)DKBC)2B]HW+VR45,2D48L9%?^Z5<M(L(5X6-0;F$NU
MB2J[?ZBEW5:K]5_M-C@-&Q:/]31GVVO6\HNE+-9*;*([M;DUX@,U4'%]<SJ[
MJ5Q\R'BM55SM.>BSXGQ3/W?[PWY/WTR QU7,=WY=IHR7'0L!,APK@ @6@$E(
M 1):9CPA4&*O""M7P5.;L5IZ5^[?J1K^?LZU\Q"XN=9# #OP]/4<T\:E'L*/
M]D4GD!?M+'94']H7C.<>M/?]/8]DS1Q3T=]:F>FJ+!Z;-'=#BJKXL7S]L%[;
M\(]O:[8L[?Q4;4U4_UK4->GD?SS4COY'M?FDO[&?G^UT:7ZQJ:=3&ZWZ;?69
MF<=LYDPFL8@S#31.$^N/0\#3- :,2:RE2C)&O+931]5^:FQI9J_E#^L@6-_4
MFAN)QMYHLS?1^"-;&V>5!V(\JKI61K1A/SW/FD=]61Q/L*?Z"@Q]+F[MC@X,
M;PI_1*\^K,KREUG40!!M,8A:(%1S00N&Z*;UFGRL7Q.#Q2QJT(C:<%@_NP8D
MX!G\2XQCJ)/]474?-U[@)8;E* KA1908J-1V>:%V:]7RL7R_K$M(_4O9KM]*
MWCR:5>(/]?:G6HNB5)_7A5#S!&FS)),)2),, V3F5D"$1D D@O%49SC%7KT"
M1M1]:I-II;E9D-OB=W*U6+!U:1?\=2&\/NVK1WH%KCD3??&!'?$L]5PQ[]*U
MFG>-@/6VM@7\MBA$#0S1%H>H F+$(M_A1V^LRM\!-9_ ,?"@0^)=(WP %:YL
M/ES5F[++V=;BMND_*C\MO]BS(;OO:B[XN%JNM_\T^A?EMZI*3JQ2*A'6((=9
M#I#@'% .*:"*4I9F<9+[;90%TVQJTYDU+*HLFT4[[2N?OZU_]+U2OF]CXZN'
MTVWR>I%!&GAJ"C0^_9LFA\(R=&OEJ_5ZF0;,H> \VZ8YF(!^%'[SR(J%?8Y9
M<GUE"V4/]5MG^7=V.?5?=B8J-Y7,>89IGJ$\!2E.;;%T#6TYVAQD/$DDQ"A.
M8^Z3TN&K@!<ACY#K<2/$PYT]"*Q\T=*S\8,W_&[,.B2H Q-H%2*TUW46[6P!
M>K4&UAKSLZT%W9![LVA?W *1I;?X43FQ+SC/J:_W<_HV?RZ5N>G6,.@;]:@6
MJZKD9LN=_E>QN7VGS /9XO>5<9*7U>]WK:(I3S+(4D 4-7S'C%/*8Z@!3#(1
MYS*/5>85+WF=.E-S1[?65!Y.RYZ#T.:_C$518U*TMZEW8.65(^I&H>.-T\"$
M.O00]>B3'0+98%VUKU)FY![<(8 [[M@=Y*D]HCRWDJO]BC_8S^+NX>XS>S*0
M+"SY?U'%'7\P'&;ES442RX1Q!@QP"" J-. ZRT .<99!23C&S#GBTT?RU"BW
M43>ZK_6-A%$X6K<U]HA9]!J";N(<%-BQ.++2>Q9M,6Y4K[S,Z,L8&'O$B Z%
M]4CQH@$Q]XN0[(-;9[2DUP/'BYSL8^=!%&6O!_1STI]M4M>==#_INL].J^GE
MSHF3G/%4"@H(Q1H@+&+KEA,@!,^)T#*5L5<K#5\%IC8K['L/UQV^H@=[YE4L
M]V>=^XCEE9'EYW%[#X^;CSTDZ //&$=GA,^;/[>[!,^B-\7BP5X]A#_=%\5
M'K2W^%%]YK[@//>2>S^G9[ )6ZBF1L]K\[D6LDHE6"WK2OUV9[@5$S./<TJ1
MH F(TX0"Q"4$3!HO.5<Q$XG F%(O,O22/C4FO+FS/0V:IA[FD[/OA/DLM:H.
M7IZUM-Q'3FY[7EIWVK=SN]=@.09V##4$0X=FL+KP_]<:W0/=HZWRD?E[2_V
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M"2MKP=^5N4%K;_T6;VR5EJ\AW$^$7G$;F>/<(7-08KX!QP!-YFLM3ZS.?&.
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MSZ4/10+D;KTVO]7J_MJ%OA["OL* 7\4^)_@\ZOC9]3^YNI\3/)<T_]P:LM^
MOUO+_?Q>UR[.DR**$@BR7$7=9"$%%$<")&F8<9S 1)AON(]:GAN3:>.L10'/
M ;N]?W:&870^,43 :GM\<;1.V^'CEB;;_EX<0'>[>_D#KGE55<7Y+W+'S*LO
MZV59O'SC/[9OEZH #I%N899C#,*(YP"RD #,,JI2JCA+"B)PSNQ2JJ[V-;>7
M4QL9W!=:*=DZF;(/5#,WP1-4([_ M95W06UG\'MM::!,#;2M'J-K#1#QEBAU
MO:>)<Z1N#OD\/>KV(VY$\9&4&YW(^6GUM-M6O_!GODR:?!Z:1(1D4  1A0F
M228 Y2232W@2"Y*F<G=IE7O9T]?<B.*W\F%5BK)0EXJ[U9HJ]XBH*ZM2FQZ\
MT<8'B>7E8A_:9@SB"<.1&419N4_)UH8J-M&(C9!.98"))P[IZVE2#C$8\BF'
MF#SB>LWV7^NE7%#)IBZJJ(H$8!3A- <Y$RF L73T:9HB0$*,XSA!842-LJJN
M]C WOFCNB/96UK4Z#8_%K^-H>HDV )UI+L^,@7&X,KLR^ %79:<M3GQ%=F5
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M_&\.(*,1('F: 9PIF4@6\AQ;*:CT=38WINA$TW6L-5E#[7$VXPU?Z(U,'.[
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M3IDZ@H=L!HJOB*S^SJ8-NC(:^%E<E=E3CBQ257Q[J(L50I(DE!'E)PL $8>
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M87;XX1G<:9BT-5I59VC,WI=?N=.U<[=U LZ'FRA;GS+8 ^;I@,"BXTGW]O:
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M^^GR5[@(,!^%[(06SI&8*1I0V35\#B@1"]'9[ "J[RMW7C\X,HY5YJR.9!L
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M'Z?XX7BY0'X@&Y,\X9#0P]90\IX2[34RZD2D'DSM\\>G:!KVKFF3H.Q%G0W
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M* XW@N>D722T%/M(&4N510 2I?#4QF2$KEW7?RBM3<8GO2'T)11Z;-C\I>_
M98MT1SXQ'R)P(C.N1PE6$FM%QJ]R8 979T@O=-RRA;HF Y>^,-J3TAH(7-[D
M#!']ZS<_XE<_/8=/B/:S:6&V_%>RI-_]9+4\48[CB&NA_.!DFNY_<.<W1U)0
M)R+CA.(2+=7HZ)G;R(C5#G+65CI9&[<]L-'(,-+:H<_0"F_ A3B*V>V]LO#[
MR679KNZ*=25J=.J]]#$K(ESIH24 B)>&DN+1F^A!TNH7"E^6PT:FQ-5>*0W#
MI(&-XSB+H;F(/.A$?$YN-;3(6LE)4LX[[;(4J?I\^]XW@_['T34%\6<I\6#$
M?NL6$DI@OFP M\ZCWZA1V-PY1:3AJG2.XP1H5DHQ91.KW2BC?]SV/R*O+=P^
M1XE'XO;-M,Z)Z^?+;]\FG2C]Y%J4[Z9Y-K]8*?/VRIX05!M+,I4"A8J;B(OX
M;0)#E5,JFER[MGA/TAH9PE<;B7THI@$7^7JP[4<_+AV]1\[J[ #]^C(5CLC(
M+'$,RMQHEK3$/R'7]F$W2!BXUU\?:GY0FWZXS/]XDWX^?SD[_<^_G;U__>;3
MYS?_\[=W7_[W?5Z.:U*ZY>D]=RM]BI_Z;4N[]'W)DJ(*R_:VO+J!(08,&:3%
M",*;@+&$TL0;4;H_>0=*)154[8Z*>Q%V]#9X_9(OW>V@: 2:;NJ(\#2C ZH<
M"8QEPJ2R.E@J)=2N[+A/03,-2"MAX<'N=KB\&]C$;JA?2:0<'LRFQ0,\^3%>
MC#SS,@9O".[OY0J(I20X47H'&>? H*T6M>LO'B6H$2P=H.E=H#E:[ U@:(.'
MU[,+/YZ.DO<I <50US@4CS*,X#^-!'=_$W!=.1EJ%WIO):01S!ROZ,TD]=%2
M;P Z=_OC09GJ. )N;%0I$J5\2?$%2:R(&3TZ3ZG6S@K9PP2 ^T0,"YD*BGW8
MW?\(*3< DY.4QD7\?E(<_W?3]57%-3.11Q>[=F,N8A" KC_Q6B<"W%-+>9 )
MZK<C?H2@88MGZL.GGO1;@%*,EQ>771G%KKDK:\8TRRSK@/M[% G7B.<D".])
MEMZ)J*)+LG8KCKV)&[;ZI0>(]:*5!N#V"98H&TAO_'PZGIXOUEQX'H)%L1#<
MY$N'$,G0=XR6T!RDM(F+5+V9]'9*ACW!KP^D"O)N #6G$[]8G.5U[>O9_%.9
M?]UYC"FYA&&')U11]!AUUW<!3:ZTP4%&IU'3ZH<KNXAIY+KN\=%8'7&WBIOU
MJN("E'#(@ 9CT7 B/X%+3J)R/DFOI:A?8K&;G&%=[$H*WP=&!TB_ 2"M>5A;
M3YNL<@&C!<H-"D7)2"Q%-A3+W JA!?>U4Z7W"&@0+(>H=59+Q@T Y,;ZOL?=
MMNNI.J+<H:G%394S)XADQA&'_ACQ"O\R(0<(O66:;ZAHY#)6Q0SA80)N "(/
M"[L>9N _S2:3M[/Y[WZ>1DZD$%0VQ-A2%4Q+3Z"4*#'9@:"\E"37KG=Z)HF-
MI!(/1,23;;[JJ:<!]#UD9H2;=T[>8L!(R[7<4MCN-889^)\/F6?/5.V _B$5
MK;47KJCT!Q;L* TT4PW77:U9G%TN%TL_+86I(V>C\\:4'$3 :)(S26S&O1J9
M8-IC+!D2U ;2)A&M=0CN$4='R;\9&-UI1?]EMB.EVK$:-F]Q?0*4YV*\A,\P
M_SZ.L*J;+AWLSZ?=4_[+3RYA!-Q&:TPDSH,K<PI#.;\61"G\*R:=??4Q 'WS
MU%J3X?Y WA0Z6MF^RV5<2*\OY[CH5VQUO+RY^#:970&\@BGD\;*TJ\+P*0ED
M).-6$DI:V)2+CI$3Q@%=[E@JP>I/(WX6B:UU*^YYX^])=^U"<[5-;>//"<&H
MY89HF=!+M]F7@D>.B$K>,\>IYK4#F^?2V%ICXQ<'9QWMM8O.;O'=EOMWOW52
MA/D!EF<9!9MAO+R<EZY"WK(0@!-OLT;A:D,<+D\BF&):.JX5K^U&'$MS:RV5
MAS&MU;7;+II7JW4OAJUC&%E2E#8O4^ED%KBY>$V2E1FR!=#5^S$?3?2P-Y(:
MP'-/^FT T'?\_&<W\[ Y.X_;#C%.8]B;BJ"-880I5_H/*D%S;3_B"'*'O<PT
M4.S6JT[;:=#RV#9T.IM^QQ<A<Z6'4OEZ.0X3C$XC_N:Z;V&(W@L,17-@1+*$
M'I60#./1D#.E)IH>;EX<0?!>2';_"DA^.;TV8(H?W7N>YM:Z<FFDM /KKIZE
M,N3)A4B4\]+P')UQ+Y1QV)/B_4X>Z+\PCOM0[<% QO>&V0O8XP_P>_>3Q4AP
M#L(I1:(L>TVVBN#>8PG'Q4DIRI.ZVK5C>Q&V'S#_=<[$JBJJ=4-ZRQ4O/>@4
M!Q(-!IP2)! KJ"N)%,Z%<%JG%S68S\3?O\996GU5-0# 727C*#$8GT]/+Y&F
M:;SZ,O?H=L=.L=/4?3?IU/R+'T_+^.>3^7B!,KDKF2[>1&=^%#&>#-YXH@24
M^BQN<$V:3+B7*DKG5':U[R6] %O[0?]?XH2M-9 TL&[NS3X?B92X"\F21,N0
M%R,T\<$RPG5,&;+*$&I/0[E'P'Y8_)<X(3M<\ V@9DM=CX[*&HD.BW$.'1:5
M)?$1-XW ==(NYP2Z%\_R@,JJ?YU#K,-5T$K#I@>%/<$+:H.P)+I06L.4(@6:
M%,D^I2AT!@R_FBBL8O\:ITE'*: JB@;LJ?.QT\M76(ZCG]QGKG:#G?NO>O%N
M.X]P^J*M=T2BX$UP)'%EB/2Z&QYL"X0Q\+#4*]/;38$^6^_L5<1U&X%=SQHX
MG2V6BU%627D7(T9:I0J&BD"\T998G4/P,;(4:P<8Q]#;2"U\-9P=5)!70Y?M
MMB7[X,L1ZRR_NL2 !Q8+W"->^<5X,<L?[[SC$(NYYY,K&<A#^*AD#\_FYWXZ
M_F?W@M/9=#&;C)-?QY9W7WZ6UWWR"ZC6T+XS!3F7>QZXQPN*.[L$2HF3.9(<
M%<?=GTNO:E_=K$+XL?;T6F&O81'GXV_KUW>Z.[NGNR^HKE>3,JG%&1U40+\7
MH*P\"65HN:8D&I-2H(9'92J+ZOE4#FL[7QZ3F[:U9[VV:U$_7UY<^/G5+'\>
MGT_'&=VPZ?(DQMGEM(SV^XB:B.6@[@"+NN>3*UG40_BH9%$?ON9VNX_."D$C
M,1KW6JF5)E:&3)1B3G-GR^7MVA[43FJ.#HX?D^SMNE Y&<>8(B)BK":U5B04
MQL&!1R\#UTCUIK/[43:LC:N$D@<!<WVEM&NL[@X#/L B/9@E?+S9V4E1)=MR
MY_FO(5R/0%]>W98&W$Y*,@J$-)(D'[NKW8Q8)SRA4F45((FD:H>P^U-W_,WM
MFS>]FZ[?]:N?_P.6Y5K[@[=.TRG,2]N=+W-?LD@GBP4@C>-%G,P6Z'G?+HQ(
M6; @RQSY(C6J.:X];@@O$W%]8A;#H_ZD5I67H>_Q]H+4AW?$&P!"NQ;RK1_/
MN]*-7\$7_@ZVE=L?5,EJ[D%E)?MY\Z9;E=^9($ ]3V7^B>.9$9E3Z;:L V'.
M4AY-:952NTOC8_0<:R.W/?N.!V"B=KJD?;I!1=0RC(X81WP;S85BJ/G:):Z/
M$C2LM:J&BTW[5$\)[1J9C_/9-[2J5WYEX[^5Y5MF/1Q@9G8]JI*AV8O22J;F
M^EWEBM[U]M>]\$Z" D!Z08F6S!&I0LD8"$=BRDY*%I-PM3-!3Q)589CT]A=L
MVV.]S] = 5L=,0H!%T@041+JA=.!<N-#;8/['/J&-4EU\;-EHG0_>FK73&$\
M/+^$].9'N=MR6 YK\Q&5S-*CE-4R1_ZJ>,3%!>Y>YR>W&UR62E%A# F(']R&
MC"76&D6THU2"-<!$[5#Q$7(J]$\N>8_%^A77;T 8CGT83[I 8!O*'95.1L?*
MK$;<YJW+Q I6H(X!2C8^:E';'!](ZL"&J1*2MG18[EUO[5JGT@%_O IDT3LY
MG76).Y@>FFU_['&UJCKVI;B2!;OSOI.-]]W"X@:)*0D$A0 2A?-$>D>)SSF3
M6+;,R!WNEK4+M9Y%8(VY%$^^[$ZD@?PJ[TKI57:E7I[B^L!U:JU*(&TV057O
MROPL"@?NH-H;MK9-NNA);^T:M_?C6#R;D_,Y')Z">OB02H;L">J:*K2(Q@4I
MC2#&6$5D5*DTX0U$>R5"HI:+4+NQ7Q.%%J>S"7XZF^.;OL-):4M\#KO"%289
M%9D*7(_)$!F$P.7I-''*8A3CA<8%6]W6[4W>OT)IQ7-0^-  ]J/)BM=<ZSMW
M=ZKQT%=:]]4^S+';\:A:3MT^E%:RB)LC#KW*T90F:]EK(B5WQ!G-"!<0E':2
MI^H9Z=IS+3?K/#_,EK!U5V<Y _.*<,DR.A!,$PLT$_#.9N949JS^U,(]B6MA
MM-A!F'CZ"DH-=;3K9'7\/FQR<TBIUO8GU2K-VH/.2A;F5MFED<+=CJ1=$YRN
M%/JV9^E'?[5101AR\%9P@MM01.>['-1$*/W( LO>*$B^MB-Q',7'6K"]W_[J
M[MMO%Y*..6@ 1H3'12IC5B2$B&O64IX5E]'$VM[ID20/:^U>$)^;UO$E5=VN
MS7Q?+K =%HVN_F6M$'0+'95LX.K1-YC!;2Y"5IH(Z@#W.@@D^)R)HA1W/W2I
M.=2V:?<I.-9&O8?% N#L&Y0(8GJ^>O@M+K.)B'HI"$A7YH8F2[S3@2@FLI0B
MV$QK>Y&/4S2LA3E"^YL6HZ+@VS4(JTOO7_R/PZS"W7]>K:1T!T752DK7S]^2
MZ/0"4A*&$F[+A#$F)0E1"Y*EDMPDJ1743J(_0DZ%<3^;C[Z%+\1@$V.< %4!
M(PT1B64<%TJ*("37'C?4_EEMQ&K4PL26B3YU--"N =EHT'V0%7GPC$JFY'':
MZAW3W3B3)]/T"9;C^4:"[S:/F+RD1ALB3/;H1)96C-YJHEW"#W(2BM5NZ/(,
M\HZNA2I-?+JW=)U]/J)+/;]YW;4.MJT$:C+(I!/![;BTP/:^K(1$C)&>ZAQ%
M\K4O6A]*Z^#'=KU@[4&UU$MHLEV;]LOL.\RGA==/^$BD\.LO!^>O=SZKDHW;
MC]9*MN[Z%0B,U_ =)K-5@=[MH4;IL/P6<!'XR2UAMX7%$K=0S3WAR76W_QD)
M23AB L_!*:YBJ-UO\#B*#[6(!0:C-U.8GU]UVMBV5%*.*N*RP 6I(I%6,.(9
MBD6;$!7-);0(3X%KC_<,:[!>$##7-JRV[!LV4S [G_MO7\?QW33/YA<'Y[^W
M/ZB6@7J:REJM;N!\90>_S>8E8K_- A@AC?.)6*-Q5P+<#VVVD8 O/C87V4+M
M6&<7+4>?N6T\=QNZ#48DE.'^JU/"G9\%1X*0BG@7>- \:<^J3]5\FJR!V]/4
MP,:#$[?*RFC7U*RSY!_]?'FW'^<AQF;7HRJ9F[THK>8.;7W7;?H1'*HX.$N$
MAS(-. GB9 PD4ZFX%4':5-OP/$73L09HU_.W83^ E"%)C9MK4J6<1>)7)A,C
MM*$NI^BJ7S!\!GE#>T85L;-IF/I24KL&ZO-E6,!_7^+#WGS'/PZJ MAX1+7.
M+(]05LOSN?^.6Q"ER(* 4D;&%"62.P01=9QX2%1R[JF#ZGW]=M!RM.>S\=P[
M5]=U-M24#&V9.H7>O"$VB$2\P!7$'(VR>BI[)S$#>SDU</# RZDB^)9-QSZM
MD_IO!35,2ZBA6D/E:#'6+HAT*A$9M2-6I%+0P:4RBE-?O7M_?ZVAUHW2-EYP
MM?KS=KUP%IC/D1%%M<3U0A-QV252;E=(4!@AY.JM\/:BK-G64,]!R8.>=O65
MTD"O]WM%[)N\L.PS[<X0E41Q^12)LTH1S51V.3,O6>T$ZV/T[ 6KWJ:X] 2K
M:@IH $R_+> LOUDLQQ<8+BQ&$+WSEJ)O8"B& CQX8D$'PI-,%J(.-M8^GKQ/
MP5Z Z6WV24^ .4+(#4#DU"]*]K[\58K*O_M)\0%_F\YO1L%N_XW5RAB%9"WC
ME!$!!JVKI.AS%A>1!9]8<D(I7SL .8[BO2#8V\B3OFS6RRFQ6<A^VH_7<IO?
MYM+6-J%P99:<!!5Q>:( LLA19E[]'O41].X%U]XFK+PH7'M08 -@O6WHM^E+
M6*"4*BT(8TF6C8)B8%WFB#@#3+$0@JP]7'HG,7O!K+<)+#W!K([H&\#0[H%I
MB_L3TQ:;C#HO?<YHU(.1AD@%AOBD->'292^H+R?LE3%V,+%[8=#\P3#X,JIK
M *-;YOQMC\>U54YF2TEQALM=ZT@"BXXPBC$4!6"2UH;DOK3MA4#[!T-@+XII
M G#3B%*=KVYYC1?_.$4:QLORU2B#S8$[3I3D99QT],1IB?(*D*5SB=GJ6^LC
MY P[S;Z_-$D5\3> I&WM>G?D$C4*17!.K"FW%#67:)-9)#9P8Y)348K:78?V
M)F[@8?-][9^]Z*8!T&W6%NVPR2'R:)PB5/G2F8D&$LJ=?EQ<RDJPE/+:%Y#W
M(FS@ ?(]@:V^3AH VL[.J)M\144QI$Z11*=C"8HT!D6F=(VP2IL@<_:U;YKN
M2]O \^)[@ELOFFD <:N+M:O[M)NL )<!>)DE%6T9=PJ*>"N0*>FM]RHX7;U4
M]Q%R!A[&WA.N:LF_ 2B]N_B&#D W=G+^>KSX-EOXR5E^/YN>O\=H)JW&76SR
M:$32WJ/GR7A41#INB.4IDY CF. 52%/[E/00.@>>OMY7TJUOC36 RD_P'::7
M\!9E6AI>%IF5>RZGEXLE1M?S3>Y43#R4GG*0/:XY! \)"ED$K2D%J[GAM:/1
MYU$X\!SWGI#8HY::P."VFU?KENOKHQ+@I8(O9F(U=:6ICD1/U3/"5,A4.\Z4
ME-6!]R19 X][[PUM=?71 ,0^PP1_=/X+3,OUO=*_/%V,I^/%<M7K\KJ]_X/X
MR##EN<2%!(5+0X$$'1C1W@3T,9C,M'I-\D&4[@?$/]J)PPMH;4!L=K<_WTV7
MR"3$Y:6?7 =178.O'0%[]I"<D41@:$YD0,?"<EJ&BQA6[I^B<[%QY+_C)N[S
MWKL?O/XHQPE]"[X%>W?3'NYN'X:SZVG)[[J$-RZA$J]?5R,8QZ26V1/*(D91
MRB3B?&+$&"6%=CJG^M-@GT_F?E#\HQU!]*VO!B#YQL^G*+;%1YAWW#X(YRFW
M/BA+,IIOM-JN!$ZE-J94-B,SEOG:^>$G2-JO)OB/=@Q14P\-P.JF;]4F'QD%
M1#,N"N\R+H]@T6(S--N:<8A*,P>V]@'7+EKV ](?[8BABN0;0- '^/V.A.:S
M*7X95UWUM_L"&;Q/B25"K3=EYIHFCM- I#71AU)X6CWQ^UP:]T/<'^V4H5=-
M_=%O_7WI)G_=YZ;FG;_U\U_TQM\VGOJ_[Z>3B3D$CIZ40=1$2HG+";^U(62O
ML[:^]MV2_N[[?8Y?(5U.2BOIK:7(G8COI ZE,#%*7[K$%MN-7WF(@5 9 V48
M]CA>_8+RLRAL]O[?<U#SP/WO3TD-;+ [#X=O.9(,,+#.AHC2_$\F$4@ %HG(
M@@.CU(CJ2^YIJIJ]$W@,U"HKHP%XW2Z>S="F7*N-)8L]GEPN(6VL(B@=U  R
M 5-.C:.6Q(&,)'"65?#,.]J?J7L6J<W>-:QC\_I36[L^W>V%CB,<MX</J=;8
M_%'JJK4WOWG+:PC7QFAY]1GBY;R;*7L#-.5 *YXT8=GBML=1_1@G2,*XU#3C
M?H<_[^V"T5/4'3W:!1]_YZG?_7A2A/YV-O^,V_\&_+F-BIN8B,HE/<,S)TX;
M2TP2V:N8G%&U2]N>0]_0S=%[0=2# 2U]*:Q=>[6M>/D(R_78XRK9L+TIKF3-
M;MYWV[GLSD9)A6,<773K;"+2)4<L5X$HZ5A0U <=:A\D/T9//9?KYBVK:BA<
M<7=&@J\EG\ZFG\IJF>,FWW4ZV5@AUCA)DU DF2(<RM'?=,6?8-Y+%)JUL7H3
MT)H,#&OSJN%NMX/VTDINUPQ>1T_^3N#T 9:'&\+''UC)%#Z#ZDK&<&>4>8-,
MHW6T8!CQP (B$T'I,K>$&R^!:>URJ#Y(X2FB7B#1@2&T"XEEHF-W,Y%ZXJGE
M&,P$!4)9CH%4FXF.W@Q87:P<D.]XCDY:'F6,@?K\$M)U6=3A1FG[@RH9HSVH
MK&6$_%7W\%(X5E[J)W=:UBHGP"I*@"E+I.>X,3(%Q$OE41(T6E&[VN 1<NKY
M8VOIWMF?-_9A)RW7*CB2 \?=-V'<8Z,4Q( 1%(13T=9N&K,_=0,;HDIXV>U(
M5=5.NU[2CDGEAQNDQQ_8[WSU'@W4YD1MEW0W3#ODTI$O!DZ"X9QD91+N<XRG
MZJF=RE/6;X"^?<#WM4C/YI_&YU_OMN>E,EL/4I,L$A!9Z@.<S!@L.,A1RHC;
M??7:PT.);6L*^S,PL]LN]:FNIDZ(5@/.KTXG?G&''2&TBRPSDI- !S"I,EA#
ME-')BN48M'>IOP3$5I*&/7KL#V-'B;[=#6_%VV;Y[A$5.8\]KU8%SMXT5]KM
MCIRHKJE+"$1%<JF[EUPSXJ+5Q!H/Q3M2Z)C5/O@XBN**5FMK=7BGP%6)^.(D
M+L??<<UNN),Y21IB+),-RR&'*X,5%0;. J1!C]8+7[U+[O%4#[N_OB!*'[&5
M+Z'PMC;F&X[7(CWYW<_378Y+ GJ%@L7B\F+UV0;W,2M+E99$.XR9T"&AQ$>'
M^Y;WOLQ6S]STN(]7X&#8;;\QZ+\0$-I;!F%SX=^VD^WDT(W3O??);]/Q<I=)
M4"# FJ2)!LF)E*7@VK!(P&CGC?&"0^VHLD]^AJV%:F>)# >2=MWP59^8P]WN
M>_^^DIN]FZ9*;O7J!3<0<QJC*24IQE*X[TO*#/%"2N*5SC*PG&GU#AWW*:C3
M<NGL&Y1+WM/S[N'7"=.K7_VR5-ULPC<PSJQ#T$H)DDAF1;'WN71]IS3XC/"N
MW2;G #*'=6R/P,GVKDS]J:B!+;GCJ9CSS>I3:5@0P1-J2X)>&$H"IX*P*+--
M5&6M:[?\W4'*L+YB530=+^IV]Z2;6Y+';$P/'U*MT/=1ZJH5^J[?<NL^W=X'
M%(D[*S0!80MR A";>239!NM%A.19[<&KCY!3SY-?O>05Y-D<;E^(?RV677'[
MNIOZ!N8UY5$R00EB&*UD*#4/*F82$>])4%&Z.O7FK!]$\M %OW60M=O9[E^/
M#>QV=^Z?840QFY:@Y9IU9'==J_$*II#'FV;:"ZVLX(Z *S=KG2YW>2TE$9QR
M027CJOM>1Y [[*[9/US[U5]34'V])@ 9W%:7NKDB8V;2\](4JLR.M@R=$\<<
MB5Q2KDP*U->N-SR0U&$S'/U#M#^]-07/-SE#2;;<[AJ?_!)=QSB;1F3U]K3M
MSDA&R44.U! #/*SN]09O$K&R)(=,H"SW9TJ?3^^P\^?Z!VK/&FPW9OD%9N=S
M_^WK.+Z;HM]S<>1I]F./JQ3'[$UQK2GV&^WU;Y!GO0.K528I&R!2)D%<<)10
MQ4-(I3-.?0=^!RWU3-FZ_>RB])]]@P*<3_WDNO=L9[WOMT1^=76K#C\YF6-\
MO[%,DN(F,9F)S,+A'S$1)X0E44J3H[.2]7CCIS8WPT9 59"XVP8.JOIV+>2'
MDN2$67YUN1A/8;'PT]1=>IKECW?>\1J6?CPYR&8^[P65K.@17%6RJV?S<S\=
M_[-[S[WIU0BUNS2<Y;?CJ<=MN-3KXJ9\_YC-*>&DX):X3&EI^\1($!)]@&#!
M:R:DH;5S2E4(KS%-=J-S#+[^\U>T#%]@?G'G=O3(2 %2RD" TTBDEY2X9$2Y
MI&R-\HE25=L"[T_=L!;UY3&X;:AL#WIL^>[2?OW [OO>L[Q%4/[NN7?YV1%&
MN'^B7K2;6C7I]=^"+8%'7R *HHT21$;#"*XF3W3T0@#3U-+:I]C]M6#;WM/K
M9'GJY_,K?%]WM7H$B6?MHB+1)(..D<W$<Z6(D<P;J[*R4+M?Z5Z$-=MP[3D8
MV6]L]S$J:2#W]-34\0^X^KOAO<N12A*T]IQP%3 XR-F7K!J4IB2@/ 2%,JT,
MMOVI:[;OVC&(ZTDY#<!NRS;R@-G[']SYS5'4(E,C.2ZJ5(8U!/280!MBF>/"
M6A0YK8W$HPANMA?;L>;P951X.%YG2S\9W@-]LUB.+TJIYV\+R)>3DOI8].YA
M/O;2%_4@]^:^?P\112@4@"<\H7V42E 2O.,$HZX,$)/(JO8%_AZ;].Y*XN6<
M+ TT$4V])5([0;S!34%QGG@0.>..,$@ZN2$_\#E(>&I,[D&";V /ODW8[NYW
M4O*PHR"9S0I]6)ID*<.D@+Z%Y43+C-9:!^EU?Q>M'Z>M6;?O*(#UH9@& +>3
MFU=77_ 1)S_&BY%)6<KBD02(Z!<X7$U!N$3*98*D2_<O]F)3F&_)&OBXIA<\
M[-OSZ$#EM(RWPM#KV84?3T>)B: 598394F<N9""^7"C/-/C(N/(VU,Z@[$%6
MH\VU#H7"WNVU#M-+ U"[8>%7N @P'RD:HU4FXTJ$7-J#*20_&1(QW&&@F;:Q
MC[8L=TAH%$*'JGAS(-41\FX +F\OY]-Q.3<MQ<#C'^6KQ9J3Z#(DF22A2B$G
MSCL25 R$:8S_9(XV^=I#:W=3,ZQ[U3>(*FFA 3R5"MY+?-SG65[^[DO1^=)/
MS\?H$W0E%FNF7!:"*R>)B$J3<E.&!/RSC'A645H==*A=*K@78<.FQ_I&67W=
M- "XG4)[/Y["NR5<+# "0I)%H!@#,T"37*XLH^2(QI6E1#8I5F^0]#15PQJT
M81WYPU33,MBN,XH91AI48#3*<NQ&B=1)(4M4$XX+Q]G(8XHOUAKXEJQ&G; #
MD; OT Y42[N5>_LEND_PNU3&SXR_ QK]BW7SG3<_XN0R02K5D*=^$B\GZU**
MU^O?[5HS]'\@4(>\%STZZ$&B_1\RF.2R%MP3GT6I6%66^"@YL24N#IXIT+5[
MCKW$),"[NKB=8W)/%9VCLRYSVYS/M-K7O,P4A:'+,/18.O=AF!8S(S9Q2ZWE
M+,?:)3IU.6CV0.,YJ'NDU_!+*[D![^)(GE]=;7] ER5+$3C-CA.0KO3N*=N?
M#D"XQ(@A!@.2U>[<WR,[K63!7QZELS8AT^SJ^> OKD-GQY+(&>7,?12E"7H9
MI\PIR1[E+IR(,=5.L#]%T\!&O!7P[ 7J S79 #+?H.L\NP*XTP;P.M=BJ)<Z
M*\(9*WLEE\27&,BY; 4+RO'J0SQW$M,B%@_5^6:.OHH"&D#21D^\-1, V9;+
MN20[!64XE2F=B\JU71NT]I$&6=O/WTK(P"40?2+H>,$W@)YU1_PU\1Y*3S,E
MB3$QH(7F@GA&(\E:<6ZBC$S4'DIZCX"!2U'[1,OA@FX )4=Z!;<9O<Q5=,Q8
MHI!_M*TN$(>(($ZH<GW7IEB]?7<MVEM)SO_1XXO#P/#'7P0G%R4[,F+4LZB2
M(RI$2Z3U OGU0$1*S D-FN7:!T]5"&_1%>P;<W6!?P  _NB'#A_*IE?$U?OY
MP8,WO>A1P.-\OL#5@<B#E]&0$$490&L<"4Q3@@\Q#'\@I:E= ]U?5O\9]\IH
M!NHD Y*EP[5D./)M 4J9 F7>"$FK3U"I?.EOD.L%ST#+$9?^GJ.<!K;WTO=E
MLQ=!]$I18!B]T4A+TTNTU8";!_6)<IH41%I[76TAH]UK!$< Z5AQ#XB8LD==
MBZ6T(  $?^D(-/>I%.O]-@WCR032[4\6(P:!<J<2R2:6*9@*(T>=<"V HU+3
M&!C8IS;"Y[^VV9N=AP"G9ZDW8($^7);<P%F^:4._OLNU&!G&;)FC2EBFZ+72
MQ$E0Z+4&IT ZIC"4JUT_M).887LD]F2-ZHB^ 0S]-IU#G*&K^L^N'>FZ02Z:
M5G!6!>#$<@=$:JN(5:")8,[ZQ)7QO';8N8.4O?"C_F#XJ2'V=H.].WOT$8'<
MEJ=4Z_G_.'W5FO[?>4VX+BI<7MTYYKS&4A!.N.0"07]&$NG $]RFT M6.GI7
M7!E>^UQY?^J.M3'E\7>>^AT%7O;;M[/Y9PP"5@E&8Y)UU'C"HD:S"9D3A^X=
MR5PDD#$&_'EE >Q!UM"M_7O!SZ8MJJV>!G:UF[9T[Z8HH,MNB%ZI*&"":9T3
M)4J67%JDD=B(F[.U2FHI##C'*Z-L!RD#C_BLK?+-NT@5Y-\ C#!6F"[RJLWK
M9YA_Q_U_>GZGZ>$M=XMRO6:Q_4?KPT ;T?MSG!)';5FB&&98Q@-Q1OKH4PX2
M:K?DK$G_L("M JA9(]IM -F_??Y2.A-?SJ^0^5]FWV$^O7/_-#%T:;G@1)O2
MIEA[1WRY/@@"V11,"&UKEQ0]2M"PV!L.)YM!0S6E-8# .P?4&]O/[<9T>PPG
M.7AK<(D'1U%LRFOB3=;$<,DP8-#>LOYFE^Q!X,!CBWO>SOO350M W-)4^,:O
MCM8XH0T0;KK&-SGAHF*""","M=P:)6H[C(_1TTS->FT8; *NEDX:P->FK#86
MZT5IN_7/U>#DKM7\"!<BLB$IT=25O%+2)"CGB1(Z>R&5J5]4]UP:!\9A-71L
M%FSTJ:IJ?1][@V*,EQ>7W13O7^:SQ:+D*/VD,/P+>BZK^7]?_(^1AL"$8Y$X
M:P3!96Y6&6Z=:(A*6R5$]8JD&H0/7) W$&A[4&K[1G4GT^_QNSM,*ZH!O:(R
MD@!](HO>LF/)$QJE4"$KR-5'&5<A?-ASVN:0?+A2GX]DMT+R%,X+(5]Z _0M
MW_>E,*),6RV[CNP:MQS%2T=V7*@Y)YFT\#RZOKV#7;0->]+[8K"LHIH&;.BV
MBAKM$I<@+5&^I"=82L0Y(4JBPGON(F=0.]YIKH#IY<*<8S70[@GP6S^>=Q,D
M?NT25NO)0-V -']OUNGZY\DO;_[);.H_%4'/Q]/SSLT^X@RY%SHJG4+W+Z-*
MY]@W;[V=,WIGRA,P[K@2)%DH]2X:+2O5F?!, V3C59:UV[ ]1L_1)X?7S]XV
MF/=:$6?3&^'C+WR8E6*..[I8)=QR=LD9&HBVZ'U([14)%CT2&W![D!;526NW
M9Z]&_,"'/;7P]N!8<A#E-K#5WS#^ZNJ.L7D[A_^^A&F\ZH[2(LT2G##$F%"F
MH N+L: 6Z,Q0EXP,$9V;OO"ZFZQ&D/BR@-D%VTK::PF0VQA:'Y5I2)D[RHF2
M%- 3*EU+K4DD!*]<3M'K7#LZWX.L1@!9"PJ[H%9)+XU";7&S8J_O5T>&X1G7
M))9+VI(IAS)+N*O8!#I0%L#6/E_<AZY&P%8+#'N [2C-M(2V5U<W7_YM#',D
MZNO5>_@.DVZ-R@#&"B<(RQ'%9G!/\%Q1XJ4)U A/(ZO>%WLORH8-O9O;;VOI
ML"5DWEUM#_E;KVMAF8K92!),,$3*S(C#M4PH]4QPB?^9WJ*7?0ALQ#)61,@^
MQK&*NEK"XKOIM\OEHI,86QM\AB8=J1($@L:5:V@BKC00]S:"UEP+HWN+0QZ2
MTPC.ZH-@%]R.U$BCX.)K5K)!&1EJ2>8I$9FH(UYKE!AH0->8EFX]+P NWD*S
MJV'!=8A&&@676+-BHD57E4KB8YDB%#'PLCD:DBGS/JF4G.LM%?J0G&$/B8<%
MUR$::0!<.V9R=Q.J%$U1Z4 8+^6;445BD0$",0IJ,=!"ABIC:S<UC4!KT""A
MDJX:0-U3+3JV?WIMOBW::*\-B1GE*"D#8@$<>KR!NIA 4E7;YAU#[[#N7"W,
M/+/'2C4%-@#67V=3N/K5S_\!R[>7TW3-A1?(AO&91%K*URSCQ)7[C^4.D&-)
M^PBU&Z]LIV18@+T<$F;5U=( N';=,E..L^ DKDON\0\6-?$L4**YBLPQ7**J
M]GVH8ZZ-]E9BU<;.6T-+#8"MZK4R 5'E@#&Y@82.KJ2"^(SKSE,+2H%7TM;>
MAO_U+Y<^"U!]7BY]CG8;0/;C]Q2U<CIK[8E#KG";R8Y8$S.&_D9*A1N"LK6W
MZO^_7"Y]%DZ>=;GT.4H[&('XSC"KG:<Y8JMZ?SM8+D;/M&$E*Y7*[0A)@M:
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MI^X[*7R74_<=I-\!D#8\7-Z!&V9TX1%\85C?\E%,F@Q"XA0W&E^":5X#>(N
M#L&RCUKGK63< 4!>_1D6N<Y27%D-<>ELS6:%K,FMUJ*^0D\@R'F;X(JUKC0&
MR"T"^KT,/L0M[2_C#@"R>@GU4UABICSC&\Z6&W5<-ZW_Z<?U[VR>@*XXOF9[
MEM^?A5FMU-B8&W*FG(P,?.(!5"ID)!%K;T3ZCY-)\/:=* ;@8^01E?O#ZF[X
M/;:..\#YFZ_?SN8_$%>FOYX*L]G1T7";@A0D5+)_)8,&KY4#FY)W'%-RL77.
M]R@Q(\?MH^-D/H32.D#?!Z0L>IK.-R]2_YA-SY<?/OZQ8<:@0,YUK(_E:Y]0
M^LHKZ2$G3O\K@7'=NE[K28)&=M.]H;"=\CI XL-'VMIZYYF6-30V-9V*%-5:
MA)*,]-G*$$3KNM,3NQIM<&YQ@,Q[ ,[U,?3ED?6J:\.C9](3E[FR(7-0A1&#
MWA&#3E.J%#%EII34=_OZ' ZJ78GL(F4]!!CWAC /J:5^GZ&N#?:NTV@Q<&7+
M3VYT&[0/'XWN>5Y/E^EL-8>N#A2_7OP#GM76&:LV/RLPQ1M^]WH.4))U?CW7
M4+AQM:2,UT92 FRH.V=P.<K69PN'4=SP'FGOB&7M6RP+W&(HH#D);%5"["-%
MM"&F&+V-Y%Q:%R8U(W[<#?2(F'WB3NN(ZN\@$+A]+F%U-HIE"7;5B9?2,O#"
M"$"5,DG=<I_'/U(\QDW7,4'PY 'D+AKI $Z#I'O&RY0=5V3.)I-A\VK8T8-&
M9#$Z0R)H_DSWA1] [@2K8QQ [J+C+BKU'C_-4BIG7V>Y^%IRJTQRX#63P+75
M 0OE [IY3<W?Z AR)Z1L?02YB]*ZP-^=<ZS+"\W,DZB=J:V1%E0@XPZ:41+(
M8\;"-1>F]5;Y("$O\-#Q$-P=KJP.?/O3)Z=(_D0XF2 ERT"E5* ^EP3/T,JB
MD).[Z>[8>[C#Q\X1>(#R.D#BI5Q6H0Q*S9F4""X9!0IKC7]F]6C7(5,DKMR\
M#.+F^MU408R8LNRMCXZPM+&Q(),+*AD(M6.$HDT8(O( W(MDA62<J]8.M*<L
M87]-/@*)/<0Z]A/5=9MAHI\^V6PV2(Z*=E>-("VO#XFX !>E ]IYK:NO,8V^
MX]T>>^]^_\/[T/@^BIHWE%I'6N=7#V6Q:!U"!'2YND5%IB"T ,Y4UHE[%_R6
M(^3N?_BX?F, K>\EM9ZT[BX;+TAC*:RB?:Y826&6H+ <DP;K*>Y*R7!Y][AI
M"ZV['J+2(;2^C]1&U/IR<3[Y4$.BM8?+-N7:7L/IVG<JZ@2!Q3K3-UHIE>',
M;%4M1I]ZP]/3=]=>_M:"W51$C! L[B_Y'N!RB?),.#;: ./)@]*4+5$*QJ"V
M9(@E$_O;]1_=!C!C1@<'*.NNNO>0W,@*_VTZFWZ]^'IY2A,*)Z\5(1I6ZRJ$
M 5]#X:)9'628?7%;E3\_H_);BXZL]'U4-F\AO[$5'_ZZ0;A!:U#X#);5Z-5R
M3W&,Y< -UT:1.;#MZMZ?4_S-1<>)"ILI?F_YC:SX3]/SZA;?SO+T^S1?A+-U
ME;[/.2OA 7/,M:>_ R>-@)!2\%$4:]161YK/ .#!Q<<=-S9^I'"X1GJ#U+^F
MYU]6E2PDO^67Z;=/\S>S\^GYC\M';2*B$+4/A8X4C)<Z@Z3X!#R)X+-D*4D^
M!-B>)FL\1]0  $_!J:$VQLYA+R\U7\WRZ^D"$_WJ9@=F,=I2I679:N)R(N.3
ME.#E$CT6'W(.=SS8(YGLHTMTA(^6&ITW%V\')]W/;N6/[>2_7A4S%VFS5PXA
M,;6ZL:2HSAKZRL?D5L]OV]<V'DSUN-,6^[BA.;+NQ]X2]V9W71.R_,>J:\^G
M^>MPCJOANQ-?5,!0!POZU5V(,1!,E(172>DP^2"2_W:'@JU)Z[S$IS&PYMUH
M^91W](T WEV<+\\#>=#9YW53/4K6C8^Z9!"^>LF<)019#W6Y1^ZB\ 5;-YUH
MSD3GM4?#&$0?D#AEF[AJ*WEO?+'W)D@G01M'?E<F"P&MA1*Y<<9)+IH7Q3=G
MHO-JJ$YMH@DD1JT6O?:3\0G^XX][SVI6_+^=I0727]Z7P'M<)/JM=^7&?K'^
MG<U/*%K%K)D-D*2J(BH<(G<9I$%M>2I"^>URSS&H'_GT;>R8JF>LO 07\RKG
M:?TGE^]Y;^PL22G#: \!U+I.@"1YQ'I\GA-+B=<J"R%[<S:/LS-RZGWB;J<1
M3$XV&5_]L1J_BQN93$SB*K-B0:[:!3)I(4:A(3J7C+9&E[NGY*W3\/M$;05R
M\\) /JIF3QS1]W.L$'74+&N0]4V>RJ% R)Y!K%,0O2C9Z1V"I8:4;85M^V]L
M-]9QMT'.),8D(EI?&XPX<CR"Y*GH#\TEUSH[(T/KF1@/4[(5,MT+0V9#Y70
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M9W.<6H'^,=]!J]I= -A/+YH#A+1S7/Z8[/A$,<JU.:?(/*!:MU5Q+@A@)HB
M1A8I6\]NZH?[<6H-_G8V/1)<7X [?CS&?UQ$3(24K45((050V6CPD;)N86*.
MM#D*AKTUA-^#S7$BX+^=Z0X-P%YL=!]U7D]E_P?.2"9GU]UXKUOL2I^=1VMI
MFS("E.<.7$H>DE,,K2M\@+DD0S)THG4&(]>D-X?**=O-TU'!C1WGU>?/B]4[
MX[>TPTQGRVE:3S-27"64)"CAK:G3C6LUA<G@I Y6AB"LZ^UY[][,GFB)>GO
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M+7X+YZ2;V>=;/]]PBEI997(M@',"5$B17(M3(&52R@>,LOE9WO[4CM\\=D0
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M\7O+K[^8\,997V:,@AL%VJ$%)33QD6OKS4 L>4NNT&^UY^\?%NYV@S=<Y?S
MZ>A^(N\ .C_/OWZ=SU;CP-Z'Q;O%ZAU;_F<XNZC#%%<W0Q.K4T'K*;:-]=V
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MAPS/;D)4>(L>8P!"OEV>FHPG/$PG.SV8%@X5PGF- ->+@SX7"ZREU/)UX)J
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M52RTJ$ENVD@&/ P)(1E^P,?)N4);+.-[$J3@&_?Y*.7ZTC#V@7IYV@U#5'J
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M0@SAAF];.1W:*BV\^5?S_&.W=7/-SF]N/Z] L)^%YCT?5]I[:)7[N,KZ?IG
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ME0]'(< ?YHL'&@<'FH@3+$\B2T0_"W&D<SX4 'B^NU"**>,F[MR:9.&FM3H
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M!QY$2<J&6GOG2GN?>KL="Z6FA\G?E#R@??B8+A(SCTLY07LI1LB\M,C/#P%
M.\6H/&W36+,;'<U3K(%A@CLIC Q;:.:GP^-F8W=-(E,_D+#G4MRAR3S&+0M"
M$^[GQ<,A9F>IX$'C+,>HWUFS<*#PEJ*VY&3WL=.)35:,">6:F9=)I%$V^(<F
MD*_O$6N@2:\V5^X- G%/46/9,%/.^;)1?WKPSLPX\+I+!'+(99!.:@Q3FZS7
MFW-*IRZ.PHGYY(F7=IQN.67#-;^.T'.QUK.$.(!N-,*=YN5E\[S;^K/)+AK=
M9LWL:5,3.BF"82^328D6$W;"Q5MXXKK+FG_=XB.=#2CW@=%8>H5%NJ)"PSQ/
MKZAQX@$NP3LQ6E/(H0J-M++)*-=,Y>1-;+];S2H.(\5(B@1V7D=3XA# +21&
MZ<"RMA"4%F1-<1&N0J+'D9#)(!A-)8YJN+=;[][#F6M<7Y@+?US??-IY?_-I
M&Z?@BV&$M3B4^RIWL*DYH#L(DT%A<AA"4[[#E>=P 3\NX,<%_+B 'Q?P\]P!
M/\<;%?#SG<IS',\KS[%!M3C.GRB<5W1=35"Y,AV7%/)H,\18E6* ,F: (AV+
MLQ1O-*(B,(E1DA-0DG!3_D74\B(9^&02#_,'/)3W170GC)P['(E4%PF!'Q*/
MCP1E*?CB7H3Q2"7$)2E6@+C#&H9P%PJMA3*J"G' _X4WB  R=Y/<LC*(98K)
M5Z@Z]R4?/D'=0P$W2E^?[:UM%YZ::;ZFZ99PP22V_9-QV D)FG<V\F$G5;))
M(68HO0!8;D+E!TE_5P@#*F$*2Q.I4Q><NN#4!:<N.'7!J0O/KBZ<.'7A/Z?[
M#U?S.ZN,H&VI"1=L![#S^K)UT;SNMAI7K>YG=!7\V>H WG96E!JF5O:C[/OS
MEX9EM/7?1?.R==W"$ZA,L*WK;K-]VVYV*=6@2OGQBY927Z<30D.QK,F80F[&
M2BTS[6G"(A]R)(4RH^O4$%(F[,J"%YM0_V7^;KS%4B0H9%_P26D5Z]D;SGP^
M82K7A9++.>M@Q7+XM<8ZH#ISJJBBJI.S 49D<-J09G07DH]C("+6X]$7K)3/
MKN+(QVV3H&W"7I$#J:=77'5'W_S]*LD=K:+^1P7V;L!5K7?,;L)#I<(L8!>^
M\[1HQ-=!"MOCK3#1\Y!GH$/NK]43NI&X=Q$D7AC#PQ5 -DY.S\\J8,>N :LH
M0)"BIY%F"X0@3=BB<U.#^Z3PTI#H"A8N5=]J)A1(T2)ZV6;NVOLX]$T)'AY5
M@<AO%J&H[^YOB6U'+1Z+=[>9Q$+*%< WNPRVIANZ!4_'U&N;+CYEBI:4JDMO
MY#:TA1>, JJ=O/:->)AHZ\J63Z'7>=.;)U#L2NEZ;2MTYQXK#ZY_YP(L6Q<J
M'0@VCZSQ:BNIV'4T88W+R]95J]%M4BU%,>S!%J#^!&<KO_08+>G,L@^IZ.W3
MN7M4\LGLX$UK\G+P;= J<;EQOQ]XU*D(RY\/1V$\$4*74(QTW!:V0]*E">:C
M>1YB65#1LQ<+NMZV@MQ(QGU![9^P>9-_#R1;4K2U!R0Y"U..5<3&@YCT.1'=
M\3L%376K@G".E5212Y>H6("/6#A*Q5?_%&#VMFGY&&\HJ7"60M$DZ^W8OQG
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M):91%2)+0KV3<1;YB4IW"0-Q+PIC8B&;4KS]?1S>"ZTMPD8@,:!;D<=2X8N
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M01_# *7A&LBU:/2AWS#(",V\(!A'2GA&.RF77T0*?&44RS2+M$E4V4TO%,U
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M>$] 10P$>KKQI""YBV5NW0#2=R=0A^KGYK=M9>/K2IA97TB*W9W@C?? ;4Q
MA[DJA*[;\&"6G8[Q*E=J2&QOK*DI:/0Z(R&5&*.9I1-$G^L\7,?13@=3.LB+
M45'['::<%C,SLF>?98G)0$&;.'XIC/K*TJY"H')#\G@04V$/;8&GDB1T&9!,
MW*.Y_D%#G<HK $:'E1&%91'/;7W+3$\.<5]>W<_%NK.%3%N-;1=!\-R;SYH
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M*R#$XG;;>VL3VF2?J[9;JV#E[@3S1Y2Q&O>QB'1G8@C<#O6BD$MKV]1CG6D
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M]15S>E8+;AZ[\IO?R58=9M6YM\:&69=N4<-)7GUXCDV,M:IY<#K#6BHX [#
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MN3Z5_"BS -/6E.[)DSB)QA5:S4I!>T?U]'L15EM&/.1:A:IXKBA-@K&&"Q'
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M89LO; 4\NW8W&DYZL$FLLCM#6"KQU[5Y* " >Z.I[X( O/?C*#2&.5-6>S[
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MFF81MA5K1-D/-+6"_TJ0T-2=C,/F>$#'R _59(9$$H83(8W1I5<S1@++IZC
ML>YWG?_.@,-E',P)FI4F/E'=YL()H(F3]SZ\*+=$%]?(YJ"^1RW&8_FN9IJ
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M=L[_Y_TN/8CGF$PEB*F(+%'^1KZB:"@3'"%%=2;@>^SUX3MB*%.9='$N!0W
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M5'F>_P..Y^\7GR]NSCZN' -8+%UI[;%G!!N/NKU]9^=SE&(-U.X+F5Z.+H+
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M\]47YPXWZ\/5S<5ZMPO]V7$4L2-\+X*,I*$;A>C5\";QGL;2E?XLI>\E&?I
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M),O6X]_7#)>J;*!^S*E_]#66\]TJ=WE;=^7TI-OK#9[EK1QV#P<O[U;TCKK
M4)MTV],7<8+43G,\NJCT7\P<@#NLR4/0D'AW?AK(6GUX6J:&CO!4TF,)J6)^
M]"N1<:TJ]5Q,)?Q5[ T%1EVNIG(L]@;.R$\F3D19J'L91#-[7DK+?IK];E.4
M\O8,P98'G\&#CPUF;!GN(DG]*4'K:=:["+V6\7Z4\9[M1VXWMUG-L+?8+(B=
M,Z[S40HLT6D9KF6XEV:XR]#+DC2>D]<4RMABNY;=6G9[:7;[&+D&ZQ1[25H>
M^P$>JT!.:#G-!"RE.PEQ)4XT_,J6K<E'*TNN9;Y6P+TTVWW!R3K7.,)2E8E:
M B\5R3>J@:6^S9;[?H#,MQ+[48/HX4F9Z>UFO4]^(),T"N&..PR(3)V:NDL3
MVWV3W9;K6JY[+8_U/;,:)C VWE=E@BYK:ER3WMT1N\X5]FC^.P,M(N-@[@Q%
MXL.9'TI8(%6:JS[G,J92B+N3B'C^^(RX?*8!WB\?7J#''^6 B<J6VK5QO+BP
M6'45$S:='Y96HZ[&@:3JQ[Q54K\:O*3J',)[C0DY,9:S* :B9U/8$/]_]1RF
M) 5I)VGVQ2B*IZH%1,!Z9^9ML4,V0*"%H6HN\K)87^]/X1H?7CW AD\_BLT:
M=EYU(L:*0>^SFSOG-^?ZYNKW&ZP>O;FXOKJY>YL5U5E_/".CZSSVS\YP]\L2
M!JAE*&OS*_9<]=^LLO765PT'%)_4H"W^</GY[&.3]K=49?#3J[N%>-GSE-[/
M:3]]!N.TRG(J%?/T#DF[EM@KCA[XYX.?A-5^$^ZW<1QE>D@A-3S.%-L-8P(D
M4%WFCP4T7NATKE[P^&);PL4TC>+BW-!Y$7J_W'EO(*W*XO+9IW_+3GRUUOU7
M&#WL_1$]O/8YW@S>>6KE[4]^U!X-R+;GS$3*$&C2%T&]P=8>M/:@U79#_(@5
M^U.<KRL$-%B=D9X; =P^3GH5,OV4AW';#UZ-R^C#@\:4]7Y<QVU()'YS,SYO
M(]>:Q8%W42H0"RDAS#MNQ2G'6QE0@/%;>>C-*(K3B0;[*D.6M0S\>E[!0J_>
MJW1)6? >:^H1,V49A,^49\J;OG*FNR==!57U*X'UX;=^^:_K+)Y%"8\]<EXG
M6? $@)VG3T%8$QS0=2SO_2A#Y,P'R;@G/+J$,#2+22J*NWI^3%*+H&&EMZ=@
M^UV<OY5-L\#4]UQ<GU'NZ?T?9RC+=']/UW&^3/P@22T@Q22:2H2;3ORA'_@I
MYJ_H67F6BD95,RZ3F_(H+'R7!)'' @\%:-L3^\/35-8U6"2:3F7L@G7F)])3
M()\,$QW+?V<(RFG#SP4^O"F.+'></Z('">JE@ZP+=HD/OS#C/"!Z3XB8FCAJ
MCBL X,]#&;H3>.UOSHXG1QI2,\IB9R91\<%1D _PQUDVQ.0[<?(?<!_0R2+H
M=IS^?G]_%[7T@T3L,>##^\C/\?'V>(&7U\2?=);D= B/0X1/!"R+"=J.DAB4
M=O5AP_@I8 3(0-YCM0'-_L!FMZ1TBKHT:8B8$8P*&4YPUAW#+N,ADN&]CT#D
MGI.7.Q7.+UR/X*IN%L<$>)N*-#/97RHI$-,IX?LGD^@A=.#WV82L9V6*F.G+
MOXL0;N!.T)YA<$DF)MN&/ /'#01B52+TLS[MZ@J\>^( VV'^)N$[C#)"(T/$
MZ'L2 (S'%(HXIG/*M\:UZ<$?!,!?>#\$7X47"-VJ-[]%1B&\.;DGO_N$;$_
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M84::"DMIP"\6ZW.&9POL4V 0-A"^4\X!MZA(.)$<IN6-F*<3] C):3&GXM=
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M1F!URB8#65Q7?<A-2)$5,5A<")F$(C0@)3&Y2 N;&IN3<$>*)J61RB&ECZ:
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M,#(R,3(S,2YH=&U02P$"% ,4    " "U@6Y6T"F(=P@0  "4K0  $0
M        @ 'FY@( >71E;BTR,#(R,3(S,2YX<V102P$"% ,4    " "U@6Y6
M$_)[%V(@  "I.P$ %0              @ $=]P( >71E;BTR,#(R,3(S,5]C
M86PN>&UL4$L! A0#%     @ M8%N5@KQTK* 2@  ?#T# !4
M ( !LA<# 'ET96XM,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( +6!;E:T
MY,U7.W$  ,VI   4              "  65B P!Y=&5N+3(P,C(Q,C,Q7V<Q
M+FIP9U!+ 0(4 Q0    ( +6!;E:OYOVG.0," $FX @ 4              "
M =+3 P!Y=&5N+3(P,C(Q,C,Q7V<R+FIP9U!+ 0(4 Q0    ( +6!;E9Y,0!8
M:_   %KP"0 5              "  3W7!0!Y=&5N+3(P,C(Q,C,Q7VQA8BYX
M;6Q02P$"% ,4    " "U@6Y6S1T4 ->*  #U008 %0              @ ';
MQP8 >71E;BTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ M8%N5F\-_MF]
MU0  KLL( !P              ( !Y5(' 'ET96XM,C R,C$R,S%X,3!K97AH
M,3 Q."YH=&U02P$"% ,4    " "U@6Y6[PO[WED#  !D"0  &P
M    @ '<* @ >71E;BTR,#(R,3(S,7@Q,&ME>&@R,S$N:'1M4$L! A0#%
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B,3!K97AH-#$N:'1M4$L%!@     .  X Q ,  .I1"     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
